<SEC-DOCUMENT>0000875045-20-000011.txt : 20200423
<SEC-HEADER>0000875045-20-000011.hdr.sgml : 20200423
<ACCEPTANCE-DATETIME>20200423161549
ACCESSION NUMBER:		0000875045-20-000011
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		117
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200423
DATE AS OF CHANGE:		20200423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		20811186

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2020331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:6d0b60302b684a29b549d2f820b84779,x:a3225c302ab64f88afbd203bb102cd82-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:biib="http://www.biogenidec.com/20200331" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q1QTD" name="biib:AverageMaturityOfMarketableSecurities" id="Fact-BE759A00528103D38E8EA3ABC08EA095-wk-Fact-BE759A00528103D38E8EA3ABC08EA095">P14M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:AverageMaturityOfMarketableSecurities" id="Fact-A4DAB426EB5BC684746BA46510DA16B1-wk-Fact-A4DAB426EB5BC684746BA46510DA16B1">P14M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-41049643AD145AA2B130F660E7E8AFB7-wk-Fact-41049643AD145AA2B130F660E7E8AFB7">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-09D506618FE158B397A0EA490C63676F-wk-Fact-09D506618FE158B397A0EA490C63676F">Indefinite</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2019Q4" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" id="Fact-E94D0F643D4B35A2A419A4B45339591B-wk-Fact-E94D0F643D4B35A2A419A4B45339591B">22700000</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:AmendmentFlag" id="Fact-A1A0BFFA652F52B587CE616D155B3700-wk-Fact-A1A0BFFA652F52B587CE616D155B3700" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-CFE018B378775665BEB08C43355A63AB-wk-Fact-CFE018B378775665BEB08C43355A63AB">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-822FFD30C861526795CB236918C386FE-wk-Fact-822FFD30C861526795CB236918C386FE">Q1</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalYearFocus" id="Fact-F801D1819F5F5765AD557D4F1A16824B-wk-Fact-F801D1819F5F5765AD557D4F1A16824B">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:EntityCentralIndexKey" id="Fact-37B8E2145E095B2FB63A8DEB5D5D10FA-wk-Fact-37B8E2145E095B2FB63A8DEB5D5D10FA">0000875045</ix:nonNumeric><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-3322F41DD23BDAF92DBCA39B1471C117-wk-Fact-3322F41DD23BDAF92DBCA39B1471C117">0.0253</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-07DA040BBC29BA113CA4A39B1440FAE4-wk-Fact-07DA040BBC29BA113CA4A39B1440FAE4">0.0240</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-2A00764DBC255448B6EC02B74F49766E-wk-Fact-2A00764DBC255448B6EC02B74F49766E">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-A2E30888404D5EE291F13A55081AC892-wk-Fact-A2E30888404D5EE291F13A55081AC892">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-89FE8A77B0C45D3A82F6A29F2BCF8000-wk-Fact-89FE8A77B0C45D3A82F6A29F2BCF8000">0.052</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-79B99F6CA97851EEB776C8B0C323E15D-wk-Fact-79B99F6CA97851EEB776C8B0C323E15D">0.0405</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-2F7550805D4E537BB3D7C2322A9346A8-wk-Fact-2F7550805D4E537BB3D7C2322A9346A8">0.03625</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-1D5B786D125A550C85CAA46161AC5616-wk-Fact-1D5B786D125A550C85CAA46161AC5616">P15M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-35B1996F33518339B93AA4619962ACC3-wk-Fact-35B1996F33518339B93AA4619962ACC3">P1M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-68DF96FB57403675193AA463CCB0D163-wk-Fact-68DF96FB57403675193AA463CCB0D163">P12M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-DD51B44FDE25AF1AAF3FA3BC205F5969-wk-Fact-DD51B44FDE25AF1AAF3FA3BC205F5969">P15M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-01FFE3B9DC0CC3E5A62EA3BBD3B0A8FB-wk-Fact-01FFE3B9DC0CC3E5A62EA3BBD3B0A8FB">P1M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" name="us-gaap:DerivativeTermOfContract" id="Fact-16B8F578928FEAE57CF5A45FC177D90E-wk-Fact-16B8F578928FEAE57CF5A45FC177D90E">P7M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-DB5B126C5A7F5C7A9460614F2442F50C-wk-Fact-DB5B126C5A7F5C7A9460614F2442F50C">P18Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-985702C93F345A6FB6E1C856D8801B81-wk-Fact-985702C93F345A6FB6E1C856D8801B81">P23Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-45DFFED86819525799E7E23409C446F5-wk-Fact-45DFFED86819525799E7E23409C446F5">P28Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-528507DB169757AC8D6CCA2B62D18710-wk-Fact-528507DB169757AC8D6CCA2B62D18710">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-C846ED53A3DA5659BC29AE7F983F2E31-wk-Fact-C846ED53A3DA5659BC29AE7F983F2E31">P13Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-B4C5093E7C8D58E6993148995BA4CC90-wk-Fact-B4C5093E7C8D58E6993148995BA4CC90">P15Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q1QTD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" id="Fact-591E504BD5C0CABE5FF9A38C98689EC6-wk-Fact-591E504BD5C0CABE5FF9A38C98689EC6">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2020Q1YTD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" id="Fact-6B7C2B625E7FBB6B070AA38B8C1BE03A-wk-Fact-6B7C2B625E7FBB6B070AA38B8C1BE03A">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-25CF6E03ED7958D8AD16550E92781BC4-wk-Fact-25CF6E03ED7958D8AD16550E92781BC4">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-DE092FFE73005195B4D6CE55AF4CDD8E-wk-Fact-DE092FFE73005195B4D6CE55AF4CDD8E">0.001</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="biib-20200331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Apr22">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-01</xbrli:startDate>
			<xbrli:endDate>2018-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Apr01-Apr22_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-04-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-02-01</xbrli:startDate>
			<xbrli:endDate>2020-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_ElenbecestatCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ElenbecestatCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BAN2401Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BAN2401Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Assets">
		<xbrli:measure>biib:Assets</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s0FE79452E1305AD4BF636EFD094F2FB5"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;</span><span><ix:nonNumeric id="d6284084e774-wk-Fact-9E1C63B980225665AFD76E8A6D49F549" name="dei:DocumentType" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d6284084e792-wk-Fact-2996D1F5C4B35B5DA7165B50326C8FA5" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d6284084e802-wk-Fact-4BAD8D88AC545954A0C837AEEE25E1B3" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q1YTD" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonNumeric></span></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d6284084e822-wk-Fact-F4BE16E5AE8F53199B9FB1B8FBD67530" name="dei:DocumentTransitionReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number </span><span><ix:nonNumeric id="d6284084e832-wk-Fact-C258B18EFF57556A8DE152F81374FD49" name="dei:EntityFileNumber" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">0-19311</span></ix:nonNumeric></span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><img src="biogenlogoa10.jpg" alt="biogenlogoa10.jpg" style="height:30px;width:92px;"></img></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d6284084e841-wk-Fact-4C9803C4D09A57B38927419263380380" name="dei:EntityRegistrantName" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6284084e863-wk-Fact-195AA48F721D5AE9844F5373280656B5" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6284084e873-wk-Fact-0C1EAD5584C5529C87E4556BBAE26CC9" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q1YTD">33-0112644</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d6284084e898-wk-Fact-75BB9BE0CBAF5EF59458C603560AC852" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">225 Binney Street</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d6284084e903-wk-Fact-AB610A1554DB59B8B681A03DFE4A23D0" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">Cambridge</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d6284084e908-wk-Fact-5DE227B3398F5394AC1AD75E9B38BCD4" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">MA</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d6284084e913-wk-Fact-10DB515F7DA35D8D804BAC1E27806F98" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">02142</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d6284084e921-wk-Fact-87238C90C6E451F48C76BDB9A3082B10" name="dei:CityAreaCode" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)&#160;</span><span><ix:nonNumeric id="d6284084e926-wk-Fact-A42B83D6F91C5B7E9E3098E576A9E3B5" name="dei:LocalPhoneNumber" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">679-2000</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6284084e987-wk-Fact-AAEA88AEE72A5FBB87EFE3DCB6DDEFD8" name="dei:Security12bTitle" contextRef="FD2020Q1YTD">Common Stock, $0.0005 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6284084e997-wk-Fact-66862D6F4C655DBCB93A2F3D9623ED73" name="dei:TradingSymbol" contextRef="FD2020Q1YTD">BIIB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6284084e1012-wk-Fact-3E64E99A15D05A7682D3F0D6840E81FF" name="dei:SecurityExchangeName" contextRef="FD2020Q1YTD" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d6284084e1017-wk-Fact-BB2C9FC847655F1384508B285EB0BF59" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d6284084e1035-wk-Fact-98C5B83D14715E4684BFF3A0C557FF85" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q1YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:3%;"></td><td style="width:43%;"></td><td style="width:28%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d6284084e1070-wk-Fact-17048B31DA565C79A1B708393154CDCD" name="dei:EntityFilerCategory" contextRef="FD2020Q1YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d6284084e1116-wk-Fact-94BDCEAA8D0454709624A539E9F7820D" name="dei:EntitySmallBusiness" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d6284084e1142-wk-Fact-51CF62786AD453089542092BD9875239" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d6284084e1152-wk-Fact-99E9A60F86325C82B3306B207984DCA5" name="dei:EntityShellCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;22, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6284084e1170-wk-Fact-BA1CC73B2B5651FDB561611DE3AE13F1" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2Apr22" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">163,187,486</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s9A113CF9805359CD87FB3059F1C681A0"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">PART&#160;I&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;" href="#sD3FEFBCAD16B5EF8B5294B5E5DFCAAA7"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Financial Statements (unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s5910BDE2F1EB58E5A086116C1B62EF0F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three Months Ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s5910BDE2F1EB58E5A086116C1B62EF0F">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s009D21B3356B59F5BAC01A5DF86727CD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three Months Ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s009D21B3356B59F5BAC01A5DF86727CD">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s224A583CFEA553B7B99A83D27DC4435E"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of March 31, 2020 and December&#160;31, 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s224A583CFEA553B7B99A83D27DC4435E">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s0FE79452E1305AD4BF636EFD094F2FB5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Three Months Ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s8FB47B4562E45083832FC0E7B4D7F4AA">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sD7C191D68C7D5C008D5276C8F5263C45"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Equity &#8212; For the Three Months Ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sD7C191D68C7D5C008D5276C8F5263C45">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s93CCEED021B05FB288D0621CF49C8052"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s93CCEED021B05FB288D0621CF49C8052">11</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s373A9FE4765555B8AD2BABD6CB64DE1D"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s373A9FE4765555B8AD2BABD6CB64DE1D">41</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s1491D5554C6250E38427BCCA34B579EA"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s1491D5554C6250E38427BCCA34B579EA">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s689DD25F3FE45E9B8EFFE739483B9028"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s689DD25F3FE45E9B8EFFE739483B9028">66</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">PART&#160;II&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;" href="#sF0C314A8C0D95B2AB4CECD9E16909D88"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sD0B48C62368352ADB22435D1990408F0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sD0B48C62368352ADB22435D1990408F0">67</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s237CF9883248521BB66122FF7B4742ED"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s237CF9883248521BB66122FF7B4742ED">67</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s87489C5E3D8C5E56B645B1115D529BF1"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s87489C5E3D8C5E56B645B1115D529BF1">84</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s1085D5D2585252D49676623F0D8D09C6"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s1085D5D2585252D49676623F0D8D09C6">84</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s5BDA7844AB515F41A553E5AE2E98FEBA"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Signatures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s5BDA7844AB515F41A553E5AE2E98FEBA">86</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3BC20384E34057F685AFE657876C017A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the direct and indirect impact of COVID-19 on our business and operations, including sales, expenses, supply chain, manufacturing, research and development costs, clinical trials and employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans and investments in our core and emerging growth areas, as well as implementation of our corporate strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intention to commit resources relating to research and development programs and business development opportunities, as well as the potential benefits and results of certain business development transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities and activities in new or existing manufacturing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) departure from the European Union (E.U.);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, including the Swiss Federal Act on Tax Reform and AHV Financing, regulatory requirements, judicial decisions and accounting standards.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174;, VUMERITY&#174; and ZINBRYTA&#174; are registered trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI&#8482; are trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ENBREL&#174;, EYLEA&#174;, FAMPYRA</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;, SkySTAR&#8482;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and other trademarks referenced in this report are the property of their respective owners. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD3FEFBCAD16B5EF8B5294B5E5DFCAAA7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</span></div><div><a id="sA2871A2FBD645644A75F1E284659C346"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s5910BDE2F1EB58E5A086116C1B62EF0F"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Product, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e911-wk-Fact-6DD5F1948E5C5CCCAEDCAF91E2F6813B" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,904.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e930-wk-Fact-7384EBD5465D5546AC62CCFE15F4F263" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,680.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e945-wk-Fact-5C1B4A3E5E705C3DBAAB3B3D2CBBDB7F" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">520.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e964-wk-Fact-C51A11646BE4542D85918CCC5A2C7AE2" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">517.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e984-wk-Fact-49E487F43286591DAFFC57ED16F39618" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1003-wk-Fact-8A0940D374CF51D083D84F7631628605" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">292.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1023-wk-Fact-67A79A4334385AEA9579EC0864CE619E" name="us-gaap:Revenues" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,534.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1042-wk-Fact-F59EB6B836105D99B02E696E73F0C35B" name="us-gaap:Revenues" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,489.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cost and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1103-wk-Fact-77CE25C6A5955795B876F6097771B582" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">454.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1122-wk-Fact-A0684D74D79157138A5968FFB4727C64" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">602.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1142-wk-Fact-6A1B8246EDC45F38BE6FCC39833F957F" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1161-wk-Fact-A07D838079A3557BBD7BFBD318C414B8" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">563.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1181-wk-Fact-B1B1C54A525258B3815BE89318686BEC" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">570.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1200-wk-Fact-836757F917F65D499520B7D6AC8AE137" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">567.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1221-wk-Fact-13DF614395235DA29BFA4FB1CE46B0EA" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1240-wk-Fact-D01715617B805CDF8467FFF75B1E78EB" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1260-wk-Fact-C92342AD40AF5405B447A64BA994BED8" name="biib:Collaborationprofitlosssharing" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1279-wk-Fact-F9AA5718E5295572BF87104C4FE5C9D1" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1299-wk-Fact-6BA6F831A1FE5DDCADE05EC186CA4462" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1318-wk-Fact-C5F084F1A6D853B18FB7DA17A7BFDDCC" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6288638e1338-wk-Fact-30C421DF9F73516DA7CC5CB1364D68F6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1358-wk-Fact-C6C1AC30CB4E5EB1972C8B88035C202E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1378-wk-Fact-EBC927E55ECC5B908782BC0037BC0481" name="us-gaap:RestructuringCharges" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1397-wk-Fact-DE085C0D0B2B5AE69525919F7BB21506" name="us-gaap:RestructuringCharges" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1417-wk-Fact-225BCF3C3F255604B4154C5CB5F42644" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1436-wk-Fact-EB31B50657855EA88ACF984F577F9CD0" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1456-wk-Fact-AA0E84E467C75D2BB452C1CF861B9793" name="us-gaap:CostsAndExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,714.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1475-wk-Fact-DDCA304686FA51309917955C5C74D208" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,987.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1495-wk-Fact-1242610DC3A558A6ADC5F3666973270E" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,819.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1514-wk-Fact-7BB1936389A0598E8E9C4EFFC9B9713B" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,502.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6288638e1534-wk-Fact-095EC1AAC9A25CD9B7B7A910B16D60A8" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">120.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1554-wk-Fact-F27571BB0E665301A0F41E41FA9CBCC3" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">357.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income before income tax expense and equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1574-wk-Fact-CB357BE0FB8356AFB56C3F00FF9F30DE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,699.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1593-wk-Fact-CBF283110D6D550C8935AFA9D9953011" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,860.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1613-wk-Fact-9156FD9A2D78535CA2B0C79FDFD99BF0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">292.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1632-wk-Fact-CBB36E1C1C7558A8A96C566D9177B34B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">422.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1653-wk-Fact-860174F550AC598398F8F8B8BF2CF6C4" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1672-wk-Fact-7B423D07C24357D7A0FDE253FD8563E4" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">28.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1692-wk-Fact-4199EDD4FFD756B7B0FD3FA1BB63DAF0" name="us-gaap:ProfitLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,392.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1711-wk-Fact-DF052A332F6F579395B041A3F28BDF67" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6288638e1731-wk-Fact-E8E6F2D8020956B982BCB7187DA957CD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1751-wk-Fact-D1AE363A3E745509A3A74EBE4BC60CCB" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1776-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,399.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1795-wk-Fact-FDA77C2428AF554989EED78CF2C2AEA1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1897-wk-Fact-58BD9C385B6153B89B00E6CAB98D5048" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1916-wk-Fact-DA4914AC28BB5D54A6ED20A7C3B1AE1B" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e1936-wk-Fact-109F49C09A985F67A8E373CDC627D891" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e1955-wk-Fact-A1A2EFBA9A5B5CA4AC66E81D00E64648" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e2052-wk-Fact-71CBFF9E20095155A1063474D4C8BA5A" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">172.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e2071-wk-Fact-8C58D4EB1D6251F29A5B7EBA8DD1F024" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">196.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288638e2092-wk-Fact-413B006A143E53BD99DB85074CA369D8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">173.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288638e2111-wk-Fact-15574C2EB65A522E829F10B43239453D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">197.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s009D21B3356B59F5BAC01A5DF86727CD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6289510e870-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,399.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e889-wk-Fact-FDA77C2428AF554989EED78CF2C2AEA1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other comprehensive income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6289510e945-wk-Fact-C0318CA1062A527494733AE65EABEEC6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e965-wk-Fact-05FB684B59A353DD936C266C7D4178DB" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6289510e985-wk-Fact-AE62E9836A285C7FB3421ED220549164" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e1004-wk-Fact-256E0EC4BCA0541ABEC01249A13890C2" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6289510e1024-wk-Fact-756171E441B157A98467E768E66895AD" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e1043-wk-Fact-07AEC6DC97ED5FFB85FBD7ED4C2514C6" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6289510e1063-wk-Fact-DD04B0206F6D5FD1807678CE6EC2B85E" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e1082-wk-Fact-5EF1AD86A1595801BD7A0AC7A2954BF5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6289510e1102-wk-Fact-B5B3A2AAF22B535993E3DC4B8B5F75B9" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">63.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6289510e1122-wk-Fact-82FA6F14E34B57E994F4988C13C3BD3D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6289510e1143-wk-Fact-5B8C18C3243E5D5AAD152B2A77B3C58D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e1163-wk-Fact-49C6AFCCB21C5CB19609F8B635C4A0F1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Comprehensive income attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6289510e1183-wk-Fact-18A41409123F57F29261C2A4D5CDEBDE" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,385.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e1202-wk-Fact-B6FDD288DEB55FA09303CFE7BD51576C" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,429.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6289510e1223-wk-Fact-05117F37C5465704ACA5654B798AD022" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e1243-wk-Fact-D4601141F4D9577F985314E7032A8750" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6289510e1268-wk-Fact-5F0BB58B6B2A5B1585B32780C8DDC783" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,379.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6289510e1287-wk-Fact-AA6713EA12EF5BB893E2E61BAA1152A8" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,429.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="s224A583CFEA553B7B99A83D27DC4435E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">As of March 31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">As of December 31, <br/>2019</span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e912-wk-Fact-9E3BC132605A53179E58E06AE7023F80" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,591.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e931-wk-Fact-B03EF7F09BF05D95ADF9E2B230C12C79" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,913.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e946-wk-Fact-AF04C9845A4550519959DBEFA976148F" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,269.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e965-wk-Fact-904EBE773D4F5E6A9D60741F7D34BC96" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,562.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e985-wk-Fact-68C9E4E720B05E3BBDD4D71786DF4EE3" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,092.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1004-wk-Fact-39E56DB8DE1C5CB0A6A73F0DF9F1D2EC" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,880.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1024-wk-Fact-15DAFABFE317534A9839B38088FE2D14" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">511.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1043-wk-Fact-AEEEAA0C876C5A738E9FDA8B17CC717F" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">590.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1063-wk-Fact-94DA70047DDC570698CB696B939357E0" name="us-gaap:InventoryNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">858.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1082-wk-Fact-2FFAC78B3D545117B101AC318FE3ABBC" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1102-wk-Fact-54AADF515E4B573589DDD09A74208296" name="us-gaap:OtherAssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">683.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1121-wk-Fact-8A2B7D1849ED507F9AE8B6BF287456FF" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">631.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1141-wk-Fact-1004E716E9D75D9EB1BD7F8357BB005A" name="us-gaap:AssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,007.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1160-wk-Fact-8AAAEB08C51B5C7C8E26895E6505B4C8" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,381.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1180-wk-Fact-9BD52EF2DF8157AA8CD120A9A1802965" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">969.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1199-wk-Fact-1A0C0F27D85653CC9255C3493714626B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1220-wk-Fact-96DE043D4B9B514EA70C9505E514959F" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,281.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1239-wk-Fact-95207BB579915990922C304989290725" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,247.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1259-wk-Fact-100DC9AF86FF5D3785AE526D70B873F8" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">422.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1278-wk-Fact-98FB78D2F30554F78D859647290D9B54" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">427.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1298-wk-Fact-AD1C5EB68CF65DC3984A7409445F526B" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,446.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1317-wk-Fact-82009BD2AC26575E958204C37D75B0DB" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,527.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1337-wk-Fact-5680A01230085EC6BEF71F889D7F44A5" name="us-gaap:Goodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,752.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1356-wk-Fact-A6A4D09C94CD5944861219FC074EF1A3" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,757.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Deferred tax asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1376-wk-Fact-FA37454DC6705F1089979A75ED1A521C" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,109.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1395-wk-Fact-77D0B708F3B3538F8CD131B724CC0DAB" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,232.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1415-wk-Fact-EB285A38F5215617B60EC7F386653555" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,130.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1434-wk-Fact-268213F6648F53EB926A46CA8BC4F44C" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,252.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1459-wk-Fact-0CDB39262C9B5C6F9B23777F80183E67" name="us-gaap:Assets" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26,119.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1478-wk-Fact-59CAF36B1A4E5EE9B24508364CA382D7" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,234.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">LIABILITIES AND EQUITY</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1580-wk-Fact-76978170110C51738E6564D3F70B968C" name="us-gaap:NotesPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,501.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1599-wk-Fact-21866A1A55D658CD8EDB6BFC2EB0584D" name="us-gaap:NotesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1614-wk-Fact-CD29CDF186285D27B67954D956C7D4F5" name="us-gaap:TaxesPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">310.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1633-wk-Fact-B6BE4939126F5963881E01F407642944" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1654-wk-Fact-A9FAC8D03FC0557AA677BAC810C75731" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">389.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1673-wk-Fact-439B48A6D7E8587688D30E92AC457B59" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">530.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1693-wk-Fact-2E91A66DD1E458A083A3758FECA481A5" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,437.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1712-wk-Fact-97EC7EE1ECE85247B1145A8455CBCD68" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,765.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1732-wk-Fact-5584167DAA415C38BE453E0D918C4A9F" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,638.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1751-wk-Fact-69EB85132FDA5106842CAFAC8A9E24CD" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,863.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1771-wk-Fact-18ED34FA4C655E4D95680B3F591943BD" name="us-gaap:LongTermDebt" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,459.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1790-wk-Fact-A88A8E8C7E785E2B91C1E4D980349CF9" name="us-gaap:LongTermDebt" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,459.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1810-wk-Fact-E660E565045D5F2A860C5F2B73E4D6AB" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,722.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1829-wk-Fact-19DC9D5C82515950976A3DC21EE25169" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,810.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1849-wk-Fact-C65F20A72D7E55BEA521049A6BD49481" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">403.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1868-wk-Fact-77C6B9EC17E1512BABEBF711DECEDFC3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">412.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1888-wk-Fact-3979DB5E0C6C5D6D9A9F95E7EF93829D" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,357.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1907-wk-Fact-13BA7A88BF675D4EA00EE608833C04FB" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,348.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e1927-wk-Fact-76B4DA13D7C2517AA56CEDFB07492F26" name="us-gaap:Liabilities" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,582.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1946-wk-Fact-6F539162417750CBADCED7D22AEFFBFC" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,895.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Commitments and contingencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1966-wk-Fact-D58DF02739465DB6B3F3ECA7F584826F" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2020Q1" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e1984-wk-Fact-165CC6763049575481A61D0D790A0AA4" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Biogen Inc. shareholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Preferred stock, par value $0.001 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e2086-wk-Fact-FE15F450D01B55749D8B184CA4166526" name="us-gaap:PreferredStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e2105-wk-Fact-7FD388D112845ED6833D944D3B2C2D05" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Common stock, par value $0.0005 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e2125-wk-Fact-40964C8781055C209A8BF33EE6F22CCF" name="us-gaap:CommonStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e2144-wk-Fact-9B2727AE3D6B5CB0AD866F75EEC280CA" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e2164-wk-Fact-D24EB0D8053150FEA91F0C9F6B25386F" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e2183-wk-Fact-2E70DC0CCE94516E8F0CB96A845EF0DE" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6288639e2203-wk-Fact-9B13E96C51445E7A8D54697EFDAC6991" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">149.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6288639e2223-wk-Fact-ACAB9874DC005EDD9E4AF5B9CE727C30" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e2244-wk-Fact-2C28C111714552F4937B90697D166F4A" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,673.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e2263-wk-Fact-7DF1742CEA145CFB8417269D6AD0A7B7" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,455.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Treasury stock, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6288639e2283-wk-Fact-1B3A1F61F6805787AC1A4C99EA9C90F6" name="us-gaap:TreasuryStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6288639e2303-wk-Fact-16E1C1AE476557F19818F5AA13097340" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total Biogen Inc. shareholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e2324-wk-Fact-A16AED5F52FF5C17821FB367F609D039" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,546.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e2343-wk-Fact-0DBEA1C192225E35B1FDAED1EDB23329" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,343.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6288639e2363-wk-Fact-8D90401DF38E5BAC9A30B4E1FF1BF965" name="us-gaap:MinorityInterest" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6288639e2383-wk-Fact-B13DD615DE505FFFA130E62DD8FDE9A3" name="us-gaap:MinorityInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e2404-wk-Fact-29BE2ECE9A485DDBB6B3AE92B3B006E3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,536.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e2423-wk-Fact-0E2A62FA2C405909B2F8AD85E16A99BB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,339.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6288639e2448-wk-Fact-8C00695905B85DFA9738C8F829563A57" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26,119.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6288639e2467-wk-Fact-7565973E1C995CE295AA15C1C55E7247" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,234.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8FB47B4562E45083832FC0E7B4D7F4AA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e911-wk-Fact-4199EDD4FFD756B7B0FD3FA1BB63DAF0" name="us-gaap:ProfitLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,392.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e930-wk-Fact-DF052A332F6F579395B041A3F28BDF67" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Adjustments to reconcile net income to net cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Depreciation, amortization and impairments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e986-wk-Fact-810637FABA705C0AA1193AA26FE78221" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1005-wk-Fact-D32407AA7A565E3E8B8A09C8FC9DC906" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1025-wk-Fact-225BCF3C3F255604B4154C5CB5F42644" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1044-wk-Fact-EB31B50657855EA88ACF984F577F9CD0" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1064-wk-Fact-A9D71A8C343D508ABF40849B8FC99672" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1083-wk-Fact-4A9D618F43F65E77823D22E7C0C3CE92" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1103-wk-Fact-30C421DF9F73516DA7CC5CB1364D68F6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1123-wk-Fact-C6C1AC30CB4E5EB1972C8B88035C202E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1143-wk-Fact-23C45A092B7D545BB21C5D11F38E5FA7" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1162-wk-Fact-0E4E0BA32F745EDD9B63D72ED9EAB841" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">115.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1182-wk-Fact-4F887C6F9AB85667B72559C183EAC8AC" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1201-wk-Fact-780860699B5E5CE8ACAA726A93456289" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">228.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unrealized (gain) loss on strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1222-wk-Fact-778B6325242B5F9C92E3E9A0201967BA" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">62.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e1241-wk-Fact-11E7182A5591570DB9FE2BE68B2B67C2" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">375.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Loss on equity method investment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1262-wk-Fact-A43B37833ACA52C2A9D06A7ADE26ED13" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1281-wk-Fact-FC17FB12F1A35F799FC5AD4283937565" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1301-wk-Fact-B8192F9CC03655CA940C4AB592450A71" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1320-wk-Fact-A3490EB2CFBC56F69DA80EB1F931407B" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Changes in operating assets and liabilities, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1381-wk-Fact-4D8532C3BED250959E6EA69BBE21B642" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">238.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e1401-wk-Fact-D224FA708E025959837C2A58669281F4" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1422-wk-Fact-8959F674F3E57403914FA3505E5EB778" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">78.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1441-wk-Fact-8AD8D46D92201C093B56A3505E8E8085" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1461-wk-Fact-2E1022760CEC58C49172AF436571DFF6" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1481-wk-Fact-FD2068B5B4975A3E90C297D1BF6AB085" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">129.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1501-wk-Fact-143B780CBA7F5955AEC0E33BD498F7A2" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">347.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e1521-wk-Fact-9F1BAAC57D3B52A1BE348B6C35CEAD27" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">138.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1542-wk-Fact-3D06773286005FECB87A0243AE6D42FD" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">223.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1561-wk-Fact-FD9C9D593E9D5551B9B5BEF6AB135E59" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">170.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other changes in operating assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1581-wk-Fact-13F6EA0871C95D3D9AE8306196A4A32B" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">18.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e1600-wk-Fact-20BDF30FF61B58E9998A410EEE744FEF" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">171.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net cash flows provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1621-wk-Fact-A53253F8727458F9B277284D06ED8BCA" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,467.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1640-wk-Fact-588C12CBFDCB573DB60B84CAD01D910D" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,459.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Proceeds from sales and maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1702-wk-Fact-B2C977AFB43A5B6D846E35244FB2DF92" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,389.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1721-wk-Fact-A4A4FD4E66E65DF4BA4CD8A5C026A640" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,489.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1741-wk-Fact-A6B124D432DA55C6B70465A17E221C0C" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,684.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e1761-wk-Fact-AE8E6E95D552529C9FFF0BE1159247E5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">825.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Contingent consideration paid related to Fumapharm AG acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1782-wk-Fact-F1063F33E51B5CABB59A12D35EA607C2" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e1801-wk-Fact-FD363536D83C54FDBA14F57929F3DC4B" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Purchases of property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1822-wk-Fact-7D32BE90701854CF8F7EB3CB769666B8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">149.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e1842-wk-Fact-73A133B00F47554F860060B3CEDF2157" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1863-wk-Fact-E5028E61DD15548A916018DD40E9F4C1" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1883-wk-Fact-F276101F49755EA3B935ED9B99354D9D" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquisitions of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1903-wk-Fact-12DD9035274258208EBDD6A25E5EE0BB" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1923-wk-Fact-D230F0689E6A5546A81B729D2D656A0B" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Proceeds from sales of strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e1943-wk-Fact-6825DADBC91F5C88A7DD8929D52D98B5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e1962-wk-Fact-ED15A26ED140519F9B607D6607E78077" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e1982-wk-Fact-FAF1E4FE04605BA389139DAE95C7286B" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e2002-wk-Fact-72D72D3CA77B51CB876492350762DCC2" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net cash flows provided by investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e2022-wk-Fact-C5D4A5E6A59A5B53A681521C40913824" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">442.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e2041-wk-Fact-73E27DAF8E70566382BB464AE27E8BF0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">238.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Purchases of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e2103-wk-Fact-F45CEAC8FC665627991A58E5F2588D73" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,220.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e2123-wk-Fact-F5F9549A6A5150D8967280D473756047" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Payments related to issuance of stock for share-based compensation arrangements, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e2144-wk-Fact-67A8DA12505C53739505B2978A1CEA4A" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e2164-wk-Fact-14EA6E04E84D5E8D89318E7128184B83" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e2185-wk-Fact-D93CC2B160875147ACC0105935028876" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e2204-wk-Fact-5AADD14A68625D21B42DDE7F5C8A063E" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net cash flows used in financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e2224-wk-Fact-B5B585A539CE525696198FCB93D6C26D" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,245.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e2244-wk-Fact-2C6C6345E35E5BB6BADBC1B200E9AF61" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">679.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d6291576e2265-wk-Fact-A1B7B85971F75F0B9C5EFFBFF870CC75" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">335.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e2285-wk-Fact-D5BE7268B09853D39FEEEE36D70F7905" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,019.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e2305-wk-Fact-7EBE2B568ADC5697BF3724791F4A54CF" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d6291576e2324-wk-Fact-C6CF844D24305DD7814C9AAA77B739E3" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash and cash equivalents, beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e2345-wk-Fact-B03EF7F09BF05D95ADF9E2B230C12C79" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,913.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e2364-wk-Fact-96E609DCAE575BEFA8157EB7A5A6C744" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash and cash equivalents, end of the period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d6291576e2389-wk-Fact-9E3BC132605A53179E58E06AE7023F80" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,591.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d6291576e2408-wk-Fact-D28BE5C30EEB5EB2A83EE108E8063739" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,243.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD7C191D68C7D5C008D5276C8F5263C45"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:14%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1314-wk-Fact-147D51E29DA753038FF6B72AC4EB69A5" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1333-wk-Fact-29AFCC29691855678DD9C4AFA016A174" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1347-wk-Fact-E00670A64B1E52D8A1E9609F6015AADB" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">198.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1367-wk-Fact-BDE06542D6775EFDB0D5CB202E7A3BE9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1386-wk-Fact-FE98E1AB4E81571589665487BF5DB7DE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1405-wk-Fact-0D1360EE860F5D16BDFBB26C49D9266B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1426-wk-Fact-A2BF105A88AB5C5989C651C2943E1C17" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,455.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1440-wk-Fact-422B65741C0D535F997EBFC221545C6E" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1460-wk-Fact-498CB27721CB574CB17A0E08ADD2A4B3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1481-wk-Fact-0DBEA1C192225E35B1FDAED1EDB23329" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,343.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1500-wk-Fact-A9BCFDE518FE5CD0A2316970AC4D77BE" name="us-gaap:MinorityInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1520-wk-Fact-0E2A62FA2C405909B2F8AD85E16A99BB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,339.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1642-wk-Fact-5B8ED4DAAEED5AF880893716931AA3C6" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,399.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1695-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,399.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1714-wk-Fact-EDD74A72062656D18F621B6FEA712DF3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1734-wk-Fact-4199EDD4FFD756B7B0FD3FA1BB63DAF0" name="us-gaap:ProfitLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,392.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss), net of tax</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1841-wk-Fact-5244F9E418825CB7A899B22D502E6D7A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1915-wk-Fact-5B8C18C3243E5D5AAD152B2A77B3C58D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e1935-wk-Fact-DCAD131E5D83508B8A391B19C9A9E895" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e1954-wk-Fact-8E4E2B856AF889A5D5EFA355A5AA2449" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">13.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2103-wk-Fact-A3719D729132566CA1CC689921AB3638" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2118-wk-Fact-61CDA54B15FE5E3180B3AC6D3628CC0D" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2139-wk-Fact-CE7CBD4F54285B4A0872A355A5B58D4D" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2178-wk-Fact-CE7CBD4F54285B4A0872A355A5B58D4D" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2233-wk-Fact-3F31435C3175584ABB84D90E7EEA56E8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2249-wk-Fact-9348561A23F551F7AACE03D5AAF507C1" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2268-wk-Fact-3A21B5C121435E7EB52DFFBDFC97BBA8" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2308-wk-Fact-7B8E26C38DD65FD794DF1D3C11B34665" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,208.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2328-wk-Fact-D00C46586D45551AB70A90871AF32DA8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2342-wk-Fact-864CA399D43E5EC09A230DE193FF5051" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2362-wk-Fact-AFC2B8379AEFAC85B66CA355A5C75440" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2400-wk-Fact-AFC2B8379AEFAC85B66CA355A5C75440" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2546-wk-Fact-7DC56ACC84EF5C1408CFA354946A716E" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2561-wk-Fact-287F5A082C7BD4A8C027A354E1E43D36" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">941.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2582-wk-Fact-A2B3291640081C21DAFBA355656139BB" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">941.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2621-wk-Fact-A2B3291640081C21DAFBA355656139BB" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">941.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2676-wk-Fact-8EA0CCDD4EA8230782D1A35654C689DE" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2692-wk-Fact-7E32FC748CFBFE9D7134A3639538838F" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2711-wk-Fact-7CE8AD1729C24BD461A9A356BF963747" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e2751-wk-Fact-DEF036E534B263DE9126A35F8BAB5F2F" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">925.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2771-wk-Fact-E424172CA32D0445D6E9A35F8E6BB903" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2785-wk-Fact-FBC23C36B89210D63908A35F90CE685D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">941.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2805-wk-Fact-0CCE965FD720384BCB42A363A9952452" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2843-wk-Fact-0CCE965FD720384BCB42A363A9952452" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2897-wk-Fact-23BF7BB1E339507DA196D751FC0EFC5E" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2912-wk-Fact-A232D6172B275666AF95342412325E69" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e2931-wk-Fact-59E26BA2405652849505221F7A5036F8" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3023-wk-Fact-137A0E62BD03FAC1BE43A355A69409BA" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3061-wk-Fact-137A0E62BD03FAC1BE43A355A69409BA" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock award plan</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3115-wk-Fact-23ABA915D9DB527BB9137164AB27A56E" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3130-wk-Fact-410ECEA64372564A864B93943F91C3C0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3149-wk-Fact-C2BA427AFB3D522996E53FD5AAD1A9DA" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3188-wk-Fact-9E88C70662925EA8935C8F1B40F3C5CB" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3242-wk-Fact-F43E86761D81B5E17712A355A683DFD0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3281-wk-Fact-F43E86761D81B5E17712A355A683DFD0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Compensation related to share-based payments</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3371-wk-Fact-EB5F804D75B75A22B90F15586A13E3E7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">69.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3463-wk-Fact-7FE76D3B3E4319519D03A355A5BB18C7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">69.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3501-wk-Fact-7FE76D3B3E4319519D03A355A5BB18C7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">69.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3589-wk-Fact-83BB0DBE0E2B55461528A360320773D5" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3682-wk-Fact-7D4728E5E93A1AC78ED6A3609963B7DD" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3721-wk-Fact-7D4728E5E93A1AC78ED6A3609963B7DD" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3743-wk-Fact-41399AB25B065C7C8FE2D69F215307D4" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3762-wk-Fact-22A19A6BAB0C557BB615DFB533100589" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3775-wk-Fact-9DA5E9DEE64751DCA6F8AF793669FC3A" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">191.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3794-wk-Fact-7341D4EC40CA561EAA15BBA734F0D083" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3812-wk-Fact-AA8AFDDD082851ABAB69E9AF9B924AAD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3830-wk-Fact-48AEBC0042B15A5D99D2E7582DEC9CF9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">149.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3850-wk-Fact-A8C4C108D3E65F93B318E87C6911D590" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,673.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3863-wk-Fact-188702686C1B5E2E88F0B60C682536D2" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3882-wk-Fact-8AEE1CBF18B55881AF1FFC4EAFD3F397" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3902-wk-Fact-A16AED5F52FF5C17821FB367F609D039" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,546.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span>(<ix:nonFraction id="d6298639e3920-wk-Fact-44EB24242A3F57CFA1C0ECC9172A9017" name="us-gaap:MinorityInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"><span><ix:nonFraction id="d6298639e3939-wk-Fact-29BE2ECE9A485DDBB6B3AE92B3B006E3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,536.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:14%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4541-wk-Fact-D365F775A0F9555188D9BFD5A4CFB376" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4560-wk-Fact-62951BA4915C56AC803CEAEA8922ADE2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4574-wk-Fact-C8C13C9944255A57817D2EB87EE687DD" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">221.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4594-wk-Fact-506A842079665D9E8E6A18F3E42CBD27" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4613-wk-Fact-4ACDA1EB70C05910A151B787E955F94B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e4632-wk-Fact-E10F4EA3D4205F73B61EE49DC60B45F6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4653-wk-Fact-E44B4063B0F05F82835F61CE0AC0A9AA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e4667-wk-Fact-07B9EF830EEF519CB546B849C54BFB46" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e4687-wk-Fact-6776CCF1E8BF59DFAEA9443F9FEE7380" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4708-wk-Fact-41E5280F7C7157F59173D118B8028BE5" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e4727-wk-Fact-2B44137F3C435981A93F9D0A63E7EEA8" name="us-gaap:MinorityInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4747-wk-Fact-F42112474AA0504EA70566E6AE468C99" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4869-wk-Fact-3A3DD757C2DC5B498B6F08B9EB2C48A2" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4922-wk-Fact-76A5ED2F7C04844A6DCEA35593BAC488" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4941-wk-Fact-DCD2FCAD6DAA57D39C1D82BEEAC5B5AE" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e4960-wk-Fact-DF052A332F6F579395B041A3F28BDF67" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5067-wk-Fact-F3FD0686FCCB524EB94E371B43673704" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5140-wk-Fact-D96ED917EADB0C08F616A355924A4865" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5159-wk-Fact-BD62C37EC73B507FAE1CE6D9F591039F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5178-wk-Fact-F19F2DEE77D456948CD78605F057955D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capital contribution by noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5358-wk-Fact-359F3B95456B1CAD1EC7A355933750DA" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5377-wk-Fact-42CB3BCC47E25D739888F1D6AE03A94B" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5396-wk-Fact-E692CE74E306582C8D22225118E54A46" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e5542-wk-Fact-C3D02352D0C379F678B2A36CD04F1883" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e5557-wk-Fact-FEB25B0F3A83886C809EA36CD3803E5E" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e5578-wk-Fact-9D5DF1D7D26DD5773130A36CD68BF078" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e5617-wk-Fact-45B68F44868F2A40BCEEA36CD9A99305" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e5672-wk-Fact-2081DA4ABD815B734B3FA36D3675B012" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5688-wk-Fact-C405B30BC513ED998B4FA36D3935FA46" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e5707-wk-Fact-346194DBE4E76D72C1B4A36D3C248D48" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e5747-wk-Fact-645119D130B664D7629BA36D3F60B691" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">590.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5767-wk-Fact-3AED67959A01286AFF56A36D43CE9A1B" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5781-wk-Fact-5C06B85EB22AF76688E3A36D46B8F5B4" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5801-wk-Fact-75C1B43FEFDED055FCB6A36D48FAA5E3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5839-wk-Fact-42028526182084CBFC1AA36D4BEBD02E" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5893-wk-Fact-6CF4159D0480561090AF1CE0D6C5C26D" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5908-wk-Fact-96884FC8CC6D5CB0902ED9E864962EC3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e5927-wk-Fact-0BC22EE0C6905205AE5D0BB9F20BA5A4" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6019-wk-Fact-1F6955F949DF796BE26AA3559355F649" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6057-wk-Fact-402E3DFDA79E56C2A92B5DC83BF1BDEE" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock award plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6111-wk-Fact-0A6174D2BDB25A4A86D849D555B82B00" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6126-wk-Fact-F6C41E3757A05B75A7E57623FD9D6BFD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6145-wk-Fact-B0CC17BA7E3A5316A9E5D0FB539772BE" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e6184-wk-Fact-E1F33DABF1EE365048C8A36E740951F7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e6238-wk-Fact-9494D6B85F263D2FDEAAA355926D7B86" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e6277-wk-Fact-8D567C16DD5E5707A8DF73CCB01C0000" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Compensation related to share-based payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6366-wk-Fact-D487A9F89FB250C6B54C78C067354168" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6405-wk-Fact-6753DC8516495FF5A875856187EEFD8A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6458-wk-Fact-25D6A85FF2F67E9FAC74A35592D48FA6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6496-wk-Fact-67584C28BBC75E06979F6E115920FF33" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6518-wk-Fact-92A30762EE2E5FEA86AF29464F78564A" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6537-wk-Fact-44102CF37349559EBA9B6CD424EE681B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6551-wk-Fact-20B53D15949B5199A585679875FF6C23" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">219.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6571-wk-Fact-FFE85BFCBB7D58249A7469B5C52AFBA5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6590-wk-Fact-4B4EF0655A1E5C5897A3B89FBD69A977" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e6609-wk-Fact-16EF8724AFCA56CD9E55FE439CAD781E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">219.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6630-wk-Fact-9181FCE451A3522EA5EA972E68F55AFC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17,026.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e6644-wk-Fact-87512526BDA4548D922D944E99515447" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e6664-wk-Fact-4D64B30365CD59488FE40F95952E03A3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6685-wk-Fact-F01B1006CAD5535DAAF5BEF311185D7A" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,829.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d6298639e6704-wk-Fact-C56083C8572E5E8E89ADF1D916465226" name="us-gaap:MinorityInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d6298639e6724-wk-Fact-F28D7B612D4F5044997580E79AE60519" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,822.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><a id="s93CCEED021B05FB288D0621CF49C8052"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</span></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><a id="s84F47B96F392518DB06A299723E08851"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-0-wk-Fact-6A013FE9853758E5803FC7E90672D920" continuedAt="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-1" continuedAt="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-2"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:BusinessOverviewPolicyTextBlock" id="TextSelection-E4522282AAFD5C7E9C31849C46672299-0-wk-Fact-C9F12BD49E795FF9A155D6B1DA896928" continuedAt="TextSelection-E4522282AAFD5C7E9C31849C46672299-1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS  and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-E4522282AAFD5C7E9C31849C46672299-1"></ix:continuation>Basis of Presentation</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-4D7AB7C514B55033B0F8247E754C873A-0-wk-Fact-71481388443358E6B297FEC0E40A4940" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6298862e855-wk-Fact-35BAF8F08B5F5BAA98689CDEF69C6A39" name="us-gaap:NumberOfReportableSegments" contextRef="FD2020Q1YTD" unitRef="segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-2" continuedAt="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-3"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-290600B0FA2259E5A6C77DDF15CC691A-0-wk-Fact-1D13E11943BE57F582EBC608080A6EEE" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6298862e879-wk-Fact-1B2B6F8E7CA558E09D5D18E3503F6B76" name="biib:InterestInSubsidiary" contextRef="FD2020Q1YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:UseOfEstimates" id="TextSelection-2D56022413645E06AE8D55F9F87ED1EA-0-wk-Fact-4022A979D0E95B32A3E9B0E8E2646BD1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-BB08D144B88E5973AC76A5570F178B26-0-wk-Fact-A5375EC6CF205CAEADBBE3C1FBCDA23C" continuedAt="TextSelection-BB08D144B88E5973AC76A5570F178B26-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-BB08D144B88E5973AC76A5570F178B26-1"><ix:continuation id="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-3"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Internal Use Software</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an insignificant amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div><a id="s091C3C3195A051B9A14D247C839A70A5"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-6B78267481905C27B5B75BEF4B35FEB8-0-wk-Fact-F7737A1D66BC57B9899A0FBF5C2697BD" continuedAt="TextSelection-6B78267481905C27B5B75BEF4B35FEB8-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Acquisitions</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-6B78267481905C27B5B75BEF4B35FEB8-1" continuedAt="TextSelection-6B78267481905C27B5B75BEF4B35FEB8-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In particular, we plan to develop the Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this acquisition, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e768-wk-Fact-3FC90659224C2907DBDBA37249E560ED" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e772-wk-Fact-99ACD7918EBAA0EA257EA78D7EC455C1" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">635.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-6B78267481905C27B5B75BEF4B35FEB8-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6299201e782-wk-Fact-660E10114389D03DEE5CA830D727C7EB" name="biib:ClinicalAssetsAcquired" contextRef="D2019Q2" unitRef="Assets" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e789-wk-Fact-97193A4702D85FCFBF4C2110AEA42926" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e793-wk-Fact-259D7FF271B4575BA9920CE2620D1780" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">847.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e797-wk-Fact-8EE56AF9C7D150C58B9B790C1FCFCFC7" name="us-gaap:OtherPaymentsToAcquireBusinesses" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e801-wk-Fact-C2B78EB9CAA2553EB224BB73F8C575F6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e805-wk-Fact-F0FC3521C49C51BFB8A625D22292497A" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e810-wk-Fact-ADA5D8E6563A5612A829A61A8C430B53" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We finalized purchase accounting for this acquisition in the fourth quarter of 2019. The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-9A7BFC6259E6569C8F823EFD7AC16B96-0-wk-Fact-F7004B6AD2E653B0884B810C9D2CD808" continuedAt="TextSelection-9A7BFC6259E6569C8F823EFD7AC16B96-1" escape="true">:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9A7BFC6259E6569C8F823EFD7AC16B96-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6299201e866-wk-Fact-1AA7CDBDCAA65C52A34E2E00BD55A502" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6299201e881-wk-Fact-EBA7A0F88E725872A0C38BEEA5CD8F3D" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6299201e901-wk-Fact-897E6E0751DE5F48943183B3EB308A83" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6299201e921-wk-Fact-427A724879C45B30B50683032B815D05" name="us-gaap:Goodwill" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6299201e941-wk-Fact-6AB40C2973DD54C2B17C1CFBC1D180E4" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6299201e962-wk-Fact-1AFA284F35D05799AA996DA293F76908" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6299201e987-wk-Fact-33B1C372116D53E7ACAE530E264F3D55" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">852.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6299201e999-wk-Fact-37862AD762DA55C8A37B792B685C441A" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">12.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e1003-wk-Fact-C3F35836087052ED98215D865377A8CE" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">480.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e1007-wk-Fact-E76DB618A8085584989BD70260C4E61A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6299201e1014-wk-Fact-070E9C6656CF7C7FCC14A832F70726E4" name="us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes" contextRef="FI2020Q1" unitRef="usd" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299201e1018-wk-Fact-B116079FFB97582C916C4060236A234A" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9C49F781DA285BC585DABCA124C0BEDD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="TextSelection-E2CB5D74CD68552FA988AF3E37C6F398-0-wk-Fact-8EA82CD3D8C85B298FD7C90262B81A82" continuedAt="TextSelection-E2CB5D74CD68552FA988AF3E37C6F398-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Divestitures</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-E2CB5D74CD68552FA988AF3E37C6F398-1"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. We determined that the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale and recorded an initial loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e764-wk-Fact-BAD3AA00C6C7B21CA71EA37E2D78E026" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This estimated loss, which was subsequently remeasured each reporting period, included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e772-wk-Fact-C5F084F1A6D853B18FB7DA17A7BFDDCC" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting our estimated fair value of the assets and liabilities held for sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e780-wk-Fact-B73ADFE2D90182E7CA6AA380AD0B66E0" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and included our initial estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e785-wk-Fact-8C54B342EE26D47014BFA38144B3A1FE" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e789-wk-Fact-EFB75A60F3EA17A2E8F6A381C54A5D48" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2020Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this planned transaction in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> this transaction closed and we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e800-wk-Fact-4FAD233BB63E5E6B9384D60E9CC37AF8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">881.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which may be adjusted based on contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e807-wk-Fact-71E142F7CC1251389807EE36C522416D" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2020Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6299354e833-wk-Fact-2FFBD82F6E845B6D84A93F33AEDCAFC6" name="biib:InventoryrawmaterialssoldtoFUJIFILM" contextRef="I2019Q3Denmark" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction in the third quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These materials were sold at cost, which approximates fair value.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1100503FEF0B57D7B8B5DF022220430A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-EB3D286995D75C2DB984870778CA8AA5-0-wk-Fact-CBA57C5E3A8C5F9C966093256BBB38D4" continuedAt="TextSelection-EB3D286995D75C2DB984870778CA8AA5-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-EB3D286995D75C2DB984870778CA8AA5-1" continuedAt="TextSelection-EB3D286995D75C2DB984870778CA8AA5-2"><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-AEB5A5FDFA465785A995381C5DC8AE00-0-wk-Fact-2DC64E2631C058F79184A45F87B207E9" continuedAt="TextSelection-AEB5A5FDFA465785A995381C5DC8AE00-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1348-wk-Fact-DD8F7BA1D8525BF49CA4BF6F0D63F48D" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">777.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1367-wk-Fact-0645B14D11A2598E990DE7F80BE7776E" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">323.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1387-wk-Fact-95EEC0A2FF375DFCB1D4D05C4E90A829" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,100.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1406-wk-Fact-36E059173BFC53018DB4DD5982DCFAEE" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">717.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1425-wk-Fact-AE721FC8DD735487B7A95C2969C42C72" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1445-wk-Fact-AA30AA6FEEE55B6E8A4695DF65150AD0" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">998.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1465-wk-Fact-9D5AEB6EC5D35A4AA87DCF1EFF4DD34D" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">292.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1484-wk-Fact-9E87772CE17F57748C5C1584A7B3238A" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1503-wk-Fact-6A87CBD94A395A78AA6D05E1323CCFDB" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">466.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1523-wk-Fact-14AEDBF812E85FCD9E66260E648A025E" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">327.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1542-wk-Fact-10B61AECA1B65E9383C6C1949FD5E9DE" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1562-wk-Fact-73D40D3DFFCB57209D9DBBD1CBB0ED0F" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">500.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1587-wk-Fact-B326E02C901E5FBDA9C3284B588C2F3E" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">277.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1606-wk-Fact-8360373164F257A8A9DFD4AA89AE308E" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1625-wk-Fact-48DC9D93BA165116BE850B9D0946F8A3" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">522.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1645-wk-Fact-7A2903761BA95B54BF1EF7D78C784595" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">245.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1664-wk-Fact-FFB940CF4F165CA5AFE785A107666BA1" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1684-wk-Fact-40DCF4E1432450B0B845A8F029C91576" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">460.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1709-wk-Fact-918BEA969C0E5F69BF518E42366EE66A" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1728-wk-Fact-937EDC022D5A5AA696D020ACB72AA82E" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1747-wk-Fact-886F75FD806F5C158C17C596E512E81B" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1767-wk-Fact-8D678ADE9F545123B04FF8313CE1419E" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1786-wk-Fact-4271413674CB5F939D166F0781D15231" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1806-wk-Fact-989F4F1608135A2CA79FC08F30BEEC52" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1831-wk-Fact-89689120EB265032A4467E302D6DD5B5" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,347.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1850-wk-Fact-6788EE24A3D050F8B613038B15265A22" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">769.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e1869-wk-Fact-D7EC36ACAD6756D1AE55ACF8E1B79F16" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,117.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1889-wk-Fact-CEC7EEB05A3950218F3F0D3A92A9D5A8" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,290.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1908-wk-Fact-AB69EFA20D5E5659A7C3A16BCD21C364" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">693.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e1928-wk-Fact-3AE767426FAB562BAF8B1C3B26E56FDE" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,983.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2208-wk-Fact-099B4C15A03D530191D4DB8AF2EA6627" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">235.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2227-wk-Fact-E28E632589465E17B201F3CA2A7379FA" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">329.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2246-wk-Fact-82EFB202B0165A83ADFE63ABA7D86861" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">565.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2266-wk-Fact-7776C0FFED5553848678104ACEE7D17F" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">223.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2285-wk-Fact-B348888A71C25B61A9F0A0C6D1636E40" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">295.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2305-wk-Fact-4EFF89F344F4532095162D10C34172A5" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">518.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2584-wk-Fact-A1AE1C9EEBF656289F625770D69DA70F" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2603-wk-Fact-A3B0CF04E2CD5B068E6469BC223770B5" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2622-wk-Fact-945A419C4FB45536A528A94FDE1B2485" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2642-wk-Fact-D52E06FBAD8354D6BEC3010A567B347C" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2661-wk-Fact-F7C4854247EA586DAE1F0B259B818A99" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2681-wk-Fact-6E7660BEFAC858B786650D38BB6B5F00" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2706-wk-Fact-EB97929C25DE5DBB91F528104B2EF396" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2725-wk-Fact-286659174BDE52B2AF74784D85FC4420" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2744-wk-Fact-6927A325FDE45762AF9F255F361634CB" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2764-wk-Fact-7E7D119BC25C5408AB0334BDC4718951" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2783-wk-Fact-78ECBC32A7265A52838B820FDD950E5B" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2803-wk-Fact-2220B05B39585E4785C5B58E44E8789E" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2828-wk-Fact-3A826B5CF31C5D3994F27282749E0F35" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2847-wk-Fact-19E87F032CA25D0B965DC5B6B987EABC" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2866-wk-Fact-D1B78B16E7275CA8B60BAD71261932DF" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2886-wk-Fact-40A8AFBC4027514BAF7078ABC50AB2DF" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2905-wk-Fact-65C17DA4F12B53D7B95BA57ED86C71B6" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e2925-wk-Fact-9EBCC6BE992359BE96381CAFF3284EA6" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2950-wk-Fact-CECB76B3052F5C40A2FC75F32C52669D" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2969-wk-Fact-D9895B16F3D4525CA46026EE41C548A4" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e2988-wk-Fact-E0CA27D4898253668D32D6D734F76B77" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3008-wk-Fact-5523430644105A31B6CA4175E7A8B3A6" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3027-wk-Fact-1C64E73DCFD758A19A46D5BD8B18A98C" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3047-wk-Fact-0C6F4C346947562F823FFC94F9A6D425" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3328-wk-Fact-247344CC304F5B90A7576657954CD548" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3347-wk-Fact-6179CA0357E659ABA2F2E28E776EA4DF" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3366-wk-Fact-0848B91759315F2F8EBC4930EFBD3308" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3386-wk-Fact-DC2075534874553AB06A5CB537E47409" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3405-wk-Fact-2C7AE49A43DC5ECC9E42BD79D7E7BEA0" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3425-wk-Fact-694D1CD487A7522EADEC037FA04078E2" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3455-wk-Fact-6F90B429EBCF5C2D866783C1E925C432" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,583.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3474-wk-Fact-BF94E08E2EB351ADA8C04A0B207F2631" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,321.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3494-wk-Fact-6DD5F1948E5C5CCCAEDCAF91E2F6813B" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,904.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3513-wk-Fact-BD3B4248CF7F5A409959F495B89BE074" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,513.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3532-wk-Fact-8B62E11CFECA543DA98233D5F6318DE7" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,166.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3552-wk-Fact-7384EBD5465D5546AC62CCFE15F4F263" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,680.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-AEB5A5FDFA465785A995381C5DC8AE00-1"></ix:continuation>We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3571-wk-Fact-516D340D51455C31BA4C9506473D3FA3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30.0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3575-wk-Fact-CA3CF5C80F4F565199C6DB7CC9E69D01" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">14.6</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3587-wk-Fact-E13D55C0C88656D684B70521B1BC24A6" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">31.3</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e3592-wk-Fact-0B8900DC61C05B80971AEDB9AD39D255" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">14.2</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="TextSelection-514D726EF8CE557985613F8E46E42B47-0-wk-Fact-8FBB4A2EEE5452138F55DB5DFDD3D337" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3750-wk-Fact-1DA42F369A6B54599BF21412911CE44D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3769-wk-Fact-ACD42097DFF054B98CB6E2557F24C003" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,027.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3789-wk-Fact-0FA2A298C7A056379A4B45B8C7259E5E" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3808-wk-Fact-69530C8A18485050B373ADC68F2B0E32" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3828-wk-Fact-F153EF29B97C5F4BA510504ED7E05B5A" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3847-wk-Fact-B377CD75C31C553BB64C5A7662E8CFB8" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">827.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3866-wk-Fact-745EB3A91A425E7B82E16BB719C8C5D3" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e3886-wk-Fact-EB09CA95B8E35D289143DF14B83BDC07" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,033.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e3911-wk-Fact-0453A8BB670357DFB7A9B3156ADE8365" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e3931-wk-Fact-73ABD40DC3DA5CDE9AFD60503B1BB486" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e3951-wk-Fact-30E079D2DAC55CD9B57891F8E4BEC277" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e3972-wk-Fact-8A0F2CB0608E5A9B988D14B9030C2E4B" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e3998-wk-Fact-914F0466C7D758188F08CD31C29A7BF0" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">73.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e4018-wk-Fact-2C76846906F055B09C9CAF94F8871EC5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">310.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4038-wk-Fact-188AAA1141675BAD9EA6C31F03F8CF91" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e4058-wk-Fact-9DFC6F3259FB5B2A8A2A187CF40A955F" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">383.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e4084-wk-Fact-71DF82A69C565876A60E700101DB4B41" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e4104-wk-Fact-8DBA303847F35C42A90325E65107AC95" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">432.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e4124-wk-Fact-4F81F818B617588E8BF33E44776C3AE9" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6304303e4145-wk-Fact-11E7BBFFFF3B57FFBB91725C6B48D5D4" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">549.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4176-wk-Fact-CAAC7B324B7851879909C250EAFEA06D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">145.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4195-wk-Fact-5B10D49C2AC15A47ACFEF3654EEC1A9A" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,096.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4215-wk-Fact-2D1FF151CDFC51FBB2F72BD78DB414BA" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4234-wk-Fact-077D868269775B1388A7EB0DC649F943" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,281.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="TextSelection-48C562B8E2E050ACA45C9BBF8C3C0112-0-wk-Fact-33315DC456925A3AB4424F8D0D483179" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4344-wk-Fact-33E531F21D0058E39FA8097C00B1464F" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">235.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e4363-wk-Fact-3F20B3F170EB555CB9232E5197D66A98" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4383-wk-Fact-625419BB27195A409EDB1EB81379D384" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,046.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e4402-wk-Fact-787C6E6AC74D5288BFC68E3A0EBA4216" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,001.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4432-wk-Fact-077D868269775B1388A7EB0DC649F943" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,281.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e4451-wk-Fact-69530C8A18485050B373ADC68F2B0E32" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-EB3D286995D75C2DB984870778CA8AA5-2"><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="TextSelection-7895875F99C25265A5D86641D476A5AE-0-wk-Fact-CE51A9FD39895C068474F877BBBB8F0B" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4600-wk-Fact-622EFBB39F1B5BDE853CEC1E2991CB1B" name="biib:ShareOfCoPromotionProfits" contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e4619-wk-Fact-DE08577F1C1C5ADA8B63DFD45DC6CB43" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">390.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4639-wk-Fact-A26ECDD7197F5337BD4852A2CAEC983A" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">179.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e4658-wk-Fact-1939D35029C15C47B4E619BA8981454B" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4688-wk-Fact-5C1B4A3E5E705C3DBAAB3B3D2CBBDB7F" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">520.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e4707-wk-Fact-C51A11646BE4542D85918CCC5A2C7AE2" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">517.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:OtherrevenuesTableTextBlock" id="TextSelection-F2D37D2DAC6956CBA7FD4C03A3929076-0-wk-Fact-892C0411B8D75BD8AFFC7D3E11965127" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4912-wk-Fact-42AF16F1B0995CEDB28E59BEAE5E1879" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e4931-wk-Fact-8E82EA88AD305A7B9E79FD695E6A883E" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e4951-wk-Fact-769DD060BF45CA98143FA4841C20CF20" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6304303e4970-wk-Fact-E7EEBB06A35FA5B6605CA48420D90117" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e5042-wk-Fact-F10EB460835358F6B4FAC3D437EDEDB2" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e5061-wk-Fact-AA8E658EE74156359E809D5D7A82677D" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e5086-wk-Fact-18049EC6E92C51BFA4C27ED406150074" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e5105-wk-Fact-7EC3CC34C2A1510B80AE1B725F3426AB" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">264.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304303e5135-wk-Fact-49E487F43286591DAFFC57ED16F39618" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304303e5154-wk-Fact-8A0940D374CF51D083D84F7631628605" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">292.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6304303e5177-wk-Fact-08E50019229A51219701931BE914D1A6" name="us-gaap:Revenues" contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">206.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we license certain of our manufacturing-related intellectual property to the customer. We are eligible to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6304303e5184-wk-Fact-BD7DDEB499A15D7BB0048E05754122E6" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in a series of three payments. The first payment is due upon a regulatory achievement related to the customer&#8217;s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.</span></div></ix:continuation><div><a id="s0B8B0FE75802563C914EF05E385DB519"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-676477A1A8DB57CF97BB50E99373E8D4-0-wk-Fact-4013F2229D345ED3912413480E6138F8" continuedAt="TextSelection-676477A1A8DB57CF97BB50E99373E8D4-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</span></div></ix:nonNumeric></td></tr></table><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-92C91D5AE26154789933330A324051C8-0-wk-Fact-A7D82601EDA254F3863B470109B62EBC" escape="true"><ix:continuation id="TextSelection-676477A1A8DB57CF97BB50E99373E8D4-1"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304686e857-wk-Fact-C143F958434656DDB8D80DC100E8B4CF" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304686e876-wk-Fact-0665F2D70D9C5B53B6D976984DC235A8" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">169.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304686e896-wk-Fact-9584344E12CA5EF29774F4B4C75A544F" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">475.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304686e915-wk-Fact-E204ACAAE47D5EAEB0C2C86F999B5FF2" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">460.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304686e940-wk-Fact-6133615B0E625300A4EC5983263E44BD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">172.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304686e959-wk-Fact-333CA897E01C54D88B8F5503CFCCD582" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6304686e989-wk-Fact-9685F4EEBEED595F81747BF356685BDD" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">858.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6304686e1008-wk-Fact-D87FD10CDF3F5AD1B31DE4EBD429A21E" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="s68210114AA085D22A8B577E9F6ABBDF8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-0-wk-Fact-327C0C1846D7593D817641A803D68626" continuedAt="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-1" continuedAt="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="TextSelection-B1E26FDB7A0454DEA17E7D19D4A4AB58-0-wk-Fact-F3010D28529555598EB1CA5FCE6AECD7" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:13%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1111-wk-Fact-384885E4CA5E5614915BE53C82FBFD48" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,379.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6306201e1130-wk-Fact-06B1CADA5C545DADA7BC54039C387CCE" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1151-wk-Fact-7CA02D290BDD5BCE95D2AF3448976FAC" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,426.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1170-wk-Fact-4DF25675EF5457B2B28B43F05E8A6446" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,379.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6306201e1189-wk-Fact-214E91B6C60A5C9CAEEBA73DDFFA740D" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,881.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1210-wk-Fact-6B6C85264A265899B13137D406A41E30" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,497.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1235-wk-Fact-9CA98E3199035460A51202DC2B91AD89" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">956.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1254-wk-Fact-FE779E823A4D55E69952F704B99D5FB6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1274-wk-Fact-9CA98E3199035460A51202DC2B91AD89" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">956.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1293-wk-Fact-9E646CAE64E45A5CB62556DC59BFF61A" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">965.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1312-wk-Fact-6FF6B36A10195F5F81602A7DE230826E" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1332-wk-Fact-9E646CAE64E45A5CB62556DC59BFF61A" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">965.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1365-wk-Fact-4EA26653D9F95A1284A3B044C20731EB" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1384-wk-Fact-6FFAECA6B9AD56199BBDB1C364674240" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1404-wk-Fact-4EA26653D9F95A1284A3B044C20731EB" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1423-wk-Fact-0D01D2578D255C14B4BF98233C18300B" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1442-wk-Fact-747771D0C5F35EF5A4EED17A0491FABC" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1462-wk-Fact-0D01D2578D255C14B4BF98233C18300B" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1497-wk-Fact-B3A7481E4282582092798A45726216CC" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,399.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6306201e1516-wk-Fact-A6646BAEE7F251C98B0F12B1CE428D89" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1537-wk-Fact-AD1C5EB68CF65DC3984A7409445F526B" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,446.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1556-wk-Fact-C9FDEBD5212F51F3B83BA35AECC81364" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6306201e1575-wk-Fact-4A782876278A5D59A2D65A565546107C" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,881.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e1596-wk-Fact-82009BD2AC26575E958204C37D75B0DB" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,527.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6306201e1624-wk-Fact-13DF614395235DA29BFA4FB1CE46B0EA" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6306201e1628-wk-Fact-D01715617B805CDF8467FFF75B1E78EB" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no impairment charges.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Completed Technology</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6306201e1655-wk-Fact-17E95872B4825281983A626C231AEF18" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Completed technology also includes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6306201e1659-wk-Fact-59F129C14F1C50E7ADC65F1AB766BA97" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">154.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D Related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6306201e1673-wk-Fact-897E6E0751DE5F48943183B3EB308A83" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of&#160;trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The TGN program has experienced numerous delays in development in the periods since we acquired the program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain indication, for which we also have an IPR&amp;D asset. Data from that trial is expected in mid-2020. This data may affect the economic value of vixotrigine </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-2" continuedAt="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-3"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and the IPR&amp;D assets for one or both programs could be&#160;impaired if assumptions used in determining their fair value change. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value associated with our vixotrigine IPR&amp;D assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6306201e1701-wk-Fact-26EFDDEED3886F349918A38E7C9B27C6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q1_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">161.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-248AB122BE845D8FAF734A20162F81AF-0-wk-Fact-E210E843BF005897B0EC6090F287B6A0" continuedAt="TextSelection-248AB122BE845D8FAF734A20162F81AF-1" escape="true">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-248AB122BE845D8FAF734A20162F81AF-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020 (remaining nine months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1787-wk-Fact-7001314163F55C92829F7DEF7AEE3833" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">193.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1807-wk-Fact-98CD7EDD59FF57DE971B59AEFC96E123" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1832-wk-Fact-E8CD205B8A3550B595EAFF119DFC63AE" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1857-wk-Fact-321B57684F045DE1AEE03BE15B7E1836" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1882-wk-Fact-EA59BD3686535CA79300975AD9D7DC04" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e1907-wk-Fact-683B34CCA9D45E988531355298A84F6F" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-F9DE9C6598635023BD69A87FA1C4782D-0-wk-Fact-7CE590ECDA165B24962EB547511C8722" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e2001-wk-Fact-A6A4D09C94CD5944861219FC074EF1A3" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,757.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6306201e2021-wk-Fact-8757DC23C58E59588930453297262B96" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6306201e2052-wk-Fact-5680A01230085EC6BEF71F889D7F44A5" name="us-gaap:Goodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,752.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><ix:continuation id="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-3" continuedAt="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-4"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6306201e2075-wk-Fact-38C8E238412C5CEB91379D3965C22977" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="FI2020Q1" unitRef="usd" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-4"> accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="s13FEB7F3F0E25369B6B8386718D8E157"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-B19DA2CAC460595A810C502CEC498247-0-wk-Fact-E39A65EB9F2E51579F700086DBA1F97B" continuedAt="TextSelection-B19DA2CAC460595A810C502CEC498247-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-B19DA2CAC460595A810C502CEC498247-1" continuedAt="TextSelection-B19DA2CAC460595A810C502CEC498247-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-2443DE88817A51A2BD7E87DD382A8599-0-wk-Fact-1274DCD8745152CC86881B61B0C1982C" escape="true"><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1018-wk-Fact-B378B551E520590AB09C3C12B9D67A84" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,974.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1037-wk-Fact-CB21E29706F55CFBB75EDA01B21AF2EF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1057-wk-Fact-6D4B9176D6F854659F64A053CF81B573" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,974.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1076-wk-Fact-AB41C03848115A0E918B7602F839ABA6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1183-wk-Fact-9EBE2F28FAA3552297BBFC18F1AA85E5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,353.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1202-wk-Fact-0FD38268214D5570A67D013F97429FB4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1221-wk-Fact-8EAAA37BE6A85C0BB830F01B490FC060" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,353.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1241-wk-Fact-E1AB79FE11A3594EA25980F0434830BC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1266-wk-Fact-DF7B3A730A3558A89D73985B4C36A030" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">710.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1285-wk-Fact-390412DD960956DBA8D95A40D253E187" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1304-wk-Fact-00CBDC438DCA547C89D27059490A5B28" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">710.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1324-wk-Fact-B8A0773AB0515FF2981B0747BF472FF1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1349-wk-Fact-6AD4605A9D82540A99B539BEFBFF05F5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1368-wk-Fact-79D7AC2999B5575F8F04B696AF1D1254" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1387-wk-Fact-19810BF0D4FD58CD97691E2B404F4963" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1407-wk-Fact-3CB5E9514CE05EC9AD9CDB8BC4B275B6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1432-wk-Fact-2D73AEFDCE1F5F98BB6455E41940C380" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">276.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1451-wk-Fact-37D9D6F03D0253FF8CF2DE7C06125969" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">276.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1470-wk-Fact-4BA70F6578CD57E48B866BE179AAFAB8" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1490-wk-Fact-8072550106E55CC0AFD306D766B6C116" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1515-wk-Fact-EFF3BDCADDBB52A7B55151C2A74D07B8" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1534-wk-Fact-5C423490826150E28458686F3016995E" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1553-wk-Fact-889E49FE89F45BC4A19AF2CBC7A70615" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1573-wk-Fact-07B4F8372C7F54ADA9AAF64F82FD3DCC" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1598-wk-Fact-FA68D0EB12DD54FFBE5F3CDEDFDCD06C" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1617-wk-Fact-1ACA410E8FD65AEFBDC3CE6C1496E728" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1636-wk-Fact-F47A25A5DB775889BC2E611919C3569C" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1656-wk-Fact-48845CF292525429AA0E035B9D9FB911" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1686-wk-Fact-C29873DD372C5514B1259FE7EE286C12" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,620.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1705-wk-Fact-C78D01BD24F256889488145C7804F35D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">276.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1725-wk-Fact-D9F6483C245A5549BF6D8691E1BC684E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,344.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1744-wk-Fact-75ADAC2E201C58F8BD075E04A0BFB3FA" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1857-wk-Fact-C4C23214E30D55F5B8402E42E6EF0842" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1876-wk-Fact-6EDE006FA19F5958AB9BC13D61CF7AFF" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1896-wk-Fact-A80D5AEA32915B068AF804A00B8CAE42" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1915-wk-Fact-5B26B75A3BBA5AD1994269ACFE5B3F38" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1935-wk-Fact-A241D77DA43757859E88B218D8DF4959" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1954-wk-Fact-C525E159E57657CF97E2BAFC8F675B4C" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1973-wk-Fact-6B2FCAA31E1154AFAD023CDFB91FE6F9" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e1993-wk-Fact-C0638850EB625735B55771C08E04066C" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e2023-wk-Fact-EB0E533AB48654E39CF13983AA19BB8D" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">345.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e2042-wk-Fact-AFF3AEC3CA515284BD696157FF53C372" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e2062-wk-Fact-E5BC5895F92E517C9787C3E08DDE9A57" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e2081-wk-Fact-F3CBC51F07A55067A576C2C60BD7DF3B" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2332-wk-Fact-B75FE33AC3135BB188DF2E822AF3CFE0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2351-wk-Fact-495016F666A1583D87BCB2F3D4AD4D00" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2371-wk-Fact-326C8C894DA857D3AFC5CDC6696025EA" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2390-wk-Fact-7E7267968FEA5BBC9284CFE1C8B5C80B" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2497-wk-Fact-CFEBE65D90025361A0815511C0DB2C34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,695.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2516-wk-Fact-8EE318626B6E506C81B7F7661605AE14" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2535-wk-Fact-3DD26F31363158CAAFD7E9D62D3C0893" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,695.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2555-wk-Fact-DDA31A00BC445128B2F5F3FEF273B92B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2580-wk-Fact-AE5267ECFCE25B9C99C822568A097BD7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,013.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2599-wk-Fact-B75D098624005C0DBD1FCC21254DA38B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2618-wk-Fact-3EB90575FE065F7284249EEA33047ABA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,013.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2638-wk-Fact-7FE4718887F559C68A6A9D8128741D8C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2663-wk-Fact-D8B3286A32425DB5B1572FD4DF27692D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2682-wk-Fact-779DBBD9B8FC59FEB60F66CD257A8EA9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2701-wk-Fact-20982C0B82DC5F61AF397F6BF8DA89AB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2721-wk-Fact-75E93F13566557298DF019946856E777" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2746-wk-Fact-F5C0D294C3A059ED908CF3CEA386A2A8" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2765-wk-Fact-BD26AC5117985F238DB14704E2CCA0DC" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2784-wk-Fact-A7FAE436542A541D860B325A3E7A7019" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">329.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2804-wk-Fact-FA5C6A5CF4735CAC8E41883231D962EF" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2829-wk-Fact-C031AD532CC85ACA98D96627EF97040A" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2848-wk-Fact-8EED231159515722B140192BD5CDDC86" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2867-wk-Fact-50AA0B03BF1A50C3AF7D99A412E5F030" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2887-wk-Fact-3B953F75E1D85AAA8E1AD772D5D3FD2F" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2912-wk-Fact-8C57280BF8CF53B884A875E0D653B3F5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2931-wk-Fact-EF2BB8B573F459DC85C2340A6CD46159" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2950-wk-Fact-010B2B3F47475461BA3DB3E7D4A4A122" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e2970-wk-Fact-2961B70F407A593BA1216DEBB77E48CB" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3000-wk-Fact-26DBCE37A7C15628864754084B6CCDFE" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,920.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3019-wk-Fact-E7FC502F5F99548A934012C0D08453A3" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3039-wk-Fact-14CC5894943D50D8A156E519922F64D7" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,912.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3058-wk-Fact-0D8ED8424EEF50D38BABDFAED0C6E7DD" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3171-wk-Fact-803038251E2F53DA8B4D781DFB1E463F" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3190-wk-Fact-2FB97746513E53708282A0A6490BDAEA" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3210-wk-Fact-C8D91EAADDEC548CB1992F6E067EAAA1" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3229-wk-Fact-919E6C5E5CBE576B998196D35F8F1DDA" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3249-wk-Fact-C50B6687D5F9558389CCCA3B381F48D2" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3268-wk-Fact-134EC611D85554C08F1A7CFDE01628CE" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3287-wk-Fact-C8764DED37D2510A9BE1E6A4C064E5EE" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3307-wk-Fact-DB8EDDADF35A5B1F8AEE066F6FF56189" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3337-wk-Fact-28C0DA8234575CC8A4473CB15AFDECF8" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">354.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3356-wk-Fact-88703E6814F9564DA8DF8361ABB27942" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3376-wk-Fact-8785C6EC51D95F868A976532B631AEF9" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3395-wk-Fact-049EEDD4B009535D943E603710DA34C8" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3415-wk-Fact-0A9601487976558EAE7B7910BBE41A2E" name="us-gaap:AssetImpairmentCharges" contextRef="FD2020Q1YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3427-wk-Fact-655F5DABF4145102817289E7009F5008" name="us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" contextRef="FD2020Q1YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. Our investments in equity securities include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares in Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-B19DA2CAC460595A810C502CEC498247-2" continuedAt="TextSelection-B19DA2CAC460595A810C502CEC498247-3"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:18%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:30%;"></td><td style="width:13%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable Input</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted Average</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligation</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>$<ix:nonFraction id="d6310551e3547-wk-Fact-A241D77DA43757859E88B218D8DF4959" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.5</ix:nonFraction></span></span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounted cash flow</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.40% to 2.53%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d6310551e3567-wk-Fact-DA15728FF32FE50F8738A39ED4488E80" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.44</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Timing of achievement of development milestones</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 to 2027</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from the low-teens to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="TextSelection-1072D17FD3CF5B2B86FC27119C7D66FD-0-wk-Fact-1D42CE31024854A191840A0EDD97DBCD" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e3851-wk-Fact-2C8E4509F9D754D7882694FD8C9774E7" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,498.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e3870-wk-Fact-06D331B8AF6E5EABBD68C112BF64113B" name="us-gaap:NotesPayable" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,501.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3890-wk-Fact-5A348BECC1BF5CA1ABC7DDF5AA3C03CF" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,509.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3909-wk-Fact-1AAB4A7855C05D6982CC667163BB4CFD" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e3929-wk-Fact-F984C8ED9C245D8BA9004864E1E4A196" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,022.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e3948-wk-Fact-94F4E7D8CC335C6793C171ECC859C385" name="us-gaap:NotesPayable" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">996.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3967-wk-Fact-9E389335BA71585AB0660C8FEFAE971D" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,038.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e3987-wk-Fact-4552C1B4936B538F9D1A7733FC089AAB" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">996.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4012-wk-Fact-2224250EEBF157DF92A9486E06B3C013" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,838.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4031-wk-Fact-7E728E0FAA6D5772AF81AC391FF01FE7" name="us-gaap:NotesPayable" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,739.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4050-wk-Fact-77CB852ECDA454BF8C90CAE7D1A9BCC5" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,897.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4070-wk-Fact-F8718553C46A557988E9B18EB903997D" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,739.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4095-wk-Fact-0112504A383650E293A8AC105042FB27" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,323.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4114-wk-Fact-A11FC8A8B2095528805B9BBE21748136" name="us-gaap:NotesPayable" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,723.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4133-wk-Fact-F976206955165000AB7B3A0470550677" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,107.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4153-wk-Fact-EB38D65108655C1E9C6B7C197259EFDA" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4183-wk-Fact-E2AB1040AA655C4088C248BD92C7C6C6" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,681.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4202-wk-Fact-8173EF9D28965CE5A58B6A5AC097E6A6" name="us-gaap:NotesPayable" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,961.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4222-wk-Fact-5E669EB166C5593FB4F67A8AB702B4A5" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,553.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4241-wk-Fact-A135B64548EA5D9986E92BBAC1EA1EB6" name="us-gaap:NotesPayable" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,954.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-F495BF14A8785FFF9049AF4E0272A976-0-wk-Fact-D8BD0F2288915206AB6D54A520142381" continuedAt="TextSelection-F495BF14A8785FFF9049AF4E0272A976-1" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F495BF14A8785FFF9049AF4E0272A976-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4411-wk-Fact-4489BAD8B5D452909EFC914606996B04" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4430-wk-Fact-0612B0E40CDC5A2893FD7E79C66873B0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6310551e4450-wk-Fact-30C421DF9F73516DA7CC5CB1364D68F6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4470-wk-Fact-C6C1AC30CB4E5EB1972C8B88035C202E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4495-wk-Fact-6F6BE75ED9C55E31A3AA80CFCFF8519B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4514-wk-Fact-55BF164BBD9C5E3099D934A584534AAC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6310551e4544-wk-Fact-A241D77DA43757859E88B218D8DF4959" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6310551e4563-wk-Fact-081BA42E46A7557EB1239CECE4D9420D" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6310551e4591-wk-Fact-34867ABFFD835ECF9406F187AC3D73A7" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">194.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6310551e4595-wk-Fact-4C3BC3AD245A5F7FADC91FACAA658454" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities and changes in the expected timing of the achievement of certain remaining developmental milestones, partially offset by the passage of time.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-B19DA2CAC460595A810C502CEC498247-3"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the expected timing of the achievement of certain remaining development milestones, changes in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div></ix:continuation><div><a id="sD0447EA5BF9F58E49F30E14F51B3027D"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="TextSelection-7B39885F71965F39AD8039949C0FD0A3-0-wk-Fact-F7CE7F76FD8A5EC0815C310FCA2A9E2E" continuedAt="TextSelection-7B39885F71965F39AD8039949C0FD0A3-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-7B39885F71965F39AD8039949C0FD0A3-1" continuedAt="TextSelection-7B39885F71965F39AD8039949C0FD0A3-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-968CB8EFDA625A3199FB4EA5A8D6A4A3-0-wk-Fact-09DAB671C23059CE9CFF99AC3AAB956A" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e854-wk-Fact-90779FD80DC956A1B7E94EDB24B514E4" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e873-wk-Fact-4698CB48202959D3984A31EE9F0AD458" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">384.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e893-wk-Fact-8D3D44754A275E42AC1A8B8A118EF313" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e912-wk-Fact-C70E6EA12D8D5DE8BB7701E461E8E156" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">368.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e937-wk-Fact-4CC5F300C041517AA4FCA679DE58DB33" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,705.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e956-wk-Fact-02653CCF02B75F0DBF0B025F7CE23C08" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,628.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e981-wk-Fact-93211B12CBA65D65A844A0413C41174D" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e1000-wk-Fact-544B874E05695356B947557AA6745EDA" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1030-wk-Fact-1161B09C0B2C59A29DA7636421777FC6" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,974.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e1049-wk-Fact-6BD0C3B3316455F0A4B8C05D8591A5F7" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="TextSelection-F86E11ED9F025A0BBE80CA18F5FACFEE-0-wk-Fact-90B6AED21D19593B88CB9AE85FAF93A4" continuedAt="TextSelection-F86E11ED9F025A0BBE80CA18F5FACFEE-1" escape="true">The following tables summarize our marketable debt and equity securities:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F86E11ED9F025A0BBE80CA18F5FACFEE-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1311-wk-Fact-26166A446C3557C69977D7B9CA9F9735" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">923.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1330-wk-Fact-1A89D61BE98E5F0CA8273775423B8205" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6314374e1350-wk-Fact-E2A6C569EB5C5D8F89429DE8DB155741" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1370-wk-Fact-BC88FE2F5F1A509DA39F1453D6B0DF2E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">921.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1390-wk-Fact-147E1FE5A80352B290352107C41B88D3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">442.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1409-wk-Fact-DD82A2756A425C2B84E0EB7053C92AC6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6314374e1428-wk-Fact-881F7EC1406E57ED848A567A1868A53B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1449-wk-Fact-ADBCF16C33BD5A50B809A7567CA133B5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">431.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1561-wk-Fact-31D6FB0334085581AB08514E118DC486" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">343.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1580-wk-Fact-4EC50D9953265108966DD877EA23A2CE" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1599-wk-Fact-9FC1E4491BE05D65BE9BA1B512CD210C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1619-wk-Fact-F18FEF803DDC56D78DE59068D9882ADA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1644-wk-Fact-69A6501817F95E5B9F9556E9668A886B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">361.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1663-wk-Fact-602A7BC36C475CBB986C45BB312BC3E4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6314374e1682-wk-Fact-33539C12010053FEA3A746F1EF5B26D5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1703-wk-Fact-45337A187BD85F1091121DAC679E7024" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">363.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1815-wk-Fact-2378BD0126965140941C7D1CA317D1B0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1834-wk-Fact-3DBD3AA7871D5DBDBBB0B0C6AC5FDDBD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1853-wk-Fact-FAE38AE4FF9355C88F266475C7C02144" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1873-wk-Fact-62CCC0A5D94153F1933BD3CC9222E857" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1898-wk-Fact-6AC30353AB29528AAFCCA5E17A5C7D1A" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">175.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1917-wk-Fact-9FED9A85C92650059930C77D7E9D4A8F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6314374e1936-wk-Fact-ECFB75F6C8EC52B48C86EBA84D757778" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1957-wk-Fact-9743686D2354570784F360067086785A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e1987-wk-Fact-318A1EACE088579DB2AA45D1147E6B6C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,247.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e2006-wk-Fact-95BB8CA12997549183CA1858F9BCA49F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6314374e2026-wk-Fact-5B0EB04DBD3F5E5D908D233DD135DA72" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e2046-wk-Fact-621B2D3A45C7509695C0040C13C9EA59" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,238.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e2072-wk-Fact-5189413FF5B957799469DE75E997BA2E" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">286.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e2091-wk-Fact-4E8D893532F35C56AF44BB941B201FF4" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6314374e2111-wk-Fact-4876887F3A345618B999B40BF9491EB0" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e2131-wk-Fact-F8362495911254FD8AD6306527F0D316" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">276.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2373-wk-Fact-F461CF1EC0725B02A28F37DD9878D766" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,057.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2392-wk-Fact-4E10D956847057FC94DAAB5BA789D002" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2412-wk-Fact-09BF3890B70C5423AF159B9CA991D202" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2431-wk-Fact-41A0265B849B5815988A6405DAD9CBD0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,058.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2451-wk-Fact-B180695013AA5C66B6281B05E5E5C13E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">633.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2470-wk-Fact-A9B3EA9BC12152BDA67DCD5F53DB03E4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2489-wk-Fact-C040EAD0C8D05D5182F6396DED261086" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2509-wk-Fact-A16B70EA78445EB3B7CFE8BC2F8D5CAE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">636.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2621-wk-Fact-F2FB0DC610F7552C8E0B480AB83FACCC" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">502.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2640-wk-Fact-B912A7350387563695A5D6E0E8B0AC90" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2659-wk-Fact-5B23808C3D7958ACBCC2BD2C96067654" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2679-wk-Fact-268F8B3DF1125AD2AE2F29E596C225F8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">503.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2704-wk-Fact-EE7FA375114550879EF4AC80E44F0C44" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2723-wk-Fact-76117572611954C28ED92395F450AD3E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6314374e2742-wk-Fact-A6FD0B82288A5A579159F85E2425CD97" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2763-wk-Fact-4287784BACD2552B9ABFD30515EF4171" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2875-wk-Fact-8C669AA726555E2C8081C1ABD1D286B1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2894-wk-Fact-5BDF942A29825AED8C9DEC9F42D98710" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2913-wk-Fact-14306C9C1495553B8DFC06F58171C36C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2933-wk-Fact-22AF37A7C3105C73B0522A4E979916F7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2958-wk-Fact-75D35BD801595C18B4C024D52FEC35BD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e2977-wk-Fact-6CCD04B7A6A95CB2A7853CD3A59BE7A7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6314374e2996-wk-Fact-CF6118A4E9375819A26E686A30BABD78" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3017-wk-Fact-336E949792F458E480707B15A467FCA2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3047-wk-Fact-36A47D9DE5B15B54B624548697E75B5F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,965.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3066-wk-Fact-14B29001654C51E2BA5FC62A41A0E282" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6314374e3086-wk-Fact-A0078BC94CB256CB80C7995DBF550286" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3106-wk-Fact-DED572DF46F352598852164663BF4491" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,970.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3132-wk-Fact-0E1E937AB90E512F8053B3202744E191" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3151-wk-Fact-6F6986382C0C57D8812711B12FC9F40C" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6314374e3171-wk-Fact-F57DA4A2E85C5296AA750E910308C574" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3191-wk-Fact-6271C274F9375EE99CAA4BEF3D38EC9B" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7B39885F71965F39AD8039949C0FD0A3-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-D4A772DF1DDE51D896F04B169A6080A0-0-wk-Fact-3AE6EF01923553E1B0C66F40C76085B9" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3452-wk-Fact-DEC0587CA2797883E8F4A3A112A2190F" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,269.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3471-wk-Fact-DC82951C5BB9364D2222A3A111F3E19E" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,267.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3491-wk-Fact-897E1F9309289B4185DAA3A112044E25" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,562.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3510-wk-Fact-31699CB0898ACF04D0B0A3A11240E7DE" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,560.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3530-wk-Fact-E21A55433BA97FDA82C7A3A112561093" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">846.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3549-wk-Fact-08783233BFB73FFF64F4A3A111D82379" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">856.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3568-wk-Fact-BDBA6A0B064E0BD8D40EA3A1121A532A" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,234.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3588-wk-Fact-17DC8C4F4F3F29438D21A3A1128D380E" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,230.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3613-wk-Fact-AEF2EFFCF42C242DD13CA3A1127C54D1" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">123.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3632-wk-Fact-4DCA39D358E321B7A8CBA3A1122B3E01" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">123.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3651-wk-Fact-80A52832F02271ABF35AA3A112B87894" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3671-wk-Fact-EDB1C9314914F3CF0A8FA3A11267C7A1" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3701-wk-Fact-A74379C1995A5B898D34690C1557D5B9" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,238.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3720-wk-Fact-318A1EACE088579DB2AA45D1147E6B6C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,247.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3740-wk-Fact-BED8FE9EA4515EA88A825A2E4DF0B086" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,970.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3759-wk-Fact-36A47D9DE5B15B54B624548697E75B5F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,965.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-79786588E9EB538FA9C48EFFE1E41BFE-0-wk-Fact-B2EEB5176ECD56D7B8A28214EBB6F6ED" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3933-wk-Fact-B2C977AFB43A5B6D846E35244FB2DF92" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,389.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3952-wk-Fact-A4A4FD4E66E65DF4BA4CD8A5C026A640" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,489.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6314374e3972-wk-Fact-DE0B565F5F5F50A8A70B4DADF3D75C94" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6314374e3991-wk-Fact-1B3485D6552458B2B5C2E9ED5337F73B" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6314374e4021-wk-Fact-DD96080551285E5DBE94EADB1B511654" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6314374e4041-wk-Fact-EFCBD32CDFFA58249F2CA392F3DF4A72" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6314374e4073-wk-Fact-B587018CF03B573DA5DB556F39954893" name="biib:StrategicInvestmentPortfolio" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">331.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6314374e4077-wk-Fact-95FAFA5D3D0B5E67B5EA9EE1798B6142" name="biib:StrategicInvestmentPortfolio" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">393.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to a decrease in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></ix:continuation><div><a id="sF8106FBC0DA0504FA6DF4C469EA5F474"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-0-wk-Fact-8C6D55FF421D5038974B41E612BD08BB" continuedAt="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-1" continuedAt="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-2" continuedAt="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-3"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="TextSelection-185A80745CB35C60835BBE8EE4E192DC-0-wk-Fact-86F27B28B2CB522184DD9E4BF48E645E" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e930-wk-Fact-6F91BF77D77555BE9CCE263ACEAE9BAE" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,116.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e949-wk-Fact-21C9F61F9D1259A08D6A2110076461F6" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,892.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e969-wk-Fact-BDCC36223FC35ECAA89E7DB78E36CF7E" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">186.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e988-wk-Fact-00C308CDDAD252D480FCE24C5EABC890" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e1013-wk-Fact-E1F41A57B81B59F680BE9F86FC3180DA" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1032-wk-Fact-647B713E25A557648CBA00B9E134CFDE" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e1057-wk-Fact-45DAC7153DDE5DFF904FCF64DBF0850B" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1076-wk-Fact-795A06A086DE528C8E200A423933A77C" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e1101-wk-Fact-E1D5AD986B915A4E98EA3E3124B2EC8A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1120-wk-Fact-D2B8359577185F9986C9E15A5C2EC0CB" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e1150-wk-Fact-E225BEA61E4450909AB665BA42AB0D21" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,559.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1169-wk-Fact-E81D1FF1A9B45BE281D0BC8822D684FA" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,892.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1189-wk-Fact-FFBF6DFD9BF9530A8DEDD866EFCE9E96" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">34.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1193-wk-Fact-920EA00334B15A6D9BDF2ECA985EE484" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1205-wk-Fact-FFBF6DFD9BF9530A8DEDD866EFCE9E96" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">34.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1214-wk-Fact-4D51F4B528E7526D84E423A88757792F" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2020Q1_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-2EAF79C70F125D09B26F6E43A454E586-0-wk-Fact-F37BC3C08C115805BB60233932B5B928" continuedAt="TextSelection-2EAF79C70F125D09B26F6E43A454E586-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e1585-wk-Fact-F9061C4D01A352FCB2B239507D35ED21" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1604-wk-Fact-A337263C3AFD57F78551E5862C956967" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e1634-wk-Fact-E49FDB41CC8E56BFB6E105B8A22BE62F" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1653-wk-Fact-5E5599F02E2F522C9C5E128F571DBDF1" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6317282e1678-wk-Fact-7A467B615E21565EAF9D54AA37F7BE2E" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6317282e1698-wk-Fact-0C3DC9FB30EF55E09DF09DD49ABBE524" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6317282e1729-wk-Fact-ACD99908AD4E57CE8037D1D7970F86F1" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6317282e1749-wk-Fact-B8A507AEEC5D5738AE2095A7BF8DAEE7" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-2EAF79C70F125D09B26F6E43A454E586-1"></ix:continuation>Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Interest Rate Swap Contracts</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1777-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1781-wk-Fact-2B76C94FFF6750199B37D2D0ED2EB644" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">675.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1785-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1789-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1798-wk-Fact-A36E5578901CC5E3BF4EA3B09DA2BC1E" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1802-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1817-wk-Fact-96BB724CF6885BCAA9AA54D473EF0BFF" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1821-wk-Fact-720567AD23835BBCB3F827AA344F9E49" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-3" continuedAt="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-4"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e1828-wk-Fact-A6D14020D25E777E54D5A3B220AA218D" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1832-wk-Fact-1BEA17CFCAA7375BED7DA3B377FDCA27" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">seven</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1847-wk-Fact-3A4A79F6EA225C389997305579DC1348" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1851-wk-Fact-5E741C66394EF1159B8BA3B400FBBB4C" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1864-wk-Fact-290391C81EC556A7B1EB024127C17FA1" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e1868-wk-Fact-D9435D5331195B74A16ABB86792871EA" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-3B179FA15228544E86A40254B3F22FB1-0-wk-Fact-55E762C32615523D837D9A555B9C244B" continuedAt="TextSelection-3B179FA15228544E86A40254B3F22FB1-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e2402-wk-Fact-2CAE2082C95A5C13BB7AE03EF045D8E9" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e2421-wk-Fact-56C7AE667D695B559A2F275DC42C91CC" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6317282e2451-wk-Fact-8557E83CB85653FEB148034DB4F81DC6" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e2471-wk-Fact-4085EE046866564DBCD054A9704543D8" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e2501-wk-Fact-D168632F934E5DCBBB94BEB10C05C18F" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e2520-wk-Fact-58F2D72753005A269686196CD6FD3738" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-3B179FA15228544E86A40254B3F22FB1-1"></ix:continuation>For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e2546-wk-Fact-F20F9B3E25B65716B0B317C047F8ECC2" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">698.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e2550-wk-Fact-FFC3C8812FBC515D80BDE3120968F428" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">793.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e2562-wk-Fact-48EEFFE8AB82596DB1EB9335577D6E61" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recorded as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317282e2575-wk-Fact-89EE4DC5858051BEBD01669A2F47C76C" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-5E24B2DCAE695EDFA13134192CD4912A-0-wk-Fact-CF63D5D2A68B53B5BC97DFCD56135A26" escape="true"><ix:continuation id="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-4"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e2756-wk-Fact-2985FA3696F351D1ABF86ED639BDCDB0" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e2775-wk-Fact-C893C4009619535DB6DA8C07648D5ED4" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e2810-wk-Fact-C90DD9BDB9B8509EA306BE6E2173067E" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e2829-wk-Fact-7241EC2614475B6D9E7BC049C8963901" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e2864-wk-Fact-7A8243527BA95A18B5451B9BC9E1961D" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e2883-wk-Fact-EE45F7B2E9EF54D9B447D3CFF37BC5EA" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e2918-wk-Fact-677730435872F5ECDACEA3B676DDA8ED" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e2937-wk-Fact-F3490844FF4C75FF0CB7A3B67D5B50F6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e3084-wk-Fact-A543DDE9BBD584524C64A3B5AA4DF62F" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e3103-wk-Fact-69206C7346BDF5CAD47DA3B5AED6694B" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e3251-wk-Fact-5F9AD274843B0B343F66A3B6C4370E9C" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e3270-wk-Fact-A36E5578901CC5E3BF4EA3B09DA2BC1E" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e3417-wk-Fact-C8877F9C594850C0B0E937B49813C0A5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e3436-wk-Fact-ACCC4A22E0EA56F7AD2B9377C6EC4234" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6317282e3471-wk-Fact-6A8E5E012454564D9656FEBA77EA94A3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6317282e3490-wk-Fact-81B4B7F3A8BD5C4CB7BB063B8DD85F86" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="sD1D01E16C91E5BE6A235CBF2EFA43732"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-3AC0B2C4DC9F5328B7C3563ADAE6941C-0-wk-Fact-55CCDB49C6BE53D992CEB7B312FA5EA0" continuedAt="TextSelection-3AC0B2C4DC9F5328B7C3563ADAE6941C-1" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3AC0B2C4DC9F5328B7C3563ADAE6941C-1"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e762-wk-Fact-FBA31F7508D2540A9A9AE7CB1349448F" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,636.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e766-wk-Fact-5B6E9214726E55A6A0AD8CF1924DEA9A" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,590.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e793-wk-Fact-AF02C0140161592097CC47CD10372279" name="us-gaap:Depreciation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e797-wk-Fact-1A334AF48DDD5A1CBD4A5DA8E293CB14" name="us-gaap:Depreciation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e815-wk-Fact-BE6E6AE5010E51C19471D0C93728D38B" name="us-gaap:ConstructionInProgressGross" contextRef="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e819-wk-Fact-1D0E809E19835E358579DD1E96302D93" name="us-gaap:ConstructionInProgressGross" contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.9</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. In the first quarter of 2020 we placed approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e823-wk-Fact-36593C827AEB38FC41B0A479DBC6CAD6" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">256.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of fixed assets in service related to the facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6317479e832-wk-Fact-FE2B53C1594859869C254C897EEEE131" name="us-gaap:OtherCommitment" contextRef="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div></ix:continuation><div><a id="sA79557DABF585FF4B1CD70A7130D5996"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-0F6C4D5E06655ADAAB19BADD301BF876-0-wk-Fact-09D4B9AACDB95ED0B653726DE40BDF5B" continuedAt="TextSelection-0F6C4D5E06655ADAAB19BADD301BF876-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-0F6C4D5E06655ADAAB19BADD301BF876-1" continuedAt="TextSelection-0F6C4D5E06655ADAAB19BADD301BF876-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6321970e764-wk-Fact-04610C96BFF3BC75DFEBA486BF2C5596" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e768-wk-Fact-0908DFEF6A98BAEA293DA486F91FD376" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6321970e772-wk-Fact-B9DFE833D7383EEB0928A4871860A595" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">941.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6321970e787-wk-Fact-539783922B5A5136A4E1486A469BF123" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (March 2019 Share Repurchase Program), which was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e795-wk-Fact-E77F395F580058B3AAE558E69FDDA5C5" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6321970e799-wk-Fact-8F89326216AA5D7BA2FC348E72E10C1D" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2020 through April 22, 2020, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e815-wk-Fact-43925C0FA6E05735BADEB82C30627693" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2020Q2Apr01-Apr22_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6321970e819-wk-Fact-4ABCDCE139FA5209A3CC8A7489F3BB7C" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D2020Q2Apr01-Apr22_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our December 2019 Share Repurchase Program. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6321970e823-wk-Fact-EEA848FB19FC58D78D30E2644FE9B4CC" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="FI2020Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our December 2019 Share Repurchase Program as of April 22, 2020.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0F6C4D5E06655ADAAB19BADD301BF876-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-A344C47FAAC25AC5A786B3EA2A7B3661-0-wk-Fact-7409F6CF074F52728C7D7F258F086726" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1031-wk-Fact-88B1D414E14359568EE45D7F309C8803" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1050-wk-Fact-C18401FCFBD6573CADA9CB87749C3116" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1070-wk-Fact-82326CBE29DE5E33A1AB7D7B0AC79977" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1089-wk-Fact-89BF0EC097F55C14A560AC276731B286" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1109-wk-Fact-735C1B32969353A8ACBB374F5E2FC9B7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">139.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1130-wk-Fact-ACAB9874DC005EDD9E4AF5B9CE727C30" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1151-wk-Fact-93983BF22D79524DA9E23C56D0E644B1" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">20.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1171-wk-Fact-23599E3663335B06B19FD99AEDD7557D" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1190-wk-Fact-BE8AE7BAFED255CE9B2C4253BD979A89" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1210-wk-Fact-AFA3207883805916A524B23DE757057B" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1229-wk-Fact-9FF6D1FB44335F3D9FC1573C361A6EDF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">63.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1250-wk-Fact-05E0F2DDB2B45FA1A46D663F3A77CAB6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1275-wk-Fact-12A18A5166CA5465A5543A3F08776073" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1294-wk-Fact-85CD3B50F3BD5D50B59D716203EC6D50" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1314-wk-Fact-2F45EDC10A705D03A6F5FD361536D507" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1335-wk-Fact-C16BD88EC6C85CCCBD3FF56A775C45AE" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1354-wk-Fact-41A89E058E825BE5B64F6BBF0E466CED" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1374-wk-Fact-1E33505B3B005104B6C62AD6462F22CE" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1400-wk-Fact-F3F79DEFF2995001B90CFD76F40BB78A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1420-wk-Fact-82BA5FE089DF58C7B21C6B0D51C8B76D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1439-wk-Fact-D743D51606E8500DA07F413094EF3A58" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1459-wk-Fact-EA92606CFB5E5E21BC5B6234FA4930F9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1478-wk-Fact-C3631E44D3F8507781067589A269BC21" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">63.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1499-wk-Fact-5B8C18C3243E5D5AAD152B2A77B3C58D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1530-wk-Fact-5C81F4F92CB65BDB980687272A68D3FF" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1550-wk-Fact-07B925C5DAEC5E128A8ED97C1426AE18" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6321970e1570-wk-Fact-FDA894B1D9A554A6A12A80F561F12F0B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1589-wk-Fact-5FA8CE828DA25F319A206B4DFBD5F0C7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1609-wk-Fact-BF3BE00F579952909C11ECDA64A8A772" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">203.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6321970e1630-wk-Fact-9B13E96C51445E7A8D54697EFDAC6991" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">149.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e1820-wk-Fact-9ABB8C30C78056D1B628EB446BB90E31" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e1840-wk-Fact-B9EBAE6B0F06562E823E81DB45C5B5DA" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e1860-wk-Fact-3705E1CB0B5C5C72927A5C576A46AC10" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e1879-wk-Fact-D22984F3D56C55229157F2C3ADF37E1C" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e1899-wk-Fact-ACD8F3CCCCFD58D0A341D9371469F86A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">243.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e1920-wk-Fact-80FC49EC49215A83A2F5D12F76D61646" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e1941-wk-Fact-B9217F4A56485BA680F30D97F9B83F90" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e1960-wk-Fact-AA7E0F4C03FD593EBD8016DC00F8762E" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e1979-wk-Fact-A9E7E80C7AE759C38364B2E10E29D108" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e1999-wk-Fact-9EE42AA61E775E50842553938CD9AE2F" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2018-wk-Fact-A6BFF2D05BA9504BAB7898BD51794AF2" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2039-wk-Fact-63F83752B1D25949B10607B2156346EA" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2064-wk-Fact-F7C32A8432785518BCC2724A37652BE7" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2084-wk-Fact-710F6A0AD3FA5BB2B0FB8DA6C996EAEF" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2104-wk-Fact-D7C76A1D104456BBB4709E2ACEB9EA9C" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2125-wk-Fact-197E8ED996FE57D492A40E223D86FC8A" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2144-wk-Fact-7D2A41ED2B0455AA876284B6323450C5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2164-wk-Fact-ACB08EA7ED7F5A15A817C67BCABF7CBF" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2190-wk-Fact-D21218962F3A571281FA8F1E273D8274" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2209-wk-Fact-A7394281D3EF504C8A16D29AD2E22CBB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2228-wk-Fact-F841975CE7865FC8B5C88E02C3C45D56" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2248-wk-Fact-A1BDF68EBCD65A48A43C863359B54EF2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2267-wk-Fact-4BAEDB36C2295F408A36D78904D73FB1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2288-wk-Fact-49C6AFCCB21C5CB19609F8B635C4A0F1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2318-wk-Fact-802A8D58905156AD984688472D6F0D79" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2337-wk-Fact-221D31ABA08F59BB94E10E51199B0800" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2357-wk-Fact-8D0D743B85EC5FDB9BD8270D2E3D9392" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2376-wk-Fact-9B1929F5F3BE5D4A817F4C2EFA704294" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">30.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2396-wk-Fact-BCA468DF086358F2AE90BDD7A85A6B9E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">261.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2417-wk-Fact-B99AFFC109AF5D9EADBDF8FDBC9E2C9C" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">219.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="TextSelection-087787AD788E5193845BA3C531BB364F-0-wk-Fact-A9F97BB9A15754B59DFC3FD352154D0C" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:44%;"></td><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(<ix:nonFraction id="d6321970e2636-wk-Fact-F479886B35765D0D9CDBDCC1C24836AD" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2656-wk-Fact-008F07EB9BC850469612FA1493547539" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d6321970e2681-wk-Fact-6D2B469036CB51D995D93CC78E00422F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2700-wk-Fact-83FB7D1C4EBB55E2A4419804D7AA9790" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d6321970e2782-wk-Fact-95C4123023A1597293155084B0EBF8BC" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2801-wk-Fact-7FA72A4E21D452238E59D5A26E925824" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(<ix:nonFraction id="d6321970e2831-wk-Fact-27350FB11FA55C86AB65822664125EA8" name="us-gaap:OperatingExpenses" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2851-wk-Fact-8CD130E0F09259F99A7FCA4576198747" name="us-gaap:OperatingExpenses" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d6321970e2882-wk-Fact-67DA7C0D85B0500DB664882FBB05562D" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e2901-wk-Fact-090FECE247D75598AC839C1132CC2043" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(<ix:nonFraction id="d6321970e2931-wk-Fact-0D103598D58057A7A2B91841306C91D4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6321970e2951-wk-Fact-F59DBBF765305FABB0F148F16FC3B76E" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d6321970e3034-wk-Fact-23F15B1A079A5931B72598455FEFAAF5" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e3053-wk-Fact-D18DF01E31E3556BB9F1CA2024D0CA88" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d6321970e3139-wk-Fact-A111FA0756FA5EC681930B864EAF88EA" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6321970e3158-wk-Fact-9BDF1893C4C6559B90EA7054D7D73C30" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="s33B630AB0948523E8F17B4F72CCA1048"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-792C7A8A9ACE5F86A97ADDDEB3D11A2C-0-wk-Fact-D3064B88F5B75D488189ED37351511A8" continuedAt="TextSelection-792C7A8A9ACE5F86A97ADDDEB3D11A2C-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-792C7A8A9ACE5F86A97ADDDEB3D11A2C-1"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-2C6C143C24EA56A2B2B672931ADB4EE5-0-wk-Fact-4958AF267CB354B19426ADB4310FA1E7" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319287e948-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,399.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319287e967-wk-Fact-FDA77C2428AF554989EED78CF2C2AEA1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319287e1033-wk-Fact-71CBFF9E20095155A1063474D4C8BA5A" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">172.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319287e1052-wk-Fact-8C58D4EB1D6251F29A5B7EBA8DD1F024" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">196.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319287e1123-wk-Fact-0B81145B9838591294F48B4A2986FEE7" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319287e1142-wk-Fact-EA13AF3E9D285512913BB10D9F30EDAE" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319287e1167-wk-Fact-70C366AF1AB9550DB8D189310F413E0A" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319287e1186-wk-Fact-48351DDD25C458A18B5F85D7A5EC0894" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319287e1211-wk-Fact-42D48AAFAB24552EA96BCC103E6A69EA" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319287e1230-wk-Fact-9986231F3BF750998789B50829D52E50" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319287e1255-wk-Fact-08A6C3F0EE6B5029A93684D05F9FBE0B" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319287e1274-wk-Fact-4E36F9A02D1E59BBA7D215E99795768F" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319287e1300-wk-Fact-413B006A143E53BD99DB85074CA369D8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">173.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319287e1319-wk-Fact-15574C2EB65A522E829F10B43239453D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">197.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:continuation><div><a id="sA3082E05A0CE5F3CAAC00E8B7B3978AA"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-09A15436B89A57DB8C5117D465046393-0-wk-Fact-AA187709E10B52C9A29C1B720C0B7356" continuedAt="TextSelection-09A15436B89A57DB8C5117D465046393-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-09A15436B89A57DB8C5117D465046393-1" continuedAt="TextSelection-09A15436B89A57DB8C5117D465046393-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-D5BAEEE1A990523A8B79BF3D159F7242-0-wk-Fact-EB4A96FCA71C51A895C187695C614FAF" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e889-wk-Fact-319C9005517D53D89FB22D008AFE03E0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e908-wk-Fact-AA60F00A92155C55921B377DE792EE72" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e923-wk-Fact-3E9FF5E93FC85533AFB5147F7EB0A7F6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e942-wk-Fact-1CE7943564E2504BA89D1E6A693B3CB6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e962-wk-Fact-C87943EB873651FBA40FD6630928A3AC" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e981-wk-Fact-B671DCE3ACFE5E019E63E9E2FDC0AD37" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6319284e1001-wk-Fact-B37CC63E45B8582DBE9A428693438297" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6319284e1021-wk-Fact-5FD4D1282D9A5CA0B7F377D6B6CFC3E4" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1042-wk-Fact-D0F1DCC5C6DD582EB75781A615A27F58" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1061-wk-Fact-56EBA1D22F895BCBB8D83E33F6DC3C51" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6319284e1081-wk-Fact-326F30EA38D257EBA29E91816CA0426C" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6319284e1101-wk-Fact-BC5DFECFF3325A05999CD86684F84051" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1127-wk-Fact-DDC3FD376F615E9D938270B8692D9AC9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1146-wk-Fact-52A2ACD0EA2F5B7E86BA9457C00E5BB0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-09A15436B89A57DB8C5117D465046393-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="TextSelection-528F3C04EA2153139EE869D7E02C3676-0-wk-Fact-56060C9934BD58C3ACA2BA154FCA1DAF" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1285-wk-Fact-B7D17B92F19E5168906348078AD1262B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1304-wk-Fact-FA98211DD6735E61BBC836FBD494FA39" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1319-wk-Fact-CED5C19B09995DB38460E20F2C216421" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1338-wk-Fact-3D216D9F4F765CE48F4DF9208F279D54" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6319284e1358-wk-Fact-CC76F5E1281757A983B9DFCE6D880383" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6319284e1378-wk-Fact-2B32211A65065A37A0364D620BC58F0E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6319284e1399-wk-Fact-9754DBC5665B501EBED87B2848283977" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1419-wk-Fact-484C161310D953B4A24BC4D214EEA57E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1439-wk-Fact-5E26E70F2E215725968AA84F26DADEEF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1458-wk-Fact-B4D289206390545C90A2D40057C539B8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1478-wk-Fact-615F5FE6916C5E8E9CDB602474559427" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1497-wk-Fact-640366E39A4E531BA455DD61D29D6401" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1517-wk-Fact-D3E76583F9185F76BC7C68B850B3B3E4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1536-wk-Fact-4D1AFAFB7A7C57889DAD0C41DE54E66E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1556-wk-Fact-C87943EB873651FBA40FD6630928A3AC" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1575-wk-Fact-B671DCE3ACFE5E019E63E9E2FDC0AD37" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6319284e1595-wk-Fact-B37CC63E45B8582DBE9A428693438297" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6319284e1615-wk-Fact-5FD4D1282D9A5CA0B7F377D6B6CFC3E4" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6319284e1642-wk-Fact-D0F1DCC5C6DD582EB75781A615A27F58" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6319284e1661-wk-Fact-56EBA1D22F895BCBB8D83E33F6DC3C51" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><a id="s53D850BBD2C35FCE91E090DF01732066"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-312FB67DE3875094889F5BF2F9137583-0-wk-Fact-BE541C1197815D7797CBDC147BF74264" continuedAt="TextSelection-312FB67DE3875094889F5BF2F9137583-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-312FB67DE3875094889F5BF2F9137583-1" continuedAt="TextSelection-312FB67DE3875094889F5BF2F9137583-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Corporate taxpayers may carryback net operating losses (NOLs) originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, or to our net deferred tax assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-D32434C967C055279AE499AF8BB84F47-0-wk-Fact-D937B1EFC8AB564D84DBAEA0D2CF3A55" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6322626e883-wk-Fact-A4C396BB3B48563791E2584A167E67E4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6322626e898-wk-Fact-4EB173032E4F583D956EB6F637204F0F" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q1QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6322626e914-wk-Fact-427D6ED1F8C558F4B5A9CC461A4F9DA8" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6322626e928-wk-Fact-10470F268CDB541E8E740ACBCA310230" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6322626e943-wk-Fact-B8DEB5F6F0365DA7A95FB1A6319FB081" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6322626e958-wk-Fact-6ADF03D30BE755BD9C64291976E9F110" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6322626e974-wk-Fact-5E651083B8145A64BF530603D1A072CF" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6322626e989-wk-Fact-C48E885EB787539A83116FE629CB2DBB" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6322626e1005-wk-Fact-06973379645C502EBA24876EACA7FD62" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6322626e1019-wk-Fact-0B5511AA6A1B5B3E9DDEC34A377CC56D" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6322626e1034-wk-Fact-ED58258ACBD05F9499CF169A17940F99" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6322626e1048-wk-Fact-3BAE5F1FA9BB531182572B4543B31F67" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q1QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6322626e1063-wk-Fact-105C314D18AA5A18B43517E3083535BA" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6322626e1077-wk-Fact-089DA960578B5CACBF677AA769B72E49" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6322626e1092-wk-Fact-2C988DA881E25FF89AC1F622569BA3B1" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6322626e1106-wk-Fact-F4B64435ACD750D29065043357BDEF47" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6322626e1121-wk-Fact-8FDA53A5CE065E87890A083A42F3F55F" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6322626e1136-wk-Fact-4A94451070785FDCB65B62A57955FCF2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6322626e1153-wk-Fact-8FDDBFE211FD555BB8E1798FD85335C2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">17.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6322626e1168-wk-Fact-DC10E59368F35C648F4130B904812F76" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q1QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">22.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2019, the decrease in our effective tax rate was primarily due to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6322626e1200-wk-Fact-7EA822A4C5DABBB17C3BA4919FC49F83" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense recognized in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations and the tax effects of changes in the value of our equity investments where we recognized a gain in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to a loss in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-312FB67DE3875094889F5BF2F9137583-2"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2020 we became aware of a withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions.&#160;We are evaluating whether the&#160;interpretation of this regulation could apply to our facts and circumstances, and, upon conclusion of our analysis, we may establish a reserve related to this matter during the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;If a reserve is required, we do not expect that the exposure will be material to our results of operations, cash flows or financial position.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6322626e1240-wk-Fact-563E9BAE229DDAD42AD1A4929FEF0F95" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div><a id="s281A9DDFB288539C953C658C2384A14C"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="TextSelection-8E35A1173AFB578598442168A2D2776D-0-wk-Fact-E3689CDA0E1C5A089E2AA393C75EE198" continuedAt="TextSelection-8E35A1173AFB578598442168A2D2776D-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-8E35A1173AFB578598442168A2D2776D-1" continuedAt="TextSelection-8E35A1173AFB578598442168A2D2776D-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-4304AC164C805063B289549A2CBB7EFF-0-wk-Fact-CF69B7A9DA88527D9D426D4E6B9D45C7" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e905-wk-Fact-F11F8A4631035D699B8F4C2474F2ED97" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e924-wk-Fact-8257096515865FE5B5F99BA194B8FCA0" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6323917e944-wk-Fact-51AC853220DB507091111736ED32AB81" name="us-gaap:InterestExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6323917e964-wk-Fact-0880B829DD3059EE87B421FF8CAA6EAC" name="us-gaap:InterestExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6323917e990-wk-Fact-682E6519C869CD502993A49E56998071" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">77.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1010-wk-Fact-7D41C22E1363B43FA1DFA49E6A1C622B" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">376.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6323917e1035-wk-Fact-4B54A42FEB145B18B3087AF552986637" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">18.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6323917e1055-wk-Fact-4D6F5FAD0D3E57F6928FFBC7BBFD1D8F" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6323917e1081-wk-Fact-F11353D3809654709602091280787988" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d6323917e1101-wk-Fact-1008E3FC67C952E5806DC6A301C1DCE7" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6323917e1132-wk-Fact-095EC1AAC9A25CD9B7B7A910B16D60A8" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">120.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1152-wk-Fact-F27571BB0E665301A0F41E41FA9CBCC3" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">357.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6323917e1187-wk-Fact-682E6519C869CD502993A49E56998071" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">77.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6323917e1191-wk-Fact-7D41C22E1363B43FA1DFA49E6A1C622B" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">376.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our holdings in equity and debt securities in the prior year comparative period. The net losses recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects a decrease in the fair value in our investment in Ionis common stock from December 31, 2019. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:GainLossOnInvestmentsTextBlock" id="TextSelection-CC9499E36B04571891C1B39568E69C42-0-wk-Fact-76EDFA7D2C975DA98821E027A037AC87" continuedAt="TextSelection-CC9499E36B04571891C1B39568E69C42-1" escape="true">The following table summarizes our gain (loss) on investments, net, that relates to our equity securities held as of </ix:nonNumeric></span><ix:continuation id="TextSelection-CC9499E36B04571891C1B39568E69C42-1" continuedAt="TextSelection-CC9499E36B04571891C1B39568E69C42-2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></ix:continuation></div><ix:continuation id="TextSelection-CC9499E36B04571891C1B39568E69C42-2"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6323917e1341-wk-Fact-5769D38011605B3DA573AC11D4AAFA3E" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">60.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1361-wk-Fact-79FCBC55ADAC5421945DC2CB390FF69F" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">375.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1381-wk-Fact-6F73BF4466A45309B65AF963448F4469" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1400-wk-Fact-4BDE2DCA0B335699B84B8D881C55C867" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of March 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d6323917e1430-wk-Fact-9136AF64C5195BB1878814864F1D0376" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">60.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1450-wk-Fact-46E7F534783E5BFEB93E0F89E1B9CE7D" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">376.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8E35A1173AFB578598442168A2D2776D-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-B4835236968D576986B8D4E14CF9DA70-0-wk-Fact-C18EC6F00F0D59F78C185F9BD0B21252" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1558-wk-Fact-625419BB27195A409EDB1EB81379D384" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,046.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1577-wk-Fact-787C6E6AC74D5288BFC68E3A0EBA4216" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,001.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1597-wk-Fact-25A4AF8C177250DC9A9B679BDF90E468" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1616-wk-Fact-F4A534EAB6335939B33E7304725A7C55" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1641-wk-Fact-130CCA166A235D2190A61AA751141337" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">209.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1660-wk-Fact-918890B4E32E595399000F4239CA1299" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1685-wk-Fact-C2F14BFE440A53EAA536AC5D47DABB7D" name="biib:Collaborationexpensesaccrual" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">154.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1704-wk-Fact-B5C273AB2D3255CBAA4818A22A84EACF" name="biib:Collaborationexpensesaccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1729-wk-Fact-86A010107361519385D36A3D384FCB2D" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">147.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1748-wk-Fact-F7996E0C67D357D68BD0B42507737679" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1773-wk-Fact-5D46B33C50765824B4E8E4B1F99D19C2" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1792-wk-Fact-7E014DB67B185D9F92682CC9EBD75634" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">78.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1817-wk-Fact-F090786751A4515786ECFAE124FF0A4B" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">662.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1836-wk-Fact-0555D145BAB65771B7A9DC7F50D63D9D" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">726.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6323917e1866-wk-Fact-2E91A66DD1E458A083A3758FECA481A5" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,437.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6323917e1885-wk-Fact-97EC7EE1ECE85247B1145A8455CBCD68" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,765.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6323917e1911-wk-Fact-3979DB5E0C6C5D6D9A9F95E7EF93829D" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,357.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6323917e1915-wk-Fact-13BA7A88BF675D4EA00EE608833C04FB" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,348.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6323917e1927-wk-Fact-7B2013AA28C755E886B74BB70700C2FB" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">801.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6323917e1932-wk-Fact-014A938CB7135118A6A1475ABFBBBA89" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">803.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></ix:continuation><div><a id="sE55B6B631C9D5C96880E9F3E5337F8D7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-0-wk-Fact-7479EBF5CD545CFF992BE62A8C003664" continuedAt="TextSelection-112A0B64756E5F33BE10C6E037DB1828-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-1" continuedAt="TextSelection-112A0B64756E5F33BE10C6E037DB1828-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early AD. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-2" continuedAt="TextSelection-112A0B64756E5F33BE10C6E037DB1828-3"><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="TextSelection-E7368F26D7A85395AB6C205E37F25955-0-wk-Fact-F1C0A9D97E7657C3AB03C3DDE776EF56" escape="true"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">For the Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e870-wk-Fact-8549370DD6F48C6F63AEA4A69D2247FB" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e895-wk-Fact-B1A0D4B3813CE7019166A4A69E9FB1A1" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e920-wk-Fact-E5660D2CA7B07A542F69A4A6DC88D504" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e945-wk-Fact-0BE9FF3D5F9FA6B836C3A4A6DF326263" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total development expense incurred by the two parties related to the BAN2401 and Elenbecestat Collaboration and our share of development expense reflected in research and development expense in our condensed consolidated statements of income were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e964-wk-Fact-AC1398E8656964F493E9A7C278FFEBE6" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BAN2401Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e968-wk-Fact-1DBC9F0C1CF34A16E48FA7C288F81554" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_ElenbecestatCollaborationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e992-wk-Fact-4967267CD22A5532ACCB542F6D21B86F" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1002-wk-Fact-931C8426CDB05B2EA00BF564B9AEDD0C" name="us-gaap:LossOnContractTermination" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1006-wk-Fact-4967267CD22A5532ACCB542F6D21B86F" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="TextSelection-80BD18242B1453C381E81529CA46C2B6-0-wk-Fact-7170E622E59151D18ABA38DCE59CE834" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e1153-wk-Fact-D637275309475B0790AB927977E0AB2D" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1172-wk-Fact-4A1EF4896F1A5D62B1F2B577898AC565" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">162.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e1197-wk-Fact-1EB00702D52A5105BEA741B63651DC92" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1216-wk-Fact-0577D09B876F58979A9229411FE21BA7" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e1241-wk-Fact-25E5EC966FCC5ADCB9A4F2878F0BD458" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1260-wk-Fact-23F69315ECA15E219AB8A5F00C12F402" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d6324929e1285-wk-Fact-62D13F35FD5F5FC2A6999592B9CD20FF" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1304-wk-Fact-C5B2B09B89FD57D5959CEAD40320D0F5" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-3" continuedAt="TextSelection-112A0B64756E5F33BE10C6E037DB1828-4"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">UCB Pharma S.A.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total development expense incurred by the collaboration was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1337-wk-Fact-BA106204D8883D21C6EEA6BD249D5AB4" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our share of the development expense was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1341-wk-Fact-94B1399DBE00EEE18CB3A6BDBFE21EDB" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and was reflected in research and development expense in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, operating expenses related to the collaboration were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2020 we entered into a global licensing collaboration agreement with Sangamo Therapeutics, Inc. (Sangamo), which closed in April 2020, to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in April 2020, we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1370-wk-Fact-63D6FE8C56629C581929A6B4D5714453" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">225.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of Sangamo common stock, or approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1374-wk-Fact-45CDB0D803B49AB9840AA6B7031F7A99" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1378-wk-Fact-4E1BD862B971C7920BECA6B7DC4BC7EF" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.21</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> per share, which are subject to transfer restrictions. During the second quarter of 2020 we plan to record an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1382-wk-Fact-992050CAFADA485F42C6A6B86E0D1F18" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We will also make an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1386-wk-Fact-F1D670F291BEC33872DAA6B8E62BBDA9" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that will be recorded as research and development expense in the second quarter of 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1393-wk-Fact-D33720C868CDAAEFF13BA6BA3A703B72" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1397-wk-Fact-8986F31A6AE761DF74AFA6BB16DADEBD" name="biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the selection of targets, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1401-wk-Fact-CD4D893C7454C306EB04A6BBFB6B8D19" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.9</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1405-wk-Fact-2453D76D8BACAEF85A3CA6BCB04C5011" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">380.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1415-wk-Fact-D80EDDCA5AFB525EAFE834292B956C69" name="biib:AdditionalMilestonePayment" contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1422-wk-Fact-7190AB5D73765397B9B440CFC2FE3C1B" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1426-wk-Fact-6FA5024678F651DCA0EDEEDFE0A3F501" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1430-wk-Fact-1138B633F0335E088B4384304C6CC0E2" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. In October </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-4" continuedAt="TextSelection-112A0B64756E5F33BE10C6E037DB1828-5"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1437-wk-Fact-22F4635E170FDC861051A6AFD622F542" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1451-wk-Fact-96BB724CF6885BCAA9AA54D473EF0BFF" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1455-wk-Fact-720567AD23835BBCB3F827AA344F9E49" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1459-wk-Fact-A6D14020D25E777E54D5A3B220AA218D" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1463-wk-Fact-70E60339614B5AFBB016F04ABFA91F7C" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1472-wk-Fact-720567AD23835BBCB3F827AA344F9E49" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1482-wk-Fact-57DF0C990B415A56871F4F2105DDCF91" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">675</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1486-wk-Fact-4AC1B97336245B03915795229E85B701" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1490-wk-Fact-96DC2E0B79EF5C07A7DB886558D5AF31" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">615</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1494-wk-Fact-0EE2480AF3D65C7D989D1EECA8254B57" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1498-wk-Fact-21C0B0E205FC584F992D32314841F942" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d6324929e1503-wk-Fact-10A59290A3815DD98B5BFD8BAD8FA203" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" format="ixt-sec:duryear">1.5</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d6324929e1507-wk-Fact-944E40874FE058FE89D24E0E98D6E051" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1525-wk-Fact-35790B70F9CD5BDB870AFD6D0E5E3A29" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These losses reflect our share of income totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1529-wk-Fact-E94D9094C44A5DD884E19EAC445083DA" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1533-wk-Fact-B59F3DA8E3E3557AACC45660A3BE24B7" name="us-gaap:AdjustmentForAmortization" contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">20.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1548-wk-Fact-81B8D8EC0BF35537BB490D634AFBC7E2" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">651.1</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1552-wk-Fact-AB8FD620FD30576EA40A1036BC9AA643" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">531.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1556-wk-Fact-CEE0BB3718C45686B3E3BF1A79CF83CF" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">670.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1561-wk-Fact-F79E91422D635C019B6AD1FF0898A4B3" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">580.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Transaction</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1574-wk-Fact-E6BD172893E4E234F182A6A6CFCD0ADC" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Samsung Bioepis in January 2020, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1578-wk-Fact-1B2A998B5AAE2766D325A6A8AB30FB80" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in 2019 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1582-wk-Fact-335FFCB1215D2C499FF0A6A949341B46" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as an intangible asset in 2019. Additionally, we may pay Samsung Bioepis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1586-wk-Fact-0707812CC54134C0D708A6AA1EFBFE6E" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development, regulatory and sales-based milestones, including a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1590-wk-Fact-8BF83ABFCAAB33FE5AC0A6AA9ACDEE65" name="biib:AdditionalMilestonePayment" contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> development milestone that we may pay in 2020. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also acquired an option to extend the term of our current European commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1597-wk-Fact-144579D60A47A5E6E8B0A6AB2A5EA7EC" name="biib:ContractOptionExerciseFee" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and obtained exclusive rights to commercialize these products in China.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-5" continuedAt="TextSelection-112A0B64756E5F33BE10C6E037DB1828-6"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Commercial Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1611-wk-Fact-EC40A27C5FFD534FA71A4152AD70BA11" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1623-wk-Fact-630E5D07AE1E5743993F855D0632EA8D" name="biib:Collaborationprofitlosssharing" contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324929e1627-wk-Fact-EC40A27C5FFD534FA71A4152AD70BA11" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1632-wk-Fact-BD36F11679355D8F8DB9AA0CE429813F" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1636-wk-Fact-144579D60A47A5E6E8B0A6AB2A5EA7EC" name="biib:ContractOptionExerciseFee" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1658-wk-Fact-6373CF7EB00C5DF1B5774F43C6B6A0AE" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1662-wk-Fact-9734F5172F0D5BBC9193F5EE5D92C759" name="us-gaap:Revenues" contextRef="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income. Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1674-wk-Fact-A85750B88405E3115C0AA6AC73459891" name="us-gaap:DueFromRelatedParties" contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1678-wk-Fact-70EC9D96256CA9EF54E6A6ACC0D562F5" name="us-gaap:DueFromRelatedParties" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of March 31, 2020 and December 31, 2019, respectively. Amounts payable to Samsung Bioepis as of March 31, 2020, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1682-wk-Fact-BC7464C60A7408F40CB8A6AE5CAE1679" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324929e1686-wk-Fact-2DAD51A508358A97D2ADA6AEB54560CA" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment related to the 2019 transaction, as discussed above.</span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><ix:continuation id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-6" continuedAt="TextSelection-112A0B64756E5F33BE10C6E037DB1828-7"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-7"> Form 10-K.</ix:continuation> </span></div><div><a id="s05CAA1D9E769503BB9E8EEC31BAE5318"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="TextSelection-0FA00EA33A865D1FB75A9B0CE039565E-0-wk-Fact-E50953CDFB91587693CEC9A56D715A2F" continuedAt="TextSelection-0FA00EA33A865D1FB75A9B0CE039565E-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-0FA00EA33A865D1FB75A9B0CE039565E-1" continuedAt="TextSelection-0FA00EA33A865D1FB75A9B0CE039565E-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years from the first commercial sale of any product using such a licensed compound.  </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of the Neurimmune Agreement and made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324126e790-wk-Fact-D8071934C330186F5A39A4B199DA0BE7" name="us-gaap:PaymentsToMinorityShareholders" contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324126e794-wk-Fact-9DC457CD2E7C5F59AC4FA4B1C2A8C60D" name="biib:Reductioninroyaltyratepayableoncommercialsales" contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324126e798-wk-Fact-ECD5B91D70A8F63F5E52A4B1EA5E63AE" name="us-gaap:PaymentsToMinorityShareholders" contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune to further reduce the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0FA00EA33A865D1FB75A9B0CE039565E-2"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d6324126e805-wk-Fact-DA77AC55AC0E7622323DA4B217F1F539" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, under the terms of the Neurimmune Agreement, we would be required to pay Neurimmune a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324126e812-wk-Fact-D626C559336DC2C31286A4B2512E5203" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324126e816-wk-Fact-3CE2E87269F2FA919EFAA4B279F14D1F" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;if aducanumab is launched in the U.S.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6324126e863-wk-Fact-2749A5C55AD956EAACA8CA34FB9603C7" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></ix:continuation><div><a id="sEAC8C4223B905671AFC24EBA9D850F09"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-069259B546075EF695AF8D9227887E8B-0-wk-Fact-3E8F6EC589165822B17B3C45FECE6942" continuedAt="TextSelection-069259B546075EF695AF8D9227887E8B-1" escape="true"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-069259B546075EF695AF8D9227887E8B-1" continuedAt="TextSelection-069259B546075EF695AF8D9227887E8B-2"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-069259B546075EF695AF8D9227887E8B-2" continuedAt="TextSelection-069259B546075EF695AF8D9227887E8B-3"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has been set for September 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court and a hearing in both cases has been set for May 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Former Convergence Shareholders</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6325237e824-wk-Fact-BA207A19AD44B236374BA47F0B115893" name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent), which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-069259B546075EF695AF8D9227887E8B-3" continuedAt="TextSelection-069259B546075EF695AF8D9227887E8B-4"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA was dismissed in the fourth quarter of 2019. We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#8216;514 Patent expires in February 2028.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial is ongoing in the West Virginia action against Mylan.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we filed an action in the Delaware Court under the Hatch-Waxman Act against Banner Life Sciences LLC (Banner) for infringement of our U.S. Patent No. 7,619,001 (the &#8216;001 patent) expiring on June 20, 2020, and claiming treatment of MS with dimethyl fumarate or methyl hydrogen fumarate or a combination thereof. In April 2020 the U.S. Court of Appeals for the Federal Circuit affirmed the Delaware Court&#8217;s judgment that Banner&#8217;s drug product does not infringe the &#8216;001 patent. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and no hearing date has been set. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing on the merits has been set in this matter.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and a hearing has been set for July 2020 in our appeal in the German action. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-069259B546075EF695AF8D9227887E8B-4"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ex parte</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#8216;755 Patent, which request was granted in January 2020 and is pending.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Annulment Proceeding in General Court of the European Union relating to TECFIDERA</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#8217;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. No hearing date has been set.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d6325237e916-wk-Fact-B66C1AEABD035AD9B9B533206E145AD7" name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="FD2020Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><a id="s373A9FE4765555B8AD2BABD6CB64DE1D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.  </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Business Update Regarding COVID-19</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To date, we and our collaboration partners have been able to continue to supply our products to our patients worldwide and currently do not anticipate any interruptions in supply. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations, including our sales, expenses, manufacturing and clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are monitoring the demand for our products, including the duration and degree to which we may see declines in customer orders or delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including those products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have suspended in-person interactions by our customer-facing personnel in healthcare settings and we are engaging with these customers remotely as we seek to continue to support healthcare professionals and patient care. We have and may continue to benefit in the near term from any precautionary measures taken by our customers due to the COVID-19 pandemic, such as increasing their levels of stock in anticipation of any further interruptions from the pandemic, but over the longer term we may see an impact from advance sales or fewer patients visiting their healthcare provider to initiate, change or receive therapy. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our third-party contract manufacturing partners continue to operate our manufacturing facilities at or near normal levels. While we currently do not anticipate any interruptions in our manufacturing process, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our and/or our third-party suppliers and contract manufacturing partners' ability to manufacture our products or to have our products reach all markets. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we are currently continuing the clinical trials we have underway in sites across the globe, we expect that COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trials. For example, our Phase 3 study of BIIB093 (glibenclamide IV) for large hemispheric infarction, a severe form of ischemic stroke, has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants. To help mitigate the impact to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. and in most other key markets, our office-based employees have been working from home since early March 2020, while ensuring essential staffing levels in our operations remain in place, including maintaining key personnel in our laboratories and manufacturing facilities. We have provided support, including financial support, to all Biogen employees and their families worldwide.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Through the Biogen Foundation, we have committed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to support the global response efforts to the COVID-19 pandemic and the immediate needs of communities affected by it, and we have also deployed our scientific resources and capabilities, which include equipment and supplies. We are also helping to increase the understanding of COVID-19 and advance research efforts and potential therapeutic options. For example, we have entered into a consortium with the Broad Institute of MIT and Harvard and Partners HealthCare to build and share a COVID-19 biobank. The biobank will help scientists study a large collection of de-identified biological and medical data to advance knowledge and search for potential vaccines and treatments for COVID-19.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the various risks posed by the COVID-19 pandemic, please read Item 3.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Quantitative and Qualitative Disclosures About Market Risk </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products continue to face increasing competitive pressures from the introduction of generic versions, prodrugs and biosimilars of existing products, as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products, which may significantly reduce both the price that we are able to charge for our products and the volume of products we sell. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to&#160;the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the competition and pricing risks that could negatively impact our product sales, please read Item 3.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Quantitative and Qualitative Disclosures About Market Risk </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Brexit </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of its withdrawal and outline the future relationship between the U.K. and the E.U. upon exit, which occurred on January 31, 2020. Following the U.K.&#8217;s departure, there is now a transition period during which existing arrangements will remain in place until the end of 2020, allowing detailed discussions on the future relationship between the U.K. and the E.U. to take place.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The potential impact on our results of operations and liquidity resulting from Brexit remains unclear. The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the future relationship between the U.K. and the E.U. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final outcome of the discussions during the transition period may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not, however, expect Brexit to have a material impact on our consolidated results of operations as less than 4% of our total product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were derived from U.K. sales, which is consistent with full year product sales in 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have implemented measures to meet E.U. legal and regulatory requirements and to continue to modify our business operations to prepare for the finalization of the terms of the U.K.'s separation from the E.U. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Therefore, we will continue to monitor developments in this area and assess any potential impact on our business and results of operations.</span></div><div><a id="sDB15086837635238827796F4483516B2"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</span></div><div style="line-height:120%;text-align:justify;"><img src="chart-a8b4db707bd75762992.jpg" alt="chart-a8b4db707bd75762992.jpg" style="height:426px;width:317px;"></img></div><div><a id="sFC13963318C458AD848055F1361D65D7"></a></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.08</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As further described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our net income and diluted earnings per share attributable to Biogen Inc. for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,534.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">1.3%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,489.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,904.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">8.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,680.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">6.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in MS product revenues, a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">9.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in revenues from SPINRAZA and a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">25.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in revenues from our biosimilar products. We believe that, due to the COVID-19 pandemic, there was an acceleration in sales in the first quarter of 2020, primarily in the E.U., that increased revenues by approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$100.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$520.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, remaining flat compared to </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$517.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$109.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">62.6%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$292.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily due to the sale of approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$200 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of hemophilia inventory to Bioverativ Inc. (Bioverativ) in the first quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1,714.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">13.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1,987.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily due to a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">24.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in cost of sales and a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">15.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in research and development expense as well as the pre-tax loss of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$115.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations recorded during the first quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease in total costs and expenses was partially offset by additional operating expenses of approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$13.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> incurred in the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> due to the COVID-19 pandemic.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. was favorably impacted by a decrease in our effective tax rate to </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">17.2%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">22.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the same </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-top:8px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily due to the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$59.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense recognized in the first quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations and the tax effects of changes in the value of our equity investments where we recognized a gain in the first quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to a loss in the first quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Condition, Liquidity and Capital Resources:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$4.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">7.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2.2 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> million during the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">first</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of 2020 under a program authorized by our Board of Directors in March 2019 to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program) and a program authorized by our Board of Directors in December 2019 to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program).</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions and Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In particular, we plan to develop this Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm in Parkinson&#8217;s disease. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of BIIB118, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2020 we entered into a global licensing collaboration agreement with Sangamo Therapeutics, Inc. (Sangamo), which closed in April 2020, to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including, Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Sangamo, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab (AB mAb)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2020 we initiated the EMBARK global re-dosing clinical study, which is designed to evaluate aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of AD that we are developing in collaboration with Eisai Co., Ltd. (Eisai), in eligible AD patients who were actively enrolled in aducanumab studies (PRIME, EVOLVE, EMERGE and ENGAGE) in March 2019. In April 2020 we announced that we currently expect to complete the U.S. filing for aducanumab in the third quarter of 2020.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8BD52B0DEA085BB4822BB418FD5BDD4F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,583.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,513.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,321.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,166.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,904.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">82.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,680.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">520.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">517.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">109.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">292.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,534.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,489.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,100.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">998.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon**</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">466.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">500.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">460.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,117.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">72.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,983.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">565.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">133.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">174.4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,904.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,680.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDA3168F8F3B95EED823E7D7ED4BDE48D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumarate</span></div><div style="line-height:120%;"><img src="chart-bec93acf6eb55fb08e4.jpg" alt="chart-bec93acf6eb55fb08e4.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fumarate revenues include sales from TECFIDERA and VUMERITY. In October 2019 the U.S. Food and Drug Administration (FDA) approved VUMERITY for the treatment of RMS and VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.3%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. Fumarate revenues was primarily due to net price increases and an increase in Fumarate unit sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Volume in the first quarter of 2020 reflected favorable channel dynamics of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as favorable demand of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily due to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with additional shipping days and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of accelerated sales that we believe were due to the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world Fumarate revenues was primarily due to an increase in unit sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was primarily related to our European and Japanese markets, partially offset by pricing reductions in certain European countries. The increase in volumes was primarily due to continued strong patient growth in our E.U. direct markets, including Italy, Spain and U.K., as well as growth in Asia (Japan) and Latin America (Brazil), and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of accelerated sales that we believe were due to the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2020 the U.S. Patent Trial and Appeal Board (PTAB) decided that the claims of our U.S. Patent No. 8,399,514 (the &#8216;514 Patent) are patentable. The &#8216;514 Patent covers treatment of MS with 480 mg of dimethyl fumarate per day as provided </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for in our TECFIDERA label. This decision was appealed in April 2020. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The &#8216;514 Patent has also been challenged pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts of Delaware (the Delaware action) and West Virginia (the West Virginia action). We are awaiting a decision in the Delaware action and the trial in the West Virginia action is ongoing. If we receive an adverse judgment in either U.S. District Court action, we will appeal but we may face generic competition while our appeal is pending. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will face TECFIDERA generic competition if our patent claims are not upheld. In addition, we have entered into settlement agreements with some of the defendants in the Delaware action and we now anticipate TECFIDERA generic competition before the &#8216;514 Patent expires in February 2028. Generic competition is expected to have an adverse impact on our TECFIDERA sales and our results of operations. For additional information, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate an increase in TECFIDERA demand in rest of world in 2020, compared to 2019, notwithstanding the increasing competition from additional treatments for MS and potential disruptions from the COVID-19 pandemic. We expect volume growth in our rest of world markets to offset volume declines in the U.S in 2020. Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</span></div><div style="line-height:120%;text-align:left;"><img src="chart-7f0043a713055b78858.jpg" alt="chart-7f0043a713055b78858.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. Interferon revenues was primarily </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">due to a decrease in Interferon unit sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net decline in unit sales volumes reflects the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies, which negatively impacted comparative revenues by </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The decline was partially offset by favorable channel dynamics of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.  These factors were impacted by additional shipping days of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of accelerated sales that we believe were due to the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world Interferon revenues remained flat. We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the three months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that increased Interferon revenues by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily in the E.U. Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that Interferon revenues will continue to decline in both the U.S. and rest of world markets in 2020, compared to 2019, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;"><img src="chart-21a631c632245214b5c.jpg" alt="chart-21a631c632245214b5c.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.3%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. TYSABRI revenues was primarily due to price increases and an increase in unit sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by higher discounts and allowance rates. Volume was higher primarily due to an inventory channel benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and demand of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were impacted by </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with additional shipping days and an unfavorable </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impact that we believe was due to the COVID-19 pandemic.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world TYSABRI revenues was primarily due to a favorable impact of change in estimate related to pharmaceutical taxes in the first quarter of 2020 of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and an increase in unit sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that the impact of the COVID-19 pandemic on TYSABRI revenues was insignificant during the three months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate TYSABRI demand to be stable or slightly negative on a global basis in 2020, compared to 2019, with increasing competition from additional treatments for MS, including OCREVUS, and price reductions in certain rest of world countries. We believe that some TYSABRI infusions may be delayed as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;text-align:left;"><img src="chart-dffb73ef4c6252a6985.jpg" alt="chart-dffb73ef4c6252a6985.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. SPINRAZA revenues was primarily due to an increase in unit sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> partially offset by higher discounts and allowance rates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world SPINRAZA revenues was primarily due to an increase in unit sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by the unfavorable impact of price decreases and mix changes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the three months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that increased </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA revenues by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the U.S. and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world. Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will be modest in 2020, compared to 2019, primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months, lower prices in certain rest of world countries and the potential impact of the COVID-19 pandemic. We are evaluating the impact of the COVID-19 pandemic on the ability of hospitals to provide SPINRAZA dosing to patients. We believe that some SPINRAZA doses may be delayed as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face competition from a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BENEPALI, IMRALDI and FLIXABI</span></div><div style="line-height:120%;"><img src="chart-d3a8fa49540b5980939.jpg" alt="chart-d3a8fa49540b5980939.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in biosimilar revenues was primarily due to the continued launch of IMRALDI in Europe. Additionally, we believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the three months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that increased biosimilar revenues by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The increase was partially offset by the unfavorable impact of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.3%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from price reductions. Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2020 we expect modest to moderate revenue growth for our biosimilars business depending on the impact of the COVID-19 pandemic. We expect growth to be primarily driven by the continued launch of IMRALDI in Europe, partially offset by price reductions in certain European countries.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="sEBFCDB6B92EE5D9887A7B7C76961DE3D"></a></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;"><img src="chart-4bc2b65e63bf598aaeb.jpg" alt="chart-4bc2b65e63bf598aaeb.jpg" style="height:346px;width:317px;"></img></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.15966386554622%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:52%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,078.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">930.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,053.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">341.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">390.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S.&#160;product revenues, net was primarily due to decreased net sales of RITUXAN in the U.S.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in collaboration costs and expenses was primarily due to lower cost of sales on RITUXAN.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, could compete with RITUXAN and GAZYVA in the oncology market. The introduction of a biosimilar product can result in a significant reduction in net sales for the relevant product, as other manufacturers typically offer their versions at lower prices. In November 2019 and January 2020 biosimilar products referencing RITUXAN were launched in the U.S. and this could adversely affect the pre-tax profits of our collaboration </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">arrangements with Genentech, which could, in turn, adversely affect our co-promotion profits in the U.S. in future years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other revenues from anti-CD20 therapeutic programs was primarily due to sales growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$162.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">OCREVUS royalty revenues are based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></div></div><div><a id="sC3395BA89C585FF3A1EF56FDD1DE85ED"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">105.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">96.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">109.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">292.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships primarily include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUJIFILM Corporation (FUJIFILM) assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</span></div><div style="line-height:120%;"><img src="chart-a0675ec327835197bd6.jpg" alt="chart-a0675ec327835197bd6.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in other royalty and corporate revenues was primarily due to the prior period sale of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$206.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of hemophilia inventory on hand as of December 31, 2018, to Bioverativ.</span></div><div><a id="s5BCD9EB3E36F53C4B5D7B9EE03C8AFEE"></a></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:left;"><img src="chart-12ab3b9cf42c502a82c.jpg" alt="chart-12ab3b9cf42c502a82c.jpg" style="height:356px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounts were relatively consistent. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher managed care rebates and governmental rebates in the U.S. as well as higher governmental rebates and allowances in the rest of world, due in part to increases in SPINRAZA sales volumes worldwide.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserve was relatively consistent.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read Note 4, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><a id="sB9179836DD295FC286387D37ABC75ADD"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">454.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(24.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">476.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">563.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">570.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">567.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(140.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">75.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,714.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,987.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s13F9B7FAD7885DDEA3E845D3C06C29B4"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="chart-9f17d12ff13d514ba12.jpg" alt="chart-9f17d12ff13d514ba12.jpg" style="height:293px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in product cost of sales was primarily due to lower cost of sales from contract manufacturing agreements, primarily resulting from the sale of hemophilia inventory, with a cost basis of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to Bioverativ in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily due to increased royalties payable on higher sales of TYSABRI and SPINRAZA.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1AD266F2162A5E77B1932BE84184DD0B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;"><img src="chart-5576b2a7fe2b5bfabd8.jpg" alt="chart-5576b2a7fe2b5bfabd8.jpg" style="height:366px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;"><img src="chart-0e90e35cb3f356fdb65.jpg" alt="chart-0e90e35cb3f356fdb65.jpg" style="height:766px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily due to decreases in costs incurred in connection with our early and late stage programs and a decrease in costs incurred in connection with milestones and upfront expenses.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the COVID-19 pandemic may directly or indirectly impact the timeline of some of our clinical trials. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2019, the decrease in milestone and upfront expenses was primarily due to a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge to research and development expense related to our collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Skyhawk, please read Note 16, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in spending related to our early stage programs was primarily due to the discontinuation of gosuranemab (BIIB092) in progress supraneuclear palsy and advancement of toferson (BIIB067) in ALS into late stage.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in spending associated with our late stage programs was primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decrease in spending related to the discontinuation of the global Phase 3 trials of aducanumab, net of reimbursement from our collaboration partner Eisai in the first quarter of 2019; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decrease in spending related to VUMERITY, which was approved by the FDA in the fourth quarter of 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This decrease was partially offset by an increase in spending due to advancement of toferson in ALS into late stage. </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following a futility analysis, we accrued approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. In October 2019 we and Eisai announced that, based on a new analysis, conducted by Biogen in close consultation with the FDA, of a larger dataset from the Phase 3 EMERGE and ENGAGE trials that were discontinued in March 2019, we plan to pursue regulatory approval for aducanumab in the U.S.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early AD. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</span></div><div style="line-height:120%;"><img src="chart-8808588ca10451cd818.jpg" alt="chart-8808588ca10451cd818.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, selling, general and administrative expense remained flat.  </span></div><div><a id="s1DF4632E3428581B964DF8C8425E893F"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="chart-e41c9713c67058c3bab.jpg" alt="chart-e41c9713c67058c3bab.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, remained flat. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no impairment charges. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates and prioritization of these programs may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">treatment of&#160;trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The TGN program has experienced numerous delays in development in the periods since we acquired the program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain indication, for which we also have an IPR&amp;D asset. Data from that trial is expected in mid-2020. This data may affect the economic value of vixotrigine and the IPR&amp;D assets for one or both programs could be&#160;impaired if assumptions used in determining their fair value change. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value associated with our vixotrigine IPR&amp;D assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$161.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of our acquired intangible assets, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s1EC3DBA21795578485B9073EA2E4C4FE"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</span></div><div style="line-height:120%;"><img src="chart-0b79355e2c74500eae0.jpg" alt="chart-0b79355e2c74500eae0.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing primarily includes our Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$71.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. The increase in profit-sharing expense was primarily due to increased </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">collaboration profits resulting from increased biosimilar sales.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div><a id="sF3010D2C9414587DAE978D27EBE6D003"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss on Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;"><img src="chart-d48ca46993295751b22.jpg" alt="chart-d48ca46993295751b22.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:4px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. The transaction closed in August 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we recorded an initial loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$174.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss, which was subsequently remeasured each reporting period, included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting our estimated fair value of the assets and liabilities held for sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and included our initial estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned transaction in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div><a id="s0BC87D4E08BD5EB5B09CFD3FCCCA475D"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div style="line-height:120%;"><img src="chart-80323542940f5f3e9fd.jpg" alt="chart-80323542940f5f3e9fd.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, change in the fair value of our contingent consideration obligations was primarily due to changes in the interest rates used to revalue our contingent consideration liabilities and changes in the expected timing of the achievement of certain remaining developmental milestones, partially offset by the passage of time.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sD59E17D1F80B5A87ACD62294D09E6BAC"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></div><div style="line-height:120%;"><img src="chart-9c451125cbd651c0abd.jpg" alt="chart-9c451125cbd651c0abd.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer. In connection with this acquisition, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB118 has not yet reached technological feasibility. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of BIIB118, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div><a id="sCE1F9093A96B5AFC88CF9CC68EB1E3F2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;"><img src="chart-2dae770040575c09957.jpg" alt="chart-2dae770040575c09957.jpg" style="height:266px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$376.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our holdings in equity and debt securities in the prior year comparative period. The net losses recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects a decrease in the fair value in our investment in Ionis common stock from December 31, 2019.</span></div><div><a id="s32E41E36FBE3587EB33D688B92193D29"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</span></div><div style="line-height:120%;"><img src="chart-db872ef72f75548e83c.jpg" alt="chart-db872ef72f75548e83c.jpg" style="height:350px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense recognized in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations and the tax effects of changes in the value of our equity investments where we recognized a gain in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to a loss in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations for book purposes, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 14, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="sBF4F39AE9CEC52E6B7594DE9E0F6814A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;"><img src="chart-23a7c01770e356d29ff.jpg" alt="chart-23a7c01770e356d29ff.jpg" style="height:266px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These losses reflect amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our share of income totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes Samsung Bioepis' recognition of our upfront payment related to the December 2019 transaction, where we secured the exclusive rights to commercialize two potential ophthalmology biosimilar products.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><a id="s85EEFB47425450B79C05AF0D7EEEE66B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,591.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,913.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,269.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,562.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">969.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,829.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,884.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,501.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,495.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,459.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,459.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,961.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,954.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,007.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,381.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,638.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,863.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,368.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,518.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s37F118AAB48A5DA0AE6611E6086AABD4"></a></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2.2 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment related to our acquisition of BIIB118 from Pfizer; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$149.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment.</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements primarily through cash flows earned from our operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read Item 3. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. In March 2020 there was a severe liquidity crisis in the capital markets, particularly with respect to securities with maturities of less than one year, due to the COVID-19 pandemic. This issue impacted pricing of securities in our portfolio as we attempted to decrease our marketable securities level and increase cash leading to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in realized losses. We believe that recent actions taken by the U.S. Federal Reserve to enhance liquidity have stabilized the capital markets for the time being.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately $4.8 billion compared to approximately $5.9 billion as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net decrease in cash, cash equivalents and marketable securities at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash used for share repurchases, net purchases of property, plant and equipment and upfront payments made to Samsung Bioepis and Pfizer partially offset by cash flows from operations and net proceeds from sales of marketable securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and December 31, 2019, include the carrying value of our investment in Samsung Bioepis of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$531.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$580.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. Investments and other assets, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also include the fair value of our investment in Ionis </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">common stock of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$271.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$329.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of BIIB118 from Pfizer, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These Senior Notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Credit Facility</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we were permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility included a financial covenant that required us not to exceed a maximum consolidated leverage ratio. This credit facility was replaced with the new revolving credit facility that we entered into in January 2020, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2020 Credit Facility</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility entered into in August 2015.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital is defined as current assets less current liabilities. The change in working capital at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects a decrease in total current assets of approximately $374.6 million and a decrease in total current liabilities of approximately $225.2 million.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in total current assets was primarily driven by a decrease in net cash, cash equivalents and marketable securities, as described above.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in current liabilities was primarily due to a reduction in accrued expenses and other, which was primarily related to the $100.0 million upfront payment made to Samsung Bioepis, which was accrued as of December 31, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our December 2019 Share Repurchase Program does not have an expiration date. All shares repurchased under our </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019 Share Repurchase Program will be retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$941.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock that was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2020 through April 22, 2020, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our December 2019 Share Repurchase Program. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our December 2019 Share Repurchase Program as of April 22, 2020.</span></div></div></div><div><a id="sCE31EFA7F95E5D3992BC73EACC317C4F"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,467.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,459.5</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">442.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,245.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(679.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s9E9FB619B5155CCBB684ADA826951887"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operating activities increased primarily due to higher net income offset by changes in working capital. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows provided by investing activities was primarily due to an increase in net proceeds related to marketable securities as well as making the final contingent payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to former shareholders of Fumapharm AG and holders of their rights made during the first quarter of 2019. </span></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to the increase in cash used for share repurchases. </span></div><div><a id="s929D6C7E674256308FA8E1F6A945740A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no material changes in our contractual obligations since </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales that exceed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized as cost of sales in our condensed consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">VUMERITY</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. We recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$735.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$256.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of milestone payments for the remainder of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon a regulatory filing with the FDA for approval of aducanumab and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if aducanumab is launched in the U.S.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated balance sheet for expenditures incurred by CROs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$602.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our global licensing collaboration agreement with Sangamo, which closed in April 2020, we purchased approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Sangamo common stock at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.21</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> per share or </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$225.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are subject to transfer restrictions. During the second quarter of 2020 we plan to record an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We will also make an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$125.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that will be recorded as research and development expense in the second quarter of 2020.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates, we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees and have accrued for this obligation as of March 31, 2020. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of liabilities associated with uncertain tax positions.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of both </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, included in other long-term liabilities we have accrued income tax liabilities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under a </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$87.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div><a id="s6FFF4CCD9FC559B6B22E92A77F4595D3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s54E67F37FBFD5402BDB815AE63D4D159"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our 2019 Form&#160;10-K. Except as discussed above, there have been no material changes to these critical accounting estimates since our 2019 Form&#160;10-K.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1491D5554C6250E38427BCCA34B579EA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and pricing pressures worldwide as well as changes in economic conditions in the all markets in which we operate as a result of the COVID-19 pandemic. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations, including the impact of the COVID-19 pandemic. As a result, our consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina's economy </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $318.8 million and $265.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Hedge Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of exercising our option to increase our ownership percentage in Samsung Bioepis to approximately 49.9%. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">seven</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement would result in a hypothetical decrease in fair value of approximately $40.8 million and $43.0 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates, including changes resulting from the impact of the COVID-19 pandemic. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $13.6 million and $21.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generic versions, biosimilars and prodrugs of existing products as well as products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions, including as a result of the COVID-19 pandemic, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. Additionally, we could see an increase in the amount of time our trade receivables are paid by certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="s689DD25F3FE45E9B8EFFE739483B9028"></a></div><div style="line-height:120%;padding-top:16px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF0C314A8C0D95B2AB4CECD9E16909D88"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div><a id="sD0B48C62368352ADB22435D1990408F0"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal proceedings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our unaudited condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div><a id="s237CF9883248521BB66122FF7B4742ED"></a></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability of patients to receive a diagnosis, receive prescriptions or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the European Commission and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets.&#160;In addition to risks associated with new product launches and the other factors described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA, and other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers within certain SMA markets to treat patients with SMA; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the delay of SPINRAZA doses as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment as a result of the COVID-19 pandemic.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection afforded to our products and processes in the U.S. and in other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. Under the Hatch-Waxman Act, a manufacturer may file an </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Abbreviated New Drug Application, seeking approval of a generic copy of an approved innovator product, or a New Drug Application under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which may be for a new or improved version of the original innovator product. The manufacturers are allowed to rely on the safety and efficacy data of the innovator's product, may not need to conduct clinical trials, can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, a major portion of revenues for that product may be reduced in a short period of time. When others exploit our inventions, the expected benefit from them are reduced. Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are unpredictable and are often protracted, expensive and distracting to management. Negative outcomes of such proceedings adversely affect the validity and scope of our patent or other proprietary rights. Settlements of Hatch-Waxman litigation typically result in reducing the period of patent protection, accelerating reduction in revenue from affected products. Adverse outcomes in intellectual property litigation also could hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business could be materially adversely affected, directly or indirectly, by the widespread outbreak of contagious disease, including the ongoing COVID-19 pandemic, which has spread to many of the countries in which we, our customers, our suppliers and our collaboration partners do business. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns, business closures, cancellations of public gatherings and other measures. Organizations and individuals are taking additional steps to avoid or reduce infection, including limiting travel and staying home from work. These measures are disrupting normal business operations both in and outside of affected areas and have had significant negative impacts on businesses and financial markets worldwide.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including requiring most office-based employees to work remotely. Notwithstanding these measures, the COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on taking similar measures. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. We may also experience limitations in employee resources, including because of sickness of employees or their families or the desire of employees to avoid contact with individuals or large groups of people. In addition, we have experienced and will continue to experience disruptions to our business </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">operations resulting from quarantines, self-isolations and other restrictions on the ability of our employees to perform their jobs.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The COVID-19 pandemic has disrupted business operations. The extent and severity of the impact on our business and clinical trials will be determined largely by the extent of disruptions in the supply chains for our products and product candidates; disruptions in access by patients to our therapies; and delays in the conduct of current and future clinical trials. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, suppliers or our collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of uncertainty and risk. Only a small number of research and development programs result in the commercialization of a product. Furthermore, the development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining regulatory approval from the FDA and other regulatory agencies that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and, even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, may limit the scope of the approval or may deny approval altogether. Consequently, it may be difficult to predict the time and cost of product development of novel approaches for the treatment of diseases. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may be required to delay the development of a product candidate or delay ongoing clinical trials as a direct or indirect result of the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business. In addition, as a result of the COVID-19 pandemic, we have suspended in-person interactions by our customer-facing professionals in healthcare settings, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">which will limit our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products. Further, our ability to compete may be impacted by the inability of patients to receive a diagnosis, receive prescriptions or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars, prodrugs and products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business could be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products, generic or biosimilars of our MS products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the SMA market, we face competition from a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products. In addition, future sales of SPINRAZA may also be adversely affected by the delay of SPINRAZA doses as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives, external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations, or the disposition of certain of our assets or operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have in the past made, and may continue to make, significant operating and capital expenditures for potential new products in our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pipeline prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement. Furthermore, if we decide to dispose of certain of our assets or operations, we are not certain that we will be able to identify a suitable counterparty or if we will be able to reach agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to continue our existing clinical trials or to initiate new clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have open clinical trial sites in countries that have had high incident rates of COVID-19 patients. Restrictions on travel and/or transport of clinical materials, as well as diversion of hospital staff and resources to COVID-19 infected patients, could disrupt trial operations as well as recruitment, possibly resulting in a slowdown in enrollment and/or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We have also paused the initiation of new trials for compounds that are known to be immunosuppressants.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML) or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data to operate our business. In particular, the COVID-19 pandemic has caused us to modify our business practices, including the requirement that our office-based employees in the U.S. and in most of our other key markets work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, regulators globally are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation, which became effective in 2018, established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4% of the annual global revenues of the infringer, whichever is greater. In addition, new U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA) that became effective in January 2020, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws could result in significant penalties and could have a material adverse effect on our business and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships, including joint venture partners, for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships, including joint venture partners, subjects us to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">delays and disruptions experienced by our collaborators, joint venture partners or third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators, joint venture partners or other third parties, and the underlying agreement with our collaborators, joint venture partners or other third parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships, joint ventures and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws, regulatory requirements and/or applicable contractual obligations in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators, joint venture partners or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, or revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements and/or joint ventures.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in March 2020. The CARES Act is aimed at providing emergency assistance and health care for individuals, families and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. Due to the recent enactment of the CARES Act, there is a high degree of uncertainty around its implementation. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The recent COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. In addition, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">emphasis on our existing business programs. Further, if members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs, recruitment by competitors or delays in the recruiting and hiring process as a result of the COVID-19 pandemic. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government regulations that may be imposed in response to the COVID-19 pandemic may restrict the movement of our global supply chain, divert hospital resources that are necessary to administer certain of our products and/or delay the review of product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;padding-top:8px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Further, certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we partner or collaborate with or acquire in emerging markets.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">diverse data privacy and protection requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.&#8217;s departure from the E.U., known as Brexit;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, in order to support our drug development pipeline, in 2015 we made the decision to expand our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity would be required. We expect the Solothurn manufacturing facility to be partially operational by the end of 2020; however, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. If there are delays in bringing the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we have made significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control, including the impact of the COVID-19 pandemic. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;padding-top:8px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, public health epidemics, natural disasters, power failures, cyber-attacks and numerous other factors. In addition, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational by the end of 2020. However, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. If there are delays in bring the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Relating to Government Actions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. If Samsung Bioepis, FUJIFILM or other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Manufacturing biosimilars is complex.&#160;If we encounter any manufacturing or supply chain difficulties, including as a result of the COVID-19 pandemic, we may be unable to meet higher than anticipated demand. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. FUJIFILM may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area. In addition, as a result of the COVID-19 pandemic, we have suspended in-person interactions by our customer-facing professionals in healthcare settings, which will limit our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Legal and Regulatory Requirements.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Any improper conduct or actions on the part of Samsung Bioepis or our joint venture partner, Samsung BioLogics, could damage our reputation and be distracting to management. In particular, Samsung BioLogics is currently subject to an ongoing criminal investigation, which may impact the operations of Samsung Bioepis and its business or divert the attention of the Samsung Bioepis management team from its ongoing operations and business. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions, divestitures and other business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">failure to meet certain contractual commitments, including, for example, the minimum batch production commitment guarantees we have provided as part of the transaction with FUJIFILM; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively, including in response to the COVID-19 pandemic. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as global intangible low-taxed income (GILTI) or Subpart F income, and includes base erosion prevention measures on U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) will result in significant changes to the Swiss cantonal income tax system. These changes include the elimination of historic favorable cantonal tax regimes, the introduction of a patent box regime and the introduction of a research and development super deduction. The TRAF also provides for transitional rules to lessen the immediate impact of the elimination of the favorable cantonal tax regimes. These changes became effective on January 1, 2020. In response to the TRAF, each canton must enact cantonal tax reform to comply with the framework provided by the TRAF and are also expected to lower the statutory tax rate to compensate for the elimination of the historic favorable cantonal tax regimes. We accounted for the impact of the TRAF and the specific cantonal tax reform changes in the period in which each canton in which we operate enacted the cantonal tax reform. Zug, a canton in which we operate, enacted cantonal tax reform in the third quarter of 2019 and Solothurn, another canton in which we operate, enacted cantonal tax reform in the first quarter of 2020. Upon the enactment of cantonal tax reform, we were required to remeasure our Swiss deferred tax assets and liabilities, to account for the elimination of the historic favorable cantonal tax regimes, the impact of the transitional rules and the change in the statutory cantonal tax rate. Final interpretation of the transitional and new regimes of the TRAF may require further adjustments and changes in our estimates, which could have a significant adverse effect on our business, results of operations or financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. In addition, the COVID-19 pandemic could adversely affect the financial markets in some or all countries worldwide. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes share repurchase programs, including, most recently, our December 2019 Share Repurchase Program. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of shares. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our December 2019 Share Repurchase Program could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders.&#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><a id="s87489C5E3D8C5E56B645B1115D529BF1"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity during the first quarter of 2020:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($ in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 2020</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">97,807</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">297.49</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">97,807</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,250.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 2020</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">975,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">331.24</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">975,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,927.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March 2020</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,248,925</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">298.95</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,248,925</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,058.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,321,732</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">303.23</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our December 2019 Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$941.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock that was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2020 through April 22, 2020, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our December 2019 Share Repurchase Program. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our December 2019 Share Repurchase Program as of April 22, 2020.</span></div><div><a id="s1085D5D2585252D49676623F0D8D09C6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4B99A0B7DEF65E8792D6D19315C2B165"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2020331xex311.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2020331xex312.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2020331xex321.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March 31, 2020, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">104++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in Inline XBRL.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5BDA7844AB515F41A553E5AE2E98FEBA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s9A113CF9805359CD87FB3059F1C681A0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;23, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2020331xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s78B1DEB27AF458F59AF129095F05245F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April 23, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2020331xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s490EF2C087395FD296953AD48D90D6B2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey D. Capello, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April 23, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2020331xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2D50F21BD7F55003BF51EC4BB2EC047A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April 23, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April 23, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20200331" xmlns:biib="http://www.biogenidec.com/20200331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2106100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetails" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails">
        <link:definition>2406403 - Disclosure - Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2406402 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2134100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2334301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement">
        <link:definition>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2123100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2423402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2323301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetailsTextual" roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual">
        <link:definition>2414401 - Disclosure - Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestitures" roleURI="http://www.biogenidec.com/role/DivestituresDivestitures">
        <link:definition>2114100 - Disclosure - Divestitures Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2130100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2430402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2330301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2129100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2421402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2421403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2421404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2421405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2421406 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2321301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2122100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2422402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2422403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2422404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2422405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2422406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2322301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2132100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2432402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2432403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2332301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2120100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2119100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2419402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2319301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2135100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2136100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2436401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2133100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails">
        <link:definition>2418406 - Disclosure - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2424401 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails">
        <link:definition>2418402 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2418407 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenues" roleURI="http://www.biogenidec.com/role/RevenuesRevenues">
        <link:definition>2118100 - Disclosure - Revenues Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2318301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2131100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2431402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2431403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2331301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2429402 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables">
        <link:definition>2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2018ShareRepurchaseProgramMember" name="A2018ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AcquisitionsAbstract" name="AcquisitionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BAN2401Member" name="BAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB111Member" name="BIIB111Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB112Member" name="BIIB112Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB118Member" name="BIIB118Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ClinicalAssetsAcquired" name="ClinicalAssetsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ContractOptionExerciseFee" name="ContractOptionExerciseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_December2019ShareRepurchaseProgramMember" name="December2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenmarkManufacturingOperationsMember" name="DenmarkManufacturingOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityAxis" name="DerivativeMaturityAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityDomain" name="DerivativeMaturityDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DivestituresAbstract" name="DivestituresAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_E2609andBAN2401Member" name="E2609andBAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveTaxRateReconciliationGILTItax" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ElenbecestatCollaborationMember" name="ElenbecestatCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpenseIncurredByCollaboration" name="ExpenseIncurredByCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expenseincurredbythecollaboration" name="Expenseincurredbythecollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expensereflectedwithinstatementsofincome" name="Expensereflectedwithinstatementsofincome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesAxis" name="FutureContingentMilestoneTypesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesDomain" name="FutureContingentMilestoneTypesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" name="GlobalLicensingCollaborationAgreementAmountSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" name="GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" name="GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" name="GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" name="GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchased" name="GlobalLicensingCollaborationAgreementSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" name="GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IMRALDIMember" name="IMRALDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventoryrawmaterialssoldtoFUJIFILM" name="InventoryrawmaterialssoldtoFUJIFILM" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" name="InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" name="InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MSProductRevenuesMember" name="MSProductRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_March2019ShareRepurchaseProgramMember" name="March2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NightstarMember" name="NightstarMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherrevenuesAbstract" name="OtherrevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PostacquisitionequitycompensationMember" name="PostacquisitionequitycompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyratepayableoncommercialsales" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryApprovalMilestoneMember" name="RegulatoryApprovalMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetAxis" name="ResearchanddevelopmentassetAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetDomain" name="ResearchanddevelopmentassetDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReserveforCashDiscountsMember" name="ReserveforCashDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_Revenuesfromanticd20therapeuticprogramsMember" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SangamoTherapeuticsInc.AgreementMember" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShorttermderivativeMember" name="ShorttermderivativeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SkyhawkTherapeuticsMember" name="SkyhawkTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TGNMember" name="TGNMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_UCBPharmaS.A.Member" name="UCBPharmaS.A.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20200331.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20200331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20200331.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20200331.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20200331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20200331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20200331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20200331.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20200331.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20200331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20200331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20200331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20200331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20200331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:href="biib-20200331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20200331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20200331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20200331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20200331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20200331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20200331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20200331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20200331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20200331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20200331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20200331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20200331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20200331.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20200331.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20200331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20200331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200331.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20200331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20200331.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20200331.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20200331.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20200331.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20200331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20200331.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20200331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20200331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20200331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20200331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20200331.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20200331.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_5ec10448-76c0-1b5e-f8b1-23925c84050e" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_5ec10448-76c0-1b5e-f8b1-23925c84050e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_c2ae13c3-1da7-9b11-b77f-890f8f8346e4" xlink:type="locator" />
    <link:calculationArc order="16" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_c2ae13c3-1da7-9b11-b77f-890f8f8346e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fb2eba1d-18a1-c88e-44d1-389c4fe84127" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fb2eba1d-18a1-c88e-44d1-389c4fe84127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_FB809A906DB9DB9F0909A7C54A1AA393_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_FB809A906DB9DB9F0909A7C54A1AA393_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_FB809A906DB9DB9F0909A7C54A1AA393_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_FB809A906DB9DB9F0909A7C54A1AA393_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_FB809A906DB9DB9F0909A7C54A1AA393_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_FB809A906DB9DB9F0909A7C54A1AA393_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_FB809A906DB9DB9F0909A7C54A1AA393_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:to="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20200331.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20200331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20200331.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20200331.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20200331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20200331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20200331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20200331.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20200331.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20200331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20200331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20200331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20200331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20200331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:href="biib-20200331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20200331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20200331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20200331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20200331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20200331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20200331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20200331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20200331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20200331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20200331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20200331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20200331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20200331.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20200331.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20200331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20200331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200331.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20200331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20200331.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20200331.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20200331.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20200331.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20200331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20200331.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20200331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20200331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20200331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20200331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20200331.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20200331.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:to="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:to="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AE01571AF2786F48EA57A781574CFED2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AE01571AF2786F48EA57A781574CFED2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AF611DE35717095A846BA781574CDB41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AE01571AF2786F48EA57A781574CFED2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AF611DE35717095A846BA781574CDB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AF611DE35717095A846BA781574CDB41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AF611DE35717095A846BA781574CDB41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_E0AEE2676127B3EF28FBA781574CCD85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1" xlink:to="loc_biib_NightstarMember_E0AEE2676127B3EF28FBA781574CCD85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A7BB2CB9F31CBAAF297A781574C03B0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A7BB2CB9F31CBAAF297A781574C03B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:to="loc_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:to="loc_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:to="loc_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2DB1DB49AEB44E09EFDDA8302848A25C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2DB1DB49AEB44E09EFDDA8302848A25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2DB1DB49AEB44E09EFDDA8302848A25C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2DB1DB49AEB44E09EFDDA8302848A25C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB118Member" xlink:label="loc_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:to="loc_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:to="loc_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_69C7E8FF5764A51830F9A830284A2D9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_69C7E8FF5764A51830F9A830284A2D9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_02DA464D78A63EECD52AA830284AADB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_02DA464D78A63EECD52AA830284AADB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ClinicalAssetsAcquired" xlink:label="loc_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F5F46CA4FA04481ADCA0A7C11F60AF78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F5F46CA4FA04481ADCA0A7C11F60AF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F5F46CA4FA04481ADCA0A7C11F60AF78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F5F46CA4FA04481ADCA0A7C11F60AF78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_876095C03AD023D7DF92A7C11F60381C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_876095C03AD023D7DF92A7C11F60381C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B225717C2F7F3C9A401EA7C11F613179" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B225717C2F7F3C9A401EA7C11F613179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6B17EFD391418ABB3136A7C11F616D65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6B17EFD391418ABB3136A7C11F616D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6B17EFD391418ABB3136A7C11F616D65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6B17EFD391418ABB3136A7C11F616D65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E0914BC1504570513A8AA7C11F61D6CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_us-gaap_CollaborativeArrangementMember_E0914BC1504570513A8AA7C11F61D6CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UCBPharmaS.A.Member" xlink:label="loc_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SangamoTherapeuticsInc.AgreementMember" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1F698BB6D1A80A83B179A7C11F62F498" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="loc_srt_ProductOrServiceAxis_1F698BB6D1A80A83B179A7C11F62F498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1F698BB6D1A80A83B179A7C11F62F498" xlink:to="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1F698BB6D1A80A83B179A7C11F62F498" xlink:to="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BAN2401Member" xlink:label="loc_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ElenbecestatCollaborationMember" xlink:label="loc_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_927EA23D7845BC6D5D45A7C11F6429D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_927EA23D7845BC6D5D45A7C11F6429D7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_CCCC5A06FE91DC65725FA7C11F656DB3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_AdditionalMilestonePayment_CCCC5A06FE91DC65725FA7C11F656DB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_FF7DAB62C03D22A2D7F7A7C11F65C64A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_FF7DAB62C03D22A2D7F7A7C11F65C64A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_60878D643028BCCFC857A7C11F66EBF3" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_60878D643028BCCFC857A7C11F66EBF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_4C4131EEF1315FC757A7A7C11F66CB72" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_4C4131EEF1315FC757A7A7C11F66CB72" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_E20AC43F5595475E1478A781550973DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_E20AC43F5595475E1478A781550973DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_7571AF31D1F49CE6A6FEA781550B8E3A" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_Collaborationprofitlosssharing_7571AF31D1F49CE6A6FEA781550B8E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_890B2481F3DA88AE4BFAA781550C6633" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_Revenues_890B2481F3DA88AE4BFAA781550C6633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4AADA7D8D461DE50F484A7C402906162" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4AADA7D8D461DE50F484A7C402906162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4AADA7D8D461DE50F484A7C402906162" xlink:to="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4AADA7D8D461DE50F484A7C402906162" xlink:to="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EB80E00A607AE2D3EE47A7C402A0F159" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_NetIncomeLoss_EB80E00A607AE2D3EE47A7C402A0F159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7A12899070067E2D9B08A7C402A0D493" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7A12899070067E2D9B08A7C402A0D493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5D21CAB18FEB8957B1DCA7C402A0871B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5D21CAB18FEB8957B1DCA7C402A0871B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:to="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:to="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:to="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:to="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:to="loc_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:to="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:to="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:to="loc_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BF8B39B5735E53735872A78155A72366" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BF8B39B5735E53735872A78155A72366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BF8B39B5735E53735872A78155A72366" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BF8B39B5735E53735872A78155A72366" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6DAD54AF17C2883C306CA78155A7EFA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6DAD54AF17C2883C306CA78155A7EFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:to="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:to="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:to="loc_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:to="loc_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:to="loc_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:to="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:to="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:to="loc_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:to="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:to="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:to="loc_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:to="loc_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_EDA114BA47A577B6DACCA78155B6CF82" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_EDA114BA47A577B6DACCA78155B6CF82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_413B64AFF4BE1D4D9E61A78155B699BE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_413B64AFF4BE1D4D9E61A78155B699BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0A81E2B529866EE3E050A781573D0034" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0A81E2B529866EE3E050A781573D0034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:to="loc_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:to="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2137356B47A33A953FA0A781555828E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:to="loc_us-gaap_NetIncomeLoss_2137356B47A33A953FA0A781555828E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A85F3E61333D33B96700A7815681F3D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A85F3E61333D33B96700A7815681F3D5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7AC1DCCDF5A519C0208A7815672F9FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7AC1DCCDF5A519C0208A7815672F9FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7AC1DCCDF5A519C0208A7815672F9FC" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7AC1DCCDF5A519C0208A7815672F9FC" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C01707701FF3096E958DA7815672AB05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C01707701FF3096E958DA7815672AB05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C01707701FF3096E958DA7815672AB05" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C01707701FF3096E958DA7815672AB05" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_50A6D20A0C48F0CBFEEBA781567209BA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_50A6D20A0C48F0CBFEEBA781567209BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_50A6D20A0C48F0CBFEEBA781567209BA" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_50A6D20A0C48F0CBFEEBA781567209BA" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A85F3E61333D33B96700A7815681F3D5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_035C20FA407CCF6CE832A78156811786" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_035C20FA407CCF6CE832A78156811786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_EE8DD866ED11813278E7A78156621FC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:to="loc_us-gaap_DebtInstrumentAxis_EE8DD866ED11813278E7A78156621FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_EE8DD866ED11813278E7A78156621FC3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_EE8DD866ED11813278E7A78156621FC3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9119DAD9DEBDD4D0D546A781566285D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9119DAD9DEBDD4D0D546A781566285D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="loc_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="loc_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ADD7E627AE2FDC753C4CA781565223F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ADD7E627AE2FDC753C4CA781565223F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ADD7E627AE2FDC753C4CA781565223F3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ADD7E627AE2FDC753C4CA781565223F3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_F112ED252A4EBA648A47A7815652194B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_F112ED252A4EBA648A47A7815652194B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5C9C1F803A8139F950B3A78156526AC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5C9C1F803A8139F950B3A78156526AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D4490D3CD612B2ED6520A7C34B876F02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D4490D3CD612B2ED6520A7C34B876F02" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_10AB70C27E7D15538224A7C34B8840DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D4490D3CD612B2ED6520A7C34B876F02" xlink:to="loc_us-gaap_DebtInstrumentAxis_10AB70C27E7D15538224A7C34B8840DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_10AB70C27E7D15538224A7C34B8840DC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_10AB70C27E7D15538224A7C34B8840DC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C82D3D7EDC58992573FCA7C34B88B7EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C82D3D7EDC58992573FCA7C34B88B7EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F0FB7BED159B68C68AC6A7C34B894AF2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F0FB7BED159B68C68AC6A7C34B894AF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_98F114108E39819221ECA7C34B899215" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_98F114108E39819221ECA7C34B899215" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2A0CB2353B176EE20D80A7C34B8982F3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2A0CB2353B176EE20D80A7C34B8982F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5B53C1F3786DDC684856A7C34B8A4E93" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5B53C1F3786DDC684856A7C34B8A4E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C08CC15D3C7C45C8586EA7C34B8A7ACC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C08CC15D3C7C45C8586EA7C34B8A7ACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4252E228F72560390689A7815633AAB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_srt_RangeAxis_4252E228F72560390689A7815633AAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4252E228F72560390689A7815633AAB7" xlink:to="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4252E228F72560390689A7815633AAB7" xlink:to="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:to="loc_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:to="loc_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:to="loc_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:to="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_A8B5D68018516F75D025A7815604C519" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_A8B5D68018516F75D025A7815604C519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A8B5D68018516F75D025A7815604C519" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A8B5D68018516F75D025A7815604C519" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A6AA996261343042817EA781560476BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_A6AA996261343042817EA781560476BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_90C6A19A0DD5A66EC5B8A7815604FEC3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_90C6A19A0DD5A66EC5B8A7815604FEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_514C9BAD1A525CB5722BA7C37D0FA917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_514C9BAD1A525CB5722BA7C37D0FA917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_514C9BAD1A525CB5722BA7C37D0FA917" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_514C9BAD1A525CB5722BA7C37D0FA917" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_673C2DE4AEA1D0CB33B3A7C37D0F2A65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_673C2DE4AEA1D0CB33B3A7C37D0F2A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_D4642947840FF13A2DD7A7C37D0FA329" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_D4642947840FF13A2DD7A7C37D0FA329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8A23659404369F6643AEA7C37D0F46B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8A23659404369F6643AEA7C37D0F46B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8A23659404369F6643AEA7C37D0F46B4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8A23659404369F6643AEA7C37D0F46B4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75" xlink:to="loc_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:to="loc_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_7746A0806DC0F75B9FF2A7C37D0FA36F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_7746A0806DC0F75B9FF2A7C37D0FA36F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9F4D36004003D75D37FBA7815539D39B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9F4D36004003D75D37FBA7815539D39B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9F4D36004003D75D37FBA7815539D39B" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9F4D36004003D75D37FBA7815539D39B" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_CEA2E23D6DCDFBA64D4CA78155394A71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_CEA2E23D6DCDFBA64D4CA78155394A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9DC92E1CEDB6375306C8A781553911F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9DC92E1CEDB6375306C8A781553911F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_7FD2A7ACD56799A7CD5BA78156B0B036" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_7FD2A7ACD56799A7CD5BA78156B0B036" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7FD2A7ACD56799A7CD5BA78156B0B036" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7FD2A7ACD56799A7CD5BA78156B0B036" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4" xlink:to="loc_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3E4042AA61A956701742A78156B02183" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3E4042AA61A956701742A78156B02183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3E4042AA61A956701742A78156B02183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3E4042AA61A956701742A78156B02183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_623BA92F255DBA769C6DA78156B05977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7" xlink:to="loc_biib_NightstarMember_623BA92F255DBA769C6DA78156B05977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_535AF43C8FC97D91A075A78156B01170" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_535AF43C8FC97D91A075A78156B01170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_E30B04311AF600B8D1C7A78156B0726D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_E30B04311AF600B8D1C7A78156B0726D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F60F8AE884B4514C106FA78156B0DE49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F60F8AE884B4514C106FA78156B0DE49" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1C8838B79EA6F6ED0C5AA78156B0F189" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_srt_ProductOrServiceAxis_1C8838B79EA6F6ED0C5AA78156B0F189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1C8838B79EA6F6ED0C5AA78156B0F189" xlink:to="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1C8838B79EA6F6ED0C5AA78156B0F189" xlink:to="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:to="loc_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_AF2B99F162CF463BF64AA78156B0B594" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:to="loc_biib_TysabriProductMember_AF2B99F162CF463BF64AA78156B0B594" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1E15293709D3E117F153A78156B0458D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:to="loc_biib_TecfideraMember_1E15293709D3E117F153A78156B0458D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C36C78DCA3C83BABCF70A78156C09AFD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_srt_RangeAxis_C36C78DCA3C83BABCF70A78156C09AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_C36C78DCA3C83BABCF70A78156C09AFD" xlink:to="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_C36C78DCA3C83BABCF70A78156C09AFD" xlink:to="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_27C116096A79D4B949FCA78156C0DC7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:to="loc_srt_MinimumMember_27C116096A79D4B949FCA78156C0DC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F793C1CC5A86A94F124AA78156C09E0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:to="loc_srt_MaximumMember_F793C1CC5A86A94F124AA78156C09E0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4E6A76C25E4767F7CEECA78156C0322B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4E6A76C25E4767F7CEECA78156C0322B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F7C2B4F75F43A54934EAA78156C03E9B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F7C2B4F75F43A54934EAA78156C03E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:to="loc_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:to="loc_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4769D6861B65F8300B1BA78154F22B6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4769D6861B65F8300B1BA78154F22B6C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4769D6861B65F8300B1BA78154F22B6C" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:to="loc_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E5060CE1A80DE45257E8A781552AAA07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:to="loc_us-gaap_StatementTable_E5060CE1A80DE45257E8A781552AAA07" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8155058CF505887976F9A781552A2EAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E5060CE1A80DE45257E8A781552AAA07" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8155058CF505887976F9A781552A2EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8155058CF505887976F9A781552A2EAC" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8155058CF505887976F9A781552A2EAC" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B934C792E9BB88EBE4A1A7C3B0E61389" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B934C792E9BB88EBE4A1A7C3B0E61389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B934C792E9BB88EBE4A1A7C3B0E61389" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B934C792E9BB88EBE4A1A7C3B0E61389" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1BAB047BBFFECBE4D984A7C3B0E61EED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1BAB047BBFFECBE4D984A7C3B0E61EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C1D87DC6E13134E7656BA7C3B0E735B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="loc_srt_ProductOrServiceAxis_C1D87DC6E13134E7656BA7C3B0E735B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_C1D87DC6E13134E7656BA7C3B0E735B1" xlink:to="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_C1D87DC6E13134E7656BA7C3B0E735B1" xlink:to="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:to="loc_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:to="loc_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_F41A9CD1D1EA509FF9A2A7C3B0E8BC86" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_F41A9CD1D1EA509FF9A2A7C3B0E8BC86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:to="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:to="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5E65D46B235B8601DD8DA7C3B0E8762E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5E65D46B235B8601DD8DA7C3B0E8762E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:to="loc_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4355CC1A7E49A9CC4AE0A7C3B0E933C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:to="loc_us-gaap_Revenues_4355CC1A7E49A9CC4AE0A7C3B0E933C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:to="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:to="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:to="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:to="loc_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0D2F9CB4CF3E96EF0163A781556875D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0D2F9CB4CF3E96EF0163A781556875D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0D2F9CB4CF3E96EF0163A781556875D8" xlink:to="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0D2F9CB4CF3E96EF0163A781556875D8" xlink:to="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_80A7DB0AE990C97F1167A781556890D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_80A7DB0AE990C97F1167A781556890D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7F2C89330AF92635A55BA781556876C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7F2C89330AF92635A55BA781556876C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E884DB4F0A529486A8D6A78155682E29" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E884DB4F0A529486A8D6A78155682E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:to="loc_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:to="loc_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_29C2B60B9F2EE6CFF38DA781571D9884" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0C0C1EF342D94DF2FFF3A781571DD004" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_29C2B60B9F2EE6CFF38DA781571D9884" xlink:to="loc_us-gaap_StatementTable_0C0C1EF342D94DF2FFF3A781571DD004" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2934BA64EA275A26613EA781571D824F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0C0C1EF342D94DF2FFF3A781571DD004" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2934BA64EA275A26613EA781571D824F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2934BA64EA275A26613EA781571D824F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2934BA64EA275A26613EA781571D824F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:to="loc_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_761476E5F40D6DA7F214A781571D4551" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_761476E5F40D6DA7F214A781571D4551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_29C2B60B9F2EE6CFF38DA781571D9884" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6D99E34186D12AA8D2C6A781572DA3D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6D99E34186D12AA8D2C6A781572DA3D7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3C523618C52B75054AF7A781572D5A9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:to="loc_srt_ProductOrServiceAxis_3C523618C52B75054AF7A781572D5A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3C523618C52B75054AF7A781572D5A9E" xlink:to="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3C523618C52B75054AF7A781572D5A9E" xlink:to="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_E7C1AB134BD1B9508895A781572D6C3C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_ZINBRYTAMember_E7C1AB134BD1B9508895A781572D6C3C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_27FED229F0D31DFE746FA781572DE8C9" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_us-gaap_ProductMember_27FED229F0D31DFE746FA781572DE8C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:to="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:to="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:to="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:to="loc_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:to="loc_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6D99E34186D12AA8D2C6A781572DA3D7" xlink:to="loc_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9D8C56BA0DA6A4B38BD8A78156FEAE59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:to="loc_srt_ProductOrServiceAxis_9D8C56BA0DA6A4B38BD8A78156FEAE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9D8C56BA0DA6A4B38BD8A78156FEAE59" xlink:to="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9D8C56BA0DA6A4B38BD8A78156FEAE59" xlink:to="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_C18C80A0112955274135A78156FE04E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_C18C80A0112955274135A78156FE04E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7D8176847FDD616B277BA78156FEE4B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:to="loc_srt_MajorCustomersAxis_7D8176847FDD616B277BA78156FEE4B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7D8176847FDD616B277BA78156FEE4B5" xlink:to="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7D8176847FDD616B277BA78156FEE4B5" xlink:to="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:to="loc_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:to="loc_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:to="loc_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:to="loc_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_5461D6F81AD88843586EA781571D623A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:to="loc_srt_ProductOrServiceAxis_5461D6F81AD88843586EA781571D623A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5461D6F81AD88843586EA781571D623A" xlink:to="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5461D6F81AD88843586EA781571D623A" xlink:to="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_487380B170652AC40588A781571DC92E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_487380B170652AC40588A781571DC92E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_91F81B4D6B703582B27DA781571DC1BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:to="loc_srt_MajorCustomersAxis_91F81B4D6B703582B27DA781571DC1BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_91F81B4D6B703582B27DA781571DC1BE" xlink:to="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_91F81B4D6B703582B27DA781571DC1BE" xlink:to="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55" xlink:to="loc_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:to="loc_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:to="loc_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E4EE3F22BE21FABCA96AA7815549D846" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E4EE3F22BE21FABCA96AA7815549D846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E4EE3F22BE21FABCA96AA7815549D846" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E4EE3F22BE21FABCA96AA7815549D846" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:to="loc_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8638122480C07C79DEE6A7815549FAC6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16C1F9FCEA25BA8140C5A78155493B7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8638122480C07C79DEE6A7815549FAC6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16C1F9FCEA25BA8140C5A78155493B7F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16C1F9FCEA25BA8140C5A78155493B7F" xlink:to="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D186E9DAD73CCFFF9632A7815549C2BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_MarketStockUnitsMember_D186E9DAD73CCFFF9632A7815549C2BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_021DA77620D1613ABC7AA7815549B84D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_021DA77620D1613ABC7AA7815549B84D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_142B42C941C5491781A7A781554968A6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_142B42C941C5491781A7A781554968A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8638122480C07C79DEE6A7815549FAC6" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D6649EC8A5F544CC1806A781554964AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D6649EC8A5F544CC1806A781554964AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_032738490BAE8BD46B19A7815549FBEC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_032738490BAE8BD46B19A7815549FBEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_216468D1B635E7A28C80A7815549BFC5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_216468D1B635E7A28C80A7815549BFC5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_54FFC70CC2E979A44AF7A78155688DA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_54FFC70CC2E979A44AF7A78155688DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_54FFC70CC2E979A44AF7A78155688DA9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_54FFC70CC2E979A44AF7A78155688DA9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C" xlink:to="loc_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_101F028F0149B8A82038A7815568F876" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_101F028F0149B8A82038A7815568F876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_101F028F0149B8A82038A7815568F876" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_101F028F0149B8A82038A7815568F876" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_E9DBC9DC3CBAE4E16278A7815578C198" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_E9DBC9DC3CBAE4E16278A7815578C198" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_C29BEC83EC48AF4EE677A7815578FA05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_C29BEC83EC48AF4EE677A7815578FA05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B" xlink:to="lab_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:to="lab_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807_terseLabel_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807_label_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807_documentation_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:to="lab_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028_label_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028_documentation_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:to="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721_label_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721_documentation_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:to="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31_label_en-US" xlink:label="lab_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:to="lab_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:type="arc" />
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8879F590FA2287DE621A78155588EFB_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8879F590FA2287DE621A78155588EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8879F590FA2287DE621A78155588EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8879F590FA2287DE621A78155588EFB" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8879F590FA2287DE621A78155588EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="lab_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2_label_en-US" xlink:label="lab_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:to="lab_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:to="lab_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:to="lab_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C_label_en-US" xlink:label="lab_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:to="lab_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:type="arc" />
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:to="lab_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3_label_en-US" xlink:label="lab_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3" xlink:to="lab_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:to="lab_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B" xlink:to="lab_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84" xlink:to="lab_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7" xlink:to="lab_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1" xlink:to="lab_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA" xlink:to="lab_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:to="lab_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A" xlink:to="lab_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261" xlink:to="lab_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3850708542374A9B3E46A7815506ED80_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3850708542374A9B3E46A7815506ED80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3850708542374A9B3E46A7815506ED80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3850708542374A9B3E46A7815506ED80" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3850708542374A9B3E46A7815506ED80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:to="lab_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:to="lab_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:to="lab_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:to="lab_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:type="arc" />
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Our share of Samsung Bioepis gains (losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:to="lab_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:to="lab_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:to="lab_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:type="arc" />
    <link:label id="lab_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:to="lab_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:to="lab_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_876AEFCEEEE36186EA9EA7815623C02B_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_876AEFCEEEE36186EA9EA7815623C02B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_876AEFCEEEE36186EA9EA7815623C02B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_876AEFCEEEE36186EA9EA7815623C02B" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_876AEFCEEEE36186EA9EA7815623C02B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1_label_en-US" xlink:label="lab_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="lab_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209_label_en-US" xlink:label="lab_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209" xlink:to="lab_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06" xlink:to="lab_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD" xlink:to="lab_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010" xlink:to="lab_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14_label_en-US" xlink:label="lab_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14" xlink:to="lab_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B_label_en-US" xlink:label="lab_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B" xlink:to="lab_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D" xlink:to="lab_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2" xlink:to="lab_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F" xlink:to="lab_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772" xlink:to="lab_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667_label_en-US" xlink:label="lab_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667" xlink:to="lab_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC" xlink:to="lab_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611" xlink:to="lab_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4" xlink:to="lab_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80" xlink:to="lab_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA" xlink:to="lab_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B" xlink:to="lab_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8_label_en-US" xlink:label="lab_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8" xlink:to="lab_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D" xlink:to="lab_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3_label_en-US" xlink:label="lab_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3" xlink:to="lab_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2_label_en-US" xlink:label="lab_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2" xlink:to="lab_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B_label_en-US" xlink:label="lab_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B" xlink:to="lab_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB" xlink:to="lab_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84" xlink:to="lab_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F_label_en-US" xlink:label="lab_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F" xlink:to="lab_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906" xlink:to="lab_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB" xlink:to="lab_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3_label_en-US" xlink:label="lab_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3" xlink:to="lab_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_F9CB1C45E8701301EFBEA78156EFCA94_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_F9CB1C45E8701301EFBEA78156EFCA94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F9CB1C45E8701301EFBEA78156EFCA94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F9CB1C45E8701301EFBEA78156EFCA94" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_F9CB1C45E8701301EFBEA78156EFCA94" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:to="lab_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0118F776101B462B3947A78155C6491C_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0118F776101B462B3947A78155C6491C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0118F776101B462B3947A78155C6491C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0118F776101B462B3947A78155C6491C" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0118F776101B462B3947A78155C6491C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85" xlink:type="arc" />
    <link:label id="lab_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4_label_en-US" xlink:label="lab_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4" xlink:to="lab_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_199BA9D6EFD528A03681A7815568B8BF_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_199BA9D6EFD528A03681A7815568B8BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_199BA9D6EFD528A03681A7815568B8BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_199BA9D6EFD528A03681A7815568B8BF" xlink:to="lab_us-gaap_EquityAbstract_199BA9D6EFD528A03681A7815568B8BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="lab_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3A375256CD14F07C3FBEA78155689BC0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3A375256CD14F07C3FBEA78155689BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3A375256CD14F07C3FBEA78155689BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3A375256CD14F07C3FBEA78155689BC0" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3A375256CD14F07C3FBEA78155689BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2374D774819D177280BA78155686766_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2374D774819D177280BA78155686766" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2374D774819D177280BA78155686766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2374D774819D177280BA78155686766" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2374D774819D177280BA78155686766" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:to="lab_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:to="lab_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:type="arc" />
    <link:label id="lab_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:to="lab_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:to="lab_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604_label_en-US" xlink:label="lab_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:to="lab_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="lab_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:type="arc" />
    <link:label id="lab_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C_verboseLabel_en-US" xlink:label="lab_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C_label_en-US" xlink:label="lab_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:to="lab_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:type="arc" />
    <link:label id="lab_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C_terseLabel_en-US" xlink:label="lab_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C_label_en-US" xlink:label="lab_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:to="lab_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:type="arc" />
    <link:label id="lab_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368_terseLabel_en-US" xlink:label="lab_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368_label_en-US" xlink:label="lab_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:to="lab_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:type="arc" />
    <link:label id="lab_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4_terseLabel_en-US" xlink:label="lab_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4_label_en-US" xlink:label="lab_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:to="lab_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:type="arc" />
    <link:label id="lab_currency_CAD_46543F75F3DB8712EED9A78155A744AC_verboseLabel_en-US" xlink:label="lab_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_46543F75F3DB8712EED9A78155A744AC_label_en-US" xlink:label="lab_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:to="lab_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7_label_en-US" xlink:label="lab_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:to="lab_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:to="lab_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="lab_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:to="lab_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:to="lab_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:to="lab_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:to="lab_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:to="lab_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:to="lab_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:to="lab_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:to="lab_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:to="lab_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C_label_en-US" xlink:label="lab_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:to="lab_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490_terseLabel_en-US" xlink:label="lab_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490_label_en-US" xlink:label="lab_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:to="lab_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940_label_en-US" xlink:label="lab_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:to="lab_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E_label_en-US" xlink:label="lab_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:to="lab_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on reclassification of cash flow hedges, effective portion</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:to="lab_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:to="lab_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:type="arc" />
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:to="lab_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8B7E9E9A78527508AA51A781566245C7_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_8B7E9E9A78527508AA51A781566245C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8B7E9E9A78527508AA51A781566245C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8B7E9E9A78527508AA51A781566245C7" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_8B7E9E9A78527508AA51A781566245C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:to="lab_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="lab_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C_label_en-US" xlink:label="lab_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:to="lab_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:to="lab_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:type="arc" />
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:to="lab_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:to="lab_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:to="lab_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:to="lab_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:to="lab_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:to="lab_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:to="lab_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:type="arc" />
    <link:label id="lab_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:label id="lab_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F_label_en-US" xlink:label="lab_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:to="lab_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:to="lab_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48_label_en-US" xlink:label="lab_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48" xlink:to="lab_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_E8AD824DC11BB436EA77A78156910708_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_E8AD824DC11BB436EA77A78156910708" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E8AD824DC11BB436EA77A78156910708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_E8AD824DC11BB436EA77A78156910708" xlink:to="lab_us-gaap_Goodwill_E8AD824DC11BB436EA77A78156910708" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:to="lab_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1_label_en-US" xlink:label="lab_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:to="lab_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: Net gains (losses) recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities held as of March 31</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:to="lab_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08" xlink:to="lab_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:to="lab_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:to="lab_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:to="lab_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:to="lab_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:to="lab_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues related to amendment of contract manufacturing agreement</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F_label_en-US" xlink:label="lab_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:to="lab_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:to="lab_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:to="lab_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:to="lab_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:type="arc" />
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:to="lab_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration expected to be received for sale of Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum batch production for Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:type="arc" />
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2_terseLabel_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2_label_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2_documentation_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:to="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:to="lab_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:to="lab_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:to="lab_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:to="lab_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_93952F6056366A5DF9F4A7815539AA37_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_93952F6056366A5DF9F4A7815539AA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_93952F6056366A5DF9F4A7815539AA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93952F6056366A5DF9F4A7815539AA37" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_93952F6056366A5DF9F4A7815539AA37" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:type="arc" />
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_4ED307D53C9118FF4813A78155F5D6AA_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_4ED307D53C9118FF4813A78155F5D6AA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_4ED307D53C9118FF4813A78155F5D6AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_4ED307D53C9118FF4813A78155F5D6AA" xlink:to="lab_us-gaap_AvailableForSaleSecurities_4ED307D53C9118FF4813A78155F5D6AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C42638E5C63F5304B0A5A78155978205_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C42638E5C63F5304B0A5A78155978205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C42638E5C63F5304B0A5A78155978205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C42638E5C63F5304B0A5A78155978205" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C42638E5C63F5304B0A5A78155978205" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:to="lab_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:to="lab_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:to="lab_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8_label_en-US" xlink:label="lab_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:to="lab_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:to="lab_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:to="lab_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_E7E78B31CAC9B0DA72E9A781572D5606_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract_E7E78B31CAC9B0DA72E9A781572D5606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_E7E78B31CAC9B0DA72E9A781572D5606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_E7E78B31CAC9B0DA72E9A781572D5606" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract_E7E78B31CAC9B0DA72E9A781572D5606" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:type="arc" />
    <link:label id="lab_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:to="lab_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:to="lab_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_82AF2C15965330B13682A781572D47A7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_82AF2C15965330B13682A781572D47A7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_82AF2C15965330B13682A781572D47A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_82AF2C15965330B13682A781572D47A7" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_82AF2C15965330B13682A781572D47A7" xlink:type="arc" />
    <link:label id="lab_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351" xlink:to="lab_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:type="arc" />
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6_terseLabel_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6_label_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6_documentation_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:to="lab_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:to="lab_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:to="lab_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:type="arc" />
    <link:label id="lab_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002_label_en-US" xlink:label="lab_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002_documentation_en-US" xlink:label="lab_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:to="lab_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:type="arc" />
    <link:label id="lab_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66_label_en-US" xlink:label="lab_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66_documentation_en-US" xlink:label="lab_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:to="lab_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:type="arc" />
    <link:label id="lab_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A_terseLabel_en-US" xlink:label="lab_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB118</link:label>
    <link:label id="lab_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A_label_en-US" xlink:label="lab_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:label id="lab_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A_documentation_en-US" xlink:label="lab_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB118Member" xlink:label="loc_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:to="lab_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:type="arc" />
    <link:label id="lab_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A_terseLabel_en-US" xlink:label="lab_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A_label_en-US" xlink:label="lab_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A_documentation_en-US" xlink:label="lab_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:to="lab_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:type="arc" />
    <link:label id="lab_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F_terseLabel_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F_label_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F_documentation_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ClinicalAssetsAcquired" xlink:label="loc_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:to="lab_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for pre-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of post-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:type="arc" />
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, in-process research and development, discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD_terseLabel_en-US" xlink:label="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</link:label>
    <link:label id="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD_label_en-US" xlink:label="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:to="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23" xlink:to="lab_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:to="lab_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_8E0B4ADA6D81D83F8C2DA78155235069_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_8E0B4ADA6D81D83F8C2DA78155235069" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8E0B4ADA6D81D83F8C2DA78155235069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_8E0B4ADA6D81D83F8C2DA78155235069" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_8E0B4ADA6D81D83F8C2DA78155235069" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:to="lab_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_C602B6B6ED10B4F2AD62A781575E0DC6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_C602B6B6ED10B4F2AD62A781575E0DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C602B6B6ED10B4F2AD62A781575E0DC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C602B6B6ED10B4F2AD62A781575E0DC6" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_C602B6B6ED10B4F2AD62A781575E0DC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_EC133C6A44C973F44483A781572DF3CD_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_EC133C6A44C973F44483A781572DF3CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_EC133C6A44C973F44483A781572DF3CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_EC133C6A44C973F44483A781572DF3CD" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_EC133C6A44C973F44483A781572DF3CD" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_463F900C808A7C92E308A781572D4953_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_463F900C808A7C92E308A781572D4953_label_en-US" xlink:label="lab_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_463F900C808A7C92E308A781572D4953_documentation_en-US" xlink:label="lab_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:to="lab_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A_label_en-US" xlink:label="lab_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A_documentation_en-US" xlink:label="lab_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:to="lab_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5_label_en-US" xlink:label="lab_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:to="lab_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874_label_en-US" xlink:label="lab_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:to="lab_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:type="arc" />
    <link:label id="lab_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:to="lab_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE_label_en-US" xlink:label="lab_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:to="lab_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26_label_en-US" xlink:label="lab_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:to="lab_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:type="arc" />
    <link:label id="lab_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4_label_en-US" xlink:label="lab_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4_documentation_en-US" xlink:label="lab_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:to="lab_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA_label_en-US" xlink:label="lab_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:to="lab_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA_label_en-US" xlink:label="lab_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:to="lab_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D_label_en-US" xlink:label="lab_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:to="lab_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:to="lab_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:to="lab_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:type="arc" />
    <link:label id="lab_country_US_80F9C82CDA7FC97DBE6DA781572D86AD_terseLabel_en-US" xlink:label="lab_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_80F9C82CDA7FC97DBE6DA781572D86AD_label_en-US" xlink:label="lab_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:to="lab_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32_label_en-US" xlink:label="lab_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:to="lab_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:to="lab_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:to="lab_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_99216856794D57E1B9CFA7C40290A478_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_99216856794D57E1B9CFA7C40290A478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_99216856794D57E1B9CFA7C40290A478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_99216856794D57E1B9CFA7C40290A478" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_99216856794D57E1B9CFA7C40290A478" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:type="arc" />
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:type="arc" />
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52_terseLabel_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52_label_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52_documentation_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:to="lab_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:type="arc" />
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0_terseLabel_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0_label_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0_documentation_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:to="lab_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:to="lab_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:to="lab_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:to="lab_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:to="lab_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:to="lab_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:to="lab_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF_label_en-US" xlink:label="lab_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:to="lab_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:to="lab_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:to="lab_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interest, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:to="lab_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting guidance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:to="lab_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9EC7636508AB87EE9BC3A7C402A0F1B8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9EC7636508AB87EE9BC3A7C402A0F1B8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9EC7636508AB87EE9BC3A7C402A0F1B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9EC7636508AB87EE9BC3A7C402A0F1B8" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9EC7636508AB87EE9BC3A7C402A0F1B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_F3AB840C3D1981E6A317A7C402A04734_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F3AB840C3D1981E6A317A7C402A04734" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F3AB840C3D1981E6A317A7C402A04734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_F3AB840C3D1981E6A317A7C402A04734" xlink:to="lab_us-gaap_StockholdersEquity_F3AB840C3D1981E6A317A7C402A04734" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_E4B592F503958A5475F8A7C402A03D11_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_E4B592F503958A5475F8A7C402A03D11" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_E4B592F503958A5475F8A7C402A03D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_E4B592F503958A5475F8A7C402A03D11" xlink:to="lab_us-gaap_MinorityInterest_E4B592F503958A5475F8A7C402A03D11" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_2DA5EB746DE847ACA4E6A7C402A02906_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_2DA5EB746DE847ACA4E6A7C402A02906" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2DA5EB746DE847ACA4E6A7C402A02906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2DA5EB746DE847ACA4E6A7C402A02906" xlink:to="lab_us-gaap_SharesIssued_2DA5EB746DE847ACA4E6A7C402A02906" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_AAEFCA42D32A5D66A00FA7C3D93D373C_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_AAEFCA42D32A5D66A00FA7C3D93D373C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_AAEFCA42D32A5D66A00FA7C3D93D373C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_AAEFCA42D32A5D66A00FA7C3D93D373C" xlink:to="lab_us-gaap_ProfitLoss_AAEFCA42D32A5D66A00FA7C3D93D373C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5" xlink:to="lab_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_302F23A73E16A5D67074A7C3D93D5F64_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_302F23A73E16A5D67074A7C3D93D5F64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_302F23A73E16A5D67074A7C3D93D5F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_302F23A73E16A5D67074A7C3D93D5F64" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_302F23A73E16A5D67074A7C3D93D5F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_325222A3B07C4C33E573A7C3D93DC420_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_325222A3B07C4C33E573A7C3D93DC420" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_325222A3B07C4C33E573A7C3D93DC420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_325222A3B07C4C33E573A7C3D93DC420" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_325222A3B07C4C33E573A7C3D93DC420" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_CE7D643F05EBAAFAEB15A7C3D94CE2C9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_CE7D643F05EBAAFAEB15A7C3D94CE2C9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_CE7D643F05EBAAFAEB15A7C3D94CE2C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_CE7D643F05EBAAFAEB15A7C3D94CE2C9" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_CE7D643F05EBAAFAEB15A7C3D94CE2C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4186B793C1EAF1B62121A7C6AD023D78_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4186B793C1EAF1B62121A7C6AD023D78" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4186B793C1EAF1B62121A7C6AD023D78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4186B793C1EAF1B62121A7C6AD023D78" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4186B793C1EAF1B62121A7C6AD023D78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:type="arc" />
    <link:label id="lab_biib_TGNMember_26512949946FAB74B425A78156B03D8C_terseLabel_en-US" xlink:label="lab_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_26512949946FAB74B425A78156B03D8C_label_en-US" xlink:label="lab_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_26512949946FAB74B425A78156B03D8C_documentation_en-US" xlink:label="lab_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:to="lab_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:to="lab_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:to="lab_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E_label_en-US" xlink:label="lab_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E_documentation_en-US" xlink:label="lab_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:to="lab_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BF5D44662551ABE41EEDA78156529D47_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BF5D44662551ABE41EEDA78156529D47" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BF5D44662551ABE41EEDA78156529D47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BF5D44662551ABE41EEDA78156529D47" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BF5D44662551ABE41EEDA78156529D47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C270B96833B8D98A22BBA78154F8C064_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C270B96833B8D98A22BBA78154F8C064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C270B96833B8D98A22BBA78154F8C064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C270B96833B8D98A22BBA78154F8C064" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C270B96833B8D98A22BBA78154F8C064" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595_label_en-US" xlink:label="lab_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:to="lab_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0_label_en-US" xlink:label="lab_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:to="lab_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0_label_en-US" xlink:label="lab_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0_documentation_en-US" xlink:label="lab_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:to="lab_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2_netLabel_en-US" xlink:label="lab_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:to="lab_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25B957A058476135F206A7C54A1E31B1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25B957A058476135F206A7C54A1E31B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25B957A058476135F206A7C54A1E31B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25B957A058476135F206A7C54A1E31B1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25B957A058476135F206A7C54A1E31B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A_label_en-US" xlink:label="lab_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A_documentation_en-US" xlink:label="lab_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:to="lab_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:type="arc" />
    <link:label id="lab_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_UCBPharmaS.A.Member" xlink:label="loc_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:to="lab_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:type="arc" />
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SangamoTherapeuticsInc.AgreementMember" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:type="arc" />
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:to="lab_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:type="arc" />
    <link:label id="lab_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E_terseLabel_en-US" xlink:label="lab_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401</link:label>
    <link:label id="lab_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E_label_en-US" xlink:label="lab_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BAN2401 [Member]</link:label>
    <link:label id="lab_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E_documentation_en-US" xlink:label="lab_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_BAN2401Member" xlink:label="loc_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:to="lab_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:type="arc" />
    <link:label id="lab_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:to="lab_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD_label_en-US" xlink:label="lab_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD_documentation_en-US" xlink:label="lab_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:to="lab_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:type="arc" />
    <link:label id="lab_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3_terseLabel_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3_label_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elenbecestat Collaboration [Member]</link:label>
    <link:label id="lab_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3_documentation_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elenbecestat Collaboration [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ElenbecestatCollaborationMember" xlink:label="loc_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:to="lab_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:to="lab_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:to="lab_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:type="arc" />
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:to="lab_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="lab_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="lab_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8F0F9887D841EE7898B3A79B25A7C964_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8F0F9887D841EE7898B3A79B25A7C964" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8F0F9887D841EE7898B3A79B25A7C964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8F0F9887D841EE7898B3A79B25A7C964" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8F0F9887D841EE7898B3A79B25A7C964" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407_label_en-US" xlink:label="lab_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407" xlink:to="lab_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB" xlink:to="lab_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897" xlink:to="lab_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_407B984FAD3813F95D0AA78157C2A18F_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_407B984FAD3813F95D0AA78157C2A18F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_407B984FAD3813F95D0AA78157C2A18F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_407B984FAD3813F95D0AA78157C2A18F" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_407B984FAD3813F95D0AA78157C2A18F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_D0A2012080CC118E4C86A78157C2F23D_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill_D0A2012080CC118E4C86A78157C2F23D" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D0A2012080CC118E4C86A78157C2F23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_D0A2012080CC118E4C86A78157C2F23D" xlink:to="lab_us-gaap_Goodwill_D0A2012080CC118E4C86A78157C2F23D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773_label_en-US" xlink:label="lab_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773" xlink:to="lab_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821" xlink:to="lab_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22" xlink:to="lab_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457" xlink:to="lab_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_1DB4033D96EAE089F19CA78157C2DF02_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1DB4033D96EAE089F19CA78157C2DF02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1DB4033D96EAE089F19CA78157C2DF02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1DB4033D96EAE089F19CA78157C2DF02" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1DB4033D96EAE089F19CA78157C2DF02" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4" xlink:to="lab_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3" xlink:to="lab_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E_label_en-US" xlink:label="lab_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E" xlink:to="lab_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015" xlink:to="lab_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="lab_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94" xlink:to="lab_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E" xlink:to="lab_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846" xlink:to="lab_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84F1DF200AF232C081D6A78157C2AF2B_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84F1DF200AF232C081D6A78157C2AF2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84F1DF200AF232C081D6A78157C2AF2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84F1DF200AF232C081D6A78157C2AF2B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84F1DF200AF232C081D6A78157C2AF2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291" xlink:to="lab_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_96333795472B2C3C26D0A78157C23918_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_96333795472B2C3C26D0A78157C23918" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_96333795472B2C3C26D0A78157C23918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_96333795472B2C3C26D0A78157C23918" xlink:to="lab_us-gaap_StockholdersEquity_96333795472B2C3C26D0A78157C23918" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_B83ACEE9A2B94775EE66A78157C2C934_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_B83ACEE9A2B94775EE66A78157C2C934" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_B83ACEE9A2B94775EE66A78157C2C934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_B83ACEE9A2B94775EE66A78157C2C934" xlink:to="lab_us-gaap_MinorityInterest_B83ACEE9A2B94775EE66A78157C2C934" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CB1C12528E7E176A236BA78157C2D884_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CB1C12528E7E176A236BA78157C2D884" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CB1C12528E7E176A236BA78157C2D884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CB1C12528E7E176A236BA78157C2D884" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CB1C12528E7E176A236BA78157C2D884" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:type="arc" />
    <link:label id="lab_country_BR_E05F1284F18CB6C557FEA78154F440D2_terseLabel_en-US" xlink:label="lab_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_E05F1284F18CB6C557FEA78154F440D2_label_en-US" xlink:label="lab_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:to="lab_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:to="lab_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:to="lab_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:to="lab_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:to="lab_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation inputs</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:to="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5BCA14B30C1B7A03B6C1A7C37D0F166A_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5BCA14B30C1B7A03B6C1A7C37D0F166A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5BCA14B30C1B7A03B6C1A7C37D0F166A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5BCA14B30C1B7A03B6C1A7C37D0F166A" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5BCA14B30C1B7A03B6C1A7C37D0F166A" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:to="lab_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:to="lab_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark assets held for sale</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:to="lab_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="lab_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_73DD0B040B1F949287AAA78155E545B2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_73DD0B040B1F949287AAA78155E545B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_73DD0B040B1F949287AAA78155E545B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_73DD0B040B1F949287AAA78155E545B2" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_73DD0B040B1F949287AAA78155E545B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:to="lab_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:to="lab_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:to="lab_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20200331.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20200331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20200331.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20200331.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20200331.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20200331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20200331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20200331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20200331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20200331.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20200331.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20200331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20200331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20200331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20200331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20200331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20200331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:href="biib-20200331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20200331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20200331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20200331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20200331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20200331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20200331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20200331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20200331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20200331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20200331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20200331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20200331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20200331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20200331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20200331.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20200331.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20200331.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20200331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20200331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200331.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20200331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20200331.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20200331.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20200331.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20200331.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20200331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20200331.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20200331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20200331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20200331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20200331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20200331.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20200331.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20200331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_199BA9D6EFD528A03681A7815568B8BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_199BA9D6EFD528A03681A7815568B8BF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9D09FF6142633C91D4C5A7815568DE77" xlink:to="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FC6B1A5E66AE775A7AC6A78155687993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_A1089AD550E821D4F745A7815568FFE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8CEF2617D26601B2673DA7815568F59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_FE544D6F8E1C01E8DF49A7815568A0B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4F28D5E92B0AFF91FEC2A78155685656" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_8752CB05902CCD45CC51A7815568B0E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_837890472651C22630F8A7815568A9D7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F71684A7A57EB97FCF1EA7815568FC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3A375256CD14F07C3FBEA78155689BC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3A375256CD14F07C3FBEA78155689BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8E897D7CB094B702ECF0A7815568AA56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6964118577B7D93A8EDDA7815568AADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5EA49840F5820C10F347A7815568CFFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2374D774819D177280BA78155686766" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2374D774819D177280BA78155686766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A0E88430F7F9AA1E0C22A7815568B087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_322A70E3C79E471E392CA78155682F04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B8AD782A88A2633518A0A7815578E14D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B8AD782A88A2633518A0A7815578E14D" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_36BF9C82507927FC7601A7815578CA8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B8AD782A88A2633518A0A7815578E14D" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8CB3FFAC344339025DD8A7815578FBF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C602B6B6ED10B4F2AD62A781575E0DC6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C602B6B6ED10B4F2AD62A781575E0DC6" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E16B5F6FBC235587FAA0A781575E5F9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_5557AA71EE1E44E42C5EA781573D0086" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AE01571AF2786F48EA57A781574CFED2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_5557AA71EE1E44E42C5EA781573D0086" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AE01571AF2786F48EA57A781574CFED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AF611DE35717095A846BA781574CDB41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AE01571AF2786F48EA57A781574CFED2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AF611DE35717095A846BA781574CDB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AF611DE35717095A846BA781574CDB41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_E0AEE2676127B3EF28FBA781574CCD85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C5AFB43D14CE60EC20FA781574CC0F1" xlink:to="loc_biib_NightstarMember_E0AEE2676127B3EF28FBA781574CCD85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AE01571AF2786F48EA57A781574CFED2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D530C9715484CB64E31DA781574CB31A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_C2E4810DA13733AD3F1CA781574C5723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A7BB2CB9F31CBAAF297A781574C03B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5A7BB2CB9F31CBAAF297A781574C03B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_Goodwill_46C2001B66A056E43E28A781574C401C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A1084ABDC5E6F642D3E1A781574C90D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_BBD06590A458DCB566BBA781574CF878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35374BA7FED8F93DC419A781574CA388" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DEA6A65C33B1EDDA9626A781574CCA6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_0E4189EF0A1F8CBCFA0DA8302845C351" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E54DE17ED3EE3753141A8302846E970" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_CA6851DBC1092BA5EEF5A83028465069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_CFF35C3BDA0788467197A8302846A51C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_65680E5246942FD81783A83028465F54" xlink:to="loc_biib_PostacquisitionequitycompensationMember_C10769F68E00675B8583A83028479DC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_5E42251764F51AD781B3A83028477CC5" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:to="loc_biib_BIIB111Member_3915DF070360ADB6B2C9A8302847F002" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_0F16A826EB72304C5E76A830284788AA" xlink:to="loc_biib_BIIB112Member_A9A366AC48D14F563551A83028488B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2DB1DB49AEB44E09EFDDA8302848A25C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2DB1DB49AEB44E09EFDDA8302848A25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2DB1DB49AEB44E09EFDDA8302848A25C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ACFEB277A3A44EB25FBFA8302848AA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E82378C34EB06191EF5A8302848FBE9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E48974E6111C0221B16A830284948CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7DA504D5FB320FE68A5AA8302849E9AA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BIIB118Member" xlink:label="loc_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:to="loc_biib_BIIB118Member_5585FD90D7A3F83545EFA83028496C6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D683CF14DE4CE63DC8FDA83028497428" xlink:to="loc_biib_NightstarMember_D386AB51DAD6957439D0A8302849CD7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0E0847FBC55D8CD13431A8302845E669" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_69C7E8FF5764A51830F9A830284A2D9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_69C7E8FF5764A51830F9A830284A2D9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_02DA464D78A63EECD52AA830284AADB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_02DA464D78A63EECD52AA830284AADB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ClinicalAssetsAcquired" xlink:label="loc_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_biib_ClinicalAssetsAcquired_46495BA07C48EC78D994A830D6E44B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1A9967816A5562A75CA0A830284AEC2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6DAF19E89C24A6353D2EA830284A3DED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1196634B2DF8D384B27DA830284AE1A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_BCB5AEF060BDEFD0C902A830284AA3C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_83086DB7B6B88AD650FAA830284A27F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C599FA8F1C3F3A13C4A2A830284A0400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_BCD86B0AFAE9727ABEE7A832F6DD0FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203B98E6EB70229298CBA8302849B2C8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_BE986235EE02DA742E2BA830284AB7CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CB90090D7E23B641B126A7815521F24F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CB90090D7E23B641B126A7815521F24F" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_29EFCBC9CCAD6A1AE7AFA7815521DF30" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9074D76DE222245DEB05A7C11F5FFD3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9074D76DE222245DEB05A7C11F5FFD3E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F5F46CA4FA04481ADCA0A7C11F60AF78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F5F46CA4FA04481ADCA0A7C11F60AF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F5F46CA4FA04481ADCA0A7C11F60AF78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_876095C03AD023D7DF92A7C11F60381C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_876095C03AD023D7DF92A7C11F60381C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B225717C2F7F3C9A401EA7C11F613179" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E8A237061DB232B7666EA7C11F60715D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B225717C2F7F3C9A401EA7C11F613179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6B17EFD391418ABB3136A7C11F616D65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6B17EFD391418ABB3136A7C11F616D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6B17EFD391418ABB3136A7C11F616D65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E0914BC1504570513A8AA7C11F61D6CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_us-gaap_CollaborativeArrangementMember_E0914BC1504570513A8AA7C11F61D6CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_EisaiMember_F2215EAAE8E3622DEF13A7C11F62FB4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UCBPharmaS.A.Member" xlink:label="loc_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_UCBPharmaS.A.Member_11D1FF8547087EAEBC0EA7C11F62FC16" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SangamoTherapeuticsInc.AgreementMember" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_458FF361B77382F476CBA7C11F62D91D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_447CDCE6EC9A2745AC45A7C11F615FEC" xlink:to="loc_biib_SkyhawkTherapeuticsMember_2ADFF8F234FA289C3111A7C11F62FA2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1F698BB6D1A80A83B179A7C11F62F498" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="loc_srt_ProductOrServiceAxis_1F698BB6D1A80A83B179A7C11F62F498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1F698BB6D1A80A83B179A7C11F62F498" xlink:to="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BAN2401Member" xlink:label="loc_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_BAN2401Member_3AD3CC8CC3A7ADE29DA6A7CB7F58DA3E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_E2609andBAN2401Member_706D40098548898AA6F7A7C11F63B694" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_AducanumabMember_75F51C857A3D7A156C9BA7C11F6382BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ElenbecestatCollaborationMember" xlink:label="loc_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D80EF7E0163EDAF32CFAA7C11F62C7B9" xlink:to="loc_biib_ElenbecestatCollaborationMember_FFE996890390077C4308A7CBF7AB80A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_539977CAA1E57A6D929FA7C11F6052FF" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_BB8D1CF19D73882322B9A7C11F632B1F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_BB4D9EF2B3DEB452B3E5A7C11F645639" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_8DFF9B8A4F1A2854EA95A7C11F64390A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_927EA23D7845BC6D5D45A7C11F6429D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_927EA23D7845BC6D5D45A7C11F6429D7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_ExpenseIncurredByCollaboration_8E8068DB90859C5F7CA0A7C11F645BEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_Expenseincurredbythecollaboration_282C7B52F0DF01B95EB2A7C11F643385" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_F544ECACA30E6D7A9809A7C11F64A5DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6A00A0E315DB753AE108A7C11F650730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_LossOnContractTermination_7F5FC1442F5020DF3A66A7C11F65EA2B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_CCCC5A06FE91DC65725FA7C11F656DB3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_AdditionalMilestonePayment_CCCC5A06FE91DC65725FA7C11F656DB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_FF7DAB62C03D22A2D7F7A7C11F65C64A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_FF7DAB62C03D22A2D7F7A7C11F65C64A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_B28AAB4DF52230B4D6CEA7C11F65FEB2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_CBFD3A1E91D9D58FEB83A7C11F65C32E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_3A339D3B6DB2A64A9ADAA7C11F65F202" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_7D282B41CF4526930994A7C11F661E6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_60878D643028BCCFC857A7C11F66EBF3" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_60878D643028BCCFC857A7C11F66EBF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_4C4131EEF1315FC757A7A7C11F66CB72" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9646B972224980B6B155A7C11F636723" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_4C4131EEF1315FC757A7A7C11F66CB72" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3850708542374A9B3E46A7815506ED80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3850708542374A9B3E46A7815506ED80" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0C6827386A3A3765D983A781550610A9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_us-gaap_InventoriesMember_75C0E2E338763E3443F1A78155077E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_C6A0AB8E0677486B8D78A78155074CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_02D07581299F19DF3D86A78155077C81" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B80C3667D75BDBA9AEF8A781550605B1" xlink:to="loc_biib_DeferredtaxliabilityMember_8A9FAB96EBFB0A0058E6A7815507AB73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C5DCE81BC1CFB5534D75A781550702D7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52E4C8E75E85E067E7C0A78155078EE9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_94B95EF802B152E614EAA7815508A0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BAE949D558E3B0355D42A78155088D0C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B267D0A9E81FC00B7335A78155085931" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_D59FA1B00351924FE1F2A7815508EDF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2B3EA0DAF6662CDB276AA781550625E1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C91193BEF01559E6D3A2A7815509E6A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_687E7026C16F314829A7A781550979B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_72936AA586DDBA615CD4A78155096EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8D5B882F42B830293115A78155093276" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_22D7A16B3F50203553B9A781550A0521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_349C85F7DB0A231FB7B2A781550A0745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5924AED3DC7C0BE3EC18A781550ABDF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_AdjustmentForAmortization_53213C379B6BA10035D8A781550A3F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_EquityMethodInvestments_A4DE3B2EC4C9D1547FFBA781550A0E41" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_A31C8C3B19D7B9AC3D0AA781550AC85D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4A1E44551F42F75FA3BCA781550B64F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_47460B33684D94AE65EFA781550B377A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_4F6F89640F35BA0A8420A781550B7A07" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_AdditionalMilestonePayment_B531EFA22284C836914EA781550BAA67" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_ContractOptionExerciseFee_6C6F3B2A47FD3EB72F50A781550B5CD2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_A5BA3AC508800DC3BA61A781550B0B62" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_7571AF31D1F49CE6A6FEA781550B8E3A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_biib_Collaborationprofitlosssharing_7571AF31D1F49CE6A6FEA781550B8E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_890B2481F3DA88AE4BFAA781550C6633" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_Revenues_890B2481F3DA88AE4BFAA781550C6633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_DueFromRelatedParties_62AF8EE1ECADDAD1E1BBA781550CBAF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2FE8656144366B95824BA7815509E4DB" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_CE68742F0F619DC6A292A781550C3A1F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17C71F5098E62DC300C3A781551FFE79" xlink:type="locator" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17C71F5098E62DC300C3A781551FFE79" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_B0558369AA621527C301A781551FC2A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17C71F5098E62DC300C3A781551FFE79" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4DC3B33618739FD43A5FA781551FF66F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1" xlink:to="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8F0F9887D841EE7898B3A79B25A7C964" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8F0F9887D841EE7898B3A79B25A7C964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DBAA9B0F290DEB23E460A78157C2D693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4EE3B8FB3584495A0E68A78157C2BCDB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_A62B57B74BDDB289AFB2A78157C24D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="loc_us-gaap_InventoryNet_D42253205ACF91BA3370A78157C22407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="loc_us-gaap_OtherAssetsCurrent_1D307A6FF76C7DC80D6BA78157C2BEEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_09DA795C076BDE77717FA78157C2327B" xlink:to="loc_us-gaap_AssetsCurrent_326778BE3CC98880C1F0A78157C20897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8FF894AA4F17E76F4FD9A78157C2F24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_A45537482F4FACF4BD1DA78157C212BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5CE582BB2034C740C0A1A78157C2357C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_407B984FAD3813F95D0AA78157C2A18F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_407B984FAD3813F95D0AA78157C2A18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D0A2012080CC118E4C86A78157C2F23D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_Goodwill_D0A2012080CC118E4C86A78157C2F23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_70D82249D2096AD57A14A78157C24883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5640B0204AAAB6B626E8A78157C2924A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_CA97E69DA5ABC6B33672A78157C20B25" xlink:to="loc_us-gaap_Assets_E11D8B83AE5B9CC3E851A78157C23773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25302DC45F80B2F6E098A78157C2C0A1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:to="loc_us-gaap_NotesPayableCurrent_E9BCDD97D01D32B05B83A78157C2C821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:to="loc_us-gaap_TaxesPayableCurrent_41E7EDEE8EF14B815108A78157C27E22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:to="loc_us-gaap_AccountsPayableCurrent_A46B1E3EBBD222809D41A78157C22457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1DB4033D96EAE089F19CA78157C2DF02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1DB4033D96EAE089F19CA78157C2DF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F3A21DCF351E9AFBA9A5A78157C2D124" xlink:to="loc_us-gaap_LiabilitiesCurrent_172E65DAAAA05AAF0C06A78157C22EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_LongTermDebt_8A46CB02A7897ECF8222A78157C28FD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1C24A0EBBC4E393B2AB5A78157C29F3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8DB46ADA1B05BC479CD7A78157C20141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_55CCA6FFDD820E88C0E7A78157C2D5CB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_55CCA6FFDD820E88C0E7A78157C2D5CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_Liabilities_E2A61166580ADCFF47C0A78157C2464E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3918E81A8C58ACCD02D6A78157C23015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="loc_us-gaap_PreferredStockValue_66FB7CE8D95D2A9D50ABA78157C20E94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="loc_us-gaap_CommonStockValue_EB9D051583910FABD601A78157C22B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="loc_us-gaap_AdditionalPaidInCapital_61D703B954B2D8F38CE6A78157C21846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84F1DF200AF232C081D6A78157C2AF2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84F1DF200AF232C081D6A78157C2AF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63795C189FC8FA574D40A78157C22B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="loc_us-gaap_TreasuryStockValue_EEC5077FF470ABDFF9E4A78157C2F291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_96333795472B2C3C26D0A78157C23918" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4100676AB8BD06C18333A78157C2D778" xlink:to="loc_us-gaap_StockholdersEquity_96333795472B2C3C26D0A78157C23918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_B83ACEE9A2B94775EE66A78157C2C934" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:to="loc_us-gaap_MinorityInterest_B83ACEE9A2B94775EE66A78157C2C934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CB1C12528E7E176A236BA78157C2D884" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AA7C149AB6D7CD3A98B3A78157C251B2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_CB1C12528E7E176A236BA78157C2D884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_816CBF84861D2A407F65A78157C2A7BD" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_500D60F6885E87E99D40A78157C21B0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_EED6C9D6744E1D40C076A78157B3626E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EED6C9D6744E1D40C076A78157B3626E" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_63BE12849B3A62CE8EF7A78157B3922A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EED6C9D6744E1D40C076A78157B3626E" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E396474669ECBE732AA78157B3ABA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_99216856794D57E1B9CFA7C40290A478" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_99216856794D57E1B9CFA7C40290A478" xlink:to="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_71A4337E790D26A5812EA7C402904568" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_B4F0F4B15C0B5D07B9B1A7C40290CA6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_E0FD52188974885F45D4A7C402908F52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5302974415FBE8CCFE81A7C40290022C" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_F9050A98BBF4545CCE57A7C40290FEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4AADA7D8D461DE50F484A7C402906162" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4AADA7D8D461DE50F484A7C402906162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4AADA7D8D461DE50F484A7C402906162" xlink:to="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_PreferredStockMember_BEA9CA67ED325B84470EA7C40290F460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_CommonStockMember_DDE01616D30929B6718CA7C402902372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6B1AA2D30C0B0A96C406A7C402902699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5852067FD94848C70BD4A7C40290E4C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_RetainedEarningsMember_2556483F9BB874E0D555A7C40290350B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_TreasuryStockMember_CEC3EB1305E2651071E7A7C402908D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1CB00C1D6BDECE184016A7C40290A616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37A6ADD451E1FA4BA036A7C40290EA55" xlink:to="loc_us-gaap_ParentMember_3F7561F36DA4555485B0A7C40290079C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98808060A2A28BFC53B0A7C40290BCB1" xlink:to="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D9B69BD189F0B4E3AA24A7C402A00758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_SharesIssued_983B14C24C7C51ECBB67A7C402A0BCCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquity_3BE9822C0D78C69EC7ADA7C402A0C926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_MinorityInterest_1E15FD7F83D61FCE7A96A7C402A0DCE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EB80E00A607AE2D3EE47A7C402A0F159" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_NetIncomeLoss_EB80E00A607AE2D3EE47A7C402A0F159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4AEBA624BD6CE097D586A7C402A0D4B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_ProfitLoss_4BED2BB0F495472D24F6A7C402A02AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7A12899070067E2D9B08A7C402A0D493" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7A12899070067E2D9B08A7C402A0D493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5D21CAB18FEB8957B1DCA7C402A0871B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5D21CAB18FEB8957B1DCA7C402A0871B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_EFDFD84ABCE7B3A205E8A7C402A0D56A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3900FD339E08DA2073BCA7C402A02A8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_FA21E0B69DFCCBB27D62A7C402A0DC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_398A89CC46999CB3D622A7C402A0570B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4F7D99BD28C93A9D2F88A7C402A06A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_3E50F1BD802576E6F07FA7C402A064A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_B6109B630667448909A7A7C402A0163B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6F74397CC2F32305C098A7C402A00730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4ED34044D7B75C758A0AA7C402A08C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_985F99E3C2FCFF0E70F2A7C402A03DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquityOther_5051F225B09CC35897E2A7C402A071F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9EC7636508AB87EE9BC3A7C402A0F1B8" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9EC7636508AB87EE9BC3A7C402A0F1B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F3AB840C3D1981E6A317A7C402A04734" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_StockholdersEquity_F3AB840C3D1981E6A317A7C402A04734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_E4B592F503958A5475F8A7C402A03D11" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_MinorityInterest_E4B592F503958A5475F8A7C402A03D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2DA5EB746DE847ACA4E6A7C402A02906" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DCE03550C4CA6607EBD7A7C402A0E144" xlink:to="loc_us-gaap_SharesIssued_2DA5EB746DE847ACA4E6A7C402A02906" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_AAEFCA42D32A5D66A00FA7C3D93D373C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:to="loc_us-gaap_ProfitLoss_AAEFCA42D32A5D66A00FA7C3D93D373C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B51BE2A87793354CC3EEA7C3D93DBF13" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_BF91E2979E6486BA4959A7C3D93DFD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_A5E830154C94982151CEA7C3D93D4FDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_A5E830154C94982151CEA7C3D93D4FDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_ShareBasedCompensation_1517593DF8C820621AB8A7C3D93DC1D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_302F23A73E16A5D67074A7C3D93D5F64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_302F23A73E16A5D67074A7C3D93D5F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_5CB5DA76468957FD7BB8A7C3D93D9BFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F8F20BBFE4E73F8DC03BA7C3D93D45D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_EFB2265EA42329F2D97AA7C3D93D7DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_325222A3B07C4C33E573A7C3D93DC420" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_325222A3B07C4C33E573A7C3D93DC420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_CBFFDAA12EF496843914A7C3D93D3ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7B6B35C8EF6F89AF366AA7C3D93DC032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_E3C60D296B01EE8AE180A7C3D93DA810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_181B8080CBDD677D5B40A7C3D93D89F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_566686A153BCC3522883A7C3D94CE63F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_81036E57DA49DF831AA9A7C3D94C38F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EE8376CBA18157A09ABDA7C3D93DD953" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_976D77805E7B53848FB9A7C3D94C7F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5FCD8138996B2C485A3AA7C3D93D354F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_575A37C93C5C8A0DAC46A7C3D94C192E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B2DFFC5B68965F33F998A7C3D94C75C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58CF680BA857F63736ABA7C3D94C6819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_945D24E8540E80BFCD9DA7C3D94C4D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8AB255E66260633AE617A7C3D94C1B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7444A473FA6A5838E7AA7C3D94CF9AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DCC5DA10448490D6C13DA7C3D94CDD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_501BF44A33E90CE7BBAFA7C3D94C0B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_025DB331227636CB015BA7C3D94C8352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38207501B58AFB67E8C4A7C3D94C9747" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A05FEDE39463B18F11DDA7C3D94C1DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7DEDDCFA5FAF94D54D17A7C3D94C4408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B511AEE41C3549696165A7C3D94C4D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_CE7D643F05EBAAFAEB15A7C3D94CE2C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_CE7D643F05EBAAFAEB15A7C3D94CE2C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60528066DD0E3BB79F7CA7C3D94C3704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3E0CA58549EA147A39E4A7C3D94C8EEE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E104EED8FBA45EE624D2A7C3D94CF824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E45A3D1B0276E9670071A7C3D94C8354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_E5761C079FC2744402E3A7C3D94C7636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_663F0ACB362461602CE5A7C3D94CDE10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4186B793C1EAF1B62121A7C6AD023D78" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_977260F22B6EC4037488A7C3D93DAA5E" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4186B793C1EAF1B62121A7C6AD023D78" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2D8C24FCE1315F5A0BB8A7C54A1D78CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53" xlink:to="loc_us-gaap_NetIncomeLoss_2D8C24FCE1315F5A0BB8A7C54A1D78CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48132C16B1F4633042BBA7C54A1C5F53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_DADF5B0F9BAF5EA4880BA7C54A1DF99D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_FDAB46D5BB57D938F167A7C54A1DBE98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_E5CE23D702F0B2F5F24BA7C54A1E7173" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_E5CE23D702F0B2F5F24BA7C54A1E7173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_501B04DDCC1779988835A7C54A1E21AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_834FED09EF6B7898A27BA7C54A1EAA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25B957A058476135F206A7C54A1E31B1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25B957A058476135F206A7C54A1E31B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6F1DF4FA18950E9C33A3A7C54A1EC883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_84B8995A46BB5BBE682AA7C54A1E20F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D6563AC39916A2F35953A7C54A1DE0C3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81F49F49CB2E5DD3E33CA7C54A1F9D70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:to="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7E5E5054333B9564D934A78157D29B5F" xlink:to="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:to="loc_us-gaap_ProductMember_121F01D84F28185C1A29A78157D24E9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E7F73A842C2AE1A08F3DA78157D29F01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_387F493020EDC4DC3187A78157D260DA" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0DBA69230CEDF98D933FA78157D2BB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AD508F36B557155B03C1A78157D2A6B2" xlink:to="loc_us-gaap_StatementLineItems_FD1E7133C6AE7A1BEB5FA78157D2B369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_Revenues_625E97E2518FFD0F9D2AA78157D2E2B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_51AAFFAB589BAFFDFAB7A78157E2BB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5D3ACEB2CC92C8BE6230A78157E2A3FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CEFD690F9C3019A857CAA78157E2398C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_CB058AF64386C8C634E2A78157E2A904" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_biib_Collaborationprofitlosssharing_9E3604BC952F39D1629BA78157E2605D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_56ECFC0662CB500BEF13A78157E25AB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6FA572EF4E0BAAD7590CA78157E2B786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_RestructuringCharges_C0BC94C01A05441663F7A78157E2992B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1A5C780D22D6B71AEA0CA78157E24F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9D2BDE920AF4EB8B9C66A78157E20BC3" xlink:to="loc_us-gaap_CostsAndExpenses_EF0D4521E2090E368C2DA78157E2DF84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_OperatingIncomeLoss_138B48F970ABFAE2FBF2A78157E2BCE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3EC924B0C13B8C44D36CA78157E2A5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B9DE52EA9216451EC12A78157E2B30F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_36981E6ECFF13D1DA443A78157E2AD15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6030AA4E014D4600BAC9A78157E2BA87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_ProfitLoss_755FF55323A5F4451216A78157E21DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5E27C20FF69959F938BDA78157E23661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_NetIncomeLoss_425CF28E0790BB8FE601A78157E253FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:to="loc_us-gaap_EarningsPerShareBasic_88CE9DEE2EB74E5B4463A78157E2556A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B87370E1E6CD1DBFC38AA78157E23411" xlink:to="loc_us-gaap_EarningsPerShareDiluted_62CFE9B3A42681AFBDBCA78157E2C261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85AADBF65A00F9CC95EDA78157D25CFF" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A9C56BF689F29696949AA78157E2D60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_717B15EF9BEBA861A57EA78157E20263" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5DE97847F781038A4C48A78157E2AFA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_DocumentType_FFEF92DAD11AC55C4C96A78157E27209" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_DocumentQuarterlyReport_A9AF06636C2768C4ADBCA78157E2AC06" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_DocumentPeriodEndDate_254532AB89D5F17D4717A78157E252AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_DocumentTransitionReport_92299E72B45F640B40A6A78157E20010" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityFileNumber_7ADDB82C25F266A3FE84A78157E2BD14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityRegistrantName_BE0B662451514671EB55A78157E21A4B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityCentralIndexKey_7F627F80421A25872E64A78157E2626D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_CurrentFiscalYearEndDate_69E75D722B85CD5E06F6A78157E20EB2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_DocumentFiscalYearFocus_1A5543A25BD0EC9F26E6A78157E2991F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_83A6E1C58FAAE40A9473A78157E25772" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_AmendmentFlag_F759D58D02485199AFA8A78157E2C667" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_C34498A5F13E7A8AD627A78157E236FC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityTaxIdentificationNumber_A73C2479CF7E6AD7D4A9A78157E26611" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityAddressAddressLine1_9AF19BE54DACFDD63231A78157E2FED4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityAddressCityOrTown_DB0FC6DD8582207CA0F8A78157E2CE80" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityAddressStateOrProvince_05F6AC1C5DED02F543B9A78157E263DA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityAddressPostalZipCode_256082E990B1D3BC0B86A78157E2020B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_CityAreaCode_0771BF640DC4EA15B4BDA78157E274C8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_LocalPhoneNumber_9FFCC1E4A52116E9A136A78157E2DD5D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_Security12bTitle_3FEA0DF9E78FFDFB8898A78157E27DE3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_TradingSymbol_2EE4E3484226359D57B1A78157E2D8A2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_SecurityExchangeName_B20796BBE14F8ED79582A78157E26F2B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityCurrentReportingStatus_E614371B0F1688C25DE7A78157E238AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityInteractiveDataCurrent_037F0853099339DB2DF7A78157E2FF84" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityFilerCategory_B1C12FE2777D315FF21FA78157E28C5F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntitySmallBusiness_C862ABB6A9AC97D1A3C0A78157E2D906" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityEmergingGrowthCompany_0525A0AD532A7D3DBD7AA78157E251AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityShellCompany_EDCD11CC38968AF0E19DA78157E297D3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_713F836B835133A41A01A78157E27FE1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_E9FF2B3124BCE9D029CAA78157E2BF55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0118F776101B462B3947A78155C6491C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0118F776101B462B3947A78155C6491C" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3296ACDA29587E2B55E7A78155C69D85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8CACBF18F4A648FD5A58A78155A7CB06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8CACBF18F4A648FD5A58A78155A7CB06" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_528B33D6A863484B8B78A78155A7B893" xlink:to="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_C4991202A4962B7AB675A78155A756A8" xlink:to="loc_biib_ShorttermderivativeMember_21D74C8346EA46D16793A78155A7F572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BF8B39B5735E53735872A78155A72366" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BF8B39B5735E53735872A78155A72366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BF8B39B5735E53735872A78155A72366" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6DAD54AF17C2883C306CA78155A7EFA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_08F04C009E6B3B978ABDA78155A78CE9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6DAD54AF17C2883C306CA78155A7EFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_24474ECDA734EEACF3A1A78155A7533A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8AFAE9AF2D1A6B297195A78155A79DC4" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E18C6B49ADA37427AE74A78155A78975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_E5C61BEA1E62509C41F9A78155A7C604" xlink:to="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_EUR_32A422A77136D76AF8A6A78155A7FC7C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_GBP_0E381548A61A5F7CE332A78155A7CF9C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_CHF_4B8A6451C5A4BB21F3DCA78155A74368" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_JPY_3135CEDB76A99F7AC262A78155A7AFB4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_C7CCB98947F6D83210B0A78155A734DF" xlink:to="loc_currency_CAD_46543F75F3DB8712EED9A78155A744AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_471E2798900B836C04BCA78155A7E53A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:to="loc_us-gaap_SalesMember_695932B5D820F49D7BB2A78155A77BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:to="loc_us-gaap_OperatingExpenseMember_578F53AA546FAA29155AA78155A7CCD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74ADA3FA54B2D38DD279A78155A76E3A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_B09AD55255FC094CADF4A78155A72944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_41522CDEAC78483F6B3FA78155A7057C" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_us-gaap_CashFlowHedgingMember_2D4C40FC7F6B130146ADA78155A78F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_us-gaap_FairValueHedgingMember_FBD225D4259E6802D5E1A78155B66165" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_biib_CashflowsrevenueMember_F6A47D8924847DE23F9FA78155B6F9F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_biib_CashflowsoperatingexpensesMember_BED3E3FCACF6972E0E0FA78155B63EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3B6F5CBD24AA85BEF79EA78155A7CA07" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_F01A9F27B80854018636A78155B6B1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_A7A5C85EFF960FBA9DEBA78155B67ED1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3063E8E93058D1DF2190A78155B6A099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6AFB544025D7A4FBB132A78155B692F5" xlink:to="loc_us-gaap_InterestRateSwapMember_0B876EB567BCC4847A73A78155B6CA46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07BBA7BE0C11644D47D1A78155B68596" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5FE1795A19107A781629A78155B6A158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_A6C9976D2E1922B2AB11A78155B62113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_B781926709FAB4A1F7BDA78155B62226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0B75E1A6C532E6EA4399A78155B6EF8A" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_457D75B7B7B4CA870354A78155B69D6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5816CBC67A2D476265AFA78155B606BF" xlink:to="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_A8614EC5891E9A3EEF3BA78155B6B93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_00E517E5B20AB30D4806A78155B69BEB" xlink:to="loc_us-gaap_NondesignatedMember_1C8346DF6D9363FF5B41A78155B6311D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1BB0C94C901CCD1ABFBBA78155B6C20C" xlink:to="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:to="loc_srt_MinimumMember_F7147134A3E9E7EF7411A78155B66940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26BACDE8891F6B3E13E6A78155B67490" xlink:to="loc_srt_MaximumMember_81C2D6645B4652FB1481A78155B6064E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_48CFFF637B82AEFCA7AFA78155A7259C" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_D116720F47DE27796444A78155B689EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_B1D6453E243FCB8C1F2DA78155B65A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_0BD63F3B16EB9004C256A78155B65176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_80739DCA599A7159F3B0A78155B68BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E6CA8F78694EB8AA17CA78155B619AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeNotionalAmount_F08E9B4A87E9ED0789C0A78155B68A59" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_EDA114BA47A577B6DACCA78155B6CF82" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_EDA114BA47A577B6DACCA78155B6CF82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0A3C7BCF375872A3C1C1A78155B67B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_413B64AFF4BE1D4D9E61A78155B699BE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_413B64AFF4BE1D4D9E61A78155B699BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeTermOfContract_043235F405B8BFB96D63A78155B65BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2411EBE49A6343D29681A78155B676D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_92A77BE53EC07370714DA78155B6263F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_602FBA55F445FC99A6DAA78155B685BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6469A6FAE57A17CB9A4FA78155B6D31E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7D8C6EC6B861FC6B91D6A78155B65FEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_6134109955E029A18A57A78155B6D9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_2D4A60EFB0D24877419FA78155B6CD57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_D7A26369C69B4DC65766A78155B64576" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3E5E2FD595AACAA4A62CA78155B6581C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3E5E2FD595AACAA4A62CA78155B6581C" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_CA07B13FFC52BE612999A78155B6AF77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3E5E2FD595AACAA4A62CA78155B6581C" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D885E04BFF5FBC62571A78155B6F807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3E5E2FD595AACAA4A62CA78155B6581C" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_FC18037B2CA200B3F7A2A78155B66ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3E5E2FD595AACAA4A62CA78155B6581C" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_BEF8EFFAB3993D6D9448A78155B697F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_9538EDC59B1C3991D295A781573DE69C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_9538EDC59B1C3991D295A781573DE69C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A9B632A65D89FCACF1E7A781573D79E7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F366B7834AD4BCB7A43DA781573D1F72" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_63A595615934C96D8A20A781573D0764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F507B60E58961AC7E8BA781573D35E2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_D720C927B923769E69D1A781573D0293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_29E3BDFB0774345D3D5CA781573DAE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_642ED040145B3DA17E59A781573DD4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0A81E2B529866EE3E050A781573D0034" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0A81E2B529866EE3E050A781573D0034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9D8BA31CD9A097C4132A781573D9E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1416C87F0E8A4781A631A781573DB103" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F63C2D43D2C2FDD54055A781573DAEFC" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_DC0CB8187BFCC4CF661AA781573DD5E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_5784EEE609427ADB189EA781573D31E4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_95F8E038733A4875C5BDA781573DDA5D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_AD386CCD57FA7B3922F6A781555864CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_AD386CCD57FA7B3922F6A781555864CF" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_DD8C1D2A9594DE405ACBA78155584432" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_617B74BDC7E63E7E1185A7815558AD8E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_617B74BDC7E63E7E1185A7815558AD8E" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_526CCAE469BA488D2A2FA78155589B0E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_45F89AF6F4CE8EFB105AA781555844C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:to="loc_biib_MarketStockUnitsMember_148C40C60379339C8752A78155589CCF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_216644B92FC99E102E9BA7815558460C" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_ACDE3FCE7F31317CB4E1A7815558E7F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_968C3EB8E4C3A883251DA78155583EA5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0D453AB281F141A32FEAA78155586A13" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:to="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2137356B47A33A953FA0A781555828E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_055D0973F162CE951309A781555853ED" xlink:to="loc_us-gaap_NetIncomeLoss_2137356B47A33A953FA0A781555828E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A852D2FB522D3746459CA7815558C73D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0DBE325E42BE8EEC4F5FA78155586313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_EA97627A802D67E52CD1A78155582579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5D8A1D61A38F8371A7D1A781555854EB" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_28B61B38D60F6777140FA7815558D1B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7991EC9B7360280E6795A7815558569E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8DC111D14CA487711245A7815558F776" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_FBBD3EE845B92E565204A781555830D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FBBD3EE845B92E565204A781555830D1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_D033326C78B6FC3800F4A78155582E89" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2B08B0B74E63CCC3F90FA78155786E0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2B08B0B74E63CCC3F90FA78155786E0B" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8CE89CE6E38788CBC8A2A78155788D97" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C511B85E6ADD892C9582A781568144EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C511B85E6ADD892C9582A781568144EF" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_BE3BF5F49C7B1B0B9EB1A7815681C6C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5F60A32E7269BC593027A7815672C19C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5F60A32E7269BC593027A7815672C19C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7AC1DCCDF5A519C0208A7815672F9FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7AC1DCCDF5A519C0208A7815672F9FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7AC1DCCDF5A519C0208A7815672F9FC" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_DD3A4F7A7AE3C11EA747A7815672C790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_16E015DAF9DD5F8C36ABA78156727EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7E056B1BF43EF84EAC12A78156728AFA" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7FFACBAB540B4AB37A6DA7815672299D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C01707701FF3096E958DA7815672AB05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C01707701FF3096E958DA7815672AB05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C01707701FF3096E958DA7815672AB05" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3CB14838ACE954A27E16A78156724045" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3D2256FB2FE91C36A0BFA7815672FDDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_50A6D20A0C48F0CBFEEBA781567209BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_50A6D20A0C48F0CBFEEBA781567209BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_50A6D20A0C48F0CBFEEBA781567209BA" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9FF436303AB3F1F2F175A781567253D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_C08F4459123A6D44EAA7A781567273F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3EB56015E2BFF741B587A78156724E70" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_86DE27D8B1CC04646EA2A78156727E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A85F3E61333D33B96700A7815681F3D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9074D74EBB3C28665018A78156728BF9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A85F3E61333D33B96700A7815681F3D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A85F3E61333D33B96700A7815681F3D5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0580FD0A25C12E679ABDA7815681C31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9A32EF73442669D2F9C7A78156816BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8ABA6067B4185BF46A7AA7815681A9E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2301F52EBCB48A26E5EDA781568120E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5CBDA2C0F1EBA0BE023BA7815681BDC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B47CADC158523EBABA5DA78156817CC6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4EE264748AC871CA703CA7815681E7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_776743C0D37F50A3D511A78156816BEE" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C5C078178DA1CB9E8949A781568103D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_035C20FA407CCF6CE832A78156811786" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_035C20FA407CCF6CE832A78156811786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5AE258AD0CD5C3974326A78156816404" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5E8F1518A7253B74D5B6A7815681AFD9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8B7E9E9A78527508AA51A781566245C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8B7E9E9A78527508AA51A781566245C7" xlink:to="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_EE8DD866ED11813278E7A78156621FC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:to="loc_us-gaap_DebtInstrumentAxis_EE8DD866ED11813278E7A78156621FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_EE8DD866ED11813278E7A78156621FC3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9119DAD9DEBDD4D0D546A781566285D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9119DAD9DEBDD4D0D546A781566285D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3C8B9E29FE936D05664CA7815662B3A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_4A7AD1B3AEA21F5FC21AA78156624CD4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29095AB08019712AF47BA78156628D4C" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_95767CED60BF4135B377A78156624921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D8683AA481AA81F038CAA7815662E355" xlink:to="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_61E50EA250CE739DFD9BA7815662796A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="loc_us-gaap_NotesPayable_B6B9114749B230D79ECFA7815662DD8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1A3CBC3571B3E0B1BE3A781566279C2" xlink:to="loc_us-gaap_DebtInstrumentFairValue_386ECA583F6BD083B16AA7815662EF61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FCC6AA15731AC3A58216A7815652EAD8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FCC6AA15731AC3A58216A7815652EAD8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ADD7E627AE2FDC753C4CA781565223F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ADD7E627AE2FDC753C4CA781565223F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ADD7E627AE2FDC753C4CA781565223F3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_F112ED252A4EBA648A47A7815652194B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_73974F4AB7C261F1E894A78156523CCE" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_F112ED252A4EBA648A47A7815652194B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_584AB4CE83C35B12C436A78156527772" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18C262AECCC48BEE9B38A7815652AA28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5C9C1F803A8139F950B3A78156526AC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5C9C1F803A8139F950B3A78156526AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_504EE28F2530323F336EA7815652564E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BF5D44662551ABE41EEDA78156529D47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6EF7910395F590D09BDCA7815652CE0E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BF5D44662551ABE41EEDA78156529D47" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FC83933916BF0ADD9332A7C34B87282B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D4490D3CD612B2ED6520A7C34B876F02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FC83933916BF0ADD9332A7C34B87282B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D4490D3CD612B2ED6520A7C34B876F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_10AB70C27E7D15538224A7C34B8840DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D4490D3CD612B2ED6520A7C34B876F02" xlink:to="loc_us-gaap_DebtInstrumentAxis_10AB70C27E7D15538224A7C34B8840DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_10AB70C27E7D15538224A7C34B8840DC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C82D3D7EDC58992573FCA7C34B88B7EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_C82D3D7EDC58992573FCA7C34B88B7EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F0FB7BED159B68C68AC6A7C34B894AF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F0FB7BED159B68C68AC6A7C34B894AF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_98F114108E39819221ECA7C34B899215" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_98F114108E39819221ECA7C34B899215" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2A0CB2353B176EE20D80A7C34B8982F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0D875F7716A3DCB7FA53A7C34B887FED" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_2A0CB2353B176EE20D80A7C34B8982F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D4490D3CD612B2ED6520A7C34B876F02" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_AssetImpairmentCharges_DFF5FD8187D2278DCA6BA7C34B89E9F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_96313FA623F29BFA47BCA7C34B8AF8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5B53C1F3786DDC684856A7C34B8A4E93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5B53C1F3786DDC684856A7C34B8A4E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_819EDE67ED022B2399B9A7C34B8AD0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C08CC15D3C7C45C8586EA7C34B8A7ACC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C08CC15D3C7C45C8586EA7C34B8A7ACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8F26A4223780B4101327A7C34B899F07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_72A49CB9714A9D6AF302A7C34B8AD0D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_306051A1745000239790A7815633F512" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_306051A1745000239790A7815633F512" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4252E228F72560390689A7815633AAB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_srt_RangeAxis_4252E228F72560390689A7815633AAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4252E228F72560390689A7815633AAB7" xlink:to="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:to="loc_srt_MinimumMember_A8F39BBB1B5D97326FE9A7815633FBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:to="loc_srt_MaximumMember_53A49644A8C8C8267BA1A7815633438F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BED4822EBCD17B900168A78156332433" xlink:to="loc_srt_WeightedAverageMember_8B8DD7D7B0B0FE199861A7815633C75F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B60CE64119E2B57E1E7DA7815633F1A1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DA6875CA0960028D4689A7815633AF59" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9B833F05E0190A57D7D2A78156335187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0CE1A88A174EB14CB063A7815633C4F5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7B02006132E69EC3CF21A7815633EF96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3BD941F3D0BDF68D4992A78156334883" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5F036FCDC2CD4301327A7815633DF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9E23F6D264F9BD665F2AA7815633222B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7D7EB2DCB5451ACA22C9A78156339BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EDD9CBAB6E76F1A85D47A7815633E905" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9426F5BD6573B570DFD5A78156339ACD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F27230C9F148FD5A47A9A7815681EF07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F27230C9F148FD5A47A9A7815681EF07" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_E53F686D32F167E4B28AA78156811961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F27230C9F148FD5A47A9A7815681EF07" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6D411BF6853360DC1B1BA7815681CD84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F27230C9F148FD5A47A9A7815681EF07" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2A71888E7575420B90A2A7815681C708" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_876AEFCEEEE36186EA9EA7815623C02B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_876AEFCEEEE36186EA9EA7815623C02B" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F116EA6246C783EF5DCFA7815623AD60" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C4003527886E1C913070A781561487BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C4003527886E1C913070A781561487BA" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:to="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_B3B97F8C602FAF026D69A7815614FA36" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_CommercialPaperMember_667E6674319E4DB207CCA78156149F20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_110C0847E020A4BACEA4A7815614F911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_576B6D7FC3C6B14DEA3BA78156141148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5857348330B3B735DDDEA781561467A0" xlink:to="loc_us-gaap_DebtSecuritiesMember_60E69394F0FAB94388DFA7815614CF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8FB6FE37FE22D244DCCFA78156140724" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5C3AED65A3F88EFF74DDA78156143E5F" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_5EE65BECAEB9170C2162A78156141E53" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_850562F25EB56D77D1F1A7815614D49F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3F9B0DDB107785920E95A7815604D288" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3F9B0DDB107785920E95A7815604D288" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_A8B5D68018516F75D025A7815604C519" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_A8B5D68018516F75D025A7815604C519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A8B5D68018516F75D025A7815604C519" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A6AA996261343042817EA781560476BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_A6AA996261343042817EA781560476BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_90C6A19A0DD5A66EC5B8A7815604FEC3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B782A323EB7A1281B51A781560404AF" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_90C6A19A0DD5A66EC5B8A7815604FEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8C88E67BC48518E2F8AAA781560470B2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_99303B7972736BC0D3DBA78156048EEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_E5457FA30EC9581A7232A7815604726A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_BB36ED0CD258ED534121A781560414B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_6CFBCAFB353EDC105B35A781560455E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_047622CE491D118D3D40A78156049C67" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_646999EEC38B0FABE48DA78156040E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584D9B5F9268EE8E8F52A7815604288E" xlink:to="loc_us-gaap_EquitySecuritiesMember_F14F7EB1CD48AAC7AE0BA7815604002C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B5F8393A07F01654F58CA78156041281" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_CAE3C7BEBCE4091250C3A781560481B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43520258468AEAF86726A7815604AEE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A304420F6175D2D3664A7815604C6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33487F8CAD3AD1FDC18DA7815604A592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_C7963AA8CE552625DE2DA7815604A13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42C3897196E6983189D2A7815604DDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1888F136D37F9DB06BC1A7815604FD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_89A6DE9B34A21E982DD3A7815604D5F3" xlink:to="loc_us-gaap_AvailableForSaleSecurities_F748E66C19BE63B69CBCA78156046519" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A0CA65EAC2A55A2A4EABA78155E5E8E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A0CA65EAC2A55A2A4EABA78155E5E8E5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3486DBBB700322F4C0FAA78155F599CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8F25D4BD6C2C6CA1BF45A78155F5732E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5F379555DCA2A31601EEA78155F511DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_212375A8C427FF005CB1A78155F5D238" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_B0463A0339DBB38DDE3CA78155F55ADC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_37C074D2AD333EC9E487A78155F54B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_73A6C99EA7623BFE5BAFA78155F55B17" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_73A6C99EA7623BFE5BAFA78155F55B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_4ED307D53C9118FF4813A78155F5D6AA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4756E5686C13F222CF1CA78155F56B86" xlink:to="loc_us-gaap_AvailableForSaleSecurities_4ED307D53C9118FF4813A78155F5D6AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_37E52BC9ABDAF2513F7DA78155E5EA2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_73DD0B040B1F949287AAA78155E545B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_37E52BC9ABDAF2513F7DA78155E5EA2E" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_73DD0B040B1F949287AAA78155E545B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_37E52BC9ABDAF2513F7DA78155E5EA2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_D5999F308975167DDCBEA78155E5E732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_37E52BC9ABDAF2513F7DA78155E5EA2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D8B1BB869127BF061A78155E5D6A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C254E8A98A210B65F227A78155D55C75" xlink:type="locator" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C254E8A98A210B65F227A78155D55C75" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_F7AD5600536820ED88DEA78155D52B65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5BCA14B30C1B7A03B6C1A7C37D0F166A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5BCA14B30C1B7A03B6C1A7C37D0F166A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_514C9BAD1A525CB5722BA7C37D0FA917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_514C9BAD1A525CB5722BA7C37D0FA917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_514C9BAD1A525CB5722BA7C37D0FA917" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_673C2DE4AEA1D0CB33B3A7C37D0F2A65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_673C2DE4AEA1D0CB33B3A7C37D0F2A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_D4642947840FF13A2DD7A7C37D0FA329" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1FCD42D37D232D9C54E6A7C37D0FEB3B" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_D4642947840FF13A2DD7A7C37D0FA329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8A23659404369F6643AEA7C37D0F46B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8A23659404369F6643AEA7C37D0F46B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8A23659404369F6643AEA7C37D0F46B4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8A46EF41C2165CEE7C34A7C37D0FCF75" xlink:to="loc_biib_StrategicInvestmentsMember_2E614423CF1ECDE8A667A7C37D0F28E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_606A3EDE9178DB3B2826A7C37D0F51CE" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:to="loc_biib_StrategicInvestmentPortfolio_C1A7E05B1A1D795279DFA7C37D0F7B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_7746A0806DC0F75B9FF2A7C37D0FA36F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C0A094E6BDCE39FB7ED0A7C37D0FFB69" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_7746A0806DC0F75B9FF2A7C37D0FA36F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2B60EC26036828DBC8BFA7815623033F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2B60EC26036828DBC8BFA7815623033F" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ED742369D47CEC7C3821A781562385A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2B60EC26036828DBC8BFA7815623033F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_80AA6DD24BC8C5419BE4A78156239F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2B60EC26036828DBC8BFA7815623033F" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_65170A35901ED53A8DCBA78156236F75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2B60EC26036828DBC8BFA7815623033F" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_B2AC3536B21193ABE297A78156237779" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_955DF3B98265F77B7E7AA78155392E26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_955DF3B98265F77B7E7AA78155392E26" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_99AA91EB6AD626C0DE9AA78155394CA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_732D619F25E587EEA6A6A7815539C502" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_732D619F25E587EEA6A6A7815539C502" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78E663CF60DB4496F9D4A78155398094" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_82A5521B39760990DD7DA7815539A4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_F1DF3C394F88A3A675C8A78155399BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E57461329BC06F46A0F8A7815539D50F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_E2F729DC7C95717C839FA78155399969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_0A0D7833A6387B6EE7D9A7815539EE5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_C338E0B47CC5CE85C6EAA781553992E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_3913AEA8FCB93C3E9CEFA78155399072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_DD7F41004C3F3B3E660EA78155394046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4588021FFFD7A3C9AAC8A7815539D75D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B52B41049B018B85953AA7815539F4F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_93952F6056366A5DF9F4A7815539AA37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93952F6056366A5DF9F4A7815539AA37" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9F4D36004003D75D37FBA7815539D39B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9F4D36004003D75D37FBA7815539D39B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9F4D36004003D75D37FBA7815539D39B" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_CEA2E23D6DCDFBA64D4CA78155394A71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_835C9903054901754D9FA781553920DF" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_CEA2E23D6DCDFBA64D4CA78155394A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_60B7E57A33F3F196EF8CA781553912BD" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9DC92E1CEDB6375306C8A781553911F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9DC92E1CEDB6375306C8A781553911F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_534224ECAFDA5F289D06A78155397C96" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_BD11894D7206CE501B8BA7815539913F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AA375383EAD58779E4D8A78155398FBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AA375383EAD58779E4D8A78155398FBC" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1CE81FDFBF4F42930C9DA7815539C7A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_67629395C13A5E7AFF48A78156CFEA9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_67629395C13A5E7AFF48A78156CFEA9B" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FA32726B26B89063469EA78156CF5D4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8AD1BD9D0D171D20ED59A78156B0AE85" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8AD1BD9D0D171D20ED59A78156B0AE85" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_7FD2A7ACD56799A7CD5BA78156B0B036" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_7FD2A7ACD56799A7CD5BA78156B0B036" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7FD2A7ACD56799A7CD5BA78156B0B036" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_7802229502EE1A9DD1FBA78156B02EC4" xlink:to="loc_biib_TGNMember_26512949946FAB74B425A78156B03D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3E4042AA61A956701742A78156B02183" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3E4042AA61A956701742A78156B02183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3E4042AA61A956701742A78156B02183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_623BA92F255DBA769C6DA78156B05977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_904864FD71EF0D0A0FA5A78156B00DB7" xlink:to="loc_biib_NightstarMember_623BA92F255DBA769C6DA78156B05977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_545A3E85F5D9568984C1A78156B0EBB9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_535AF43C8FC97D91A075A78156B01170" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_535AF43C8FC97D91A075A78156B01170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBA113370D639C47649FA78156B07E36" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_84721DFBBC6A884B9072A78156B07983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D03CAAA46561628A8F0BA78156B018F8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_535AF43C8FC97D91A075A78156B01170" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_biib_OutLicensedPatentsMember_73D419685E7572E3AA86A78156B0AE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F60F8AE884B4514C106FA78156B0DE49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F60F8AE884B4514C106FA78156B0DE49" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8047602D102C3CBCC54DA78156B00277" xlink:to="loc_biib_InLicensedPatentsMember_394EEAF99311B82D4E24A78156B01B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1C8838B79EA6F6ED0C5AA78156B0F189" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_srt_ProductOrServiceAxis_1C8838B79EA6F6ED0C5AA78156B0F189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1C8838B79EA6F6ED0C5AA78156B0F189" xlink:to="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:to="loc_biib_AVONEXMember_2F069081E5A7E96939A8A78156B0155E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_AF2B99F162CF463BF64AA78156B0B594" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:to="loc_biib_TysabriProductMember_AF2B99F162CF463BF64AA78156B0B594" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1E15293709D3E117F153A78156B0458D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CBD376E4A319959F375EA78156B08545" xlink:to="loc_biib_TecfideraMember_1E15293709D3E117F153A78156B0458D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C36C78DCA3C83BABCF70A78156C09AFD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_srt_RangeAxis_C36C78DCA3C83BABCF70A78156C09AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_C36C78DCA3C83BABCF70A78156C09AFD" xlink:to="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_27C116096A79D4B949FCA78156C0DC7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:to="loc_srt_MinimumMember_27C116096A79D4B949FCA78156C0DC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F793C1CC5A86A94F124AA78156C09E0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DA5ABD3F847E4E4AF0ABA78156C0D6F6" xlink:to="loc_srt_MaximumMember_F793C1CC5A86A94F124AA78156C09E0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_FA3AA38E807E4B3EB726A78156B021F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_67667EEBAAE876A7B6C0A78156C08B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_536FC98E9B761835CAE7A78156C032CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_76E4B70D2FFA5C667E97A78156C0A938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5D5970B7B88EF6D5357BA78156C00A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B88DE04AA725F1AEB58AA78156C0AE47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9AC42EE914FAFB305112A78156C0EF8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37BC7F139D74BC966624A78156C0610D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FA32DA4AD2A8D638B7B4A78156C0D345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4BC3FD177178D5179209A78156C0DD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_B6E0AF834DB941457E74A78156C04E06" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F28BB78E493F3D2AD0A0A78156C08958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4E6A76C25E4767F7CEECA78156C0322B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4E6A76C25E4767F7CEECA78156C0322B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F7C2B4F75F43A54934EAA78156C03E9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F7C2B4F75F43A54934EAA78156C03E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6A37403A0F9AC7251D56A78156C03A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_928C3451A1CC0A91D2A4A78156C00E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B9036E39DD5EEEA73A99A78156C01581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55C218DBA227383B8C7AA78156C0D12F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C00CE7B753C51577ECB3A78156C0585C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_298E93435DCB2B538A16A78156C0C95D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8564FA0D983F4ED67F6CA78156C08852" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38E69755BA954E102A42A781569116CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38E69755BA954E102A42A781569116CC" xlink:to="loc_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:to="loc_us-gaap_Goodwill_F6AA845E6B480B144814A78156910A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_1FBB23299C281AE30C0DA7815691B1DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E8AD824DC11BB436EA77A78156910708" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7B27B98F36C966238817A781569198A2" xlink:to="loc_us-gaap_Goodwill_E8AD824DC11BB436EA77A78156910708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38E69755BA954E102A42A781569116CC" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_286247A7B4DB7F6C9919A78156919ACD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:type="locator" />
    <link:loc xlink:href="biib-20200331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_238B96A511F8A1CD51D8A78156C067C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_D97231316CF7567F4EABA78156C0846F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0C0AD2BEEB0A9245594CA78156C021BF" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_3C41139B42FE702D6396A78156C07DA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_C5F4381D4A199D619B37A78156EF2F04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_C5F4381D4A199D619B37A78156EF2F04" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7C0B4D6FBA85ED428B95A78156FE24AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F9CB1C45E8701301EFBEA78156EFCA94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F9CB1C45E8701301EFBEA78156EFCA94" xlink:to="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_09EB5446BBB535AE3AD8A78156EF344D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_851A2C56C8A786926E8DA78156EF6BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_DDCACA5C01567460AC56A78156EF517B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_4000321B0B406EF21040A78156EFD97E" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_CA7709353CE56E473C0CA78156EF4606" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3C54F8BA53A90B4415E8A78156EF15A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3C54F8BA53A90B4415E8A78156EF15A8" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78FF3713093C13D6C1B7A78156EF7F9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5DD8CE68BB4E808FD692A78155003DCC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5DD8CE68BB4E808FD692A78155003DCC" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_A86B5A5DF792811D64A8A7815501EB85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_003BAD1445D415C772FCA78154FB6998" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_0F73F6109DB53169753CA78154FB9E59" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:to="loc_biib_RegulatoryMilestonesMember_FFAD525EC13E9963B7A0A78154FC55A1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_926BF19C8C12085A2E25A78154FC3994" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_76E3CE251730A82EDB81A78154FC9807" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_65E617486BFCF5B1C3F1A7AA238A1028" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_E56EDA713810E9BE4999A7AA23924721" xlink:to="loc_biib_NeurimmuneMember_7E11A81960BF761BC79FA7AB1EDD0A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_41B1863230A6FDD25990A78154FB2A22" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_91A021FD1099644742B5A78154FD8DDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_93F7CE3C44B00370DAAAA78154FD19F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_68F82130F44F3368A6B3A78154FE1313" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_43AE71F86FBF97630323A78154FE9DF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8749758EB9E389EDE9DFA78154FDB093" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8ADC2CF75870C49159BAA78154FEF334" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C270B96833B8D98A22BBA78154F8C064" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C270B96833B8D98A22BBA78154F8C064" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CF8BDF96D54CD6A344ABA78154F8D7DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B4E587755F5A6E147916A78154F16D45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4769D6861B65F8300B1BA78154F22B6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B4E587755F5A6E147916A78154F16D45" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4769D6861B65F8300B1BA78154F22B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4769D6861B65F8300B1BA78154F22B6C" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_85542709B6B7621A385AA78154F35FD9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2022AB38B016D513FC51A78154F3EF78" xlink:to="loc_country_BR_E05F1284F18CB6C557FEA78154F440D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4769D6861B65F8300B1BA78154F22B6C" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5E23EAA3E28447DC3F5CA78154F4BE84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_6DE320C3EACCA11C1150A78154F48B05" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_6B7A88C8B92E789206C9A78154F54A8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3858AA8CC5D5823C35BCA781552A5822" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3858AA8CC5D5823C35BCA781552A5822" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_AC29A9FB3D68A2A51352A781552AA2EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E7635D4BD4DAB2A11141A781552A9E0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E5060CE1A80DE45257E8A781552AAA07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E7635D4BD4DAB2A11141A781552A9E0D" xlink:to="loc_us-gaap_StatementTable_E5060CE1A80DE45257E8A781552AAA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8155058CF505887976F9A781552A2EAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E5060CE1A80DE45257E8A781552AAA07" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8155058CF505887976F9A781552A2EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8155058CF505887976F9A781552A2EAC" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05563C20299DBA1CEBDDA781552A5DBC" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6E7752EB72EDFE1584FBA781552A99E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E5060CE1A80DE45257E8A781552AAA07" xlink:to="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_FB3571827787B2B321E2A781552AEBA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_InterestExpense_D1928548956C4D86260CA781552A3AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_1FA1139D4AABBA36477FA781552ADACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_837444654E6A7F2CA1D2A781552A72A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_45B91F56714357B25269A781552AA219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_8862EDFBC63BB6BDED08A781552ABEE4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3E1B090826EFFDCABAD8A781552A0651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_46F4C1F717674B8A7923A781552A1D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E58399B474B5E0F3B8A4A781552AA26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_225E1CA43B20C6157A79A781552AB909" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3C058FF455E6A5766F67A781552AF292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1C3F576CBE6394D5C745A781552AE663" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_B9D54223C07D8A8DF1E5A781552A04EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_356D10DCFA34C851D7BEA781552A2384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_02C1C6CF7FA33CB5D5BDA781552A1F0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_biib_Collaborationexpensesaccrual_10C02B38C3BBF7484E1AA781552A9152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C8C8EA50596EEFB72552A781552A02F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_098132FD8EA41B462A75A781552A14D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AAC80A4FB44579947C81A781552A6B78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6FB78EE7072E1F0C699FA781552A35EC" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3D1C5E004BE6B160791EA781552A4E3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94049A06DB2CED088C8EA781552A0EAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94049A06DB2CED088C8EA781552A0EAF" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_6CBBAD79C3A2643F4ED4A781552A09BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94049A06DB2CED088C8EA781552A0EAF" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_C128C2D65E0F22226118A781552A8656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94049A06DB2CED088C8EA781552A0EAF" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A82A96D61C39822A0B43A781552AB6A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_761A06EDD7BF41A21F78A78155232C65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8E0B4ADA6D81D83F8C2DA78155235069" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_761A06EDD7BF41A21F78A78155232C65" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8E0B4ADA6D81D83F8C2DA78155235069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_761A06EDD7BF41A21F78A78155232C65" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_A91FB7EC1B3838FBF943A78155247651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_761A06EDD7BF41A21F78A78155232C65" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_486BD569A04A74E477A0A781552461B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_6932A38175C022D6745EA7C3B0E55F08" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B934C792E9BB88EBE4A1A7C3B0E61389" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B934C792E9BB88EBE4A1A7C3B0E61389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B934C792E9BB88EBE4A1A7C3B0E61389" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1BAB047BBFFECBE4D984A7C3B0E61EED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D6BF0593BE0A6B75A695A7C3B0E600D3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1BAB047BBFFECBE4D984A7C3B0E61EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C1D87DC6E13134E7656BA7C3B0E735B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="loc_srt_ProductOrServiceAxis_C1D87DC6E13134E7656BA7C3B0E735B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_C1D87DC6E13134E7656BA7C3B0E735B1" xlink:to="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:to="loc_us-gaap_RoyaltyMember_F22FD8BD86A99D9BF0C0A7C3B0E75A1F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:to="loc_biib_OthercorporaterevenuesMember_8013EBDDEE3A45D78E6FA7C3B0E7F94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_F41A9CD1D1EA509FF9A2A7C3B0E8BC86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6E302F1F6CFB5BC4DC13A7C3B0E758C4" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_F41A9CD1D1EA509FF9A2A7C3B0E8BC86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_F5C30A4456D8C3E2BA1DA7C3B0E81045" xlink:to="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5E65D46B235B8601DD8DA7C3B0E8762E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5E65D46B235B8601DD8DA7C3B0E8762E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_70B6FB8E0AAFDF66CFBFA7C3B0E8833D" xlink:to="loc_biib_ZINBRYTAMember_757C58195A1DC52D2565A7C3B0E90FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7858E3CBE24C6BEC4B29A7C3B0E5163A" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4355CC1A7E49A9CC4AE0A7C3B0E933C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:to="loc_us-gaap_Revenues_4355CC1A7E49A9CC4AE0A7C3B0E933C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AD00B0AE98109A624F20A7C3B0E937A7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_32F6C0EC9B196AEBCA23A7C3B0E9238D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C42638E5C63F5304B0A5A78155978205" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C42638E5C63F5304B0A5A78155978205" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:to="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_2C456DC68447F9B196D9A7815597E5C2" xlink:to="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_90C633B9F0EACF468B58A7815597C864" xlink:to="loc_biib_SolothurnSwitzerlandMember_6ABCBEC121F875C1C54FA78155974063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_CD92C869449709C49E0AA78155971EA1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9665868A5CDE8794268A7815597A284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_Depreciation_C29071C5DCA0988D9D4CA7815597F5B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_ConstructionInProgressGross_FCCE2FAF22395D5083E2A78155A7811C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_B4A0B5B15DD5CE055750A78155A76FF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_86BA76A858E03F0FFC97A78155976FAD" xlink:to="loc_us-gaap_OtherCommitment_F43FD16E6D6B26FA0470A78155A72315" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5AA08C4DA91F8CEE25F6A78155A7D7CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5AA08C4DA91F8CEE25F6A78155A7D7CC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2D7B019C47365E874E05A78155A7EA7C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_CEE3B9141394944044BBA7815568B411" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0D2F9CB4CF3E96EF0163A781556875D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0D2F9CB4CF3E96EF0163A781556875D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0D2F9CB4CF3E96EF0163A781556875D8" xlink:to="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_80A7DB0AE990C97F1167A781556890D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_80A7DB0AE990C97F1167A781556890D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7F2C89330AF92635A55BA781556876C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7F2C89330AF92635A55BA781556876C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E884DB4F0A529486A8D6A78155682E29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C370023621ABE34AF10FA7815568E585" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E884DB4F0A529486A8D6A78155682E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_333EFC44C11D92E90D00A7815568C7C5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_E60DD645EA95D1ACB734A781556832E7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_22A3B17C80544C8CD6EEA7815568B2D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_CCE3D47260BE94E5C420A781556829A9" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_D872B73A6DE6F049A9D8A781556827BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_690B4FC84D7E415CBFAEA7815568FD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_Revenues_8EFFA8167A6F52266670A7815568C8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_OperatingExpenses_DC1AF80F205A4B0D134AA78155683B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2210CB60F3751ABF5DFEA7815568F966" xlink:to="loc_us-gaap_NetIncomeLoss_8C91F2E7636260EC9E22A7815568E291" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_E7E78B31CAC9B0DA72E9A781572D5606" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_E7E78B31CAC9B0DA72E9A781572D5606" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_279EF868EDDE6406721AA781572D237D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:to="loc_biib_ReserveforCashDiscountsMember_F4288A6A7D79F02D7B89A781572D1EC3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:to="loc_biib_ContractualAdjustmentsMember_1050EE02054B74EF3FACA781572DE007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_02F0A1C3C082FF0E0899A781572D4C07" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_DA9DB0EA2368F729527BA781572DD85C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9FEBF972C42CD3861797A781572DFF48" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_920A41D3F99C98DD1C7EA781572D8E16" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_42337D654F46F8779AEAA781572D4342" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_723108CDB13C7BB25225A781572D5FEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_CDFAAC68C8FCDD0B1885A781572D0196" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_66A6F55ADC4429654803A781572DD58C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_82AF2C15965330B13682A781572D47A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_10B598B69FFAE783656CA781572DBD40" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_82AF2C15965330B13682A781572D47A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_078013A76B0DFA1C52FCA781571DDC0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0C0C1EF342D94DF2FFF3A781571DD004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_078013A76B0DFA1C52FCA781571DDC0F" xlink:to="loc_us-gaap_StatementTable_0C0C1EF342D94DF2FFF3A781571DD004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2934BA64EA275A26613EA781571D824F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0C0C1EF342D94DF2FFF3A781571DD004" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2934BA64EA275A26613EA781571D824F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2934BA64EA275A26613EA781571D824F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:to="loc_us-gaap_AccountsReceivableMember_66B882EC988F6A2BCE81A781571D7357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_761476E5F40D6DA7F214A781571D4551" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CF41E9FE56101A4FEDF8A781571D4116" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_761476E5F40D6DA7F214A781571D4551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_29C2B60B9F2EE6CFF38DA781571D9884" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0C0C1EF342D94DF2FFF3A781571DD004" xlink:to="loc_us-gaap_StatementLineItems_29C2B60B9F2EE6CFF38DA781571D9884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29C2B60B9F2EE6CFF38DA781571D9884" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8DBC46A6987D89FABC1FA781571D6127" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_EC133C6A44C973F44483A781572DF3CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_EC133C6A44C973F44483A781572DF3CD" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3C523618C52B75054AF7A781572D5A9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:to="loc_srt_ProductOrServiceAxis_3C523618C52B75054AF7A781572D5A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3C523618C52B75054AF7A781572D5A9E" xlink:to="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_TecfideraMember_463F900C808A7C92E308A781572D4953" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_InterferonMember_D4B3EB6165D6A4D64154A781572D0A2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_TysabriProductMember_6D6EC530EC2D343DC5BFA781572DDBB5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_FAMPYRAMember_31174F409711E6EB0D82A781572D9874" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_E7C1AB134BD1B9508895A781572D6C3C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_ZINBRYTAMember_E7C1AB134BD1B9508895A781572D6C3C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_MSProductRevenuesMember_DAC1BD412359487FABC1A781572DA52F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_SPINRAZAMember_0CA5685C793C4DAEFA73A781572D77FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_BENEPALIMember_CE3A71FD9A3F051C45EEA781572D5F26" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_IMRALDIMember_7374D7DF239DAE087472A781572D2AA4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_FLIXABIMember_E6326277B6670F084D1FA781572D4EEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_BiosimilarsMember_56BB97811B8C876B2CFEA781572D88BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_biib_FUMADERMMember_97CBB10E2B728B6EA9B8A781572D333D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_27FED229F0D31DFE746FA781572DE8C9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4DF04C8C17A88C4DBF1A781572D2EBA" xlink:to="loc_us-gaap_ProductMember_27FED229F0D31DFE746FA781572DE8C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:to="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_91345FF4A01CD8918FF5A781572D5A15" xlink:to="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:to="loc_country_US_80F9C82CDA7FC97DBE6DA781572D86AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1BAFE62D46CF6F1468AFA781572DF4D5" xlink:to="loc_us-gaap_NonUsMember_9FC528511D0E69F8D020A781572DFE32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6D99E34186D12AA8D2C6A781572DA3D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D5BB6FAB67ED9ABF0DF2A781572D6797" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6D99E34186D12AA8D2C6A781572DA3D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6D99E34186D12AA8D2C6A781572DA3D7" xlink:to="loc_us-gaap_Revenues_5207AF5F57E408871F4AA781572D2B68" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FEE05B0BA9E9C949D172A78156FE34E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FEE05B0BA9E9C949D172A78156FE34E1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9D8C56BA0DA6A4B38BD8A78156FEAE59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:to="loc_srt_ProductOrServiceAxis_9D8C56BA0DA6A4B38BD8A78156FEAE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9D8C56BA0DA6A4B38BD8A78156FEAE59" xlink:to="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_C18C80A0112955274135A78156FE04E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8E1ACF065D9ADBB6E1EBA78156FEF472" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_C18C80A0112955274135A78156FE04E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7D8176847FDD616B277BA78156FEE4B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:to="loc_srt_MajorCustomersAxis_7D8176847FDD616B277BA78156FEE4B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7D8176847FDD616B277BA78156FEE4B5" xlink:to="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:to="loc_biib_DistributorOneMember_9F45C3F385790E1F780BA78156FED595" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:to="loc_biib_DistributorTwoMember_17A08941DEB32660CA3BA78156FE12B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9979AD76F82724C4BF6EA78156FE50B9" xlink:to="loc_biib_BioverativMember_76CF010243CB97C32904A78156FE93B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_DFF7A342BC85ADEF398EA78156FEAC8E" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:to="loc_us-gaap_Revenues_8B5C71918293D132FD00A78156FED4C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56C7C5C630555FF1F1B0A78156FE2131" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7C01468459093EA7609AA78156FEFDD9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C24BFBA6CD34E2BFAC34A781571DB79B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C24BFBA6CD34E2BFAC34A781571DB79B" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_5461D6F81AD88843586EA781571D623A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:to="loc_srt_ProductOrServiceAxis_5461D6F81AD88843586EA781571D623A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5461D6F81AD88843586EA781571D623A" xlink:to="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_487380B170652AC40588A781571DC92E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_41C67654E610574252C5A781571D4431" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_487380B170652AC40588A781571DC92E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_91F81B4D6B703582B27DA781571DC1BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:to="loc_srt_MajorCustomersAxis_91F81B4D6B703582B27DA781571DC1BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_91F81B4D6B703582B27DA781571DC1BE" xlink:to="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_32F129AE8386E414A723A781571D7A55" xlink:to="loc_biib_RocheGroupGenentechMember_F7A58B70E81D045B5E1FA781571D4C64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E8D20D9242DC65ED739EA781571D7D3D" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:to="loc_biib_ShareOfCoPromotionProfits_F3A8BA545705C8055DD5A781571D6E27" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_131E8F2DF2F0033735DBA781571DD9CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_31229A8E24AF79AD35F1A781571D5DD1" xlink:to="loc_us-gaap_Revenues_B97A2764352DE2C3F618A781571DE62B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6A447BD5BFAED37CECF2A781573D7BAB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6A447BD5BFAED37CECF2A781573D7BAB" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_F0F599FE14E0D56BC0B5A781573D08DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6060B5F4C68D10354097A781573DBC9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F837360A939CCB777481A781573D77C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_59071D75AAF46F4123A5A781573DF4DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_D81694F9670703EA8CB1A781573D45B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C0C6A0F25461F017E13BA781573D1162" xlink:to="loc_biib_OtherrevenuesTableTextBlock_03F6695EF0721BC60A09A781573DAF7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8879F590FA2287DE621A78155588EFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8879F590FA2287DE621A78155588EFB" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DD6A03DC7810CB8C4170A781555819C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5199E98B7ED709A7CF1EA78155492F21" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5199E98B7ED709A7CF1EA78155492F21" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E4EE3F22BE21FABCA96AA7815549D846" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E4EE3F22BE21FABCA96AA7815549D846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E4EE3F22BE21FABCA96AA7815549D846" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A2326AE7D369939A1DA5A781554915C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_38A1B021940090933B82A7815549A92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_584B7030BEF31C74AB26A7815549DC10" xlink:to="loc_us-gaap_ParentMember_2F2845A24614687741B3A7815549384F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_31EDFDB2CF72E8874624A7815549B310" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8EBB8C51F4A34D1F7782A7815549AFC6" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75B144E516AA3869CCFBA78155497D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_042C88BA699DCD577924A7815549F37C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62861972D11F058337A8A781554967C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1C3C1676166CCBDDE989A78155492DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_AA07C20E2886EB28F031A7815549E243" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_546698DE4B2DF6EA58C6A7815549EDD9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A591244F0D9D39A8842EA78155490011" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16C1F9FCEA25BA8140C5A78155493B7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A591244F0D9D39A8842EA78155490011" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16C1F9FCEA25BA8140C5A78155493B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16C1F9FCEA25BA8140C5A78155493B7F" xlink:to="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_F0F4949B5F6C69680B46A7815549EE26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D186E9DAD73CCFFF9632A7815549C2BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_MarketStockUnitsMember_D186E9DAD73CCFFF9632A7815549C2BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_021DA77620D1613ABC7AA7815549B84D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_021DA77620D1613ABC7AA7815549B84D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_CashSettledPerformanceSharesMember_C1E4CDA89B44D51F18AEA781554982C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_us-gaap_PerformanceSharesMember_C4A12AA00A14E0703162A78155499599" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_142B42C941C5491781A7A781554968A6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_142B42C941C5491781A7A781554968A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_7C5FF77880E8EE5594A9A78155497A99" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_803833D7C207A647CADFA7815549A52D" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_2F41B311F7712AEB6D71A781554911D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8638122480C07C79DEE6A7815549FAC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16C1F9FCEA25BA8140C5A78155493B7F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8638122480C07C79DEE6A7815549FAC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8638122480C07C79DEE6A7815549FAC6" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D6649EC8A5F544CC1806A781554964AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D6649EC8A5F544CC1806A781554964AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_58CD4F6432DD97F4DC27A78155491114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_032738490BAE8BD46B19A7815549FBEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_032738490BAE8BD46B19A7815549FBEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_216468D1B635E7A28C80A7815549BFC5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_C415708304846BB99767A7815549B05F" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_216468D1B635E7A28C80A7815549BFC5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93936F71FFC165B36C40A7815549F9CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93936F71FFC165B36C40A7815549F9CB" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10A50C9052D75E492600A78155497567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93936F71FFC165B36C40A7815549F9CB" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_DB047C3753D0E8DEAAA8A7815549C7C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_05CDD7E5C166D3333F9FA78155680C0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_05CDD7E5C166D3333F9FA78155680C0C" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_54FFC70CC2E979A44AF7A78155688DA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_54FFC70CC2E979A44AF7A78155688DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_54FFC70CC2E979A44AF7A78155688DA9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_822CA38BC31CF0325016A7815568794C" xlink:to="loc_us-gaap_SubsequentEventMember_E6E7E6CEAC2203640F30A7815568278E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_101F028F0149B8A82038A7815568F876" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_101F028F0149B8A82038A7815568F876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_101F028F0149B8A82038A7815568F876" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_E9DBC9DC3CBAE4E16278A7815578C198" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_E9DBC9DC3CBAE4E16278A7815578C198" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_C29BEC83EC48AF4EE677A7815578FA05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_17CB40C19B76F4AD5C7BA781556868E7" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_C29BEC83EC48AF4EE677A7815578FA05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_F27D0E12F19A4F6270F1A7815568F586" xlink:to="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1FF5AE4F30BA1C79D25BA7815578C687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_BAC34DA3C0522963EF2BA78155788653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59B7785F05D1D687F1AFA7815578AE4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4D389B9AC057531B5663A7815578F442" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90EA26221C7E15F8385AA7815578A515" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended">
    <link:loc xlink:href="biib-20200331.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_B44AA0C3B67910E8E03AA781575C6D9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_B44AA0C3B67910E8E03AA781575C6D9F" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65ABF1B772E1D061E13AA781575C412B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_945313456D61C6A2138AA781578EE517" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_945313456D61C6A2138AA781578EE517" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747EBF5156131B71D9ADA781578E7D96" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ACD04AC7B6D5E3603536A7815787C90D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ACD04AC7B6D5E3603536A7815787C90D" xlink:to="loc_us-gaap_NumberOfReportableSegments_FFE8E11EA2066DF13976A78157874D23" xlink:type="arc" />
    <link:loc xlink:href="biib-20200331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ACD04AC7B6D5E3603536A7815787C90D" xlink:to="loc_biib_InterestInSubsidiary_B75FDB62B7AE8CFD1CC9A78157889B71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:type="locator" />
    <link:loc xlink:href="biib-20200331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_DF96C5FBD1075E8D1EAAA781578A9026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_795384106CECB61717AAA781578B85E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6D1AA3629731A8CA222CA781578B00FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:to="loc_us-gaap_UseOfEstimates_AA3D38ECD05C6B21F207A781578B9F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E864549970E26BCB693A781578A0E4C" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08354D532ABC425543CEA781578B75B7" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biogenlogoa10.jpg
<TEXT>
begin 644 biogenlogoa10.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _+_ ,0V3>&_'&L:>PVM8WT]N1C&TI(R
M]/PK7TC4]H7FM/\ :_\ #A\%?M+^)H=NV*^G6_C./O\ G*'8_P#?9<?A7&Z;
MJ6%ZU^N4VJU"%1=4G]Z/RVHG2K2IOHVON.\MM9PGWJ;=ZU\GWJYB+5L+UIES
MJ^5ZUE[#4T]MH6M8U7<#S7)ZU?[MU6M1U/.>:YS5;[.:[Z%*QQUJAFZM<Y)K
MGK^7)K1U&YR36-=RY->M2B>;4D59WYK$\:^+[;P1H$U]<'.T;8HP?FE?LH_S
MP,T[Q?XQLO"%EYUU)\[#]W$OWY3[#^O2O#O&?B2\\=ZQ]JNOEC3(AA!^6%?0
M>I/<]_R ,17Y%9;BHT7-W>QSM]<W'B#6+B^NFWW%U(9'/N?3V'3Z"M+3;'&.
M*DM=,P>E:]AIO/2O*C!WNST92Z$NEVG2NDTJVZ53TVQZ?+70:9:=*[:<3EJ2
M.Z^ 6@MJ_P 3M(4)N6&;[0W^R$&[/Y@?B:^K*\S_ &<OA<W@_1&U2]C,=_J"
M (C##0Q=0#[MP3]!7IE?QOXQ<24,USSV>%?-"C'DNMG*[<FO*^GG:ZT9]]P_
M@Y4,->>\G?Y=/\QR#FK4"5! N:NVR5^5P1[T2Y:1UJV472J5G'6M8Q?=XKMI
MQ-8FA80]*]&^ MCY_P 1K!L?+"LCG_OA@/U(K@M/ASBO6_V;M)\S7[V[(^6W
M@$?T+-_@IKZGAVA[3,*,5_,G]VOZ&_2Y[)1117[D2>8_M=?M,6/[(OP,U/QU
MJ6EWFKVFFS00M:VTBQR/YLJQ@@MQP6R?I7Q[_P 1#G@W_HG?B;_P.@_PKV+_
M (+6?\H]O%7_ %^Z?_Z5Q5^(-?K7 W">6YEE\L1BX-R4VMVM$HOH_,_+.-.*
M,PR['QH86:47%/9/5MKJO(_5S_B(<\&_]$[\3?\ @=!_A1_Q$.>#?^B=^)O_
M  .@_P *_*.BOLO^(=Y'_P ^W_X%+_,^1_U^SK_GXO\ P&/^1^KG_$0YX-_Z
M)WXF_P# Z#_"C_B(<\&_]$[\3?\ @=!_A7Y1T4?\0[R/_GV__ I?YA_K]G7_
M #\7_@,?\C]7/^(ASP;_ -$[\3?^!T'^%'_$0YX-_P"B=^)O_ Z#_"ORCHH_
MXAWD?_/M_P#@4O\ ,/\ 7[.O^?B_\!C_ )'ZN?\ $0YX-_Z)WXF_\#H/\*U-
M-_X.$OAE*8OMG@OQW!NQYODK:2[/IF9=WXXK\CZ*4O#K)'M3:_[>?^8X^(&<
MK>:?_;J_R/VD\(_\%T?@1XD=5O+GQ9X?#8R;_2#(%^OV=Y>GMFO</A5^W-\(
M/C9/%#X:^(GA>^N[@[8K26[%K=2'T6&;9(?P6OYZZ*\S%>%V6S7[BI.+^37W
M63_$]+#>)680?[Z$9+YI_?=K\#^FRBOP1_95_P""E?Q5_9/U&UCTK7KC7/#L
M) DT+5I&N+,IW$>3NA/)(,9 SC(8<']?/V)_V]O!?[;O@R2ZT&9M-\0:>BMJ
MFB7+#[39D\;U/22(G@.H[@$*>*_-^(N"\=E2]K+WZ?\ ,NG^)=/Q7G<_0LAX
MPP6:/V4?<J?ROKZ/K^#\CW*BBBOCSZP*X/\ ::^.]G^S+\"_$'CJ^L+G4[/P
M]#'+):P.$DE#2I'@%N!@N#SZ5WE?._\ P5A_Y1Z_$O\ Z\K?_P!*X*[\JP\*
M^-HT:GPRG%/T;29PYI7G1P=6M3^*,9->J3:/G?\ XB'/!O\ T3OQ-_X'0?X4
M?\1#G@W_ *)WXF_\#H/\*_*.BOWW_B'>1_\ /M_^!2_S/PS_ %^SK_GXO_ 8
M_P"1^KG_ !$.>#?^B=^)O_ Z#_"OM3]F7X[V?[37P+\/^.K&PN=,L_$,,DL=
MK.X>2(+*\>"5X.2A/'K7\Y]?O)_P2>_Y1Z_#3_KRN/\ TKGKXGCSA;+LLP4*
MV#@U)S2=VWI9OJ_(^RX)XFS#,<9.CBY)Q46UHEK=+HO,^B****_*3]/"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X[_ ."H7@-K35O#?BN)
M/W<T;:7<,.S*3)%^8,O_ 'R/P^6[2_P.M?I)^U1\*6^,OP,UW1X8]]^L7VJQ
MXR?/C^90/][!3Z.:_,&&]:-MK95AP0>U?IG"^)5?!^S>\';Y/5?JOD?GO$F'
M='%^T6TE?Y[/_/YG4)J>T=:CGU3*GFL-=1XZTR74>.M?0^QU/!]H7;[4<CK6
M+?WF<TV[O\*>?S-<UKWC&&S#+&&GD]ONC\?\*Z:=.QSSJ%S4+M45F9E55Y))
MQBN \8_%*.U5X=-433=#*P_=K]/7^7UJOXCU*\UUCYTA\O/$:\*/\?QK"FTG
MVK24FE9$1BKZG,:G'<:O>-<74CS3/U9SD_Y]JACT?GI73G2?:E32*YO9ZW-_
M::6,.VTK!Z5IV6F;>U:<&D\]*],^!'[+7BKX]:H(]$T]ELD<+/J%P#':P>N6
MQ\Q_V5!;V[UEB*]##4G6Q$E&*W;=D53C.K)0IJ[?1'G>C:-)=W$<,,3RS2L$
M1$7<SL3@  =23VKZN^$'[".N^%O#=OXH\262^<O[V/3/O2VR]1)*O3/?;G*\
M9YR!]%?LY?L9^%_V>;>.\5!K'B+;A]1G0?NB1@B%.0@Z\\L<\G' ]8EEK\+X
MV\1I8RC/+\I;A"2LY[2?^'LGWW?D?;93PRJ=JV+UET71>O=_AZGRO0!DUZ_\
M1_@S#K,DEYI2QV]TQ+/#]V.4^W]T_I].M>476GS:9>/#<120S1G#(XPPK^9L
M5@ZE"5I;='T/HY4W'<6 5?M8ZJP)6E:1U%-#B7+**MBPBZ50LHNE;-A%TKT*
M43:)I:?#TKW_ .!&@?V1X*6X9<27\AE_X"/E7^1/XUXOX+\.R>)-<M;*'[UP
MX4G'W1U)_ 9/X5],65G'I]G#;PKMBA01HOH ,"OTC@? .566*EM%67J]_N7Y
MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
MF;DGZMWDO6[]#]!R/Q Q&$M1Q,%*G_=2BUZ)6B_2R]3^C^BOE7_@G!_P4ST7
M]MC0FT75(8=#^(.EV_FWEBI_T?4$!P9[<DYP.-R'E=PY8?-7U57XEF&7XC U
MY8;$QY9+^KKNGW/V7 9A0QM!8C#2YHO^K/LPKYW_ ."L/_*/7XE_]>5O_P"E
M<%?1%?.__!6'_E'K\2_^O*W_ /2N"NG(?^1GA_\ KY#_ -*1SYW_ ,B[$?X)
M_P#I+/P;HHHK^KC^7PK]Y/\ @D]_RCU^&G_7E<?^E<]?@W7[R?\ !)[_ )1Z
M_#3_ *\KC_TKGK\R\4_^1;2_Z^+_ -)D?HWAG_R,:G^!_P#I43Z(K\M?^#A+
MXW->^+_ _P .[>;]S86TFOWR Y5I)&:&#/H55)SCTE'J*_4JOP=_X*P^/Y/B
M'^W[\0IS(TD.EW<6E0J>D8MX8XF ^LBNWU8U\1X;X%5\W]K+:G%R^;M%?FW\
MC[3Q"QCHY5[*.]227RW?Y)?,^=:***_H0_!0K^@3_@G]^SM'^S#^R9X0\,-#
MY.J-:+J&K$C#->S@22@^NS(C!_NQK7XE_L3_  U3XO?M<?#KP[-'YUKJ&O6I
MNH\9WP1R"28?]^T?Z=:_H<K\?\5,PDE1P,7H[R?Y+]3]8\,< FZV-ENK17YO
M] HHHK\;/UP**** ,/XE?#[3?BQ\/=:\,ZS#]HTK7[*6PNDP,F.12I(ST89R
M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
M@K#_ ,H]?B7_ ->5O_Z5P5]$5\[_ /!6'_E'K\2_^O*W_P#2N"OQ/(?^1GA_
M^OD/_2D?LF=_\B[$?X)_^DL_!NBBBOZN/Y?"OWD_X)/?\H]?AI_UY7'_ *5S
MU^#=?O)_P2>_Y1Z_#3_KRN/_ $KGK\R\4_\ D6TO^OB_])D?HWAG_P C&I_@
M?_I43Z(K^<O]J#7/^$G_ &EOB)J6[=_:'B;4KG<5VYWW4K9QVZU_1I7\W?QQ
MB>#XU>,(Y%9'36[U65AAE(G?((KPO"F*]OB'Y1_-GN>)\G['#KSE^2.7HHHK
M]J/QT^J/^"+V@+K7_!0SP?,T;2+IMMJ%UT!53]CFC!.?0R#'?.*_<2OQ1_X(
M;RI%^WOIJLRJTFCWRJ"?O'8#@?@"?PK]KJ_ /$Z3>;Q3Z0C^<C]T\-XI95)K
MK-_E$****_.C] "BBB@ K\C_ /@X3T3R/VE/!.I;1FZ\,_9MV[D^7=3MC';'
MF]>^?:OUPK\H?^#AUA_PN?X=CO\ V+<<?]MZ^X\.Y-9W3MVE^3/B^/XIY--O
MHX_FC\\:***_HP_G\$=HG5E8JRG((."#7]+WAO5&UOPYI]XWE[KRVCG.S[N6
M4-Q[<^M?S0U_25\)+&32_A5X9M9L>;;Z3:Q/@Y&Y84!_45^0>+$5R89];S_]
MM/U?POD^?$KI:'_MQT5?DO\ \%CO^";MW\//%^H?%CP3I\MQX:UB5KG7[.WC
M+'2KEB6>X '2"0Y+'HCD]%8!?UHJIK<]G;:-=2:D]K'IZPN;EKDJ(5CP=Q<M
M\NW&<YXQ7YOP]GV(RK%K$4-4]''I)=O7L^_E='Z'GV24,TPKH5M'NGV??T[H
M_F>HKZ1_X*5:=\![7XPRR?!:^O)?-E8ZI;6L(.B12'))M)2V[&[^!5,0!^1@
M!MKYNK^F\OQGUK#QKJ+CS*]I*S7JC^<,=A?JU>5!R4N5VO%W3]&+%*T$JR1L
MR.A#*RG!4CH0:^V?V7_^"Y7Q(^"^D6^D>,;&W^(FEVRB.*>ZN3;:E&HXP9PK
M"3'7+H6/=J^):*QS+)\'F%/V6,IJ2Z7W7HUJODS7+LUQ> J>TPDW%^6S]4]'
M\T?KMH?_  <'?"FXLE;4O"'Q"M+GO';06=Q&/HS7"'_QVJ7C'_@X5^'=E9,W
MA_P+XTU.XV_*FH/;6,9//!9))B!TYVGJ?3G\EJ*^77ASDBE=PEZ<SM_G^)],
M_$#.7&W.O7E7_#?@?4G[8'_!6SXF_M9:1<:"K6O@_P )W.4FTW2W8R7B?W9Y
MV^9QZJH12.JFOENBBOK<!EN&P5+V.$@H1[+\WU;\V?*X[,,3C*OML5-REW?Z
M=EY(*=:VLE]<QPPQR333,$CC12S.Q.  !U)STKL/@E^SYXT_:-\6QZ)X*\.Z
MEX@OV(#_ &>/]U; G :60X2-?]IR!7ZU?\$\?^"1>@_LJ7%GXM\92V?B;Q]&
M \&U=UCHS>L(8 O*/^>K 8_A"]3XW$'%."RFDW5?-4Z06[]>R\W\K['K9#PS
MC,TJ)4E:'63V7IW?DOG8D_X)$?\ !/B;]E'X=S>+O%EGY7CWQ5 JM _WM'L^
M&$!])'(#2>A5%X*L3]F445_..:9E7S#%2Q>(=Y2^Y+HEY(_H3+<NHX'#1PM!
M>['[V^K?FS\W_P#@XEUTVW@/X7Z7Y@ O+_4+K9SEO*C@7/IQYWZ_6ORSK]-O
M^#C+_FCO_<:_]Q]?F37] ^'\4LBHM=>;_P!+DC\'X[DWG=9/IR_^D1"BBBOL
MSY$**]LTS_@G#\<M;TRWO+7X:>))[6\B6:&18DVR(P!5A\W0@@U8_P"'9WQZ
M_P"B7^)_^_2?_%5YO]LX!.SKP_\  H_YGH+*,<U=49_^ R_R/"Z*]T_X=G?'
MK_HE_B?_ +])_P#%4?\ #L[X]?\ 1+_$_P#WZ3_XJC^VLO\ ^?\ #_P./^8_
M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
M@OQ\ F\9_ ;P[X^LX"]QX-OC:7K*.EI=;5#-[+,L0'_78U]^USOQ:^&.E_&C
MX9:]X3UN+SM*\0V4MC<J/O*KJ1N4]F4X8'L0#VK\>R+,WE^/I8Q;1>OH]&ON
M;/UK.\M6/P-3"/[2T]5JOQ2/YM:*ZSX[?!O5_P!GWXO>(/!FO1F/4O#]X]K(
MVTJLZCE)5!_@D0JZ_P"RPKDZ_JJE5C4@JE-W32:?=/8_F.I3E3FZ<U9IV:[-
M!7[C?\$B?VI;?]H[]DC1["ZNED\2>!XTT74HV;]XT:+BWF/<AX@!D]7CD]*_
M#FO6OV+_ -KOQ!^QA\:[/Q5HVZZLW'V;5=-:39'J5L2"R$X.U@0&5\':P[@D
M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
M)=.[U['[GP5PH\OA];Q2_>R6B_E7^;Z]MNX4445^=GWY^#?_  5?_P"4A/Q+
M_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]79#_ ,BS#_\ 7N'_
M *2C^7\[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^#?C_
M )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@HHHH
M *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OTKPM_
MY&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\ V!;[
M_P! 6OVJK\5?^"&O_)^NG_\ 8%OO_0%K]JJ_GWQ,_P"1NO\ !'\V?NWAQ_R*
M7_CE^2"BO(OVM?VF]4_9@\,V^LVGP_\ $7C;2X[6[O=3N=,ECC32(;=4<O+O
M/1E+D8_YYM[5X==_\%?TTKX#)\1]0^$OC&Q\+WES#;:?=RW4'EZBTAE4^61_
M=,39R*^4PF0X[$THUJ$+QD[+WH[]K-WO\MM=CZC%9Y@L-4=*M.SBKOW9;=[I
M6M\]]-S[.HKY0^.?_!6KP5\%?@)\.O'7]CZIK4?Q&MWN;6PMIHUFM%B"B;S&
M/RY21Q&<=6!QT-%=>&X1S?$0]I1H-J[6Z6J=GN^C31RXCBK*J$^2K62=D]GL
MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /E__ (+">$M6\<?L'^)]-T73-0UC4)KRP:.ULK9[B9PM
MU&20B DX )/'05^-O_#+WQ,_Z)WXZ_\ !#=?_&Z_HRHK[CAOC>KE&%>%A24D
MY.5VVMTEV\CXOB'@VEFN)6)G5<6HI623V;??S/YS?^&7OB9_T3OQU_X(;K_X
MW1_PR]\3/^B=^.O_  0W7_QNOZ,J*^@_XBMB/^@=?^!/_(\'_B&%#_G^_P#P
M%?YG\YO_  R]\3/^B=^.O_!#=?\ QNC_ (9>^)G_ $3OQU_X(;K_ .-U_1E1
M1_Q%;$?] Z_\"?\ D'_$,*'_ #_?_@*_S/YS?^&7OB9_T3OQU_X(;K_XW1_P
MR]\3/^B=^.O_  0W7_QNOZ,J*/\ B*V(_P"@=?\ @3_R#_B&%#_G^_\ P%?Y
MG\YO_#+WQ,_Z)WXZ_P#!#=?_ !NG1?LL_$Z>58X_ASX\=W(5570+LEB>@ \N
MOZ,**/\ B*V(_P"@>/\ X$_\A_\ $,*'_/\ ?_@*_P S^>O1OV#/C9KUSY4'
MPG^(4;9 S<:#<VR\_P"U(BC]>*]2^'7_  1@^/WCZ>/[1X7T_P -6\F,3ZOJ
M<**/JD1DD'XI7[A45R8CQ2S&2M2I0C][_5+\#KH^&F7Q=ZM2<ON7Z,_.7X _
M\&_&@Z'=6]]\2/%]UKK)AGTS1HC:V[$?PM.V9'4\_=6,^XK[P^$7P3\)_ 3P
MA#H/@[0--\/Z5#C$-I%@R'IND<Y:1_5G)8]S7545\7FO$&89B_\ :ZKDNVR^
MY67SW/KLKR' 9>O]EIJ+[[O[W=_+8****\8]@*\#_P""GWAS4/%W[!WQ$TW2
M;"\U34+JS@6&UM(&GFE(NH20J*"3@ G@= :]\HKJP.*>&Q-/$)7Y)*5N]FG^
MAS8S#K$8>>';MS1<;]KJQ_.;_P ,O?$S_HG?CK_P0W7_ ,;H_P"&7OB9_P!$
M[\=?^"&Z_P#C=?T945^G?\16Q'_0.O\ P)_Y'YM_Q#"A_P _W_X"O\S^<W_A
ME[XF?]$[\=?^"&Z_^-U^VW_!,'PYJ'A']@[X=Z;JUA>:7J%K9SK-:W<#031$
MW4Q 9& (R"#R.A%>^45\[Q-QI5SC#QP\Z2CRRYKIM]&NWF?0<.\'T\IQ$L1"
MHY-QM9I+JG^@4445\2?9!1110!\2_MH_\$5O!/[0-[>>(/ \\/@/Q3<,TLT2
M1;M+OW/4M$.86)ZM'QU)1B2:_-SX^_\ !.7XQ?LXW,S:]X+U.[TV+D:GI2&_
MLRO]XO&"8Q[2!#[5^_M%?<Y+Q_F6 BJ52U6"Z2W7I+?[[^1\7G' N78Z3JPO
M3F^L=GZK;[K'\R=%?T<>/_V<OA]\5I7D\3>!_".OS2'+2ZAI,%Q+GID.RE@>
M3R#FO.=6_P""87P"UO=YWPP\.IN<R'[.);?GG_GFZX'/3ITXX%?;T?%;!M?O
M:$D_)I_GRGQM;PQQ:?[JM%KS37Y7/P-J2RLIM2O([>WAEN)YFVI'&A9G/H .
M2:_?;1?^":GP'T%HS!\+?"LGEC ^TV[7.?KYC-G\<UZ=X&^#_A/X7PF/PSX7
M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>chart-0b79355e2c74500eae0.jpg
<TEXT>
begin 644 chart-0b79355e2c74500eae0.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M-=UR;1/ WP\T#Q/XMU+3O#^B6L^K>(=7MM&?2]#L1#+J5W;M>6,=S\<_%?\
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M^A> /$7@[X@?M$7/COQ'=>-? 'Q@\-?%W3OA!X0\)?%>S^/7P^U>#5;+XO\
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M>7]_S?W>8'W=17PC_P )SXS_ .AHUS_P83__ !5'_"<^,_\ H:-<_P#!A/\
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M%G947)&68 <D5^TL?B7P]Y<8_MW2,[%'_(1M/0?]-:_%[_@I/_RDD_X(4_\
M9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(H _/_77237-:DC97CDU?4G1T(9'1[V=
MD=6!(964AE8$@@@@X-95:_B#_D/Z[_V&=4_]+KBLBOXWQ?\ O>*_["*W_IR0
M!1117. 4444 %%%% !1110 5ZG\'KRTLO&*3WES!:0C2M14S7,T<$09FM"J^
M9*RIN8*VU<Y.#@&O+*];^"O_ ".R?]@C4_\ T.SKZ'A/_DILB_[&>$_].Q&N
MOI^J/J+_ (27P[_T'=(_\&-I_P#':/\ A)?#O_0=TC_P8VG_ ,=K;HK^KQ&)
M_P )+X=_Z#ND?^#&T_\ CM'_  DOAW_H.Z1_X,;3_P".U@^-?'=AX(337OK&
M]O1J3W21"S-N#&;18&<R>?+%PPG7;LW<J<XR,\%_POK0?^@%K7_?6G__ "57
MSV.XKX?RS%5<%CLSHX?%4>3VM&<*\I0]I3A5A=PI2C[U.I&2LWH]== M_5U_
M7]>3/6_^$E\._P#0=TC_ ,&-I_\ ':/^$E\._P#0=TC_ ,&-I_\ ':\D_P"%
M]:#_ - +6O\ OK3_ /Y*H_X7UH/_ $ M:_[ZT_\ ^2JX_P#7KA/_ *'.'_\
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M=75U/<^%YO'&J^1X#\56FFV'U?\ %[Q#X_L_CI^QWJGA?XK+;?"CQY\4-?\
M"&M^!/#>F:)-I_CU;C]GKX]>.(=?\1^.?MFIW>L^']/OO"7A2[\(^&_#<.B:
M9#JMI?>(-<U;Q.9=%L-$]X7X2?"A?'5U\45^%_PZ7XF7UM/9WOQ%'@?PN/'5
MW;75DVFW45SXM&E#7YFNM-9M,NYWOS<W>F,=-N9I; FWKS[Q!^R5^ROXL3PI
M'XH_9K^ _B*+P'X<TKP=X'BUGX4>"=0A\&>$M"6X30_"_A.&XT=XO#OA_1DN
M[N/2](TA+2RL(KJYBMH8XIY4=5,?@JM6C/ZO["-/!5,)*-/#4*BFZE&M3C5E
M&I44?;TY3A+V]/V*DXWI4,+9)NZ;5]-NBM96_)7WNW97W/H(=!GT%+2*JJJJ
MH"JJJJJ  %55"JH X"JH"J!P  !P*6O$)"D;[K_[C_\ H!I:1ONO_N/_ .@&
ME+9^C_(<=UZK\S]!M%_Y VD_]@RP_P#26*M.LS1?^0-I/_8,L/\ TEBK3K^R
ML+_NV'_Z\4?_ $W$04445N 4444 %%%% !1110 4444 ?B!_P4G_ .4DG_!"
MG_LZW]J#_P!8Y^(-?MY'_JX_]Q?_ $$5^(?_  4G_P"4DG_!"G_LZW]J#_UC
MGX@U^WD?^KC_ -Q?_010!\ ^(/\ D/Z[_P!AG5/_ $NN*R*U_$'_ "']=_[#
M.J?^EUQ617\;XO\ WO%?]A%;_P!.2 ****YP"BBB@ HHHH **** "O6_@K_R
M.R?]@C4__0[.O)*];^"O_([)_P!@C4__ $.SKZ'A/_DILB_[&>$_].Q&MI>G
MZH^O:***_J\1\[_'[_4^%?\ KMK'_HO3J^;Z^D/C]_J?"O\ UVUC_P!%Z=7S
M?7\R>(G_ "6&;>F _P#59@P"BBBOB@"BBB@ HHHH **** "D;[K_ .X__H!I
M:1ONO_N/_P"@&E+9^C_(<=UZK\S]!M%_Y VD_P#8,L/_ $EBK3K,T7_D#:3_
M -@RP_\ 26*M.O[*PO\ NV'_ .O%'_TW$04445N 4444 %%%% !1144WF>3+
MY+I%+Y<GE22QM-'')L.QY(EE@:5$?#/&LT3.H*"6,D.H!)N7.W<-WID9_+K2
MU^2WC_XY^$?"7Q.7P]??';]KG5O%FG_$6X\ ^*O$OA&/X,Z9\,O!+Z3=? OP
M_K_B:X\#Z]H<&GZQX#T'QO\ M(?"7P5>PV&@>-?&\FKZKK9M!K.G^$_$?B"V
M_5K2H;ZWTS3[?5+Z+4]2@L[:#4-1ALETV&_O884CNKR+3UN+I;)+F=7F6U6Y
MN$MP_E)-(JAB ?B7_P %+8DG_P""D'_!"J-S(%/[5W[3I)BEE@<%/V//'[KB
M6%XY%^91N"N RY1@R,RG]IHO#^G!(R'U7.Q#_P A_7NN!_U$J_%W_@I/_P I
M)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"* /S_UU!'KFM(N[:FKZDB[F
M9VVK>SJ-SN6=VP!N=V9V.69BQ).56OX@_P"0_KO_ &&=4_\ 2ZXK(K^-\7_O
M>*_["*W_ *<D 4445S@%%%% !1110 4444 %>I_!ZUBO/&*0S&=4.E:BV;>Z
MNK.3*M: #SK2:"8*0QW()-C<;E.U<>65ZW\%?^1V3_L$:G_Z'9U]#PG_ ,E-
MD7_8SPG_ *=B-=?3]4?47_"/Z=_?U7_P?Z]_\LJ/^$?T[^_JO_@_U[_Y95MT
M5_5XCYI^.6G6UA#X9-NUV?-FU8/]JU"_OL;([ KL%]<W B/S'<8MA?@/N"KC
MY]KZ0^/W^I\*_P#7;6/_ $7IU?-]?S)XB?\ )89MZ8#_ -5F# ****^* ***
M* "BBB@ HHHH *0_=;_<<_DI_/Z'@]Z6D;[K_P"X_P#Z :4MGZ/\AQW7JOS/
MNW2-!L)-)TMV?5-SZ;8L=NNZXBY-K$?E1-15%4=E50JC 4  "MZST^VL/,^S
MM=GS=N_[5J%_??<W;=GVVYN/*^\=WE[-_&_=M7$6B_\ (&TG_L&6'_I+%6G7
M]E87_=L/_P!>*/\ Z;B(****W **** "BBB@ I&Z' R<' ]>.G&3S]#2U6O;
MJ*QL[J\G\X06EM/<S&WMKB\G$5O$\TAAM;2*>ZN9=B-Y=O;037$[[8H8I)71
M& /R<UO0=/UW]K7XIZGXE\'Z-X(U"/XN?!N&SU71OV"_C-\3U^*.A>!K3P#X
MF\"^*O$W[2%EH*^"7USPYXU6[@M[N*2/1_A1>>'?#&HZK)J%[HFFZ\?UK'3\
M3VQW/^<]^O>OP^^('ABY\1?M0:CKVEV%S=:WXS^.?P%^(?@[]HO5_A=^V-;_
M !<^#G@&PTWX:W=_\%O"&BZ;^SA?_"R3P;X@L;#Q!H^K2W_QC\$>"[&#XH>+
MY?C!X'UGQ%X<\01^(_W!'3\_PY/ X' Z XY&#0!^(/\ P4G_ .4DG_!"G_LZ
MW]J#_P!8Y^(-?MY'_JX_]Q?_ $$5^(?_  4G_P"4DG_!"G_LZW]J#_UCGX@U
M^WD?^KC_ -Q?_010!\ ^(/\ D/Z[_P!AG5/_ $NN*R*U_$'_ "']=_[#.J?^
MEUQ617\;XO\ WO%?]A%;_P!.2 ****YP"BBB@ HHHH **** "O6_@K_R.R?]
M@C4__0[.O)*];^"O_([)_P!@C4__ $.SKZ'A/_DILB_[&>$_].Q&MI>GZH^O
M:***_J\1\[_'[_4^%?\ KMK'_HO3J^;Z^D/C]_J?"O\ UVUC_P!%Z=7S?7\R
M>(G_ "6&;>F _P#59@P"BBBOB@"BBB@ HHHH **** "D;[K_ .X__H!I:1ON
MO_N/_P"@&E+9^C_(<=UZK\S]!M%_Y VD_P#8,L/_ $EBK3K,T7_D#:3_ -@R
MP_\ 26*M.O[*PO\ NV'_ .O%'_TW$04445N 4444 %%%% !67KF/[&U8DR@#
M3-0),-KJ5]-_QYSY\JST:2+5KN3_ )YVVER)J-P^(;%TNGA8:E(W0_0]#@]/
M4\#Z]J /P_\ "'PKU?PS\2? EI>ZGXEN9+/Q/X!U)WTW]F'_ (*VRZ.\.H76
MA:W DGBS7?VAO$/P[TN1;6]BBUB?QA#J6A^%]16_L?'FFYTC7M+C_< ?U/8C
MN?7^?0]1Q7XF:C<?#V;]M3XO0^+[[]FB;Q);?'SX;C0(/CY\7?%-Y\9K:*3P
MA\-_[.B^&?ASP]'-X8T#PFVH1R?\*Y\'/*MZGBE?$&J>*"E]XB:*']LQ_4]/
MJ?\ )]Z /Q!_X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@BOP_
M_P""EHF/_!2#_@A4('CCE_X:N_:=VO-&TL87_ACSQ^7S&DL+,3'N"$2J%<JQ
M#*"K?M-%#XCV1YU'1,;$_P"8-?9Q@?\ 4='- 'PWX@_Y#^N_]AG5/_2ZXK(K
M5UT.-<UH2%6D&KZD)&12B,_VV?>R(S.R*6R54NY4$ NQ&XY5?QOB_P#>\5_V
M$5O_ $Y( HHHKG **** "BBB@ HHHH *];^"O_([)_V"-3_]#LZ\DKU/X/+=
MMXQ064MM#-_96HD/=6\MU%M#6FY3%%<VC[B=NUO.PH#91LC'T/"?_)39%_V,
M\)_Z=B-=?3]4?8M%8GD^(_\ H(Z)_P"":_\ _E[1Y/B/_H(Z)_X)K_\ ^7M?
MU>(\2^/W^I\*_P#7;6/_ $7IU?-]?07QR34DA\,_VA<V-P#-JWE?8[*XM"A$
M=AO\PSW][Y@(V[ HBVX8DOD!?GVOYD\1/^2PS;TP'_JLP8!1117Q0!1110 4
M444 %%%% !2-]U_]Q_\ T TM(?NM_N/GZ;3G_P#7SCT-*6S]'^0UNO5?F?H-
MHO\ R!M)_P"P98?^DL5:=<GI$/B Z3I9CU#1@ATVQV!](O6<+]EBP&9=;4,P
M'!8*H8\A5S@;UFFI)YG]H7%C/G;Y7V.RGM-N-V_S//O[WS,_)MV^7MPV=^X;
M?[*PO^[8?_KQ1_\ 3<1%ZBBBMP"BBB@ HHHH *0G )] 3QUXI:J7R7$EE=I:
M2-#=/;7"V\J"$O'.T,BPR*+F.6W+)*491/%)"2 )8WCW*0#XX3]J3Q)JWQG\
M=_##P]X0^$UG8_#OXA>&_ 6NW'Q&_:&MO GQ#OQK?A_PMXC/B7PY\+++X;>+
MI-0T&^L_$KVG@Q]4\6:)>>,M3T758DMM'LEMK^;[2K\=!\.O%\7Q*TSQ'XQ_
MX7]XN^(MGXFT'5[^SN_V%/V7=3N/$DNBW]C<1))\<=%\&OX)L!<PVL=M;^(/
M^%G:/J.DQNEW;2Z9=6B_9OU\TJXO+S3-/N]0T]])OKJSMKF\TN2YMKR33;J>
M%)9["6[LVDM+J2SD9K>2XM));:9XVD@EEB9)& /Q/_X*3_\ *23_ ((4_P#9
MUO[4'_K'/Q!K]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;
MR/\ U<?^XO\ Z"* /@'Q!_R']=_[#.J?^EUQ616OX@_Y#^N_]AG5/_2ZXK(K
M^-\7_O>*_P"PBM_Z<D 4445S@%%%% !1110 4444 %>M_!7_ )'9/^P1J?\
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MQ_Z+TZOF^OYD\1/^2PS;TP'_ *K,& 4445\4 4444 %%%% !1110 4C?=?\
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M :6D;[K_ .X__H!I2V?H_P AQW7JOS/T&T7_ ) VD_\ 8,L/_26*M.LS1?\
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M1HN2 "SR?"%44$D %F +$*.2 3^P,^_Z$F<?^&S&_P#RCS_/LP/U<HK\I?\
MA^'_ ,$H_P#H\SP6/K\-_C^#^(_X5!Q1_P /P_\ @E'_ -'F>"__  W'Q_\
M_G04?V!GW_0DSC_PV8W_ .4>?Y]F!^K5%?E+_P /P_\ @E'_ -'F>"__  W'
MQ_\ _G04?\/P_P#@E'_T>9X+_P##<?'_ /\ G04?V!GW_0DSC_PV8W_Y1Y_G
MV8'ZM5ZW\%?^1V3_ +!&I_\ H=G7XE?\/P_^"4?_ $>9X+_\-Q\?_P#YT%>A
M?#+_ (+Q?\$D?#GBA-1U7]M'P;#:#3KZ R#X;_'P_O9FMC&OS_".-?F\MOXL
M^@/2O>X7R7.:'$62UJV49I1I4\QPLZE6KE^+ITZ<(U(N4YSG1C&$4M7*326M
MWHQKKYK]4?T845^+'_$1!_P1M_Z/<\'?^&V^/'_SJ*/^(B#_ ((V_P#1[G@[
M_P -M\>/_G45_3@C]'_C]_J?"O\ UVUC_P!%Z=7S?7P=\7/^"^?_  2'\51Z
M NC_ +:O@V<V,NI-<9^&WQ[^47"68B^Y\))/O&%QSCIQFO%O^'X?_!*/_H\S
MP7_X;CX__P#SH*_G7CS)\VQ7%6:5\+E>8XFA46!Y*V'P.*K4I\N7X2$N6I3I
M2A+EG&496D[2C).S3L'ZM45^4O\ P_#_ ."4?_1YG@O_ ,-Q\?\ _P"=!1_P
M_#_X)1_]'F>"_P#PW'Q__P#G05\?_8&??]"3./\ PV8W_P"4>?Y]F!^K5%?E
M+_P_#_X)1_\ 1YG@O_PW'Q__ /G04?\ #\/_ ()1_P#1YG@O_P -Q\?_ /YT
M%']@9]_T),X_\-F-_P#E'G^?9@?JU17Y1K_P7&_X)0MNV_MG^"&V,4<+\.OC
MZQ1P 2CA?A"3'(%96,;[7"LK%0&4EW_#\/\ X)1_]'F>"_\ PW'Q_P#_ )T%
M']@9]_T),X_\-F-_^4>?Y]F!^K5%?E+_ ,/P_P#@E'_T>9X+_P##<?'_ /\
MG04?\/P_^"4?_1YG@O\ \-Q\?_\ YT%']@9]_P!"3./_  V8W_Y1Y_GV8'ZM
M4C?=?_<?_P! -?E-_P /P_\ @E'_ -'F>"__  W'Q_\ _G04C?\ !<3_ ()1
M[6_XS,\%G*L!CX;_ !_ZE2!_S2"A\/Y]9_\ ")G&S_YEF-_^4>?]68UNO5?F
M?TP:+_R!M)_[!EA_Z2Q5IU^)>F?\'#/_  1QMM-T^WE_;;\'"6"QM(9!_P *
MV^/'$D5O&CC_ ))1V92.<'CD \#[>_9!_P""B?[&G[>C^/X_V2_C?HWQC?X7
M#PR?'@TGPUX]\/?\(\/&/]N?\(V9SXV\)^&!=_VI_P (YK7E_P!FF]\C["_V
MO[/YMOYW]:89-8>@FFFJ-)--6::A%--/5-/1I["/M:BBBM@"BBB@ HHHH **
M** "BBB@!"H;&1T.1P#@X(SR",X)YZTFT?Y"_P#Q-.HH 9L7T'_?*_\ Q-'E
MKZ#_ +Y7_P")I]% #/+7T'_?*_\ Q-'EKZ#_ +Y7_P")I]% #/+7T'_?*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>chart-0e90e35cb3f356fdb65.jpg
<TEXT>
begin 644 chart-0e90e35cb3f356fdb65.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +^ 3T# 2(  A$! Q$!_\0
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MJ][<%M4M)->U-=/D1+:QV>=W_P#P3U^%_B./XV:5XS\3^*?$?A?X[^"_VGO
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M#OX1?"O31I?AW1H/(\,Z5X&\&_!OP]%HNF07VIS:GK&J>(=9US4[N:]MX;,
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M4,2)'&@&%154=*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(WI7]R\_\&VL?_+"@#>HK!_X1O2O[EY_X-M8_P#EA1_PC>E?W+S_ ,&VL?\
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M/_6.?B#7[>1_ZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\
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M&+EI)',A#2%W=C(PR0\A8DNX+,0[Y;+-S\QR (S,[,[L7=V9W=OO,[$LS-C
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M#K#_ -)(:TZS-%_Y!&E_]@ZP_P#22&M.@ HHHH **** "BBB@ HHHH ****
M/Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@BOP^_P""ET\%
MK_P4?_X(63W,T<$*?M6_M/;Y97"1KN_8[^("+N=B -SLJC)Y9@.]?M+'XF\.
M^6G_ !/-+^XO/VVW_NC_ &Z /B37_P#D/:[_ -AK5O\ TX7%9-:FN.DFMZU)
M&RO')K&J21NIRKH]]<,CJ1P592&4C@@@BLN@ HHHH **** "BBB@ HHHH *]
M7^#/_(Z)_P!@C4__ $*TKRBO3OA)>6EAXN6>]N8+2#^RM13SKB18H][M:;5W
MN0-S8.!G)P<=* /L*BL/_A)O#O\ T&]+_P# VW_^.4?\)-X=_P"@WI?_ (&V
M_P#\<H \7^/?^I\+?]=M7_\ 1>G5\YU[]\;M4T[48O#0L+ZUO##+JIE%M/'-
MY8>.P"%_+9MNXJVW.,[3CH:\!H **** "BBB@ HHHH **** "FO_ *N3_KG)
M_P"@-3J:_*2 =?+D_P#0&H ^_P#1?^01I?\ V#K#_P!)(:TZY+2/$GA]-*TU
M'UK3%=+"R1U:]@#(ZVL2LK OD,I!!'4'@\UOV6IZ=J/F?8+ZUO/)V>;]FGCF
M\OS-VS?Y;-MW;&VYQG:<=* +U%%% !1110 4444 %%%% !1110!^('_!2?\
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M74E6&&4E2"6T %>K_!G_ )'1/^P1J?\ Z%:5Y17J_P &?^1T3_L$:G_Z%:4
M?7-%%% 'SW\>_P#4^%O^NVK_ /HO3J^<Z^C/CW_J?"W_ %VU?_T7IU?.= !1
M110 4444 %%%% !1110 4U_]7)_USD_] :G4U_\ 5R?]<Y/_ $!J /O_ $7_
M )!&E_\ 8.L?_22&M.LS1?\ D$:7_P!@ZP_])(:TZ "BBB@ HHHH **** "B
MBB@ HHHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"*_$
M/_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(H ^"-?_ .0]KO\
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M^I\+?]=M7_\ 1>G5\YU]&?'O_4^%O^NVK_\ HO3J^<Z "BBB@ HHHH ****
M"BBB@ IK_P"KD_ZYR?\ H#4ZFO\ ZN3_ *YR?^@-0!]_Z+_R"-+_ .P=8?\
MI)#6G69HO_((TO\ [!UA_P"DD-:= !1110 4444 %%%% !1110 45R-QX_\
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M7P#_ ,-8Z[_T)>B?^#?5/_D>OJ?_ (*7?\>/P:_Z_O'G_I'X7K\I:_S=\?\
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MZ_Z9?]_!_A1_Q*[](C_HS?B!T_YI['=;?]._[R_$/];>&?\ H>Y9_P"%5/\
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M::=FGB**::W37/HT>WT5XA_PT5\)O^AAO?\ PG=;_P#D2C_AHKX3?]##>_\
MA.ZW_P#(E1_Q%[PJ_P"CD\"_^)7D7E_U'>?]75S^T\M_Z#\'_P"%-'_Y,]OH
MKQ#_ (:*^$W_ $,-[_X3NM__ ")1_P -%?";_H8;W_PG=;_^1*/^(O>%7_1R
M>!?_ !*\B\O^H[S_ *NKG]IY;_T'X/\ \*:/_P F>WT5XA_PT5\)O^AAO?\
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M]NT_U4?^['_[+7XB?\%)_P#E))_P0I_[.M_:@_\ 6.?B#7[=I_JH_P#=C_\
M9: /YFOB;_R4KXB_]C_XV_\ 4HU:N(KM_B;_ ,E*^(O_ &/_ (V_]2C5JXBO
M\',]_P"1WF__ &,\=_ZE53\;K?Q:O_7R?_I3"BBBO*,PHHI-R\G(P.IR./KZ
M?C0 M%("#R"".F00>?3BER.F>1U'IGI0 4444 %?:_[ ?_)P,/\ V(GB_P#]
M':#7Q17VO^P'_P G P_]B)XO_P#1V@U^I>"7_)W/#O\ [*S)O_4RD>AE/_(S
MP'_851_]+1^Y-%%%?[3'ZP?FC_P48_X\OA%_U^>-_P#TE\,U^7M?J%_P48_X
M\OA%_P!?GC?_ -)?#-?E[7]0^'/_ "1V4>N8?^K/&G\.^,?_ "<7B#_#E/\
MZI,N"BBBOMS\Q"BEP<;L';G&[!VYYXSTSP>,YX/H:7:Q*@*Q+X*#:<N&8JI0
M8R^Y@5&W.6!4<@B@!M%3"WN#,;<6]P;@9S;B&4SC W$&$)YH(4[B"O"\GCFH
M@K,P159G+! H!+%B=H4* 26+?*% R3P!FBS[>7S["NNZVO\ +OZ"44]XY(G:
M.6-XI%.&CD1HY%) (#(X5E)!!P0#@@]#3*![[!4<W^IF_P"N,O\ Z+:I*CF_
MU,W_ %QE_P#1;4X[KU7YBEL_1_D?TD^!/^1)\'_]BMX>_P#3/95U=<IX$_Y$
MGP?_ -BMX>_],]E75U_%V+_WK$?]?JG_ *6S_2? _P"Y8/\ [!</_P"F8!11
M17.=04444 %%%% !1110 4444 ?B!_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?M
MVG^JC_W8_P#V6OQ$_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV[3_51_P"['_[+
M0!_,U\3?^2E?$7_L?_&W_J4:M7$5V_Q-_P"2E?$7_L?_ !M_ZE&K5Q%?X.9[
M_P CO-_^QGCO_4JJ?C=;^+5_Z^3_ /2F%(>AZ#@\GI^/MZTM%>49GYZ^+/B]
MX]\"_M%^,[C4?%'B/Q3X9'A_Q'I/P[\'^!=;^'OB#P)<>)M/TSQ%J'AWX:?$
M7P,]I:_$WPQ\1+_7?#VHVU_XRT2^UIRLVA_;)/#W@_4_L=IG:+XP^*NH>"3I
M5SX[^(%OXP^*WP1^&WQ/\):OK'Q@^%VFZ7J%OJWQ'^&ND>+=6\+ZW9^%=-7]
MG[7]8L?&A\->$_"*7/C;PE<P:C96^@:I?_$KP[K5K??=J> / \?C=OB7'X/\
M,I\0VT1/#9\;IH>FKXI.AQW#W*:=_;@MAJ B621HQ()Q<FTVZ>9CIZ1VJ4+#
MX5?"_2K7Q18Z9\-O %A8^-R__"9V-IX-\.PV7BP.\LC1^(K1-.%MJ\'G7%Q<
M):7L4MI%<W%Q=PP1W5Q/-)^JKC;AI8?+X+AC#/$83!</T:]66"PML57RBK4J
M5>94J]']W6E*%3%59J<\S4'0]EE4UA\9A_1^MX?E@OJ\7*,**DW"/O.FVW\+
M6C>LFTW4UC:G[LH^:?"+Q8NA:1\3_#'C*]\6GQ!\)?%%Q:^*[CQ#\2-4^-M_
M>I?^ -&^)5M%X0\07GASPMXIUMK/PI?1F;P+/X3LO$NC:S'>6PM+VWU/3KZZ
M\A_9@^/\GQ=^,/QLTV\\9ZKJ*S^"O@MX]\.?#N\\/>)]'L/AAI^NGXCV&L>&
M[:?7/"F@BYUR*TLO!,OC>\GO+H:OXQGUAO#BR:#I6;7ZPTGX:_#K08/"]MH?
M@/P=H]OX(U74M>\'1:7X<TJQ7PMKNLZ5>Z%K&N:#]FM8VTW6M6T74M1TC4]7
M@9=1U#3;ZZLKNYFMYG0]6MA9)J>HZTMK -8UBVTBSU;5?+!U'4[30!J2Z%:W
M]X<SW=OHRZQJPTN*9W2P&J:B+81B\GW_ #E?/,A=#B*G2RC$5,1G6#P-+#8R
MI6HP>6XG"XW!XC$U*-+$4\SKJEF/U25>HJ>80Q.&C6_LN&)KX:-;%XO"5:C:
MNE2DY58049-Q_=RC.$I.*:F[5%%MM3YHW]G>4;RE;HHHKXTY0K[7_8#_ .3@
M8?\ L1/%_P#Z.T&OBBOM?]@/_DX&'_L1/%__ *.T&OU+P2_Y.YX=_P#969-_
MZF4CT,I_Y&> _P"PJC_Z6C]R:***_P!IC]8/S1_X*,?\>7PB_P"OSQO_ .DO
MAFOR]K]0O^"C'_'E\(O^OSQO_P"DOAFOR]K^H?#G_DCLH]<P_P#5GC3^'?&/
M_DXO$'^'*?\ U29<%(>AY(X/(&2/<#!R?;!SZ4M%?;GYB?FQ;>)H="_;MUNT
MF\37OC/4O$-C)I M+3Q?\1O"_B[X3>'YY?&5S';^)/A;JT$WPQ\;_!#PM_9+
M:O%XWM!H=K_Q/O#WB5+CQ/XD35&O,+P[\2O"=Y\./VA/#GA3X]3?$VQTS]K3
MPK=?$7Q/IGQ5TSQE\0;?]GK6+G]GZS^+/C*VO?!NHI>^'_"*V.H>)+*]O_!&
MG:%X<\(^'Y_$EOX5@T7^R@MK^G_DP^>]T8HC<O9QZ<]P8T,[Z?%<S7L>GO,5
M\Q[&.]N+B\2S9C;)=SSW*Q">:21HK:QL+)_-LK#3[&7;Y?FV-A9V4OEYW>7Y
MMI!#)Y>[YO++;-WS;=W->"LFJQ5:*Q<%&MB,?6TP\[PCCJ+IRA?ZS>I)2?M)
MU*KE.:BJ<'1@H\OUDN),/)X>4LOJRE0P>4X9WQ=)JI/*\1&LJB7U+EHPG"/L
M:5&C&-.G=UJBQ%1RYORIUB^^U^.9_"&E>*O .F_L=M\0O',7@KQ?\1/'OC:3
MX)6_C.P^$_PBOKKPA+XA\.>,-"U3Q3\/-)\8:E\6;WX=:/'\2-.\&Q>/+'Q+
M!IUUJ4O@GPWX?;ZDT+XD_#O7OV>O#.C^/_$FH^";Z\^%7@?Q%XAT'5OB#X^;
MQ3I/A36O%L_@WPIXC\6^.H;6R^)5M\,O&OB'0TTV_P#'VOQZ+JUSX*U"[/BZ
M]TNY?5[E/KDQQ&$6YBB-L(XX1:F*,VJPQ.LD,*VQ7R%AAD5)(8A&(X9$1XU5
MT4B3)+O*3F616224\S2(^[>DDO\ K'1][[T=F1][EE)=]UX?*:F'J8FHL32G
M]9A5ING4PCE2IPJ*FH4*<5B(N.%P[A-4<.I*/LZTZ<Y2<:4X98OB"CC*6"I2
MP5>D\%4PU6-:CCU&M5J4)574Q564L)*,L=BU4A+$8N4)2=;#TJL(14ZU.?R7
M^R)?O/X8^*FFQ7>BWVC:)\9-9M_#<W@3Q3K_ (X^#MIHFI>"O FKQZ'\&_%W
MBEY?$&K>%-%O[N_7Q#:WCFRT#XBWOC#1- 6'0;33[6W^LZ155$CCC5(XHD6*
M&*-5CBAB3.R*&) L<,29.V*-51<G:HR:6O2P>'>%PU+#N?M/9J24E!4U9RE*
M,8P4I*,81:A%)V48JR2T7BYCBUCL97Q:I.BJS@W3=1U7S1IPA*<JCC%SG4E%
MU9RDN9SG)R<G=LJ.;_4S?]<9?_1;5)4<W^IF_P"N,O\ Z+:NJ.Z]5^9PRV?H
M_P C^DGP)_R)/@__ +%;P]_Z9[*NKKE/ G_(D^#_ /L5O#W_ *9[*NKK^+L7
M_O6(_P"OU3_TMG^D^!_W+!_]@N'_ /3, HHHKG.H**** "BBB@ HHHH ****
M /Q _P""D_\ RDD_X(4_]G6_M0?^L<_$&OV[3_51_P"['_[+7XB?\%)_^4DG
M_!"G_LZW]J#_ -8Y^(-?MVG^JC_W8_\ V6@#^9KXF_\ )2OB+_V/_C;_ -2C
M5JXBN_\ B9:W)^)/Q$(@F(/C[QHP/EM@@^)]5(((!!!!!S7$?9+K_GWF_P"_
M;_X5_BEG7AIXD5<XS6I2\/>.:E.IF.-G3J0X1X@G"<)8FHXSA..7.,H233C*
M+<9)W3:U/PRMFN5JM53S++TU5J)IXW#)I\[NFG5NFNJ>VM]F5Z*L?9+K_GWF
M_P"_;_X4?9+K_GWF_P"_;_X5YG_$,/$O_HW7'G_B'\0__.[S_/LS+^ULJ_Z&
M>7?^%N&_^6^?Y]F5Z*L?9+K_ )]YO^_;_P"%'V2Z_P"?>;_OV_\ A1_Q##Q+
M_P"C=<>?^(?Q#_\ .[S_ #[,/[6RK_H9Y=_X6X;_ .6^?Y]F5Z*L?9+K_GWF
M_P"_;_X4?9+K_GWF_P"_;_X4?\0P\2_^C=<>?^(?Q#_\[O/\^S#^ULJ_Z&>7
M?^%N&_\ EOG^?9E>BK'V2Z_Y]YO^_;_X4?9+K_GWF_[]O_A1_P 0P\2_^C=<
M>?\ B'\0_P#SN\_S[,/[6RK_ *&>7?\ A;AO_EOG^?9E>OM?]@/_ ).!A_[$
M3Q?_ .CM!KXP^R77_/O-_P!^W_PK[5_8&MYX_P!H"%GAD1?^$%\7#<R%1DS:
M%@9(')P:_2?![P]X_P N\4> \=F' O&6 P.%XGRFOBL;C>%\\PN$PU&GBZ<J
ME;$8FO@*=&A2A&\IU*LX0@DW*229Z>39EEU7-<OITLPP-2I/%T(PIT\7AYSE
M)SC:,8QJ.4I-M)))MO1*Y^X=%%%?Z[G[*?FC_P %&/\ CR^$7_7YXW_])?#-
M?E[7ZA?\%&/^/+X1?]?GC?\ ])?#-?E[7]0^'/\ R1V4>N8?^K/&G\.^,?\
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M )22?\$*?^SK?VH/_6.?B#7[=I_JH_\ =C_]EIQW7JOS _G&^(__ "43Q_\
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M -V/_P!EIQW7JOS _G&^(_\ R43Q_P#]CSXP_P#4DU.N,KL_B/\ \E$\?_\
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M<=UZK\S]!M%_Y VD_P#8,L/_ $EBK3K,T7_D#:3_ -@RP_\ 26*M.O[*PO\
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MX@_Y#^N_]AG5/_2ZXK(K7\0?\A_7?^PSJG_I=<5D5_&^+_WO%?\ 816_].2
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MV0?^CEO@W_X6%O\ _&*/^&V?V0?^CEO@W_X6%O\ _&*P_P"(=>(7_1!<;?\
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M9!_Z.6^#?_A86_\ \8H_XAUXA?\ 1!<;?^(IG_\ \[_-?>'^M/#'_12</_\
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M'N.R2MGCQ$9Y91X>H8ZGAO[+Q57*(\N*GG&%E5]M# *N[T*?)*JZ:YE%3?\
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M>#/_ )>4?\+4^%O_ $4_X:_^'"\&?_+ROX=/LMI_SZ6G_@+;_P#QNC[+:?\
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MSX3:KX_\(VDXUKPYK.N:#JF@>&-/;Q)%;?$'5M+F\(ZEXFT_3[W4K&*+)_;
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M[/0=)\1GQ(_A5/AQ<ZK->:A9RS>#+/QE<>)[:WEEA>R;5[*_T>VS/"?P)O\
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M-Q$,-C<RGB)T</6A4G&C"KE%&G*HU%J,9U:<6]YQ6I_4+17XK?\ ##/_  6
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MB=%I[^$;?Q_J7AB\L=3LM&EU!;>>YU#3?#BZ@/%NIZ?X?N0#Z<HI 00"#D$
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M4-'U:RM-0LKB"/N: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O+/CE\+-/^.7P5^+WP5U;5+W0]*^+_ ,+_ (@?"[5-:TU0^HZ1IWQ!
M\):QX1O=4T]3)"#?:?;:Q+>6@\Z(-/"BF6,,77U.B@#\G/ OAS]I;6/CCX<U
MCXE?"'PI:^./V2?V<?%/@?X9Z5X>UGQS!\+OVC_$OQ53X+G7_'5M\7=9^%3>
M%?AEX?T.7X51:/8_";4?^$P^)%EKVH:CK^LVD_A?P[X0\3>*/HW]A#P3\=/A
MC\%(?AQ\=? '@WP7K/AKQ#XNOM(O/!OQ4G^*%GXBLO&GCKQAXZGN+JXNOAY\
M/[C1[K27\1V^ER0R6VI?VC+%->I/;QA8Y/M;^O6B@#\[/VR_!7[4_P 3=4T?
MX4?#KX5?#[QC^R_K/AEY/B_IA^.UQ\(?'WQ-O;W4[RUU#X1:@W_"HO'%KH'P
M>U?P\N_QUJ/AS5(/&?CR+5Y_!D-SX2\.PZ[<^*^9/[*'QH;Q%J'PRC'P\A^!
M&O\ [8WAG]LV]\>2>)=:D^)FC7.A?$/PI\<[CX.V7@R'PC#I5\\_QG\+QVUC
M\0CXXLK.S^$^HSZ"?"7]NZ59R:C^G-% "*"% ."0 "0,#/? [#/0=AQ2T44
M%%%% !1110 4444 %%%% 'Y'_M7_  <^-?@#4OVK_$'PN\*Z=X_\"_MO^'?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% 'B?Q,_9M_9^^,^L6'B'XM_!7X7_$O7=*TS^QM-UCQSX(\/\
MB?4K#2?M4]]_9MI>:O8W4]O8_;;FXNOLL3K#]HFEEV[W8GS=OV"_V*&5E;]D
M_P#9Y*LI5E/PD\%$,K JRD?V1R""01W!(KZTHKU\/Q!GV$HT\/A<[S?#8>DN
M6E0P^98RC1IQO?EITJ=:,(*[;M&*5]=SRJ^19)BJT\1B<GRO$5ZKYJE:OE^$
MJU:DK)7G4J4I3F[)*\FW96V,_2=)TS0=+TW1-%T^STK1]'L+/2M*TO3[>*TL
M--TW3K:*SL+"RM8%2&VM+.TAAMK:WB18H8(HXHU5% &A117DRE*4I2E)RE)N
M4I2;<I2;NY2;NVVVVVW=O5GJ1C&,5&*48Q2C&,4E&,4K))+1)+1):):(****
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHBZ/H>JV=Q!:7FFZQJC7PL-+O[6ZN;>VN;*_N+>Z@N)X898DEEC5ORJ\.?\
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MS^$DU[17\4VVE1Z[<>&UU6P;7X-%EN39Q:O-HPN#J<6ERW8-K'J$EJMF]P#
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MTOX=>'=(T_2_#5V)2;OP_HMI/T7AC_@GI\1(/ WA7X:>*/ _[--Q:>"?BQ\
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ML;WEC:7;QJ2RQM<01S,BL0"54N5!(!( ) -7JQ_#W_( T/\ [ ^F?^D4%;%
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M1=?\-?#CX>Z-=Z]\/=0\+V%EX#USQ#?:EHY3POIVE+_P2T\4R?"W7?#$>@_
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MG'XU\'RR>*(8_%7AN27P0@D\91)KVDM)X31K*34@_B9%O"^@*=.AEO@VKK9
MV<<ET#]G1I!\7_%S]FKQKXK_ &F[+XOZ=X)^!'Q*\,:[X5^ WA*YN/C"^O-X
MG^",_P &/C#XR^)VI^,/A1I^E>&-536=8\<VGBS3U-O%XL^'4NC>-_A[X"U_
M6=1\7:'9_P!CZ9\@:?\ \$W/B:_AFX\+>(/#GP&U%/"/PI^(OPPC\3:5XO\
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M35'_ (0WPD>OAG0?_!38_P#QBNDHH 9'''#''#$B111(L<4<:A$CC10J(B*
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M+2SLX(;6TM;:)(+>VMK>-88+>"&-5CBAAB1(HHHU5(XU5%4* !/110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>chart-2dae770040575c09957.jpg
<TEXT>
begin 644 chart-2dae770040575c09957.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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M:>*=(T&./X?_  ^U[7_!ME=-9:WXG\$Z/?1ZCIFEZCXKT/Q'VNM_LK>%=?\
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MK^AVFKZ+>Z>E]JME=Y^L_P#!-SPUJ<GP\BMOBIKVF6G@;Q7XN\46^JVOP_\
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M@N/AIXKUC1/$WCCX'ZMXLT*]C\&>*[[PEXKU1+OP]:6]_P"'[7POXS2/Q9&
M??UA?6NIV-GJ-C*)[*_M;>]M)U5T$UK=PI<6\H25$D02PR1R;)$5UW;64,"*
MMU#;6\%I;P6MK#%;VUM%'!;P0QI%#!!"BQPPPQ1A4CBAC58XT4!4154<"IJ
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M /A&-'_YX7'_ (,M5_\ DZC_ (1C1_\ GA<?^#+5?_DZ@#H**Y__ (1C1_\
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M %/A7_KMK'_HO3J^;Z_F3Q$_Y+#-O3 ?^JS!@%%%%?% %%%% !1110 4444
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M 4'_ ,FT?VY+_P! /7?_  "@_P#DVM^BBR[+^O\ AE]P&!_;DO\ T ]=_P#
M*#_Y-H_MR7_H!Z[_ . 4'_R;6_119=E_7_#+[@,#^W)?^@'KO_@%!_\ )M']
MN2_] /7?_ *#_P"3:WZ*++LOZ_X9?<!@?VY+_P! /7?_  "@_P#DVC^W)?\
MH!Z[_P" 4'_R;6_119=E_7_#+[@,#^W)?^@'KO\ X!0?_)M:%C?->^;NL;^S
M\O9C[;#'#YF[=GR]D\V[9M^?.W&Y<9R<7Z*8!1110 4444 %%%% !1110 44
M44 ?B!_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$5^(?\ P4G_
M .4DG_!"G_LZW]J#_P!8Y^(-?MY'_JX_]Q?_ $$4 ? /B#_D/Z[_ -AG5/\
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M>NM;^)=:T[PY!H.J7&G:UHOIG[6B?%+3_%5YIGPC^,?Q&TKXP:W86^D_L]_
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M#\=O^%@?\%WO^C8?^"77_B8?[3W_ -"E1_PL#_@N]_T;#_P2Z_\ $P_VGO\
MZ%*OV)HKZD#\=O\ A8'_  7>_P"C8?\ @EU_XF'^T]_]"E1_PL#_ (+O?]&P
M_P#!+K_Q,/\ :>_^A2K]B:* /QV_X6!_P7>_Z-A_X)=?^)A_M/?_ $*5'_"P
M/^"[W_1L/_!+K_Q,/]I[_P"A2K]B:* /QV_X6!_P7>_Z-A_X)=?^)A_M/?\
MT*5(?B#_ ,%W@"3^S!_P2ZX!/_)X?[3W;_NU*OV*I",@@]P1^= 'X6?#O]I?
M_@MM\3=1^*.E^'/V7?\ @F?'<_"/XHZS\)/$YU/]KC]IFUBN?$FB>&?!WBNY
MO=&>+]ENY-UHD^F^-])BMKB[6QOS>6^HQ7&FV\45M/=^E_\ "P/^"[W_ $;#
M_P $NO\ Q,/]I[_Z%*OTZ^'/PF\,?##4OBAJGAV?5YKGXM?$S5/BMXG75+NW
MNHH/$NK^&?"/A2Z@TA(+*T:TTE=-\%Z0\-I</>W"7<E[,UX\<\4,'I] 'X[?
M\+ _X+O?]&P_\$NO_$P_VGO_ *%*C_A8'_!=[_HV'_@EU_XF'^T]_P#0I5^Q
M-% 'X[?\+ _X+O?]&P_\$NO_ !,/]I[_ .A2H_X6!_P7>_Z-A_X)=?\ B8?[
M3W_T*5?L310!^.W_  L#_@N]_P!&P_\ !+K_ ,3#_:>_^A2K[#_9/\0?MXZZ
MWCK_ (;6^%_[+?PX2V'AS_A7)_9N^,7Q0^*[:NTQUK_A*AXP'Q'^%'PR&ABQ
M$?A_^PCI!UDZB;O5?MPL/L5K]K^QJ* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ H)QUHKQ[]H;P5XP^)/P$^-OP[^'OB >$O'OCSX1?$OP7X(\5FXG
MM!X8\7^*O!.N:#X:\0_:;6.6XMQHNM:A8ZB9X(I)H1;&6*-Y$52 ;'@3XR?"
M3XHWGB73_AI\3_A[\0K_ ,&WR:9XNLO!'C/PYXKN_"^I22W4$=AX@MM!U*_F
MT>\DGL;V"."_2!Y)K*\A0-+:7"1=3X7\6>%O&^A:?XI\&>)- \6^&=569]+\
M0^&=8T[7M#U%+>[GL+AK#5M*N;O3[Q8+ZUN;.9K:XE6.ZMYX&(EB=5_%WP-=
M>!O'OQ/\"Z-?? 'QGX T3]DO]A_QG\$?VC?@Q#X6L9OB!X@LO'\_[/\ ?^"O
M@]X"\#> M:O?%/Q6^'OA>'P)XFU^V\<^$+#4_AU>-K\/A3P=K>KZQKWQ#T31
M_K?_ ()GW5YIW[,?AOX<:G\)?B;\'[_X;ZOXQTT^%_B)\+-:^%UK;Z7KWQ'\
M=>*/#%OX2L=1LK/3;_1;#PSJ6C1&/P^'T_1&D@T>1;6X@>S@ /JC5/VB/@%H
MB>#I=9^-WPCTJ+XB7MUIO@"74OB1X-L(_&^HV.J+HE[8>$GN]:A7Q%=V>M.F
MD74&DF[DM]5DBTV54O98H'Z&3XM_"R+XB0?"&7XD^ X_BM<Z6VN6_P ,Y/%_
MA]/'\^BI#+<-J\/@]M1'B&735MX9IS>IIS6X@BEGW^3%)(OY<_ME>%_!7A1-
M0_9E^''[*GQ-L/!_QC^!][X#^+?Q_P#A1^SKKOQ=M/#?P8U?QGXTU#5/@YX&
MB\.6>L7L_P 4M?U?Q;XX\2Z5-XDAL/ _PYD\2+\0]0/B[Q"N@^"[^*?X1_%%
M_&^I?"8?"?QG=>*]8_X*(^!/VO\ 1?VA7L(!X)L/@WHNM^#O$-[-J?C"^OGU
M.Q^(.E?";0M5_9+;P%<6)\3ZGI5[;ZC%:7'P^OM6U^T /V-HIJC"J,8P ,9S
MCCIGC..F>_6G4 %%%% !1110 4444 %%%% 'FWC#XR?"3X>^(/"WA+QY\3_A
M[X*\4^.+H67@OPWXL\:>&_#FO>+;QKF"R6U\-:1K&IV=_KEPU[=6MDL6FV]R
MSWMU;6:AKJX@ADZD^+?"R^*8_ [>)-!7QI+H,WBJ+PDVKZ>OB:7PQ;:C;Z/<
M>(HM!-P-5DT*WU>[M=+FU=+0Z?%J5S!8O<BZE2(_C)^V3HU]\-O$?[=Z?$SX
M>ZC\0=$_;=^$?PQ^"OP"\83)X=C\"^'?$T/PU\<^!+#X0?$CQKK^L:-:_"'0
M=(^)>IWGQETSQEXBN;/PY>77C/4;?PGJ6I?$VTTKPOJ7I/A.TA^&W_!07P5J
MK_!3XYZ]XAU/]G.Y^"WQC_:(L/@=XXO?!_COXIWGB/X"7/AS6=7^)#V=Q9OX
M0M/#G@WQ)>?V@MX/"'A*]?5[9WLM;U74([\ _5:3Q-X<B\10>$9->T9/%=UH
MMWXCMO#+:G9#Q#<>'K#4++2KW78-&,W]HS:/9ZIJ6G:==:G';-9V]]?V=I+,
MD]U#&_#:M\=/@IH/P_L?BQK?Q=^&.D?"[4VMDTWXCZGX\\+6/@34'O;B:SLT
ML?%MSJL>@WKW=W;SVMJEK?S-<7$,T4*N\4@7F/C?X#^$][H'BGX@>/\ X9ZI
MX_GL_ &I>"]7LO"?AGQ#XL\:Z[\/M6\1:#X@U[P3IGA[PN7UOQ#IVM:KH>E7
MFI^'K*WN3J\-B]K=6]W927-I-^37P9T3QOIO[+O[)6N^'OA!\>_A?\2/V1_B
M7XTLK3PCXH_91\0^+O#NE:-\2=%^*.AM?CX.1^.OA+XC\1Z%I7A/Q)I6C^&_
M%7P<\17>K^ =<U2+2=3TF7P+?^.[6S /W0T?6-*\0:5INNZ%J>GZUHFLV%IJ
MND:QI-[;:EI>JZ9J$"75AJ.FZA92SV=]87MK+%<V=Y:S36UU;R1S02R1.K'1
MKY$_85^&?C;X1_LR^"?!WQ"L[C2O%$OB/XL^-+C0;NW\.V=WX7TWXG?&+Q]\
M2_#WA&YT[PC-=^%M'G\*>'_%NF:#)H'AN_U30/#CV#:!H^LZUIVF6^K7OUW0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9W]CZ3
M_:CZW_9FG_VQ)8+I3ZK]BM?[2?3$N7O$TYK_ ,K[6U@EV[W2V9F-LMR[SB(2
MLSF^JJN=JJN>NT 9^N *=10 UHT8Y9$8XQEE!./3)!XY-+M7.[:-V,9P,X],
M]<>U+10 4444 %%%% !1110 4444 %%%% &=JND:5KEC<:7K6FV&KZ;=*BW6
MGZG96VH65RL<L<\:SVEY%-;S*D\44R++&X66..10'1&%[RTW;MB;LYW;1NSZ
MYQG/O3Z* $(!!! (/4$9!^H--\N, J$0*>2-JX)'0D8P<4^B@ Z=**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>chart-4bc2b65e63bf598aaeb.jpg
<TEXT>
begin 644 chart-4bc2b65e63bf598aaeb.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: 3T# 2(  A$! Q$!_\0
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MMY?B1^T[^SU^T[?0166FO%IWB#]GO2/@AI&B>&K1I!OET?7X_@AI,VJ7<_\
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M*7C;PU+\3=1\-V_P]?Q!HWPR$_Q%.C0>)9=0OO ]CJ?B?3H+O2=-O;F'SO\
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MWCJ0D@$@$D D =20.@]STI-Z?WE_[Z'^-!9"""RX(P?F Z^X.1^%.S[/^O\
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M/VWST_:A^+W_ (44/_R!7QK2@X(/(P0<CK^'O7[-_J5P;_T27#/_ (8LK_\
MF7R_/NS^;?\ B)_B3_T<#C7_ ,2C.O+_ *C?+^KL_2V;]H[_ (*<6_PF@^-L
MOQR^-2?#N>^^R)JY\5:;]L2T9K:&'Q!-HGD?VS#X5NKZ[ATNU\3260TBXU-E
MM4N3YD$DL5U^TA_P5"L/%_@_P%J'Q?\ C[IWC+QYX9M?&?ACPYJ.O:?I^IW?
MA2[CU>X3Q!J,-]%;IX<TRWLM UG4]1N?$TFCKI&D:?<:MJWV'3@MRW,O\7O@
MUJ7[(ND^!/$GB2?Q-\0]*U.&Q\&6.J?#ZVTKQM\,]7M=.\,PVFMV7Q/\-ZQ#
M-K_PPT>*'Q$FFZ=X@TG7_$-Q:WMKX/L])T=="L-?CQ?&=W\%/&VO_ 6'Q!^T
MQ<C2O#GPZO/A[\5/%FA^ /BOJ'B>X:3Q1\4_&NK:I9QZ_H.F2:_#XN3Q=IWA
M>:34;F:=;_4;_4]=TF\T>TG2\_/*&69>I8I8K@/AVE"EF6?X:G4I< XG%)83
M!X3V^68B$*.'=7%)U8JA6<:>'CF5:HJ&67Y'B*O[+BL[S;V>7RR_Q9XPKU*V
M3<(XRK1Q'BM@L#*6.S+,EA,[PE6IB<2J&":P\OK6'3K8MY/AJ4L5G27M?JE+
MT\?M!?\ !3[^VKC1'^/GQ-@-KX5TWQQ+XBNOBO\ #VT\ 'PAK.J?V%H_B.'X
MF76LP_#RXTG5M>$F@:;<V_B>7[;K\%UHD"/JEG=VL''0?M>?\%(+GXB/\)H?
MCI\=F^(T>O7?AF;PDVN6L>IP:U8&;[=:W!DMDL[>&RAM[B\O-1GNX]+M=.@F
MU2>^CTV-[M=N/X\?#JQTWQ=\,M$\:?#CP[X5ET+X6Q_"+Q#+\(_%GQ/\*_#B
MR^'?B/XDZAJWAGQ+X?\ B%X-CU;Q1XM\:R?$G7?%^K>/CX*U;39?$]U=6&GZ
M5X6TZ]LG\.>>>&/BC\#/"GQX\3?%3P\L.E>#/&&H?%[P!!X%N/A[<7UOX1\(
M^.?A=+X6TWXE'0?[9;0K[2)O%>MZEJ$WPBL=5EGTOP]:7/A[[;?Z=<V=M.8;
M*\+*&9O$>'/#:G2RZO7RJ-/@WD>)Q<,)@Z]"GBW.C4IT95JM;$8>6$HU*\H5
M\'B*<L8J=3 5LP,;G>.A4R-8/QGXQ=+$9UA<)GLZWB*ZOU++YYAC<)BJN C3
MJT:N)C1H4,'C(X[$4L-&>&S'"U89=.I#,\-E>_XW_;+_ ."A?PZO]-T_Q7^T
MC\4[5]:T>W\0:'?Z5X_\,^*=!U[0[JYO+&+5=!\2^%9M:\/:U8B_T_4-/FGT
MW4[D6NHV%[870AN[6:%>+_X>&_MO_P#1T/Q>_P#"BA_^0*\T^/WBOP1XGO\
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M/VBO^3@OCM_V6CXK?^I_XBKQNO\ 9W)?^1-E/_8LP'_J+2/^:WBK_DI^(O\
ML>9M_P"I]<****],\$**** "BBB@ HHHH *_7+_@B? UQ^VS!&MQ/;$_"#XE
M?O;9D249D\,)@-)'*HP7#CY,AU1L_+@_D;7Z]?\ !$;_ )/>M_\ LC_Q)_\
M2CPK7YSXO:^&''7_ &3>9?\ IAG[3]'/_D^GA9_V6>2_^I43^O?^PYO^@[KO
M_@7:_P#R!1_8<W_0=UW_ ,"[7_Y K?HK_)4_Z!S^;C_@O_8O9:3^RN7O[^]\
MS5/C& +V:*41[+#X<DF+R[> J7W8?);(5<8P<_S;5_2S_P '!O\ R"/V4O\
ML*_&;_TW_#>OYIJ_U!^CG_R9[A3_ !Y]_P"M'FQ_AC],S_E(KCS_ *\\)?\
MK%<.A1117[>?RZ%%%% !1110 4444 %,D_U4W_7"?_T4]/IDO^IG_P"N$_\
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MG">-K2A.,E0:<91DFFMTUW5_4:*\N_X7%X%_Y_=3_P#!-=?_ !='_"XO O\
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M?D];$8K$95C*-"A2CB8.52K5G1C"$(IWE*322U;MJ?VG4445_E@?[MG\J_\
MP<[:SJ^D:)^Q:=*U._TTW&M_'L7!L;J6V,PBTGX5F,2F)EWB,NY0-D*6) R:
M_DN_X37Q=_T,^O\ _@UNO_BZ_J^_X.A_^0'^Q1_V&_C_ /\ II^%-?R-5_6/
MACC\=0X)R>G1QN+HTXRS'EITL36IPC?-<9-VA"<8J\FY.RU;;>K9_$GC#DV3
MXOQ"S[$8K*<LQ6(J+*E.OB<!A*]::ADN70@I5:M&<Y<L(J,;R=HI15DDCI_^
M$U\7?]#/K_\ X-;K_P"+H_X37Q=_T,^O_P#@UNO_ (NN8HK[W^U,S_Z&./\
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M/A)\-7DD=BSN[^"="9W9CRS,Q+,3R223R:]@KQS]G?\ Y('\$O\ LD7PS_\
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M\^("("[E5!=V5%!/S,RJ,D@5^TR>(= 9(E77-'9F\E54:G9%BQ9 % $^22>
M ,D\5^+O_!2?_E)'_P $*?\ LZW]I_\ 3]CKX@D?D:_;A5411X5>D78>J>U
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M22.6)PRR1NC%7C8%74E6!!(J6D. "3TP<_3O0!^5UAH7BOQ+^TA\3I;/PO\
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M7^/>I?LXSV^AZ'\0]#U/Q=9:_+JVK/+X:T>P\"^&=6\;>)?$AU;1+'6+O6M
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M5M-T][R/47LK5M0BA>WBOVMX6OH[>1BSP1WA0W,<+,<M$DJH3U6KM 'X@?\
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M%O[J3/K.!/\ DL>&_P#L<8#_ -2*9_>U17/?VCKG_0 /_@WL/_B*/[1US_H
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M]IW]I(A6P?VA?CD1\I_Z*KXN]J\(V/\ W6_[Y/\ A7]KX+_<\)_V#4/_ $U
M_P ^\PUQ^-M_T%5__3LAM%.V/_=;_OD_X4;'_NM_WR?\*Z3C&T4[8_\ =;_O
MD_X4;'_NM_WR?\* &T4[8_\ =;_OD_X4;'_NM_WR?\* &T4[8_\ =;_OD_X4
M;'_NM_WR?\* &U^YW_!O#_RD6L?^R!_&+_TM\ 5^&>Q_[K?]\G_"OW-_X-X@
M1_P46L<@C_BP?QBZ@_\ /YX!]O8U\YQ?_P DOGW_ &+,5_Z;9]9P+_R6/#?_
M &.,!_ZD0/[T:*3(]_R/^%&1[_D?\*_D(_N0_E%_X.A_^0'^Q1_V&_C_ /\
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MQ-MMMN[>K;W;[L]!))62LEHDMDNP4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %%%% !1110 444S>OH_P#W[D_^)H ?130X)P W/JC@?F5
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M]>\1^+_$VD^!-1TOQA<:WXBT?6;RZ^OK*'X6_M4_M8C6OA)\=/B]H'PV\)Z
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M(V/@G6+#1KOQ%'XGL?A7)%9'P9.OJ$/[1?[7'P(^ _AKPK:^)M/\:0M\$O\
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M.;<E'^6[_@EBK#]OS]G E6 _X23Q7R00/^2:^-J_N*3[B_[J_P A7QE\,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart-7f0043a713055b78858.jpg
<TEXT>
begin 644 chart-7f0043a713055b78858.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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M_#7X8VFN^'O#OAG5_$5KJ^S?_!7]J+1_">F:KXT^'7C"]\?^._V%/V5OA?\
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M^V%^T3\7/B#=ZQ\%?A])\ ;7X3_$N/XIWWA;XP>"_CC=>&KGXA/\<$\+:_\
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MTS!'H?\ BHZ_"BBNC_B"7 _\F;?^'!>7_4/Y/[_(P_XC#QE_/E?_ (0R\O\
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M(97AC$LJQR-%$T@B$DBH2D9E*N(P[@*7*,$!+%6Q@R4C8VMD9&#D>HQR/QH
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M4T-?!<T/B)-%CTQ/!$D5PNBE?WY']3Z>I]/_ -?KSF@#\/?^"ED8E_X*0_\
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MPW-8_P#1,;[_ ,*VS_\ E'1_PW-8_P#1,;[_ ,*VS_\ E'7YZT4?ZN91_P!
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MA1117H'  )'0X^G%&3Z]>OO110 N3TR<>F:3)YY//7W^M%% !1110 5^Q?\
MP0M_Y/TL?^R*?%3_ -*_!E?CI7[%_P#!"W_D_2Q_[(I\5/\ TK\&5\#XI_\
M)N>-?^R=S+_U'D?=>&7_ "<'@_\ [*#+/_4JF?VFT445_EJ?Z7'\T?\ P<7_
M /((_9$_[#'QM_\ 39\-*_F#K^GS_@XO_P"01^R)_P!ACXV_^FSX:5_,'7^D
M?T?_ /DTW"_^//?_ %HLV/\ /3QU_P"3H\2^F3?^L]E(4445^RGY$%%%% !1
M110 4444 %5KW_CROO\ KRO/_2:6K-5KW_CROO\ KRO/_2:6G'=>J_,4MGZ/
M\C_2,^!7_)%/A!_V2[X>_P#J'Z-7JM>5? K_ )(I\(/^R7?#W_U#]&KU6O\
M(3,_^1EC_P#L,Q/_ *>F?ZNY=_R+\#_V!X7_ -,0"BBBN$[ HHHH **** "B
MBB@ HHHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OVZ7_51_2+^:5^(O\
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M\KS_ -)I:<=UZK\Q2V?H_P C_2,^!7_)%/A!_P!DN^'O_J'Z-7JM>4_ L_\
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M\0NO[!__ $<'_P %$?\ Q+K5/_F)K^DO_/Y]:*/]8^(?^A]G7_AUQ_E_T_\
M)!_8&1?]"3*/_#;@O+_IQY(_FT_XA=?V#_\ HX/_ (*(_P#B76J?_,31_P 0
MNO[!_P#T<'_P41_\2ZU3_P"8FOZ2Z*/]8^(?^A]G7_AUQ_E_T_\ )!_8&1?]
M"3*/_#;@O+_IQY(_FT_XA=?V#_\ HX/_ (*(_P#B76J?_,37:^ ?^#;[]E/X
M4^(!XL^%_P"U[_P4^^'7BE;&[TM?$?@G]MKQ/X:UQ=-OS U]IXU/2?"-K=BS
MO&MK=KJV$OE3F"$R*QB0K_0M16=;/<\Q%*="OG.;5Z-6+A4HULQQE6E4A))2
MA.G.M*$XR2LXR336C3NRZ62Y-0J0K4<IRRC5IR4Z=6E@,)3J4Y1MRRA.%%2A
M)65I1::MHS\6/^'+&A?])./^"S__ (L=^)W_ ,HZ/^'+&A?])./^"S__ (L=
M^)W_ ,HZ_:>BO*/3/P(^)7_!O5^SY\9DT:/XO?MP?\%6OBE'X=>_D\/I\0/V
M[?&7BQ-$DU1+6/4Y-*76O"UX+!]02QLDO6MO+-RMI;K*6$*!?*_^(77]@_\
MZ.#_ ."B/_B76J?_ #$U_2717IX?.LYP=&&'PF;YGA</3YG3H8?,,70HPYYN
M<N2E2K1A'FFW.7+%<TG*3NVV_/KY1E.*JRKXG*\NQ->?+SUL1@<+6JSY8QC'
MFJ5*4IRY8PC&-Y.T8J*LE8_FT_XA=?V#_P#HX/\ X*(_^)=:I_\ ,31_Q"Z_
ML'_]'!_\%$?_ !+K5/\ YB:_I+HK;_6/B'_H?9U_X=<?Y?\ 3_R1C_8&1?\
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M,=/T9+V^%C]MN/<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5A;P/\S>%_\ @GUXT^&.A^#+GX6_'ZSM/B3X5E_:4\,S>+OB'\*+/QWH5_\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chart-9c451125cbd651c0abd.jpg
<TEXT>
begin 644 chart-9c451125cbd651c0abd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110!^('_!2?_E))_P $*?\
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MQOB_][Q7_816_P#3D@"BBBN< HHHH **** "BBB@ KUOX*_\CLG_ &"-3_\
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MF@#<HK#_ +8N_P#H7=<_/1?_ )<T?VQ=_P#0NZY^>B__ "YH W**P_[8N_\
MH7=<_/1?_ES1_;%W_P!"[KGYZ+_\N: -RBL/^V+O_H7=<_/1?_ES5ZRO)KOS
M/-TZ^T_R]FW[:;(^;NW9\O['>W?W-HW^9Y?WEV[OFV@%ZBBB@ HHHH ****
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M7B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"<
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M#_D/Z[_V&=4_]+KBLBOXWQ?^]XK_ +"*W_IR0!1117. 4444 %%%% !1110
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M "']=_[#.J?^EUQ617\;XO\ WO%?]A%;_P!.2 ****YP"BBB@ HHHH ****
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MD_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(K\0_^"D__ "DD_P""%/\
MV=;^U!_ZQS\0:_;R/_5Q_P"XO_H(H ^ ?$'_ "']=_[#.J?^EUQ616OX@_Y#
M^N_]AG5/_2ZXK(K^-\7_ +WBO^PBM_Z<D 4445S@%%%% !1110 4444 %>M_
M!7_D=D_[!&I_^AV=>25ZW\%?^1V3_L$:G_Z'9U]#PG_R4V1?]C/"?^G8C6TO
M3]4?7M%%%?U>(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\
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MG2]/AM['3M.L+2**VL[*S@AMK:"-(H8D10HV: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>chart-9f17d12ff13d514ba12.jpg
<TEXT>
begin 644 chart-9f17d12ff13d514ba12.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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M\/\ ABY\,:MXCTSPCJ7P^D;2[7XF>.M#T/XB>(+J]^(/BVV\)>#]%(!]E?\
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M_$&OV\C_ -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\
M5Q_[B_\ H(H ?1110 5Y?\9OBWX5^!?PT\4?%/QHNHR>'?"MO82W<&DP6DVH
M7=SJVL:;X?TFRMVU*^TK1[-K[6=7TZSDU37M7T7P[H\,\FJ^(=:T?1++4-3M
M/4*X/XG>%=;\;^!/$GA7P[XF@\(ZQK5DEK:ZY>^%]%\:Z7$HN[:>ZT_7/"7B
M!1IGB+P[KEE#<Z%XCTA[G3;R]T+4]1ATK6M"U9K'6;  ^3],_;CTM?V2)OVH
M_&GP?^(7@:^D\/B_\.?!Z[U'P1X@\8?$+Q!>^&(O$WAWP]\--=\.>)-1\(^+
M(O$UO)*MAKC:II=GI%OIGB#4O%UOX<T_PWK<]GR_B?\ ;\M++QK\%_"'A3X;
MZ9K"_%_X9_!CXEV^H^,?CI\'?A/):6WQNU+7+7PUX9\.Z'XXUFVUOXC>*K'3
M_#6M:KJFF>#+2]"QIIEE:2W%]JL$*?/?PY_X))66B?L]:3\-/$7QE\0>!/'>
MG:=XVN-./[-L=S\*O@QX3\1^/O@AX>^"GB*X\/\ PRU2Y\6K>IK&FZ#<Z]XD
MUJZO].US7?$OB[Q]K%B?#8\8ZM8R>M:Q^P/X\G^"7A[]GNQ^+O@36O!&J?LR
M>"/V8?BEXT^)7P4T_P ;_&R_\->%(-;CO=>\#?$6W\3^'$L;N].MRS>&=#\=
M:'XTT'X?:_I^D^+]!M[C4$UC3M; /I^__:G\&VW[4OA;]EBRT/Q!JWB37/!'
MCOQ7K/B^Q_LW_A$/".L^#+;P!K$'@'69I;Q=4F\9:[X3^(&E^,8=/TZQN(-%
M\.2:7>Z]<6)\4>&X]0Q/VC?VK)/V=;Q;W5/@W\1?%W@+1],T'6?&WQ T#4?
M6G:;HUGXA\03^'H-,\*>'_$WBS1O%GQ/\6Z7)%'K&N^$_!.C7FH6VB7NF1Z5
M+K7BG5](\+7WB^B?\$[-)\(_M2?#G]H[PI\>/CA%9>$/$7[0_C'7OAOXC\8C
MQ+X>\2^)/C[)X2N-13[5=:;#J=OX;TZ?PTJOH5_>ZH[6-AX2TO2M1TC2_"UK
M8SR_'?\ 9"^-W[1?A#POX6^)?Q0^ VK79\$Z!INM^+C^SC=-XR^$?Q2MK:\M
M_$_QJ_9+\3S?%%_$/PC\9:N)-*N?"TOBG5_'E_X U_P_I&OV.NZS;1W7ARZ
M/T<4[AGW8?BK%3^&1Q[>E+3(TV(J%F<JH!9CEFP -S$  LV,L0!N8DX&<!]
M!1110 4444 ?FC_P48_X\OA%_P!?GC?_ -)?#-?E[7ZA?\%&/^/+X1?]?GC?
M_P!)?#-?E[7]0^'/_)'91ZYA_P"K/&G\.^,?_)Q>(/\ #E/_ *I,N"BBBOMS
M\Q <-N'#;%CW  /Y:2O.D6_[WE+/)).L>?+6:2255$DCLTYNKHE6-U<ED;>C
M&XF)1@" R$OE& )&Y2#@GGDY@HHN^X-)[J_KJ3"XN5=I!<7 D< /()Y1(X4
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MUS56&E:)/87?VK3Y--6WQ<2:I=KY6+J7S(_*R_R$.NTY_*VOLC]A3_DO4/\
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MRP<:FK:=M)^W*UIYP(!^-OQ/T#QS??M4>(=;LO"5UJWC.[^/'P8O?A=?Z7X
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M_P##)F?_ ,R^:^\\XHKT?_A4/Q+_ .A-U?\ .P_^3:/^%0_$O_H3=7_.P_\
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M\?/C1XJ^&7Q(\.P?#31],\':!XBTJR\2_ 3QQXI\"W?AKQ5JU[KC7&NZG?\
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M@"BCG^ZW_?+?X4<_W6_[Y;_"N< HHY_NM_WRW^%'/]UO^^6_PH **.?[K?\
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M]UO^^6_PHY_NM_WRW^% !11S_=;_ +Y;_"CG^ZW_ 'RW^% !2-]U_P#<?_T
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M+QY'HVF_$.X\8SZ78_"J^^,?AW3/B[>>'IO 5[XM/B'^T-#A\:1^&]0CM+
M^^ <@$9P0",C!YYY!Y!]CTI:0#  R3@=3U/N?<]3[TM !1110 4444 %%%%
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M$   1  J*  J@    4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chart-12ab3b9cf42c502a82c.jpg
<TEXT>
begin 644 chart-12ab3b9cf42c502a82c.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %D 3T# 2(  A$! Q$!_\0
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M7][IE_;GP_XID,%]I]U+9WD!DBT1XG,-S!+&7C=XWV[D=D(8TO\ AM']FO\
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M@;B3DUMUPM6;5T[.UUL_-7L[?(]-.Z3LU=)V=KKR=FU==;-KS"BBBD,****
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M>/\ X=)\*;G6+'1+*+PA^PT$4<$,<,,<<,42^7'%$B1QQHO"HD<8"(%4!=J
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MPQXL\??M$>#OBIKOP*N8]:G\6?"_4-:U?7_V8?!:BZU[PO;Z!I"^-M=;2O\
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MQX'\5I^ZM[FY?<T^B8_=6L,\N, DMLVC !8%E!^-*^U/V!/^3@X/^Q%\6?\
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MKI?Q U;4;WPIHUCJD^/"6EV=B-6OO"&D>$_$VN7OB", X[6_VJ[O1_"'@CQ
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MNS6_X7=GV?\ 7_#K[SQ&BO;O^&=_BM_T ]-_\*+2/_CU'_#._P 5O^@'IO\
MX46D?_'J7^M/#?\ T/LH_P##CA/+_I]Y_P!75RS[/^O^'7WGB-%>W?\ #._Q
M6_Z >F_^%%I'_P >H_X9W^*W_0#TW_PHM(_^/4?ZT\-_]#[*/_#CA/+_ *?>
M?]75RS[/^O\ AU]YXC17MW_#._Q6_P"@'IO_ (46D?\ QZC_ (9W^*W_ $ ]
M-_\ "BTC_P"/4?ZT\-_]#[*/_#CA/+_I]Y_U=7+/L_Z_X=?>>(T5[=_PSO\
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M!K]O(_\ 5Q_[B_\ H(H ^ ?$'_(?UW_L,ZI_Z77%9%:_B#_D/Z[_ -AG5/\
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ML]?]'!? +_P^/PF_^;*O6/\ ASO_ ,$H_P#I&[^P]_XC#\(/_F5H_P"'._\
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M%% !117E_P ;OBEI7P.^#/Q;^-.O6%]JFA?"'X9>/OBAK6FZ9L.I:AI'P_\
M">K^+=2L=/#AD-]>6>CS6UH&5E^T2QEE9000#U"BOSB\(?M#_M0>&_&_PW\#
M?$_PQ\'?B%XE^/GP!\=_&#X::#\-9/$WP[MO!OCKX;3?"QO$7PE\6^*?&&N>
M.X/%/AV\TKXLZ7?:7\7;'0?"EREQX3\0PWWPW6;7_#.GP?07['_Q=\<_'+]G
MGP%\2OB/9^$+#QWK<OB^P\46?@--:C\'PZEX6^(?BSP;,?#P\17%QKKZ;+#X
M>CGMIM6:&^N#(UQ<6=BTIL;< ^FZ*_-#XX?&[]M#X*?!^;XH^*8?V9M"U'P?
MX-O]0N/!GV#XB>+M<^//Q>U3QGXKTWP%\!/AA;:5XHT.?P9K7B[PU9>"]-T+
MQ-Y'Q7UC7_B)XQEL[3X?VFA>$[YM>6;]KCXOMXEO_B1;Z5\/5_9_T/\ ;%\-
M_L<:KX+GTGQ!)\7)-3U_QSX<^"%S\4X/&=OXI;PQ%;Z/\=?$]II)^'C> ;@:
MA\-M.OO&</CR/5;ZPT*$ _2ZBD!) )&"0,C.<'N,]\>HX/44M !1110 4444
M %%%% !1110 45^:/QK_ &J_CII_B[]K%/@KIOPM3PQ^Q/X!\,>,?'VB?$72
M/%-[X@^,WB35_AKJGQFU7P+X1\3:/XL\.:1\+--L/AS'H,&G^/=4T#XEI?>-
M-?FMK[PSINB^%;U]?]0\ ?M)?$GQS^U'X=^'LGA'PAH?P+\>?LTZC\;/ASKD
MVJZIJ/Q1\27ECXD^$%BVH:]ID45IX;\&^'6L/BA+IMEX?\[Q%XEO=6T.\U:_
MOM#TU].TV_ /MZBO$?'>N?';1/&$USX'\%^"?&?@&W^&6N7,.F:EXFE\)>*=
M1^+K>+O#%IX7TN37KB#5=*TCP*_A*Y\4ZAXAU,>']8UB"^L;!-+LKZ:1=.N_
MA&T_;7^+%U^SM^R;X\\6ZW\"_@[K_P >/$WC+PQ\3_C;XMT;Q3J7[/WPFU#P
MA:^/'LK2+3-2\<>"]4-U\1-7\*VOA[P+-XY\?^$=+,S7[7U[=>*)_#?@O70#
M]7**^;OV2OCA?_M$? KPS\3]6T_3M.UBY\0?$KP7K/\ 8MOKUGH&JZS\*?B?
MXR^%>I^*/#5EXHM;3Q'8^%?&5WX-D\7>%[#7HFUBQT#6].LM2GNKRWFNIOI&
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+UO1-(\2Z
M-JWA[Q!IECK6A:[IM_HVM:/J=K#>Z;JNDZI:36&I:;J%G<*\%W8W]E<3VEW;
M3(\5Q;S2PR*R.P.I10!^?GP__8:;X>>._&U]I?Q;^(-SX,O/A)%\*/@QJ&H^
M+/$NL_%W]G#PI/=>%Y=9\"?"GQEXEO\ Q!X;B\%ZK<^#M UVZU3Q%X0UOXD:
MGJ>FZ)H_B;QGXB\+^$O"6F:-[E^S-^S5HG[+_@V^\!^&/B/\7O'WAVXU2[U;
M3H/BSXOT_P 87/A^?4]1U76=8AT2]M/#F@7$%KJ^M:S?ZK?17KZ@QNI46UDM
M;6*.V7Z1HH ^/?C=^QUH'QL^+7A+XSS_ !G_ &@_AWXN\#>$K[PCX5MOAK\0
M-&TGPSH<.KW5]-KWB'2O#'B7P9XOTK2_&NOV-ZGA_6/&6F0V7B&[\+6=MX:^
MVQZ-)?6=[MM^Q]\()/BDGQ2E'C&2=O&FE?%2_P# A\8ZJOPNUCXRZ)HEGX<T
MKXPZKX#CV:5=>/[/2-.TXI=AHM"DU[3=-\:S^'Y?'&GV7B6W^IZ* $    &
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MWCGQ#I>GZ1<@1[-Y^PE\&+^T^'6A7>K?%*Y\#_#G4/!^KV?PWNOB5KMY\/\
M7]:^'GQ#N/BGX%USQ!X9O%N+8ZYX=\<31:LVL^'I?#FI^)+:PTG0_&EUXET#
M2=/TRW@LOV"?@GIWA6\\(V>K_%R+3+#4_!NI?#"1OBUXNN+KX#CX=:KJNL>
MM/\ @D]U=3VW@C3?"]SKFK:?;VSVFL/JWA*\7X?^)9]<^']EIOA>S ,"/_@H
MA\'6\*_%7Q/<^$?BGITGP7^%>N_%#XA^&]0T+PY%XDT)_"?Q7^)?P9\7> C;
MV_BV[TV[\:^&_&WPJ\2Q79LM5N?"6IZ/-HNO>'O%6L:5JUO<UYK\9/\ @IEH
M?@'X=_&_Q/X0^!'Q<\2:[\.O#O[7S_#Y?$2>!O"?@_XK>-?V,?$7B3PQ\7-
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MQ+=VT6H>+M!\0:@T]U/]?@!0% P   /0 8 _*@!:*** "BBB@ HHHH ****
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M\<ZCX9N_':#Q*0#R&'_@H[\.?(\*B\^#?Q^T_6/B*WP3O_A9X8NO#?@,:_\
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M ZS\-OB9:726<MK<II%_X8UV_BTBRM+JVE\/ZC]FU;2[J"_M+>5-[P7^R;X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>chart-21a631c632245214b5c.jpg
<TEXT>
begin 644 chart-21a631c632245214b5c.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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MX1?6 #[0T[]K?P->_%/1OAK=^"OBOH.F^*OB)XQ^$/@CXJ^(_!D6C?##QO\
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M0LG\(:#<:;X3U%=5U/2+K6;W[?H **** "BBB@ HHHH **** "BBB@ HHHH
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MP   222  ,GBNPY1:*=*K02/#.K0RQ2-%+%,#%+'*F2\4D<@5XY4 )>-U5T
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MM'26.IV6H^;]DE:3R=GF9AN(<;]VW'GPQ;L[&^[NQCG&1GF_AV/^* \#]?\
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M_,REL_1_D?U5_#K_ ))_X'_[$_PQ_P"F.PKLJXWX=?\ )/\ P/\ ]B?X8_\
M3'85V5?YTX__ '[&?]A-?_TY(_OC!?[GA/\ L&H?^FH!1117(=(4444 %%%%
M !4<S2)#*\,8EE6.1HHFD$0DD5"4C,I5Q&'<!2Y1@@)8JV,&2D;&ULC(P<CU
M&.1^- 'P)XP_:&\=>$?&>D^&->^/'[(WA;Q7X@\>V7P_TGX.ZAHOQ%U[7_\
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M?_(HR_HW?JOO.CHKG/\ A,?!_P#T-WA3_P *;0O_ )84?\)CX/\ ^AN\*?\
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ME1/FHM-*U:_@:ZT_2-7U"U0E7N]/TK4;^T1E5697NK.UGMT94='96D#*K*S
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M'X*_%0GR+FXM9/\ CX\')_K;66&4#:[?*'QG#8W*I'P/BG_R;GC7_LG<R_\
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M4ITJM*K2G"K2JTISIU:<X5*<Y0E&3*K7O_'E??\ 7E>?^DTM6:K7O_'E>_\
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MB#7[=+_JH_I%_-*<=UZK\P/\Y']HW_DX?X__ /9<_C%_ZLGQ/7C5>R_M&_\
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MZ5^Q?_!"W_D_2Q_[(I\5/_2OP97P/BG_ ,FYXU_[)W,O_4>1]UX9?\G!X/\
M^R@RS_U*IG]IM%%%?Y:G^EQ_-'_P<7_\@C]D3_L,?&W_ --GPTK^8.OZ?/\
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M\&5\#XI_\FYXU_[)W,O_ %'D?=>&7_)P>#_^R@RS_P!2J9_:;129'O\ D?\
M"C(]_P C_A7^6I_I<?S2?\'%_P#R"/V1/^PQ\;?_ $V?#2OY@Z_I\_X.+N=(
M_9%QG_D,?&WL1_S#/AKZCVK^8.O](_H__P#)IN%_\>>_^M%FQ_GIXZ_\G1XE
M],F_]9_*0HHHK]E/R(**** "BBB@ HHHH *K7O\ QY7W_7E>?^DTM6:K7O\
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M^(77]@__ *.#_P""B/\ XEUJG_S$U_27_G\^M%'^L?$/_0^SK_PZX_R_Z?\
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MU_2911_K'Q#_ -#[.O\ PZX_R_Z?^2#^P,B_Z$F4?^&S!>7_ $X\D?B;8?\
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MVM*VC_M7Z5X"^'_[2W@>QT'P]/\ $E_#&E^%==^%^L?$CX"^+_%OQ"\!>"-
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M/%0L/ "VD7BS3=#L+.W:VU[6?#FJ:IHFB>*K'2[VZ;P1JFNZ3%XX;PY%>),
M#[!HKYL\,?M,^!E^%'PU^)7Q:U+PY\(I_B+\/-?^)4&BZUXE.HV>G^'/"GA6
M;QUXINCX@GT30(;B+PYX+A;Q'K3W&F:9+9V$%^YMGCTZYE63Q?\ M=_LU^ ]
M%A\0^+/C)X)T?1KFYTRVM[^749;F&?\ M3P7IOQ(BNH5L+:[EETVS^'NL:9X
MYUO5XXVTGPYX0OK;Q)XAO=*T>5+P@'T?17RWXJ_:]^#>B>*M-\#^'?$NF^//
M%TOQ$^$O@#Q!H?A;4;>\G\)'XR'0[CPAKVN701["/3M1T;Q)HGB#3(8KMKK7
M=%OEU#2%N;6&XFAI?"?]LCX.?''XQ:Q\)OA3KMCXYBT7X7V7Q-N?&OA_4;>\
M\-SV5]X_\0?#^"QL'\N.;4H+F^\.7]_IOB/3FN_#6MV4<CZ+J5^D$LH /K&B
MBB@ HHHH **** "BBB@ HHHH *HZG_R#K[_KSN__ $GEJ]133LT^S3^YW$U=
M-=TU]ZL?YF4UM<^?<?Z-<_\ 'Q<?\NMQ_P ]I/\ IE7Z]?\ !#B&:/\ ;YT%
MGAG1?^%/_%?YG@F10?+\,8!9T5<GL,Y/:O[1?[,T_P#Y\;/_ ,!;?_XU4L5E
M:0/YD-K;Q/@C?'!#&V#U&Y$5L'N,X/>OZDXH^DK_ *R<.9UP^N#7@_[7RW%Y
M=]:?$"Q'U?ZS1E2]K['^Q:/M?9\W-R>UI\VW/'<_FGAKZ.[X>XAR?/O];EB_
M[)S'"8]X7^PG0]O]6JPJ^R]M_;%;V7/R6Y_95.6]^1VL[-%%%?RT?TN?.?Q^
M^"WB?XGW_P (/&GP^\:Z-X&^)/P/^(6I>/\ P=J/BGPC=^.?!VJMX@^''CCX
M6^(_#_BKPUIGBKP1K%Q8:AX9\>:E<Z?J&B^*M(U'2->T_2;UCJ6FIJ.C:C\E
M:E_P3CGU?PA\;-#U#XP07/B#XX?L[>/?@YXB\2#X=P6D5AXP^*/QZ^,O[07C
MKQWI>CP^*Y6@T"]\6_&/4++2/ KZM//IVE:)IJWWBS6+QY+H?J#10!^9WQ#_
M ."> ^($7B[2+WXGPQ>%_BCX7_;A^&GQ,L/^$1O1K%S\-?VS?'NF_$R:W\&:
MQ;>,;2W\/>,OA[XJ\/:#!%K>LZ1XHT+Q5X?;6M/N?#>BW=Y8ZA89'PZ_X)Z^
M*_AEJ7A;XC^&?BA\/K'XW^%/B3_PET7B:3X<?%GQ-X)U[PO<_##7/A-?^%O$
MN@?$;]I;QW\0;V[M]$\0ZAK?A35M.^*VD:?X/U9(-(T_P_=>&+G7K#7/U(HH
M ^0O _[,GB3X;_LD> OV:/!WQ3@MM;\ >#_"_A.W\?:]\.] \3Z'XIM?#^H6
M]SJFG>,_AKJ-_'INI^%?'&F)>^'O%NA:5K^A:B-(U6]/AKQ'X>U**PU"T^<O
M O\ P3KUCX>:QHOC3P3\1OAU\-?&$7QJ\8?$W4] ^$7P3'@+X.^'- ^(_P $
M/#OP.\;Z-\)/AM_PL#6D\#>--1L_#6G_ !(;QQJNK^*])U?XGRZMK/B3P)J>
MGZG]@MOU*HH _('PC_P3%\8^%4\2^*!\=/"^I_%?4-%_9>CTOQ=?_#+QYJ>F
M:SXR_91^.GB'XU>$/''Q0M/%'Q[\4^,/&FJ^/9]?FT3XA0:3XZ\)VJ!1?^%4
MT@H;6;=\-?\ !+S0/#OBOXI:H?%WA#6O#WC&V_:2O?"&F^+? GCGQY?>&_$G
M[4.J>(]:\?MXDT;QI\;=:^#_ (G\*1W?B_Q+I$FA^'_A#X"UKQ9X1O['1O%?
MBFZU+3;G7]9_6&B@#Y@_99^!'C+X">$_%>A>,_BE??$>Y\2>,/\ A)-+T^-O
M'[>$O &EIX:\/>'4\*^"5^*_Q-^,OQ&@T6YN="N?$UY9ZY\2=8TVSUO7=1M_
M#6E^']&2&P/T_110 5^0W_!4)'?4_@QM1VQ8^/<[4=\?Z5X3QG:K8SVSUP:_
M7FHWBBDQYD<<F,XWHKXSC.-P.,X&<=<"OIN#^(O]5.(<#GKP?U_ZDL4OJOM_
MJWM/K.#KX2_MO8XCDY/;^T_A2YN7E]V_,OG>*\A_UFR'&Y+]:^I?7)85_6?8
M?6/9_5L90Q7\'VU#GYO8<G\6/+S<WO6Y7_)BL$V1^ZEZC_EC+Z_[E?TH_LI@
MC]G'X+@@@CX?>'@00001:XY! (_$"O>OLMM_S[P?]^8__B:F554!5 50,!5
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>chart-23a7c01770e356d29ff.jpg
<TEXT>
begin 644 chart-23a7c01770e356d29ff.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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M:>*=(T&./X?_  ^U[7_!ME=-9:WXG\$Z/?1ZCIFEZCXKT/Q'VNM_LK>%=?\
MV0;']D"]\1Z]%X7TWX*^%/@W9>,+2'3(O$=O#X+\.:+H>@^*4LYK:XT5]4MK
MS0-.UF33Y[.;2+B>.2QGMGL97C(!P_@;]NWX2>(_BG\0_A3XJ.I^ -6\*?%J
MZ^%_AW5O$'A_QO9^&M<FM_V??A[^T/&OBOQ3JO@_2/"OPP\9W?@_Q;XCNK7X
M;^--<L/%<FF>!]7U/[,)6DT^U]H^#/[2'PE^/@U/_A6VM:U>RZ7I/ASQ*;3Q
M)X(\<^ ;_4_!WC(:HW@WQWX?T_QYX<\-WOB/P%XO&B:S_P (OXUT.WO_  YK
M;Z5J,-EJ+SV<\2>"WO["_AGQ5I&JV'Q$\<:SXMN?%WQ_A_:#\?RVVC:?X;L?
M%'B"\_9HL?V:/%'AVWL=/O;FXT#P]X@\/6]YKR&RU2?5M'U*^-K9:@]O:P35
MK?L>_L1?#W]C^U\21^$1X1O;W6M$\'>#X-4\/?!;X._";46\(^ 8M6B\/1^)
MK[X7^$O#]]XV\47;ZQ<WGB/Q%K]V]A>Z@B7>@>&?"IN=5CU( \#G_;I^/G@'
MQ)\65^-7P5^"VA>!?@_^T;\ ?V</$&N_#OXT_$GQOXDO]?\ V@9O@/J.@>(M
M)\*ZE^S[X7-YI^C^&OCGIPN=%MM3N=?UGQ;HS>'M&LYX-5M-33Z8L?VZ_P!F
M:^30R?'6J:;+K'A7XH^-[VVUWX?_ !%\/7/@KPM\$?$$_A3XQZU\4(-<\*:?
M)\*[+X8^)(!H?C23XAKX;&BZE=Z7;2[Y-8TD7MCQ)^R7X:\2:Y\2-<N/%6NV
M\WQ(_:=_9[_:=OX(K/37BT[Q!^SWI'P0TC1/#5FTB[Y=&UZ/X(:1-JMU/G4+
M:36M1%BRK!:8\]OO^"??PL\01_&C3/%OB#Q-K_AOXY^"_P!IOP'XPT4QZ58F
M'0?VH?B:OQ*\6#3+Y+:YDBN]"NU_LO1'N[>[M9K98Y]4L[MT:&0 ]!A_;>_9
M\N- 768=9\>MJ<WBS3?!5C\/&^"WQFB^,>J>(-9\*:GX]T>#2?@O-X"B^*6J
M6.I^!-$UOQI::S9>$YM%;PSHFN:K-J$,6B:LME!^T#^U7#\-_P!E6\_:<^"_
MA2T^/]M=0?#K4O!7A?2O$<WA<>-])\<>-/#/A^<Z9JTN@:W<VNM6>B:UJ.HZ
M9H5YH:76I^(--MO"FH-H=Q>W%]IWRO<?\$F/@S>>"]+TR\3X52>-?#_Q*@^(
M^C:U:_LH_LW:3\/KBYA\ :W\,IM-\7?!K1O!6G^$O&IU#PUXBU;5+C6];O3K
MVD>,[@:QX,OO"6@FY\)77V]I/[.'@[P_\%OA?\$- G&B>&/A9KGP@UW1Y-$\
M.>$/#45U<?"/Q]X:^(5K$?#G@_0O#7@[1;?Q#J_AW9JEGX9\/Z+IEG%J5V=)
MTZT"Q1@ ^>=<_P""AWPVTCXZ^&? RV^C3_ W4/V7?%O[27BC]H-_$MS'I?AI
M=+/PVUKPGX0M_"4'ARZN]<G\4?#_ .(5CXQGOK75X=0L&U/P5H6F^']?O_%\
M3:?WNH?M_?LS:7;6'V_Q%X^M]=O]3\?:*/ 9^!_QMD^)]AK'PP\,>#_''CC2
M]9^&$/P^D\>Z)?:)X%\>^$?'/D:IX?M?[1\&ZY9>)M):_P!(D^TUXCI__!+3
MX0:9X1M?!5EX_P#B5!I&G6O[0EIHMW]LT:XUKPY%\8O&WP;\6?#M/#]_>Z;=
M6UE;?LW:=\ OA-X-^$6GW>FZCIC>%O!>DZ?XKL]:C%W'=^H^$?V(K32_B&_Q
MA\9_%CQ3X[^*6N1_%E_&WB&X\.^%O#NF>(+OXF_#KX2?"JS73/#NB6R6OAO2
M_!7@WX.^'K;1=.BN]4N=1U+4M>U;7-5O;F^C6V /--8_X*@_"2'XCZAX(\/>
M$?'7B#0]%^.7P-^$%U\0H?"GC:3PCXML/CU\!]<^.'A#Q5\'[O2/!VLGXM7$
M]I8Z-H-IX6\)&[U?5SK]GK^FF71I;&6^^B-%_;9_9V\27_@#3?#GBKQ+XAO/
MB)I&AZ[IZ:#\+_BGK,?A;2_$?C37?AOHUU\4YM.\&7"?"!;OXA^%O%/@9T^)
MQ\*2V/BGPOXFTG4TLIO#VL&S\1^'O_!.KPS\./%/PNU;1OBCXJNO#OPVNOV=
MO$K>&=0T'P](VM^/_P!G7X#:Q^SCH?B=M<MQ!>Z;8^)OAM?Z;'X@\-QP7MI!
MK^AVFKZ+>Z>E]JME=Y^L_P#!-SPUJ<GP\BMOBIKVF6G@;Q7XN\46^JVOP_\
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M@N/AIXKUC1/$WCCX'ZMXLT*]C\&>*[[PEXKU1+OP]:6]_P"'[7POXS2/Q9&
M??UA?6NIV-GJ-C*)[*_M;>]M)U5T$UK=PI<6\H25$D02PR1R;)$5UW;64,"*
MMU#;6\%I;P6MK#%;VUM%'!;P0QI%#!!"BQPPPQ1A4CBAC58XT4!4154<"IJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^('_!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 017X
M?_\ !2V:&W_X*0?\$*I9Y8X8E_:N_:=5I)75$4R?L>>/XT!9B%&YV5!DC+,!
MWK]I(_$WA[RT_P")WI?W%_Y?;?T'_32@#?HK#_X2;P[_ -!O2_\ P-M__CE'
M_"3>'?\ H-Z7_P"!MO\ _'* -RBL/_A)O#O_ $&]+_\  VW_ /CE'_"3>'?^
M@WI?_@;;_P#QR@#<HK#_ .$F\._]!O2__ VW_P#CE'_"3>'?^@WI?_@;;_\
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M@Z_OKS0-'NKR1IK7SKQ_\4/C/K7P]\"?$/X0?'67Q!XW\::'I.@? GX+:)\
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M]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\
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M7M)\/6\=A;7?[.^GVDDB7FLV\\WVF_M(UM(KADDDG6&WG_I&KR[XS_"/PO\
M'7X:^)_A7XSGUBV\->+(-/M]3GT&[MK'5DCTW6M,UZW-I=7=EJ%O$S7NDVJR
MF2SF#6[31J$=UD0_U!X1_P"A/3_\*L=_\U?U=^5@_%MO"/\ P7!#R*O[-O\
MP2UD5))(Q(O[77[6 23RW9-Z"3]FF.0(^W<HDCCD"D;T1LJ$_P"$1_X+A?\
M1M?_  2W_P#$N_VK?_H:Z_?55"C ]6;GU9BQ_4G'M2T?Z@\(_P#0GI_^%6._
M^:OZN_*P?@3_ ,(C_P %PO\ HVO_ ();_P#B7?[5O_T-='_"(_\ !<+_ *-K
M_P""6_\ XEW^U;_]#77[[44?Z@\(_P#0GI_^%6._^:OZN_*P?@3_ ,(C_P %
MPO\ HVO_ ();_P#B7?[5O_T-==)X5M?^"YGA75AJUK^S1_P2XDE%K<6NP?M>
M_M3I\MP8RQW3?LQW2<>4./*SZ,IZ_NE171A."^&<#B:&+PN5PI8C#U(5:-18
MC&2<*D&I1FHSQ$H-IJ]I1:>J::T _';_ (6!_P %WO\ HV'_ ()=?^)A_M/?
M_0I4?\+ _P""[W_1L/\ P2Z_\3#_ &GO_H4J_8FBOJ0/Q!\8W?\ P71\8KIZ
MWG[,W_!+B(:>UTT>[]K_ /:EDW&Z6%6QY/[+UF5QY*_>,F<\!2"3P_\ PB/_
M  7"_P"C:_\ @EO_ .)=_M6__0UU^^U%?-YAPCP[FF+JX['Y;#$8JO[/VM5U
M\5!S]E3A2A[M*O""Y:=.,?=BKVN[MW _ G_A$?\ @N%_T;7_ ,$M_P#Q+O\
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M2?3$N7O$TYK_ ,K[6U@EV[W2V9F-LMR[SB(2LSF^JJN=JJN>NT 9^N *=10
MUHT8Y9$8XQEE!./3)!XY-+M7.[:-V,9P,X],]<>U+10 4444 %%%% !1110
M4444 %%%% &=JND:5KEC<:7K6FV&KZ;=*BW6GZG96VH65RL<L<\:SVEY%-;S
M*D\44R++&X66..10'1&%[RTW;MB;LYW;1NSZYQG/O3Z* $(!!! (/4$9!^H-
M-\N, J$0*>2-JX)'0D8P<4^B@ Z=**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>chart-5576b2a7fe2b5bfabd8.jpg
<TEXT>
begin 644 chart-5576b2a7fe2b5bfabd8.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N 3T# 2(  A$! Q$!_\0
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M'[;O[/=QH"ZU#K7CUM1F\5Z;X*L?A\WP5^,\7QCU3Q!K/A74_'FCP:3\%IO
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MGPRFEGX;ZUX3\(P>$X?#EU=ZW/XH^'_Q"L?&,U_;:O#?Z>=2\%Z'IN@:]?\
MC"%M/[W4/V_OV9=+MK W_B7QY;ZYJ&I^/M$'@0_ _P"-TGQ/L-9^&'ACPAXX
M\<Z7K/POA^'LGC[1+[0_ WCWPCXX:#5?#UI_:'@S7++Q/I37VCR?:J\/L/\
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M4<"IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6=%\*ZKXOUCQ0;SQ#I?AW4+36[#0-2T^T>ZLD:+ZR'AG2  !#<@ 8 &I:J
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M,6'[!I6N:S:^&;365T2!-7C^P?\ A?>I_P#0N:?_ .#&Y_\ D2C_ (7WJ?\
MT+FG_P#@QN?_ )$H_P"(C\(_]#&M_P"&_'__ #-_5GY7+/R^]?YGR#^TY^Q#
MX\\>_%3XE>./A=IGA"^G^+7PU^&/@SPQXF\1?%3XA?#C4OV5OB)\*QX_L?#O
MQK^%V@> _#NHP^*-5M]&\9Z=)9Z/;ZYX&U.TU/PFNA#7AX5\>>)Y=,^D/C;X
M:_:&^(/A#Q7X+'PW^&/B[P7<^,)M!GT _'WXK?"7QKX]^&D/A?PAJ^B^,[/X
MG?#;P=8:A\*O'%G\3(?$>GZUX)TRRU_2]6\&6.FZG8^/]+O=3O?"PZ[_ (7W
MJ?\ T+FG_P#@QN?_ )$H_P"%]ZG_ -"YI_\ X,;G_P"1*/\ B(_"/_0QK?\
MAOQ__P S?U9^5RS\OO7^9J?LH_"KQ=\$/V>_AC\*?'&LZ/K?B#P3H=UH[R^'
MXYCHVDZ1_;>K7GACPGIVHW>G:1J?B2V\#^&+O1O!B^,];TK3O$/C@Z WC'Q%
M8VNNZ[J,*?0U?,O_  OO4_\ H7-/_P#!C<__ ")1_P +[U/_ *%S3_\ P8W/
M_P B4?\ $1^$?^AC6_\ #?C_ /YF_JS\KEGY?>O\SZ:HKYE_X7WJ?_0N:?\
M^#&Y_P#D2D;X^:H%8CPYIY(4G']HW(S@$_\ /I[4?\1(X1_Z&-;_ ,-^/_\
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M_8PQO_J35 ****\\ HHHH **** "BBB@ I&^Z_\ N/\ ^@&EI&^Z_P#N/_Z
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MJ'AK04L+YUTNU#+9W14[6R"(),$9;J.U?!X^ZI]54GZE03^M?H9J7_(.O_\
MKRNO_1$E?GFOW4_W$_\ 0!7XMXN_[QD/_7G,O_2\"/H_5?J+1117XZ(****
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MQ!K]O(_]7'_N+_Z"* /A/QQ_R.7BG_L.ZE_Z4O7+5U/CC_D<O%/_ &'=2_\
M2EZY:OX_S;_D:YG_ -C#&_\ J35 ****\\ HHHH **** "BBB@ I&^Z_^X__
M * :6D;[K_[C_P#H!I2V?H_R''=>J_,_0S3?^0=8?]>5K_Z(CJ[5+3?^0=8?
M]>5K_P"B(ZNU_9E#^!1_Z]4__2(B*6I?\@Z__P"O*Z_]$25^>:_=3_<3_P!
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M_$&OV\C_ -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\
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M-:IQ'7PL,=&C3CSSE@ZE)57)^QM:)_1)1117^,Y_J"%%%% '5>!O^1S\+_\
M8<T__P!'K7W=7PCX&_Y'/PO_ -AS3_\ T>M?=U?NWA+_ ,BS-?\ L80_]1:(
M!1117ZT 4444 %%%% !2'H>O0].O3M[^E+03@$\\#/ R?P Y)]J /Q^N/$FA
MWO[7?Q<T_P 2>+OAW<:EI/QT\ 6&A:1\7?V^?'_PJ\>:39R>#OAS/:Z=\/\
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MS2AF%'&YOP;EV%GE\*.%AAWA:5/&X_/G.%6<56E.%7#QYK)TY<JDO=4_9M^
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MX(P,'J,<')R<CIG/?&:6@#\0/^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\
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MEO9VO:]GV8UL_5=?7_,GHJ'[3:?\_P#I?_@WTK_Y-H^TVG_/_I?_ (-]*_\
MDVOR/^S<Q_Z%^._\),1Y?]._-!;T^]?UU_/LR:BH?M-I_P _^E_^#?2O_DVC
M[3:?\_\ I?\ X-]*_P#DVC^S<Q_Z%^._\),1Y?\ 3OS06]/O7]=?S[,FHK#U
M[Q1X8\*Z+JGB3Q-XG\,^'_#VB6C7^L:YK/B/1-/TK2K%'CB>\U"]N+](+6V2
M26)&FE94#R(I.6 .P\]M&[QO>Z8CQNT<B-JVE!D=&*NC WN59&!5E/(8$'D4
M?V;F/_0OQW_A)B/+_IWYH5OZNB2BH?M-I_S_ .E_^#?2O_DVC[3:?\_^E_\
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M?_B*/L%C_P ^5I_X#0__ !%6Z* *GV"Q_P"?*T_\!H?_ (BC[!8_\^5I_P"
MT/\ \15NB@"I]@L?^?*T_P# :'_XBC[!8_\ /E:?^ T/_P 15NB@"I]@L?\
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MY+P5DF0XWZ_@(XI8CV-2A>M7=2')4<)2]WECK>"L[Z;>H%%%%?7 <)J'PO\
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M+1=-M5VVVGZ5I.F06MAI]E;K\L-M:V\4,8SM09.=ZB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHK@OB;\4/ 7P:\%:Q\1?B;XDLO"/@K0#IXUC7]0BO)K
M2Q.J:E::18"6.PMKR[;[3J5]:6B>5;R8DG4OMC#.O3@\'B\QQ>%P&7X7$X['
M8[$4<)@L%@Z%7$XO%XK$5(T</AL-AZ,9UJ^(KU9PI4:-*$ZE6I*,(1E*23YL
M9C,)EV$Q6/S#%8; X'!8>MB\;C<97I8;"83"X>G*MB,3BL36E"CA\/0I0G5K
M5JLX4Z5.,ISE&,6UWM%?"'_#S;]A+_HXWP=_X+?%_P#\S5?5GPM^*_P\^-?@
MO3?B'\+?$]EXP\&:O/J5MINO:=#?06EU/I&H7&EZC'''J-K970-K?VMQ;.9+
M=%9XF,9="KGZ+/. ^.>&<'#,.).#.*^'\!4KPPM/'9WP[F^58.>*J4ZE6GAH
M8G'X.A1E7J4J56I"BINI*%*I*,7&G-KYS(^/>!N)\9/+^&^,^%.(,?3P\\74
MP.2<191FN,AA:=2E2J8F>&P&,KUHT(5:]&G.M*"IQJ5J<)24IQ3]#HHHKY0^
ML&[TW;=R[O[NX;ORSG]*=7X4?%/XL_'C3_VTOBK9^&_$7[1&CZ=:?MJ_LK?
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MH>GZU;:K-K&J:C)I/A?6P#[*HKQ3]FWXRVG[1'[/OP3^/%CHESX:M?C'\*_
MGQ+B\.W=U%?7&A?\)GX;T[7GT>6_@6.&^;39;U[,7L<4"W:PK<""#S#$GM=
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>chart-8808588ca10451cd818.jpg
<TEXT>
begin 644 chart-8808588ca10451cd818.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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M_P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\
M",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \
M[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK
M_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!O
MT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI
M/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\
M!KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P G
MT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3
M_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\
M\&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R
M?0!OT5@?\(SI/_/.[_\ !KJ__P GU?L=,M-.\W[*LR^=LW^;=WESG9NV[?M5
MQ/L^^V=FW=QNSA< &A1110 4444 %%%% !1110 4444 ?B!_P4G_ .4DG_!"
MG_LZW]J#_P!8Y^(-?MY'_JX_]Q?_ $$5^(?_  4G_P"4DG_!"G_LZW]J#_UC
MGX@U^WD?^KC_ -Q?_010!\GZM\7?&MGJNJ6D-WIXAM=2O[:$-ID3,(8+N:*(
M,QE!9A&BAFP-QR<#-9__  N;QS_S^:=_X*XO_CM<#X@_Y#^N_P#89U3_ -+K
MBLBOY4Q/%'$<<3B(QSS-8QC7JQC%8[$))*I)))>TLDDDDNWJQ_)?C_G_ %=^
M5O5?^%S>.?\ G\T[_P %<7_QVHI_C;XRM8)KJZU/1K2UMH9;BYN[NSL[2TM;
M:"-I;BYN[NYN8K:UM;>%'FN;JYEBM[>%'FGECB1W7R^O'/V@O"%KX^^#?COP
M??>&?&/C&SURRT6*Y\._#V]\)V7C>]CT_P 6>'M:6X\+KX\/_"$ZQJNCS:7%
MKL?A/Q:D_ASQO!IEQX+U>TOK/Q!)97$T>)^(JE:E3GQ!FM.$ZM.$Y_7J_N1E
M.,93]ZM"/NJ\O>G"+M[THIMA\E^/^?\ 5WY6]3U+]O#X;Z+X$\,_%#6?V@/@
M7HWPV\:3_9/"'C_5_'/@;2O!GBB\%O<W;V.@>)=0UZVTG5=0AM;.[N;C3[.Z
MEOK6"UN9+FWA6"4I5\1_M_\ PI\'R>'8O%O[1W[/OA:3Q?H&E^*O"D?B3XB_
M#W0G\3>%]<=XM%\2>'UU3Q):G6= UB2.2/2]9TX7&G:@\;K:7$K(P'XX?L[>
M ?'MK\#/@3K7Q/\  ?[1_@G3O"WB7Q-<:#XP_9R_9\^&?@GXVZ[HOCGX*>!O
M#6K:]\7?A%H]IX^UG0]0F\1:9J/@CPW\1_!_@^PU_P 3:+X9T:X^(_AWP)X;
MUO[?J?V%I?AOXS_$/PO^QGX+^./@V2^EO+WQ!\1/VEKB?0_#4-G(OP?TZ77?
M@YX \<Q>&A<^%=.U3QWXSU;P!XE\:^&O#LK^$;WQ%\//%GA_25;PX6LIO;Q.
M;9QAJKC_ *S9M6IPJXF%24,UJ1J<M%8FHE3C*#C4FJ.&BIJ4Z<O;XBA1G3HN
MJF#2OOY?E?K;\;;]#]$;?]J'[7XQU+X=6OQ"^'EU\0M&TR'6M8\ VVK^&KCQ
MSI.C7'E>1JVI^#X=6?Q'I^F2BXMF2^N]-AMBEU:2&01W=J\VU??'WQ'I=QHU
MIJ?B#PWIMUXCU.71?#MKJ$>G6-SX@UF#3+W6I](T*WNKR*;6=5@T;3=1UBXT
M[3([J\@TG3[[4YH$L;2XGC_(3P?\-/'MMXT^%7@>\^&7C.T^(7PV_;E^-W[1
MWCOX^W/@^TB\$^+OA#XZU#XXZI]KTKXGM,6\3>)?BMX,^(/P^^$&I_#>!Y?$
M?AU_"5VWB32],\+^#/#>IWEOX[^)/"VK?%K]B?XX1_L[_M,ZGXO\.^+[3QIK
MVJVG[-?Q;\7>*/AE\*->^#?Q\\-W?A;7[#PY8>)-%\#>,[CQUXL\+Q>-?"&E
M.OC"]MI-#N?$4VH^']$TS^S^=YOQ![:-.'$F<5(O#UZG/3QM2IS5*<:[H-)8
MA.%+%^QC.GS7JPC42<)\T93.VBOYNV]K=5_E;7I<_8'_ (7-XY_Y_-._\%<7
M_P =H_X7-XY_Y_-._P#!7%_\=KR>-M\<;@.H>.-PLB-'(H=%<+)&X#QR*& D
MC<!XW#(X#*0'UX_^M/$G_0]S;_PNQ'_RSR_/NP^2_'_/^KORMZK_ ,+F\<_\
M_FG?^"N+_P".UW_PU^(OBCQ/XF72]6N+.6S.G7MP5AL4MY/-@:W$9\Q78[0)
M6RN.>/2OFNO6_@K_ ,CLG_8(U/\ ]#LZ]WAGB//\3Q!DV'Q&<YE6H5LPPU.K
M2JXRO.G4A*I%2A.$IM2C):---/6^[!==-EY]TNY]>T445_2HCRWXF>.M3\$Q
MZ,^G6EA='4I+])A>BX/EBU2U9#%Y$T7+&=@^\MT7&.<^4?\ "]_$W_0(T+_O
MG4/_ ),KH?C]_J?"O_7;6/\ T7IU?-]?@?&W%/$&6\39E@\#FF(PV%HK!^SH
MP5)QA[3 86K.W/3E+WJDYR=WO)VZ6#V__A>_B;_H$:%_WSJ'_P F4?\ "]_$
MW_0(T+_OG4/_ ),KQ"D;[K=>A^[][IV]_3WKY3_7?BO_ *'>+_\  </_ /*?
MZN_*P>V#X^^(3<-:#3/#QNDLX]1>U!O3<IITMW+81:@]N+[SEL);^">PBO60
M6LE]!/9I,US#)$M:R_:*U/4WDCTN/P=JLL)59HM*U$ZG+"S%E59XK#5;F2$L
MR.JB54+,CA02C ?S^:CX?FTG_@I%\0+K0O!WB?Q[X@\;>#?$(US4M=^$_P 6
M=!^*OPF\+>(K+XEZ WB_X:_%K1M6_P"%3?%#X$:6=-TNQ\%_#OQ)+H]UJ5WX
MIL/"V@C_ (61X7Q'YOHO@J\T#X-^+/AE^S[H7@OQK\-S\//V:Y_CUXT\+_L:
M:_\ LY:[H]CX0^-?P_T+XM?!OQ-H/@G2] ^)'QC>\^#!\<^._&GP\N+_ ,2?
M%70=.T'Q=X6U?QG=O\4-.BMOHUG/$[5#_C*,6G6I9?5O/"4XTX+&3Y:G-4Y'
M!*E;]RZKH_7).4:',U%R=EU\O^#?M]S[;IG])-Q^T;J%G;VUW>?\(596EZ"U
ME>7NJK9VEZJ[MS65W<ZM%;WBKL?<;664+L?)&UL2R?M"ZQ%:?;YK?PG#I_EK
M*=0FO)(M/$3D*DIOY-36S$3LRJDOG^6[,JHS,R@_@M9^ ?"'BK]GCXH^$=#^
M$/P=^(.D>(_VD_ 7PV^ OQ6L/V8K/PCX(N[CX\VWPL\$?$7XY^"O@CX\LO$W
MAGX>S?"BTO/%MA?^,/A_IOAWX=^/-?\  UAXG.GOJ;^)KS5/T!U6P_9_\)^!
M=;_9\/PYT7Q!X ^$OP+TWQ@GP4O?A[<^(_"4_P (O!JZOI_A/0+2+5_#M]X(
M\0:O+?> Y["R\.Q7.H^*(=4@L?$%YHL$6H:;J%WY^(XHXHH.*CG^8U9.O*$H
MK#8:+C2C'#R=249+FIR;Q,*:I553E&JJM.M[&I#E9976O7\';[NM]7KIYGW3
M:?M"ZQJ$7GZ?;>$]1@#%#<:=>2ZA;AP 2AGLM3GA#@$$H7W $$@9%6?^%[^)
MO^@1H7_?.H?_ "97YY?L>_"C1_A/\ ?!$%IX/\+>"O$_Q'LK?XT?$W2/!_A7
M1O!FBQ?$KXIZ9IGB;Q!I]GX=T&PTW3=*L/!]G/H_P\T33X+2+[%X?\':5!.)
M+T7=Q/\ 3U<6(XSXHI5ZM*GG^+JPIU)TXU'3P\/:*$N5S453G:,FFX^]=Q:;
M46^6*/;_ /A>_B;_ *!&A?\ ?.H?_)E(WQX\3A6(T?0<A6(RNH8X!/\ S^>U
M>(TC?=?_ ''_ /0#6+XWXK2?_"WB]%_+A_\ Y3_5WY6:U:]4?H=I]P]W865V
MZJKW5I;7#JF=JO-"DC*N23M!8A<DG&,DGFK=9FB_\@;2?^P98?\ I+%6G7]0
MX>3G0H2D[RE1IRDWNVX1;;]6[B"BBBM@"BBB@ HHHH **** "BBB@#\0/^"D
M_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(K\0_\ @I/_ ,I)/^"%
M/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"* /@'Q!_R']=_P"PSJG_ *77%9%:_B#_
M )#^N_\ 89U3_P!+KBLBOXWQ?^]XK_L(K?\ IR0!00""",@\$'H1Z&BBN<!&
M ;.[YB222WS$D]22<DD]R<D]S2X'' XZ>WTHHH 3:N=V!NZ9P,X],]:38G'R
MKQP/E' ]!QQ3J* "BBB@ KUOX*_\CLG_ &"-3_\ 0[.O)*];^"O_ ".R?]@C
M4_\ T.SKZ'A/_DILB_[&>$_].Q&MI>GZH^O:***_J\1\[_'[_4^%?^NVL?\
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M -!% 'P#X@_Y#^N_]AG5/_2ZXK(K7\0?\A_7?^PSJG_I=<5D5_&^+_WO%?\
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M!K]O(_\ 5Q_[B_\ H(H ^ ?$'_(?UW_L,ZI_Z77%9%:_B#_D/Z[_ -AG5/\
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MNI-<9^&WQ[^47"68B^Y\))/O&%QSCIQFO%O^'X?_  2C_P"CS/!?_AN/C_\
M_.@K^=>/,GS;%<59I7PN5YCB:%18'DK8? XJM2GRY?A(2Y:E.E*$N6<91E:3
MM*,D[-.P?JU17Y2_\/P_^"4?_1YG@O\ \-Q\?_\ YT%'_#\/_@E'_P!'F>"_
M_#<?'_\ ^=!7Q_\ 8&??]"3./_#9C?\ Y1Y_GV8'ZM45^4O_  _#_P""4?\
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MN#]57_XFD\M?0?\ ?*__ !-/HH 9Y:^@_P"^5_\ B:/+7T'_ 'RO_P 33Z*
M&>6OH/\ OE?_ (FD:-2K  9*D#Y4ZD?[M/) QD@9X&3U/H/6E_S_ )_,4 ?+
MG[./PQ\7_#WQ)^U'J/BO3H+&T^)G[3GBKXE>#I(K^POSJ'A'5/AE\(?#=GJ$
MT=I-,^GS2:OX2URW:PO5@O8TM8[B2$0W-N\GU!Y:^@_[Y7_XFGY&<9YZX[X]
M:3(QG(QZYX_.@!OEKZ#_ +Y7_P")H\M?0?\ ?*__ !-/HH 9Y:^@_P"^5_\
MB:/+7T'_ 'RO_P 33Z* &[1_D+_\32@8_P#U ?R I:* "BBB@ HHHH ****
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MZ1HNB:/IEO'9Z=I6DZ7I\-O8Z=IUA:116UG96<$-M;01I%#$B*%&S0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>chart-80323542940f5f3e9fd.jpg
<TEXT>
begin 644 chart-80323542940f5f3e9fd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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M_P $*?\ LZW]J#_UCGX@U^WD?^KC_P!Q?_010 ^BBB@ HHHH **** "BBB@
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MU^\O^$T\(?\ 0SZ#_P"#6R_^/4'QIX0 )/B?00!R2=6LL >I_?5\&TC?=?\
MW'_] -)^+69I-_V5@=%_S]K]+>?D_O\ (%9M+75I;^GEZ_TM?T6CD25$EB=9
M(Y$62.1&#(Z. R.C D,K*0RL"0000<4^LS1?^0-I/_8,L/\ TEBK3K]THS=2
ME2J-).I3A-I;)RBI-+R5Q!1116@!1110 4444 %%%13>9Y,ODND4OER>5)+&
MTT<<FP['DB66!I41\,\:S1,Z@H)8R0Z@$FY<[=PW>F1G\NM+7Y+>/_CGX1\)
M?$Y?#U]\=OVN=6\6:?\ $6X\ ^*O$OA&/X,Z9\,O!+Z3=? OP_K_ (FN/ ^O
M:'!I^L> ]!\;_M(?"7P5>PV&@>-?&\FKZKK9M!K.G^$_$?B"V_5K2H;ZWTS3
M[?5+Z+4]2@L[:#4-1ALETV&_O884CNKR+3UN+I;)+F=7F6U6YN$MP_E)-(JA
MB ?B7_P4M$K?\%(/^"%0@DCBE_X:N_:=*O+$TR #]CSQ^7!C66!CN0,BD2KL
M9@^&"[&_:6.V\0^6G_$WTK[B_P#,"N?0?]1ZOQ>_X*3_ /*23_@A3_V=;^U!
M_P"L<_$&OV\C_P!7'_N+_P"@B@#'^S>(?^@OI7_@BN?_ )?4?9O$/_07TK_P
M17/_ ,OJVZ* ,3[-XA_Z"^E?^"*Y_P#E]1]F\0_]!?2O_!%<_P#R^K;HH Q/
MLWB'_H+Z5_X(KG_Y?4?9O$/_ $%]*_\ !%<__+ZMNB@#$^S>(?\ H+Z5_P""
M*Y_^7U'V;Q#_ -!?2O\ P17/_P OJVZ* ,3[-XA_Z"^E?^"*Y_\ E]1]F\0_
M]!?2O_!%<_\ R^K;HH Q/LWB'_H+Z5_X(KG_ .7U'V;Q#_T%]*_\$5S_ /+Z
MMNB@#$^S>(?^@OI7_@BN?_E]1]F\0_\ 07TK_P $5S_\OJVZ* /FGXY1:C'#
MX9^WWEI= S:MY7V6PELC&1'8;]YDO[[S0P*[0!%LVDDON 7Y]KZ0^/W^I\*_
M]=M8_P#1>G5\WU_,GB)_R6&;>F _]5F# ****^* \0_: ^#-U\<OA_>>#--^
M)_Q!^$NJ2,S6?BGP!?:6Q>*X>U%]IGB?PMXCTS6O"OC70;J&VCDBTK7=,>32
M]6@L-<T:^TZ^M)/M?C_B']CRX=/@EIWPU_:!^)7PD\-? /6M7\6^"?#^F> _
M@EX]:^\<^)+#XFZ7XH\9>)]<\?> ]1U#4;[Q)9_%OQB]]H6FQZ-X2T_4KNVU
M#P_H6CI9VUE#]GT5UTL=BJ-*-&%2/LH3J3C3G2HU8<U6FZ4W*-6G-2O3<X)2
MNH*I5Y%%U:CD'S"W[/?C!OVA6^/W_#1GC]0?";?#T?#)/AO\%1X33X?-XB/B
M_P#X19/$1\'-X[$J^*L:POB8ZZ=?"J-,-PUAF,M\6_LVZUX\\)6_@7QA^T?\
M>-;\(ZY\/-&^&_Q@T.27X96EK\:-,T^VNK/6M:U5K3X>QS?#'Q+\0+&^O-*^
M(VH_!R3P9;>)-%EAT^TL-%NK.SU6#Z@HH6.Q*E3DI4U*E&G"G)8?#*4(TFW3
MLU2OS0E[ZFVYJ<85.;GIPE$N^^VP'&3A409.U(UV1QKGY4C09V1H,*BY.U %
MR<9HHHKD *0_=;_<?/TVG/\ ^OG'H:6D;[K_ .X__H!I2V?H_P AQW7JOS/N
MW2+?7CI.EF/5=+1#IMCL5M$N795^RQ8#.-<0,P'5@B@G)"J.!O6<6HQ^9]OO
M+2ZSM\K[-82V6S&[?O\ ,O[WS-V5VX\O9M.=^X;8M%_Y VD_]@RP_P#26*M.
MO[*PO^[8?_KQ1_\ 3<1!1116X!1110 4444 %(W0X&3@X'KQTXR>?H:6JU[=
M16-G=7D_G""TMI[F8V]M<7DXBMXGFD,-K:13W5S+L1O+M[:":XG?;%#%)*Z(
MP!^3FMZ#I^N_M:_%/4_$O@_1O!&H1_%SX-PV>JZ-^P7\9OB>OQ1T+P-:> ?$
MW@7Q5XF_:0LM!7P2^N>'/&JW<%O=Q21Z/\*+SP[X8U'59-0O=$TW7C^M8Z?B
M>V.Y_P Y[]>]?A]\0/#%SXB_:@U'7M+L+FZUOQG\<_@+\0_!W[1>K_"[]L:W
M^+GP<\ V&F_#6[O_ (+>$-%TW]G"_P#A9)X-\06-AX@T?5I;_P",?@CP78P?
M%#Q?+\8/ ^L^(O#GB"/Q'^X(Z?G^')X' X'0''(P: /Q!_X*3_\ *23_ ((4
M_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\
M0:_;R/\ U<?^XO\ Z"* 'T444 %%%% !1110 4444 %%%% !1110 4444 ?.
M_P ?O]3X5_Z[:Q_Z+TZOF^OI#X_?ZGPK_P!=M8_]%Z=7S?7\R>(G_)89MZ8#
M_P!5F# ****^* **** "BBB@ HHHH *1ONO_ +C_ /H!I:1ONO\ [C_^@&E+
M9^C_ "''=>J_,_0;1?\ D#:3_P!@RP_])8JTZS-%_P"0-I/_ &#+#_TEBK3K
M^RL+_NV'_P"O%'_TW$04445N 4444 %%%% !67KF/[&U8DR@#3-0),-KJ5]-
M_P ><^?*L]&DBU:[D_YYVVER)J-P^(;%TNGA8:E(W0_0]#@]/4\#Z]J /P_\
M(?"O5_#/Q)\"6E[J?B6YDL_$_@'4G?3?V8?^"MLNCO#J%UH6MP))XLUW]H;Q
M#\.]+D6UO8HM8G\80ZEH?A?45O['QYIN=(U[2X_W ']3V([GU_GT/4<5^)FH
MW'P]F_;4^+T/B^^_9HF\26WQ\^&XT"#X^?%WQ3>?&:VBD\(?#?\ LZ+X9^'/
M#T<WAC0/";:A')_PKGP<\JWJ>*5\0:IXH*7WB)HH?VS']3T^I_R?>@#\0?\
M@I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_#_ /X*6-(O_!2'_@A4
M88UD?_AJ_P#:< 1I/*7:W['OC]78OLDQL0L^ A+[=@P6!'[0QWNO^6G_ !(H
M/N+_ ,QF'T'_ $XT =%16!]MU_\ Z 4'_@YB_P#D"C[;K_\ T H/_!S%_P#(
M% &_16!]MU__ * 4'_@YB_\ D"C[;K__ $ H/_!S%_\ (% &_16!]MU__H!0
M?^#F+_Y H^VZ_P#] *#_ ,',7_R!0!OT5@?;=?\ ^@%!_P"#F+_Y H^VZ_\
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MTN2YMKR33;J>%)9["6[LVDM+J2SD9K>2XM));:9XVD@EEB9)& /Q/_X*3_\
M*23_ ((4_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;
M^U!_ZQS\0:_;R/\ U<?^XO\ Z"* 'T444 %%%% !1110 4444 %%%% !1110
M 4444 ?._P ?O]3X5_Z[:Q_Z+TZOF^OI#X_?ZGPK_P!=M8_]%Z=7S?7\R>(G
M_)89MZ8#_P!5F# ****^* **** "BBB@ HHHH *1ONO_ +C_ /H!I:1ONO\
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M4?\ "Y_A_P#]!+4O_"<\0_\ RLKX[HK+_B+.??\ 0OR?_P %8[_YN#3S^_\
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MVT^S>5O_ +9\/ZSH8D\[S-OV<ZM96?VG;Y9\W[/YGD[H_,V^8F[;P/0?D*7
M'0 5^J4X*G3A33;5.$8)O=J,5%-VTNTM1!1115@%%%% !1110 4444 %%%%
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MB+J.E:MJ&BS^-DT0:PMG<RWL4D>OR3:U+;OO^"A7_!$'Q)\./!?@#XJ_M>?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>chart-a8b4db707bd75762992.jpg
<TEXT>
begin 644 chart-a8b4db707bd75762992.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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MM_$_]G1^*-'\/1Q_#[X?:_K_ (,LKA[36O$_@G2+V+5-+TG4O%>A>(NVUO\
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MIOB#4[JWBU!-2TM/#MEH>L/XB;4O$]MH%K[%^TQ^R?X<_:7TC7-.UGQIXO\
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MN_\ P:ZO_P#)] &_16!_PC.D_P#/.[_\&NK_ /R?1_PC.D_\\[O_ ,&NK_\
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M$MYVCF:W7SU0Q,KG]Z/^$E\/?]!O2O\ P/MO_CE &W16)_PDOA[_ *#>E?\
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MXHX+>"-(8((46*&&&)0D<44:!4CBC152.-%5$151%"@ 2$9XY_ D?J"#2T4
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MX,O?&4O@#Q9H_B;X7>$;C6O#4'Q<L_AAXWNWDT:]\(>&=(U&X\ET?]G7XO\
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M*,<(/%=[\.-=M%';>-8T#5->('0%KU9"<,S-@B31MM)_:'LH90/&7PMU=N3
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M$KN09=?T*T/7_CC=:-I-SJOPX\!V>J7&G64VI6C_ !)U:)K:_DMXVNX3#!X
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MS7_P3DGE_P!2?R_'UOY/_P )-\6_^B7>'_\ PYL7_P QE'_"3?%O_HEWA_\
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M)5D=2&1E)5E(9200:?0!^'?C_P#Y6(/V</\ M$W^TE_ZU)\(:_<2OP[\?_\
M*Q!^SA_VB;_:2_\ 6I/A#7[B4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S]^U'\&
M=2_:!^!WC/X2Z;KNGZ)_PE;>'TU2UUW3;O5_"7C'PYI7B;1]:\3_  S\=Z;I
MFH:/K-[\/_BAX?T[4O 'CFVT;5].U*?POXBU2**2ZB>;3KWZ!HH _([X4_L
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M?_\ EG6U10!B_P!@V7_/QK7_ (46O_\ RSH_L&R_Y^-:_P#"BU__ .6=;5%
M&+_8-E_S\:U_X46O_P#RSH_L&R_Y^-:_\*+7_P#Y9UM44 8O]@V7_/QK7_A1
M:_\ _+.C^P;+_GXUK_PHM?\ _EG6U10!B_V#9?\ /QK7_A1:_P#_ "SH_L&R
M_P"?C6O_  HM?_\ EG6U10!B_P!@V7_/QK7_ (46O_\ RSH_L&R_Y^-:_P#"
MBU__ .6=;5% &+_8-E_S\:U_X46O_P#RSJ[9V$%CYGDR7LGF[=WVS4=0U#&S
M=CR_MUS<>5G<=WE;-^%W[MJXNT4 %%%% !1110 4444 %%%% !1110 4444
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M._B_\,+^U!_\Y*C_ (B'_P#@CU_T=_%_X87]J#_YR5?M1@>_YG_&C ]_S/\
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M_P#!'K_H[^+_ ,,+^U!_\Y*C_B(?_P""/7_1W\7_ (87]J#_ .<E7[48'O\
MF?\ &C ]_P S_C0!^*__ !$/_P#!'K_H[^+_ ,,+^U!_\Y*OM+]D#_@HG^QU
M^WH_C^/]E#XPI\5G^%P\,GQT%\ _%'P1_88\8_VY_P (X2?B1X(\'#4O[1_X
M1S6<?V.=0^R?8S]N^R_:+7S_ +6P/?\ ,_XTN,>OXDG^= !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 =.M)N7&[(QZY&.>G/3FO
M'OCU'J+_  M\22V7QAB^ ME9?V7J?B?XJ&Q\.W=YX7\%Z7J]CJ'C)M)NO%PG
M\,:#K&J^&[;4=$TSQ5K>EZ]9^%KK44UU- UB\L;6S?\ -7P'XG_:#\=>,/A+
M\#?$OQG^,_PZ^%WQ:\4_M/>-OA/\2]?T3PKX2_:8\8?"GX0:'\"[3X9>$_$[
M>(? 7V/P]J?B;Q)X]^*_Q*TV'7O >E?$K6?A#\/?!EEX\M(-6N/B!;7H!^QF
M1Z]>GO29&2,C(ZC/(STR/>OR,^#GQV_:/^(E_P#\$X/'7B3XEZ=%X)^+&I?&
M'P'\0?#/ASP+I.GGXP:QX(^%G[0.H:3\7M1\1S7%^FG>$?%L'PU\$?$#P'X0
M\&:1X6MK>?Q-JUUK&KZ_I+^'M$T/)T#XU_M#>&_VF/AEH_BK4OC5J&O_ !&_
M:W^+7P=\9^"-2T+P./V9[7X%V/ACXY>*_A;XC^#7BC3=!36=?\9Z%X>^'_@S
M5O&C6'BK6/%VCZK+\3=+^,'AKPM91>#+72 #]BJ*0$D D8) )'H2.GX4M !1
M110 4444 %%%'T_S_*@!,C.,C.,XSSCUQUQ1D'."..O(X^OI^-?G)\4KWXR6
M'[3G@S2_AM\=_&_C+QCJ_P 4/ >J^(?@IHOA3PI;_!/X3_LLQV=I;_$&\^+%
M^^A:IKL/CGQ:^F>([SX5^);CQUHGB_Q3X_U#0=&\)>#C\+_!OQ*N*^:?AE\7
M?V@/$F@?LP^*T_:9U6VU7]MS]GSXT>/_ (@S:WX;^'VL>#/V7O$/@WPUX.\:
M'Q?\//#]]HN@?V)HGPBEUG4_@GXETSX@>(?$FD7GBW5O!OBGQA::CJVE^(H/
M$8!^V.Y<;MPV_P![(QQUYZ4M?C%H'C[X[:KJG@/X=V'QH^,5O^SS\?/VFAX!
M^$_QU\9Z7X8T?XW:[X!\+?LS?$7XI>+(/"GB"[\!Z19P^$?BA\5?!=GHOPC\
M;:_X+7Q?K7@VQ\?ZEX0O)/#6N_"/Q&OW7^QGX_\ &WC_ .$FN?\ "=ZW=^,=
M3\ _&GX^?!_3?B->6FC64_Q,\-_"+XO^+_ 'ASQM=V_AZQTS0O[9O=+T.#2O
M%-QHVF:9H]_XMT;7M0TG3-.TZZMK.$ ^LJ*** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\307]I<1:UI.C3Z_K<^EV-^D]O83ZK?S6J12W,KMA:%\ ?@AX8TKX?:'X?\
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M/XWG!(R/@K\0B#@XR#_8W(]".".17T'28'O^9_QH ^?/^&CO#!( \!?'$DD
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MXUZY\)8?!,<>LP_!G0M4M_'VD^)+;Q?X1AL])\,>,+'2/TC^ 7Q5M/C;\'_
M7Q/M9O#\C^*]$%SJ47A>]\1WVBZ?KVGWMYHOB31K67QCX4\"^+H9=#\0Z9JF
MC7]AXI\&^%_$FE:C87>EZYH6FZI9W5LG)VW[(/[*UGX/\0?#^R_9S^"5EX(\
M4ZQ8^(?$/A2S^&/@ZUT+5M>THSG1]9O-.M](CMWU/1/M,XT.]1(Y]#262/2'
ML4=U;V_PSX7\-^"] TCPIX/T#1O"WAC0+&#3-#\.^'=+LM%T31]-MEVVUAIF
ME:;!;6-C9P+\L5O;011("=J@DD@&[1110 4444 %%%% !1110 4444 %%%%
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M=#U/16N&M%U&V-N;E8A,T.65MXB9XPY&W&TNO7K7BO\ PH*WSG_A*;C.<_\
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M?#[4=<.K"V^W?VM?^!?#?A_P=>:AYWVJX\,Z)I.B2RMIUA:V\?T"VUU?5[7
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MMHNBWL?5+;75]7M<_%WXK_\ !1W]IKQ'\*/VJ-;^#?PID^'MQX1\!_M2:O\
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M-9\1^+_VI?'^G?#S2-8^ UU9>&X--\2^$?!^HZSIEQO\1VMMJ/C36K#Q_P"
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MMFD,6N:A9VE]J,<]U:V\L0!^>7C/XY?M+V?[3'@KX9^$=>\$6/C6Z^*7Q/\
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ML;FWO+*]MX;JTN[2>*ZM;FWG19(9[:Y@9X;B"6-E>*:)WCD0AT8J0:\IT_\
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>chart-a0675ec327835197bd6.jpg
<TEXT>
begin 644 chart-a0675ec327835197bd6.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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MU'X;>%M$U+QOXLO9-7NKSQ'XAUN]73+V_2.[T'PKX7>YU5=3 /";K]NKX[>
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M^S)\8]:^,NGW=K8:/IFG:/96?BK5-;E\,SZ1;V26GASPK8:99Z2\][;SW]T
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M>7P_I.H>.?'OA[POJO@OP'IU_KD1TV"]\7Z]HT'F;[J1H].@N;V#SZ']NO\
M9;>[\;VMS\3'TJ'X>V?QFN_$FKZ]X+\?Z#X;\S]GGQ?=>!/C9I6A>)]6\+6F
M@>+?$'PW\4VRZ9XB\.>%-1UK7HS>:=<V6G7EM?02MY;^UI_P3X\'_M:^+I?$
M7B[QYJ>FZ??> M$\$3Z+>^!_A_X[/AF;POXGUGQ;I'BWX4:KXXT?5KOX3>+M
M<U'6O[.^(NO^%(5U7QMH'A_P=8"^T*]\*Z9JJVO&_P#P3[\#^/O#^E>&]:^(
M/C6VLM+\1_M?^*8+O2+;0+35+;6?VLOB]J7QI?4M/N;FQOK6TOOA1XQNM.N_
M!3SV-]::G_8UJOBFQU.WNK^UN #V/X'_ +36E?'/6/V@;/P_X.\5:;9? [QQ
MX<\%QQ:]H?B3PKXQ\176N_!;X=?%V9+_ ,!>._#_ (0\0>#]7LV\?)X>@T?6
M8V%\+*UUE;^&TU1(K;YYUC]NCXD?#S4M0\+?%_\ 9Q3PW\0=;^&WP^\??#7P
M)X,^+VB^.M4GUCXI_&?P/^S_ .!OAE\7=1?PGX=TCX8^,M7^)GQ%\-62:OHE
MS\1? 6H:5I?Q*O\ PUXG\0GX;:I'J?T?\&/@)K_PJ/QGU_5_BIK'CWXA_&_Q
M-H_C/Q/XMU3PMX:T.QTOQ#H/PL\&_"K2T\/>%=#6/3[30[72? VC:BNEWUYJ
M%S-J,NHM=ZK<I=@Q?,?P]_8"\;Z=X5^)OA?XP?M*ZK\6K_XFW?A#QCJOQ2M?
MA)X-\!?&D_&+X<>-/#_COX8_%2^\<6>L^)-*U*?X;:WX<TX>"/A\GA#3?AGX
M>TNVM]!TSPM:^'_MNE7X!-\0_P!OCQI\*_AQ\>+[Q/\ L\7>O_&7]GC7_#%C
MX]\"> ?B/IVI_#Z+P9XN\(V?CG1?BPGQ0\5^&?!FIV?@>ZT0:_HZV-Q\/)/&
M=U\0?#.I>#=&\.ZO!<:?XCN.P_:+_;8U'X'^)?C'::5\.- \3>$?V:/@SX:^
M/WQ\U[Q)\3X/ &N67P[\37OQ AMX_A3X:N?!^OVOC_Q'9:=\-O$NH7*>(O$/
MP^\,76JC1_!NE>)K[Q%J6HIH',_$C]A#QQX]^$_Q?\&P_M(:CI?Q&_:+U:RE
M^.?Q8OOA#X'UVZ\0>%]#\)6W@WPKX)\%^#'U/3?#_@/0_#&FV,%[I\OVCQ)J
M$^MZEXFU>_N;FZU]FLMKXM_L,W_Q_M/ T7QG^+&C^+;W2O!VM^!O'.L6_P"S
M[\%;3Q!K&B^(=3U&X\03?#/Q=K6B>*/''P/U?Q3H5[%X2\3:CX4\5:L7TJQM
M=8\*P>$/&J#Q2H!]^:??VNJ6-GJ5C*)K/4+6WO;28*RB6UNX4N+>4*X5U$L,
MB2!7574-AE# @7*@M;6WLK:WL[2&.WM;6&*WMX(46.*""!%BAAB10%2*&)$C
MC0#"HJJ.E3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?XMT#Q!X?UW2K]DN+:\GTW4K32=?TG6='T_W>@ HHHH **** "BBB@ HHHH
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M?ZGPK_UVUC_T7IU?-]?S)XB?\EAFWI@/_59@P"BBBOB@"BBB@ HHHH ****
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MV7Q&^(WPI\#ZII%GXE_9%O-4U;XV:6NJ:EXF\)_L_>,?BA=!?&/['NL>&/%
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M+DDZ\E&5KV;BTF]MK&EGOHK[WZI=EW/L7(]_R/\ A1D>_P"1_P *PO\ A&-
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M=S-]W<V,8Z\]J_LK"_[MA_\ KQ1_]-Q$7Z***W **** "BBB@ HHHH ****
M/Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@BOQ#_P""D_\
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MS/T&T7_D#:3_ -@RP_\ 26*M.LS1?^0-I/\ V#+#_P!)8JTZ_LK"_P"[8?\
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M!8?%74%\-7&C#1[+4_$]D ?;=%(#D C." 1D8///(/(/L>E+0 4444 %%%%
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MC1KO5->\%03^-="T*/4CKNM>#H9?%>EZ9=^'XWU$<%;_ +>O['=W9:!J=O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>chart-bec93acf6eb55fb08e4.jpg
<TEXT>
begin 644 chart-bec93acf6eb55fb08e4.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MOAC3]:.N:3#K&H6GA?6-9A]&^./[$7@7X[^*QXK\2>+?%FE2CXD_!/X@/::
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M_P#U/^"GQ$\::5XG_:7LOB#).J^"]'^%'Q&UC3+"VUWQ1%X+\7^,/@O;:_\
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M+_3+T074,MM,;:ZE\JXBD@DVRQN@_"OQ!\$_B'\1=#^%NI> ?V7O'?@+PY\
M/V>?V>?AQ\>/A+K_ (5TGPY/\:7^%'[3GP ^*NK_  2\$IJ]W9Z5\4=,\ >
M?AG\99-"\5V%]>?#[QQ=_%2V\'Z)XCU-?&'C2#2_K7X=3>.--UG]JSQ=X>^!
MGQ-G\+_M9?$?69O@_P##OQ!X1U;X:V=UXB\'_LJP6/BGXB?%]Y%L/$'P)\._
M'/QIX%3P/I^M^*=)T_Q-/KL/AW7+_2+'4/&%K.0#]"?!'Q7^%_Q,G\06WPY^
M(_@+Q]<^$[]=*\4V_@KQCX<\5S^&M49KA%TSQ!%H&I:@^C:@6M;E19ZDMM<,
MUO.%C)AE"=_7XL?\$Y?@_P#%CX<_%/PY!XGA^+?BOP7X(_9.\/?"*VU_XR_
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M\$Y.?7-?A311_P 02X'_ ),V_P##@O+_ *A_)_?Y!_Q&'C+^?*__  AEY?\
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M> IQ<Z=)14IUX13DU7;2NU=I-^1_7K16!_:FK_\ 0NW/_@RTK_Y*H_M35_\
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M^)Z\:K_7?*?^15EG_8OP7_J-2/\ *;-?^1GF'_8;BO\ T],****] X HHHH
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MG_J53/[5**P_[ M/^?S7/_"@UK_Y.H_L"T_Y_-<_\*#6O_DZO\M3_2X_F_\
M^#B__D$?LB?]ACXV_P#IL^&E?S!U_3=_P<1:?#8Z1^R28IKZ;S=8^-0;[;J-
M[?[=FF_#8CRQ>3S"(G<=YCVE\*&R%7'\R-?Z1_1__P"33<+_ .//?_6BS8_S
MT\=?^3H\2^F3?^L_E/\ P'\PHHHK]E/R(**** "BBB@ HHHH *K7O_'E??\
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M@W6/#=QH]E+J'@S5M6M-)U3P[<2Z=JMXD7SK\,/%_@_5X_V@?BCJWP$^!O\
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MW!>7_3CR1_-I_P 0NO[!_P#T<'_P41_\2ZU3_P"8FC_B%U_8/_Z.#_X*(_\
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MB6L>IR:4NM>%KP6#Z@EC9)>M;>6;E;2W64L(4"^5_P#$+K^P?_T<'_P41_\
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M^&_#&DWFN:[JMQ%:Q3W,D.GZ587=W*EO#+,Z0E(HWD94/45POQ0^'7AGXO\
MPU^(7PG\:VTU[X-^)_@?Q;\//%ME;S?9Y[WPQXU\/ZCX9U^TBN#'*(9;C2M4
MNXHIC'((I&23RWV[2 ?*O@']M1=;U:QTGXD_ [XK_":Z\:?"37OCK\(]/O+/
M2OB'XE^(OP\\,7O@ZR\1:9!X/^&-WXG\2Z-\5=!'Q"\#7^I_#%M/U6^;3/%%
MK<:5K6K7&C>+;3PW[I^SG\;K+]HCX->#/C#I_A/Q%X(@\7QZT6\(>+)=%F\3
M>'KK0O%6N>%-0TS7'\.ZEK.A_P!HVM_H5U]J32M6U.QC;,<%_=H@GD^// /P
M#_:ETKXM-JOCCQ=X4\5ZO\!_@)>?#']E7XKS^ ;#3OAOJ<GCJ+X<1>/?$/QR
M\!Z3\8_^%C:Y\7Y+CX::/ISIX-B\$?"I?";:EK'AV\T[Q#XMO?"OA3WG]C/X
M(_&#]GKX4_\ "L/BM\0?AK\1(=&UK7M0\*:O\/?AUXK^'<D-GXJ\4^)/&>M6
M_B"S\3?$KXC+J-S%K/B2:VTRYTVXTF*+3+6)+NWNKJ1IT .!\;?MJ^+?!'P_
MG^)VH_LJ_&R/P=X.^'7B;XN_&+4]5NO!/A<?#WP%X6\1>,-(U&/2T\4:YI/_
M  L#QU'H7@O5/'T_@C06LYK'P9/HUS>ZQ#K?B?PGH>O[UQ^VIH</Q,.@1?#?
MQE<?"&#XTZ)^S7?_ !V2\\/Q^&['X[>(ETNUTSPO+X0GOH_&K^&O^$MUO1_A
M=?>-$TX6]A\4=03P[-H[:-9ZGXHL<G]JK]G?]H?XY^-_!TGA#XJ?!BQ^"GAG
M3M/U34_@G\5/A)\0?&6C>-?B7IGB%M7TKQ5XZU;P3\:/AR/%_A'P_:VNEGP_
M\+-:TN;PH/$\,_BWQ0OBN[L_"UEX8K/^QEX@E\:75B_Q2TU/@!K'[1^A_M:Z
M]\+XO MP?%\_QBT+6M"\>1Z-IOQ#N/&,^EV/PJOOC'X=TSXNWGAZ;P%>^+3X
MA_M#0X?&D?AO4([2P /O@'(!&<$ C(P>>>0>0?8]*6D P ,DX'4]3[GW/4^]
M+0 4444 %%%% !1110 4444 ?$/QF_;3L/A=XK^*6B^'?A/XY^*7A_\ 9V\%
M:+\1/VD/%7A74_"6FP?#3PQK^D:QXGM+/1=%\2:OINK_ !(\9V'@G0K_ .(.
MM^$?#4<$]EX/?3'L]0U/Q1KVA>%=1]$\-_M0>%O%O[1+?L_:'X4\;SAO@]<_
M%^P^*%[HPTGX<>)=/M];\"Z6^C>"M1U*6VU3QI+;V/Q#\-ZO>^)M TRZ\$0+
M?#0[;Q'?^);#7](T/YE_:C_9:^+MQJ'QS\5?L_:TK:/^U?I7@+X?_M+>!['0
M?#T_Q)?PQI?A77?A?K'Q(^ OB_Q;\0O 7@C0/B6/ASJNC>';_3OB0NO>&GT[
MPSIGB3P\EMXETB;P]XU]"C_9R^/FC?M1^ /BUX1^(OP,T3X,_#KX8W'P.T+X
M87'PC^(E_P"-HOA7JNM_#?Q%J<7_  L,?&N#1/\ A*[.]^'5K8:#J<O@272X
M-+OF&J:3J5[;FXF /HCQQ\8SX"\7S:#J7P^^(>K>'K7X9Z[\0;GQEX3\+:QX
MOLVU+2?%7AKPQ8_#_3]"\-V&I^(-7\:^(?\ A(CJNC:;I]G+YVGZ7J$TQABA
MDGB^>]'_ &W8O&/PE_9Y\:^!?@YXUUGXD?M,77B>T\ ?!O5O$'@OP]K.C?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?[%H^U]GS<W)[6GS;<\=S^:>&OH[OA[B')\^_P!;EB_[)S'"8]X7^PG0]O\
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M:3P-XTU&S\-:?\2&\<:KJ_BO2=7^)\NK:SXD\":GI^I_8+;]2J* /R!\(_\
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M3[.R\92MI6Q9?\$WM9T_P+J%I:^._A>GQ/U3XH:+\0+SQD? G[0$MJEMX=\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>chart-d3a8fa49540b5980939.jpg
<TEXT>
begin 644 chart-d3a8fa49540b5980939.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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MU'X;>%M$U+QOXLO9-7NKSQ'XAUN]73+V_2.[T'PKX7>YU5=3 /";K]NKX[>
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M^S)\8]:^,NGW=K8:/IFG:/96?BK5-;E\,SZ1;V26GASPK8:99Z2\][;SW]T
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M>7P_I.H>.?'OA[POJO@OP'IU_KD1TV"]\7Z]HT'F;[J1H].@N;V#SZ']NO\
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MQ _\%^@?_-#1_P -X?"C_H6?B!_X+] _^:&NK^U<O_Z"J73J^MO+^\OQ./\
ML+-_^@"O]T?+^]YH^:]3\36'AC_@H3KQOO%NJ>*;[Q!H5[I-Y);^+/BO\/OB
M'\"O!MTFN&YU2Y\':K;W_P &?'W[/G@B'2;CQBOC:6VT#2[-]<T[Q,)_&7C?
M1+F"_B^$/B[]F+Q=;?%?Q1\.OB[%I_[/;_"?PCX/URQLOC?XS\1>//BCX@?X
MB:87_:4^*EGX7\2ZY\1_AAX0U9KFP\!:_P"/M4A\'^)O'W@_Q3XN\2_$"W\,
M>#+'P<X^D_\ ANCX1&=KH^$_'AN6M!I[7!TOPZ9VL!=/>K8-,=?\QK);V22\
M6S9C;"[=[KRO/=I"0?MS_""V=I;;PCXYMI7W;Y;;2/#-M*^XDMOD@UV-VW$D
ML&8AB3N!R:^.CEN$56I.6:X&=.6*QF*A3E@ZC:EBX1@HU*JQ2JU(.]\1%ROB
M+0IN<:,73G]?/%YG.C1IQR;-*=2G@<LP4JE/,:<(RC@*OM'5A16#=*E52<(8
M.7)..";K5_9UL756(I<S^Q]XU\*:7IWQ&\!ZMXD\#"P\6_'SQ!X9^$MA\/O%
M?B7Q/\#?$\%Q\$_"?CC7O!7[.FN>+I+CQ%JFC>&],TKQ7K?Q"TMKR31=#\?2
M>.XO"\UOI$4.G6?8_LH_"CX9^'O%/QT^)OP]\":/X"TO4?B-XF^"GA72-"75
M;6Q;P=\#]?NO"VM:]<V5]?W<4^L^,_BG;>-=1FU,QK,OA?1?!FE6SK;6=PUW
M /V[OA.%C0>&/'X2)0D2#3O#P2*-00L<2#Q %BC4$[4C"(-S8'S'*C]N_P"%
M SCPQX_&23QIWA\<DY)X\0CDGDD\DDDDFO3P5'+L/'+85\QP^)66/$/#OV"I
MR_?*"IIR<ZCBJ//5M&+49<U.Z7LKS\S&0SC$2S&5#*\;AO[3AA(8F+Q2JPDL
M.XRG)Q5.BIU*\Z>'G*I/FG&7UE*3AB90I_;=%?$O_#>'PH_Z%GX@?^"_0/\
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MWF[=WVK4=0O\;-V-GVZZN?*^\=WE;-_&_=M7 !=HHHH **** "BBB@ HHHH
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M&A_C%_T.4O\ X)O#W_RIH_X:'^,7_0Y2_P#@F\/?_*FO8_X@OQ/_ -##(O\
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MPC]K_P _VN_^%!K/_P FU_.1_5!^5_\ P51^/FH? ZQ^!LNG^&=/\2'Q-?\
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MQ#_T2_P__P"%5J__ ,J:/^&_O$/_ $2_P_\ ^%5J_P#\J:_/I00JAB&8* S
M;0S  ,P4D[0QR0N3@'&3C-+7J_VMF/\ T%3_ / *7E_T[\OQ?<\G_5W)O^@&
M/_@_$^7_ $_\OQ?<_03_ (;^\0_]$O\ #_\ X56K_P#RIJ&Y_P""@'B)+:Y<
M?"[P^2EM<.!_PE6K\[(7;'_()[XQWKX!JO=_\>=Y_P!>=W[_ /+O)V/%']KY
MDO\ F+G_ . 4O+_IWY?B^X?ZNY+_ - ,?_!^*\O^G_E^+[G]XGPYU,ZQ\/O
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M_P!I>-O"7@7Q9_PBOAGQ!\3])^UG7)1^Y@&!CTSZ^IY.>I/4GN>>] 'X@_\
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M_K'/Q!K]NE_U4?TB_FE '^7O^U#_ ,G-?M(_]G!_&_\ ]6EXLKPRO<_VH?\
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MDZ;<^!'P.^&'Q&^&&BSR'PGXL^-GC7XE>-? GA/X>ZM^TIIWP=\07DFF^&_
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M_P"DHT****@T"BBB@ HHHH **** "BBB@#\0/^"D_P#RDD_X(4_]G6_M0?\
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M8&C_ %MPW_0)7_\  Z?]=_Z>A_J7BO\ H-P__@NI_7?^MOXX:*_L>_XA5_\
M@GQ_T7'_ (*!?^)63_\ S T?\0J__!/C_HN/_!0+_P 2LG_^8&C_ %MPW_0)
M7_\  Z?]=_Z>A_J7BO\ H-P__@NI_7?^GI_'#56__P"/#4/^P??_ /I)-7]E
M'_$*O_P3X_Z+C_P4"_\ $K)__F!I&_X-5O\ @GLRLC_&_P#X* LCJR.C?M5S
ME71P59&4^ <,K*2K*>""0>#0N+L,FG]3KZ-/^)3\O+U_IZ'^I>*_Z#</_P""
MZG]=_P"GI_0#^SV<? ;X*Y!_Y))\-.Q_Z$C0O:O8LY]?Q!'\Z_$O3?\ @B1X
M6T;3['2-(_X*8?\ !9?3-*TNSM=.TW3;#_@HC\0K6QT_3[&".ULK*SMHO#2Q
M6]K:6T45O;P1*L<4,:1HH50*^W_V0OV*[/\ 9#;Q\UI^U!^VE^T=_P )\OAI
M9%_:[_:-\1_'U?"/_"-'7"I\!#7]-T__ (19M<_MQAXE-KYO]LC2M#$VS^S(
MMWPTWS2E)?:DW][;/T*$>6$(MWY8QC?O9)7/M6BBBI*"BBB@ HHHH **** "
MBBB@ HHHH **** "BBN6\<>-/#7PX\&>+?B#XTU6'0O!_@;PSK_C'Q7K=RDK
MVVC>&O"^DWFNZ]JMPD$<L[0:=I5A=WDJPQ22M'"RQ1O(54@'4UG:MH^DZ_I]
MSI.N:9IVLZ7>+&MWINJV-KJ-A<K%-'<1K<6=[%/;3K'/#%,@EB<)+%'(N'16
M'Q9X&_;8M]7U:RTKXD? _P"+GPEN?&?PH\0?''X1:?J5AHWQ \2?$CX>^%[[
MP58>(-,MO"'POU#Q7XDT3XK:&_Q&\"76I?"^ZT^^U&2R\3V\VC:OK,NA^+[?
MPU[K^SM\;;']H?X.^#_C!IWA+Q-X%M_%O]NJW@_QB^B/XI\.W.@>+-=\)7^F
M:\?#FJ:WH2:G;7V@W1NX=+UC5+.!R88K^Z\LS, >W_Y_/K17P+XR_;8\6>"_
MAU-\5-4_90^.MOX,\'?#OQ/\7/C)J6K3^ O#)^''@#PKKWC?3=1^PP^)?$NE
M2?$'QLOA_P !ZMX_F\$>%@+K3_!MUH-SJ6IVNL>*?"NBZ[T$_P"VOX=C^)']
M@P_#GQK<_".#XS:)^S=J'QWCNO#J>%K'XZ>(3I=EI?AF3PK-J4?C63PN_BW7
M=%^%MWXWBTLVEA\5=13PQ<:2NE6>I^)K$ ^VJ*0'(!&<$ C(P>>>0>0?8]*6
M@ HHHH **** "BBB@ HHHH **^(/C/\ MJZ;\+/%7Q1T7P]\)O'OQ4T']G?P
M7H_Q$_:1\5^$-0\'V-O\+_"^N:)K?BNUM=)T3Q)KFEZU\2?&5CX)T"]\?:UX
M,\)6[:C9^$KC17LKC4_$GB+0O#&H>B>&?VHO"GC#]H;_ (4#H'A+QW<*_P (
MK_XMV'Q5O-%CTKX8^);"QUSP!I4NB>!]5U*YMM6\;7-M:?$;P[J^I>(] TBY
M\$6:7B:+!XEO_$MKK>CZ( ?15AI&E:5)J,NF:9I^G2ZQJ$FKZM)8V5M9R:GJ
MLUO:VDNI:@]O%$U[J$MK8V5M)>W1EN7M[2UA:4Q6\*IHUXEXZ^,Y\ ^,IO#V
MI?#KXD:OX=M?AAKWQ#N?&WA+PIJOB_3CJ>D>+/#'A:P^'=AH?ANSU+Q)JWCG
MQ'_PDAU;1-,T[3IHYM-TG4IKB6".!Y8_G_1_VWK;Q?\ "G]GWQGX'^#7CS6?
MB/\ M+77BNU^'WP:U77/ WA_7](/@*#7K_QS<>//%LFNZAX,T*V\+6&@207Q
MT34O%%Q>Z[JFD:5HMOJ=M->ZM8 'W;17DWP0^+_A_P".OPVT?XD>'-/U;1[6
M_P!3\7>&]6T#7AIO]M^%_&7P\\9^(/AUX_\ ".KR:+J.KZ+<:GX2\=>%/$7A
MR^O-%U;5-&OKC3'O=(U*^TZXMKJ7UF@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KA?BC\.?#'Q@^&GQ#^$WC:VGO?!GQ0\#>+?AWXNL
MK:<VMQ>>&/&WA_4?#.OVD-R$D-O-<:3JEW%#.$?R96278^S:>ZHH _,KX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&]K:(H^MM)_;7U+2?&/[/O@[XM_"";P1_P +^U+X@:38^,?"7Q/\%_%;X?\
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MD+PH+R1LQ R< G R<5#_ &/I/_0,T_\ \ ;3_P",UI44[ON_O8K+LON0  #
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M,/A]\9_BUJWQL^+/@7PAX6U/P5IWB/QK)\%OA'\,?"5GI^K7/C'Q%K&E^'?
M/C#X=WOQB\,Q/<7FMVWCV#X:WXUE)/A[<3^*.9N?^"<LOBJ?0OB7\4/C;XH\
M=?M->$?&_P"SQXM\,_&."Y^(GA3PJ(?V<[GPL='LO$?P-T+XJ1?#7Q)?>/+>
MU^)TGC/6=2TV6\M;OXT^,5\+G1M/T_0K.U .*\.?\%5M.OO#7C#QKX@^!.M6
M'A;3OA5^TI\6/!\WA7XK?#GX@:_JNC_LSV.M:GXDTWX@>%]%>TU3X1W_ (JL
M]'>'PM>>(!JVA+K=Q;>&]>U71]<OM*LM3_6RWF%Q!#.JE1-%%*%;!*B6-9 I
M(X) 8 XXR..*_%W1/^"3>MVGA+Q9X$N/BC\'/"^D7GP\_:F^'VC>+/A1^SG/
MX'^*OC2T_:5\,^/O#$+_ +0?C>;XKZS'\5]&\!#QO%XIA\.6FB>%X_$OCOPQ
MX5\43ZGHTFB1V=S^T-M#]GMX(-V_R88HMV-N[RHUCW8R<;MN<9.,XR>M $]%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ,,<;'+(C'U*J3^9&:3R8O^>4?_ 'PO^%244^:2VDU\
MW_71?<3RQ;O97WV]/\D%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>chart-d48ca46993295751b22.jpg
<TEXT>
begin 644 chart-d48ca46993295751b22.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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MJEEH7AJ^\'^*;Q]>\.>)O#UAI?BS2=2MM+N;/78I-&T@V(!RG[)7Q \0>*-
M^(W@KQ]KWQ:U?XI?";XB2>%?']I\98/@@WBC2+CQ!X0\*?$'PO;:=K'[//AC
MPC\,_$7A>[\'>+=%U/1M5L]&M?$$<EW?Z7XI@MM7TV2VB^LZ\W^%WPC^'WP:
MT"]\-_#OP^NAV&JZW>^)M=NKC4]:\0:_XF\2ZC!9V=[XD\6>*_$^IZWXJ\6^
M(KFQTW3-.FUWQ+K6JZJVFZ7IFG"[%CIUE;P>D4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_
M -!%?B'_ ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!% #Z***
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M)M8LDGN36E69HO\ R!M)_P"P98?^DL5:=?V/A?\ =L/_ ->*/_IN(@HHHK<
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M[3_"CR(/^>,7_?M/\* ,O_A(M _Z#>D?^#.Q_P#DBC_A(M _Z#>D?^#.Q_\
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MDL5:=9FB_P#(&TG_ +!EA_Z2Q5IU_96%_P!VP_\ UXH_^FXB"BBBMP"BBB@
MHHHH ***BF\SR9?)=(I?+D\J26-IHXY-AV/)$LL#2HCX9XUFB9U!02QDAU )
M-RYV[AN],C/Y=:6OR6\?_'/PCX2^)R^'K[X[?M<ZMXLT_P"(MQX!\5>)?",?
MP9TSX9>"7TFZ^!?A_7_$UQX'U[0X-/UCP'H/C?\ :0^$O@J]AL- \:^-Y-7U
M76S:#6=/\)^(_$%M^K6E0WUOIFGV^J7T6IZE!9VT&H:C#9+IL-_>PPI'=7D6
MGK<72V27,ZO,MJMS<);A_*2:15#$ _$__@I/_P I)/\ @A3_ -G6_M0?^L<_
M$&OV\C_U<?\ N+_Z"*_$/_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]O(_P#5Q_[B
M_P#H(H ?1110 4444 %%%% !1110 4444 %%%% !1110!\[_ !^_U/A7_KMK
M'_HO3J^;Z^D/C]_J?"O_ %VUC_T7IU?-]?S)XB?\EAFWI@/_ %68, HHHKXH
M HHHH **** "BBB@ I&^Z_\ N/\ ^@&EI&^Z_P#N/_Z :4MGZ/\ (<=UZK\S
M]!M%_P"0-I/_ &#+#_TEBK3K,T7_ ) VD_\ 8,L/_26*M.O[*PO^[8?_ *\4
M?_3<1!1116X!1110 4444 %(W0X&3@X'KQTXR>?H:6JU[=16-G=7D_G""TMI
M[F8V]M<7DXBMXGFD,-K:13W5S+L1O+M[:":XG?;%#%)*Z(P!^3FMZ#I^N_M:
M_%/4_$O@_1O!&H1_%SX-PV>JZ-^P7\9OB>OQ1T+P-:> ?$W@7Q5XF_:0LM!7
MP2^N>'/&JW<%O=Q21Z/\*+SP[X8U'59-0O=$TW7C^M8Z?B>V.Y_SGOU[U^'W
MQ \,7/B+]J#4=>TNPN;K6_&?QS^ OQ#\'?M%ZO\ "[]L:W^+GP<\ V&F_#6[
MO_@MX0T73?V<+_X62>#?$%C8>(-'U:6_^,?@CP78P?%#Q?+\8/ ^L^(O#GB"
M/Q'^X(Z?G^')X' X'0''(P: /Q!_X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C
M_P!7'_N+_P"@BOQ#_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(H
M ?1110 4444 %%%% !1110 4444 %%%% !1110!\[_'[_4^%?^NVL?\ HO3J
M^;Z^D/C]_J?"O_7;6/\ T7IU?-]?S)XB?\EAFWI@/_59@P"BBBOB@"BBB@ H
MHHH **** "D;[K_[C_\ H!I:1ONO_N/_ .@&E+9^C_(<=UZK\S]!M%_Y VD_
M]@RP_P#26*M.LS1?^0-I/_8,L/\ TEBK3K^RL+_NV'_Z\4?_ $W$04445N 4
M444 %%%% !67KF/[&U8DR@#3-0),-KJ5]-_QYSY\JST:2+5KN3_GG;:7(FHW
M#XAL72Z>%AJ4C=#]#T.#T]3P/KVH _#_ ,(?"O5_#/Q)\"6E[J?B6YDL_$_@
M'4G?3?V8?^"MLNCO#J%UH6MP))XLUW]H;Q#\.]+D6UO8HM8G\80ZEH?A?45O
M['QYIN=(U[2X_P!P!_4]B.Y]?Y]#U'%?B9J-Q\/9OVU/B]#XOOOV:)O$EM\?
M/AN- @^/GQ=\4WGQFMHI/"'PW_LZ+X9^'/#T<WAC0/";:A')_P *Y\'/*MZG
MBE?$&J>*"E]XB:*']LQ_4]/J?\GWH _$'_@I/_RDD_X(4_\ 9UO[4'_K'/Q!
MK]O(_P#5Q_[B_P#H(K\0_P#@I/\ \I)/^"%/_9UO[4'_ *QS\0:_;R/_ %<?
M^XO_ *"* 'T444 %%%% !1110 4444 %%%% !1110 4444 ?._Q^_P!3X5_Z
M[:Q_Z+TZOF^OI#X_?ZGPK_UVUC_T7IU?-]?S)XB?\EAFWI@/_59@P"BBBOB@
M"BBB@ HHHH **** "D;[K_[C_P#H!I:1ONO_ +C_ /H!I2V?H_R''=>J_,_0
M;1?^0-I/_8,L/_26*M.LS1?^0-I/_8,L/_26*M.O[*PO^[8?_KQ1_P#3<1!1
M116X!1110 4444 %(3@$^@)XZ\4M5+Y+B2RNTM)&ANGMKA;>5!"7CG:&189%
M%S'+;EDE*,HGBDA) $L;Q[E(!\<)^U)XDU;XS^._AAX>\(?":SL?AW\0O#?@
M+7;CXC?M#6W@3XAWXUOP_P"%O$9\2^'/A99?#;Q=)J&@WUGXE>T\&/JGBS1+
MSQEJ>BZK$EMH]DMM?S?:5?CH/AUXOB^)6F>(_&/_  O[Q=\1;/Q-H.KW]G=_
ML*?LNZG<>))=%O[&XB23XXZ+X-?P38"YAM8[:W\0?\+.T?4=)C=+NVETRZM%
M^S?KYI5Q>7FF:?=ZAI[Z3?75G;7-YI<ES;7DFFW4\*2SV$MW9M):74EG(S6\
MEQ:22VTSQM)!++$R2, ?B7_P4L$Q_P""D'_!"H0-&LG_  U?^TYAI5=T"?\
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MB@#YW^/W^I\*_P#7;6/_ $7IU?-]?2'Q^_U/A7_KMK'_ *+TZOF^OYD\1/\
MDL,V],!_ZK,& 4445\4 4444 %%%% !1110 4C?=?_<?_P! -+2-]U_]Q_\
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M"3'(%96,;[7"LK%0&4EW_#\/_@E'_P!'F>"__#<?'_\ ^=!1_8&??]"3./\
MPV8W_P"4>?Y]F!^K5%?E+_P_#_X)1_\ 1YG@O_PW'Q__ /G04?\ #\/_ ()1
M_P#1YG@O_P -Q\?_ /YT%']@9]_T),X_\-F-_P#E'G^?9@?JU2-]U_\ <?\
M] -?E-_P_#_X)1_]'F>"_P#PW'Q__P#G04C?\%Q/^"4>UO\ C,SP6<JP&/AO
M\?\ J5('_-(*'P_GUG_PB9QL_P#F68W_ .4>?]68UNO5?F?TP:+_ ,@;2?\
ML&6'_I+%6G7XEZ9_P<,_\$<;;3=/MY?VV_!PE@L;2&0?\*V^/'$D5O&CC_DE
M'9E(YP>.0#P/M[]D'_@HG^QI^WH_C^/]DOXWZ-\8W^%P\,GQX-)\->/?#W_"
M/#QC_;G_  C9G/C;PGX8%W_:G_".:UY?]FF]\C["_P!K^S^;;^=_6F&36'H)
MIIJC2335FFH1333U33T:>PC[6HHHK8 HHHH **** "BBB@ HHHH 0J&QD=#D
M< X.",\@C.">>M)M'^0O_P 33J* &[1_D+_\31M'^0O_ ,33J* &[1_D+_\
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M@_[Y7_XFCRU]!_WRO_Q-/HH ;M'^0O\ \32@8_\ U ?R I:* "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>chart-db872ef72f75548e83c.jpg
<TEXT>
begin 644 chart-db872ef72f75548e83c.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %> 3T# 2(  A$! Q$!_\0
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M;R_$C]IW]GK]IV^@BLM->+3O$'[/>D?!#2-$\-6C2#?+H^OQ_!#29M4NY_\
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M?Z1HGQ)T\>"(E^",VG_$3X;GX>0S?%#4/#YU#QWJQ\*30:;K.G2VLW/^%?\
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M"K3#H7A70A%IUGHMKH_@;1;U=+N[N_N9KU[_ .V:M=+=;X_F#X>_L >-]/\
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M'_T#M$_\'-__ /**MNB@#$\[Q'_T#M$_\'-__P#**CSO$?\ T#M$_P#!S?\
M_P HJVZ* ,3SO$?_ $#M$_\ !S?_ /RBH\[Q'_T#M$_\'-__ /**MNB@#$\[
MQ'_T#M$_\'-__P#**CSO$?\ T#M$_P#!S?\ _P HJVZ* ,3SO$?_ $#M$_\
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MZA_PN/Q[_P!!"Q_\%=K_ (4C?&/Q[M8C4;$$*Q'_ !*[7J%)]/:O,*1ONO\
M[C_^@&L7Q1Q&D_\ A=S;1?\ 0?BNEO\ I[Y(%NMMUT7E_7W]V?HA92O/9VDT
MA!DFMH)7(& 7DB1V( X ))P!TJS5+3?^0=8?]>5K_P"B(ZNU_6%%MT:3;;;I
MP;;W;<4VWYMB*6I?\@Z__P"O*Z_]$25^>:_=3_<3_P! %?H9J7_(.O\ _KRN
MO_1$E?GFOW4_W$_] %?BOB[_ +QD/_7G,O\ TO!#Z/U7Y2%HHHK\=$%%%% !
M1110 4444 %%%% '5>!O^1S\+_\ 8<T__P!'K7W=7PCX&_Y'/PO_ -AS3_\
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M+5U/CC_D<O%/_8=U+_TI>N6K^/\ -O\ D:YG_P!C#&_^I-4 HHHKSP"BBB@
MHHHH **** "D;[K_ .X__H!I:1ONO_N/_P"@&E+9^C_(<=UZK\S]#--_Y!UA
M_P!>5K_Z(CJ[5+3?^0=8?]>5K_Z(CJ[7]F4/X%'_ *]4_P#TB(BEJ7_(.O\
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M+^O(_P >^>_^?ITH _$'_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\
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M_D:YG_V,,;_ZDU0"BBBO/ **** "BBB@ HHHH *1ONO_ +C_ /H!I:1ONO\
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M97OA'QMKVBZ"R)H>JW_DSWD6J1B2X++9Q7,-M=P>##]AO_@L$  /^"Y=R
M!_P[0_93Z#@?\S%0!]=^./\ D<O%/_8=U+_TI>N6KXUOO^":G_!5+4;RZO[S
M_@MM<2W5[/)<W,O_  [6_98'F32L7D? \1X&YB3@<"JO_#L?_@J3_P!)L[C_
M ,5K_LL?_-'7X+CO##B'$XW&8FGB<H5/$8K$5X*>)Q:FH5:TZD5)+ 22DHR]
MY*4DFK*36H'VI17Q7_P['_X*D_\ 2;.X_P#%:_[+'_S1T?\ #L?_ (*D_P#2
M;.X_\5K_ ++'_P T=<G_ !"KB3_H*R;_ ,*L9_\ ._U_IZ!]J5#<VUO>6UQ9
MW<*W%I=P36MU _*36]Q&T,T3_P"S)&[*>XSD<@&OC'_AV/\ \%2?^DV=Q_XK
M7_98_P#FCIK?\$R?^"I*@$_\%LK@@NBG'_!-C]E@'#NJD@_\)$V" V1P>>QJ
MX>%O$].<*E/&933J4Y1G"<,7C8SA.+4HSA*. 4HRC)7C)---)II[*48SC*$X
MQG"2<91DE*,HR5I1E%IJ46FTTTTTVFK'UKX4\,Z=X/T&Q\/Z7YC6MD)29I@G
MVBZGGE>::YN"@"M-(65"1P(XXT& @%9/CSX9?#7XIZ79Z)\4/AUX!^)6BZ??
M_P!JZ?H_Q#\%^&?'&DV&J?9YK/\ M*RTSQ5I6K6-KJ'V2XGM?ML%O'=?9IYK
M?S?)FD1OSQ_9I_8I_P""I_[0/P&^%?QHN/\ @LD_A2?XD>#]-\4S>'(/^"=/
M[+NL0Z.]^9@;&+4I]8L)KQ(A$")Y+2!G+',:XQ7N/_#L?_@J3_TFSN/_ !6O
M^RQ_\T==6,\.N,LQQ^*S3'9IEN)S''8FOC<7C*F-QCKU\5B:DJM>M.<<O7OU
M*DYRERV6MHI1T6.%PN'P.&P^"PE&GA\+A*%+#8:A2CRTZ-"A"-.E2@ND80C&
M*NVW:[;;;?U-X<^'_@+P=8>']*\(>!O!GA/2O"5IJ]AX4TSPQX4\/^'M.\+V
M'B">&ZU^Q\-V.CZ=96N@6>NW-O;W.M6ND16=OJUQ!!-J,=S+#&Z\WXJ^!OP1
M\=K<+XY^#'PB\:K=^(;WQ==CQ?\ ##P)XG^U>+-3T73_  WJ?BFY.N>'[\W'
MB;4O#FD:3X>U'Q!-OUB^T'2M,T6[O9M+TZSM(/GW_AV/_P %2?\ I-G<?^*U
M_P!EC_YHZ/\ AV/_ ,%2?^DV=Q_XK7_98_\ FCKF7A?Q3&7.L=E2F[WFL;CE
M+WFY2]Y8"^LG)O75MMZMFY]0:5\-_AUH.@Q^%M"^'W@31/"\7AU_!\7AK2/!
MOAK3/#T7A&2]O-3D\*1:'9:7!I4?AB34M1U#4I/#R6BZ.^HWUY?-9&[NIYGZ
MNUM+33[*"PL+2UL+"QLX[.QL;&V@L[*RL[6W$%K:6=I;1Q6UK:VT$<<-O;6\
M4<$$*)%%&D:*H^-/^'8__!4G_I-G<?\ BM?]EC_YHZ#_ ,$Q_P#@J201_P /
ML[C!!!_XUK_LL=#P?^9C]*F?A9Q/-/FQF42;;;YL7C7>3WD[X!W;ZO=V7R:>
MJ;Z-?@?N_IO_ "#K#_KRM?\ T1'5VOQ3C_88_P""P$4<<4?_  7+N52)$C1?
M^':'[*9VHBA5&3XBSPH Y]*?_P ,.?\ !8/_ *3F7/\ XK/_ &4__FBK^@*4
M7"G3@[7C"$7;:\8I.WE="/V<U+_D'7__ %Y77_HB2OSS7[J?[B?^@"OFR3]A
MC_@L!+')%)_P7+N625'C=?\ AVA^RF-R.I5AD>(L\J2./6O/Q_P3'_X*D@ ?
M\/L[C   _P"-:_[+'0<#_F8_2OSSCOA+,^)JN63R^K@J:P=/%PJK%U:U-MUY
M89P=/V6'KII*E+FYG&S<;7NVG?2WFG]U_P#,^U**^*_^'8__  5)_P"DV=Q_
MXK7_ &6/_FCH_P"'8_\ P5)_Z39W'_BM?]EC_P":.O@/^(5<2?\ 05DW_A5C
M/_G?Z_T]$?:E%?%?_#L?_@J3_P!)L[C_ ,5K_LL?_-'1_P .Q_\ @J3_ -)L
M[C_Q6O\ LL?_ #1T?\0JXD_Z"LF_\*L9_P#._P!?Z>@?:E%?ES^TM^Q5_P %
M3_V??@/\4OC1;_\ !9)_%<_PY\)WOB:+P[/_ ,$Z?V7=(AU=[26WC%E+J4&L
M7\UFD@G+&:.TG92HQ&V<5[@O_!,G_@J2P)'_  6RN  [J,_\$V/V6"<([*"3
M_P )$N20N3P.>PH_XA5Q)_T%9-_X58S_ .=_K_3T#[6HKXK_ .'8_P#P5)_Z
M39W'_BM?]EC_ .:.C_AV/_P5)_Z39W'_ (K7_98_^:.C_B%7$G_05DW_ (58
MS_YW^O\ 3T#[4HKXK_X=C_\ !4G_ *39W'_BM?\ 98_^:.C_ (=C_P#!4G_I
M-G<?^*U_V6/_ )HZ/^(5<2?]!63?^%6,_P#G?Z_T] ^_O W_ ".?A?\ [#FG
M_P#H]:^[J_!VQ_X)J?\ !5+3KRUU"S_X+;7$5W93QW-M+_P[6_98/ES1-NC?
M!\1X.UAG!XKN?^&'/^"P?_2<RY_\5G_LI_\ S15^F<"\-8_AK!XW#YA4PE2>
M)Q4:\'A*E6I%05&G3:DZM"@U+F@W91:M9WOH@_:FBOFG]E7X7_M$?"3X9W7A
M;]IO]J)_VN/B-+XKUK5[;XIR?!3P%\!6M?#%];Z9%I'A#_A"/AU>7V@3C0Y[
M74;G^WY)AJ6I?VJ8;J-8[&W+?2U?<@%%%% !1110 4444 %%%% !1110 444
M4 %%%!..?\_Y]J "D(!&",C(/XJ0P/X$ U\L:9^V/\$=6^)UM\,;;4O%*2ZC
MX^\0?"/0_'UWX%\5VGPC\0_&#PE'K,GB?X4Z%\4;C2T\(ZEXYT1_#OB#3KG3
M(K];*Y\1Z!KW@_3-2O\ QCH>K:!9][\&/VAOA'^T$OQ"N/A#XL@\::9\,_';
M_#KQ'KNG6=^GA^Y\21^%O#/C!SX8UNYMH=.\7Z$=&\6Z.T'BGPU/J?AJ^NS>
MV>GZK>3:?=^6 =[X"\!^$?AAX.\._#_P'HEMX<\'^$]+@T;P[H5G)=2VNEZ9
M:[O(M()+VXNKIXX][8:>XFD.?F<\8ZZOF7QQ^UC\*_ ^I>(O#T]OX\\3>,=
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MGVBWFB3%/Q.^' T*V\4?\)]X*_X1J\6^>T\0?\)7X?\ [#NDTR<6NHO;ZO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFKVZR:<][&]HMR;A&C'XPG_@FE\6M3T+1/"6L:?\!+:V\"Z9:>#=0\<:??\
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M&RFBTGX:PWESH^C^'GUW7=5U*W:.Q^ZZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@! J@L0H!8@L0 "Q "@L1U(554$Y. !T I:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>chart-dffb73ef4c6252a6985.jpg
<TEXT>
begin 644 chart-dffb73ef4c6252a6985.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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M.B^*+[Q5H-GX=U<7<$EU:G2];NM0ATS41<VT4MQ;FSNIA-#%)+'NCC=AK_\
M"5^&/(T"Z_X2'0_LWBMK=?#%P-7TXP>(GN[5KZU309A<^7K+W-DK7=NFFM=-
M-; W$0>$;Z_F[^ 7PS\.^)?V6OV=)/BMX(N_A5\,O!OC'7;[PKXW^%7["WB#
MQ'X;\=2>-OV?? NFS^+K[X ?%/PI\7S\(=>MO$D^M^ ;7QW<?"[Q'X.^)^I:
M%K^J>'+7PK<_$'3[V[V?B/X&^-WB73=-\8?&OX1Z*/&^H?LD_ S2/V>/A2_[
M(7B#XDZ#XF^('A#7OBY-XG^"QTWP\]U8?LHW?C2:'X1>-M?N=(\4> O%W@T:
MIX9F'Q BT;X!ZUIT !_0U!\0O 5SXIF\#VWC7PC/XSM_-\_PE#XET27Q-#Y%
MLEY-YN@1W[:O'Y-I(EU+OLU\NV=)WVQ,KG=O=:T?3;S3-/U#5-.L;[6KB6TT
M>RO+ZUM;O5;J"W>ZGMM,MIY8YK^X@M8Y+F:"S2:6*!&FD18E+C\<OAEX-F\
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MG\.Z9<>-]6UW1? OAWQ+J%U;>,O%,'B*W\0>+='F^'WP_?P3/=:=-\=OC/\
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M>*_$'CVR^'^D_!W4-%^(NO:__P );?Z3X8UVS\(:K\2]-\>:;_8FK76F>-O
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M3_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]NT_P!5'_NQ_P#LM 'XI>-O^1T\8?\
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M *,TNOFBOI?]DW_DKD7_ &*WB#_T9I=?:>'7_)=<*?\ 8\R[_P!2:9[W"_\
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M7:[X/T[QI"WQ TCP%J?AJR\;2IK*OI^F_05<1X#^&?PY^%FDW>@_#/P'X/\
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MA11176;!1110 4444 %,E=(HY))'2-(T=W>1@D:*BEF9V8A515!9F) 5022
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M2_\ I\OZYBOP8^.][>K\<OC6JWEX%'QA^*0 %Y=  #Q[XA   F        '
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M[[_G]O?_  -NO_CU'V^^_P"?V]_\#;K_ ./4?ZDO_H9+_P (W_\ -(?ZO/\
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M $*7P_\ _ ?Q'_\ +RC_ (;X^*7_ $*7P_\ _ ?Q'_\ +RC_ %3SC_GU0_\
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M L\;02^%=(-J?#ND>$ULDBF@L+?P[X?U236]"TVRL+>>&ST[^Q]7E?4M-O\
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M_P"JC^D7\TK\1?\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]N5(\J/KTB['U3VH
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MOR_/NP^JX7_H&H?^":?_ ,CY+[C^<S_B&6_8O_Z.?_X*4_\ B9OB'_YD*/\
MB&6_8O\ ^CG_ /@I3_XF;XA_^9"OZ,Z*/[-R[_H P/\ X28?_P"5^7Y]V+ZK
MA?\ H&P__@FG_P#(^2^X_G,_XAEOV+_^CG_^"E/_ (F;XA_^9"NM\%?\&ZO[
M-'PVUL>)OAW^VA_P5/\  OB-;.ZTY=>\)_MS>+]!U==/O3";RR&H:=X5@N1:
MW9MX#<0"01S&&(NK>6N/Z!J*J& P-.49T\%A(3BTXSAAJ,9Q:M9QE&"E%JVC
M33^]E1PV'BU*-"C&2=U*-*":?=-133T6W8_%C_ARQH7_ $DX_P""S_\ XL=^
M)W_RCH_X<L:%_P!)./\ @L__ .+'?B=_\HZ_:>BNLV/P4\?_ /!OS\"OBNNE
M)\4?V[?^"LOQ%30GO9-$3QK^WMXX\2+I$FHK;)J#Z:-4\,W(LVODL[1+IH-A
MG6V@$FX1)CS?_B&6_8O_ .CG_P#@I3_XF;XA_P#F0K^C.BN:I@L'6FZE7"86
MK4E;FJ5</1J3E9)*\IP<G9))7>B5EH8SP]"<G*="C.3M>4Z<)2=K)7;BV[))
M+72R['\YG_$,M^Q?_P!'/_\ !2G_ ,3-\0__ #(4?\0RW[%__1S_ /P4I_\
M$S?$/_S(5_1G16?]FY=_T 8'_P ),/\ _*_+\^[)^JX7_H&P_P#X)I__ "/D
MON/YS/\ B&6_8O\ ^CG_ /@I3_XF;XA_^9"D;_@V7_8O"L1^T_\ \%*<@$C_
M (S-\0]A_P!BA7]&E%']FY=_T 8'_P ),/\ _*_+\^[#ZKA?^@;#_P#@FG_\
MCY+[C^3S]G__ (-[_P!E;XG>(?VE-+\1_M-_\%$TMOA-^T?XH^%?A4Z9^U_X
MCLI6\*Z3\.?A1XJLSJSMX:N?MVJ#5/&>LB6]VVY>U%G"8C]G$C_2'_$,M^Q?
M_P!'/_\ !2G_ ,3-\0__ #(5_1'8:1I6ER:C+IFF:?I\NKZA)JVJR6-E;6DF
MIZI-;VMI+J6H/;Q1M>W\MK96=M)>7)EN7M[2VA:4Q6\2IH4?V;EW_0!@O_"3
M#_\ RO\ KYL?U7"_] U#_P $T_\ Y'R7W'\YG_$,M^Q?_P!'/_\ !2G_ ,3-
M\0__ #(4?\0RW[%__1S_ /P4I_\ $S?$/_S(5_1G11_9N7?] &!_\),/_P#*
M_+\^[%]5PO\ T#8?_P $T_\ Y'R7W'\YG_$,M^Q?_P!'/_\ !2G_ ,3-\0__
M #(4C?\ !LK^Q:RLK?M/?\%*&5E*LK?MF>(2K*P(96!\'X*L"00>""0>*_HT
MHH_LW+O^@# _^$F'_P#E?E^?=A]5PO\ T#8?_P $T_\ Y'R7W'XGV7_!$OPM
MIMG::=IW_!2[_@LO8V%A;6]E8V5I_P %%_B7;VMG9VD*6]K:VT$>@K'#;V\$
M<<,,2*$CB1$4!5 K[:_9!_8IL/V07\?O9?M/?MI?M&?\)^/#(D7]KK]I#Q/^
MT GA'_A&?[<V'P$OB.QLO^$5.N?VVW_"2FS\S^V?[+T3S]G]F1;OM:BNQ)))
M)))*R2T22V271(Z-M@HHHI@%%%% !1110 4444 %%%% !1110 4444 %<OXW
M\9^&OASX-\6?$#QGJL.A>#_ WAG7_&/BK6[B.>6WT?PWX8TF\US7=5N(K6*>
MYDAT_2K"[NY4MX99G2$I%&\C*AZBN%^*'PZ\,_%_X:_$+X3^-;::]\&_$_P/
MXM^'GBVRMYOL\][X8\:^']1\,Z_:17!CE$,MQI6J7<44QCD$4C))Y;[=I /E
M7P#^VHNMZM8Z3\2?@=\5_A-=>-/A)KWQU^$>GWEGI7Q#\2_$7X>>&+WP=9>(
MM,@\'_#&[\3^)=&^*N@CXA>!K_4_ABVGZK?-IGBBUN-*UK5KC1O%MIX;]T_9
MS^-UE^T1\&O!GQAT_P )^(O!$'B^/6BWA#Q9+HLWB;P]=:%XJUSPIJ&F:X_A
MW4M9T/\ M&UO]"NOM2:5JVIV,;9C@O[M$$\GQYX!^ ?[4NE?%IM5\<>+O"GB
MO5_@/\!+SX8_LJ_%>?P#8:=\-]3D\=1?#B+Q[XA^.7@/2?C'_P +&USXOR7'
MPTT?3G3P;%X(^%2^$VU+6/#MYIWB'Q;>^%?"GO/[&?P1^,'[/7PI_P"%8?%;
MX@_#7XB0Z-K6O:AX4U?X>_#KQ7\.Y(;/Q5XI\2>,]:M_$%GXF^)7Q&74;F+6
M?$DUMIESIMQI,46F6L27=O=74C3H <#XV_;5\6^"/A_/\3M1_95^-D?@[P=\
M.O$WQ=^,6IZK=>"?"X^'O@+PMXB\8:1J,>EIXHUS2?\ A8'CJ/0O!>J>/I_!
M&@M9S6/@R?1KF]UB'6_$_A/0]?WKC]M30X?B8= B^&_C*X^$,'QIT3]FN_\
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M1VE@ ?? .0",X(!&1@\\\@\@^QZ4M(!@ 9)P.IZGW/N>I]Z6@ HHHH ****
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>chart-e41c9713c67058c3bab.jpg
<TEXT>
begin 644 chart-e41c9713c67058c3bab.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMY[ :E;B6]AE2-4;P#QQ_P $T/AWXHN+N+3?&=[IWA>[\;>'?$,GP[\3>!/
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M;^U!_P"L<_$&OV\C_P!7'_N+_P"@B@#"QXF_OZ'_ -^M3_\ CU&/$W]_0_\
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M** .?QXF_OZ'_P!^M3_^/48\3?W]#_[]:G_\>KH** .?QXF_OZ'_ -^M3_\
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MT_ /_0QV_P#X":C_ /(='_"T_ /_ $,=O_X":C_\AU^$?_#2_P 5;3]M^_\
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M!9=G_P"!+KM;2^O_  ]C]M?^%I^ ?^ACM_\ P$U'_P"0Z/\ A:?@'_H8[?\
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MBBB@ HHHH **** /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\
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M7?Z?\/\ A=:;OXUT#]I'XUW?[35OINI3>.!\$_$/[5OC+X'>%?',/PU\#O\
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M?MY'_JX_]Q?_ $$4 ? /B#_D/Z[_ -AG5/\ TNN*R*U_$'_(?UW_ +#.J?\
MI=<5D5_&^+_WO%?]A%;_ -.2 ****YP"BBB@ HHHH **** "O6_@K_R.R?\
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M_$/_ (*3_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@B@#X!\0?\A_7?\
ML,ZI_P"EUQ616OX@_P"0_KO_ &&=4_\ 2ZXK(K^-\7_O>*_["*W_ *<D 444
M5S@%%%% !1110 4444 %>M_!7_D=D_[!&I_^AV=>25ZW\%?^1V3_ +!&I_\
MH=G7T/"?_)39%_V,\)_Z=B-;2]/U1]>T445_5XCYW^/W^I\*_P#7;6/_ $7I
MU?-]?2'Q^_U/A7_KMK'_ *+TZOF^OYD\1/\ DL,V],!_ZK,& 4445\4 4444
M %%%% !1110 4C?=?_<?_P! -+2-]U_]Q_\ T TI;/T?Y#CNO5?F?H-HO_(&
MTG_L&6'_ *2Q5IUF:+_R!M)_[!EA_P"DL5:=?V5A?]VP_P#UXH_^FXB"BBBM
MP"BBB@ HHHH **** &E$)R44GKDJ,Y]<XS3J** /Q _X*3_\I)/^"%/_ &=;
M^U!_ZQS\0:_;R/\ U<?^XO\ Z"*_$/\ X*3_ /*23_@A3_V=;^U!_P"L<_$&
MOV\C_P!7'_N+_P"@B@#X!\0?\A_7?^PSJG_I=<5D5K^(/^0_KO\ V&=4_P#2
MZXK(K^-\7_O>*_["*W_IR0!1117. 4444 %%%% !1110 5ZW\%?^1V3_ +!&
MI_\ H=G7DE>M_!7_ )'9/^P1J?\ Z'9U]#PG_P E-D7_ &,\)_Z=B-;2]/U1
M]>T445_5XCYW^/W^I\*_]=M8_P#1>G5\WU](?'[_ %/A7_KMK'_HO3J^;Z_F
M3Q$_Y+#-O3 ?^JS!@%%%%?% %%%% !1110 4444 %(WW7_W'_P#0#2TC?=?_
M ''_ /0#2EL_1_D..Z]5^9^@VB_\@;2?^P98?^DL5:=9FB_\@;2?^P98?^DL
M5:=?V5A?]VP__7BC_P"FXB"BBBMP"BBB@ HHHH **** "BBB@#\//^"EC2K_
M ,%(/^"%1AC663_AJ_\ :< 1Y/*7:W['OC]78OLD(V1EGP$)<KL&"P8?M%%>
M^(-D?_$CML;$_P"8TG3 _P"H=_6OQA_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;
MR/\ U<?^XO\ Z"* /S_UTNVMZRTB".0ZMJ1= V\(YO9RR!\+O"ME0^U=P&=H
MS@95:_B#_D/Z[_V&=4_]+KBLBOXWQ?\ O>*_["*W_IR0!1117. 4444 %%%%
M !1110 5ZE\()+J+Q@K6=LEU-_96H@127 M5*EK7<WFF*;!4A0%\OYMW4;3G
MRVO6_@K_ ,CLG_8(U/\ ]#LZ^AX3_P"2FR+_ +&>$_\ 3L1KKZ?JCZ>^V^(/
M^@';?^#J/_Y74?;?$'_0#MO_  =1_P#RNK?HK^KQ'S/\<)]0FB\-?;["*R"R
MZMY1CO5O/,)CL-X(6VM_+V +@G?NW8 &W)^?Z^D/C]_J?"O_ %VUC_T7IU?-
M]?S)XB?\EAFWI@/_ %68, HHHKXH HHHH **** "BBB@ I&^ZW^X_P"6TY/X
M#FEI&^Z_^X__ * :4MGZ/\AK=>J_,^ZM(O->&DZ6(]%MG0:=8A'.L(A9?LL6
M&*G3V*DCDKN;!XR>M;]C-J$WF_;K&*RV[/*\N]6\\S.[?G;;6_E[,+C.[=N/
M3;RS1?\ D#:3_P!@RP_])8JTZ_LK"_[MA_\ KQ2_]-Q$%%%%;@%%%% !1110
M 4444 %%%% 'X@?\%)_^4DG_  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!%?
MB'_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4 ? /B#_D/Z[_V
M&=4_]+KBLBM?Q!_R']=_[#.J?^EUQ617\;XO_>\5_P!A%;_TY( HHHKG ***
M* "BBB@ HHHH *];^"O_ ".R?]@C4_\ T.SKR2O6_@K_ ,CLG_8(U/\ ]#LZ
M^AX3_P"2FR+_ +&>$_\ 3L1K:7I^J/KVBBBOZO$?._Q^_P!3X5_Z[:Q_Z+TZ
MOF^OI#X_?ZGPK_UVUC_T7IU?-]?S)XB?\EAFWI@/_59@P"BBBOB@"BBB@ HH
MHH **** "D;[K_[C_P#H!I:1ONO_ +C_ /H!I2V?H_R''=>J_,_0;1?^0-I/
M_8,L/_26*M.LS1?^0-I/_8,L/_26*M.O[*PO^[8?_KQ1_P#3<1!1116X!111
M0 4444 %%%% !1110!^('_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%
M_P#017\]O_!9SXW?"_\ 9I_;#_X(Q_'[XW^*4\"?"#X:?M1?M%W_ ([\;W6D
M:_K&G>&[+6_V5?&/AS2[B^M?#>E:SJK+>:UJMA80K;:?.YEGWNJ013S1>V1_
M\'#_ /P1N"(#^VYX.&%4'_BVWQX)&  ?^:4]OK^- 'U1X@_Y#^N_]AG5/_2Z
MXK(K\MM7_P""Y?\ P2>N]6U6ZA_;.\&-#<ZG?W$3'X;_ !^!:*:[FDC;CX0L
M/F1E/!(YZGK6=_P_#_X)1_\ 1YG@O_PW'Q__ /G05_)N*R'/98K$N.2YNTZ]
M9IK+<:TTZDFFFJ-FFFFFG9K4#]6J*_*7_A^'_P $H_\ H\SP7_X;CX__ /SH
M*/\ A^'_ ,$H_P#H\SP7_P"&X^/_ /\ .@KG_L#/O^A)G'_ALQO_ ,H\_P ^
MS _5JBORE_X?A_\ !*/_ */,\%_^&X^/_P#\Z"FO_P %QO\ @E!&I=_VS_!$
M:+C<\GP[^/D:+D@ L\GPA5%!) !9@"Q"CD@$_L#/O^A)G'_ALQO_ ,H\_P ^
MS _5RBORE_X?A_\ !*/_ */,\%CZ_#?X_@_B/^%0<4?\/P_^"4?_ $>9X+_\
M-Q\?_P#YT%']@9]_T),X_P##9C?_ )1Y_GV8'ZM45^4O_#\/_@E'_P!'F>"_
M_#<?'_\ ^=!1_P /P_\ @E'_ -'F>"__  W'Q_\ _G04?V!GW_0DSC_PV8W_
M .4>?Y]F!^K5>M_!7_D=D_[!&I_^AV=?B5_P_#_X)1_]'F>"_P#PW'Q__P#G
M05Z%\,O^"\7_  21\.>*$U'5?VT?!L-H-.OH#(/AO\?#^]F:V,:_/\(XU^;R
MV_BSZ ]*][A?)<YH<19+6K91FE&E3S'"SJ5:N7XNG3IPC4BY3G.=&,812U<I
M-):W>C&NOFOU1_1A17XL?\1$'_!&W_H]SP=_X;;X\?\ SJ*/^(B#_@C;_P!'
MN>#O_#;?'C_YU%?TX(_1_P"/W^I\*_\ 7;6/_1>G5\WU\'?%S_@OG_P2'\51
MZ NC_MJ^#9S8RZDUQGX;?'OY1<)9B+[GPDD^\87'..G&:\6_X?A_\$H_^CS/
M!?\ X;CX_P#_ ,Z"OYUX\R?-L5Q5FE?"Y7F.)H5%@>2MA\#BJU*?+E^$A+EJ
M4Z4H2Y9QE&5I.THR3LT[!^K5%?E+_P /P_\ @E'_ -'F>"__  W'Q_\ _G04
M?\/P_P#@E'_T>9X+_P##<?'_ /\ G05\?_8&??\ 0DSC_P -F-_^4>?Y]F!^
MK5%?E+_P_#_X)1_]'F>"_P#PW'Q__P#G04?\/P_^"4?_ $>9X+_\-Q\?_P#Y
MT%']@9]_T),X_P##9C?_ )1Y_GV8'ZM45^4:_P#!<;_@E"V[;^V?X(;8Q1PO
MPZ^/K%' !*.%^$),<@5E8QOM<*RL5 927?\ #\/_ ()1_P#1YG@O_P -Q\?_
M /YT%']@9]_T),X_\-F-_P#E'G^?9@?JU17Y2_\ #\/_ ()1_P#1YG@O_P -
MQ\?_ /YT%'_#\/\ X)1_]'F>"_\ PW'Q_P#_ )T%']@9]_T),X_\-F-_^4>?
MY]F!^K5(WW7_ -Q__0#7Y3?\/P_^"4?_ $>9X+_\-Q\?_P#YT%(W_!<3_@E'
MM;_C,SP6<JP&/AO\?^I4@?\ -(*'P_GUG_PB9QL_^99C?_E'G_5F-;KU7YG]
M,&B_\@;2?^P98?\ I+%6G7XEZ9_P<,_\$<;;3=/MY?VV_!PE@L;2&0?\*V^/
M'$D5O&CC_DE'9E(YP>.0#P/M[]D'_@HG^QI^WH_C^/\ 9+^-^C?&-_A</#)\
M>#2?#7CWP]_PCP\8_P!N?\(V9SXV\)^&!=_VI_PCFM>7_9IO?(^PO]K^S^;;
M^=_6F&36'H)IIJC2335FFH1333U33T:>PC[6HHHK8 HHHH **** "BBB@ HH
MHH 0J&QD=#D< X.",\@C.">>M)M'^0O_ ,33J* &;%]!_P!\K_\ $T>6OH/^
M^5_^)I]% #/+7T'_ 'RO_P 31Y:^@_[Y7_XFGT4 ,\M?0?\ ?*__ !-?+7[:
M7PN\8?&+]FCXH?#CP!IL&J^+?$UAX>@T>PGO]/TJ*XDL/&OA?6;H/?ZC-;65
MN([#3+N8&>9%D:-8D)EDC4_5 (/0@X.#CL?3ZT4 1)$ #D#)>1NBGAI&8<X[
M@CW]>:=Y:^@_[Y7_ .)IV1QR.>G/7Z>M+D9QD9QG'?'KCTH 9Y:^@_[Y7_XF
MCRU]!_WRO_Q-/HH 9Y:^@_[Y7_XFC8HZ #_@*_\ Q-/HH ;M'^0O_P 31M'^
M0O\ \33J* &E >N#]57_ .)I/+7T'_?*_P#Q-/HH 9Y:^@_[Y7_XFCRU]!_W
MRO\ \33Z* &>6OH/^^5_^)I&C4JP &2I ^5.I'^[3R0,9(&>!D]3Z#UI?\_Y
M_,4 ?+G[./PQ\7_#WQ)^U'J/BO3H+&T^)G[3GBKXE>#I(K^POSJ'A'5/AE\(
M?#=GJ$T=I-,^GS2:OX2URW:PO5@O8TM8[B2$0W-N\GU!Y:^@_P"^5_\ B:?D
M9QGGKCOCUI,C&<C'KGC\Z &^6OH/^^5_^)H\M?0?]\K_ /$T^B@!GEKZ#_OE
M?_B:/+7T'_?*_P#Q-/HH ;M'^0O_ ,32@8__ % ?R I:* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KQ_]H7XB:Y\(O@)\;?BOX8T >+/$GPR^$7Q+
M^(7A_P *E9W_ .$FUSP5X*USQ-I/A\);20W#'6;_ $NWTXK#-#,PN2(I8Y2C
MCV"@C((]>* /RL^&'B_]H'P[\2O@=X$TC]HH?'"\_:8_90^(7QFNM;^(GA'P
MIJOA/X>_$#P9>_ <Z/\ $'P?H_PNLOAW?I\&?%\7Q=UG1(_ FI>++MY;S1/!
M_P#PC_C."]E\9:EJGTM^PIXT\?\ Q _9<^&OB3XG^+[WQYX\EG\>:7XA\9:C
MI&BZ#>^([CPQ\4_''A>WU2XT7P[8:9H>EO=:;HEF/L.EV4-I;(%CB\S'G25/
M"O["G[/O@OQ)\8]0\->$]/TCP5\=/"^D^&?'?PITW0?">E>"'322%CN= O-'
M\/:=XY\-6%S#YK3^#-'\8VOP^@U>]U?Q3I?A/3O%6OZ]K.I>K? []FOX&?LU
MZ1K.@? OX:^&_AEHFOWT.IZMI/AB*\MM/NKZ!;A4N1:7-[=PV\C-=W4LOV1(
M%N+BYN+J=9;F:25@#X?_ &A]-_:6^&'P]T"RTK]JSQ_XL^/5SX1\0Z)\"/AI
M\._AM\.(]0^,'QRF\3^*-9T[Q!\5H]>\/>(UD^"/A3P_JW@'POXZN+9OAWX:
M\">%;#Q3XN\0^-;GQ5XC\#C0.=N_CC\;1XPU;XR#XIZI;)X=_P""@O@W]C>3
M]FU=(\*?\(-J7PYU[Q?X+^&NI:NWVKP\GCX_$F6P\5W/[26D^*(O&D6G1>!+
M/2]!ET)_#K:FUY]L_%W]C;]F/X\>-;;XC_%KX-^$/&OCRS\)VW@2W\7:E%J5
MOX@3P99ZS?>(;7PL=3TK4M/N9- @U[4;W68]+E=[1=4G:^\HW*QR)WB_ #X*
M+\3[+XTCX6^!_P#A:^GZ;%I5G\03X=T\^*H+6WTE] MW75FA-P;ZW\/2S^'K
M?5G+:O!X?N+G0H;]-(N)[*0 ]>4Y4$D$D#D=#QU'L>H]J6BB@ HHHH ****
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M&C\+6GB/1+35Y=8C>ZU*R\@74?YO>&?BQ^T9XG_9/_8XU[Q!\0/C)JUCXO\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6592179504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Corporate taxpayers may carryback net operating losses (NOLs) originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, or to our net deferred tax assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2019, the decrease in our effective tax rate was primarily due to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$59.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense recognized in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations and the tax effects of changes in the value of our equity investments where we recognized a gain in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to a loss in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2020 we became aware of a withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions.&#160;We are evaluating whether the&#160;interpretation of this regulation could apply to our facts and circumstances, and, upon conclusion of our analysis, we may establish a reserve related to this matter during the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;If a reserve is required, we do not expect that the exposure will be material to our results of operations, cash flows or financial position.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6916403280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has been set for September 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court and a hearing in both cases has been set for May 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Former Convergence Shareholders</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent), which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA was dismissed in the fourth quarter of 2019. We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#8216;514 Patent expires in February 2028.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial is ongoing in the West Virginia action against Mylan.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we filed an action in the Delaware Court under the Hatch-Waxman Act against Banner Life Sciences LLC (Banner) for infringement of our U.S. Patent No. 7,619,001 (the &#8216;001 patent) expiring on June 20, 2020, and claiming treatment of MS with dimethyl fumarate or methyl hydrogen fumarate or a combination thereof. In April 2020 the U.S. Court of Appeals for the Federal Circuit affirmed the Delaware Court&#8217;s judgment that Banner&#8217;s drug product does not infringe the &#8216;001 patent. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and no hearing date has been set. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing on the merits has been set in this matter.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and a hearing has been set for July 2020 in our appeal in the German action. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ex parte</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#8216;755 Patent, which request was granted in January 2020 and is pending.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Annulment Proceeding in General Court of the European Union relating to TECFIDERA</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#8217;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. No hearing date has been set.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919165648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>210.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>475.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>460.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>172.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>858.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>35
<FILENAME>0000875045-20-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-20-000011-xbrl.zip
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M,&-&8O5X"I)GY=U1]#%?%1D81YAQ@-V4\9>*H)Y/5.WQZ>GID?J:5F6>KJ)
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MJ=]$XZ9FS+H_[JI[;1KWM1?8JN=<<'#\)W6%J*W7_K#O_O#M#('=V!]WU/7
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M>F]=O0=:)W+*1B"(-OU5-G'(_1U(I<1F9+9$5,SQE&^$%:?D11W/"#89V[M
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M(+2#-[&._[AG\ S"M5IX^31;Y2C]VDHC>?AQDQ11-I@(,:< 0N8,PO,,"O<
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M9PFF*,))$&$C:MQ"=C@QQ8\-KC[9>C2 W09);XZAW@=F.[IJC!)"&9O &,?
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M+)12PAUNB>J(V%,%\% K4 NYGV9N,K]>T]L=AYMQI=C<O&A?S>:6RQM=TUL
MW-<03?8L>4<C4%.>KAJ30(B(4S(VB)Q*B8@.]=;JW H<$\='7(A3$,3ORR]6
M63S7 7C3^6*6%J-U@K+KW#0E:JH_-:/#B(W//O"$"TW+'SZ'DE[)*\A>$&ZI
M3IQVR,I1*0CN5*5VW84Y!?#C-L?UGJRK;H6O*U'@PG56VXV"H2/V#Q^P4<8Q
MI6S *9:UMHHAFZT$X@7C-$0AN[RTKE/[Y%217W593M_U^!+'_2[=Q9/V/[Y^
M88@]LT2]>F'Q?Z^)Q;_JEU*<T;,S;OF).RBW3*U-L?+#F-:J#/INQM(0DI4:
MM. &A,XEPXKGP'EF7B:I".WROKK.>5T/6@]+]YS:\M0ZM;=,?9WR%N>Y\:3H
M<P\<,M)NI@>A%<W.0 S,06*:@/"RO,NC*,*=X2Z>_L/=$]P2I[):IW&^G\IM
MXG%OUP:+(?CO6);FT/5YBI5G[J>T7%?-6Z+@^)82^KOTSVE^$PAS(UO0=&B5
M&',+ABI2T41-E;#)@]3*@N4\@K:& 7/,16>38[*#'[$.2 ^%UM9\IJ?&]FJ.
MDYL4+ZWD]X:O&Q,]H5%%<"@O0#*> 7EOP3@O7(S",7;R)=].%@N/E0GNQ/]:
MV/J0/J?)<FMXW<TGC6 29\\M9&H%.+;*6^8"Q$ALR,;:[$_^].R\.@^J*!W,
MG'H6W'Q5<?8Z9>_V^K[W/VVTBDQFQ4$1IT!$W!(T1P)&.+ZJ V7,Z0=X][WF
M/7"IYMJ_R[],IW%5T#C-/H]"FG^<CN,.%&QNU' I;*"! ,O%"!/"ERP0>*(+
M(AB5/ ES\MF"NBW?!BSTQJMZ0G_3<_AK?MR^XKI^[QQO7]&7N6X])P[NM;$I
MNB"91_U0"?#*&^"2>M#(*>Z<L"*<? Q(K[BJR\Q:P/N85DZ?7]($)?*X%*R,
MEZ-)J3^PBE'9G<^_70>-L3D$+CA0U-V )HTBOH0!*!-I8)DZ(OIY0/)4X#08
MWVHA9UTMRHU_F4V75[]-%QNK0Y63O=1C>S?Y)ZK]Z=7TR]:BM =VV7@JJ261
M(8-0=TA"$XA9)^ N))NR3\;Z4W\_TBNZ*G*R%M[N5M(M/MS6V5>V-VPTF@F)
MJE)9A4IP1$O(3C'0S$;B@PFQ2SQYG>"!7K'3.[]V(\2/1A[7O<S]>M7+;W!:
M8US/Z1JM5RL'UA@Q.[]PI>KCAB5OT:HQ0F@N#7)%LA)0:3EP3PQDQ:0GR<9.
M=TSJZ:SW,,PZKL9\^A6KZ^3(J:#Y/H6ZU/]3<[B_FL.54NWTBMQ3YGU%0;F8
M+4/)BCPY?XER_7R';_GAYTT4*/^I="C\#>[P3"FX4LB',UF2US*K5 ?KS3Y)
MD=@'EZJE8YI.IO==KKL-^T?;-*58@=8N(=89@U*\ *(N>:YR9JXP ;7 4W<-
M/96[JSY7H6Z P#ZUE!\K_*N4"LYF CA9"IY1!X1)M$858\P0XU1/3L@A3[1>
M;][[X-%Q D6ZAG@\MKN,BBE01H!SR9"$@-9)4!2DM!8-%F%\[">S^%.!2/\,
MJW9,W0VDZAB[NG=?C>-.^10\A!+$R#,/(*FWH%*,AE":8I>Z&_529_44BU:#
M@97B03^GV7MW_ET\QVV@YS4!78?Y]K#WS:0HA_>D6\4A7Z6%&XV/,?*G@HZA
M!QZMTJ"BXIUN9OH)QUBZ<<5Q[_P\[*@WYN7[M$Y%5W>T[4@:_CCXYTI>IGB&
M^Q>W[V_+2Y]FI5#Z>%DBN@N)\W=HNR_<)&[V!Q_84V."Y085<S0(O0>=A 04
MHQFDHZLT]"R05CI%5;X\F$9Q7H3]N;*YGR;[Z#U!V\5(PT&7#'91)0;*9L.8
M#8ITR2Q9)]!D4!Q,ZW*WEE*V<1Z/<>S;*]!]<;>[QT:C78MF=$9%AED(@6LP
M'.UHQ4P2.D@C78=;WCI^AZ,C<! ^5[0HUTY<-[Y.#;R:QGWM]%O2UNO\B&>S
M6<E]W<+<[-AY8XF10A..N]AZ8 %7RZ7,(#)-%-.>4_$T963?J-E4XK0VZZL8
M']_K5#5TY/N%0X898]/-RL#3VCCDL774._7I;^DKP3;C:2%QB[39WK")S$M#
M%0?K-0'+HP$35]<40D<K<HR\U8W+,+-^L9R/)JO@QDL_FJQ6<^U"QT5;E&>7
MN'+7,48W=V=;6'% ;PV)G!FN#!"-7+'!$B!"E21OQEF'_^=5/Z_G!Y2T?4)@
M>@R65KO&OY^#I,QDYL+BV\7L?EOOD.X:2KBGDB4@+AF(EDI0"?7UH)0W,D>+
MZOJI*Y\# JX23ZN<V=L.&GJ\,^ZQM#,5AJ[B8MM(P,9?/B+*JG@^-Q)40ZN[
M3N[NQM7<RYM&K,/CQP=^;/]5B#_^+O-L*>Q\)_OL.FBV))V8+U910]LBDO?L
MJF':"N)\ !*\@%02V9J42VBV<"(0[P65Q],&MQ>__O:W/3CR6!=-D@IM.^.!
M)VO1S)-H92:K('!O*)$*3[ .,6YU]+YAE__[:.[A.%LM\G\[OT)87BY7%7Q^
MF4WG\]\GL^3&A8$E7&\=Q;,]/UHO_3<V>Y=M\""4R<"]I:A#9P;41*90RZ&:
M=XA#J'1]?%1HUN+[J>.V7+@/B=M[_3>.<><-;G3"15IO>>J, ,5SR5":A.UB
MV-2)GWD2L.W*]F/!]A%&'G2:W^NA$=$:G+.!H*4$GU, 01B!1'4@/(GH>:L+
MG>I\Z/W(V5_LH6QCS'*4>()SX.76$"UI#39RDBQAIM.SM4KI(P<!2FL%:#A6
MG\!6[?UTV5_$)<JRU8F C):AD,T1/-<.@B+91)F$3N+476:GBM"NG#X^0@^"
M7J,R=U(GAS,-!@<5.-V@(SAC&$E24VH[O-X\CK92%U,'L+".U_5QI\_Q$F[_
MC]/G,*?/KVYQ_;?RW*ZD&$C_)[G9K?/T8%?0KHZ;:#0Q4F4P@F8(/!)PG'((
MSD;)T!Q4KL/CI/]V#J(!^'W\H^?^Q,[R(LUP7I\N9M/E^<7KT>?5%.=]@G7G
M&(URS,GR%L,9@K(XRP0B!@J1I>21EYR2#H[-XRA+)X';(5A_<$:+O8ANA<0^
MNFVR5<)**=#"":J\5[60;:EOODKS8+WGA#TUK6H0\!V)V\<7F<?5UD](A>GN
M VO;><.4L9Z:"($8@Q I;],EY^"]#TJC!<!#A[)&QU%E#@5''TI+5^X>?Q>V
M.]GZAFBK<9H4+)7.$_!$!3!,*% 4%4&:<Q2<>IK$R4?G'QFM0S&ZLKJR"W]]
M==U8P4UT 6V/F 00RP4H&>/U06J"H?K)J2T=(7=$WA[;2_1=EH.*04EUPN,V
MC+^;IJ&#!C<04",8[DY:EFH#'?NIP<\YI["XK>V$-'UPB[0I=<V6,[]])XUS
M-GN#$B!)-(M5E"5;-E?@B!$Y)6:-;75]4Y,;]]-XG2U>IQ(<.B[5GY9(V==[
M'^_-IKUZ;R0:D\$$"43@'S10 D[:!#PA9P-:?-QWN/ZJH[X/!9?I*;"[EC[?
M9G:K^F1GD_@6(3#>(-T.Q.ACW3;9,2-#)A $SZ"*W\.1S"!P':TTF>73OYL]
M(7#VR.=30N7UJXY[7[P:8<-2<GCT3>,Y$)V[NF^"UT):S<%R:P M&P/$&P%H
MN0N2O:5$GKR"?T(H'8#?IX16_.7+68JCK:^\]^NHT8HD&B)%9A@"B00!5)=<
M2BDSP8QP-/2367[(,*L3@F GUIX2V'XK54;C$C]#:^<Z)=^K=#5+X5I=F<2[
MB=0[(G+/T1JAB/?*E:1NN((ZXQX.*9>Y.I>\TB'8#HD3ZR2U/R'4#L_^4X+V
MNGC$J/SX+N\LKW!@CTV65@4534E9*4&L"N/@CQ"\HKC[I<Q=SO8Z>?A/"*+]
ML/A@3_$MB1N)^^7-VT]O%AO#3?=HW=CL#',>E9(8&%IWQ""\5;KV2:H@C.N0
MH;%.9OZ!(3,L.T])2FV2R>\6%VDVP%&[ZK=1G":'&PJRE@:TLP(2"O25PR%3
M&Y7O<L-E?@3X'8O1IP3,U1R^)4;J>G9^WUT3J'(D>8ZK$1VHY A8FC1PAB)9
MLZQI[O#0L$XR_A."80_\K7+S]? FHLJUTYUAZUSLW"\WA9IU*>7Y930>?)Z/
M#GSLBY_7HPGNIK<(X_@]E;^E;0$>VQLVR6@?E>-%G</]9%#69D$=^, ,33)*
MV^X\&V;6;Y"[^?$)W%;<_!X>&S/[[==5$SP/5MD$*>0(T2@&!B4/<!N00<XJ
MT<7K4^?JIL_%?Y"N;W!^5DLM]?@T[CR^:NG)V;^S1DDJ2/ 2*',EQH/C8:,3
M*R7UH@O)Q2PZO&>JE#5@0*A58>D)@&WUO.\P:*V:-HE2Y'/QU6<6(3@>P-E4
M8MHI118+R;J\'ZAS57(<'!W*OWI);Q^P8K_#;W?SQAAC%5$>C,D.6"SU8[*W
MP+CQ(<1LI=6]''A#BJ'^9_HC"Z.-VZ +L#9WT#C.@J,2=ZW3&@+U ;(D"H+V
MBFK<58JU>L9XW&IA R-K,%Y6,DUWV4X#ITW<0D =H_5SFI2(I$K#'&Z0/N*]
MO^UYDA9AE<*SY/>>3"?7?WG,;[^K72,EX9+AJ4HD C9SW Z:9W7M8O9..'W$
M0AJWY']P7WY%T3T;N7'9V^]R*7D[^[PU_&IWX\91P9)7'%PV$02C#!1G%*(.
MQ 6F422<[%OD =;W@<P;@('U3L]KXO\YG?WKMA3RWMAYO'63A65$&PE1!0*.
M40V)E.)^B:0L&=K,O,/KKV'/S8K@Z96#U=%3-,KY15J=5ONCY_'6#8LI,6T8
M&*XL2,4E".$S2!I),LZ13$\VJUM%]/3*P4JZUC7IM12;ZVN1-Y-_.)30JX+9
MZWI_/T\6]YX&'Y&$*EF)W^)0Y_=<@$./4V5:J_NODD=[.A[%8K_>ONE9!347
MSJ_I.!$RCGT;LZZN\NU)W>O/OXUN"L-ON^K=TJS)G!%E.(>(1Q)0K01P)0-0
MM">ITHS9U$I:UYOQASN9\@Z8^??-FRQ-B+%X]'))X&H"4B$3 :VTP[]Y:^7)
MYW7N;XF_O\8>AH/5@B8VD'\_U^(!"'K802,LI<*AON>BB("Z 05DB026E6'<
M91+4Z;]IJ8FA7GA8"T6_32?3=51(*3E<@A*N8X:V .?1-@TS.6GM$B3*&"3!
M#!J5U*"AF1E.74@?6IGFP]D':Z5G376+>M>/-6DBS=R9R,IUAH>8G8-HHH%D
M'?,FB)"Z7 S5D:P]K>,&*Z GEE5TVJ\5WYW0_^[+AJIDLW(*I&0"G/84=-(!
M;::4K%:4I-"A8%:MZN8#X: KJVHM_\VA_PVY17#/B^3>ZC'8VJY1)E+C P==
M\N8SGG*!.X$DHR@%P33E'<[-.E?'PR"C;[Y5"S2X7XWKT\Q-YBZL@K^O#_HV
M&:#WZ*6Q*F3%% 5)C 4:,X?L<X!@@K'4*-WIL;MXPA@:EHNU$+4RSP]1P;8W
M;+3CSFI.@)4,>-*2!")I!<JEDG]/,]FE^D2=AVK#X*9WQE5Q3[9VX]1P7[8F
MIDXH]8J<#^ESFBPKN2S?SPIZ%E_?C]UD<3:)Q0B\NC/M(XW^Z#\,2\^'%,9N
M/A_E45A'_B\7[_*=P)UKN%Q>S=(%[K';9P-%1E=AV,W= QX9I4KF=#E9A3*<
MC<?3+XC;6] ,'$W1EHR!<TO=[)077Q$OY9U0I36XMS^K"(:;,5_CT7(V68Q>
M1D8^(1;=55HN1@&G?SYSET=/0'5#YE9#8_U)(YATT7$+F5JTH9BV(+0+$".Q
M(1MKLV]5GJ9E ,NJMOJ[_'**O+J<EC7 '_+F3!#;&S0^^V"]\2 "T>"L5R"(
M,[?9><N#VE/WEQRV#-.!^%-%\;B9\O<@'7;'UM!B5DOQPLU3?.^^5BC[^G"\
M8PN><O*$<D)_(ZT<TWA&KR9XK1*OKN]WU#3:JZ.&,B(DBVC66T(0Y5E"LC:
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M[[/)NGA2@*IOBI\:1V*0(P("JR#F&"N+/32E+BA'S1,;>\M+&S_C.P;]&C^
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M/1UO$2SWVTW .1KLF_O2]__ZL8E?T>_()]KE:Q+)"--A3D.(2 &"<0@I5=Q
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MURL3+8 )DP"WG&JK@SOKO"@1!E3#<9ZU[) YA[@X#J#_IG3W2%^&RB<J0/U
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M%I/:5*C1/-% *DLIHM0;($FPM7VUQ8,D:>X7]E::N"=B= _6<)OD>PX(_A[
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M?-#]#1(:%CRC#>,*!6N*(495M?4'F&Y>O.#\"VZOW0/M!.'+\:=N2MQW31(
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M8,@:\&<EI5R*H\]/XHU&-8,="-T[X%J;\Z>:)@@R1HB6*)X#<Q @)W4I,6'
MC#N%9!1<J,7/UI#_%<@VRI2/'Y)C';GM'P**_QZ\J&SZ+ORWF$W"W]ZO\LF?
M?P05G4CHJ-,V(=0+J3SSQ#CAO(: 5O84"0O'^+;:NU--WB]8C97^*BW^S%9U
MU;S_Z00280@P#& N,99&<(HJYALSPO*__2BV$W@:JS),4C=Y<;\)+55#>)^M
M5O-X[G?SH^/:K=U!$JNF8V\<]QCB>!*8.%A*%'[8O)I?;SN\_2B\+\0:<T"G
MR]E$+:8VBII-GZ]?ZN/R4*VC<YHG2E!DD=<4(8LY881*4TIC.&Y^]=' ,_D
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M=PS44%;4TX&:=)7=YL7LOS:K[\E-OM.-$RK"@DT$QB#(SS&UUKI2:L85&'=
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M]ZM@ \1W/H[.!4M33:<;U:5S.UO&L:^+;*F_A7]\RI?I_/<B7W]:AB[FZVD
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MJQI#-G$:A@U]@306$=P_-^EN4NI2MC61_:^O\W)S4XL(4BIL_RMK8(0>^::
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M19((IH1EE;[J4/O-<^ &$P-P_]U)8[P,W'86T0'SL<MK \;8>4.(@="FNB[
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M<L H4H8 *JI:D*GDR'1,M9XDE(\$U50#3Q+&CT(3RS0'\:M &O&JRJ.!NKW
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MV!COO62XBD<9I-]/*&0DD>5]0]I:_.?Q4_E+MEIGEV=9JDMUD1SE#<G09&P
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MN587%PG2B/?W?#&_F$]B"O6Q^S%GTNRI!M#MF)?^\3,2^?_\K_\/4$L#!!0
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M*^5S65U7ZTJIH;VQ:?N03**TSNL/-\]RRN-SXW[HVH%C&A[")*F8ONF/QJ/
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M)Q=$?$RKILBJ#;1-%" [,L/8CT*([-@8KH6 9"@5,Z_IZ#&O6:EZT.U:\/T
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M\P-Z>P5.!YH46C^DO )Q=MT,3[R2B)"_.83D#0G)&QJ2*_ Q;;>1_MXYL]P
ME(EKMD&HVK"M0USUN7=Y,*J#1P%)'NP1."BM[Y)]^8UNKLBZEMNC@*81A#!V
M70,'%BD[$]\9"\\DP4QWHNJRO:0@;PEJ<$-@@SN*FW.Q4GD4N"5X]@"(3_(]
MT5Z"]PI0Q(!";C>=K4AL65AETUJE\5F=U*KU[K+2:F!1\4K*<9O;OQZ(V-P\
MTKUM=0L2?Z>+H-ENK-7'5=&/]%G!LH!-4^77AX96'E_*]R0*9=&0B!!4M^U;
M8"2Q]#X&"">69_JQY7F&&5F>;\>CCVZ(-2S5K,0SS4GBEQ>9@1XBRL>DWJ4'
M+8L_*R%8[>K22IQ:R?(5'6N,&ZZ/A("T'C+?0,IQ9N9TVTY/##AE!C0E>,H-
M&,A9/H$NWS3DU^-6UH17E_S_3-R)K2BNS0O1PB7.;O(BVT5907[1?"0Z5L/=
M?QRZS#8,4['K.+&7!-A$AHF#.''"<=W4B)A>&=9D6OOX\.904.FMV^>=Z442
M#V7=5%F35^U*#KCNT(,'"E^X!E 2!>XD/7< Q+-HCQ3T4$&+%1S!OLA^:QDM
M,E#,EHU4QFIUZ4*I<Y?U7#V' H+[I2)F]^TFUQ?& ]^U4&2XH6$A%#LN0NYQ
MPY^!N99E%9G4++#= ];;1] <,8)T!"FNJ%(T<ROI7 R+*VA25EE^6X"1\#^!
M>$ZPRB::*L*R.K%4XM1ED53'F>)IM'=$N]\VV7V]@08. L<V$C\)(32Q@2SK
M""/0L2F9W?BZ-B93W* %KF=W,D=0E,XAZ8F'QFD>ME L.?<R4BH_/<(?G=6I
MK&+WQ"891'E4K+SM'7I?TN^;Q#>]P($^='T<A7Z"$A./LQ'(AYN'K,K+W><F
MK1JE\LN,@*>W/P<KU/'+MN-OGW3\O._X^VY^M^ANH&S2[^ ZN\T+^I(-N$[)
M)[=Z5@W8XZ54D[4$2>O,>W\W*,&\2D4>")479.[0_*GTF-\[,3D69%&7&MO0
M)O6XZZ'8=!+#1_;P7 ]!$4;(T% &,]O67 5'G7I>@7])BP-]'M2\ J2O!?]?
MZ<:L]/\YNS&S=Y+=F(]%UFX\93K*;LHJ^Y1M]VE=MP]LMH?=1T0!#D(_]LD8
M.W0BW[ P2HQQ]A'RG<O0B4-S]_[P>E%UW7H JN<NG)9;?,65UKBQ%5IK"1E?
MT<50:/71>H%^N1),@NH)'9\C@.O0]%D\+>?O'GQ:_]Q>0GABR$+=)'SSL1V
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M'8!=)-QL!TA5,GVF1E@NFBLX8+J,W^72_8AOC,DP:7FR@_E]V4R^:%!O_#A
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M0Y_2'(]RGQP+K1?;H33%TL0:O1)RU[$TK\:54D/CDWD_NNW&I+#R AM"NNX
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M?NJ@*DJ7%M- #9N*8G4Q&U#-+6,C5,GHF0FF%R9L1ERZIG#F^ )+'6[V@G<
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MH3GD"PR.+< 8C\(R%-""7U*M(_69DR[IOJ_+G5C6SJO#9V[\/(OQ>*5HE>+
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MG(MM-V,KU!'._"C!S*4LHD$:AX&/A@G?T 6VGC)DU+H:7> $;GHQ1:N<0LW
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MXU2IW4XX9TWLYX'YK&E]8-9*4H?'[5=/Z0H>&TOHJFR;W6R2^#CWJ1=QLT'
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MC;)D>+,BA*5[4Y@T.L_FBQNG1^O\I<?[5Z=!#&B@8)3\\=)\5MZU]FLLF')
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M65W4'XOLAOZD>?HU*\J/5/HO2P:?F46R';OCH5[%,/%=0F+'3V&*/#MP''?
M3U( A>JBC$&M>9TCJ<J&XF#[V=2.NJ!/?VN(58R;EPNG54LQ?RH_,\[[9FB7
M@;R\S!C-0ZAJMDQSJY47H21*'2_&D8^2. Q#=]SR"AT;B]QP.G,H(5V2NI%4
MV229B[G94V35I*F=()_B<^GI,<4B-SD6H=@0Q51D#/_$6)PCV5*B=@K^.HU,
MH>=BZ$/L0H!##]#9^3@X]GRQRDPU0VK.H;XR>7N]='YAW9U<E=)*LEP%T0+\
MSJX=:C$:,>7EX4Z@6&@F^68(GFJCWBD04L*9@N0,KM?[A_V6E<? AVK7%/_L
M=@JI_'HI=J+(B0 .G"AV[7@$@GTPW),[.V63!<#UZCZ_*%=,'"? K"DR9=F=
M-/6S,SZMG&O) H6=L71J>(12N71QKG_,4%2=!O*GE6JX5%FUODI=@% $B!][
MJ4>5'MOP4# ?!T!D,JQD0,U3XE<5ZA=6*;[?HH)8N>12.Z>S4\MC9>GFU:+/
MK$'GIMT,"51KDD3-N2!?*A+*B<B2[X^LH\:7G+6.HU2SJ]7J=;;]CSS;K4+H
M1;[M03N-81*Y@8.#\3"F!T.AZ?82>#3/Q1FV]@[IVWVSWU&EG."V\@[XA<7>
M/.NG76L >],;^O[FUD-5-O?JRMD5^G!^JGH.]RG.7:>>)(,G1RNZ"RF9'18S
MQ)R,EI-YR117M5_-$/Q%+19(@O6PK2=<?,J_-U__RK??\M]:75O%+D@\/W"@
MD[""3H>&L7%1Q"8NUXV8"T$Q)$BXMLY8(.X@'6% JV^6B #, *NSP.I,,%G[
M7]*M3/:E_?@C*KZ\L;/$?B;'>G2>!9RO?U4K%-M>2+P8XX 0 B,/QN-*C!,
M=77T,S!HKT3E5G9'I[)SNT2'H.OPQ1(ZSG!3':],5N^>6V6B+>JK'U&KA6V<
M)=%RC&I49K:RL J"Q'4 1M!U(P]X""316%J+'3?5EWKS8S EYW:U*S.?2[1I
MLW)O+*?.#+KQ^LQ JE5H(8_]L!HM9N5\E99@59].I_1U6=&D/2$1B@(O"9P@
MBDB"O %, ()$=PK-!<*<'-K3K=1\3M$EU,J]L9A.,^2FRS3#J%2EA=SUHXJT
MF)&S-5J"4XT237]W!8+03Z&-8^"E/L%AE(;)N!$+ E=O)LT%P91$VM<NSUP.
MT2;/JGVQG#S3OS%>GNGOJI5G$7?]L/(L9.1\>1;GE%>>K]?W^6:_S3_?HGU=
ME'E=MY<^U06#4*.GR5>'(Z3)] 3I5W;6;A4 'R(_(<!+O  Y;N)[_4YHX$91
M)*372V'2+."#&:QB83#$FEK"+G">?'UA30[I/C/'^J,U2/#:@\5<RZ?\)GI5
M+!0LZ% MT4&1!TZ$BZ5];$;\6-SJZKQOEEB$>0/3$10?QYLG0I)&L6-[<9 &
ML8WM&.%D0)(0F^N6+YWC:XX<;XG+*3'Y*'LSCA;?\(6#<[M%3/IU>$2+QDO0
M>D+/=3K)#.W6:F&UW",OI\E)]7!3E-E))'V+C)4#$C=T(4F2Q >(D!AY8$ "
MH0M6C_FNJ#;73;9KQ)19)0H1"7@)F']-("MVUC?6?N3"NLGOBK(M+J=98?>)
MYWGC!5CD>.-U^,2L-UZ+A4?>>'ULGJD]UW7>--OV0^I58/N$N"!U \_V7"_U
MO) ,@(/0)X)GG\\'E$L[YIR1OLJ>'O@ORS: $=Y%7<-])K?PRT3^;YW(3^RR
M_J*&65/+K,XTZ[EM[,A*;YW5FG=AC09>6!,3?^BV:Q,[3JTBG__Y,"/VF$"$
MWDYJ\K[1F;NB-,"^'X9N$#@0$=\A! ](8NQ'?>Y*2LX@I0.#>.8ZP)7*6_-R
M\W]OQLKK"S-40ZN%"C)6,3;%=Z8^56R\; L?JCW5E<^WGZD:-5G)3FYC^OQ^
MHWB^Y5=5O^#9+F9^S;\WB)+XYRJ!=H0<+TV3P$4D=-RXKQ .4 C32+!I]U*H
MM%=_I=4N+^Y*BZEX7JZ?K-MJ]U>VV[#VL.V]:[75W&<TW<EW.16+AOY/>VU(
M9='_4 [N<O87^3JK68W"+O^6EWO.2UL6][#H!I4YKI7?H!ILL'HCV/<F9E@'
M.ZS1D'Y;RF*V6*TQ9]NAFN4"KAVJ99QL1@19W.JC.U1+LBX>:0X(+LNZV;4W
M+=6'YL#7#9WS=_?\IC0XTF0XVU[E.ZJ##_2+"4X' Q 0VT=I&J0HH9$Q<@:<
M*;"E8\Y2^+1'G^O]PT.V>V*BU-S3^')[FZ_;F[9I/+FW;K?57]9FM+6F_ZYI
MK&K;F65U&WV8A!4'#JRJ;#^(O@\;5C73AK&ZVA:;]H_J@9A6!HMR73U(QZK%
MGA'1J&7BPR$6OR8Q:6+"A<6,L'YB9OQL4(A2Q#=7L%K:MZ:%K<7M/QK SN,)
MB4E3WER65#L;!N;?6+Y.T4VZ^WVF<KFCL[S'77Y/%;.UA\DB,^-%U$T3!]A>
MA-P$4B\B+XV@.T -(<)RM7T+ M1=Z'<LF!T/867>T# T6'\LHM$!C\2Q^6%L
MR>=#>/YEYJ,Q8S)&W7VPR.I,H@Y\UJBUM<IZ9I;5V65>[%/G(;ZYVO(/A&D1
M\!P4')_%G<L?BJ9T1^)T/^L<MT0.*!%) 4E3B+PX]G"(8]\' \HX2F.E$SKE
MZ):<SMV.>PSM38'T":B'ZXI?A$2E$S#U'E4R_3JK*^7CU=L3,1:PKJ<9R&C0
MN(1X81VVS0T*5TI\(S]1T_84F!:D%K9>;)*FV0O\/<^_4035[@D7]7I;L3WW
MPY!18B,?ARF"='*(?1>@..BVTE+B^C 5O6%VQE#:@\:(3K2U^1S^^%1],>+$
M)'J$91UP494]E[Z>8NF$6"HAUPSE4V/*JT;EROCA3I<;^MGWU9;259-_[(OF
MZ5/5Y&^-#Q("XH2$Q ,1  E*P)"NTR]Q' FM!2D;5?,"3P=.,%]51REG)GH6
M-@5SS G&?[$ZE&RG.C=#T+@I/)4**G>#&5*GP:Z7Z9LFYMX3P9NBN%GU,]CJ
M%JYIVDC'_I*W*QE-1=S0CNE4%L%/KF\[2;6E?U1-SDU.$D8["( 7QA"&KA.X
M4>+9_9J^DR8NY+JC83DTRZV*#U98O1FLA*@WH%TD(-N\O,G7.5O>MIZ9Q*>Y
M"WKPM!:;Z3Q!C3[MM]:&UFN#!Y^9(3+I/Y</-]6ZG1&V?_R#^?(9=FZ?OG8*
M*]ZSE+B:.T8S0C^P9ONVU\==912_$8^7=]]YX_09[*W.]:(HB>MPLU]GY?XA
MNSD%R<>)ASPO=$#DQ2GV/1BD Z0T#+DZ^BX"Y+S1_&"#AOBMR%.S0O?R3E(:
MM8_Y1U>X5N0R)9%Z>=<M&:3?\:R^Z,Q%JWA@5NLMHV.R8E/YPK$.?L5WY<?=
MEK[O7;D9CA,5>=V?1-Q\?G'(\ 5&$GAI"$+LN:D31L1'+NA;2@/'B4/!BU"6
MQ;;DCGQWB6R;QV\/AEB[?,T>_(U%Y]R'37O93?E%'"JZ)6^:)^4WY*>'T>'!
MGQ-SAC/J&U8X^.+HN4$[\0I<PK4/OZ3K#5F@/8_M1_?@E_> >!A*LMWNB8[=
MXF002=T4#RQ0CNAK5DUPTTSJ"%Y@#+'O.(C"#&B\M''B( <-&!,,?-DPM 2V
MQ0O#F&BM>\/Z*K&V*.RFF=8^RP:A1=PI&H1,\Z-\$!HLZ0)1%X%&8R8AJNY*
MR&Z:9\5CYL0@!1[ABD%+>MZT&+2H[4=CT/(>$.['Q1$47[5B>=Z)Y0#5A9$#
M "!1$ 6^:Z/8[O=%&=3(!H+WVIP#HO:(=.B!TAXW/73P7#_KX%G=;(N[]I^R
MW;H6=2Q?4#+>HV*Q:3HIXIP)7;S1N>M%XZZS!RH=7CH1K\[Z4)@1MLY+P;&&
M7.?S!V\08\=YQNY ZZ?+LCWFRD:&-]6^^4BQ=QKZ6]:P/2=X4[>M95:)&U$,
M(? \!' ,H.NB+J;Z*4CLD#?)UC:^/LUBD*T)Y@MK@MK*&&SK@-OJ@5M_#- 7
MUB)9AD_HC7:GF:$I^LVL%GX9!+4AO\NVPU#EYH",RMFDH4L*$$[C$ =^@D/H
M^3X<Q\81AF(9JYHQM:>@!U>(I9:**.74UL6Y%!12AF_41[84\0SB&:N(N9@[
M)9!*F3=$#=7:]%+Z-##&55V$"ZJAQ<V>4ONYS'_+'V[RW2I._2#Q4@\$46P3
M)XV C88C&CB(^:N I3Y=<QW0!)-%00D4B\AQQ5&THYTF,6%ZP9#U1X=(I*Y&
MCBJ!8AGME,E5P$RIJ\K\EYFU*V]9>:P@918C!E29S,-?J7HVY+3SZU]5/XX3
M01O$OH,)\MPPM!/HC>,X+K)EM)/_TQ?43@I*3A $N!+33CTTR6LGQ3-3.P6H
MDM-./93-U\[FKTJA=HY6<FBG."-F::<$_B/:*<L$EW:BHOK6[E1\Z\>(PB2U
M'=OUO03%4>*YL>T/8\2>@&X*?[)FS3S@$=  <7HXI%(K,V(R>8 BHY#B[ BH
MHU:6Y)11A"T^<7QIY#%AE";# %&4QUZI>!S$%AN_=.WGZQ5 01(YL0/<V,..
MYZ;8ML<\U4_<59ES7D['_9%<#_!X:Y3@37-=3\ !R[+K6,.H)Y:JA$DR8S5*
M''8U\^$0B.VD;(KFZ>_%)K_*Z4-!U>XN_WS;CYA26W[+_K/:33*-FC4%<?P0
M^$%LQQZ!46C'<$"18AQS1W\-8VO.#PXX63E'?PU%;3&?6P\,K+69H!6(DCK<
MP)%EG-D#8GE(!]9B:*V)(S[?#HIE,<16"]G"YOA!()\YLS_D,I[>+W\QOSR^
M]8(<>S_FSAK%V3J6.FGDW8#D2J=UU3)/KVB#J;'S7M<)MMVF>=4?=MR3]@$-
MIHD3(B?U0\^S_79/.@E\Z"1!&GC</9'4#JM/2I_UU7RS!_2Y2D $.3R1+>KR
MAAE)I3;K7K5)TLDB[PM]JL/SIYQB^YI]OZIV;?E)TZE+6U9=764[BGU$A\,@
M]&#BQ;$30C?U@CCP>G28V(DG5@"R%"KM)2+=O&_]3 >Z?O__*E8SLIB?^ 39
M1 >)"?6[7?HOVF[_5,6I*1=6;XPUM88=V^_L.9NH*_+#";%?VM-F!('%K:[.
M^WZI"QKP6U9L&9:TVEUGV_R:%3JWQ<]P\Y_[[J:!P8(5AC@-D)W&"*8!@3YH
MMZ,[>&D<8W510RDL[6'C]W*79]OBG_G&NLN*LK9^VE(;\OIG=A2B'J%;V6!5
MVV&DIG9=M%?2L!MLLN_J(HQ:I\X/,6?SIO(8<T!^88U6?:#>_-!Y\V#/A97=
M-O3COIYP[.(Q1L01DD%&BZ_-CS)ZS!8(,QIY5Q%G#E<#U/][3[7REIT/A75W
MB<V(*\40^2$.$ HB''N M1\8<"$2 Y$VU_K1:%YC/QE5#A=VMI="UWH"B2*O
MS8\@RSM,>>B8F& =;&"WTOU;[\'#!,:<B,%%O&2H4.M4\V.$8GL%@H,.IE5$
MA2OV#3HG*KNKRZXJ.@_*FV+7+K2AO,QOB^:*OFAOQ;# =I#M8YPD3A3%,0#
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ML]6#9E=EBO9K5N\+CJAS5C>(19\?T0,"\>BLGI"+2ZH]PA>A1(DZ%JFT$6Y
MQ-)G6[7$(RMV (I=9/RY3-A%K]FZ^9KO'HJR>^&B-$@3Q_?=-*"/$4X]&(;#
M> 2Z2.0TD_PHFB,3 V95)7W-ZIQ2=M^>7'G^%G:8:ZOI40^WMPD(I *R3X>C
M97D6"ST#Q0,J:P)KV2,_1]EY0^74,6K&81P%=E2JGS75E4Y?^I<8'][?+_G=
M?LN(?Z(O=E(]/%#5+;+M;\4VKYNJS/L[Q.H5<@&$R,=IX+J>3?\1)D,3[2 E
MR%5;#:43J3$54X.1%];$3/;MP=#N-N'15&NT=;@%4:1OZMEY5U9^9<K#(2;S
M__]S<>RY4%WO9<KSH;LF3.=SHK!X;(8[9A68+?$8&# ;,X<+X4*UY3RD+H?J
M 5SG;#V5_J"Z_9KM[G***$$I]J!#8@?'.  4!!AN:@H23Z!SNV8<QN0_O0D7
MUF@$6^GIS5 =P6;X357>LHS+=&4E/XJW5&<3RWA-=ZX@YSV%6<!1&F?%^/G.
M^5$BN )+A>.S*G:51U^XOB]HSL#^6=VFQ:YN#JG"=;;-QW2A7GG0\V+LH1 C
M%X8^C"&&8YY GV4M45DA/O.B]<0XIB&M>=-9!C/P,-70%1I4/@** _R9O*\]
M\/_7<[RF7.%,#\!B.82J!T%]>L'/O(JT0X.??[!T1 <#LFF*-F_H35^N'_-U
M<5NL&<0:L0-[$Z 1=H&+?"=)_< -8\^.8[\'&CHD3/1G+[/@&9^\#-:UDE5;
MK7T+A[!Y_M>9NBSF^J4SEQ_>ZTOD+8MY_UQIB^Q3H#EK.<6[\J1%B9-_Y)Q%
M#0%*4A:%ON M;KL>ZL _TX2IS$J6*EU5==%BO:G;PI65&WBVBQ,_2(&-W#0D
M=@Q@!)P@2MS$A@YGZ962L?1%E1%>-Z/I 5H#0NN/ >/";9AY:#M1GJ64=3,J
MM=2:5&E\2L5>1EC7>5./@R0PCD@88QA E(3(8PV4AT'HJ,'J6[Z[J7@+3 4_
M7.0]F^+@?MW@]37Y>BU6'2I*$)\N:61&3($Z(&<3FN<\G) 42<+,$ ]9\)62
MAT9&$!)V"IBF"L-8-ATFBH/$CD*$211%3I0.8WENA&1T070,[?+0 [*R%MZ_
MRNB$,&\B<J&3,!G5N+ &QLXK'R]X>5=%9'DT24RD;7A34^8QPGVM3U;?L_\G
M_]@7W^A\HVSJ+W2JL2O8&5'V UANGG]C\ILKD-II#$"$@>\0$H$8((^"I$)'
MIR1QZ(M)D%XL^J6* FH++=?L'_D!VL+7M<QA\<1[NHQWS'B?%[+UY0TL"S+,
MG7I\RPKZ]39/JQU;C[C.U_L=G03E-<YOFL-7O5JM,((P1G;JQC8FR/6(']J#
M2N$P%KK92_78FC<A?LMV?^8-PVO5(S;!A$4UVYRIS!F)%DMR&![K .C"&J%_
MN*UV'VH*?LR %DY[Q#@\E1!I\H89TJK-NI=)E%86N>5SO6;W>E =7^=4J2F<
M3WDS#.D3XB&0(B\ OA\'T";AN'J$$BPZ@9LSE/YEGAZ=M1OA75AE?OPEU4 G
MIQ@NQ:/@]&X@\,N$P.R6QBD+;K?57QE]^RRJ@5:RRS=%8[%#I^>2PA,,GM(]
M%<0;(G)*3'FI:.KXX2IDP?N<69:539%@UV874V:/^;XIUH^[ZFZ7/=0K&+HH
MB%#D(XR1"V*8HG&YR\=QR*=@JD;3+F(4H\5 6@SE!P;3FN"T!J "90,J.#XM
M:^<@5S"G,Y)5@<J*A=F5*Y,XJ 8/V6TDH1]EU:QA/-L)99U#'W?YAR;[;JVK
M#_07'ZIV/Y3^Z[:@<>DN+^GGL*8?[>>S/W[V>]GDEEOVZ75;;$$_^<OEU]__
M'7Z:VW3Z?2\<*YI0Z#\#*B!46E/I><K%<NC+\ALKB]@]T7"WPK[K!IYK!S!)
M8P=!SXO&--WU[4@L9Q;Z:.WA940CEA2+\<.7!&LC1BPTC# NK$\GY@I:LM@I
M!2>R5BFFS,A2Y:!7"IX4,0%H[T1_MBFR<K!G1S!,TRA,(IP &X=H3'<)$9PZ
M2PR@70RZB^#7S[8_Q71!AC8^==#,EYA&=$2]V/U<5BI>\W%",&:09X9LS#&@
M4O8@S:B@6'EN&$4 $2])8@" G3CI*%,VB*-5P^Y)X5QV$_IDH2V($03WN]#=
M[S)'- 2)XEQ2T\:1X!K:.46"5Q_DR#)#&B2QGZI_$&1 ];[FIZKL7Z<52%,0
M^Y#=FA:1*$S]%,<#D-3UN2X\T#C\?YW=31'.U6YP:J);PQ[G :F9VYP'? IV
M.B7<8H@>:C10<K]3FDM>9;W:58_YKGFZH@]U \L-JU%I.WJQ"2+T@\"+?.#2
MP>@<T4?8P<.0CHNPV+QMUE#:9W #N@OKD>%K2\/R :'$YN<\8OF$<C%&Q23Q
M0.752"4Y4+GXVM IFD[HG1)VS5 V-:94&IX^P;6E1[9I491W'_.LSK\4=_?-
MY]O?Z[S-05=!0@+@(N3:GI]$OLW.](PUM_2_1%*^>2-ISNY&<-:6H9-;;YI'
M)>?2TV(L"JY"C02VP"ZL%MJ'ZO8#!=>M3BV\)G6*J%/+4TH(-D.D%-GR<M%*
M(4/\>V -?=H*FMYUDV,JB.3[>KO?4!B_5M7FKV*[7?EVA&) U1%[P/'2., V
M'(:&#DA%]\84#+G GMF LM>LTXF5IIVB]YDZN8.DD&@S7CRU)KW:<5+.%^]K
M.'X\_33Z,+@VL)/$<0#Q$Q >IDX>7M&'D.\UX_Y(KE<I[EZE873NUVA L>R+
MP_%R"--CQ@L@#KN:^5B(/<@XO\W9G;*7[9U_7[/OXZNTBFP,7->/L6O'(<1!
M!!U_+.( 0.@$QXQA-">\ S*+U3-E)],SY03R9;H+<2>Z-MG3UJ&R**QQZW7Q
M6?AQADX(B@):S9 8%894RA\YZ<J.R;ID$/HVLEW;AQ"B$(5N2,9:YMCUH71Q
MA\ 8BQ1[U0U;W*C;Y:RJ+6.86><A0B+G?%L[>X+S[&?5'N?:!7F3%;Z:#PD6
MS=";F38<K_R09D2L^&-%' <#UIZ<!"A.$H^ X# SCR)/O.KCW8]<I-Q#OLSC
M?4HXMU?5LR&F"O T!1KK.=XMY.!FQ8RW7!3TFZ4;@C9SW\!:9#?%MMW%A.7F
MNJG6?]Y76TI(S38*FJ>Q509PP@2EP >A@UWHVU$:!N/D/Q+=950VK/:<XN,E
M1)<?+[]>DFL+?L(6^=^_7W[]#\&;5Y61S*<=9V%73%TF$,>=Q^;I; UV>!D[
M(4W*23=#O-2;]?(F5SV\20C@R^Y J0==!R>I%SB$G;N!,1P'Q(XKV(EGQD#:
M16[H;[4]8!1L"S:'1F%1T\F?M(R=OTO8<8;X9$N65N.$2MJ0X](TCQM>,?I4
M-7E]E3VQFK.A5I?$*,$XCK#M8,]%=M#>!M7W0P6N([)V+//YFA>-AY?FL=H-
M%Z>5#*7UV,$4DR$I OGT1S=W8L+3HK%Z.&>JOG^#D1-",X<_,Q1FE@65NJ=)
M3%.^9M]?C>0[)"*8$$!2QT=T!,<>UX0BXKIBF8W,"-I3FA:4G(A(,<8G(KJI
M$A.1CJ/SBL@;C)P0D3G\F2$BLRRHU#U-<CVW7@P&_1 YQ",(8==U@1UC?UR3
M<OU L'. Y"#:I61L$R6E)K+4<2X3Z^=,<-EX(.N\LO(V+Z=6EN<1:8:XS#7B
M2'>L69P([5N_GG&M'(Q\V_-P'!)(;!"G3IR,,ZW4%LQ59$=90F1V^WQCY=\?
M\[+.)QO89]B&?4W0>QNQ,R@UX]69;<5;F[&S69%?Q5PYD4O" $/Z?W8 86HG
M]ECDYA+HBVS-2GS\(MNTPZG\R;KEW&7+]WF37:Y42MG\9<ISKTT*K4ER<V>&
MF,PQX-TU2$$NN"6D*N^^YKL'=K1U!6B,3Y#-.HW%$4E20 /], 1(L2>X]2'R
MT=HC[2?YY44QCCB%0A<Y@A)!87QH* Z+ 5E8'"84G)(%&:8,$00IZ"^E0-Y^
MZ1KVB?RPDE4G<7UHT\P_\8D7>\B%:-SVB%-/L$?8W-&T2\6SBO8AR1!L)3B;
M4CX969)+,65YJ[[]64)R_B+WYUR=D"!5+)NA2LJL>:_F?19+<L?.AR&?ILTY
MZ-PKA!@Z;&\E\:,XP='8]LCQA;92YX^F>6/U$-"K%P?1I6=+"ACF$[-ER163
MLU>GTD=X9ZR=?X^O4\LWRK@V0]04VG/RD/I\IB06=U;$A:'CA&$ ;(B3-/6C
M9.S<YH<^D5S5>?=S%UG.4;&,\SY#PNLW2LF17K@YVWH-WT(--TEFJ(04\N-+
M,X+6<]\D63T\%-V!-EANDJIDZI.7:S:B%SN   >")  P2;#MXG$5R+,=P2NL
MYXRD?1HV ===!CF%)Z84LQCE4XZEJ!13DI<<)EP<ZKE-\SA!)[1&!:UF:(\2
M2U[><ZF,'5YM>EVI3Z=[7<>0JZZ6$S;-KKC9MPU.OU8L3:*P*%'T0^\N2SHU
MR>M#02V$4>+X,40ACA+LP>ZJS0YDX"#!;=Z%P6E7P,X&P9K\I3W$)X\&NT9,
M4:>&_$M_@.G"&HVQ>FNLJ3E64UG/#;(&B\YV;$"M0TXH^)D\;X;HG\OXRHBW
M;VYH&0?T'=L.HQ B@+ =)@[PO'% '$5@;IC@'DB[Y*.BH@'<NMSD:R8JOW37
MAHUZD[=PYP8$?EYEQ5T+H?.%^I4J7V5G/;LE=>14 =NFBJ.X(>\*G20W_#VZ
M^UV/=N2_9=M]O@K#%$4) 3@.L MC'-APO'C%)K'@"5*9$;3+U C*JAFJ"^LQ
MVUG?&#;K_[%_L6W'>LS[*P]%6W-+\,FG4KJ)%).G X/7'8,M()I)UO4^WRS=
MA/L5,R?T9PZ/9@C/+ M>==J>RX;(LF!53H8A*,9VX 2 3O7M%"(<VH>*;.03
M\;5 H8]?9 &0SJ3>5A@[D)48<1[Y5P"U$2B^[$>9.[^RO.3DG94^*?K,T!1Y
M^&^LZ<W@@?MLUV93L(E?MKW*BLUEF62/19-M5Z&#(]M#<> C%X/4 PD9EPT=
MX'->1#YW%.W:<@!&A:78?"A*:]UA$SSG)4LCGZ8LP9^8M$R(8Y L2ESR#G%Z
MCGJ]S<P)@9G+I1DZ,]N*EZ>]E+ B<*)T_[#?LLO-VZ,R5.P>=_E]7M;%M[PK
M'/M8U:Q<[//MU^S["OBI@U/*$TQ=STULX!PV,>BW!"M/58^N7Z4.@/NVINLI
M9&M+T2Y^PE*$PE.OHR9G&/*:ZK+N]6%-C2SROM9?\B8KRGQ#LEU9E'?U!!7.
M;XMUT:Q"+XJ#Q %QFH 4!I&/_<.%UB@2;$6L8$#M+^^ T<I[D&*9A0I.^9*,
MA<D4RS=&%@=TUD]35>P!_KRL"K[/V GA4TBW&5JGTJ!*VZ,IV#]GEV?U?O<T
MG8>1)+"CB%5YV706EJ8Q&1NWIV[LK,K\C@'C4S") ;A>LO'>D@,6[G=MP#0L
MN60-S3=JP?L<9)CCTRE=E,EUT1FXFBZR+-Q$YQ4?)U1G!GEFJ,P< UYVT)G+
MA?R6]BH./8\IEA^YR$V\Q WQ*%>L9$NDE%OBXT5>".F*[F$3^^7^]?_X[\!U
MHO_YWB[V0ENM0ENLW,2:\;+,,>#=+55!+GA?EM^*LMJUI2E=N<F*-<)+"(FA
MBV(_B@)"PG&NDL2>X#ZJ\,=KGR"\* DK>F +S^A?\G+BM9"FT(R70AY^I>A1
M.D>M[2I!3N*X@0M(1)PHA*X7CKN1& "AEC +05HD2ID1A63X$XI<6AUDQHN]
MM-%:JBL%.5=UU<<JL&T<VFD(0$! 1.)X,G]VD)U(GBV4&VR1%W]RX+ ]%"-3
M5#F?5KXY[Z*,BLV W[[,PZP;/$XHI3)FS=! =>8(WM0AR!/_/=W#S8G[YK[-
MMN#WHEZ!(/#=R(Y1B*+0=: '@NXV8C_U@A3'(LT<)(<0TBCQ#@[3^T '7-8?
M#-GQXF2E#/()TP+DB<F1#&^:+C%_BYD32C232C/T9ZX1KZXF5\")O-;@ZB$K
MRI5KNRY$'D"V$^+ \=*DOWV-#D?2",Q3&\Y!SJ(W';;9BL/+HZSF:*!0A>J\
MQ]Y"NM/!$%(>04)-U1Y1,]Y5'RE>WM.?ML_V[FF%OJR(':2.RZHS0(+") BB
ME/0?[/LV=GF41N#C-&L*VF7_+#@K*45(."T3FNP7$P3T!?Z?RX\B;WX]O/IU
MOO[EKOKV__9VL#<_&KY@+WTT>>D/MK[Q>DL0<=X7609P)>UTT0ZY=7WHK/!$
MZJ9XR)K\\^T5_4%QLVWKJU8!<3T"H4?H^'Z$$R\-DF%L1-@B*W^FH&9$S:\X
MPS!I)_)T80TXV65> U+KXZD*19U\<RZO+$ZUX!J+ I8U->_E(.[4ZHM2XLU(
M0Q3;]*H/L'K&)#409P_975Y?5_N[^Z8_\H8B"$ "4.R2",2N'29Q/V[@0Y#.
MT#^)T19);]KVP.S*^+IF'7@NK&)L C)LY;;KHH]YF6TENMO-YUQ* S73/5?_
M>GA6A^\L=5?O$L:O>S/(-E+SYMAS6N]F,\5_HI]USFV>KNB#V,!RPU:Y']D+
MCHMZO:WJ_2[_FG]O$&7ASY6+(SH5C!,_\D*V^NW3'+2%0/^;YIZ)B.PI'5BS
M @Y8+ZP6[;C_T^(5/?&ODF\^R3L;U6+J=Y)EZX#5^H.AM5JX"R\ZB3!Y0A:U
M.,0,A=1CVJLN!-KX>T\W;XKB9O6E6M_GO^ZJ_>.O>4F'S=?WO^4/-_ENE48P
M "BR"7"P[0<H($[:[0XZV$]"KHGQS"$T:^$(AT_WYO)U6N$6I$I,RUI,5@O*
M&E%9':QEB-M4ZSU[)3)6D6,"@<\ "1)Y]YS(7WA5GYE'M9R!Z)7\M,%O:+8B
MALZKSJJ,J)0^-0**>\WJZC_?)A65_H>*/4'T'[=%4Z]2#P($ S^([" !=A!@
M' R#A<2-N!57?@C=\^_V?,&_U-WA K82]KC+/[#I^&,'D'4E:.A;\OLOU[]8
MM]7.^G+Y]?=_AY_:#.I7^'_^XV]00'-F4,TAULNP+";6+2;K\RV=>ELC+*O'
MM0QS FJ]#(-R:GT]/*'KBCV</9/]8SI7M8\:?DRUYS-E@&HK,*)2^O0(J'9[
M1G^7?\O+?5XSNVBZ7B38M=GWL\=\WQ1K^G#<[;*'>N5X#@&IBU,W98Z/O "C
M87P<)Y!;R)6.JEG;6ZS6 -9B:"T&]P/#:TT 6P-B 3U22S^'N)^->3&]_X%(
M%X@+9R-?+E2(.X%=B5$7-<UW:(#I_]!B'?.R;=Y^;TA[JGU3%YM\S(DNK+_N
M"SK]ZO^>_2I%]3J=6E<?7@6MKN-3F6VR-IO:54_9MGEZ<_C/:_K=_>PP)^+'
M8Y%/R[-@0##48U>E^RT2;2_3C;Y"<03=*/2]P,7$3;PT=,#P\21TD<A9%>X/
M%0IXLF=2E&BOIEXG';(3J[?"5)JQ,BL.^U5W$BF[N9NEU77>7#X\9L6.19.$
MJO,='0RG:9!BX( (NVX$< +9.;'$\Q&(29QRE0K.'$)S#MBBLHH1EK7N< FV
M9I2DCV\+:0'FQ'*XCK0#(BMYAS0]_>'>I.6$=LSDT0PEF6O$RZ9N*CCA/F6>
M[[X5ZZ*\:T>%34I';??7Z; E'?:R'+_S):_W6[8AGU(&QA^S'[69[F7Y2//,
MS[OQ)_03]P^/[$<UZQGA>"D,72]U8Y1"/T))#QZF  JIEB&0-:L@LZ'O>/W0
M]JO)VXN^+I@:,K L$?\V&$*_8)8(W@QB!H^\MXR8@5;CJNM@H-5I>=98[3/0
M]^].#FX_?-L:3>TRQ\DOC>9:G;U4!J<_GMB\< ^$1?QX(N08]B"9$<),(^5E
MCP7#X F%6+2OBS)GY6P/-T79HA@KVYJ$K<%LVCNFJ_+-ZZ6=F-!91$2P[;K(
M]>(8Q0,F;$/!-DAZL8B(H^2=$ /6;O%J &M5-]OB+CLM9^=P#E]L,\<K8B%K
MP&U-@%]8$R<]PWYAC>@OK /^9<//+*I/1)5E7&A&L%C(UNH<+XF8M(]1Y[=#
MBO[WHKG_O:QN:AJS6,>?+N)\R1FY%%6+D'Y%<5'H**N+>L1[G3?-MLOS5Y$+
M_3A!<>3X,,8A3#W;/0#F.Q)J $S=LZ1]PRI@'[.GDZ7'6J1$'ZLG=,8 5YHA
M0B8041GWFHG>*;:E7U9,-;_E<+=C*?'1LN&8I E*XB2!='P'D@AV16R!ZV *
M1_2Z,74C+Y!U3L"VVY[=9NV7?-NEG/?%HV#:J91YOB3S7)2+I93/N9[ -./
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MF]L$P"5 \,R3+A3:)TTMO%9R-AW L>. ]9COK)J9(!M1%#M$-'*<SQ/R$6+
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M+K;].+XKIO6MFYA3H!TJE+TA',;3"]=JQ_T:DCB"<A:M+_6E6!P@U\%ZF;1
M>L\@"</$1D)+#*W&:AV_,C9U0X.R.\#[(M>SKMKR?E3,CJ[0S\IGQ"-AJ9-(
M ^6]A-X95(V-,LJNBTPMR;EL']F^6/-D.@5+X_?9/!]-B__*G]R0_SET/LZH
M7_/[3_F\V1;8J*G,&Z:AHHXQ%= ,T"K#*D2XE/BZN);(BOV[81=@7X!^57_#
M<*K[V/^23V[S]>WY4]C7I*5,02"DLI0")U"8VIZ3>G)[[V@"^=!W1+X.L+X
M]PZ;7-7=WW]]#'/LYFLQNU6+U2#=E_'T<1(OIF]P#;7"!RN_V'Q%BN5R7GQZ
M7$9EY&/Y6QD:G2V#V,)8;JN8L%.8??E^9L(XCQCD%C$&H$:,8UO+DDJ7,&_P
M=S1O7ITD+S K;7Y3S/*)SF?AAV4,:%FHR7\\KK>W4Z9-@X:RL P18ID7#AH
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MKY#7Y,INDG9-A41XSQ;Z[T:_NQO-[T<?_J[^?ECX.XIF$%KHO:"$ \&=<MH
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M]F;.N%PL%_-X)SZ?+,M5F-\^PIW:3L84  HX#*G5G&+EX,K-&L=' 4]*US#
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M/(9$(!E#,=<8<*E3,F$,\I77#@G:-?B]A6#WF R/(XG#5D0%LU8K!JFQI$*
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M9^O4ZP3GOEBF[N,9YW^M)!>/ QL_ G&X8F8TB'F1&<&"&6$8)F$N57-*]IN
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MF7(VD+T9!D_3(B?>$#^YK8PZQ T"WC,IJ?0RV$ZU68T92R'7&7Z*5W?9LVO
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MXAX?X!%+]TM1*L(]AQ$]L2>.F'*[*V0T;-)&&\85"MHC0XRJ^A ),)UR-7U
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M^\?[@]+^IDSF.20<8A)V0NFX\YQL/55,DFN3]ZD2*]O!K5.9C[X<E_G3,IF
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M]\OO( EBGL9]B'*L*0?66UKCHDP79>1"7>AGX?.)<CIG9.'FE+NL8$&/.,+
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M<P6P9BG\U6!N@8>L6=ZXH3,-Z/5R.B^62W45V;R<)O$O]=V#OS6O"]&LJ\
M4]A9)R$75F.-1'J$N46%0G-A64#[ILK>9 .#H)]+4>VS0@2%Q$BM+%044:,I
M1TA7,U2RD\]XA/P:C@!-"T6<AO<Y&=6E4 3TQA)DXZP01E::>,+7L+D(XV6Q
MJKNPFQ>*. W97/SILU $X]@@ZXAR"EI@-,8:5S-$*J^J?-8T_XU%W;10Q&G(
M9N5.KX4B+&$$2<(% =Y#K)"UO%YV&'5Y8C1"U]Y0#.H%W%PDZK%0A$*844D
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M>7&3QO?Z&3FX',;D^N[H\@X>":VY<$1BC^/B3)EE:J>_I%T8>')YW LY@0?
M/1?C'BZ*YU=&![AVN&$@CBG.#*+1!&3<<^.<N7>QHB[.[5$ZB0:]4.D5ZUS,
MJA)<F?+VZW1>&4>[RA]OKB.FTV_3R8.->I/\ZEK-KRNK:5HLX\_6MPG2@UZ)
M S3-.(H0D4>:>$X]P8K&=4Y<[0K!KE/AR]?U,JL[X\<KMC$HJ@^V _?7C_1P
M[5.1HITC55)<R_)J,OM7,3GT$+6'W@-3F!. %?!2&8XHM+26+5:LBVDU0J_3
MH'3/+XYQTOA]\=?JRY_%[&?QKIROOK>\IFK0<9!(F&B$0@5-NJ>#42&K53W@
M4)><QR,,CQ\1>3M*8IR\30OPRY]E;W3=]1>T!)@Y+*VESCG%L9*UE0JIZ'+5
M>K+WZM5KT3E$,&)ZQE_?+F3I8(^!4H.@L%HAQ+' 6AA>:T\6HB[5$9L[M'[%
MC;2M",9+45^N^]-9JPY#/$6,XYI3;"BDG#NC<84.%;3+27^RO^L7W$-;R&#$
M#(W?]LO0^&T0E!&O@)4">^(LXY[5_ALA*.H2" K^WD/[%\$]0<]<$^Z)]G'Q
M1>&P<$QR2K62E#@(HJFPBY60$#)SQOJTU3P^E;.9+Q=_3A;7#6;]X.O ->):
M"H]9NJ1'6 C(J[E)H3KM F,\IP:2_)[:D.V1SG4:-;C?N[]+8DH)0AW31  -
M"1&05#, JM,M\LE<^5$LIN7UY]5DL<K"EU:2W,.*$X',384/J^_%XLU\6SJ]
M*J'>@!\OM@O0:XTPDM(@ 97#(%H'U5PUM!>6N'((NO2!ZQBW$R>4%8A8 Z'6
M!#.G>(T+X*#+=G+R9>UV.W'S8<-2!ME,3H,Q-Q&V3T.+ZP<1,?>O1=\>?A/2
MN(^ !$,DSEH3JY,2+2-V-8C*=(GO'.5#RKQ:3-_XG]^0V3RU_]5J6\<30EFD
MG=- 240HE:2V-A'4C7RFC=\@'GG L1' H5+W;;H)<??4DBD*H8^6N[$4VJJ4
M.V#<9'W2/[YMH+'\RVPBR'4:5?DWRD/Y-_QZE>!Z[J\Y2M8A?DVPDB,,<=R@
M/:>,>^+NL\L(PKI<<8Q8<1Z&RB,04&ZJ?_A6K] 3F/M"JX -@1!+39!W'*!4
M%:AVBG*KNE3G&F5095XJ=D<\FSKU,S8M%W=G4YOJ$9RD)!UH%4R*OA/0$@6E
MM Q*C7>VD_/(@T9Y:;/-M<DZ/M0L< .B@LZ\5H(Z2U \J7<U3WQ*,=_E1!FE
M>M2+Y)\%W?<&<.YUN[N]N:#EZZ71T!#J! <0 ^B\=I40C6J65GK@N;XO5J=,
M\L'G@8!(^7B$1$Z!Q$H("*AF%W6/K"G2S[U<&TMZWW)M#VR^5UB[H7Z:_/EN
M$C7NZ626WO1\^)8*62U^%H<+4A]K'(!TFA+"M-:I^)7#JK+,G,>$=/&1C9M.
MK42_CT=]X9N=5?\L%W_4I=%.IM7^UD%0J)")JFF:+9.(.6&K>4<PND2+CM+W
M.@RO>@,X.[&2);V,MDPR8TXGUO[6P5JCC*(IX)5QPH RU=,"YRGD%_>8;QAB
M]09PAX1TNZ',BU5*4Y+D,;^>E_/=7_9[?P^W"]'.YD!BBHV+0R8<&V"J\<?I
M=$F?>?K+MPQOBGN@QQ# YK9CSGQYT[\9@PTE7FA%L9)1D 1&-;>"&U+5Z")\
M:&=B/7ZSY<C)/O%C700NO,<\*O<I)3JVS$!=6^3<RU_*.]&8$7N=BKV"G7&%
M+U?I4GGY9OZ/R6*Z37<5M>WXSVZ^VCRO;;'N#YQ+1W_=@:5]>B>!6BN,8T)K
MX@00WD9U;@,[C6.SYXPD?7'H)SH?&_<1E&":*FH]ETA :!G9U2VCT;37XF(N
M:H>D2)D'_#&M_?8>S/%L 7$$6EE("+5Q6S><HUVA%^(UDW(4A_V^26P.D49G
M_<$> H$:"H81!HIY:Q&5$E08((6R!IT/=[4])#GVGOM] M_:XMO>H)LR_NYY
M7.FK=].HL*_*>?$E]KO<4TBN8<L /,>>02"MIABFP#9<8R0=[5)4>$3D&4RR
MY9!H#\28O86$&[<-$C'MH33"0 0$5<@ANIN'P;)3!=(1L:9WJ39G2RN<6_/E
M4W&3 E&C?5./XDAA^_TM@O?*4D1=M(2<E Q'4ZA:.X92U<6#_;JX<:H,RR'P
M[8$3ZL>/1?ES,JM'TI0:>QJF<@O81!0@C_NK0,YJ :L92 &Z)'T?42Q>-H;T
M W,GA_1.)]-W<:;+<C:]WN3JG%^_+^=7#_ZEUM .Z"PMNPN,.@8YB=:8-YYJ
M:+"/LU4*I6?' %U8]91!%9D\(LA)N,,J3^L.0W+H6\4A%A XJ1V1*;%,FK%$
MA*-+.NL&)T5'!K:22&L.OB_6B^GM[?K88?CTN\ =A$I R8#VG$%MN/1Q?!HZ
M:X'"OSAC3A5BV1_4N6[Z7_8LOFU0"?9(RR XB::'<-'FP$(ZZZ3UN[W>:B!Q
M!VJ=?,/_>D_ 8=#.Q:Z/D[O-@OM2OIO.RT4<\>?O$<[OY2S*\1"Y#C<,$JI4
M+]=&(U<R0CA!NE)1K;"=WIV/:-OJ7?;E@"!WL.RNUU=)"-/YHKR;S%9WB[@'
M_YC<I2FG??GVMEA<I9"\R>S%L*,6O02)4TYK; C1<3@<6*54-3<H?9=G+R-4
MS_LFT/"(MV:3NKZ>ID%-9HM>>-6VO\"$%PABX GQ&#.AV"X_&?$.8GAAQ]\@
M#,N$?6NN?2Q7$9KX6[=NE=KA4>VK)@YKNM$XOY1?OD\7UQ\GB]76/_+7]#9.
M8':WCW8]=!T(5HY#+YC77G*&0=0Z*A0B_%TNXD:8.WX0!N870P]NB#=S/8WC
MOOH^+V?E331U;G],YDD!_3Y9J45ABPC0;<3E^DNIB]\?&3['XG+VNRH&^*5!
M*&M0>G\K.#!$0BIU=62XN*Z[7.N<G T^1]#8(!0>DX@RA9N\C6.[>51H*WL<
M:4J<4KO9K^[>S+^5B]LM";^6Z]7]"-]-5FEO;!!DVK;+8! '6C*!L18V91U"
M6N]D) Q@9WQ(][:XF<RJX<ZO[V>76-D@)JU1^V"\T-9+9BDQEBE,B*KG;[GM
M4LIT5/%H^8A2#B^&[%O%N1_0CFG'T,3%#9U3ZJEB#A(N=YERB8?,-JMP.51\
M?A1=\67RUX-Y'0M<V]LF$,ZD98)!S:@7&  -*TI&[K,N>;Q'Z$8:G@[/GBGU
M WR^5V^[\:KUZOO&'[;G9OAP@R H)7$KE9IISA!46-!**<+4VPL+8NM!ROMX
MTP76\Y%F[^WNL28A6G5(:2PTB.N*0NP-K4(DL/,\:P[>C,1I*>:CK&F%:C/>
M+"OB+*,V<5/^_(^K<CU?+>X2;WCUET09_H RNW\.^M,+Y+C_87" >HA$W%V%
MB<N$4N[=;L"$ 'LA$=3]R:WLB&#VK>+!3MGDIO5@N\"LPP@8[)0Q"D(#(:UN
M%$G$KLMSFQ%>90QXVO2 ;BXF/5'EW'*U\39^^/8Q_B!E-#N2?+=1^T =BO-6
MV,651+@UV-,JD)AH)RXDK+IG'CRUC0= ^DPLLY/;R4VQ_%RN;[ZO_C&9K0\9
M74?;AGB\*R&,T!(Y+B0"S,C=G"E1XL)28&9A5V>4,WE=-DGO'X9@^>E\,D_W
M=Y]CAT5R5F_=,6?SQGQ8W$SFNP2A]P--+)M??WPP\U0N]>G0F[AF>ND_1-58
M*"6,H98*A VF>KMM4*3B/S12%(?![_[JMA[_ W_#:2^/3^XK*(.DDE[CJ ^H
M" 7$%%6X*.0N+KE:9C8]+24_L'S&MBF=VU/\.O8FQQFFEFA+K-(H'FJ0P$K&
MTH%&&>F&P:\>[-$7SX\^#(X"!HR#2@#K"$64[_)V)-:J3N^$1J@.9V;!TS?/
M7:#/I1_KR2Q.O/C\O2A6;Y.X$SJ'/<;[FH1-A@8JC$__*;CDS,MJABBJA9=%
MKK;B+0=!\YQ\.>HLWM\H $H9-@@@*:U6T#AM;7U@6WUAG.DN[ ;L:85L+OYL
M-91MRJ>WT\G7Z6P3A+/WR4^C=H$YSBERFB-GO8-4$*_K+5JZ+H&JKX1%IPJ]
M' [>7%2J-^ F_N?G'X?T;HYR9K1C6!)+#2>TFI5CK MI1NB\Z>FXZHQCOHN*
M;9C?UFFU*Y#2--GYX:9!")96@C8,:\VT=1;4X&GGLCJ5<]CF783^[*:B5VSS
ML>D^ C4-O)K&01:]W"1XC2F' G$NN$8:(^AJSX'3G<K5C/"PZD_@+R00[@'?
MW/O1#H$&V\_NRV"A1((2(2DSQ$:T&*A]6EAERE\NMWR9%S?)K?1:&=,%V%Q$
M^51,9M/_256_*G[_%C6[9;HF.9BQ_&"[ +U*%9LL44IKA1GAW%=SM<IT<2>/
M\"G78!3J$^1<A/+EHIC>S+?:_=7=E\5DOIQL7J*EL:>AZ^);_.;+Y*\#]#JA
MER P)X0P2AQ3W".CH*UW8![75@>RG?QJ*T^FY('H-ASH6>W]]^6\_%$L)NF.
M]Q%&QPS^O0T#H5I"3QF'))[V&E'$Y/WU"^P2GWKRNZI7O)_UBG(N3K6AT_XY
M8@<UD$ @YKRW1NFJ+$Z<(V"TBWK%QEBD82 F]05P+A*Y_UZG9!'%U7JQ<77Y
MG^^GU::J9A&D>9S*SR:5$T[L*2!$'32*8(V 89!RQ>M%I27HLG6-V>_4W7<P
M+-!C(%Y+E@7"/#'0<\@9)SJN+KE[GQUG"AL^=NK-I3#X'C88#T[@VXF0GY-<
ME<W2DF1/FP='!992DSAMZH#'<?+D7BE@74S)4=93.R?=.H)_3MK]/E]T(][S
M#@(V@ KO":71R(E'"/.,5[/W2'9Y53+*BFOGI%YG^'.13UU=+=91:/?7EKN+
MS :ZV]&V@7G-A7,<<.2@CZA*6?MT,'5= A1&2;D>];6^P<V73W*VWLIJ-BO_
M3%?M*25 595P=_M^@%2-V@<M+24(Q37%HSTDK(>N1A40UZ5ZY"@O$7MDP[.\
MDOWCG>WDO/TQ*^^*XE,QVURL/$/GT*%YK&W E%D(K/$*$R,HM'Q7E3J%%>%.
MKY]&:&H.Q["^D<Y\-'[:Y)MKQ*D]+0) !AIF/(\3Q$932W4=6!21[)* 9I3'
MX'!<Z@?AUCG63#F+8B\7&RD46Q?=<I+&-)F]P(NC;0($!B"-A<%:>TX$<5#5
MP6&07EB*OOYYT3?"V2*!U\NH(::W>[=?I_,JQGY7E"-%VT^OB\7N%<L6K+OC
MVT_[3H,11CA% 97,N2@#1.\?Y #DL]X(O>X=*IL0<E$UC7FUV&9?_;A-N%IA
MM<V;?Y27#7L(0 J(D;<1! (U87'RM9()B>UR\WWZ9=(KW R'Q3OKI?=><(Y=
M>N]M&)0R BCB-2&42TFX$?5+)*8[Y=;AO]86URO066EU.I]>LE8L--0!0+1C
M&C+ ):RM%>)P%VU>_$K;5#_XCNUQ\.:%P-]O@P^_"I4$$*D LQJ9%".Q47PJ
M3<>I1JD_!GH74Y=Q.1S=LQ%SD^0%[3H,S&BM+)<&*\0(]L39^JH*2'UQ.6LS
M\VIOA>4!A93KI*MNG#[,'U2\:D+5PPV#@4@89%FZ.D7Q?QB$=2B28)1=EC_T
MO(3L5139WA36J^BYTM!BOSS625 "*<DL@P9+@2*@FM11))JI+@[Z4;I5Q[)'
M]BR8L6EPFW7VP*'[MP[W(H\X@Y%%SEJN/8$*0<^K/0@CP\Z8(WR81T#"11HK
MJY@5T KLTP9<S9<"EB>I\^.79%]>R2G8F"HG/1@Z32#G\C,T\I#N;Q24A-&^
M=@9J++!()83JO93P;A'VHPP8/"_C>A-$YDOJ.KMD0\(=:A92<61+6502HC5#
M'.%<@6JF#.HN =$C?.YX7L+U*(B<>M2GXF<Q7Q?+]JGP]MRP;WI?['H_H,OL
M_S@PB9'" G)J (I&$B<T*K@&:^ H]:"1HW^8Q6JGR\G-S:*XV1%JA^*Q-'2'
MF@4NJ'#8:(>(8=H9HI&L9@M9)V_TB!(B]"'N<C!4<VWV7^)OB^;78C&9WVSV
MGR/)YE[\/FB)B>$2.:FU$$X[HN!N;@QB<6'52?H1<]D_L-DTA/M1+K?WOY/[
M?WGP*/IX&K$3>PJ6:0^HQ-J!=/%'%9.TP@. 3O?Y(R1:1TX\U0L&Q3I?[$@=
MF?6S>#"EHU0[W#! K30@7&OO75R]Q$I!:E2=:Y1;]O4P:S N/(L;Z1'TEA1;
M+E8/Z!7_]I1:\9_"QT69RD%_6'PN%C^G5\6>8W#?I\% *[@U;%,+FKAHO3&]
MFPG'-%-2H-=Y O:$:09VI*6R&^!R;Y+5@]\'YC! 'GIFO*;:$&L@KN9$A;F0
M^B?=1?J<&YW!S)8P:EM-_NB!].B[X%$*F]-6,"6EE7&[-:">BX)=2I>,DQA=
MY/G4J=L!R=:!^QO3\:I<_$BG6U'9D'NE?K1-$ #BE!_6.:P(M5PXYJMQ>TFZ
M/$ ;T1'2+P/Z1C77'K%#X!Z S1R.;AF'FH7D))3&0@M3Q+?T7BJTFZG01G0)
MIAB1CW68':1'8(?40]Y-_ETNS'JY*F]3,=W].NKS#X.G!@-%"&56&.R05M!6
MLX"@4TZ2$=%C, VU,Z)#\N+]Y+;X\.W1$ _JIWN_#QQHYK6(9I[RUK.TCJKM
M4@B,+\0,[BK0LG\H6^LAGR>WR_7\1D_+Y?1V.ILL5*3]89=(HW:!.D8M81I%
MQ5PP *T5-1J<H:P5KX:E0@\R+(=#MC4S_NO->_WI7U_481X\_BIPR@T54$9-
MV1J*+**L\O1(X,V%9$,;0.J=<,RE=^XY%M\VJ-APK&E0%@ -E)-QKY2*(>)1
M97=)S%676E8C?'@\R"50SQAG\WCL3*Z#@7#;3P+!E!H#%7=$1JW:$.7N9X!-
MUM1X.8*/^A/ILTBV5HAFYL2G(NVHT_G-QV*QJ=\XC[;5U]ET"\=QPAQN'S"*
MIAYP1FHHF7+:*%39>Q)AT45='=%IE8M+O8*=*78H6NX_BL7J[N-LLGF,G%*G
M_7@0>7VVD.N] VL03GVT;3 $,2P<-0Q[B@&)4M\]M)9<H*<UY,_SW&WO+(X6
MR6S813!6(B.8)$1R( V1267;H0"=ZG+K-B(390!6['V(T2O@K2T7/[G:I+%X
M>[@"YMYO S+)B#=,$,+]9K^RLAIGA*=+$IP1$J-_\97] MP;$?9ZM0Y\'22(
MZP%KZ8%3QA,F-!756",:%W+GVH.L#DF]%9;MG5KEK%Q]7R_FG_^<KOZG6$0Z
M7Q]Q9^UM$9C2T10S$$$O.#704.*K,1/0J;#@V.5_JM3*(1#->*GV\N;7Q+UQ
MO'$0*5:!J63; ^R!]T;R:M;,JPLS-@8[5 9#/.,#F?7M>I-YTA91;%?3[5HK
M?LR*W2L/=5LN5KL7('OG>2@NMJ=?$:QDC HF%#76"2ZC@EBO?(4Z91P=T=XW
M!*6>OZHYAT2R.88?S.F0$_C!9\$@"7C<^ZU10 IAI26FFHFGNDOZJQ'NAP-R
MJP.JYTC9]R:Q^R8*;OG;XG 9@0.M@C?&(:\\0EA22X' 55G0])\P:R+W5\V>
M_D ^NZ)VC$^'&P9-%-!40VHM-0Y0RBFH9LN\O[ ;J $IU2O.69_)F_+V=KHZ
MHET]^3)X@KV%S#'+-(JX ,+K^2 ,N]Q)C;!XX8"\Z0;LN6\,CBKJ%W:'0)4"
MPA";TA (XQRBGE72L=PT.H$SS]M.EU>S<KE>-$K\=$HW 5FNXV@,X9C1J)B3
MN+%5:*37O[^(I70Z.YJ>'=U!S[1!?"JN9I/E<OIMNG6B?5BO-AFJ*ONOVN7B
M[_A>S)?3G\4VUT)*(M-[]H(7!E,V'<RQ9 =]]!TB-;"6D$ LB20$$*+U5H1,
M: (;W<$-%8+03H['KB<[]1NB1HXMX8@![21QU! $*KR05!?R5OX,_'H6TY!/
M2MG2(5998K8%XM+HR_GF#>_AK T'VP5@D9=&$^.QD\QYD$+4=G/EU';QXXR(
MD9EY\?2&O4<)Y&+;DZ'NO7L]^'TPF . ,$-0:8>)\A#X:FZ.BKRU</.55^XF
MYQ?K079#]@RW(^^+U7W5RL<9]](6?SP[R(E=!1'7HMT$P$D0358/8540DPD)
M[(6<K3VQ8O\%QQ!@GX%^U7CC=,QD^=W/RC__L[B^*3YNT#V%?4UZ"MPC(R3&
M0'F)&*:*TEI1X<Q<V'7(8.0; .LS<.^PC;B8_MQD1/G_UW&-?;N;SF_4<C-)
M]]?5;!TMQ1K7V"K^0PK)37>+D12KU6+Z=;W:9$<N4V*_<KZ*8IMM\LJGU\_+
MDYA]_G$&)P2QFGB@*))$,"4LJU4JA[ILVB.\"!ILW;PZ2>9[B=!.X3]B4W7I
M-F",G3>$& AMRN0%+*C-",,[O8(9X5EQ'I,KHX#&3N6CIENWCH-CP%J6LF1*
M:J$RFF-2H861ZW+Q.D*].P^Q>F)S*PF-G<_'<RMUZC@@I+"&W A HZ2$L<RY
MVN>(+BW-9"YJ]<3H5C(Z%Z/5];_76^NYZ?0^S.^UM>7;!I'+0_W*B# $1C/@
M,:=1+_74^AIA+]F%)!0:EY)R)N'E6AY[RZ =X/?>-L$*CN)NHYAUS*<21-**
M&G2N+R1GWGBH4@XCF%SDJRLB[(:IBWGQ;7HHAF9/B\ DB&:NB=8N=P12H[VZ
M1\R2"ZM;-SKB]2.6,6;'$,Y[)9(CG7F*$&.,WUL'PG4IO=#\R,U=$6IT_&HI
MCFR!KM6FNZ/_(68]^S98 Y47P"- %=' PJBMU^JZIET.S>9!TK\\Q;K*)9O"
M5JSNW<B'E+2'WP5A)/31]&.818W8&>D0JMW92';)RS#"@.K1D:N+,++%6"Z+
M19RL+Q<I+K1<;PL1J-FL_#.EG:D"*9^,KGWL=:,\FO^8S-:3W6N^!S<E5[OQ
M[0^G;-XX..ZXT!@:961<YHHCMWV-SY&E##32'7/-^$'([IZ8R)/["-([[25'
MT4(V%@L&^>YM09R_]^1"HLV&($29!_)<1\O]'.I%'V=3;0RI]LV1&[AF'03$
MI?,B[G4V6J,$,(Z@JF:/,+^@E+8#L:+, /LX2'?TGJQ)\P"0!PH:;(! W@,'
MA*P7-#'@PF[#^J;#26QKA7CKK#2[W_JM7*3(I%IO.9R8YF"CX D20K'TI$9Z
MD)[#B'KDT)D+NVGJ5YCE0"BWYH=)D3'Q2(];[[T-<(0>A]H$""AP+OX>2C0G
MSF.O3#5N!SKM)"/T,P['CAY!SO;48S(KEI^*U7HQ?VP8';W[/M(R6"6M!DXA
M'*U(CB1%7%?SM8)>6.*%04@U#-0MJ=6KG7?HPKE5/W%Y:2J%9M)[%0T=S"BK
MEY>V!%S&'C:\^IT#_7%HX7HR2__46@W?M0\2 46@Q5Y*(X6UT'!7S5TXV.66
M[F3=ZD>QF);7GU>3Q>KL_&O!CI.4\G;XM]>ZMJ7M/R[*G]-E'-/R2[DKYU2G
MM=Z.ZU,QV[C<OY2;??O-?-?R7\5DOWK61^>!(!Q-'$:))\P+SJ5RM?%#,.F2
MCO:5[H'M.7@VL;0FZ .5L_$P/\;M8I$&N3?O<;=>0\J_ H2Q&F+#M484(5I[
M'>/1=(:;YM=.RJP2:<W&CY.[S1 KM?7'C]FTN%8W40]>KHZ-NL&.V5?_P5BO
ME$D7[=Y8"S04HL8CJA5=CN^V%]6OG:%GDLUYN%HOK4&86O<>&$O1(5190PB2
M\301 -=&'A5=[.GFE]U_\[2S9"[+^!%(>60@C=/&."Y0S 2J=9MNU;A8.^/'
MS5\S+X=$?V0Q%T_TW@N(N0 \E8%6G&D0#RYH*/([84-K#6@4\S:0F[?*%W*T
M)LZC#P,PP$#GHY%B);$>>>]Q/2, +B2O]Q BWI>8IPVNN8Z,W;;R^7M1K-X>
MKHESK$E $A.M&'$*<:H08Q"[:H8"D0M[--%6O.4@:)Z3+T=C&_8W"L83Z*1W
ME$$ %?'.>E'-DL"\GM3A.=-=V W8TPK9C(E,-KOKI^*JF/Y,*Z=)3I$7FT0E
M7 N!G)%">*:0-D[ :H8<TPN+ANE#U,]S?/2!;+;7"9L8YZVOX.UT\C75(YHV
MN+8^V"YP!@EGCGH"++.*>P1)#1ZE72+*1^1!'Y!%?<*;+0:B.KP/W4KO_SCN
MUP9I!K3TR#EFXEF?ZJQO9Q4731<E>82DZ4G5Z8SCA?E1K#:$*28%MT)ZI0WT
MU=P91!=V?'41?CM'R4GP9G.4;-__Z;N=K_'<M83W%'YN4 7@2,O@#,38,$6(
MD1Q[0HBH7:0>FT;!\5GG?,Q/<JA9L%1K%DG&N+-2:0_BOEC-EG%Y88NY-]D_
M+5?5'\1#AKSMUNZ'Q>>XXTRO]KTFV?=IP(8BS*"(_Z4Y!90H7P=H427=+T&6
M$X5:]HII!G:D,VDWP/VO/PY^'WS4KD#*0 2Y$JEBAO:P?MG@=)<W^R/B27>1
M/N=&9S!;7RQ_*:Z^Q3-_,3D<G/_DLT 8]A( (T"TN8Q$#@-17^M(>B&O-7J2
M4-D;D*W%O,E/&C$MYX?E_/2[8(G&3C/(J(WGHV4$4E+'-RC494V/R'(<0- =
MD6R_H.^6DZ^+Z6XV1U;U"]\&9IDS% -GD,4$6T.UKV,%M.Z2D75$KR*&6-K=
MT6PM=:_>??S7)W58W(\^"AA"3CP!DD/HF-/ WM_,1R.TBT]H1#4B!Y!S%QA;
M"_B_WKS7G_[UY8B$'W\5'#=0:8B)ME!+"H20=7 :,SA/0-9K%'$G'%O+^-WG
MQQ%=1QY,[OD\6&6@M@0B3"41?.-*JD:K*.IRKWURP-.KDGH_@+86_^>/;]Y_
M4O]U9(D__BH HR@3U'")4XE"%P^7VG7!N>]BF_.+%G8G'%O+6+OW[J-Z^^:P
MC!]_%8R+0X'>2H4]H- 0ZNKG0]2C+D$'XJ)EW G']K;6NT_JK3TBXD<?!8XY
ML=QZA&7D'HAJ Z^5"*14%UU,7K2$N\#87ME^^^;_*GU$P(\^"HYAQ!#G.B5.
M]$ 0"VLS@+A.Z2PAN&@)=\&Q_38]+9?3V^ELLCBB@SW[,%"FM8PC@EH8P9E&
MQM^_]13=G*"7[1KKBF7[]?S[.V7=IW='%O2CKX+D1FL('-(<"<V<DKIVW&&,
M.R73NFS/6"<@<\54'/.?O?A=0%%3M A)#RR&UCM.6+T].6$ZE5V\6.=9'U .
M>4%6AX+\5I0WB\F/[].KR>S '>K>[X.$F%#OB0+06"&A\/[^8:N"%U;LJO>+
MU+Z '90LQ<W3$1Z\3=W[?8!:><>B6L.,9QX2)E2] .(2NY!RP3W)M>P?T68L
M658T6197_^NF_/D?FQ#EQ5UB"J_^DHC"'Q!E]\_A]\\OL.+^AT$ +XU )L6A
M&LFM=LS6^@]3%Y2PLP>AE1WARZ59O"_GOQ\/ G_P59#>4"0HA!8X)KVP8%=2
M)T'@\ 4E3>F/!MUQS,6'/<?DVP:1WL>:!F:E=)A P2Q$2@F+#*L]U]AV"?,;
MD3HZB,(Q$,:Y6'5*K16* %>>>LH= 4)PZ,E]1EK-+B01>?\"W5<LY30\,X=R
M[R*XOQ1_I22@CX>2,9![-QP?Q5/E)/WG=/7=K)>K\K98- CH;MA#\,X!JH%6
MTDDCB;1PYQ1F<<\GKM&#J5<4V.T]5Y@@;015UGDLA:MFJXRXL%C=WCEP4H#W
M25"/.<!;6F$HTPI8Q1316.A=E;HT$T<[N:W&1YI^A'HLP/LT3%]'@+=P4!D/
M&(T:E(WJE(-.5W/RA'<Q1$;$D^XB;13@?1J8F?W>]\/=/)=MZ@9_L5DP4!@!
M%( 024H1)Q#3:J:@X0G\JFC31=HO.\7[ ';(/>;=Y-_EHCIVEP?.G^<?!FX%
MY$P0[JUED.ETO5O-PI%. <<C<F\,=OIT1G1(7KR?W!8?OCT:XL&S9^_W04H>
M5PYG7B".B"':LQH:"O2%Z"A=!5KV#V7K:_7(]-5B^G4=Y?!AOC]ORMYO@_2$
M&NRQH%P"!ST7H)ZUI?*";D!ZD%79+YI]2/W+GV5CJ=??!L@5$)) ZS1&C &C
M<#U.B/0%E4D83NIMT>P2,/5S4\?UY]%XJ4??!<ZB5@0!(MAHR0U&$I!J?!)W
MDO:(/-0#2+LCDI=PNT&9X88:A@&EU'OHH0;5C!'$7>R*$7%G$,5Q((S'>+LA
M-#4<2BB0Q!9BY"VH9V")R>.TJ+-2#U/TI']Q[BT$?Q*:K<\3-U]-5W?_G%X7
M'XO%58+^IJBGD]R]FWWTP8FWMSK$Z3T%;D"Z8"94 IGR&C(@56VK6]O%U!B1
M!C(89_+ GOG:+ U9Q3F9:P2^?(\'[X]BO9I>?5RD2(7;Y;GS(N6[3C,HZB=:
M,6,Q^7_M75ES&S<2?M]?@_MXV2J<*5=E8Y?M["N*H4;65"B.PJ&2:'_] A0Y
ME"61',Y-QGZP5?( ,]W]H='H"PYIKPRN&N1I+FM=EW(YX30G+ )6(H*L8=19
MCF75Z)3;=EG>TU,%G6/@G'#:>:R><CB-$@9MM.:ALD((@JE@%24,X2OI@].M
M4$^%T\[CZ66$TP@TC#-*'(. <H(H,K3J-4I:G5\FA)/V(JT53CN/F8T-TYT]
MD.B;17M@'NV!]=X>>-C: Z=NPCYCDD $QP)HR &C2!D"J*@:W::.05<'DS;2
M+09B\U2#:1+&!:6)99J#N**01KQJ4FJ@;@.6RSF[--][6G/T,H)I\=P.D51.
MX*AS2>IPC:J6R%S1*XJLM!%HK6#:>:QLON\4\[OLIU7Q^/!3MHPT9_.[$WO,
MH0'!Q\\2D78GH 6$:NKVG8:)85=T8TX'4BMZ8.DU^-XQ1)%_PJ'4Y5(JBZFO
MKER@UOZ3?._G[C,]\;BQ:OER%WGP\=:DFUKOB_0M\8?;?'W0I7IP0/!8":TH
MH1Q0(P"-7UF9:<Q=6X_X[@18],#=QGC89)BM7MG.QKYK.Q^"R#ES!(BA$QZE
MJQG2IW!,K=[19:6YDAZC_:*F1X9/,:BG)5>(,X(IL@X9[!FL#FN.H6$N[=Y!
MIEC/%I<%F9;\'#CV\AH85QQ=27<0<&U3DUAG,3?.[*H4L>5:C1A=.4%!JB?3
M\<V_-V="-47PP%,IO8/$ 4N9-D#3'1> L%=V,V/GV'A_D7?-]H&5P,;6_B>H
M  ,,4\"CY![W '('MQE[40H0LEKY*L,'6.NL_UKC P,LXL['8[.P$&":6BOO
MZ-?FVFX;Z1P59X1<F_*\\<E"+6>+IS(O/]ZJ^]2F(_Z[O#%WL^6W[,/R_=OL
M3X*KFXF#%]$,9D!)+(W1G'.RNT(R*E=NKJP(I2_4C2*,YHZ/Q_O[V>KIX^W[
M'_5A.5\\QMWEPS+RJ"P6^<ULG=V\O)&R)CJ[?D^@$B3?$E7*$^938VI5;=2>
MV#8J<H+.MU[!.K)L.HM#'SCJUP-HH\F"%9!)XB7C@ /LE#"Z6J6$MJK(FM %
M$H.@< @!=.,/K >H(T,"P)XQ29T''$%MHIH'<O?5RO,VKIL)74HQ"&RZ8_-
MA[F-;UO/RNSFT^PI=?H:]2;1^:(H'Y]][?</V;+<D/0Y6R05;XIR76X^][>7
MGUOOHM$6$P<E!)?Q' Z\0DCPY'U[7M24"N'\N/FU]0C[3L U#X9M9@[6QK6#
MK8EL D8+0R '.YY!V:[M[KDJY<]L]5O1?PAA$(B]/4L.**;15-+8N?Q3U4P4
M2NFDT-Q9GO82X^%SG)L2B3P:L9'6E_E==O.XB&2Y^X=%\91EV_3!O7!?TION
MX9Y7_I!Y\6V9_R_2FZWRXID)ITH&>GE?P-!9;U.3>XY<7**$(;+CK\:P32GL
M!!U?0X&QF)[HA@JHQL-KM#'W-]EO*3F04%IC5'#$.>P1T@[!= V6DDSMZ+2"
MM+F):((0'1DK15]R&1E_!W-6:XT+5)"4N FT\Q@:3I1&K*+57)N:[$3J]9#4
MB+_#)8>467S7G5K>V'C@710/Z=/=WVGU'>XM<\;HH!".A#IN,9,22P7MUG$7
MZ8;4#)J[-L0AHB,4O DV=\WIH1#V)5O$.;^EU-[5;!&_7]W<Y\M4H)R:;&1;
M$DYW;C]KGH"%@AH@* D J>X9Z^WUL9$72J(V5[2>'7>Z7-3UR?.A\/=IP[_3
MG19?/!:BI2L(58BP5#G/.8$:[RC!@K1)E#D[$'2YZ&G!TJ' T8T!^G.-S/^.
MWQ2$TUH8FGJ@XW1;'^<O%ILW;8X,$PRL3^O(,*XL!]NX3Y"5L@\6L[+,;_/G
M7WQ8^GPY6\[SV:)2)77\9]V^*"@%N$' (2&8TTAX@.&.FPX1?&T&YVAH?&TL
MC"G&H1;%EISLYGUJMQ;1$;#7FR!PJB$ACL)X],2"26.\WE'/+1@T57<($(\%
MGF( Z4P+F[]DZX^W7V=_M\;H;J( "#+IVMAXZK3&4L[E?AOUF ]ZUNJ_:.2B
MD-I01I=E?IO90QZEGG[[G!G9NQG^YHV!(<&@Y,A"Z $5&',E=OQE[?)<ZY\8
MJVZ(WQ(POO9OE4]C*4Q#INWJA \MX)>)DN6F@\O.Z7(P*[;9= $:;"#C##)F
MC+;622&KR)]5;<SF":8=C@S= 24U*5T>MR*=+;/;?/V<N7>.Y=S-"U)[+":%
M=40CFQI"4V$J;Y9KUX6T?I[D]YKZFI$^JO3&SG5ZE;OS(]DI*"HA(L0#*RV6
M2@B"JOP2 ."/9*>6+DW(#/32&Z<0U4I  DP5 \2:7UF)[U!@'"39Z3S1#>94
M^&NVNOD:7WDBO>F[YU+),Y%$:NJ989()H,E>33OT(Z&I2SR\]@RTD,3(L875
M*E4S;A:I?GJSJVX(VU.WO/FTF"U3+[*3F4]]O"X(@..9T"9KB"M&N%'65WYR
MBJZLAW5#5-6+$0PIB,;G]/_,5K]GZR_K8O[[K\M\?:(7[?M/!PNCV2RMLAP;
MX[V7#%?!%8/T/\6O/Y# BZX%TA@\7_/[[+]9&8V2SUFZFV&>/+<UH51G;  (
M6L4Y0\!"!K'2AE=)BUJ0-MIHD@E/TP%6#^)I##,S*^^^9.OU8F-/W!:K^^>"
MZLB'$R [/3(8Z(BQ2DA-B*700Z$J<UD@(X;,BAK-0S@"P#H7S6"I=[4A>&)$
M,$1!I!0 *C51X@!#5FEI2>65U<1/ GK=BJ2Q1GOY^DJI;E=#OMS\ZKABJSU!
M@ 1I@HPDT*2,:9Z:HU3Q'J':'%HG6$$_"9#U*J&>,)?4<1O([<<';JA/^54"
M..$<I9*H*I+#52NUQGX@KBGB&@NH,> JMU'ZF$^/J_E=Y$ B]#C.3@P+R*<L
M:YA2^**J=II97L5J(+1M2F_XCS/!,8!U*YE)A7"GF0W/L( ($0$,X(9+ZUSE
MC_+J1S9\G_[F<679ODO=T30,59;%/$_!I-1>R.:W$0A10KO[*8\$3+M_232Y
M(>5 8$ $85I+R5EE_FA 6SH/+R0[O2XZWNU&-X(8II7]VSXSW3)&I#-"44\)
M,08*4 F $37H+8Q]&A5C J=95OIYDID6+KO/2J?"6.(9P<A:R3VQ!O&]B07;
M7,<T*8?XQ>&TH80NRPB>0DXZP(AC0230R@EMHRAA=7CUVK6IRYA>3OJ$EL$T
MY'GI^>@(,I+:IFN&J>,*"2- Q7W?JJ)B0B[_"<!V0"F-EH\[\BT74\W&E5AB
MYCGTWD!&-6:&5-+STHS8%+5S%T>-=JF]O3- H"@P$E!D.75$(@8J/G/*KJX'
MTE"P[#LOMZ$ !\NBK.A]25;Z=%^LWCJZ7_C!7Y+^/G,V#-!/R6==^R*:4;XG
M6 T(-YA3;($3UBFU+],SW+1I7#>I@]YD%M=TA3ND??$Y>]C&=4;O;.S^>,S7
M3S7,A>\?#( ::[FC$0C,XOC'RVUHBR7W:JT#8M^:;1-!TT^;$K7Z)35O1@6/
M>$001#Z>F8AGB(/M58Z15D_%E54D-!7TP37?EJ&#;8F/OY79'X^I-^*?\:\:
MA2L'1@1*HH;DP!CD)(\DIBM =_0)JP9M?C]D2+&%I%^CIQ/.CHB<TW4EA\8$
M@9!16&B#H?$ (PH@V]'()6GC>YLB>MI*^C1R&O%U).R<[F7ZWO/!,<<=,TX9
MA !F!'@,=K0A+J[LAL8.9'P<-8VX.F@!W-Z$W#KQ3FU5!P?% RKT(%7CPU1/
MH$0D550Z6O"K38#I<+?JBKGC0JA>+>2!80%RHPDP4&K./%&6&JYWE#+A!G54
M#920VE+DM5#4B+N- S@VFV]47\+-^]]S/*VT[OC@9+K%UAILM'+$P;C8MDSB
M(E+9IB#H8M!RKFB+_AG=IL)U?M<4-;4&!X.D=D9@9XA0GCC'.-]1XA6XLON
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M)[".++.V8JNZ8R@36BUK>/)Y^GH&/#D_ ,H,@42>[P;^?XASLR=*WL<@1D/
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M->.6=D).XO3/FSCJC[WT.KY#\9/OH2ER[FXNKF[U?^EY4(<;3TC_!>$:G='
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M;3?=1QI#["6&V/],\\S$Q1]N,,Z2^4$0/>,4?Z*'_5N4 .E0@H6JE//,OGT
M.7>3@>4G6<*_&\ H%,%J R[RH8M&W,6)C0W97S2_<P.4W*)T'(>XW?2FP\1
MT7[)L+L(A%*I^B:JP(1GQ:Z7CMU [_\;K#X>W(&B@&B"10,^%N]A0\!0Y;$?
MY=$B\,P70%%5TSI5L[VBJ'>:&NIU[LCK/!!]0?&R\RAEVV64U%RTV%QL(43=
M1/:IE[GO$'5;6F"BU=W8&[AAOX^>4!"-<%_=)$%I:3.3+U=S6?>+L(\>_-!/
MT5?_"?4OX);PT>\%2,=W)L9KEK8.X$$S*+H(;^((J)<4[P6:6M/W=@-+$^.P
M@'#%?B@%Y1K*QJ])]RF.5R)\1]7:"HOT]#^NK^Q_SH'8V0# .<U0_QYY@S *
MHL?76_]QT!5+N"2-7R930XA=@\A3M"ZA\N'BM'+SLDWPFN^]_Q6>'B:H?P-1
M0V?<M=UO<K816//S "I)W%&$SCB(:\/M>IQV$F^;<[]NQ%UV"]_KXMW';A\-
MW?@']I?)ARMWV+4P86,_:^'H.ZH5&H'%07C^U U?%2;4>+3:>&S;=Z!:XB"T
MQ+8W;* ^1B=]C!W,9%(%TF$%TJ(9S[FM0V]Q?3(!3%9\_N(/Q\,C3K-,Z''R
M.2LV+Q'D>'(JG<$KD)+BM8S7,D$H7@\4KUT-#5L+V-U'GNU$+ U#.AB&M!-*
M6W,N#TGYM<*[I,IO>^;Z@*HDVF:X]UX:T1D4OUOO'C"*]ZV!*8H73)FY?HS+
M4Q&0#;G)."8+Z9T8_35&H?<Z \U)VU)+O$/H.([]\+$;^)P :/FXI\!99> =
MG4";E(?-ZK-_("P8J*_C WT>T9Q>*Y'A(AR-TS=UV_,-BF4,MP#=;N"D0H]5
MTJ0A?59'T2D&EY.THPB<+?^:BN7DS]^ DW@ZX?4KUM_5&HF0)"$-A'DC3#7<
M E)6*+FWM&S*:'=1YVY[-KI$%.*_O/4(R=>&Z_U _3L\_M)NZTW*#4?E9AZE
MLPPI[8Y>SY'F165CX>6H\.Y0>(]51B@8&M3!/-7!C:D_GJJ__?LN9K$[FX5Z
MZ3:]%RHY*WLO"WG2(O^%"G 73!8-&ZC'WDW$[]MDT435P9DLFB]K@0!_N[N/
M"0U>];#_)7I"<3BM/Z>F;R\"O) G+1)@:H%;(, [2GA3^WM@"6]J?5L@O&M;
M7RIK>S65%-LM# VI9WEPH2'U+%L@P&MZEE36]N@&4ERW,.5!8Z:V^G$T:J("
M3.?)CU& Z3QY"P1X[="02MM>XSB*[=;EXZEI:F<@1@U3>X47*\L+>&8\QMV<
M;N!PAT(_BJ^B%"6._X1N(C],[Y^C&Q1[T,X:H_MG^/WJ1#'\@ ;=DI"WHRZ.
MI]YHV!T%PLPZ7@J$C@!AVRLH5P%"-(X)1?Z%XHB09XXL.7$.$P[K#OY(M,/]
M($:9G-SY+R J]:2!BX<'BPV&WU%ML;;9H-JB9=JB!2:$:HLV:HLVF!%PLC!=
MKORPAB('B(85QWPLNH%"8*\0V+86H-/(K5HT1N=OMW^N$)W^:0KF=/KG\+%-
MJUX/35QHU6LG!)C.O.[?':.3GBTP670%8=L,5C<J%F@LU3WAI9)&%VFT"]<T
M_MF_&T8#C^YI<BHWAV4<J/!V67CI-DKM$]^N+$FB GQ, DS3( <GP#01TD4!
MIM)&MU+J"+;IQO#M$Y>N3"K3*;86"#!=%-PV\>U&;H<*;PN$EVXWTS[Q[4IH
M2 6X!0),#ZEHGP!WQ7VFN9TMK9+BJ91T$0R<=LK*IP+;+!@JM3D%0Q? T+1F
M4*EFZ"@8U,8U _'SDCC]\]8-'Q%A-_YTZ;[XP_%PSMDJ#9_8[_O7$9I!R'P#
MRT^\:!RFM^"%= ,?,/CS"2E./N./,[1HR$NIH^04<\M)V5''I YQ?D@15R"N
M3 N*N&:WE_1#-_1\-ZC:-> RBM-'%U@1]J_3 8HK4YA746B"YI_D0MH.L(D5
MJQYYOGG 1D/?D0>TW?U&:P!17+?_&D-GY^/GSC.]:% ]O$-F+)'TFN3( 0KV
M*B,]>':OI-T.D/GKC_O@H3"=RCAHSB\=YL$SND;Q':;[MN)@#Y[I5; _3(ZO
M,M*.LGMV\I'*>/MD?.LSSC1*[U:4OE= 4)?N2!A-H_:C8C>-VML4M;=.Q1^F
MB6^+7[\O=M.\>\<9>Q$^H23%77PS6VM&PR&*,5EN7'A'MUCZ=ESE6LN*@764
MF3/)E@7,O(Q"]'KIQC]0ZHS#?L<$=!$WJT?6T63*JNRLJA(^!&:N6_W<8E:N
MJF8I*P]&R5*+>4!R>8M&X]@;N G2'V.4E9$>#D?K1]=1&5V5K=01Z@0[5U6Y
M5$H[I7QGV&JX 83=Z&Z 4/HU\MP4Z#+#7))/NXI"+TNGD,S:FV6*BQ)1=RG.
MRC[ZWI3('4-''8VF&%E I$4@:2P%5D_CCF)T]3QG]^'59M9NVZHL53^ZY\5C
MU/_JNST_J%HB_1OJ/_KAHX42_S%\>W_Q/>KK2=YT2N9NX62Y&JHC5D,ZJ)K4
MY6AS*:T/01VM9C+-!?9R"6;!D/0GI#PTC-819T<8K:!M1_7H;C%Y5'ITSQAM
MB1[=.V:7VGX+7O\$]SVA*7UN_>3'S%,NH LQ>$YX5=[=LSM:X1G)%]</OT9)
M8KSF]+]% >E?,O!'U4N\\X:')@I;=BD6<7#:B6H6;K$+RP%0L=9]!@%40*E1
MH<YY"P/*I8[02D;%B6($Y+1?O %>B6Y"EV+72YNU+5<HG0;]!VI?MNQJK69?
M%G*S)6:F'@P=C:D;%EMJ:FC\TL8\T)*I$PK;7<ZB= 2Y[7"2*'(I<EN@<W<[
M7W30N?<]AZ![RKWO'9-T/JB]ONJQ8I+FUO</?9I;;V]NO1W!(\U3MD56:9ZR
M$WG*MD7.[[2O.Q%?TTT&3A ]'[+D+N (E> Y":[$PU'87)H\H,F#[1N4=TTB
M4(.R=T&@!J4K!F6;AS%DL4!^X(N7?_CSBW&S#8$\_+D6?(I#F:0GGPN:G@--
M#TZD.C*=L^UPBHK(!A:*HGC_<05!<;T9^)^;[Q3C#9L!H"DU P<C0$O\*/,W
MAPI0PP($-*4"=#!^U$P6@8H(]:,ZB>(E?A0-IVDX?4 "M <_2K>H #7M1^D6
M%:!CL4!4@*@ '9  [3X59G^[I0+4L  !3:D '8P +7'AJ !1 3H@ =J#"T=S
MR327?#@"M'L+1&<SZ6SF 0E0TQ;(R@3H]_NM9 HVK,7,3G]TD\%#$#TG,7I"
MX1C-/?HB]*(ANDN!(_BIE>6G=V[0M0-1VB,0FQ9.9@=:5C*OH9XM8/V41"7>
M;T\N0?;BU()^Y)+)P7^3)TZNE6Y 8;_4O"S(Q94#%N0(!@37X2TO(^#IFR+P
M543ZNGB&G3V#2O<^I;N&H[N4\VI '(O(0_38:I&GMKO#TGT\MAO"TG4$&3<_
M,D&FMOO0I/O(;7<W1/ZH-K+HXNX-[8+4*A%@(Y!:3^_G:TXG&B>[Z6"LP/8Q
MVKCB78$CQQ)"[4QF*,2/!5([L^Q4#5,U? BN2S&-2V+.*6\OW12?_OXZC4?O
M!E&<IB@>]J>-.@%<$GM5CZPX*[-N:%V<5IQ?XW6X>P\=S]8_,YL?4(9V?-/=
MS$T1OU//=]]>Q3ZM^ RDWFG%,:+4W\6KZ(D[A1\"2ZJR[H"E_7& KA_LO\8P
MF$N4#J+^E$QOOT7HRAVBDLUWA\DX?#3\*/&'?N#&DZ/LNX$N7$CU'BH4_L$2
M,NP(8NHIMP[$2'.!;=I1I,@Z"&2U;).!)3O"'W[-YWIS75O=??U(ZS%7P2WU
MR5KNDVT[#*/V[^#LWWQ&;1>;%5(]TAD]LH7H'YL9'/UC57*+:U4(P_&G2S_T
MA^-A-_B+=<"D^R>?\<>9_A_1G)-(V7D0B92R=-(9D9W.B+1+IA>H:/>EVS)=
M[O^QL'.!BJ;L[)B*GIFQ=EP/'Z+P.E-VD6GG*(C2P3@.[Y[]]#\H#MRP(]-A
M1 -7#:Q0SK4CZVY<+5)V[H>=VYG<Y,J3FY-2G"PA8$;#413B&' FSM4];SP<
M!SBM>!^[89)%@WK_W^,L\.L&LR?K:!:->>9PI!4&W5:UWG0A$I[#I*AI/VI*
MVD/=QKYPW.8@N$+IMS!&;N#_!Y52D46VZ=#AL-+PNYA4;<*L%%0 (I6/ED(W
M;GP$FF*5T1^-H7F7CK'0@Q^BOH%"^".] 7\M.1Z#L\+@NZA?WNU]4%"T !0-
M>R--&!V*BWWAHF4FYUW:A;HN^W-=VJU?:,"SSX"G13JF"3"157&X68P&F#>X
M8@,OB\.DG,X7_CX&<C^\^N%C5O^'[!<O&/=1?_("N N^@ 8W44Q2$VD:^[UQ
MZO8"=!_A,Y#QYAQ1$)#2P:R4\="1NG_:'H48O-O4[I]/5 :Z* ,M3HKNG^P4
MTAV']%9J9-\!:3K90W-N-/9IRV1/VPP>39>T(EVRG3G \O8^M\@+W"0!6F=E
M-=?C]/IA!>L\ YQ-'S*W1O&H4?H>1DQ!_#Y.+,+T 0M<BX+OBCW=.BVA^W?N
MJ?QW0/[W#Y/=:)=6U/$?CG8YJ/#EJ!4 G84Z5 ^ ^N@'(J+M\='W;T5;**%4
MAIJ1H4."Z4$Y>_N/$:B(=<!,[1\FU$WMH':AH>2A*( 6A9+4 Z".:@<<U?V:
MDLR2\/HHAD[ 3YZ?:O$!Q):W:#2.O8&;H)LX>HS=X71+@TL7+N .53><MPGC
M7H+^&F-=\@0_[E]'L[">N]XMM-:3*M\D825:-:6TJRE=.B2SBM2[T\GB>CI9
M/.7Y)JMKRWL;+H.XA3Q"A66<.QB<KCK@'=5?;+<LIPG]=C"<?[>&:FO9S?R^
MR)3MK63[MH^=H26ZW2C1W8+*IR6Z'8WF=[*+,540K5<0+<KJO%NC[#]#?KC@
MW#]MNZ@+WSC(QUQDTK7*C-V=)T,U78M MW_:=A'237A]=$.D-FR(M/^YO7<#
M:?\B?+@XW3]MJ1A0Y['USN.!08DFZVCI33.A"TWM[3[WW[KXE:J3=N3^6S<S
M2$/ %NR5W+:90NK'MB$)VKK<.-45^]<56THCEBN[=>A/WP_&.*UPASQ\'J6/
MDB*?X,31$)-KG&95R ^V&X=^^)C<H)C4W1BOU0^85B7= S_^P$=0]V_A9^Q[
M\-==&GD_OH5^VC%?9(O$RJN:5J'6441"%8L0M@[52S?^@5(*SCIP5M-G-W!L
MW[JUK<,16CY$\= -/32E^1U*TP#U_9!\11$ZB]"5249U* 4M!2W5M-3PM]WP
M'Z$.I2%3-T.F%FK.9S?N3U:LKF"@<0ZL8P K#W$EBSH=X]%JL+>P."B=4P$)
MJB76TA+V<!1$KR@3GYMB:5W@AMU'PI*A'8M.6 $$5"<<#QP6FXCBV[)AQ>Y9
MMT%0?%TSJF,Q!RMX!]0<4!#0R&'GD</^8;&"E]#QY%D%"(X[W?7N'$(7D_QK
MJX(CG$M: 1A80>8D.BQ7D2!B^>B.!0HK> O4+!R3)T #Q..6=NH1'.-$_0K
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MXA,EHK*:6Y%8_S73C=D'E=Y@H3 :^F'M.Q:/=/8E<\\J+DV&MI N?[_]QR)
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M,QMM B)$!@?=03&\@="P#^3TDS3.%M=@C18F^"5 ;T#'?]Q"[X.F<L-'K%5
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ML=;#J-V$HM7 1YL];KW7,8S9 U/K779I)[WJR&)2GI6CZ?#W\MKTPKH"K"O
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MD+(5=M4'A*A6K6/DSR[SYUIU"=UKM+ZB^DFR1)[61D>T!^K *Z\CD]I E$#
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MK7*P50ZVRKGW0H78,=VW_7Y6Q%E5VM\OAW6>+QK):Q5D\"4_5P0-G'GN8F!
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M"9:JR!CUI#'TXGWQM6XY>#JV_7]?#2?EP]H<RH\;'8)!#Z06V^ENMCMQ?$R
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M?3MY?1W-;VVUD<-]!Q[%>3'JEP>]4/;K?C@]3@]ZC%"])1GH8+^+[U;I<"%
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M"F7^KZV"3?>_:7X4\,Q3A3N+;1PF3.O5KU= =2A>>VKZ*T4.]W0P^IODHM7
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MU?X\<D#B6H,-_&$_=0CM::VJ2]GDZ=D;5HSMUHA*T:"8K1I651S0#^Q52%D
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M%*O\,^M/.?U;6A9?;O= ;I79:E"VK#K7JIY=EQ1XK:J$EDX;R2KB+-0,"B6
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M65:[#^NUL)+)3<%C=;1"7$D@KR5 8+I"<5N[_+ =I\37/"N7KJI>YW,?*['
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MOXZRR??NRFUAA ]P#W4]U/50]^:A3C10)VD4&:!0'&-.P]AH&)(04$,B"91
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M4RV!XI0S1KFDQ(24B,X++E2T^S8"LYY.6QL;T?&61>\>,GX:,EI!(0QR:13
ME$>,2J45BE&$1,0YBQ190XV6IT#&FFJZ'N >/'KPZ,'C>>#1*O $!!%:0DXE
MAC1&L8BT(1*#*-8AQF#-\D8/!7UDZ MR_#8Q]B-9N54@*C0(<$HQ$=PU%E<:
M,$6-IIA'A!/0><?4'5$=>L[N.?L5.)NT*DPAPU5$I"(X-#0R1D8$Z9#+D$=<
M1ZKS+JL;(.&3 ]CS>,_C;YS'6Q6JF"0A-*$]O!6G"$66 0W /%:  "XBM%X>
M[SGVL1R[,Q6L3ESYJKYDU5-)%5M2'6;STW'Z4\"U=D7S)^T,_[*.A7K0(K.!
M2/\< XQ5SQK<CR70!+D"A3$U*!2,<8$-C"2BAN GX/Z#!IA:4JM^? &][6;J
MWQX5^ "M[9AX"DEMK,CWEFVW&X2C+Y(V^M9 =B/3J)^%P+SI5:IC22)@1>Q(
M8PI5J(0!1 &- (\1PT_H5;H6!%Y3V80]C. Z\K"?07B;F<'=XW2/TSU.OS9.
MRU9[]S"D,91$1-108XR*0J-B"2,4,P%QE^W=5^)T%_7G]B0@W39YWS'4[<&U
M2ROHNFU(:P'&#38&/ [4*&QZ_>H06^V?"!/SF"H"I*0R)I)J(74$^!,J\CYH
M]MT$]1^N,UQC!:WT./:6<&P39<'7 [F-%/(>B8 8+1!0:(8B"$T<&44)#I44
M"&,KZEG56X31$^H*KP4!UZ5^0\:Z;4WXH"#8RWL]3O8XN5TX21N<Y%B02(>4
M,!I2^[<R#!F+FI#&Q-DIUXV3G:B_3( #T*.>#R+XMUEB1[KXWO_=&HZEI72_
M*O@"$?CS+W>/3W1%FN6#_C6>7R:Y/1"#T60PG@_3(CB)3'P81M]4D$R&P5^_
M?XZ^'9[\=K#X5W":#BSU!<F/9#1VT[*W!K.+-/A^<'S@_GUD0==14>#([V!Y
M239CTO]Z:+DD/TMSQX7UO-5?OQQ%?_>3_OHI^O7;8?C;C<%7M'PTO[2/'=P_
MF398"8M,?G*CB3V#9A^Q@ZIUPHT=IP."T62>+)#FQ [@.!VGG@WW5:2IHG$8
M*XLQ7%!EE5'7)H^&1J@(@'WXKIQO^SE_^5L:Y.D@.Y_8EPT7<2+!69Y=!K.K
M++BZR,9I8=$A+X)DX!5*NP8.)H)Z)5\64SEL*N%#%F("0@H)I09#K8B1%##"
M<8ACM<!4%S'U,;(#GUW_;31,OZ;YP.Y9<IY^.:M@-K;3_9S\,\O#43'+1Z?S
M698_8'GTEYMY89'+KDT3F=5ZPI=)>@M\+:;Z+QK\/3R*%P"\C^[/EE@%OW^^
M@;^=;8?GFU?:Y";"PBCL0BL$L.<D911*:5BHN0NC93($\+4W^>0JZW:3X2H3
M\_HV.3L+SO.L*&[%BGD>=X= Y^^<7>1IVOU,+NTW%T606D1> ]U^3O+!1:DH
M8+@7.#KI_!U[K\ARHDE)C:!5X*D!1@A&6<@$T1Q0!#74!I&FPTAG+-<6:3O#
M5?QH5(4KK)IO$55EHXX +20 H6'0 *H%D!RJ*-12A5B&B-+7WN+'H>JCM]AB
MZNVXM?5M<8^<]R(GE)V_XR!8ENN7Q/J51_QO)^$2D:M),KXN1L67,W7II%S[
MW\G07"23\_1P4JG2%<E_2^TH?J3%B5.5G!"NQ]G@]W<K9'(KF88<L2@6)J*4
M2T$9Q+&("',Y0(3O-\U@1:PU42B*(DHLUF(14QIJ&L9A:*59S-\%J:7UJ=-T
M\WGZ;G-5%36Q$%>NI1,N'!\,_#(Z13*OELZSR'!4>(6B\)B8C,?953(9V!_M
MG<7\TFJQ7BE)W-7NQ^+CXS7/VQ-L7;UDE0,WUL=];C]NXF!EO+2D$)1626\"
M" ;I>%S]^N_OP#O_V0YS4']>L:@GHTL[S:/T*OB672:W;)A7H^'LPO[3SJ.R
M@ SL B33(OU8_^.6:OUND=>P2-F!_-W=:0_E.XCX\R_O;EEKJO<_[R?0^1/[
ME]UYVZ/S6=:1GO7\=)=.K3_^TU7)K*?9V 6'OS^<!/9)8XO!Q8?=]%L\ODKH
MZU*&DR?3_ 5I(ZQ/G9XN>KIHT86Q7SG58)Z,[Q0S7G-\:OA/JS(Y+W=/N3WE
MMBGC6SJ;YY.>*GJJ:%.%SP#>X?80.AD[;7+/Z8]6#PW30>G"O&F#V"UVZ7Q^
MNY?ZT6=VI)C3QG(%0T50C)E43%-"I=0Q@@0B":&)" EOAK;\-1F7SF>UL/BH
MR; VJE5L>\."?.@MR&01VW+_,TZNIZU:&=6W9UENDN)B(?YW%PV(8;?%,]Y6
MSL?.9MKUA2-^'C"W"A.97&"B,B%!0/(PC@$E6@JC680HY3$B!H!;X7XOC8DM
M9;>E5W88( T0[S97I*\$T>->CWL;B7NBP3T0*Z20A3NN &682T4TH=I^1E1&
M-'I%W*LO/[;X550F$WM=<U-WM=3  >VAKX>^'OK>.O0)(%HE("D&1B@HB*"
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MQ-OUDUDZK$CF^")-9\6)F]2)?8\>9X/?WWFZ=1^/TW'J=WJ?"$,9TB)"$:!
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MTWGLDB2#TH%HY:9!.OKA1(B]8)+.=I-_.I_?FS02[(@- !/24I0BBF&,8 @
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M7K1*2F:#B_17NQO37U,7>IL.+KHKRD/@R_1&W4QO3@^&N^R-WE8P>R1\0;F
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MDD6)U+.+%!^8B'&+KZH"D/E#(I&9.)#X3PIQ,PL$XXX([@E&@E$);<S'I\'
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M+KJ3?G%V-;^OF8Q&X:_G2[M*%%3?4N40@Y1P$?HZ_ \HC B@T(B%H57<"L0
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MQ1 Y$@*V:A/MTAKR;:O&Q+,M&L ]Y=G3.$-PH=YI()F@B!&%&!52:H@AYI8
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M:IQ[]\++>2@^"'(,Z(NBAVAB65INK$ > 1 U(34($42!<]I#RJV72(75"'.
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M;"HO[UXA:ALC7&-5YIM@(5>6V6VP-4>'J52MMV\OS^C:^R.X".:D$+2)19:
M<^G#\M*:N"*#FCM)G-6(: J)6XI3>.BS&)M\-+H+??'$(83S*+F3P=>B',<E
M]\7=;7$O@*[1TE^CDK9W#BV"[=8P2<EJ^P"OK9RI4HFFAZ#B33PP85(8341
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M3X"L%*,W86771;<HQ<@'KG&,*'H.):,>2V4%P%(2:8"W0.$/: V<S:L:9=N
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MIEJ'E\6@^S6*O 5R+DG]3:=6LD)@U@]SE31+USD6BH]U0P&+!N%HBRE+K^&
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MP5=C]H$U*B\'+,TWM8+L<8L-Q6JIAF_SR8?QHC]T1N%(6JOJNB*^3'JOY3.
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MC/>3L6+E(]WWA\63L:73*6MS/WG%%)#EW9S[]D(BP@'._&AHH <L8WXO#O3
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MR/<8?M(I=^\B4\]\DH7_>WSQWE_R838]FH8EV/][5H01+@O.4#UF0RL,/:=
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M)C'@6&)B+R KNY"GD%^0^/>4^1?-C9%5'$L2N-9BYRD@1BC(+)+*(H>0T?I
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M'WZT"#7J;5Y+;X<I5!**)A1-*/HLBN+:*$<(6@R55D!X*K66)/;JHA!*J8$
M6Q@7]$THNJ.8'85;U,P3BB8432AZ_"A*:Q05-FB<!&M!G:'>:JECHA*PR&$K
ML5R*3.P914\C^,FW,74M873"Z(31QX/1:^)/F+.ZRZ2&$DE//=:.6A(S\#TQ
MR'G% 4%R*:UTSR"]Z]EM8(OY^R\0WHE.]4BXG' YX?+SN"QK7-9&$2:L!X)A
M*CQ23@)M+5>"*J;ETB2 />/RKL;#,=CH2(\$R F0$R G0'X&D GD<Q.7I/+>
M0!#^AUKIE-76"V^UD0Z9Y2X^C0!RH]@)9:/)5>>.G66.QE]*M\[T_48<&-4!
M78T?PD]:4W?;Y.52W@T"96+?ND+IC^- 91M0Y$WII HWT-U^Z[=W)3O$E]=%
MMRCIY0,0G NN+!?"42BQ(%0K;"B&6F-&_(>Y84;22ZZU5)!R2C25UAOL+:8(
M4F)!X)@B4/!C/,G!N%@\VW XQ8?[HJ0<B,"?%TA'!#IY>OCEZTXO")31#SBV
MW]TB-=S<%X'1ND&&A2?*2@K(AN.'AWP0OC3,PMYF^3>VT_UAD2A>VIFYG8B*
M5^?NZXJUSUU@0:2!Z59.MBZ^GK]#+^))=V'W(:A$>K7N5M'M3C[]]W?@7?DZ
M/'EK^GK%?M]T'L(N715?LD_]AWQ) ?C2:8_NPY]A:1,P:(6]SA^'Q0_3/Y9.
M_]TL6VJ630C!N^>3J:I[$/+G']\MH5WU&1+/?P;?]M$;?[;-F\UOS:#_I=HY
MO(<\S+>GI8FFF#M>J'SUI2+]VWZW':[\W64O"U?JQL[ISZC0:>=6[EPE4K*9
M+9G]U*^DT7D:(C-DXH?4%*95Q!#4#JEBVFC^TY)DG--/LFHL[H*&DE7TU%R3
M_D1%N[%L=TYBOC\HE;";^T%19#^'+]P/LU+5=D'+:=?YQHF6FI%;MWGKM\^#
MP-?MJ*OU!S_\J5W^IZ%-.D2RFZP349ZW;E<18;3-SES0';@ZM'-<>J:Z8<>0
M<Y@>EIC#.*SZ7!7#[[-^N&K1&@?:ZP1;,?\][W1+<_,N0/LP[Z[2 LYY]RIU
M:=HLK/CC,:A,17+X-[.^9Z7;GHY[K>AYDZM_G0@_P'+KM1NQD9.?X3KJZ@F7
M0C"-*6?4 BN-U=88:! 1F*DE/^M5O]=_+ ;!JHVY?)'[7,5[RQ62T5/[ZUP)
M]EM=M L1V+=>I(K,'DC=SH:--$F3L8MUU'X,%>-KR3\)@(8$P$'*_+>@_+''
M:]<@.:V1' #A 7=::B,H($PRB+R"1&)*.,5+A9"O0/))K7M"\M=UYMG"_*@#
M2SL_)]_1SM>W0V2=!"Y&^1_9;95H?.XVU>8]6IKT!!ZX7;%&& E8#W6V2 <1
M!# SFD(K);42&\.% X @M-3G?IJ,\<=$!DW2W9-1T8@HPKLQ)5+UTP'@T3'!
MSH;^"@[J%"N!O>86&N*TIM0A10B4(O:.4TIRN52HOC&P)!WWV^8T-YFD?DP^
MB2:G>FP)FB:9;?15.8+'H2.GI>Y@J9N'-[<;%3^4_4A'?]++WBMV[S4 W<J'
M]UG<\>P^-GH8'@CY[W!//A6_%[WQP:S\4(V,Y/28V28"U9T%J"$088"P@E1R
M)#&D% BB@=->Z!5CSRMB.W$OQXZ:=2'>[!2,Y.4X8  Z)IS9#$@$J+VGW"N.
M%'$(6D(1PL)1::E"S$E$!5IJ4?(\D)R45Z-)(-DH!8,T6CZ:HG0I2O=M.8_3
M<'TVB<TE-36IJ1OZT 6NQ0OBF *O(?2*4B.8TBQ(%<18T%ZI4V)I=L*4[B8^
M]*2P-I0@TFACEY3@EQ#OJ(!M4^2B-7()8R$&#G@0%&'II53<&T4H___L?6ES
MXT:6[5]!>#8[0J7)?;'C340F%C_UE%6>DMQ^\ZD#(J$2VA2I)L@JJW_]NYD
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MB:R3'!^AY["3<-UB%BXORK&C6IB"$_)V=D\ANZQ[5@6-1!*KD M!=,@5AD]
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M!SDQ82*4=TM.)H16A"EB"D<8N*BTF+0NM$JDGVY$YM0,<24/SN?A)7^!!H>
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MENL> :$=$7'5JO4RD^RUR?4 ?<EE&.'-K$$Q7%$'0A/'-=6#<E"5.UPTG?A
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M-O-!59NL25M#T0#4'9HH+]#JU$SF!0;\-WJ@Z89.X%G,KVHW*A7!-7(M,[?
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M_1E.YW2DX4G,0C"7K(F+1U;P(7<6"B_.G"8A<>TEG/&9 ?LR9PX*+%(]Y?Z
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MZ-YL_19% S\JPE9)&1_)J0CS@TB"6TGB)A GN(6^(M7DO(')WZ-@5R1CQT&
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M>L_;UGOR3Z)LY%K)(3C( ZF3CRCB>#$'4 XII=FYD,(M,[5\2G<4L[9M]\Y
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MG<-92T&0J.7AW9#4*(LGY&T12$:R:;%@-?!X;TK(3VO>9(8L%K1!&)4_3HW
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M+NJ^HC?.>H/.67_4Z79;H]&XWQAWFZU18UAK#^N]01,FO4/W%:26@^X=)\&
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MF+7=P6KVQSL=*RX13QU%%6Y4:RR.&.>'1 P$PP+^0L7,ET%CV/TGJ@#LI(?
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MG&_,01!"NMDG?YF7<)).HE2M(A82KA*RO27/+9W/<[@GJ&(GT]N47Z4GR])
MJ5 ^D(/PT3,V2MZW:EVM97N[U;*7QJEQ'4%FT#'^6(K/@KL&_Z*&(\I"S_R8
M[%.^4/CA':F;ISAL].;Z9'CZ4.C$KQ([FV5K5,R@<TI*V]6\7;A?7>)VL1Y_
M&@_[W1UZ,[@4.WCH2:\[V-E#=[2[3$FF+GH.]:W \X_ZZ)H,)1R_&/0()G5
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M<8-GL9NIU$.7;'0GPTQP;"_H6@IM%VD<JHQ<H(MRZ:_@=TOO^&_D!#E_@V4
M+XN<\IP)3QUZGWF4Y87WK]+/"B2[F#.GZ0-5<UU_]7=*GGBW9KXPV<9MFKF-
M1/C]/1'^*R;"W_L(>Q_A9?@(M^'!FOV#^@7I8G09K-60370(Q_(&,V:+EH/I
MV>'IT?GAT6@P/ASV)A?'D_/^Q>'Q=#0^&O6.[UVTK(0F-7LW>+2S.'#LW=&D
M/SUL4F>HQ3)8PQ(\GO<SL%:^31J^G\\/3OR8*F"?%@IVXCC+,#1;5O1>"R*Q
MK^*7:EZ1=D1G[WENG7F!U-E2>S1PKE#$?',T9M'Y$!.8<84FP50KFSL3W=,
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M?+.1V!(=?.^JUC__\<OYQ\O/_[>UL<_[H$@-FSY&$1=GQSPL 6'H^O4,_KZ
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MU.3448-FO;(QX,>4F6#H>(G;*^*TT23BN][0P]Z@.][ICKKM,)*3<]I.I*H
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M%TY5\7<Z#-I"""+2HQ/=J.Z<,'X6"Q5>C2I+5:-5#>BTP2,V7,=!V;#*G-I
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M*)W1$_".@BC3#R%$2"BP]G:^ [HQ8L"DTZ1LXTHKKG-]"I&4$+*0?V0O:F;
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MZQ@R )BEA]?0 S_T<I&"[PKX+.1-K,Z"H_FX^')R/.1)\*'$DEC# VO>H;=
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M!M)5"!JD':B"('N_-3G5T%TY-PHR9Z@-R.5[DNMS53NGP.SY[\6>M9-P70U
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M5\,2'I;P9B^@@I%JUM1.OL<>C\5$A0)^R7'FWN&O+E+6B6BO<1L99\52W$H
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MFASC86*L9SCAO-URQI&D"Z2:R@ 75(;'I<K"LV-,8HC&Y*0$:N!U%<Y(@U-
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M.V5O[SOM^J6G%_F%^\[7RX[[,MKI_P!02P,$%     @ ]H&74#V^4+J:"
MV3D  !8   !B:6EB+3(P,C S,S%X97@S,3(N:'1M[5MO4]LX$W_=?@I=.G=#
M9Q+R#WH04F9"$JYYI@]T:.YZ]U*QY%B#;/DD.2'/IW]V93LQ)$ R35N@80:(
M]6]WY?WM_E9VVK_T+KO#?S[U26!#23[]>?9QT"6E2K7ZI=FM5GO#'ODP_.]'
M<K!?JY.AII$15JB(RFJU?U$BI<#:N%6M3J?3_6ES7^EQ=7A5Q:4.JE(IP_>9
M9:73UVUL.GW]JAUPRN#_J_8OE0KI*2\)>62)ISFUG)'$B&A,OC!NKDF=5"KS
MD5T5S[08!Y8T:HT:^:+TM9C0?(055O+3_DT@1L*VJ^DE"*MFTMHCQ6:G;28F
MQ-B9Y.]+OHILQ:>AD+/64(3<D L^)5<JI-&)ZS/B?[Q5K\7V!+6'F:=M2B(:
MPEQS<%SKGS>ZM:/?F\>'Y[W&\;OCPV:G=W#4.Z[UWITU2J?M*H5?-RO_DTN6
M(N*5@*,MK7JC]NNRN#:VK%)41 '7PJZ8,=(@#IMSJ079KN]1+2R_L14JQ3AJ
MN7TN"FD\K-8Y>,4U+$C^4#80'CE3ZKILP%,J!M3U[Z[D+J>IZ)&2#);.[AQI
MUO<;M^UX2.68,@;N4K$JQI5OBC9XX%5<?U<CNOVKX>!\T.T,!Y<7Y/*<=#\,
M^N?D?'#1N>@..A^A"7K[5X"QJ\]_=BZ&9'BYOK$_UK;/_:ZSJEEKH&7##WWR
MN7-UUKGH?ZY<_OVQ_P_I=(?8TZC5ON8.KH^%#6Q*5QJ4R7^X[VL^([U]TJ4Q
MEU*5B<>U%?Z,V(#:UM/4?!G=EHXD!]6ES/1X7ZJ5W+6)J9=?KQ'JR+(P"\(L
MRR=/!;-!Z^ (+,2H9AEV9A^J;NBMX1/<38_*S%-A=TH;!;]\6R7W;:N6"MW:
M/M;W[\3(U)K[=3_93/FM>BL)Z(03S2>"3R$QPBQ#_DVH!N3+&;3'2ENB?'(F
MU)A'9!!Y^R<KS'/WJ.K\93V'=COO[O?.HY^\1S>>D4>?40-^K"(2SLAUI*:2
MLS$OIXZ=N3-3<"LC!700)E-8FT8SDD16)QQ4 (+HN"(X/24A7&E!)?&I!TV:
MJ!#X@U7IN*4!$?>X,53/<$A(KSG(+:QIH(V!,B!2.I(),G" )S005!@6P730
MA'%-IF!M0$R"?Q;SIUSS;!$T(!1& O5$,CL5-@ #3<P]IR"N&X-JBH&9<(=@
M4T:SXC;L8/RSP;CY$F#,B2\B  IB;@&,,F 8AD.W+O2+R%<:$ J%)'SV9,)@
M35"B@((R %=@JHL!.PA[# =2+G"=0<K<$0VA@[D*M8PC$@D# ,P*$.?$&:>/
M1TU ?*FF)D>ZYF-A+&R&)10;4[U!RW(!L"979DG;'69_-LP>/"/,#F\Y^&]O
MCAKUWT],ALJL ,)4I7Q?P.6>>>N\?T"HY@YG@!N!3@)X(-R@PP@3X P<%D*F
MQFR-UTP83RJ3P#S,X5K)%'"Q5AYGT&S('N"+<0!L"J+^C1?0:,Q)!]+C52)A
M1+U)G8[UD_KA'D]UJ1^R8EO:*+ .CE+0HRR"^;00"U)LHEX;"O57"/5!*-I_
M-UK .*3JK9\E N2ZCI2U*BP4OU\7%8[?_8BHD,>BK6WN'GV[Y;A0./A!E;^E
M9_2X 3$ $<=N'\=R&8FW1Q.S_A1DP",.6,PDI9Q:)1H6@"0[$<:E;AC%([<.
MGLLLDGZ1.&@NJ0-W1JH7H"QGI ([!1  T,4H*9@[8C;)R @FJ!9H@$BIOZ,R
M$:Z4&*3C+C0:Q]U=HE>&@T(6B 5.BBG>Q$12Y"=@EE-B0>MA1EHD%&L;^#3B
M.! H!,SG[%'*L$/E]E Y>C&H7#OG+8%S_6RY-D8!UQ/!$'K4J,CY*S4 6ZR7
M$8]4LQP;@%9!1T(*.T/.O4HL1@H'(X>0%.2WAA;J;<=$;C*#XD3'@%#C:@3/
M4YHY!5SE/>814'\)0(4>'F,$P"%)9%,P0J00,1" '1R_(QR]9PS'_H3*Q&42
M]%7N^U"$B@EXF5E13,ZY]AJ9,;U<75\Z],%$R&HFK6)'*K'W:[!.[J;ST1Q+
M=/_QDRDRRHM_%U!XNA.@SPDNO@/0]P,0>\8 ZJ6^N>SC>-J;U66N9R60-LAB
MR!R5YR4:/;E TU:L&BICH1V?K,):!K8N?]A"]NZ9X@,D(;_<&9TI[@%0W$$U
MGF%'R5ROMZE6 35S3HN9R4&8,Y>RW7YDZ71&I+CF,CNUOC.^_-5;]&Q@^S*.
MC Y_AB,C]]B2Y1 O+U(&9K BS!;9 X&R :U=*O?FVE$H^:S29LXD70,L&8;"
M6LX?R,\C!5P5^YD _=PB>P!&2(<&TRW\Q\(SCR#\WT2 ^BY:))'G#I;?/GH"
M]!20]%(2X',^9NE(*&5 D #HX!$B'DQZ@H.C9RQP?MPQY?0::5U:VCABYXHR
M]\ S?Z2Q$7RRDXGT8'=%EJ$,)AH^3S+W0BTKY6 *X 4JKG+*+0T02Y.$(=5@
ML#,F2^XK'_X\FP3T4F#SG,]!.D /?0TAO0Q.S%TB ABXI^T97LHINQ+11,D)
M1XH5T7'VTH#.<A</8ZEF''JG@4JS%;V%1D#/5OCGJF2_]@.!Y6TLC%XB*>XF
MB(B!H>ZZN%R$6).WWU?+B,W6'OS=T3:%3+T&=HP@,G!=\924-#:\E7]8\IL%
M[F (B(_>EYJE^V&6BCAL_%H Y>V^YOU=!X>+OK4@?!N5&%**VUF\SL).L<F]
M3>M:;M_%;UEA 1Y:I!-K(4FC67:O3&^"^]2*;V+U_?'B:%N;D"[TVYOZN]JJ
M0[T';W3FKWGVB&^(>W! WM3<SW?>DJT[1M545[P$>U^@>A 6W]!',*+BRQFM
M0#"(:=MX07YS;_@Y,;!5JS,PN92SA*0?AH&=_^_\_VE9O?U'%#?<2_"1 /E+
M>)Q\TE T(CDL[SS]J=SSG:=OQ=.[@> ^.9]77Y?I<:0[>$C[.HN'O5GG8W79
M>E^@6_X^UM8.:S?]FM^K_,)]R_%UVWW]\O3_4$L#!!0    ( /:!EU#<><9S
MX 4  "DJ   6    8FEI8BTR,#(P,S,Q>&5X,S(Q+FAT;>U:ZU/;.!#_W/X5
MVS#MT)DD?H2TD*3,Y'GEI@5*0GN=F_N@V#+6H%BN)1-R?_VM9!L2'FVY"X5K
MS0Q))*WV^=-:DK?S;'#0GWP^'$*H9AP.CWOO]OI0J5G6IT;?L@:3 ;R=O'\'
M6W7;@4E"(LD4$Q'AEC7<KT E5"IN6=9\/J_/&W61G%B3(TNSVK*X$)+6?>57
M=I]V=-?NTR>=D!(?OY]TGM5J,!!>.J.1 B^A1%$?4LFB$_CD4WD*#M1J%Y1]
M$2\2=A(J<&W7AD\B.65GI*!03'&Z.SP/V92ICI4U49B52^M,A;_8[?CL#*1:
M</JF$HA(U0(R8WS1FK 9E;!/YW D9B1JFS')_J8MQXY56VN/,W<[!"(RP[G2
M'33MD>OT!J]'S:9M-WJCIC/L;_5Z[K!O;[WN5G8[%L%_,ZOX*"1S%M%:2+4M
M+<>UGU\7U]$]-RG*HI F3-TP8YJ@.-U=2%V2;<:^J86BYZI&.#N)6L;/RT+<
MKZLU0E2<(D/X3:B0>= 3XK0J$2DUB>H&5SF9YCP3/17<1]9YY*#AUIU5.[ZF
M<DQ\'^%24R+6G,^7;? 0533YH4;TAT>3O=%>OSO9.]C_?BL>5NG#XZ/Q<7=_
M I,#& _[6G78L5_!P0@F;X<P[A[UNOO#<>W@CW?#S]#M3_2(:]ON?PT3BWRT
MMM70'=^_ NY@<,;I,$UD2I"9$B"IIU.7L4\$H$(*8Y),241E[>"<TP5T/:5'
MM'VP*=-I/D/")GGY8L-Y9;=)Y,/F-&\@:<'3:33M*G@AB3&"\*IA!.@T!,YV
M%8XCIK/;6&&2DYC+?/JR"I1X8:%'BMY()&( J400, ];>JS'Q F-8"_RZE4@
M,*"<S$E"P1-)+!)B1&]J!B\VMEW7;O?%+";1PK2<-@KQ!0K$K$&G"T"FB@6+
MJO%%:H0;29K:>=V6<!J).:?^"462D*C6_R3&$[3_0TH2]#Q?P!%%SV 8(QB)
M9 :.7?L @4B,F[]D5$!1,1\*\]:FR'N2>&$&C893-4^JM<MXL=%PV\LAO["R
M"'J!J1P+$*0<W>)ABS,$PYRIT(PG]$O*$JJ?OP9KXPS*F?Y. R$/Z#:GN>E?
ML$22%!] FLWP',$>G=!BS3@[C2V$*"X/3<@B=/DLPZ>')A"FD8UFZL&EN!"F
M0Q8G5&HMJIJ"< XX$ZTG''64,:HEJV9BP"(2>;H?>?IF'V(D(E7*,R-$3+-E
M(:^XH?[]8+[T^<ZZD+J3QTZ[]M\H4JR9)>IBR7$:J)9]9<GI]C*[2$>#KRY3
M38,L%9EBEO(HY_GHFXI=,6T9$Z]HWWW;-&>^"O$GVC$5"::WFB<X)[&DK>+'
M\K-/FV'4P=V*\C' 6GSTIM+0FRGEZX_D8C37)A/1=)^W"Z*K8XW;A[::EV,W
M\#[3R=(C/%<//=9>\;C.:<ON7&Y/A5)BMM)E]E2FIW)]'WH_:7& BZ@%W3AA
M'-S&:CK*-XFK?KEB<F;%O5A]->Z7NF^ORPG;MZZXKUNM YWC-3?(B<]!"LY\
MV+#-WP]VR=J!84D+WC,OI!P^BC0B2@IY@XN^O2CN$2$"105<S%LA\S&CK>.0
M='<L_)HKX$&L7CO(2X _UE _.,#OZUG^ ]'=#QD-< ^.^W'%SB@<9">Y$N0E
MR'\>D/^)6U<\[L5XWJ,72,_O+/ZZ#>J6.<]<NP8M#WOE8:\\[)5)\E<\[&5^
M^9T&04(7,*A#G\2XXD6Y6R@7PD]UYBLA_GB#74)\+1"_//)]Q&TP'"94,KT)
MK)9(?RPQ+Y&^QBN.T<4KO_R*P[SPR\:ZGB?22.F*H?+^XY'!H5P$Z[X"N7SY
MO>XKD <MWNA"4?:"[D83>?;>GDF8(_X5C5 *GFU-E6!>L>##=+%:K: K>D(B
M84J1/D[$&=/U'4JLU$'HQ#%GG",5<LI+$I#359H@32(FPTL&2U4/>ORB\@$G
MS9B4N@I!),"4U*H& :0Q]FA=J537RPYN*<B[7@96N>M]T9USR2UE@T^*AJF:
M?-HQY9R[_P!02P,$%     @ ]H&74*0RP]*CO@  HO0  !$   !B:6]G96YL
M;V=O83$P+FIP9^R\![CC5ID_[#M];G)))9  R3"I1$QDR98M#VFJEFS+MHHM
MV\""NF4U6Y8MR;2E+X%=>NBP!!8(L+"4),"RE-#+TCLLF\"RU(4$" 0"Y#N^
MDS()82G_Y_L_W_<\G)EK'QV]YSWGO/7W^E[YUJ_<>EWA^ ;+LX6-C8W"Y>!?
MX=;_*3RX.XZ2:#Z.I@=*%Q0+.,D+._^GL&['KRD*&X6-V]]OO5XZ:YPDT\,P
M',XOT,Q(MRXPH@#.M"F,7%"$"Q=>DDTUP[.2 [KEN.%%!W_RK^\]>, U+SJH
M8D)1F%+6V.56L26OVHJQ\HR:>?"2B[<V+\P.9\$TL!+M0!;XX?QP=M'!;>Z'
M07\]#!\\L$V2>!<=)-8W#@R$[@$JBJT#V 6E0T8100Y4*A<@9:Q201Y\ "TB
M*%P$_RN'D/)AK'(8K1ZXK1T$R^V_,#;MPQ+-WK8:N+KHX&WG2M/T@K1T010[
M,%*KU=9<4/00H#@TS\-$RPZ%\S.W>1QA0EMS(W:GB1N%!];7FAXMDHL.'KR-
MLVG<P7BZB/UMMJ8!6[X56&$R!T)#X"/<]E]H&H?M* ZTY&(WT!P+GDPMYT+X
MSM$[J!(W\:TCET<V0?BWW;WMVG?7RQ_VM="YZ&!VR+1L;>$G!R\FW<BQPD>T
M(B=Z!((62TCY0O@(_>W<X+NPVU[]SM6.W#WJQ'^R&(#F[I##/1K.481U/G#^
M=V('=@/G#K&!*8<%8"*FEFBTEE@7 ^67#R'HH2*F(,7#Y=IAM CZAXO%"^'?
MHSV*162Z=OY[#+!M!M71;7/O)+IS)A5;8.!/6?HHRKM-CV(EBOR+CY@V[_N+
M>1*O1P]0<N7 >8)FN.':11]T%)_;IMS)2!DO CW47'_^1VQC_3;5XKFEY%/K
MHH.2-8\6L6$=O)UNF]U:#8=3UTS&%Z-897O=HX9^CW)LN<XXN1C'[Z2\;>CW
M2&\SYT:7J=])?+2-'TV\[0H7P[4)7"8(4?9&#<DA2,)AR!;!S F"AJLB,>_5
MQTNS7EMI]5K*T\)"((BRZ/EM BH2VXTD /VZ,<36)B&N9X(F$B0,\8+*^+2(
MU,2>5ZO+O8P%5"2X*\A,-M4#G&+ A:YB1<-O<*)+#M5^Y) XV(]#-  W8D@(
M(GA5VRN#013)%[>9R[T^S7-M62KRQ.^UKJZN][)NQ1SA>Q3@!=J:VU_<I&&)
MS,UUK[]]O=K:'-7[JV$*^L/UGLBY69+2;0I[FZ(W#)(CU\[VGGN&/QZIZYV,
MM[?3&R&W7;OID;WUAK=3>$<XC.K(8K3N;9^:3,&UMWT]7U]3O!GV_>WKXGH;
M5-T,?-],MT]:VU[3T[E^HJV[\)$U=;4_-M*URM+M^V:]/]'6O.GM%07#EV1Q
M?9]>WW>$$2+)6YM'CPSO1@$XE+=/"4;T$HD9(-1HG.@TZ\*4IQFLHSB.7.^7
M]'J_:%*(N+4)=!D/!PV/9]I+?4".]1 <MR[Y!BK<(6XFW-:ML]9S>\)@[<DP
M$=QR=C>M@+T9R+;=-*2>@ J*A[;=8MZ:,'^1DN]F(2S0AGO[!;WJ 8O>[DJZ
MH+*^=@^6MY;"M@7?R4VO #IZ@JQ9>'?A2+H!T$Q2[H'N1+L+1TI><^B.P4LR
MKWFC07MRU-[(T?JTCL9)18..EJV263)S;#I2A<40=>ZVG7NF!=9[3]1_9KO=
M ^[8VV+;+^EAUE&&:$OA%X),,B-U-#;5K,BSVYJ:Z&BV- >\8Y3(\1#M.2V9
M7/4\D[J=Z_]+W.[:[F9O+;;ACX)^/E*QR4@F54WMES05"[=M-)"F9MU?ZBX)
MY*;_,5NC,AGLT3>"_F*]G_[:)U%_,<J!?Z"8IPVDJ8Z6'4TM.UN;?\2^[Z&1
MZ'IOMUTHTVZ98%E\ 9RON[4)@BM=!>Y-D@((R&TCW%8O>X=%@MD"U1\2O>UA
MP\90Q!\.[I0"(=[9O;O<FMWMM[ ]'>6W$2.-'E]O(T8XO)WH-E'T",HAN@0I
M$G61L A* -R:P)0)FB?:*5%=TTDBV208'(13<D2P96*8DA%1+Q*&0Y8(+@5!
MDZH3_!R$0JI/-"(B3"F/:'I$[% YV%O+()8$31+"D,A36B3:/0)-:8?H](A*
M"D)3=TA *<@THD'2(J,0DD=R*>,3\IP4'*9,*&52$EF!Z//DUJ8JL@ZA&J3N
ML @Q2$DGK;>($4\&3GU,:!XY%^L883!D+G(287ID6>2FA,V3D,/3A)-2+,&;
MA#ND6BE?!GOS&$I.&SW"+U*CM)$1842-B6:'F#I4Y#3G1#RD4K'5(I(>529:
M,;'L@>@+-)8-:5X4$F+ET&+:[A)(1 ,_==HY42K3KM-1B0I/QTZG0N &74R[
M#C@B#8EB'>B;X0DQ(>DY(Q-2GZP+C"%*$,FG3.#($=D:,AFA*%N;9(<!,E<@
M4BRR'-&+225B9;$_)%6#-5.U3HZ&[-11$=+HL8@X\$E[6">=H4JZ1KV= I'X
M7EUS1E4R2NM;FZ&H+<DYT)JH3\AECR-38T3F<ZXKFET293B3L.HDYG$Q8<%D
MC><PT2Y3Q)SG4B>GF"&O.N,%Q?.\[[BSK4VJ5>:+SB2DNO,&0W@^I40-)?4]
M:N U)FG@47K46*6A3]GS)B-&(34I-OO$=$9%3#,@9@MJWFN6B'A%I?/6UB;O
MS#$*85J:N" HS&G-B25/04P+$E.9IB)!3#.#YGK"Q,E#6B $5%RM:+'8;C@(
M0?>CMDF@'5KSVFE:LK8V:=OI,&EY07M>9T1@,#V==Q*G*M.+<I<2<9\N,MV!
M4ZO0V+ [3^$N#:4B)1$!PPCB4"(AIC$7%Q(]8+H]:6N3R<"_'B[I$E"4%DFY
MQ$6,8\B-<8-E E$>D\T),Q?D<B;03"XH8@9B1%E0IF279:!>CQR+(<MX/6TL
M@Y.RS6)O-5925N+[;;*OL@,0=#*UQEJ$"FPJ8#U/U4FMR\:\BHSU"IL5!Z)D
M^FS9&\1C6V9A8UC/QD2]WAMN;;IC=UEO]X;0V'/JO=Y(RP*IKANCDA0Q=3?2
M>M*T5)^6M4R*Y_5,U#M9,JF7(WT^7FH<P1O-<29SW-R(LI6PM<EU>R8W1CAN
M0)B!5*(Y*[78,49P063Y9 7B%I[-9#C$H9[MDQ#,09'#RB3)UU,GH&B&[Q)C
MCF)Y?M ;;VU&,M?A[;G;R!M]/N+=.&^9?!I-.E0[X#%QDKK=M$'BGB)+>*,Y
M]U"WUV@HCJ]1ZJ!A&'XM'X8-$)G'N5;:VFPLG+!.F8U&*0IGN6TTB6+4S<=9
ML\E'".75FXHSU?+ ;)K$C' CI!DXLR"/N\V4C]MN,FUBQ;@HIVR+]N;KO)"[
MK;:1T!1"M@;#9):7QJWQ<*%0%:H5&XNJBWLM)%IZ,LRUX'+:5LBYT!13=,7(
M0B_*G$F](MA\WIPT0*X7IO,<H86V4!RN[%6G+,!,L;F2_':C7$3IGM+N%9'Q
M:D"U[2+:7HWR]JR,5A3#:Z-$*:3M08<4RSW:%3J"@P&O5WRJ,\"Q)1UBG<FP
M8M*SO+/ JRTEB3N5J%JAT[!;[^%3>C7IRGQMJ*#CKD5 /(TYW1D!E6E\W$49
M.)K +D"#5)L8,50@=DRRV6-GHI:158]/Q;!!);U625Q-:;O7)22BS4A%N2D)
M&##6?E\:3=F2-W2EP*S/BGHJK?K<UJ95M D9A&&YZ$IRVVQP/7\B:WX#9Z*2
M'"+-;.T(2+L5>$M7H::"X>4516RT90]5%#/K-'K80HG-+L'40+V@8.UNJ4^$
M/8X5%PA3[_5)*4"XH#=A99MM<;VLK0R0SJP'CWJB+W?[[:3?9/M(WVBH-#(R
M^C-?K2$FT\<:@ZW-,NLL50X9YHBGJ:H_6K 1!]ZTJ1\C:K&O^_VE/Z#[QMA?
MJ0/9-"VVU!B,IY;.5FJ#M&8/^]!J2/2=/DJ!^#;L9F,%K;M#N^_*:M,8+LF)
MB'8&0RCQ1% ;C3J^WU55>62905?5Y-%B''952QE!?M1%757K9%,1#33-9@$W
MN3ZSM:49*^@BU.#:O(_F2UT<)\,ZBNGCQD)#JXR>84NK#DL&E:3CD'8,99KY
M RXUO"2?A@)I(,AJP8F]K4V3(XLKKA>9PSY2!CLRIPD*<:9J5MME9C!>6$*&
M-<.@85EF10IGOI5*U6%I2=D4BSN#U=CNL;5H4";MH %M;:8A/K'+$HP-2<YI
MNB05L;%CH)3 -V5G*=/]<J<R!@G"X97)N&>QL_*P,PZ;=:1L5,<8Q)/\>.H*
ME890#D8@(MF5YHB/F^Z*:OG1$I_4.T(>%;/)R&W#92R8S"O==@19'J&)^I16
M/0629@U>\L*97,;:;:^J]?B&W/2[<G]K<X -&L#"U! SFGY)'90;8R%HN:-&
M(Q #.]>T1MP/BDT]QE(CY .CAB%>:#8ML5%9A!EJNQA<B>J!@S998+V1KKF-
M65.-4FUBSKK!E-6\K-(K3[4@J,^TUG2)AOK,=F9L,\J:7FFF!3.N.>O.TF9L
M:LMIS.;S8A-A8MU=;&VVM,HXSK2E6P4E'J>FE9AUYJ:6R]46-5^YJS@6_:21
M(TQ5;29.';5T/4U0MU1NC4>+=AV3XY!:3!:51)\#;HN*A?-ZKB\EM3:IEIO+
M2(;@:JVRA >$(=#S5+7),MZPTV1)JT(7U.8<LYKW6YDQJ4MSG<Z*'+?$G5K>
M6@'/ZLP#+)],F@D^1_.J+K2-'%DI@W9BE-%5K'?;.%0NTJ&X2!B\J%?E;JU%
M%HN*DB52 Q&6?2492(@_4-&V:6QM(A ]'+4G$:JN1K@Y1='E4G?:*5OB8Y-I
MHVIIO+*B!)^6*K#37E"U<D\9KSH-I9PL)T.H&V-<UX,[*H,YI6!KTU\ +%L)
M(V'AXI6>/BUVIGIE,8B-SK):Y?6$L5"CZDX62:=&5/%5JG9I'Q^T,AAN"G@6
MKJ:P6*P)+:37'8!<7PM** 1;38@,R[.N5X8,N]*'XQ JV3@)YT-8#FN+)=:"
MDQ6LVS ,0^5U:>?I:,,GZLH1"&S#.L&+ />2C@A@:(\AG1Y+.EZ=%(<-*G4
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M0*(Q%S-3,U["';&?P\VNF+15WIZ7V+*EV+CK\4076G74,K"W7(+KMH=@%J+
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M3R"U9<OZ+%^,IM' &TWYI5(. VS8PP2ZM&(1>X3/%V).TEYE,,BRE)&IG!H
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M #,""U"+H;\HZ?UVKV=/W8KB\F,1&M?-/)$0<XG. "[BXII>GI:'L RV#FK
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MP73".V@[U&27:C85NTSB'KX8 !RH(3%L-)3JK+?& &W,QC)(5Z!^9J\DW,,
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M8WYU[(G'GG\L=>S#CET<^P_'OO;8]QW[U6-_MK6U=<[6I5NCK63K'[:NW/K
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M?'%V5R@I68D//'(1+A<0GP15%G5':]T($*0 35-Z2U^]^BK4<M0I=!%>#&F
M+8@7*VX?X67;$)=![0P [P8Y3OW3]9 G$@Q 6F4])^BVWG?A5$)M;;O==,]=
MMRH]R4@K(3[A>\BI[[*J:<HLVR6-0]G)!W; =9KL&*%X/FT@*48"676732+O
M[7^7H65.:]+PF$+":Q!<]QF 'R,[]%$YUC#I2,#%39Y[3%F5<8 ^.^TA90&]
M2XHC52^A8F39/2 [YV1^D;_H]4&HOBPNI'O?^B&YP_G;KS\6+;<02[78:IW
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MX:**H)PI6KU?X,).4\E^?DZ["2V32!T&(,H;MED)6V'^]&SJ?D""2J_$>*I
M;;E$7<9*SL;DCJ!'J XG^Y"K>;R-CR>_Z.AJ!-J2 !_(D#J<IE\?9 !*NAB
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M#W']%R;NU'(F*%,R(!2OP_"7)&2[@ D\1-W[BVN&?7:YLW+)E<4^\N1MF35
MQ(FEUY9OKPG?6^8R&"E#")+6]$BN6-M![TZ![!QX_L:F\.K^KNEEN9-M]UYJ
M<%2>VM2!7C?)'@S6W"NH1QD&(JK&5E9""+6U+1-;,)%(!B!"@J3( -Q/QL+I
MW!,@J@N<]!P>!CG4UV(2$E;&@0'H+E6@"[/C0/28^G<PG"<O:9@!X&(A 1D
M'=M6%$DYENHZ10CL<4$=JRX'/RQJ!E%31O_5;".:+4!;'\<;Z5X3SV4X6F-W
ML]=@>O+QM%AS$R"I4_35R:^BR:U7D[?LG_V+]1'JQ:5LX"(XW.T(S;7I%]0-
M_WHKV+5?__ZWH5,\8H]?OVZ%?U7LB4M0O1?J;)+& +AF8(Z/U+XEM?X E:K8
MS[_$U/?GENM<!N<$_5^'S6CJ?5(I%O'!1M %*HD_ \?.:GI3:+K[ZC[/U6^]
M41;.XDA.[%%\]*%(C$^J?OB2:O?%U<PJ.^M?IA 1J@$S0J9"6$BPU[C)+8&U
MF((X;$1\H8*$%EHU6G#S2X)K[Q&*I.+=5D=!54.%2!E;A?,U\_<\$4]VN. 8
MK?'#Q] +0ZZW7SU;.2#"#@OA)U$\*Y?MBJ+@_7/4"FB4*22KP8EZ50=;_.)9
M( YM]TZ=S_=5@3A.'GF U"7!& "6!9+(8G\4=CP/#PNOOZJ!F7)!LU%69Y??
M@!;X2\K;?HR+!3Y;V:]!W?R9WS6I"7Z%@0]M'3R@F,5@Z5S0D3D [;-TW!P[
MWB]L4:9$^$'Y[?&*ZZR%)&-1$Q)WS*[4FJMIL8$'S_-%C&X9?3641?)7J7"0
MN[Y6\2R4N796+]_]CQ/[V"5X5!!KAPR;D7EGQD3RYXUOM*WROW?57X&GO3\J
M[%CR]9FD26Y_TM?QUI\4M #W02Z!%FJ )[2N]HLJT47'FDR]SEW/'_;9$.,7
M3C)<Z9RW?"/5TZ3/#.OS),DI*WH/*7 Q=AE]9G^?W4Q/,WV L#=#]C[D@UX<
MDBH=[>A?_0$[+!7F%(FIBN$<10*35YFK%VD*^>0-:^L^6ZT"7Z#<?98PX<GC
M_ER=6ZO[=6@53*#V"U/==66$#-*S<3G[,QZGB,(WK%OLUU;KC$-1IG;HM]7+
MR&W0_BO8OI[ 4EQB8S",F@:C1I,M=4($L4"2"B_6N&1+N!(+N[HAW2.X%#&U
M*;HU%FW9K'9KF<R! ./FJ5?8"<%XX7A%+'YA=&H.=,<P>/;.KNK;PT<BUZ<G
MV04.*J]*90Z3< ?'-QD J9QPSIM]I2%\4=19E#K0:!B2#1-"+2P@.%[IND(B
MH5QCM1N8%5N:_3U'-RYBFMBL"/RE/&(+[]F#(DEZ=J.GSA5$, !=1($SF;*L
M)K\4BCK"QJZ8.;X.>C8;'OS#*3*P3G*D)%6" 0C<(DJA6GJB/WD1P!%$9V4S
MR.ST7E H!O02J@*=!+$S $YGF2OSH;^[01CN*["K9.^/".H8L^UI,#^:CCF.
MZ:"SYRZ@A$+\<45A5'%LZ//]CDZU\8I4K<IB@S1GC^J'E<?1%^8&SFQ35\[V
M&(^3:-+E&N6B<4.[A@KRO<^#DESF(Q6GX>RDB [S6O=Z&]]._T>5V^MMZ4<G
M6PY8L0D0@TS"?JK^Y/1VZ72P#)2 CNPBP>&EIL%\)5X-!^Y^C:.[#^C_2)1H
M7<6X4\VQT^>-Q^MM-I6&9_\.-1V[@_@9TPSYH']W&SV=+SK^RU3G<L1E<WN=
M:/Y/[TOBDDP X(B0/YW+U)"+)*!&'1G3>5YXD<QM6GZW:BJN;ZGDVUL5;?JQ
MS4;[ I[OT_ZSA56*Z/RR]Z)7BAQ^K=-(Q]]==H!H([4PSP=K:T6P^7S*T11L
MIRM/\*MPZY]O+C/YN?ZP;%9A7,\D)$%WB\XI^LL,^P'$?N1\'=V'+M>-T_M^
M\2KT9<M[Q.DU;_!C_P,O2*9>F'E<U2MUM:WE3&HRZ($$$HWF9'IE.X)SM\AR
MO.G\DCH?J=^FU]U'#\F!/US:0O^B@-L1)*F>5DC,@=Y)TF"(>J#X ]]IITI+
M<M^]#] [8"6I<.\0M=72R-2F5*979?-!)?I*6VQ\EV#*GD,]HW<M[7AMJ_$W
MTUD(B$!WF(-/(_9[?:ICC..1E=D]X<5R,+IFM%IS>13\/YX;"DR/9P#<T.'
M\R'F@;FDL$7@!Y]0!Y.GZ4K^02E>1B<D^<Z8O;E3QO4KII\!B'Q/Y6( \LH7
M(%3!+KKB[-5Z?M$" 3/GG5W4OLK*IV<WCAVM;B'W9 \T(V+P>Z0 V58&@"PY
MQ\*\Z2;(DAT#T"$;J\5/0F,G)C3$D<[0&R,3+^M=2]G#,Z[?>&O@81[WM@/N
M93W1NNBLEU.NJN/O7$#*^[KT[<BQW^#+"\I-Q+*/A:G.F^Q[.B%KE+^81BVA
M;- A8O+O36%)N^#']6(O1FOXZ+-WY!9*56Y<?AH@.7*2R^-\R,$B,YZ#VP@8
MZ0:3#@2WO79C1",J8CRJQZY$E!_MQ@"$AY[A8JZK1>#ZKU0$N("F6N[=UH77
MLHQ(%W/!HQR1\ZZ(/ OP6GTX [" A9V8'>2;T#BU.*O)%[+CY.7I!\YIRY#&
M'R(_T\\PYV2N=38DN#%BU B?79%88OR7K9"+0M%/_?7<>>+#GD*>7C0V-0[K
M-LTN'/0[T+8!#%&JL+H47=7T\(<$)IZB[$3Z31:(X0FKT+MVJ%4#?AO\[M^=
M.]JSXY,) !RP"QC%*RSY?=0#.NM[8&]S[_6S^J:0Y;Z_L4T=,Q$G&HYZM8YT
MG$TNVB1!VSW.E]K?1N_I\N!J2@L$ALT,[2S1G#AP.YPS1"$\[]>AIKH^R'>*
M[^3/^3W0G&=GQMS+$ZY->*X/N1/O$F'>7I.MV!;4TA/=VH(GZ]5NW^/3AU'A
M+1$HS<%O 26^0C8[3-GH/$LC3JP>+IW52V/KKY+\H\IMQ-)*^F5"J*NON/LM
M"]*B'4M&^NFA4FG>MTY7,0 (@](_XAV<9K.<U7?.L60E5KF6A3G$!W>>[,R<
M6B7DKQ(*(GB_ISK$6R][AUOR2X>&!_&^@YXU\NOU+?.($,[[#<QF .9 [9H-
M-*GZ$^G/Y9.7<P6)H;REE_Q4F=Z*XKS=Y![ 'Z9=U T+5E)C *I:B@Z!'[5F
M"YRMR&(?_.HJR^3^EBM1AQW1-@T-5<IDDO@<'CR/<[>X%VZZ+6E ,[G9Z_ST
MUD;9W-ZA7?JJXZTG3)5+Z/V/1QU,_]T)"2646;++&("4X(!2.LJ' :!)Q: N
MN!+WF&EWV1Q$/I:EW13'0D69XGD"M #)>A\C@1R&H]%S)B11(C4?@RVB!3Z!
M;3PY.M0)V6,B6@[35!#U+E-V2\%I4CDM4<@5#B)=]S&<? RBW4*,\0.IL=^8
M/AE)3_IC2N+H/]J]*$W4 C;^S5FM4R16HY<,@$$C9N5'7- 7J^UR\@ B&_H!
MLXBD7LDGY-?2/H-<''_5!*<V_&H!MI.?/XC_<;/IY9F-,?+)RI[=9^*B%R'N
M6/J90A'5(C.IV:) Y7WGT!UD)VE.O;L]PE3%,'#J5L@H[(T)3DN3*:;)*O10
M-AJ.N3!V) ,3%GHKC,-M&=[G7),/Y>7KFQD4:\]I[OQ,UVP 8Y%ML/"@]!ZN
M6"TA7$)202W714B7P\7N^\&_SWC3^RH>Y[09P71S+N!J$>]"Q O6,]R@QHC\
M*1T'5R#Q1O3):U0>':CA8J&:9#B'N-5,B[YU*!'F149$J*BJC5=ZODB!NL_2
M)B"!!?_;'9YC>VT&0$0#1 N)I*? 1[W__VWQ\.AUVHN,4J]_GMW,*#^JR"S<
MP-\E*H/O1.76Q^LRZ^@)"\[53XLH'N>6,[A!>G69_?1&@U7ZJ9G966.*2'WT
M">GM8, )9.<\Z98L]7*U+:TZ!*(4GS<8^"5$==3QQDB'E]XXOPDO[S5?C9-?
MWUP(JM,G>_!CLW2]($G"VR)XP_JDW7G/IN,YD44#?B/.0,IH>H<PW;/*#IW+
MI!,4Z7;3CJ\_=OX][LOKPN?)G<0)RB=T>1FG'"OE35@6XN-3>>H6*1*OW F[
M$J*O5+D8[VV)/U.L/-\P=CMG\6'0R4ZLWE,YP$9,1Q[J\SY4N'4EY5CN6_66
M>!FBE'8E1V_A1UUH_$")]V*1[XC4 Z0.>6^5N2K!3@E_^D\VPXK]>QR;$^2(
MS$#?HGF;[TGLF<XVMW*?#:>FO"^:$: D$YC!\!X;@,;JS.;$XE5?XNLC]D7H
MPWP"M1G+;VS#OP.<(CNR:'1YR-EA>WOGI(4# ?M^7I;;Z)+#X/R1?N\X^Y-%
MM>V#74=VP)))Q(AX.S NAY]TM* .NA2@][@:<]<62VF,]:.4R:?X@NZHH"5;
MY7:EOB+7]@BBM'JJ)86;:@Q_//PB>(<;GZH8*J#/-KTI'T2<E#RH^^L.%ZND
MM<DN;)L!P.]UP&IZVLL5NH4O-U->)A<7S3X]/5'%A>(H3:Z[KW$QR^?:QWL@
M] RXW;(J* M/+#9T]MM/1ZP1"RCU['C+JU,(Z>:IRCE-*B9]A:@\-:S#L\\Z
MP7+'VNILACZ_Z84K+QW>?O85'=W:GZ>S,SV<!=C4C#GB"LMA'1.8:Q_@TS"'
MG7JV6[#W(D[M1H)HV_$_*2IL6%I9I @R8W'B2D2V[7HZ;-_.>FGMTSA'-1M>
ML78]W8H"RUQ/*"7L_5G=:9(6G=B..M-56!!Z3OY)0 ;V=%VEW$+L8S3W1]A*
M/C7K=<59%^HX*1\?VP41##&Z6;FX=\%E[L;8%W$B$2-SZR]8^ DL[[ %0+Z5
M9W 8,OQ)]OS"FP87E5?!LR^.DH_I,3_IL"&52,%/%JN=)K,;/#AD^N9N>XQ4
M"<D()]4-$:HM'*4*8N-=.]--EP9LV753G[+F)KZ="IN-XMFQ*&7S\OXZ8N@W
MF[@T6J26]*@PTS-O/*N<YR@]$K00S0#4<#8^K1[$-HOHOP1$(14S80I PF 6
M5Z[JVB8+B!_6Q@]Z!3P[6=L)Y:Z><+!DZ<XNF7ZPA<E3*)7?(-[;.NI)^)YY
MZ\WRXW\@5$,JVAJW^RI_ '=03X(< Z6';8752/Y(JBR>H\$D^JX=^*_QZRL[
MBNS@ND]Z#K6M*IIP[<='.W][):W&-CC!)?IDTPP&F 4C[^\8BB#A G-ES3=
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MY]BPMQC$U.I.JZ3'E@-@G*D)GY!VLWB# A-/_;TT89J>,-$#6F/J]-0%F=7
MG;\I$",$U#X!ID6(_(1E*(=+J[C#ZL+7K="EG9G??$A*K'K$^H =*M7+ HJ2
MYK@-,ALV?Q]QE2H/JKM!F<#.JM@S= M$@"N:$[-_4)1;J"V$)0*L*2%N_S5
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MH%*J^+B;Z>2#Z*+K-<*+W008,)Y(.&!!:B9743JU3-LCTTIXOUZ:?"N8Z_0
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MY3I^AE0E3[-F_5 %&&?I.47(W8M1?W)JX0X_/GKW*XV['6KP$GW)$::\>R)
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M-&+*#VL@,-&PDVY >B00NRH@9;:+G KD?NBI-I( %Q,0:ZH.XZ7UVG1ADI2
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M2DC$5G<VX'5E_E7+[*_B;$PEEZRX-JMUY^G@:1GD@G A:IWT-"EQW>U%__9
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MC')L;HIU<'B>>:7]@L'U:[%N,A>7KA1T' Q HC&[^0EQ;!A%;/JD,!&SJI,
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M(@ZW.+O]/WC[_Q/>NGD_98X&'DI=)_U]F]PWW</NK6##K;G/A5-^J]J+/TB
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M:)X$B!/B[11>808G;7"HB>W'S2$!K.7)0@2$]I#G;1H72P#A$^3+[-N+3W$
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MCJ><)R#R7W2=7R?US&%.X8M&I>#/7-39.A'PVQXA$!_$'T QB9(5?\8G28F
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M F!]EP<2H,8Q.#*_^);)]U;K[^<J=^?X:1]I\1OYP6+D9B:I97RX)>">X2]
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M5JR*T;'X.V\D_N\PI"1=_Q=02P,$%     @ ]H&74+K*_--/Q0  (^   !T
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M282RZ=.[@\]5,VOV#N+KW2T&;14"W=JP_2^Z!F$O*$4H,1TK<QBK4(U&Q6D
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MOT4.+'E:G;NKB_:UE$6-I^R&FU6N"(&6@#>H67,'B85CN72QHBF8^*RC9O6
MGLBI+45,:M!EI>C*MG'VBVJ\Y"]T[57]FYK]+R_/D7'G1/:NG_XQH#DU)O![
M:73;%G@8W-M,,K9JK+&$G@3!$9%B8IF,OY!^B@4@&^!\*=]@V+6[_>7Z8I<D
M=$EX7%)M<<;$/;^1EFV]Q)[86Q9Z>_<\@5PN,O;.>)3=_#G?1[D43KI#YRM#
M:^']*J\@3,4IQDJD478R3&A*9M%39';)1)N1Z8(4[80)3DK &,\>3BB!<[Q[
M*WW)@> ;=F3).5KQV\KDHF\4IUCH\:&;VGT2@QIO.6DNC&\8L %3$F)8:1C,
M3#PO A7G)]S)VSJ<<494/Z<SXA._5DM2%:NC?4UZJ<_E\3X'NY>'1Y>MW=2Z
M.4#20K-,:A,V*WOAK"AY*U4:\[F>,K=5Y17(H(#- E_<M@[>#\$CI-FTSQ"A
M7B]6F?@",N%"VS_+DF\,6LXDS$8V@F^*L>JPAB#P:3/<4D(EZ0]VE9V8(*2*
ME_.C)JX] C\/GN&#87)R0DKS"X4.@PR=J8)<*;.Q\RL2W"SN17+F,USDK,6C
M><7"?I>=8%/)$7Q2C6<)8Q-H^8DMV^',61#Q[679B"L%6>;ZVG_JZVL1W@FV
M41I"Y"0B'J8*OS%.5Y'QC+5PSFF((K/#6LE\AB7X)JDTG+<&TK[(V"_EI.;E
M-F3HG6L86)\SZ"!I]-5N8EIGR.<\DK=&BAKR*B?' L:+GA?#*3]V5,9OT"($
MJE_P;(5@3C/>=(+PKLN'AF/,;6>NI3 [%')%UC0^^3AB(Y<D%#A 7DEN46";
M[-JM"&D_DY9:L*HZ1>"/_@#RN/):>QDET9FL,SHPX]SXN9TB-__X.W#(HQ?J
MIY,[D#WWJ =8.D*TK< ,AL I9214W-#OT]12""L\X%O04M9,^AG!-#XIEVAR
MY=5H7; QG O9"4BZC*B2(,:6KIJ]=^BW$-][@73B-RRY<OUZ&-\:.2"9935
MELZML5#MDKR%SPFJ11E8LI8(\ O0>70MC*6(MF@[N@E.+$6\1$QW^HL=B?M
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MG# G/C$(E(522\N0]7D//*.^O7FDBF9XP6?O1UJ9P+6J#<7)Z!(J2X^'IVL
M67$"PP**]81Z[Y\L9>R%VZ2L=QJ@3C*?YSA"D)'TA_'SW<)*D!_A#%F)4\^$
M#R>5-Y/?6<%/PT ?(J62A4%^[C[#N$3\#&<,_KP&B?P29%^OVSD(-\A*JV"9
MP9S&ZN*D&I=;;X>9UNU,$[J+[, UGA58GOIH6)EG69XCC;+88[Y_\M.MD^L+
M'>^( LH$08FFKTDXUD\$B^$!8SA?QLHD593?AR(U@#Q*<M$MY 'B5PE[224
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M;?)XXL&PGE(>'F<03#^U*";<83G;7*ALATBIDXJWY$:B*2RY-Z(!=)"SD'T
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M#,*\T'V:#2F.I)KZ6CH#W'K3V_9^P/ZN(OT36_3V*SZ9'.M+.^>HTSK9\?&
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M(U9PK5!N&#7ZR9I,:.@"X:@VP3#(T$ZM3<"O7TE_*8,C:W+)%;NR -_C>U<
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MX6OK1T*Z<6M!9:V8M=:PFO(1TRZ*@B/G''R&WR\U?))-3-8Z\N8R2O(NSU\
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MPV?HXZS!J9L*!] R6S)F5PKI\VBIQ+HWC?38D3,S:0/.!R/ U])E5(JH^\S
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M60>;R< :ULRYBYQ6*X_BS(:BO)S(T:+\C"-?:+R>[/E,[GCD"&UJ8+1/U#G
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MX>[197GWY9.N35:G.$]?5KS(/%==6UE7'1/Z+;1\=<3M)>+KDMMVWID?C^O
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MVS>/E2V.8",K3M"A>7S--'Y>?90(;WF&FO%II9^%:-06"H!)2*3/_!SBR<S
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MTRZ]=X/O17)3PAMQ6W1V4E.,<S-YE2*5KH%G)HHFK62DM.Q@@>(,XC',TD0
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M_6<X@\@W]6G)V]HU'6&&G.A!4Y[6.$]':>;R =XM/UJ1;^+A[T]:';K\WN?
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MB!%/W_J7+HW_3P.WV/>_ %!+ P04    " #V@9=02[K#RUMF  "C;P  '0
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M\_CX<<HLS$,Z#CW $T2\"S>K[+U4%:CNQ!9LRT:?>'#_"!4#YT8^)O&69L!
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M<7@K,@CG\1=+'U#<:B_<6E^!]&)[92W,6F"LI*0-M!Y/S_<C*B Q8274<-$
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M4@O.K\H(*J,FN=75=<\S#R#3D$L;2<GC%6(Y=N$EU-7E)>,%L1+JK71NU$O
M.A@V=J+[H6O+^3EJ<%]:F!0CN3(BI.[9!].6VKI.J=2RDM-(5A-Q9W6 ^6-V
M1"]XEAQ?ZYL,7D@2 S%@96@;-HE #\';0])<SLIIK,$(5K#T24ZG2J,:B<O<
M8,]G:OAK[ORP8.7BU$_0>^AA$Q@6F/]1#/SN7T9\<+;G 74>N4[\C*3Q@]8C
ME@WL';#1S7K9QS1[^'!:?L<5K&,E)CSN)N7Y$W?TJ=Z6)1UU\&TVN^JQ-R7
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M4C6D["#7%CD=$51"O;QTM%,,N-LN$'.*NN?G4NN_<0BT T$";21I,0;6S V
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MAC6AL;"TWB@\"+64NY57'R0@O(8&&T7XY[ I.R[?D_*,:N0"%<:1DC3?=]C
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MY;O'A3C8\MWJB@80<M-RWPW^-$Z.[!?^Z)-MT [DH8D=JJ*2:/))YV4/:O_
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M0<S/E/!3/D&@%V4J<KB^A-\(O&P9E2 $^GNZ1$[E0$BMFQUPJV+9'S #P N
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M-:R/7S]\14#7R,GU<=JGVO197D_!DM0Y= -?D6\S/IYK>(6"4KQE V (2IO
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M9!D&D Y6#]*I"@/X.F31@M<DAY8%R)R[R=Z%<#[3 PP5. RIMGXW>_RK$C
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M(W( ?)(_I+J_BZ*M& !717GD:*&:Z4LKJT,=#T+$)OS*:DS"\%(H41&S)TI
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MC/O2Z37-^-5B!'<MYGQN<:L@\^3)X-/!.3[+<SR.65[--WNX<=V7($^!YK:
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M%N_VG>O6".][EY?E_G?\OX&_-N7 _P!02P,$%     @ ]H&74+*7R/A)/0
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M,&_L+*T"@TB:1$31 _J<6N<N,.A(SG))*AL;>RC!(04EK?QP')MJ/4 U^#)
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MJ#-ZMIU7WF.K@R:9:Z=OE%I2U[P?VT2Q*T?:(@4!88$0@6VAQ%(SF_PA-.\
M),'=%$=!MG]350X6IB7+C,A/_PSAH++1P;AP@KKZ4%U/V>2E]F'_+VOQI\2H
M-6C$4_3$_N0Z)*-9MK7WTA1^XK6?7IREM7N'HH0 MT&241V86B ,UVMFJL[2
M#+YPJG*A@F9.5?%3BR1:98?R%;^D=&L+Q4;1Z>G=O0[F>>-CD2U<R&L:(,^Q
M^HWT^^O"A:K1YFK1(B:\4B_JH)U%?D%8B:R?KC.+O1[IEY? %F565<VANR,Y
M%5% 1#:7E42H&CI7^*^3>!>$WKG('3H:&S7PFLFY^ LR]51"K>QT6"%XNZ&5
MEYDNL>+]$2YQ?HC<;\);P6KOF) 7G]G\(V,_A*'5.?*FU1%[WW(P69D_:!T3
MNC%0FCA\6*_3+S3%L+K#KGJJ!S;C?\TK(OL+YB;'E))DJR8(2QL,)<Y(.(^X
MD.+?XQ!1Y/Z4<ACIX#%C Q<B)^!(;WKCJ$$/7A_IV8_6('0/A[86\W]031"C
MN5^Z\29$,HF-7X66L2N7L@:ZP44-"\*8*B#_0MA\:[,%L16M1 VVR'U7N"!5
M<NHIXL^*,LS+3+'&)>0L10[E;TWB!RQ:W1-N[>^!?5UC,1X2Z>L[8!58#]?U
MG4WHNO0CB3\]J2 ,L$<E V4]G"3*[*=:!E(\2,KD E\D6ZF)N)"L)+2F+Y<9
M(NT[X0X6F!:5>>/2B#NQ)\)].LEO(.E2!42('6B* EE>2\>V^F0MOLGW]\*4
M?KI-4<"Q<</#K005JCXENM?A@-BQ38"YSBTO2):8%R!SKYD8F?'0.(@10L3K
M=6M/";.5!+V@IL27#RJ%]H\NHN^VDZ6L?4+'G'4X9LO&+AW':W8[$(H/OS^"
MY'BVBVY(*R.(5QO,$%9('L4>XB9+L&(;BC8T,*4(?PZ ">Q!&7:B"EU,!Z]"
MR<ZJRB2^:]+9.L.R(3*:)WX@BZ#%#0";G 58!>3X].%PU<8HWQ2<P\ZBT"#6
M^P$V;="I149 O&"P,4R\9YQ#8F,Y5D>>O42F8)\)OFU<1'2')N*_"\JF7W,P
MYX%*R(Y0N\!XGH<J2U<_O+2?OH[.SDIO*8@1.+H>J*FO'<CQ=Z2E$9_53[>*
M20MP+;0TN\BT635LDWYK'.5\22.DQWN;4UL:HB]C% 8B<4)^0>ILNA9[=!N"
M+2:7[ZJG->:8-T"9J;.[:Z'9O'JTPD]1<$)K6O/-V!CIL9BPHL&A\:U;4B89
M4^'3X6:'+FGYC31EZGZ[=EMSMR;+Y,*9FSH#E_OWO4ZMWC?LWQA"6E1:LME_
MV-]YI2[DI.^\5'U7VLI-+.UC^[<]2O?9UK7CH/.AE2I9L2KK'O_?;>8P5Z:"
M@:T$MM>8)!)B[!M+62^<7H&<:"3H@B%TCH$3ZO"\EB%TORX' JRU&YJ>+!(R
M-+_XX=(K2BU%_1WL><^; @/_@$BOGHB[C(VE$6G^ 7O7Z7X;79$K/4UCV>W<
M;6H0MW>]F=C]T(??"&/SL78;S.ERX-H)5SF0HX=%MO2!/^QHB(LU^(-_7@[$
M6_C*@8Q"Q8>/7\F!O_;^];98.Y7_WL]Z&1.(61R\1K%DM#4_+7=5M6U40X'>
M@V-+3FE\$G_:G&)L<>/^0/]SL!J_'.QD%<@!WMQ^.?!AG%^:=>INZ*W<Y#_/
M69OO>C]3?!R:>>J:M<'[T[5Q%^]/UW^_W5WG%^9R=U),>#F[P;S]'QY ^&M'
MNSC,5 X\JCJ"4AQ"E/GIQM#?=^Q_7%<MOLA/DBZU V68")S,,_>OE_^?N^OA
M!%WUM0F2Y@4LS9#6%IU3DC*]I9498.?P1CG0),') 0M5?,?7H"+OHQ\"5W9^
MNK']\8V0-;<U#W\(\#JT ?[CT<U>:>WM4ZNO?E4+&1R['$6Z+]I]TV'JOJ3]
M?NWUR9%J;$A.^-W1B^5GO]H&*1K="GG2XV&=%3)B/>MAD^MQAAWL[:S]^J]O
M?20[4).3(0?>N!%X"011!+-22?:\@ZTOK:-)CX)?<;(X<Q@C4_&2 ^M-T)':
M<F"H7]:+G6\EJ(>)OA%F4<B\9,XO>:C4Y:P->/_SIO"]M56P&Z_3:#S':96E
M]11_DM /_,B:)PCGYNFH<!\(/R$'G,?ZOL> 6\@I<F!M8OA8K!SH.[TT,F;P
M%;[@NW7"W04N@ATFP!639?'O9Q[';5GBN*1Q:N#]!8(*\K#VJQQ@(*?FL(M"
MZ)6T&].H[M:1O=5/2FI8CIS8TRTQ!Z-YW&7(<+/1%BBH!9=2?MCP[*>>5NXR
MLSX*%L<BK43,B3=:.$,46WYZT$%8+]%Z6R5)=R*+)LI/*B4;#5S-$+U%7H4K
M32GSJ[ME2A,R1\2>WW'-+J%Y+O82DX8WAIA7ZT[ .*$ALXFICFJ7S&LV:@0W
M) /V=E#XE507@*$UJ ^/96&N\Y[1G>V\KLUNKYAIF+<Z(KU5IRK 78^DZ\YR
M]2F_]EF<KM!#*\]ZV=JPYQ(':#H]G7L]"*ON@%M4]QM"9]4TIY(_LVT##;HN
MT32&$&*CS)3Y"DY*O%1J?SC:^UAHJRBP9TU]GXTT2$B<6B&@KVSG.>+X2==D
M)F%8C9D 0BM=3:*<B]2ZPB-E*3RI?U/@$N@=_0H^5\# !/O*</T.5W(1KC<\
ME9.Y[*I0.8*$&0FM.9T[8ZYQ"W=2QKCT;'!Y'\WBX.B:[&!WC6UMK\ST?^_E
M'[)?]WW]KL/9(>F$3&$XL[TC7//]-PMW43S21%>@A,&XO7#'Z]MP4A-1:X)C
MVXS!D.D\I2DLW\+OG2P:HT9@=216$93KO&%?5"BKSV!39)MZ*8?XA17W2Z/]
M>QUP@@FO%62?"=9F_R'WR")"KVU-=4NX'J^OK+AH#*OZ&>$>XTEUOS=S3H0%
M6G93-8)'-QP^\P3^.%*5&WX*-4!$LE,CE'UQ7\_D&7X=K)=VP*6Z^PQC9B+]
MM(5G:_H+Z;TZW2R+=_0R\GV!TO7*TC"A:U,'#15U!:D1I9I$3>1SBQQ8/$TQ
MB^"9JUW@.D'OXOF.]J_G+:JO2BR><,A6350]Z-/M\/RQ#:)/CC[3^_K.BNDK
M))OH+9F<RO=T;2H.\5&5*C;5G,[,1_2:18$KRJ&"Y#IC@9BQ_+#$"9IHY8O;
MJ^#$HHW]#0:P1T'R5XHSCZA-MOJE OI4SBN^:]J;S^07'UBT_D"ZC=$>@>'>
M6]DZTP<^/A*_K/'.77] 1-,<L YYVW70UV)#2G-F7U3!T"4Y@/-L,R*)-T@B
M>\%@C")JJ09>(.8'TYI ;0<O:-H#3F)5P)?O\7'8L5%L-V5S$2-UAKN$LLL9
MB>>Y)7Q.)E%LB\@GFCNNG(O +GL_P5E66D(^<+2S4IEZOVV6<(]ACA ANCMR
M3 XHESUL,(7I- <4_<U;&ZR1-%A1L#@/M14;8#"Y8EKEBY%2MUE-&BL+DU"'
MRQWC8*\YX!XBH$L793N_WMBKXL5S*R_#3WF1T>#Y\8CVM-O*@M!V-:.]:LU-
M=E]^&'><[B5A0SK:+?<>[:JXK:\GVN0QD9]="EI.-:05#U^V]"J2O#76//3-
MZSU5#DQFK3?XRA33Y,!#_8]W.KID.^[7##R5#/S O90N[@(_J#V1 X-;4)"Y
M'2^U^_.O';(W37*@%@UIHADKM=58I.WM'_M7%D.NHIYJW2JP<0]:FA*VKP);
M?*D]PISMA.<#;'6EWEO K)F.F+02NG)>-H][R?S61:AQG("U9"I'EAY [<X>
ME&"]O;0O[N961DXY^&WW/NFR7FPHV7%I[4J=M0&'>F]^>Y&X?)6^M)#&XBC=
MH</&73+4:?ZYI;T3[%$!^K_ST'K=!7+9<D#? 2%\KB#.P826<@+?J)/P12D7
MG=*+=CEPW5L.+!&A$]WAB$5G>X<H.1YK+?G;<!H>\V-*3RKQ@DLZ$-<*S+S"
M%U0Q;'PA!X3:8)/C0[ 3@\J"QE.9<F#Y0S7"WT;G=L3+HIWE *@E";.2:4PI
MRF*C"#+5C4RD&0O1@K$SBEUR #IR2@ZTK%/T^M?!P?]VUG^BJB,:+3</C=!-
MBFO'R3:[2HPY2E)@!I3H'@'A5*#GOT^0+"I^#PV34&6'-^VWJHP_L7EL\)UR
MR[GS,S;?TV.4X0[/GLG54-OSY^4OMKPM5O;(*]%MV7%S[./"G+VF4,+=LLFI
M]X,M'I0YXI\Y:\"V8_>C?B7,'HD''J>:"V+_;7G^&Z:S_)SF_(=6T@H/Q"/[
M?\+;R9]QZ ?]H9]U9SK6;?'A1OU3B3MO[L1^>7[9M-)G-V7R$N6$_>&M5@^"
M%@JW;9O7_V0=H[@KQM@]LNM29F3/F2,C%<-;3Y^N3"ZW6NYVVN26FTE&6^FP
MA[W7L^]XUHF@4Y^FOE/;PA95WRN_W&'5MIM;?C%\)+OV_O*V#I&/GG08(P<"
MU\F!L9?)KYRU?7C:WL[ _VS>'F892U_\N.#^T=4DY^CZ3^ZF[* A[5_CON%'
M"F/3W^WZ$&2M8*'S[5TQG"D\32\Z["8'5 Q8HIK%I25.>2'ZD<EX!\1V)Y);
MXF61USP_%!*H"F*(Y"V?_>ZT=(]_&]Z=(6#;8D@+7W0X/G6ZT!FS.6^T(2]_
M,%3S\.C8+>*1X8"V_'%OEFYN0=MYE;TB7WCX:,#PVH_%F^,^AI>5E;*[F#<O
MGE_6]D 1MO]?2QH&FX"L)TB>9,B6H.D;Y"_>!TZLE.QD#/^!2I/6G[GY94TL
MUEE[G\*_TY3>R0$LLQ?QE=6&8>=QGHS[$V,8&G><8BX' BII4KT"W[>SDC:!
MF>3.BNI\13EPZ.XFU/<TK%N0NN[AW]K-A@ET/G)@7B'O":E&#GPER&)#W(-0
M2*]NC1AG6LT8H)#];2LJX7YMQTC7IE9,6/VU0VRN*IM*0D62-CCS?C>Z46?_
M-LT]@XUMKQO;#'>TFM[Y;<8A*+[E?(Y=4%5,L"*LVLI4F"&F$BN#V-E!NY($
M<[1)BKUX!Z([#VH&$Q?7Z5P)@G(%J_L(IT!]R2_N7JE&&Q$6GZXQ;E=*BY,I
M2S9#2=?JB'P"\ 2[1&(@("535Y9G"/ %T5+Z0]GHU:O<HHFO;I)ZQ^?$)*[6
M=$NF^"29ZQ._J[Q'9CPJZR0H6AOJ\6Z7T<7[P:;7R#3/YP5"*ABAG.N6@'QB
M.@?;.&7/HF)Z(KPTWW=H,U5LY " !+D@Q&(D2)#S*JPHK)RN(N/=>""6.<RN
MS,'LLWHMB"5@0%Y>AA,))8U5Z,[KM#L\9VG*^K@54,C:B!LV.+$19<?N1>^?
MQGU]DZK\X]YM%[<%S! AC$VJJY #*5_3Y_1DQ^_@XV7W!P2?)=ITV7X4O@O7
MRX'R4FDA8?8&==7 U/M?KYR'\ (1=D1;X39:(;%)S"_VN2"ONU4.T+K^VM'?
MHO10DK#<*/Z;M@+M_Q_]#Z._$UL=W3U[5T-_/&.^J-_L4;S".:]7SW05/+AP
MRY4M^-<?#UM.GN4,OE.C_"#NH5 !)_Y1@!!3 GZIMVL@,3YY:1 ^/'M;OPD[
M7]*(EG,=>,>_,A7:DKY6UVS#[B]0A/\AM4I1Z=!1.P.J!Z]_$A(\/_K;C:SP
MU)JM>2=+2JJ>+_8YL&G#Z[@EJ]3)-K4A12&<I'LB5;$YUQPU9.Z%EI1Z<=65
MG%]HY=3^X5J#JBJK^&3K?83G%3E*DOB-]F!/R:&B6#O _#_(RB-V,X'4E&*6
MF#LZ%G6=^#+ HT#Z\<&8^'97?G4?)Q"\;%V;;*,I=K[>%7 W(.)IGC2[X=&I
M*\<N)[K[#_NGN=]EOWA]LOI5 N_>PDXW[2Z]5%=OD_VN&T].IW?U'0:H:\DN
M/8)E#!C[NN9&"5=7PP"MMIAC==4T7J1$1]C$41P.SC0RZBX=G1]@8_6]6&FK
MSE@7^_15DO2#,^<-^]X$A.78I?EJ35P,I')IXS$Q7@PY4-QSW5?06Z/'BI[F
MY#;/VWOP0,Q1BC52"[$::Q;??B)9+7TAVS:>N54?&X]?$1#<3<X5<&,;K(*)
M2G4KA,J2F;B)IM'5T)U'ME<KDNL<4;9P$ZB2---*W46_@P>FWL_+@8S>\SNP
MR01H/_C#S4RB7B![5RUZ* ?ZMR/QQ.J;Z!1HTF8YT.E,78T6=S0Q/YK0H5UT
ML1V7$R\'#G\6J%%'765EA#D].;!3&YC_#PZ>\)&(5%;0Q)P=/BP'NJ(B*-R?
MX)(#!_C$^:G_++C2YXA2%,Z=:A;&,0-R "TJ,XI[_0FN/Y;9_TOAYN D5ROH
MXL6'P;&-APJ.9/W=)7'H,''N#$%*1B5/OF 5*@O._6V"3G&H^=T^O[_/?^)J
MR*G(2R="$BI+FQM33E5=?:+>].TN>R##G[/[J&G7VCZV+GS+Z,KCE$!G ,&P
M(=F?#3K21Q%?SA)"<?IDK" RI2Z"]S:(35=VV YGA9OO> F?^DKGMWNHM/I
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M%AVVT7=KY)URC_ (DLG%G1MOVCWO8MPD'",F4K<BKN(MB%DC5[WDJS5#VUU
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M:0WCX1#,3,1J!:I'N@61\%D[!<I*7@O74[B[065YQAN$%CB[<5WRNY<4J("
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M^)VQ3E:L0'VX"B.4\=@5Z%:@CB0O;\MEIY_/8?IO:AY+F-X]7M=B=U'@W[U
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MS;U?/(^XTYHTCQB_I,:V[M206;;K%5&_X[ 2@53IC&.A5&QU=/L< @6;?*2
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MZ+74ZVBDMW>F&TZ_N<PF:R[5SV^CHF^9\<2%"1_Q:VNIYA<*J(V&]0DJ*GU
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M+2!:M:">9R?.Q!->.3*2[;Y"U IB5VM=;[ETC]ELP!\,.W(7[ZEP8GT)-(_
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M#:;-UH'10^RR0.CZ.X O]^QQ7@,Z#LBP--5F5^D\(CFV-H-K1=H/CN>XWY
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M#)0@5T$$\9-L5+KSGFN5ZL%8+V6H:UY0-R<8& L4<K!J!H!X@GY?VDRDYR&
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MGI48[)-O#Y$TWOFI/F\!HRHHMY!(:13IPN;GQ!/N4FRS*(6G!R^0T!-JS%8
M=O)*<)/HL".:REU.C.6W9*N/:3')0&(:C,L4.,2NII@-$?G^O79*;Y^>2KO
M<+E2U?'?O/!U:[KJ?O%H2J09D]D7KAD2'U+:OW&FJ*&_?]0Q:NS*:<K%6MW7
MZQJ>OSB0_WYR7;9AU]:VQ;=?/TH<W;PHB0T% ](6RJI!/TBCT2<;LZNG@CVU
MYE, T7MO;6YSW5"NK:_CU6?2:Z>[[N!6AM<8K=RW)ZN@G#TQ4?BAV9H#OD[E
MEW(ZHQK<XFW&CG1=0#^)\ISMB8J@M3E%E$[G'?;"S",\XMT/Y1 +[S0II]7Z
MT!7TO>/1RP@=-]6;(GMA]@[/1ZZ(RT^)1HT^G:+V2 E2NQ%33GCB'WZ%+U%N
MV,(VP>N/7HD(,J_AW=O6,V4]HSPCC??U3_I21//I+LZ:1QSQS'UI=KX=M.0C
MDU0[.FSQ.L2J5V::()9*VGV%&011]H'(6S"V\EN=Z5?ZLIK.B]/Q5L>[GHS;
MUN?9?%IF.T8SB;M6<=KL1'DSJBVP9]6"MZ/Y2X&@6F9$G5N5!+4\O!^7,J,=
M&2#(.<]\&.:8E"?5.?;.MK"ZFUUO5;^[,CI"<?;#](E:3O>&ER\3H]*WN6[5
MP?SCLD>4P-E(L;EM-YOD['3-_H9&7_7NB]5>-E^]C <FC%U%MXL\[ JX><C^
M:AVMX;?/0\U_3$=NBN1>S#T+1$4=6>K*I$Y;Z>!]P259M,+^".XZVB%J8&]E
MU(!5?( ?U37CJZF9J>^QI,4-W6<Z'S=PZ%X9\FN=34[E=ZM/^EQS^>Y/:$(G
M^MO.);[/!(2OC,^]KZSTD.XY)L,!^*0+S&[./IO:0B@K\+(J(-!F"SHZQ=GU
M86CL=$Y1FR=YKC>]*)SU)V%ZS"IYCUXJ0LRF)%*6<_9]IER$G0'[*CE^Y1!4
M,Z (:#(S[>:V2RO=WGLY'0&W+9SU8KP!E\S<>OYQ*.+H1/=DQ9<[O7&EZZZF
M34 )31@#,(2*YIA*Z3JA9N9 %O-LSM4"27J<:Y<=?<6H,>G\3M-$.;74?S L
MYNKOIY.+*IL+LT;/I%7\T9(8NW7SHJP/'!TQ3[O<,@G>*&$@"T9Z<UR>I#P,
M,][/O??'DQK'")N\D LFN.=^II';DA5VS^LK=-W6W/CAA.R+DT=T<@*91,4A
M)0.C,3*TNQ-]8<;4LL4'I8DQZX-8A[IM%<>?/>5VP>Z1DM?L<JLVJ\T%U=5U
M-=S4N(C0SJ$U>JN.FXVY(JX,-Y&-',^_?,S0^6;I#CKG"(8L.C/2B_,<\+F"
M+1:QTW6#-]B*396;:M<^+V9M>J3##P^SH,6&^/YQ,A\)%/K,RF]#(7RP/[S.
MM?A&Z< F6O%&[J-'(W)?_^B,]'BM_N0GT^5[,/+O+5V'7WALFZB8G(P\?6-=
M_DE1P>/K5GY]_6'RK!I#PQJYC[T/X*_^>Y\!NZBHLMIC"9O-YBS[JY% 6!ZV
M?*4@9=71#>[&99L7OOO?O<RZ?M>:V44_UE'\802(@XT8C4&K06P*R0X]+I%I
MOR3MEEK'\*=BC 3X%<VF7=]B&[[>%7KH0Y?R+5Y&['04C$_HO5Y9?V^(S+L%
M(6G$K\7VV5J?9W:&WX_:C#,Q)E:L,/GHKK_UV<.!%NG3M^2.CK([Q5]E;5.;
MF2:J:ZTJ*R)%$KWV.<_LDH$9JN!!=_/1MI" )?=EAEN+M6PWIMSR";C9\C:W
M:*W7TL$37AZX3Y<OW<%_6&( 52E^HS2>Y5@J#I*BH6N RV%(7TK1"B+.(X[V
MV$(D%XHL#WF\NLOD$/"5+37,BL0(][-?U.EORI"7/?MTX.BPG\>Y_>F*@ROV
M8AZBWK]\49Y S+YYJ?NWH<UOA^\%/]OU>W#)D=+D1FG@(8LQ'WY3+49;-X6Y
M:NSTF$N6=SKNROUFMZ.7Q\587<A*\*G<( ^PO^:)?0N<G+L?9&GDJ?GW'S)/
ME*=.8G,WO^Y:AKZ&_^%=I//&3.<M;S-/'#_^J<#.H-!B0>;<0IQXJ0?FE;XG
M7F,>T;AW$Y<FX345]5KV1I(UVA4NI.T)\D<O.\[U6'/HUY^[2O$3/J#.T"U?
M7S84CQ;L WI%TJ)_?G,IX@/O"88.J<.T1@9PNPY^(Q\>E-Q8LP;>MSA^'X(N
MN-+BF.JOBH )I40:G[N5&@2Y@.52#?[4QPQ\.I;M>U.UDAC#GY4_A4VA3$*%
MBA^$XK(!1J*SBW00Y7M;91*N)I+B/'"G.V0>+,X[PW>K!U>1+9]!OA8^[HV9
MK!(7A:M*B%JH9IN(IAKNIBXX3)ND]^L62JCJ*)10&<K5@\B,A; YV(NB#6E
MK:64)D]IY$X!1M]8(]$"VBG1?PB52X?HTGM 4#VX:380HL=)D=HG_4_V7:?L
M7>7[)6;\'E@N_QMJ!1TD/70Z)UH205D\0EG(%B4[#K(2H@(U!-OA0[Q<V7#S
M5!(6.7.-0\Y?VVE+K)Q!4O.-?DW$P4=X2-MR[(JQ_"T9[3[ IO((\1Z/2CN"
MH_(Q+W0>T<]\I:^F#"S5V?LT06R*E+\!4.-32_Z9(_"G%H>)EI)UAN E +89
M90#["3$;U5S1GLI!F]67PV[J<[6&>$40Y-AIHS(A'A2U&,Z2S3MF!MU,/*I?
M(?O"K4!T(XH]-9$!$K%\XQKJ8VBJE;**NVH(O@8%(&\Z.RD?/?[U]K4%0JD/
M \0U/8/NV>H8'<SVA8I*0D55%QPO,@E,$\] 7WEF+XMLVE9"]&[RW]AM%@VX
MRVN4SU1688SE47[<39!9E\H0W4+I$S8.;5332B79C.0&HFZR,.M)5LJ'SH$@
MZ]6E,(P98)\B;E^"O<4B+1 SH/W5R&0K*3U5A&1'M U:R19C-E>_[/(^B5#^
M?,S3W*1LX#H1\1)AFA2LI=FF[VQE2I@W;.FW8K  JW)B4HV-^X&8B690(8^&
MVJ7I)OPW(3$K*N,T^*CE)#.0EV&KLQV3(';"Z;5)ZP.\3)IF"5<NM.N0^_ U
M-CPILC]\]PP^4<W/SB@)KC]G3*6+- JO(]"8D&:<VOT(,,NAC95CZHC! [(C
M$+,X5+49\)F@-,^U"R9<!#EXFLG)3NXFDDUG$73E$9'*GT6@ZKNO?SX; BY&
MO;[N+K7ZD2!V:,&;DBXJ;Y/WC&:I*<S/,LW9TJ&Y?>FO=>OR3@,4OY?Y7UM?
MY5!2U"HWCUA(;)?<]6<UXF@U0V8OP.6.9\EVP%2"LV7!)ZC I=?9^@F,[>#L
MD^2=LU&904XR!EU4-8]XE>?+5^F U?Z^?,(MO";E=-L>3W\NY"6)4'KR^^D3
MNZ\\^I5"K D[V>MJ+_W?*0:G8(?.Z'1":R33;\!O0.?/B/R=T+-KTG?V [X>
MK[ /C:T O(#!9DZ<(=F!#L< 5',Z6F!F##D 6/E[J$T=T-)0R%L2Z'GXUQW&
M?6VMC,5X258!1>=>7E8F,A$.CI2R4K#+.4=9\&]TOIR,I?,3I Y-I1SKB+CB
M58IAB7LSCV9LP)LH*B"Y];+Q*3M5[=Q-"4<!'_9#DET59IO0%JE+;C=; KU5
MK>[BZ$MHZ2O:6V(S;D@INA'YQL"]O,3>O,JQ_K..9@E/PF>'+#(4@O[K&H/3
MMV1"X77<=Q337T7AZI(_XMG,9N0:8H2D.!/TWEL/3*5CK,AM?_J3SG384JAX
M/3LKK 8<"ODJ B-$^O#&):)$KBG15^)V6\I83*2)L;>D3SM]T*E&V!5LY1G9
M?E"8SMVP/MX:0NN3(B!0NL=-T4(QP&P-KW6D)&//4#(P2SNX.J.JU4!#=A,E
M#66@TB#W<K="T5*D23]Q_YA;IA\/[.;I1$7J2Y')\ X)867 0%]?D,>5X!#D
MC8K/71L0*KKGDI8K[8^K4(+-%L@K+<2Q?7^N6'&MU>DD"SNQH#K>@]6"I<>J
M[DFQ_:B]+Y4\DG4DP)-'X6Z@C*PQAD3R;&LL,YFTYAI8]3M4;#T%N]OPQ/6!
M>A])%WK)*]W%$\%B(VK_%LSZT-I:E&ZERMCCFO1ON_N9G]M-3L%Z7K[R]R^?
M]9"\C2:Z#.\IMKDJ3/=)E8<G17+A2]"9]YSRZCYY]0 ^%&A'T9Y4*]I3+X<G
MR#CZ'[%\H0AT4!D>*[Z9;Q'Z"ENHY.\:=OY^XB8H_&I.D##P+GO_&-P)E>(%
M9Y?3+]W&W^!N!85-V#6J3I%N->]CNY1W:X.R1+4V',M^D&\#.J2J=FYL%8@R
M*"8$KB[)JY.#5J")3A)5O=2NAW,:*! +Z03.;NE]MK4G_T^2/81W:*(OAYPD
M71'YZ^JA] HH8E!M,8<A,L8.(JC6M,PC!-FBY9/8LY%F8_(<KV,*?$.^2)Z#
M7PUYD(Q%NDD-SITCZ@1)'*;FRO9"D@ABUM">[Y4<?4O!LH/HA(/7R=QA6#R/
M8( 3KA1GU6(</5;8BEL.+<&&HY.-Z0*"CJH'#WC71^(#05\JC)2J97H3L.=]
M7F0E;  T\Q+U^3F^2=D'A!P[=!(I1'R?<^EQQ%5OR.EX0Q=G=0XY6WG;AMI'
M6J=\R8N82F&8<)>&.4Y0KY/,F409G_$\HX*')-AY:? [20< R^:IZT&:4*:Z
M@E*32";E1'6B&K$C&$N) P*UQ10ES*!U(/XA*%*RA6P\"%&D@BNBB,L1L7]J
M3-D9P-])OLH:2@0N4515VX@W8:38Y\RV-%#DASNQ$::>?/_6FR1M8+81JQ<=
M?U[DRGT!.8B==CL;R*90)/=NSL["D^'9^1NA>+$52MW> ;;0&B9(\3356F"R
M5"):/H))!'?*/RF9I)U2?-IE&"6LIJ0S=#E&,OI <--V<ELYT&=]D6,G1MUD
M()U#I*Q$K-&3F0GCU<[G*)&6 E.3QGD$DG!Q2#[&1^GQ)+_-(VZA&NO.U0K>
M+3K2/8G 7@UMGQZ/ ^<18].C1%8S^B:JAMKB&=">A-D L4'T*^/65P%3]+EA
M?CI%*F=(U;77_GGWMFAT'R\(S$IX2*2UJ,N"C@1)]3]?9-GBA3W\@6.$2I#D
MGN1DGNK@&D&-Q5#"VC IS@BR!F-D#AEVGB)C^ S4H#Z?X11C[@I*XP;59BA$
MC$J''<1*\Z8Z;T@HOP'$4,D.Q*E77"1F;9>S-W,(<@JJJ\+I#9KN#\ O)>:>
MZC@'1O_]\AD0&R9&?:@T^-FC6$&*!F=;//.NCK7.(PRW.7O)UL#H"!;)$T)%
M H^'^4;8*J1@-QPFK33^(=DSE58AKG7!9!>/W![IA'RE%G4\0;S_L"M#2LXM
M'8 Q8$9BX4ERZH?_S-6+ A[.(ZYAI^U8/ZJAZLIYA+:O-.:MZ/M1..[C/.+#
M8(7"=V[37TC\$<K*R]BC^(7A#,"3]]'!OWO&.L1;F>^\)Z8T?"Y=55DRB$U1
MK2\8##?.^R2<%6Z[36S:=9M9_R+GS&VWV^OC;V]P*TN8%2WD^+PFV31?,B7]
M6)0;'/S@2-N6T[TG/#5\C@^M*/XM.I!0*?LS?*NG+O+\2%TZ&W/.Q#WWI]/(
M4;&E 7$L&[BHG[0S"/5VF/_W/V.Z:5GQ^!T%QA_^*3UW]UOK\N]P[8[+=\VT
MRLLG@CTV;KZ\NW8CZDN]2O-,!9;0WO?JWA]8B06(MUB)_9P#]?->%"IHO]9H
M6X]?\VOQG)NQY%:4!NF*9"H%K\-=%IIO"/(2+]JHZRBK'TIHF<TVCFR>S(LK
M_/3&M*942E-HIM61'UV[X/.U,_K$@[JM;Y^]9H3<N''CPY]6KT&>X )#,&39
MMI.3J7%?_/2C<VJ2KT]^F*?V04YY5^O7U2\//_CS;\XY!]>NYJ[4RZ5K?K2$
M\>^Y'9LETU3+U22T5C?OSW:]K[MM0M+_><$TR.]@W>YM]6GB:R>_O7QA<=B)
M+.R"[)X3/1?JJHM6'\NS.QR54_;YR^I[;XEMK1A-*+X F^P<KV:$Y9#E7H\[
M?3,\PXC^$*IMX0LB\T7&HM)PX=6K-*?&B"NVEZXUN6<,G7<];2(K9_U%N8"B
MXG55&T(9B[TEY-N/PH<V "$3ED"F=%NYE&;7 'S)R!;WL95ND_,(O_2+E:S*
MRCLQ534)OIW!W78$I&C0;TQN[%9IGZMD7(+>*#?'OB5_F$<@@G3TOF+319IF
M(D&^;JXZUYBX%#-D:+1HX;[33\*SS>PZBU7]W]DHS8"1_#6@V2.'Y(G\0..A
MMKV]-N<XJ::_33P:AO<I_%3_F!E!E"+2<2$O%)L02^&S5GJ4!T 1+5Z@9=.5
M4+,MW;8&]]F!YDW9\ISJ$6G\Q?>>URK/?:A>4#)F'5O.M$X0>>I4,Q:/X $O
MG#ZER10\84<QAAU0*\D;(=\FQT+'1-;U&1/>4K40&F8K+L#GE;6<?>)[P,QD
M^8I'):3%/1P\:,)7+>(!KWLJV/254+!;KYWU46L[G6.]O<*OV/XXN;^RT%9D
M%D2LP>EXL-"M#0[R="XD*8"1 "XM>FI11(W(, K5ERWYKGI_=2XIT;15@-,,
MPS@ S/%Y1(@4;T**Y *B6]X^X-72LO /8UR-NJJGG6P$LD\9(G^DS(5WK"A%
MIW(=84N %JH7EJ4RKP*I=(Z=Q,N7;U3WS[%WQ2/DS1VP>VE8#B]I)K?HYA=?
M5^&%:F7@QFK.S8#-7Y[7_U_S,/G*?TO] =O4U2_OR5^U,_^C?/GKVVC?YNA+
M6[+O=]KQ;;E:JJOT^'!YG>'VJSDZ:M<6[]IS6?U#W_SZ1QW 3#GI4CU_9.QK
MP5._2O=<Y_Y0<W_C?X;C_ (_*O^$+LN.D_U1_,B^$U@WEFW_[?XG_$?:/(V/
MQUO7GXD7V,=5$?WPRCWN/3\>?@@._O#]B,4?UP_S RYS=@=\<-N\I*+\4=G4
M1;=_1$?MN;3'=J7)M9KEA^I_J+5W[I/](7_03NAJ3?F#^T*Q/]P#@'FTR--L
MLUGKVBV_EO:_L5RW;.FJ->VA.ZZ6BLX^:E"[^I_@TKU7335-NF??GG:UE'NG
MVLX].QG^BN7?LO]6U7?_X=G'?TI^V&V;+]Z3_6'1VW]J%2;1-3[&,8>3.3[(
MO%_[LT[?..[.[4C7ORW7GWG?7EVMHO;ND8;\+0?FA?;=PI?[GORS6S[Y;)U[
M!; \^?TQ]MF&G3]*'\]OMQ/X*'J];Y]MUG=[P;4/?G0"XY'[1_6C]6\+']^_
M%>^X:>>'W'D;"S_,?@Q:L>XO93?A/O<__0HM6W&?C]6O_AD VYFYBZZF7_)_
MW2$A,^>3OT^I2N/Q!1;GZY9/=F"[..?S_.\=[^<Y6-A6_[4*RI7IGY%N*]D>
MYV=0\>V8X6U)DU<:#,QR>^9\\OQ7R[[AT82>'OD+$R_?2;ATT8&#06[O[TF5
MW]7M_1T/'%BZJ(O!@>'K'T^[NR?_,]A\72SS?%Y+J>W/EW/2+WR596/5%6%H
M=7P]KZ7@S'+VNQY_;/F5V7J8#,^Q64^\O/'@DZKF@^]X@4IFR'R\OG[_]3]?
M'C4L*#GO4^3Y(/W*G-)_<4W3@*8;OK[SR?/U5_OECK=Z%UL^W_Y1IH#CY1RY
M/;\^SGF0F+& ;5,;B\P$-XX[!P3O6]C^GK=\:?$\Z0_U;7L4^=;F/URK=-VC
M.?:CW/Y'=Z.T_2U4OW?\"5YQ>G7VKSV'/%/^,WA?-95<NGNGYB9[*S=#=ZFY
M6X$>Y+UE^Y_A_;+S/J7G"M]>MOGZ;+I\W.&5;W_\_E0U[R?0PPT"#%;I'U5^
MS3/RL_KVMO$"CRZ!H27?U+!C3\..*Q>PLU])*?1;A+$Q9Z"P_?^; %!+ P04
M    " #V@9=088E;35YZ  "AAP  '0   &-H87)T+34U-S9B,F$W9F4R8C5B
M9F%B9#@N:G!G[+IY5!-;M^Y=J(B($$ Z08@*B(J8K8 H32(B(")&0:43LI4M
M"(C(%B1J2%2$@ C9HL*V(R*=2!,5 @HA 0+$9B/21J,0DJCTIDH!2]+=\ISS
MOO>]IQGGWGO.-[[OCR^,Q1BDBE4UUYKSF;^G$M5;U3"@N\O+QPM04P, ->0'
M4+T'/)"__FNOGY/\5^=04S4#>HO43JBYS5=;!<S34YNOIZ9J ]#(?:K_\PG
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M,4?+D!,0L1G(!FU:#PIR\K6+E18P130AHVG"(T&0<1LEPVJ\FXC?Y;?PU8Z
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M8A<$QMZ(T8PC!8(TJFL E-4ZY_48PC2?S<]R72MB9.(65M[GL\BD6-EJDM5
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MQ8@/Z8:,6_"H\;DNZA3+LQSV%7>U5IUK4Z+C3>F:1(VV$.<8)^4Z14MVSX[
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M/3NY &O/*%)IN"_ 1"=J-RXN>F?'&'G=O0!;]' !)MOXW]U\^ZE=2U_:V]Z
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MVM*_P3_FY)G=<,?Y!Y5$(^JQ R SF1<\=XPZ)VT5QE)D_%R9C@5<RHFK;%N
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M\$WF'Z+Q3R&X.\26,%+XKC6@2[+2ME!I;=;:S-:A!F)OT)T! 9/&F$.3$6@
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MSQXX7"IEW,A;50V1*1+L"N6QNBS9?BY)%@]FM;"8LP(1=OE!(*WU>(>L6QE
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M)PUSMU=(;,3H2+F7F[>J?3Y.Y3A,-6@>E>/,B=I#*>;M22J+V(W4/RR,R2T
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MRSR6W"@M/N\H!#Y>7MG06^:SLOG0S8R3'>$1 ]F_J19%"W[DJ&:Q<F*/C=+
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METZ5_]^$[?XW16NA__\ 4$L#!!0    ( /:!EU"'3(LX &0  #-N   =
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MUH \/\XE^IHY>> FR4"0%HCS[8K"RE=!(I1_J 2;;MM$5NHUM=&,D4A>I.Z
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M.E.Y"L\ E?9MY"/N[3\<[?]_,)"*[G\#4$L#!!0    ( /:!EU#\;XNJ(C@
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M,"XN6*!!JUIH;]K@-8!8UU%7S''U_5K%,VJT\-!V:T$E%56+.H:\?(+Z]<@
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M<1CQ8&G1F'4C>T8O2W>A 0;;>CD[< EA><]IH5)EE6'!VR'*N_)@IC+8H%I
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MC.*Q_JN>#H&/3^R#7XF_M%ZXXA^JFY%@A0L,6O'DE?(+]CT+W%NR> _4<H/
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MH[T$,VD._K38CNP(<8976CMQ>/2HM/[[3X0I0W2=76E,WQ!,/%[U_L#IJNC
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M?AYG&]\I_Z#/#4D<:T-*4"Y9BFP<8JR\9-U\O71:ML6';81=$J2OC\$@8'/
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M=01#G8![E4X/QX<)^,H4>GUU[5TD/,LP9G_O-\L6)G?UU[&J*KHZS, L2_)
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MY[FQ.]?NNZB1&_VC6K.)HB4#=6,9S<39KX7@4"E.9G,&$TO\2"R5 WU>)^1
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M4411$*="6?:DE:<G9=&E9\ O.%F$J>(0=A7X G27 X_?%LF!@E[M6ZZR;^3
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M/IZ^/_'CPK#1R6:KK=/N*+Z'J]1Q%\&;BE7 AW#*'P6FY3]AR\TA7^6<XRH
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M;[@1D6)Q.V6B7/[<DB8A?B%VLD<W/6(/A=:><H>$ULIQ##Z.+Q1-?+B"*3H
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MVJP"M.PPLN14R 8]'F$E7)?>3&N7KZ?(5K90!OB-J(XM#=V6@RX(,D,CCJF
MOJ+#&/P:2[&6Y/_J*8\5#O<R<CXI;W]D6YQ1 1N[/DM-IH+JNS)C6)?L+IWK
MKAL]Y;O]W[DIL?7_&S3]ZU"'U/_?@Y&-3N$34W^79?_.H.A1^N[_UJ=3X654
MY3WZ&.:S)\'0'!'=3 6X$V<P-I,9CT:P^XJX)D(\VD I(2+ZG/ZI.A5@F'>5
MK,>T4>:+_# Z:PKWCNSJG$QR%%_RE(X^[B?.]P_#=PA-6OCW#M_YZME^=NTR
MKR!RV,;&RO:E\9>S%9C9^F0J #8[_YVFXCUXOB:? @4)20O6 Y2O>R(BV<;
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MSC>_MFM)<DQRSMM)0EOQOWT00+S)+;:NLTYR1]<K!9,\7<2ODZQUE(59?HY
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M)7G9Y[Y[[GW_<^Y[;[S[3AB5,4)JK)ISK36_^?LJ)?DH&0-4CQUQ/ *L6@4
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M@VM1"2S3'JH>7"=HXW0.R;3BU\Q:$!5SE#S@8;"40UT/=MY!7((%]!D8(13
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M7&# 6\?CJK93#>T#($_/GK)Z90%3FYRO?+Z3/\=Y(-XR,8@S%>5ASZ[8$9U
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MTRFT;V#,F9ITMM^FL%G>CTML?R/#K3^$O^;QK]D_VD^*)R1 43_<)@'D3"3
M_7NT)D7:S#0M$"7R9<1;KMQ$+[^6 )^)(MD3:[2PSB(12BP*I"'AR>3LE66T
M:+E/ L +(=(@\'1U&LU. K ]&%(W6F"X52R6%@2U"B\^X"6GL:I3R.7QNB3
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MQV9K\IU>*6[+?VFS.G';X__Y0'%1\'8\\B1-O%;:-?P\5T[0IC<@AYC#?TN
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M86V2TL/*OL#<S?#U%6/D,-29*C:96'9OGI.GJ/=1G# M!D8>8!@GTE=P@RE
MR<*;/PP>HG/$:\#<NNM/[&\*WB+63(3P\&2KLPQF.NSC9?'H,O/33G;5EAY^
MU]>^^@=BWM8$$NW:L^&)'N_@%;O)W8&9[AZ/](*.7L[OV^77D"KW)LO1PS8'
MX]00^VUTQ:EG;I:Y?A\SN$IY3[-X:'&;)\7<>]C;DR W<X+=*>ONTK%!Q8G[
ME)NU%#BN$>BZ2'/]FM;TQXM[SZ=:0]6;!@L]LU33T;YZ?RX>PS6=/#5\(N=X
MQ+$]I>7/),!@Q_>Y&Z-O_:D6B#J< Z8)\$UHV.3#78@FC+W[3/SA!Z()I_A
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MBA-2-TLQ<JN?!'C/"IK#"A+G:? I_'II?W*6SKHM2NQ<\!^&)Y*UQ4G>JA*
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MDA\85*OZX%.7:(UJ9QE1WM^=^+G(5QFLZZ).OJ!=M&=M.ZWVY939\2]VT1?
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M"-^N+X/.TT6/]$0,7CS@![HQ*$VT!V)@<:C@S;C!^5M5,-,54HVH1IYS5@N
M((6#=$\+M)-3M*8'4:.XCTPQ,BUK9OXF=U\)F_/R-V04P\Q);;_W(=O#?AV&
M@0,#P3VC=05NCW/,>C^SPI<=WZB2 @.R&+D)1.1S<?*M4+"T@E<8S,.MPHF
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M!BYX5QXLF 72\SOIM'5R,K23+B%HPZPC("NYWL'(FF^/;>M>@G);+V]8]_6
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MX(O*6)-%&WX)];<&N"M<DHER=RNR#B9#ZJ+@C-N@'9^;0MO4 GZNO >'![:
MS&1YY)WW?N&!V@.VW2O@#!['# 0RHK":%""@A_G.RI)IWAMMX65.ZHDNQ!'G
M8O^G'RQL=XJ=F;O#74<@,S, ;;FJC JTKD'E"1<'L]HXZBB0>-#>&*,^2A2@
MZL_NC<*E^F%34*9A&%*J_A1VY4/[<N>_%I92LMIZ_7JGK'/W143O6L_.7 2Y
M3<Q_US?3+/)P-9V_L1ACG[ZQ>.%_.KZ1THML!ZA&QLGSN^K,#V8?]*<W^K,E
MJYZ%O+D49YYRZL7TH\)WJSNV==.5F+8IB#D719)C"I28['!Q'<WQZ;<3;9SC
MUXX)TGAQUB%?1")[@%-R@+W[]'@K]T-_IJ(_-"#\$2[@X"555=4U."*-(AGF
MN"HQ24,2TM<O7'B!G1*SX8T2H\[JX'YX X +R8@7TPY93U^NQ%B=09GBOA+S
M">'VOG8T;!?>'^4#6L@[56EIAIC$\X\!A],T.GE3Q_$K-4PD9IP'P:'0PAZ>
MJ"*3LQ[VY@\N,MX":S+ O-"7-5^R0P[!W'9[?$H)?%$66,=^<Q**F-,33;^U
MDP1GLO4A0U=%&6>=7 -.@E0[!J=;4?GP&_7D:XZ!W#7/=P"_7KX<SJZ@>L"7
M2N"25N-M<.$]2B#VLI_E;!F2AGW"7=PMREPG)XB)JPQ;?IMK'[:$B-=FF679
MTJS^,]":HA49?N#I(NL,%Q;DR-')\H^!;&B&S7T;>B(<]\XO'*_P"5@Y>N1*
MQ$[AT9U7GH=_&1[8G7^H7M###2THC#4Z.[H7\D7E^1 OCQ5+3OT:Y13D-A#!
MWGUW#'*<FP=2S]N\C/VJL01I6_JQ:+[[V(WGGU\M+2OZC%:8NS^:1B$OE_SN
M;.[^[>3Q"P^OS60 W,$#<F9HE- ]6 $$AOPH"%!BKD2$<\SL\]+8WO&R[90)
MU$QF40])&*NH*I!P<NKN!&I]AB:*3$%5'C;Y8I'E:P1+X(=,WX'+1-W+Y?9]
M)HUPAMB(Q,=6=D)ZXB5_<(S?>'OWD&=(9QH5US@F0U0=$/?D$GY7:"PS!='Z
M(EQ*]06Y'4VCEQL^!'?,XSKI5P&]KS3SD,'AB@UET(;QH6.P";GT&$P2<>C@
MO3@F_'.]4"5TOH@1#44>[6-6-\0[/'R@J-C0[[@3V=$C]P5'O<%S%^WF"^#.
MGP=LXMW;M,;R][^:KRTS3Z]NF*!C.RM"/<*CYLN^CWN&EI<U=)&\SC=^UQ$V
MPA*)X=NI3P_M=2=]K[?:_M%X\7! YR6-%Z&V]0,W_(7[\@Z=:#?];<CS?(_[
M!9WKS]3M[1\0^8AAYH_;MSI>M@N7+0ZUB#2/'7\9'C7K%RAX<UQJSWTG&\GE
M@L^5&#&+3EL+TWF()5P'<3L,K#/8,5443UX,H@TFWU)-HJJ+&"DT33#OZDP
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M&%G#%$W/>S#DJV*4F%4$")5,-V< 7HX<O<QC!VHF4'85=R*;@6]%;.W9DAE
M,KT5]L6@\F;  ?=CM"+.]]5J?,HWVV_$5!2TKY+4J;]L$;1SP8-,V&(N+>_
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M]VNTN=[4;H-'?2\M\51CDOY&YMF26[^<+K,*^>#%+E_QQY$U^7\<=?NDN^+
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MG=F<QS0@@)DN@['X.U:/(Y@ZEF!6K0%>.PZ>I4+VT=!C%!I=,QBJ7J&ON D
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M_-.H]FHI5;MLFK\]MG'N#A+3@R7\#K$)ZI:,-XE X,P:7D.$QX22X*%I]0D
MPE].F![8>TY^_"[&J+7=..6$2::NOKZ?16YT[L_AZ]S_FT5,Y_XY_?-&A/7[
MU^M,.DO[0\+JUF#%ZFL9>[P&DT=&6GU@%88<^+[B^4FUY*_XJR3=-'JB(UOO
M^R[AV:[#8>%&;:</3A-*,X[FNG<<OY6Q]]&%?S7$\L-9HLE]HIF=1GN??<T9
M3>SK-=A$ 7ULGVH' #.$P0YK-*-2=WB_(EKP_K9E[_]W$]G_'X%?&_H/4$L#
M!!0    ( /:!EU!S:TES:8$  "V/   =    8VAA<G0M83AB-&1B-S W8F0W
M-3<V,CDY,BYJ<&?LNWE84]O7)AA%0,;(K"!$103%@ @(0DA45 2$"%X&08@3
M,D1$E"%"2%2$, A<44!!B,@D,D2$$&5(@ 2XCLQ!088D>IGA'&4X2D@ZMZJ>
MZOI^]7U=]51U]S_=)\_ZXV2OY^R]]E[[7>^[3R+^+!Z';7(Z[G@<MFX=#+9.
M\H&)AV'VDKO_O>N?A_SO/F.=N 6FLG'=BW5V4NMVP-:KK)-262?FP!"2<4K_
M9P?8?[G6K9?:("TCNU%.7D'B0-\$6[].2FK]!BEIZ0T;)*UQDG;8!A5IU>UF
MAV74W,[+[@A7WW_[?N%&_2,UK1KN/<!.\PO7[\C):VIMWJ)ML,O0:/<>"\L#
M5M8';>R/'CON<,+1Z?0?'IY>WF=\+EX*N!P8%!QR(R(R*IIP,R;^;D(B)2DY
M)?/!PZSLG$>/<Y\5%9>4ECTO?_&JMHY>SWC]IJ&-S6GOZ/SK[;O>OOX![N#G
M+T,\ON#;][\G)J>FP1\_%Y>65Z!?O_^):QU,ZK^&_N_&I2*):_V&#5(;9/^)
M:]WZZ'\<5#9(;S>343WL)GL^7&W'_ML;U8_<+ZQIE=,W=P<T+ESOD=?<:<$S
M /\)[3]%]C\7V)W_I<C^:V#_9UQ#,$6I=9+%DU*!86 BD=&S%-C_W68LZ!JV
M7RYL6,L2R@$K[9I1.(71";Y6!TZ:N#/#%^H#7;'Q5 6A@1@F=SF/G^;6Y,@?
MT[7G8;:\+1MJ*=@2:HZM]5,7PX)G;.KS+EV=VU!P?E6YZ2)_I34.P5\3P]H4
MYG!_-/6Q>*>$YX&)#MT#HUQN[[3NQ3^ "0KQ/&\FU/"45LBHR[T:B,D')^H1
M(>G\CL_'C]0EWD+Y\@;GJH B'VJ+OS+(2$/)B&&J1/\"G=J"E?&1L0RFL5 F
M@S-JTW.5>!Y8:?-QZ/P)_&3[;VP$K3*:X&OY?*PL%';FP2$0D8Q<<K&,<-DA
ML@MCG\9G"<FK!*(.0)U-XV.';=M^1W-PR6-R%J'&]MRZB^,+B:.VZ&U@]0.^
MKCU[6=N?SE.2=0=&2FNJ"-?#^<:^=-"N(!]#&>(.B;SI<NZ?/%6@C&5D+WTL
M)7<LE0?E\3\:\QBI)&,A"A+#!/#XJ%RK!-?;5<0KD >/)4<(;"7M9H"8Y0B2
M48_0;BL9SD3@?XMA\7NK]?I\0,R=B-3/=!=3Q_XFKT)":CU7# L(4\"/O9+.
MF+U]D^\28ZHXQ9)&[0:NON_0O!9\GY RBI&&PH[U6"#42QYR5[2-I[,'&V3R
M*]^68?$''H1;7/?NDOKB-'G(FKI>-$+=*'0$G?F(-JK&@;)Q)5P;5?,J<S,A
MV@.4N2W 8Y7QM;ZB+A:<%43H3&ER>P%A3@",-C%LBQ]DV\[<T4"'0@5^U]GM
MF5,%,ES+8_2?B@UQ977$+6M%(E4AT>^DT)*[E#<5T6S(+MB)QZE ^IWH]<S^
M)H1@^PNK>&(D;Q6N1[C!CF;N!+12.Y(K);EA*@B5'SL%<%__]BS22"_9R[W1
M42 ;MZI "&N/05>5"8^!GVC\]U0M4?<F43<)D]UWM 88R4A>6NWZ4M"Y' 1B
M*:&55\+FYR/@<$(\>WDE=S$T\,77D"%T4=RRL]T1;^3V)S.D3E:-%GOALVB8
M$PZ=)*"75WVZA3KCGRUQRD0-R![(<R=O)*S7]32%._!C%Q+]M;H7FD+Y>1U<
MDS"B(U_W^L_5 RMN1YL ,2RAR6C0YU7(.3TES%P?.-&"UH=>L;29<D*M;J("
M0%Y.@Z17K0D4?^@FR.!CTE$.<311MSE1MI^(X2,-VQJHLRL\''UJ")/(/#CU
M;.8X8\"$>+B2P#A.5I[D1F\*J8_)C3.[N!HA^L!X7QC8F9N=;U++PZ7H'6BL
M'R2N [78#+0"P&A%;,+R</=\!CFK<=%MN426_"QS,Y2YKA#BXI*2>86%TUXQ
M 54=E[@6]^-,DS&7:$K0@[/0_>JS!-I91@[?8<YNU8[4Q^@^%E#:Y!/%6K6;
M0FRP2%-C>Z9M&S/)H'4"]HYY?S12U]!<%[R;YE%D<RGJQZI(;@EHY*@(@_M0
M?GR$*EZD TV-LX9NM/B;]A#S][06=I-#$,D5H''[Q9,LY]B<])DC#6XED[3H
MT&B\78-#^(LO(PUUJK"8G8CZA=F5&T]-Z,H,04?_9= _;[S"E/(1\!*@<)N7
ML)OP:/5^X<VBX2F,]&5 $:<1Z8S$MC28T 7.=I<[V\PGNWAQ:F<'OK%2QHX.
M,#MEYZ17/5J!P67/IK52D2+D/BA8J^I'*---I2&<([B5J:5GU8NZ(< H0J2H
MWJ6;$4K7^8-G7O585CF<[K,P_JAD0G<AN]0#):M!T5I]8\%C>[Z26PU$2OX$
M<^>^,'T(:Y@FQ("[X$E#!^CX52/2IUPL>S@OB83 DQ5W]1%Q0)@#D$9)$(8,
M41*)QRI":F=R/Y6M-1=!G\;Q>@K-0/JM09)*XVJLX]H3%((GAMT94V#*0J3(
M'I090/.#,-53JD$%.@ E\5GC:\A!L*!$/$)/@L):?R,2FQ#/?*%4+V#*Q;6+
MC4;TU+TW6C*N+0GF%EZX!R.N5)-;[4G:DV*8+M%RW(/1,P'I/B>]9R+7BH6G
M5X]@DJOU>XEF>MFDK7A_=> >6HW"SO'*_2HR F0Y.H@M+N30"C:Y+-^Y-5<O
M_RE^4+0OH4ZT<FJ-1;[L9S+4,@;E=&;__KOP!6'UJ-X&S :TE2.(9I^!SO,R
M-A($G3;^M0 30:$)UE17[0&K#**^(#O> U@J[$=MJ3Y#*'+"S^EAZ8,4;W+K
M7J;*5($*'7#)X9@F[YO2CBR;DPM\-I)7I2GP!;YA-J-" 7P[68D/K*W-YT?C
M _&K!Z:H,+0J9,XSR;]9.NUSI4 3N)Q5!E7WG<F82[XY[:^REE15QTH* RD=
M5$T45L!*\?E&UKP$LI(,@;$$X<&2F16R&DF7N!/RN)2+HT1X,[MXS<:M_DJ0
MK:38Z&#35SP;^NEV6/^!R(\^/V(_9WZ6^KA$AO; VXS0^M-ZLL#*W:9(OI+:
M,4@ V/*DQSA&1$-!-$!)F26AA!L'T=8$3#MNHZE%ALR,(7_VYY!WT)!260)Q
M6YAEVKF991_1H\L]I2]SQ;#).*WESVOY30YQXTI6;.9>4"O)1+0CV$;O3=FN
M>*"3GUV+2%CL4B5T^4'AST:([E17((!#EN7^Y",2FDZ/7\:FR+9=_T*H:!/M
MZEE2KWT#++_<*[3E+0C5)"NGC#H--'KTB'83GLVPJ4K58E@@3LTJ,5("@R1'
M2Q9"](FU+I+\A7T4-,?7+TC_G5<&47G-R[F2<25F#OWFCG&T-:IIS\8^.\2]
M^#PR,8,!7,:40ZX342F#_.HW)3Z03KN_"7A4NYG*7DB< HV/O0%Q<W)\UI#V
M,BY!#-N\HV<<>@!(NCW-)9XBJO'?6N23O;N%;N-^!X;>"BU+9KQ\LAE1ZY98
M':9#ON,K+:G->]A\3%(D7F?MM#V(2'7)H! U!&0]_\E162 B]ZS_/BB!7X%=
M#T5SHO54H&B>([UY!T(%6N#T3)$T>PW[*\<;!U2#N3;\9VL,S.5D"0AA9-Z"
MJLXZ77)XDAW0F40\_ *R[]3&LN>LVA&*1'FT$33,WB]TZ2=:A0)+0OMGPOUJ
MPJ,V%FB#G%-,P"Z]C!]GH]!L>)+Y)OX3"X_XK,:+GO,5(&2A5<X,[Q$*RZ/)
M$&IY6=]$^R!GH%& SHF5%(".!F9:]?3R;P>*:"\4R\DU31!>+ UIV*FEIP,F
M4@-NZ-99#952^1@X@>::^ZX/&YC,&J>R%(3G>2-AK0WSC33)\U,%81T9J4/5
M\24^4[E'CW0)<+-S('PYC$M4*<7BMX0:G^@F&H#R"^[ TEHE!E_7OUBU7_/6
M9_W60^I"*S%,6@,RHQ&Z^,J4 WF"*LPAH(,*[";JV K-H)8Q5:8!5"2(2@-O
MM&OJ:0*=K7(B'1^B2].;/I0!4'0*)%H-7:6\\ GQ5\_Q!+=6E4Z.ZO2'N6:T
MAT%&5JVF&Z"+A[E$A6@R>-H#W :IE7M_GM1#@%])B-ZF@Z! X$5A*D*^[B K
MK0JE54&XP>N@19=/Z^VB'@%R,JJ)!_FFFT)(\H-$6]VTK#GZAVRFLP '[7)-
M YV<:>I$/XAAU3Z6_.<,69X^!\=!CX$P'B(5I11V \AI)6\6Z01[2FA0F^_:
M9N@TI[Y@&^#5T:5);COZXVQP[D-_DP/,/4!I"8\P5VEAJYPLAHWG,57Z(D:,
MVT8W0GDT2*$E.@;38DM.$LD#K%MHC<E<1/J2&/:%Q4?2.!F4T1TO^R2;)PPN
M 4SE/+?^9P^<P/KD<3^=DSW$PT6M)7D*H;+>\6<&A$?7S>.T,2&[T4JB;DPM
MMDW)OM4M1 \._0P7?-3!05F&2:,MQ(,@^K'IW45:PE!H)T7K"%,TTB<R)# X
MH>.U+\2PT* )=L&.-P"=]GGI(:C/S/G&DI>,MY"D!-(9G6DWVDD;P&B*T !@
M"YA%0 5ON6H<HRP\# V\$+H!=E0)WY(5GJ1#C' >C4*&TY5.M]K(%)5"\:<;
M&*FG7)R=L<I?@F+84#+=5&TX2)/9OGJ2]%:T=:UD,>V&*Y<8S!?#-HR%(.0E
MQ6GA,(BX\_U5+:AU1WBX"EK@D3E=<D(LT%$8K=0V1.CCL=)):@1?#DG]YGA!
M:Z1Q0/:RG*?!\5]B6"<"<(%3_(U>-Z:>!/.7\WFQ+!U"-,>=: N:WB;*@N:\
MQDD?^.P"4+M\K;;7A*@B&#'WZK;$;(+(;53YNC5\BYX5=R]=R:%5>R&IR?O/
MX ;F_>JQX#Y8+'&,09EM>C43'BR&;5I '5M+>";<-VB8TX;>((& X3A']('@
M4:T!DO*D2/L-,)% -T)Y\248'WW/PK=K'63+S@PA[0$-G@]4ST8DU@'+S>%E
MX7IZDLJ:(%3CHO?B<?"%8FX$5;FS2-2U4K 5["_0@.+M'N:R.KLTB:<@<M$D
M6=4"'$_*&7_(1:B@MY+;FA+#4FPHE+Q3X&@UT=!"^VIMF3/>RI:'@PRQ\1)>
M1W.%XGB(9+1)G^78QA!$K6R2:"LT'Z?/CA[*2$!YK>X1;@=,6Q>D0Z)S=V;W
M!#$-^HB.O 7I=P5F/:;ZKYQ3P]3P40U*HMO1FAD5P?D!7;.' RH_$\0PD>I"
MZJ@U2$XF[3J\BF2D",]43*$U&?W52Z9?* *96C#5L>G.>X>7?1%YSEC5D(9^
MIEZ.4WUM^O A8" ]'U_6/#*K-N8'B\+0!^<,^8@OU%: ,#W,'I/#M7G&7&4]
MAS(Z$#IHNZ"Q]41]_/.I:T-8W@*,0!()VD@'N2@'$,%7C@QJ,BSN?/IY,B7"
MEE>.K\%A2Z9\TOURYD(K0Q!;6('8A#'@&7.[1%] (##!05LU@67I\Q$X1:OX
MR!%#GH@"KA_FM0#%T=K5S7RXQA?OD)QLM%7CB<4,1<CA="VC#TFGJ4PSHF-(
M]R=QNFAY@H!?=(8J2[P"RK)MST0@H]N8NX"?!/T6A(H0P;?3X<#7O>[_!@RF
M+Z:^CT5LGM*<B@YX.I-Z(_I9JJZO6RUH=;?)XPHW_ QQJ8+$H:I8=&TA?=2F
MM+&&;"9:6'")5")+39%@4/1X6C3/E$+:-AT]I WIGX!N\!U1;H)\AW;M7>4O
M0FPF$BR<K:MHR,5&M>*0-'3A]^E3J!CB(<15HB-HE=2D.XY3)^2T^<L,B"1P
M>J(W\(T$^F];V#D?ZXF$J^,5W\I02TSH?)U&I,YQ>O;?0=_ZZ;%3ES*<^W8T
M,26B T^H6Z51.N?*0!.X^@QY@ZDD[N-A0^@N 2*1M"EHZ$ R&",IG)!^7#C?
M]/;0V)Q2+!]YFI\UP58R[HC9ZZ\(A?-&CN"T",%,E5$H70E_!HI3SE,:30:E
MG :OB/[DDK8*PT#95G)R@0PN(WH4#A7RU_#\!Q!" *<TR8Y_=/" _'@L=<*$
M7[](USL8K350J0_0DI;"*&BIIIXF9&@%(17[)B[,K;<SR?*O)9U?@;'4/)3*
MJCQ$:V.N U8H$]!WO$3M#[*QR3^(9Z%CH"$;)XNR?!K2@+AG*9&P>:W430ND
MG6=F](S M+$.?$:JMM4]HA-5)3)#@W"GDS,T,%J^1L/3@G\OYQ5-_[XF<[QQ
M-5KH4@\=$X2E_C:<72@2P\X1Y;I)^\=(/0L2P$H;,DV\(C3DC]W6,_UGD<.!
M][RTM8QXE'TXJ-">\Y+@_K-]5'6@R;=8: Q<IO$R-D$;_&>&_!G\.*P34!88
MNWH%OPEBG.(B26H5HBY_;4FZ_EP.!G,X(\X=% ?P[P30@7^4N:'[BN5FII8?
MY%8W0Z6,:D'W0>,VC (JN-)/:-^'<BN&RIN<XX)Y.@MP*&AL6A3+[X(,NS+F
MAUL.C"JL/;=$VK)'-0:(.-"0,ZH&40"O%H0:T1)$+*> 71RD%_\X??40@>%(
M.0W8Y4^D6(2&N7N+$ 1W@BE1&EBZ4K>&93=L(.GW6BC=.+ZL0/O\JN-GYTKN
MAS%UE"M5H<D%C&[%U'EED!2')O6T&,!*"M.6 !>IZ(P8MKM!][Z\Y\?!VW)S
M4E%R/'@221^0+AEHSZX25*T?=L\X4]-KB5&;M(%DZX1_K!4SU82:7(M\!/]
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MK!W]>Z66&*;0%'"C=(Q@/?)Y^H!V7E!].%3DVE\Y;SI[%69W8QPW=["$&#5
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MW5^PFQ&RT@^W"J03K\<H!I:7>0FL.+0,D@I0UJ% E>D48(8Z.:-(8*$=C]D
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M(9$S86A>35$/UL^[VWDP<I_]\VD5=L9NTZMM"LFHG^.TV<+QL'C23J[PM/1
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M!*0)"%$!46E;:0HA4=F(B!"Q@( 0%9$28[8*$B D"D(H(I8-;$&(2!,!(Q!
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MP]XXHE]<8DV*%%4ZTA5*YW,^WGO_)M9[>^P/L(HB<*7+8=_?9<X:6/\#C;"
M)UR%/8<&G#RVQOJ_[%;1\IHW,K(=7;)#<6&9W\BPUO^?^O-\]/V!X"\Q>X)>
M?9G[*.YQ.S:TN_8ZDM5PYD.,WX?HF  '0?0WWLOF__$3^?^E9Q'_N\6WC<)
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M_GO72(\<9D=2%E)X\.Z@7T='.7!8>C(;B2,4".(ZT8RE#*:FQ.,744,>XK]
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MI5"OET.6G]/B,ASCFM?Q/)S&_KZ,^O/)#50@1%W6(K^2PW20+H),;<GOT J
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MB6[P/#2RKOC.3JLJ)-ON159+77YPM,^I7?S\1-FZ.L'=:'@ZRD)-3;"C+_+
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M+KID)E<G[YG?QP S,_SR%MGK$3(<5&8O6RMF("LG 7FB\C1$Y:"T:J'@B9E
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MU#6)M6\?]FE<=6!WI>65KO]O @!02P,$%     @ ]H&74!WK-(#U:   KG$
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M[%A%E.O25@?IJ235F">(9-D"+3W7ZIS@%U?W#%W.W3U04)_T90K#N2<&-A9
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MPMV#5A)-]":E)F98G2*91#@H\A!S4A3A ]/6@H=BH#8C(P(#9\N?]Q3&L\5
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MT<?(Z=RSZ.)/^EO:YM9%G;QGVKK=[53H@=]F-T;Y)3Z:./6%^?/-TW:S[E3
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MA#T05-^6HG8V\.8(RZD(L"^MZ%[Q;SC>^C<XYBQ?_*\X_MG(VX!_45YGL%P
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M5#-G:KQO^K )9"LB^,1^_+@(]T&G/G_ZM$3XJSD,$=$+F=L[/M+=E]/9NZ(
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MQEYH/GC?CT>5'QT=8@)/B3X,X>B8F_62[\;_]//^_^=MA?3#_P)02P,$%
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MPMI,1DP(,\C  .R[);%127[N^.S UL:B4P=$)JD?S,T\0@W?O:I0LRUP_LO
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M&EJJ1T$TX:#1^@4IDRYQ/%=$M8;,\Z_D;8"PW)E5/D$%CN#%#&'PC%J05TK
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M5-MTASGN1O8.6GC87]%V8[;$&G+@//,>6[#4?N,45KR[]D=Q1%%_8&4E0>G
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MV[^AB/NO/;!72M^BMSXJYX8H/L;1XHS(GZ]%2A88B'(Q*O8X-'5PCU-(2#R
MPFG8 36['RR!_]IC!59H L%^G-%O .A#1/837_V<^3U'E.BYRS!W">BH"2]
MAE01V82R71HJJ'<#_N>N8$'09J2W&6A[CXY:#4B2@-/?^;\F -BZ2(;9&-.%
M"O)) 7%!2X*&LEA=E$4V=OS/77T-W6[2TMMH2+J#VA%T[K]5$6X+9[0;Y8P0
M$G)PL0C1+6L 9DU@-)0MM000)V8? &_ -_LH"+'3K?Z":>*^WA?FWL-MO$7H
M<HSU0['0SHZI8-)TO-\_ZY^P2S4JUIC2MS<. !9SB_$RC/P\\''_"V#JAN1O
M&::S;4E?5NX(Y>,[5S_7B T"^TT!'Z)WFA2MSBLV8CLR_W5NC>ZN7L_CN;N*
MNYK:'WH76]^[U^7:^F7!8I&-6CLH?3X.)"%*Z'*NXW_)01H8JX'9P>%#"&U2
MC$54"'"6D)SH19RB(?K(/Y^8+R27G-NF]>2B?WX)9*S*QAIKJZZY?;'P%[:5
M%;)&[PJ0A8,#F<F,.3-@.(WS^S2Y\A+M7 +WDE@^[8#;IQV-52V:?;6W>$Y!
MWZJMVA% ]+! .T5(;:K%G_NP<_C>M:?=M5_E=<W']PR<J F:[98J/>;L)@J>
MLHV [@KTF%BC;B@>!W:1-8@3*+SJ]8"?#>R<17^%_BID"0XY_!L_M0J(PL$[
MR)+8A7RP65AUFZ9*N45AU%57!\Z_V2-V<6@2?VSS;*]HL?*SM(X:27[&O7RZ
MN#XP\CO_B\YCC<_\??JM3\!W6?^,6<HP_1HBHX==+KBT'^9S"CU6+E>Z3O7,
M$I6"?0W;(TJO] ZUG>AA&0J5/??6]+"T8YYYG_S2; *[SCBD?.WW^G!:^6%O
MNS/N&R"Q[..U+:#IT8$O>56 Z 8+_:7.9-@P%#EQ7*/YNX?QUHQM'Y^,KFER
MSS.X5[BY2?+<]6A(X3^=I(+*9A?[*MO"%>Z%J>'C7??0!XT>-T]O^?GKT-8M
M&[^)5O=/,-E%$_\P= @;G04G)#K&204ARI8^>.Z.G>U4RVSI:+RE\YB5F6&#
M+2,UW8&\.FA(O2NTU'2T APJ+!T,W&HZ-?VD(O-39W^_J0M)B$V-"+ /";[V
M;*"TB$=6"R280/$9M^F/ X][Y;W+/S5I$W6@M38SJ^AD_YBX4MM@7<_WN$,=
MZ[O*"VWVN-QQ#O9(_*7PGXIS0T%B!5D@A4R)6I4,8[KE1;-IVN]+DJHLN^_<
MSK31UI6_:IQ\3\V.M^30 O8,06E/3[I>MMMRYMK=Q+)3GY^_;/_^<)=65_FN
MK=V)6[LRGXB"79V0^ YR'N,_;S_]/QTW;^#"\.)Q%-DHJ7RX#_SMM]B.7H?J
MYC=L>S43E5B#2,;<:*0,\^2GY^CH?]J:YWV<<CZOYS7G-,KHGXXWS"6$&QF:
M!&_743CR[>P5N\4C90\- [TJ.5]1H!CA/J]!9HF@WY^!9]GP'P9@"+*DZ7S4
M DS@"ST+/-,E"C69**'0ZR>_B*_- TH$_4&7[R]YOR[:ZSUV,6K\T%\S6/G2
MM:?N0U-PK\GOIK+:H-(+$\>"1XW:)JBVE[GMJ8-N3QC/;QYQ.Z#UX)7; 4W,
MGW:<QEPV[W6\,"3XF_2IB%1[@S^]8[ ^=+0UQ/32[U^?G;1FM_V^Q;Y0>:4Y
M8FUTWM#^!VX)\>O'+O<IX+Y!O]L5A+0T@9*/A:BT*H&*-Z30$:T^'BZ1K0L]
M8>NP4'SE4YV[J#8BJPZ)AI"L-N;%2 MG:$ZB=".J?FT[ZSG2S%N(_Y3U>*QO
MX119]>\J8K]8)*X#W"<G8@"I[T//D5F./,T"9=WR4!Y^39N I _G-/B:PD4"
MO,88NF&),DPP?[5D$RBF"TJ)?X%Y],M%0<!2B<:3<=IJR"30,XI0&!T#")U+
MPWADU9!0#2?(Z''V<49!H!AXLF\A[_<,0IGNO$Y4)?XW-23^5S4\1M]*<#Q8
M0S_&Y.'@+>$; 'CSO$3UC88IF"@M(09"(]Z'V@^_E=Y&UME\V"KYJ*=W"LN*
M_Q?8Q G(VD,_&R(M%<HA+WZ]./7P&W-H:@]B+B^XTQ0@)VDD!N%^[V+V.R*?
ML"( *<6O]DSP?(MTM92)[TL+_F7QEH1J;M#%.ZGO!VB;X=>1!T>SKC;YM)GR
M7D_ZZI-?MR/+<0MS:$X[F S[A I[9!AF.LK:]]&=+;[__^SLG^;Y0UNB-RC#
M;%%[C696)0B089SM%<B)%8L1Z!XL#J0RX<TAMQRB2R[_^1Y9^.M:9B0V9-O
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MK^2OY!VWOLA$[V*?7CC0]V=RG5(VFP'?!L3K?!NIP>!L'[ *MC\(7Y9BUHT
M6KRM^?)C4*M0A4+[!T8,4&-LSTK'L+N1[#MX"U@&!X>W!@97<74&/^_UJV%9
M)5_2C'"J"L,,5$BHL3-818!P -U0M\D3;]6OW #;'ZN L<-K)AFK:$^;RGP<
M"D>!Q1^5[:;U.QP5G()WGVM_LC_>R;-X1)Z-_!17J3 ]$3^*F_+35L0:6(V+
M Z)*/0+"TFIKOC8[RK$9P4MG9]*( SV\8TY3+T8V_UD\&35E@YU\^8W;_C#_
M=L*Y@$NGO',<R<81R,G)L.+YIC*<<<K+KWL"+IT[Y>SF$'1&YR\GA,03C/=
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M<RTVY]_0GHH_-1&6U;7&9;B#0'Q8"74_9%VAIBQT^]%HG6PW?7DG$("+X>O
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M?W/_F#K@2A?-=%YI^MK\]"WI2AWA^2)MM\-W_P5._)]L:JJW_PM02P,$%
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MZS&JS"OE<5$U3]OMFZIK.E0S2^\?07(:B9LJPW<\Y,3U@-]24JI#KH GTA5
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M_AJUA4]4%2$%+7CEBDB#L9@G6'(Z#JV$@ZK,FA.H2XM$+\G+D0Z]IC,7XA7
MT?CP^P-')AP^2YUB3T?,1%@=BM+S?_M%EN''RU=]W'5Y%GL,=_E]U1_MJZ(1
MK5I1;G@.\O?G&=15E&\;'&Q80=7?ZK;<YBN>?JB!9=K*JY89^D#*@X*+!]J5
MW/6_^E\[&*YR(=>0:$4SDB!8D3D@1@UY)!A,I!O#9R4W97<()-BC4:"68K_9
MV@U)OHV DH.P,#7*Q;39/_ &WR'/HG.6I>,OF*R.SKQOT%IQEQT><8^G^W:0
M9P>RKU[;K_[N!Q_R_=5?*=_[B[/QC5JN.YI/G\E;>J:9?#2OO%Q[V>HK"0UJ
M^>9)%TAKI[BA0F8L#M7W\D.HL&/3->3 L )(F3V.H7>CYI(6T=!5,3M![M2]
MI0)G*J!].R0=\4BN=3LO;DL"C>=R0QIC/]QZ0!5JHRY'10&I!.O[B'4CQZ@O
M.CQ7KRE&/BYUQER7%,#L!&Z8F6E3WAJ$_(A^#(F3ND]R<80U49Q5?;.D1,[*
M]E%(K8%E*!C/""D.]![!&_4C+O1H]H]SFEX'.Z+9>,H1URJ_O"6/>RS3>8P6
MHZE$J7,#W'9 5E J-PXUY!I%1^AZFT\V&9YI/?;RS.GHPS/T ]2C(3:&AD$N
MW3;V.=,F"J"E]R:$<"9W?4_U"<<?&V*^H#E*=&4_<? #Z*XG4.8-F+*'*7ZJ
M/%)S5?HEHZM*<+<"E+!P7Q.Y6F7WT>"ZGEF*X2N./C27V':%3HHOHCV8W-TY
M76Z:>R)0K[7K5V#!<0^2)0U&_64_*H!O\48T:SY)WQYO2'=%J ^0@A$PC:,V
MAB_#)Z&>I4C:8(/@=/N1:3 TU[*)A*LU$,6?I=1TL]]70O/)T;F^+KY]KNUZ
M/D\[3\V9><LS85P3RPS=+TM%'6%KR:D^SOIP<T>8D0A5:N+YRCR\^AJ$;SC3
M,F0 <?FM;NBVD0UV,Y>VTKTZ[?;41MA(8AR8T,0@O_*SML+#$TXJL=$5O3/)
M"N ;\D!XXY *-,^+UZAGK"V'JB[;![0&--QW;+;--$GB#F=USP9$XL(6R9<(
M(??0O=5P<0+=^M%8KV^E^6K(+XF^LXA&XFO7)_NWLXO,C\=J%4FMY&U.CVZ=
MS7]+W]*NY_H,"1[F)G0@W_T2$>P%-=_"4DK4EGH*#1[>;.D*]68].!(:9,*!
MP+1(?! TBE'IHT5(F6=W:7E-CLNYC781J_LO?,=ZZL?':=,*7)&,838^7&A8
M :91U#D6GB(*7D _GC"<0"O8\PQ6NTS8"*LU2@3GGD@)2' C:07J+HKCJM&J
MW+MG(WS;=E? *M\%"L<9&R\-^G4=JTR?=/H$)@J7R?%TDW9;NB,TPYO,[P^K
M?CN36C%8DD'VAY=RQ9&Z$UN/# PAUYORK&%B<2E2TL2Q>/ZD*ZK5*2*&7]U;
M\J RIV@\^W2-H5/TC5KSJZZJ^OO_RX%/P4,^X(*G%:I=+']=);FM 'H_1Q(H
M55<50 E3UJ0 VMT9:S#"YJD ?EW+@KY@29V$@@0%<'A4K,D8\I _(LT;*0 W
M?6!QPYT+R_^+08Q%%M9>Y8DBMWA:OA(TTY^;;4^914."MYRY?F54K3AVX>6T
M(^G3)TPA@[]BS75RC,T43M"M%4!@!5-F5.S7.H>VBE>]?\9UV.NSMU]3/YOR
M<7,#A_E,+_[NJ)QQBC2#<M% //6Y F#E,*4*P%8!&'W503&8MD(_*8!ZUL*"
M[3-U3M=9!4!RQ,_+*?(MS/(W"J"MM46F +(P<GDOM$! 7AA5 !=)GSY23O_K
M]WJ4LSZU*8 EX.@[SO!ZJ7<;BKX!A0L@4DW\YR7R[S"II%&67 5;Z$5\O;<D
M![/CF0+@?E0 <%3&F=.'%$#G%B+&;5^>!ZO!P7OW33]PI9B$O6UBYCD@_3@@
M*Y8SO#ZLB@DJ^41RF_79QRR\YFGUY>.U>9[K>VVNQ5WW/W3KC@+XV10+S>/C
MR?)K3?[1,F:B CC'4P!]::3%4Q;8WE<!=](V_/-0AC[)EQ^Q^PILV$,:3O1I
MLSG=S*V(F2:8> 8&N]M*S>FNNU3?/+CT^I<'ZB^WJQI_JR0K9O+]U6ZR8.=.
MHE@!O-K7T@YV-3&V@ U[ 1+D0T+6[',EP3>$Y0NC>1Y3T;!*PIS*$I=EK8S!
M%A7SK\'GZ1]LT3+R!V88\%H!7$YWQ1P<PK(KP1DOWU,@U]VL+$^(]9"OF (7
M+"H(*:31*Y3Y:5(CTP*W,&(DDY*AVRNXR)YRW*+F.![9_D0!O$LCB2S:26..
MA>#PZQ8%<,WZP,\)<AJ6JHPN=,/'U0H@;QLH+%< RX&7_W?!/U\0ER/_?,(I
M'B4:&SKVQB1MK C>4%%]Z5VSN0MAS?6?KWE?3'L<V/^V?&3'CH6/G$QDP60M
MT; _Y5;.X=<]&C]Y% ?O4-[QHJ6[[[4]^D)LA=XTKKJKK  ._;@52SC.AB5I
M&V[_8WPOZYWW4)XX.,RP*\^8I\@P=]J]-YZ4X=_95\]1;LTSF&+-Y2Y67AZ]
M43>BNDX>NE%AO>[X\8J4SYZ6BVY<_'GU!;>5]C74>^/S\I#^R(<SA%).Y,"I
MV\\_SG\8X+ZXYIU36?FV_VW%DY]6'>K(OSRVZ+EMMV>7S6=?AF%%X9[^W.#!
MDSLAWUJ$& ORSUX9^;O5$E\CV2!. 01M4 #CSU*B]?<'7-COK@_\TU!"+BH
M52L%\,,UL&$Y.#4)AN%DP:P4>^EY_")6PV\H,A4_,1[59\E]L)54-BJ LE+9
M/=)<)F-UW_0[< *KZC/@K(XK[@_5][M*' 7_"'.SR2TS<T0#!?!(T")/[RIY
MOR@_!NO)O58,=BDI@ >O5F*83='_':';(\2TTAM0!G1V.KX%Y_$*P-6NJ&P6
M_'[DM_U=U/PC1/QGS+CQKS C+7+[BZP746F4+>1-GL'4@DSOY. 7NB^5]Z8@
M(1DG4G/=W&R.)7^E[KCEW ?3NL^V+T07L5]$XM&S$/,RQ\HVF<UQ9O0Y5:7;
M8>RMREP)]DNE6^(;<K>+LBY1/*L1(Y$,Y/>9J_65[["3!=?'XC(4 !5WF;.\
M+HGG"K,SWO7,!9X4:(:0(58*ZA:Q6%&T,S[R+E6R6#3KGU>DFEMNDE2@>6W\
ML7"(M]PC^KQA7I61U[&L[26O*DO.GKXI0@NSW;_B*\,D^7*R MBX%N.[^@I@
MH%?>C5]L(6F'2SZ2YK"F\XR[N(S-)R$;26CA=?FR PH@)$#Z%3BY"G5C#_ZL
M 'I:Y!CPC5E<P/\+9JV&H1N>VXWXR6O"\8NV^]@YD^.X_]3&_JI<KG(F,7L4
MP*)246%DM0+X0))?H'J%C"F -2W1$]SMLZ;N"N![A^L83WJ)DZU+*Y_<_L<;
M4FL-^31&I-CZX.R;7?K[W4_]1ZZ\U5JZ3TN-;;;CQ>@8-:QBNMO7(<;O^D*C
MAA?UPPD'29_1]912\?G"K0*!NTO/JQJ=VIJXT/7/<B5-*WSVCEU16OB\=,R)
M42/U1P]THU[#,M,&D\N@$5&3%_)@3/B8TAR9.@E[? '9%U^@>P]3#&@YDN^?
MMOLUV#ZBG6TNB5&M>^/C48!NJ(5FDNS-?+V_F-_5%3VRV.O$L*IT9GW*D\7U
MB>;YN!5?(^F2V]W1TUL:WT\&P*P6T@6N-FHF=9]0 !K<D^%@.DN-H'ST+FI?
MPT4VBS2-O&4_V<H-/8>%VH?[:0D>/45<I&68J=K? .]L^HA^ Q'+Q+9:M$LD
M'?EP)HLE>C%\>H>94HOET@LD;7"X4 %\O$9&UI!EN9'3;@K@X5F,8T5:*@ _
MO#0=P]4T=">6-=CV_N*)M4N2))I;H29_TL8WD=4R95^#'VSEES8HS>YW!_3_
MBT&?@:4R<B(X68DA^YW9B04.YWM$)B]NY,X-'E8 ';'1="'E59X%^.)H3NPW
MI+DC"5C568LO_$XK_8,9^.^6LN48N(PM_:&2P?SX=W)03EE0II(D*QYCC.)P
MR;XRN]]?<Y\^YG[H!Q=A#P7@S7=SU_<=_G?K#+(>!4M-?=?^ G39+_G2H?K&
MK! >)=)+7$SV5(0_)XWF5F99A#GB4DX&;LDS-/DAHUV&VYG0U0T1Z^XI_Z;%
M\,OGP!6H)[2NZ$.Q.."6#4H>-O,4>LM^!(=+GX[-:.5'YX>?7IMGTP>&1FJC
MSIWO @+Z[_1:P9>=;B:+XMTCI^CG[X[NZ2O'4OZTVIQ+RH=XD+6S^PPE-3NC
MA3? C2"GMR,<J20TAW]3B">:9BS!,5E&] /GX6S!1L(:2"AULDUBK()FS]*"
M7:&<,)T76%,<;6C;-%2<YL<W*4Y;3J&EWDF6O (/=$V +^9OX_CXORQSKK8"
M^.N\ .+_%:UV1AD*X("(LCC]$!RK<^)$L@N))/ ^Q):=ZR7-!N52'/L^6:6P
M/AX^,?0C3N;[33T69N3V[WCS/R)]\Y] 83.K $TVZWN MK5'&,E=!619@@UI
M]N:FKH>MO[MD3SVTE5;BY;7[%4#7&>W][@;/_F'?FATJBTMHDTV;#W*\4FT>
M=7;N3AJ??F0X=% [*_-<DGN2N]&VEZ>.K-OPBU7:'D_ R[3E^1ZU%G6I#^VZ
M+](VPDTR-X>2&\.=\<F@=JWC\.9S(V+':<V(87)*S$C ;T>LM;OI7J*VQ)L4
MS=K ]?FWA4>0&].$E8O%Z79>;<9AL5M*= -")5X1H*/@$#)&-*-Q;%/]0U+0
M8*R\I4U"G9.H]^V)>4D,^+AXJN;^&]JU0$-YLWCM]9',].$^R/O"\Z1>YW!0
M&VQ\W3%GMM[1JX8:];+$7>HX^?[&F?/G[U+G8Y/R%KWG>G(K6M]GK6NM>)<=
MT0T5EO5[Q9SH] _T#+&TK\TRO.85L;VYT\WFR6=[ZO&I(.33L TK\^^Q9G]9
MTP1+(DV*=-_1(K\H=06P(@Z+PO9-3%/#CU673;LC!VNLOP=#+9E-YOY8C-U^
MRX8M@BQ,.!4+?O/A+[!"6>,E[('.MX.0J0_&] 0$KC[8%J^F )0J;.7>CRZE
M :/H[VX5_'[^V(;;6N#_/UZQP!JY-)&.2^*6%SX^?;R'SGK<=-98[7CRK?>R
M.^>?+ALL^^9KL\&RJTS6_V"C!)\M+$9\CI[I&OICA215!=V3%N\AZ^9:>6UK
MRT_!V-G#<VJ5W8Z)4IN G0:URP]K%0+J[Y0ZJS4,>HQ:Y9W7&CZ5O9#J^VT;
MF8G\1.P@#+2]*#OQYFA5B.6*#O"=)@8&_9]A#,GSVU(G^2^-"J#FJ *8;,++
M''54_\@>.U/V[=WH\MW!$.+S9FKW_S:%'?.?>LH>^A\AZ#U9A_3N<6O=5OSB
MPP;,: /8]7?=ZM_YN>9FR_@^C, J@%GEO0$DCP4M9_:A!=9M@2UZL9PE77H8
M'+<Y5'PD^W>7E('#E/F3)!FM0 '<%:_&>MCI/QI)TB;]G]YO_WTP5H-_%7 #
M)/DO-<A7RF/_?*Q:L'K690>QI?/W)ZT+PI'Y1=9RC.!'8/CD/M[S*3Y^S1\W
MB7N+L M3FCR'V7IPHFPI1A?]FOY9$0$^_U 7_]!QFO^FXW9\J/-[ST@(Y7Y<
MV@E.&6.54?C$-_?$'Z[!XT?!M]C^S(F9\IR42VD;2NO_>"*,NOY5Y*T7IK$I
MK^FG$(K43MX/0KM)3*$IZI.G@KA!79([LCLS:,Q(7*DEI==N1G,@''S*OD+_
MO.@-Q1^)W-L;[1O0&G[H\>/$B/*%-R^)\P<O;7R?/J@GU\*\NN2HX@I&M*DM
M,7##0Z4<0C00(J=B8>KNH*3C81TU5*=*SCS;($0B. 3PT[T"N<7JWP[/L7SZ
M0'/&VD55"U,>K:\D);LS;$#^+CRT6[CHTJ8&BBH16 &\OL-$4A+DRP85@,?S
MX1G406A.6NC^2FUZNZ[^]ZZK=37BV\]T2V.EF*3D"P771^8;R8/6XAL2KIAI
M3"L0W64-@\:'T360!R\G,G%H*Z(C9AE1S4W@W/D$SDH$$GR&?H?$PWW^<'*B
M?;RI3^\K 2LQ2-+G#2U4==F]#6JVCHC\D_7]4JQ00P^YYJ=*I(\TO9I;3FK8
M0'1L%;V#^ I G]S O/(8*1Q?WK7:MV=0I%L;T^G_AGA]RY/GT=39 X8)FS^-
M;VLZ!A G93]RUJ 'RY Z*+F!LP$1WD/CH!DL/?HA>>=B97').%'C,;.>Z-")
MDJ&2O9K#'A"83-\JH6@0-U 5@(']>HB9A.[FK.LN/X>$V%4&K7D>)]3V)HT'
M@B36"M)P.1=RC;S41[2J1<C2W:@Q<O[LB.G/M@0OV\MR#3JU@W(P[G/;D"<5
M.5.L92,?HUJ=1@[TG(IZ:]@=,+9XO+?DP9M^JJ3/)!?-,G^N '2TP093<&R>
M8*8 D@9',"N=T@!9\1VN(4EL@4,L(V7FHPE<:)!.4P"C^SW071A"J40H@((W
M4(S<-)*)1R<V*$ORTE ,25)22,,9W-FX/"T%P(N ,9#(=?^35+F-$\1:P\%_
MGC!_EBH72![R/U#%!J$1:9@#0GM  X_;6YC2,,3A;/"6PCYC) *>^=5(_82%
ME*6^5MILM&JDV)AMJ "215A#V8#!UB<"!B5)(YAQF*O+Y=$CKU@.36=\J12-
M&^]W9!L8JEVKQ"NGE>ZE/V?HZOYZ?]\/^5N.-.^_43B]X86SW12^Y*#?K[8H
M"2=7QZ#,X]8P%W7$8]6RT([12AS6$"]AOSO>TVPQAUJPS91'&6 N]!O/R]2W
M,U&'8'#!@S4Z<'&QPIV!<00>1@Z'?P!GS^=I8!=GX-]LRE7%0R@)68>7F8=<
M4@#0&SJ([;R;AV1IO +XXDO,;LT?A?+]HPN2;QBE^RD_A&.0V(RM^U7E-+<2
MO&0:K'^:J\4A/O$ =#.-1.K;?C:X<26RHO'IDZ^,/6/^U'#911;8?GT'9L$)
M1PQ;S\OC?_SO=U,?_"9$.+OV-0D:R,!0W!QDG5";Z/F/KDGY0?AG;NT10E^3
MD77FO0K@RBOHR"^/5R*1V#;<]U%#.Y?C<:.]()3ZTTD%\/[(W][:\V/O9 \C
M9+;ACV<V2-9=L(%'@CQ,(QS)55F20>CT30W3/<?^#;O.K/6%"Y@+Z\QN[1E5
MRW0EX*JXQ_#(!M8451I+8H[(KLD=QX0KA:+3T MXN)-N/R+$@8T$0K ,*Y!E
M S\A@XV,E4:@@ 5EA@=1)-2ZCT2,\81+23F1HZ#_T>N'8]7O9A=XVO5DA^EX
MV\UYNYC$+9/Z8X!^X8^ _D7^DZOM[TYK:2UK6WUE."^V,P+_#MM#O7UW+IB6
M@]]S46]3CP4L%_A=]VXOG?[;L]T=\B\4 &PWL4&IYF\/^UY2*K-XN)7HM[)L
MX@;Z#FAIKE:)6*AWF!:K:=X8_P5O;YHX &>"!!^IQH'W6B..G[+LFGWYXF)>
MU!&3;;IZ-BG%$Z?=QMP:&EJ"Q^?N7+#85?_Y1-#NL>*DJS^>F[44]K+^9LH6
MCU69L6?[QB>]KOYT+,2XA1X[TOG?8V;'WZ9B>$)UC1V6'0*1;/+F>#791^PF
M,0T(N<E)D"]0Y.N9?W;S:H'/0\!XD^O"@?OX#UTOE(U7AUR\WKV(\Z=\DH/;
M7/%;&*])*^@4:)[/JC O$-<Y:9B24UGEHVF<=32G/>PIV]?Y(K,#HJQ&O.;
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M:)@;4AA:O9YY-Z EI)CJOR^KF!<97$SM-;SJ'A%R/$3%H;=]]]6=NA:)IG;
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M, /XGPXK$6O(;:&H47I'H@8N<O5.4-4+QX3Z;3@5LCDM .Z!#N.2Z.J2C7)
M[=Q]899WL[N0;[)?@#%X4S;XFFG@>(Y^KG&[K*>?&+GK]^%!-6?VPD92!W<F
MR1##%<N!:_J#S/++9=36(I@MX%]WC'Q555OZAW];N:!#$V:S^P>]'MCT-=\W
M"(82N**.\RJ]L7J[6G?HEM@I">F:K$A"LF.O;!D8FR4)'W6 <X1SX' !=[&E
MB8&2G(#54>G-T0\_DMB"F6LU--J88"Q%LIHH))C"*+$#IQ )CE1;7!7:KG%Y
M$I[^,-P!FBHTO'\J28B8%H"$5NH+AS0Y<'Y&/9RUFF))-N^:JT+Z=]&29$;P
MC&P-TG "O:'7>>^9TJD@K4XB1F-PRG @U=+4K+8)I_UAHF<<&1Y)W>I_K2+<
MRLK93:PWX3_#]<1S0<G/4-0=<(C+TI692J@0K:7)$]5:]E._;!?9"N1?D^P<
M9>FZ"(,?\819*#;$ \6";Z\8\*ZW@LIYAC9L>8B9>;1[KLJ-&Z>?)@XD+)P
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MP=2O34+^H <756,&YW_9:\7>7$I/61JX)C%#7!. G_M&ZC$9SDK02E[;3GY
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MMRX=?E-\$JZJ+7=6'AMOO&V+KF6PDF>(]ZW$@D>'Z9=)5/= Y7U=-?:]Q,C
MF$@;]F'#IZ^H%A5/(_9C:S-ZII?>E^\H:<PNC_U\>7&Q^^&;6*)Y=6/*C0Q
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MR8] B;]I>JB094 2"9$<6U/8U1)"I-G9PC]1S\F!M5AAA15V.B$(NX+R<C"
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M>G\M?9 N4)AL;7_2F/"=C"5BI5-4JT%6&HI-V=/3["JT1< X[U>=SAH5^.J
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M.2_L 9*#_$\= <N..OJ _\R!0QC2YK)>T+G()%RMKASX6@HE+;C#.2)ZNBD
M39>UL%0E4?4-3&B&7;5?\*@J)%Z ,L(/VB3^GF]:0?W4<5FO?.VMT1<?N-$:
MM1]-5V'.L."M6@ 2M@G\'0 0$J?]"T?'=Z-FMQ]!#/RC3&1D$5BC^73PN/7!
M[Y.R69EZY 7KOJ_?3WULEP.:_=)<Q#V[RB"WUY#IBB_FH[]N84B<4+*5.7+
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M![^5W-K;LT9B^-]^@_Y/]H[/&KW&G5\RHK9?*.*'2)+\MM:D8(A@FFPX_FF
M"@=,-?XY$\LT^-XS JI.@H'YJ.P\*DHY^G[RJXF#P"CJ/M.E]23)NX=\*L[C
MK+UC)$<X&%@:(J]8,XI4LF4DM-[W[-QM'\EE-G9\A-^H.*ZE+E\<ECQ5%!!6
MBW&P*2%6SZ6Z3P4YSY2M#=RQUQ_SHH#9C%VMT3IV=)<1\6]O*Z#\(Y"Y'*_W
MV8\N1/W213<>I3MES<IFD]6;Z>\8)K1PQ2)L;8!O-7/>D6K9C%ZEV@^:-O!V
M+L)N4YH=HQ+I1E"":D.RV/[Y7'6F;05EVF&\;WX5[1CD.G^<1#!079"78%QE
M8_B-]"[UOH_<HZQUY$F[BG6>\Z[4CC&AS5-J9D,,HX&O,RI'K";..EZ/W]J:
MRL/0CG9=RFY0Z_5C+&45NHG,8\ ;K=&MHC2:55"Y4!8K6?O=/M>,=;A6) 46
M.EX5#8R%AWJ=2J;8_5'UL#SS1.:1JC^2RSFVU23C:'RV71.VS?VF7*)#+:$\
M:G8Q_4@[5!OPP3 F,]2OXU%I.2LJ/(A4,B"6V#^)O&9E'=)#*>.L(D\>.XT+
MCB)%(>WJ!7NP7RD"PJ=\>5(JSYG:TX(D5S0=L<4:J.* J GM(EI8'\<D#)NA
MUJL$*(TFIK)+K$HULVB NB-6"T"G4*9C(6O,P5SGRI[I11B,Y@$EY0VI7/KM
MQK+Z9A9A[@M,;%![B/)2/Q=M:Y@+ZZJR<E#N6'C 6THMQ@-[!L5/8N6=C9:2
MY"1AX"[>[>\Y9V+:'ZB?R(<<!SQ ^U)+Z/Y/4U[:R=>OW=++82Z2^%:U5NTC
MGYIJD)E0;@ZHO/3'7C;*K9#$")](W^+JGJU]^1D_69YI)]]4OTELPOUUT^:W
M6Z'L'-\M]\Y&3*$@4Y_>"5M/\Q:48>],VL(*VNG@0J)Z<]=4I"4?[MSC4Y%,
MOFQ%":Y[\S%G!M45F7PASG:PU#\M?\]K1#-;1ZW]$XR7\YO3C[?Y00R *;M7
M"T7.GZ+M?U.;\[<0Z9WA8N.GNK; 5EF!>[JQ:;4G 1/NG&&VM&*%:O\;;E>N
M1$AW<MDN4E$H9:$E4L\M.NWV\Y^FIR!SA #NI"P"&0(=&]1HK@E$*E-YB^A6
MD*LP=P64H/%8JR"1K#:,M5P.N>6KL$#G#8*2*K)&'P/2RTX1Q48#]'UMP"#D
M);>M@_#6%9?N'5\RYU&L[D8OX>#U:($ IUC(7P*/E:+RGXT0-D;,\]>-Q)!H
M^^M!P_1"*-Z-*71 /F@O+'IDF%<XYAAQ=^@=]E/_)-&VY(II'YNRD[RP!;T!
M.BZ39R#TJ3%$\P!MV6$-([H_P)PPI\"KPK(O7R+H67&:0^_<3"Q_>2Q"<<WT
M&C]S&+.02+<=^>>(H:N LE/&3+>U29;H\T/XJ;EF8&<&]T@>1%(XI'^%3@..
M$FD17[80)-#HS$ZLWC1S-;4Z+L2]R\7*G^8/3*:$EXRAQ;G[@9793VG[ZT07
MP3_;H"4:;E1#$T"LD/"Z(LV.H$?;"R[G5Q9EEJI<1!%O(_D&HT%R[UM<"F@J
MGTK9 NJ6E(WR3%)/*Q"?^<UJNR[V(BQ$4C5R9(V. L&<@_?R4!PH_EE8( JV
M<*Z79PJ1#H';2F1#UV73&Z99NM\#MSP2Q QF.7HGA*01^*!G>G4VB3TL<5U?
MV_>"ZG&Z-U)'*]6F<H1"C,G\</]XM9@!/(9LHA*,U.LD:R9!\4;:.FS-]!VH
MR>YEP,D"X.7\;[1#:45[1K=67: ]$V8!]RZW64!)RN2%>Q@/L$;!2E#%VM)7
M]'*UBZBER@,BNPH$E(4;*;>9P(9(-M%[AJU!,ZNB\I38XL"%9_@[J-6/FI4U
M40?[E5.X_NQ3\\N]JBG/(4(S2Z/X\,V49*2])MI5#N,#H%:3R&5S;K<00\(F
MWU<HXP!6$O8*(D-2Q4^PLXF/V?9(FG5KUJN?NP3$-N:L5Z->B]2;1H81&K71
M)%DYM @C45N;D.>0Y)=:HZG4L<93YTC*%/G4&F=1@DW$D(- V2:';^J4#7GX
MAIX^\E*49U04@)H]0TJ+[&%'FG'>\(@RPWL?@G]M25/P5U#OQSH1$%!=,_*O
MCKP\\]2=5M,,/2*R8):'O*_TW(\Y$ )/F!!D^QF/KCUR,:>^]EVQ\S@EM&:;
M#+D;:F)(<PB&'&>=0T#6JV+5\NIJP/HA43KDVHJ,6X0EE]/\YT^..&9// 1T
ME.G]JFA0+%8T>!$+H I/H+B)LG[BH\0/2M-*=MFN.@(>SR?*T:NABY.C)MY!
MK1H(XA9A&ZF/#D$WGT%[ST!$H&.^18U=J#>O I-N]\_C0*U$NC&]EZ'-Q<G0
M2T,=@T:&-]SR.=_%#6(4D'(M ,Z3ONJ4L)?GQI!N'7GEPLOC2^;-99WK(5(+
M\ER,Y+;JP#/J(_>LV%(?#@41)J;7%!T)#[JZM7""&Y.8'1[UV]^?A]RL.+T6
MN^\/R_=O?GCJS"7C/J!XW'G>#FI5QG6[F ]#7PX4C['6TD[*AHY!L3@H[0*H
MY=H]CC&7+C@T(2.4F1!#2A@?DY'M?XR^;S*V>-9-1S9'A^=_5Z/BH@+Z(BVO
M9[1.UOZW+OW7%SIZ3PU_>05;*H ]?65R^.S9Y5^D2SZN]OM?M@7]?] 0BY__
M!U!+ P04    " #V@9=0;"(0PT9B   );   '0   &-H87)T+61F9F(W,V5F
M-&,V,C4R838Y.#4N:G!GU+MY5!-;F_9=B(@(&.91B J*B( #@S(D(B(B!SF@
M@H*0XXB &)4I0DA4YC%'43F"$I%)Q! 1 LJ0  G@A,R@1(8D*K-4*4-)IK=.
M]]?OU_T\W:M[O>_WSQ=6P6*G4K7OO>]]7;\[.Y%^E(X!*H<.N!T 9&0 0 ;Y
M :1<P!GY[__N\?=%_F^O(2-M E17RVR2<925V0BL4)615961<@ TTD^Y?ST!
M^'\>,BMD5\JMDE^ML$81.8&A JR0D95=L5)63F[E2N39..1Y8*6JG-J&'4ZK
MU+U.R6^\HK'SQJV"U4;[*ILUO;M!XUVGK]Y46*.EK:.KMVFSR1;3K5;6-K:[
M]]@Y[W<YX'K0[="1H\=\?(^?\#MS]MSYH O!(>$1D5'1A&LQ\0F)2<DIJ6FW
ML^_<O9?SU_W<QX5%Q26E3\J>OJBJ9M34OGQ5U\+FM+:UOW[SMJ>WKW]@\..G
M(1Y?\.7KM_&)R2GHQ\_YA<4E^-?RWW') ++_._3_-"Y5)*X5*U?*KI3_.RZ9
M%=%_GZ"Z4F[#CE5J3E[RIZZH;]QY8[7&OEL%E<T*1KN\0<W35[O7:!E;\39!
M?X?V+Y']SP*[^7\4V?\.[/^-:PA0DI5!)D]6%< "$LF6QVG _]>'F:"3Z[Q8
M\$I\5Z0 +G$6HW"*(^-\[3:<G,@XW1_NA@Y[QI.5'#833Y3 A4?QJG!M^Q6"
M>]OMX,7G)DG^O_7.#+K@9QV#CO5>S!Q^].=K$INN [- G"O<3 9O+AWOM[2"
MP&0!*AFS?7)@<: FY_=IO=(DD;T A?(/MKM>K_SEXSMT^GA#;/J5Q2??MX4E
MG#4[N%<^G6@G9C U0H_ \LU,&XA^/8_OFZ'.OA<^0ES7 "VUDJ]#<%Z[W:;.
M#(PA['X0EI ,X*!F;9()-'>CC<K'R<.A?ME[(9/4L 4/ZPA'H]_3_<#/RU\,
ML>(&C#+!<]$50L\^Y,79\RTY<PDQF)R":;]=!'M>;1:78VC=0W1^0HAANP\T
M;'@T%:A?/6!-7WO8P34TBFGRHK<4%/IQ<>^T"K9^>O]..X5U>M@R "ZEP76H
M5*99#TD/KN>WLSN'9-NPJV:M<&L>*OK!7+"<35(#.V^*O,+XE!E8Y%D(1QK!
ML> 2#I*/W_8M-BR4(U'HL3S5'T$S\H8"$_F807_Q7:(YG=2^B'TA-YYJ_;%A
M5PE1 RQMKD?K?&HN<>&;$43:O$;M_5T.WO>..%UYS"P-BWT4//0^]^)BSZ2M
MNNNFC*[&.Q75,JT$[<49V)7OF496D6C Q0PL$&JH 5>%@VQV76F*%4K_!!P>
MD(OZM,1;FD7I0)YIUCCY24,M^)3 GB4/UW-\?5C*#:$5DQ+S/'?0INHIK?3^
M>/ BJ1<,7<R"W2$H$@O[U'VK(EOD%,'AG,Q0ON5*>+S)=R@GP>%L71[!MCT0
M_1P:3W:PCN5[ G!CA$>01)6L?\%F.3DI<K"'H7/1VO1\U<LLK Q3G-BPA]^(
M]GD.IPIH_JW1&$OQHPWB1R*R>4GJ&5X]2CUTD%7E2)GIYE/7^GW\.&4;[2>?
M+'+B"6,[8FRK^R\QPO2]F,)-#T7/_=B7(Z7 F=&/Z;RE&7(8?[=HLX-!;!SM
M0J R>%&/GB19(]H(NS]A)3C(:-&TDPLAESFVI]*%G!$;R$,0JFW+-(;6UD99
M<8==M'ZR1[3 PH"0[JD_#)6QL_V0H EC!+]@Z4D4B#I=#HH@>3$#EA/N)B3C
MX&L0BX_-<G"-XZ.&5N&O+U.212Y%L.\1<3[1=+'#WA4<;/>P"K@PL%S<GF)-
MT9KHY WKO>4K^W0>]2S91KY$_73O5\0V>,F[MWB@P1QR;JN-&EJZCMD(1XTW
MYVO#F^B=/%R&7R=G.BZZ)9<XNN894P>^C9KQU'>'-!UV6ID?FOZ-\>I]+O.V
M93%D,G.7QU(+I:I9OQ'YTKCO(*/%?'$^*Y@[L;&R-]#<'B?.GZ?<6#Z0SBL_
MD#V>XSHH@#<4=3P-])100S?7/DFWO#<RT/!#*%%8 .LYJJ+@7H< OJ5:J$0?
MGAQC#84W!5IV)]@=BW=Z).G#JOOR?=/:[I-JECP-1N(C"MV[ [\/?1_@#Y]Y
MV7_Q^["> N"HA>*&+\:^ZM+V3_:'!"'J!+H'>"R'O0B;08\M,_Q*4R*I:T)(
M#CWF\]2;5815V+2AXGNE8P':?E!Q?M49GL)\$,A,K0A5P[6&/0X9/4T3.I'Z
M+Q.MQ7?QV.#.>(P& Y8"H9'R;)I[,TF[Q\'-)$D^<YZR#NYD8]#WYQL#P^3]
M\[G'7W1'TIR/]%K9=ZA:,#S('K5@L?!"M&WO:/#HUDXIL#('WG-MK,/R<#V%
MMRU_-R@%.']A-DX,]=-G"H0.P3B41<4&.*Z"N#W/ R(W-QJUU&#TH$(<',J)
MJ2FW>?4LI#"@NR'XLC59+I#@RNZ(Y"FR:N<IGUC-$D/8#*P?(]VX7&>2A-&<
M9JVV'M[HH<XFJ8)]MM%H!0<RCY[BTTUNL>4IH]B!J&YSD<LS0D1):1"/)NO:
M>_%Q7\6'NZ5<N;3M,C^_O9("<LIP<*$H$AR\H:6L1[ZQG#Q3SQ\=\FQ%5QO!
M^81YBI)+,3I9;S#1P0B5P -G^[_58M,P:)%3)71G<'&H07N9O$B)M_*PWSM(
M%YU2#!9_+Q"2).]S Q@W6)!MUNQ"O?A(^]!ZT(RH @^;<*:5@WC)2<0- O*Z
MR9C!%IAIR*+,V\\J-HTX@)0LP]%CX&P!"SS_ZAP_TY1>'8P9#-0ME0+-VYBJ
MD_FJ#- CAV.9NGU2+Y(^JQ#T>,3Z0WHX#;Z*3I?8P-9\5E(E@;2\Y%E77<T0
MYUEU7D<K$'7!G,,-O=;F-CA%>->AYU! R7/J1??.(R!EQ@5?+-I/S@BT@JOX
M> .1]Z 1S##)%#G9)C7LX'68!=;#>> TSZ2E7*.':%]XX ]PX.X8?97( %Q@
M4DIIB_3HLJF8_,:GT[F,STM_MH?(C.NUBS1E>4IHU064+$QN(=E!JU(?BZ["
M!B!ICJ^!48?J8>=6'ZPA:64H65^$YM,3M.M<XR,+H:AKL]LBXE9UMC!1MKEM
MSX?$]UC%]ZN#GVWNPR1UD\,HGP8YT2- +]&>/ZH"WYSC;\XNF,X-F< JD4Q#
M=Q!P[I!)QD)GLI[U8*MI]=RJDRY@'!ZS@8!K-5RU0^2%5W /XM,5X;P#?6>J
M7H&+S[<UV//&1>KE;.I:AR-@_;%NB2DA?XY-5:Z0 D&>ZK9)#!2*$/=U0$06
MVHGD!K!!RNJ<TH#:VXJ-MH<A+#MV=@<BA\J;: N,VA0KLP!_E[YMIYG]VR[]
M7*#"F\>3&:8D0Y=@R-^_A]:@S*=K$QXKG^[DS;'_DFR:&,28B0L<3@B=<>X@
M2Z!DY\'B4!)SADHJ^=EC%"V;''IH#"K-0;&$>Z(V*8)V:=I[8 [ U,*M0G>B
M(:P:6?R1Z JM+3]#?GJ!9 0%5X)S-QNN".J'T4V2M=GNR:U20*7A6/"8YUK"
M;4$+>JW(U*:VR)F/-23DFINU##DLWWV@G?O8PZ[]Y%%<S>A,MTEZ@^O8)\S&
MQL2Y!$8GFG"&8R>A\=#K@K&H^4X-X@YPJ\@+JDTJ@?.>P)>XO&DXV04^;P*G
M1%P@NEL4Q(W%&KBWZD4VCMPJP9UDCV,9E!D%D+5(@RCQHCC^.?"]H0DX>E/D
M"[;]$+2A%4@ZQ* >.@8-#_IV,X8#E=%L*: YCU*]P-2&[MU_>N'/3AY+Y_B)
MSZUA<HMEI7 VF[FM]_R+ZMY/?#QL,M<B!70(T?[@^7IZ:&GSR$:8"Q7R%\L?
M!?O4G;^E4@7W(W/E+,Y;H*P,SAYJ.WRWZ )&'4Z,+B/$2(;0C*&0&)_[BOYY
M*PE;5M"3I,#88Y;<PIPNT:E[<V]#9.F$H78O4\XROI2<A-7!\3TY+ WBI6ZF
M!2&?W3*B#6_ LOT]4P=K[8(2F!HAAI9)0H^N!7</]Y:K4TSCN]7#^NR8S,DN
MF(9HB1R\:8RJ=,&N_4;%G&1K"-,(O2)27Q^%@LGM5R;T?),Q#J(0<*F9JA@2
M: LQ2F\NX-<2=_?3K>VE@%IG <&S?1"S#M).L<;*38\8I+5]6!SXYH\SAN@B
M=1-7N'A39QK)0N2?PU_B?+1F)=I]3Z:+W&%K,*>5)%=;![N/L3+(RM7E<63>
MIL5L*;"Z-C6,Z#S&RLS?AMD87=>SL(6(6\1IP)[>8+7/@)UR\GXI 'J,*@3G
M7KK+PZ\D>@PVR(V9=:#'-&LYY)4PK@FM:.6!:H^1 C.CD-X@WQ69,=6/P1(#
ML#UY'I]L7A;BY58$C^X';3)++S#7=X_U#+6,.@W\,1!)4;D>2VVC#*5*E"5=
MN"K/%F7G9J\00Q5XX8I@6#\0OFN2,M1,6@=3W;-;8G MXIT"=GH!CGSI(_$P
MA$_A-I.'6%R_/>!X2@71/'31\1SQX%SQ+]L6%KP%%^\0BH=&_2'<#6( 3PHH
MB'; T!/15CBNG(!BLU1(UE/(Y*D&@:QF9$AGF1:>/'HR#L50]FW&H/LBYE2F
MHJ.@*86RX"MPU#OG 6-(MX_H$?9H2"@_NTMH D<OYO18=]@?A^CI(M6X)T13
MB,QNE.?D*]YNZ^4$KD% 1L!*E +J#IL@9[9>XA=;A5 !-DFR!_;@(2SO55J;
MWQ3BP_?_>.Y@OWZ3PQ7$!KO@:'YZ^LOJ4=V1R1'M>J@VF>ALPF:I$]2;J.HD
M?6;\(\D'*:"(#5+TV#S=;.C0RPB0/0JADD5F(-US@(F&1X^_Z+-&R4XS-T)^
MSL73>@=>Q97^)O-=73(L!5[\>$=K/06M_<EQW==-TIG.48-=FZ@JH@#\D]*V
M#FS+,KUY&,V.QJP#*XKQ?):FR+M7=.KQ" '5S-3//@KYIIJ3&17/K*(9X&(C
MYB&'$"M9HPUZ'H?I-"*6F7,<T7W#3"%VA(!O]R;X\Y46O:>D@*'H!(3E26X5
MB X^-UR=2E+P+!7MAZ^2#)UM6_6EP-J'SNTQE>"=KN"ZD8?F19]'$\EC#S%K
M0<N61EO>4@)I$Z$6R;,-3TCO#3?"X8+Z3*1_0\F)1%_A5M$&T+9Y3BXDNDZ?
MVUI(R/& 3))%VCL)[?OKW35>UD"8VM!'HQ.V5X+U:O(&/I,X6C$=R10IP+.
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MH@V#M 8W3.V8/L[@,]$"0L<S3:;\M%A/"5<'6VJQ*A%";B,U1;(*'N8'V'I
MR6VLA)@M$+- :"Q2ZL$&41(MA1L(\?S#\7Q\BJ'*(-/"@T^^V>X!_AP^3GIK
M2[+*12<$V@Q^CZ!H$!1;1Y3U2I/.HU4V=C-EIOTB '17'UJE02Z<?[\!%2;
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MA0?*KQ$TB*?@(D [9R_@$,M7 5;\\:]?BFP"_O"](V8*)60\&;291A+:%[3
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M&VZHZX][KB,KZ->=,>/TG1<_7SJ-__;G.#)'DHPPT'R)97PQ_QDN?O_=_U=
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MWJ0Q["!V _@2@QI!*E"SVII0J!*!3+2.IEP+W%9)LG5IT3Z,JW*;GENUDX2
MW)@G */%)48;M\[F8"%QI: 0<!$5-KG$8P]TUI% S$^@2L"*6V)=6 G%2.S
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M45U(+!J"V@C=*;6YX]<X^K7=/X,&+7TEPLN9K>&DEKRJ_.6HLEEJ<&"(T:W
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M47H"UED_ KCI=I%+W+=OVC>YOZ0J4<]$#WH"2C$2C/ ('4T:5EM :HS3C*L
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MX*H_'!N6Y]SN^VG@4X]@R.]E][E/0[J*@*T6;O"B,.I5F[9W@C<\&J1.8;I
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M(#&S@LUW<J8R@L9)JVA;@W=0R,ZPT?7YU@1=R][&K>6S\B<<H.A0XGH*N=%
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MCNHIVH:NAZSJ9^6"(JKT!AOS*.DNL%$"JOT-I?G[:F>-ER]@8F7P ]ZXU85
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M @!B:6EB+3(P,C S,S%X,3!Q+FAT;5!+ 0(4 Q0    ( /:!EU#,8CH6@P@
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M+FIP9U!+ 0(4 Q0    ( /:!EU"ZROS33\4  "/@   =              "
M =#?!@!C:&%R="TP93DP93,U8V(S9C,U-F9D8C8U+FIP9U!+ 0(4 Q0    (
M /:!EU =3+'^_68  /-Q   =              "  5JE!P!C:&%R="TQ,F%B
M,V(Y8V8T,F,U,#)A.#)C+FIP9U!+ 0(4 Q0    ( /:!EU!+NL/+6V8  *-O
M   =              "  9(," !C:&%R="TR,6$V,S%C-C,R,C0U,C$T8C5C
M+FIP9U!+ 0(4 Q0    ( /:!EU"@HE/XI3@  $=#   =              "
M 2AS" !C:&%R="TR,V$W8S Q-S<P93,U-F0R.69F+FIP9U!+ 0(4 Q0    (
M /:!EU"RE\CX23T  "9)   =              "  0BL" !C:&%R="TR9&%E
M-S<P,#0P-3<U8S Y.34W+FIP9U!+ 0(4 Q0    ( /:!EU":"&CUZ80  .2/
M   =              "  8SI" !C:&%R="TT8F,R8C8U938S8F8U.3AA865B
M+FIP9U!+ 0(4 Q0    ( /:!EU!AB5M-7GH  *&'   =              "
M ;!N"0!C:&%R="TU-3<V8C)A-V9E,F(U8F9A8F0X+FIP9U!+ 0(4 Q0    (
M /:!EU"'3(LX &0  #-N   =              "  4GI"0!C:&%R="TW9C P
M-#-A-S$S,#4U8C<X.#4X+FIP9U!+ 0(4 Q0    ( /:!EU#\;XNJ(C@  #=$
M   =              "  81-"@!C:&%R="TX,#,R,S4T,CDT,&8U9C-E.69D
M+FIP9U!+ 0(4 Q0    ( /:!EU#>CRTPDCH   U(   =              "
M >&%"@!C:&%R="TX.# X-3@X8V$Q,#0U,6-D.#$X+FIP9U!+ 0(4 Q0    (
M /:!EU <$9=1&S(  ,X]   =              "  :[ "@!C:&%R="TY8S0U
M,3$R-6-B9#8U,6,P86)D+FIP9U!+ 0(4 Q0    ( /:!EU#NAK"(#5D  "5B
M   =              "  03S"@!C:&%R="TY9C$W9#$R9F8Q,V0U,31B83$R
M+FIP9U!+ 0(4 Q0    ( /:!EU!'XKTE)%0  (1>   =              "
M 4Q,"P!C:&%R="UA,#8W-65C,S(W.#,U,3DW8F0V+FIP9U!+ 0(4 Q0    (
M /:!EU!S:TES:8$  "V/   =              "  :N@"P!C:&%R="UA.&(T
M9&(W,#=B9#<U-S8R.3DR+FIP9U!+ 0(4 Q0    ( /:!EU =ZS2 ]6@  *YQ
M   =              "  4\B# !C:&%R="UB96,Y,V%C9C9E8C4U9F(P.&4T
M+FIP9U!+ 0(4 Q0    ( /:!EU!9WK3YX&L  %5U   =              "
M 7^+# !C:&%R="UD,V$X9F$T.34T,&(U.3@P.3,Y+FIP9U!+ 0(4 Q0    (
M /:!EU"Y^Z@:*S,  (\^   =              "  9KW# !C:&%R="UD-#AC
M830V.3DS,CDU-S4Q8C(R+FIP9U!+ 0(4 Q0    ( /:!EU#3X:Q]#&,   AN
M   =              "  0 K#0!C:&%R="UD8C@W,F5F-S)F-S4U-#AE.#-C
M+FIP9U!+ 0(4 Q0    ( /:!EU!L(A##1F(   EL   =              "
M 4>.#0!C:&%R="UD9F9B-S-E9C1C-C(U,F$V.3@U+FIP9U!+ 0(4 Q0    (
M /:!EU!M4$?IE3L  -=&   =              "  <CP#0!C:&%R="UE-#%C
I.3<Q,V,V-S U.&,S8F%B+FIP9U!+!08     'P ? +\(  "8+ X    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6922043552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 331.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912487744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="num">$ (240.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(149.3)<span></span>
</td>
<td class="num">(219.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">37.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(14.8)<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(13.5)<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(149.3)<span></span>
</td>
<td class="num">(219.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(20.8)<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">60.7<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(26.9)<span></span>
</td>
<td class="num">(14.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">33.8<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">23.9<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(32.0)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(32.0)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(139.5)<span></span>
</td>
<td class="num">(243.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(203.4)<span></span>
</td>
<td class="num">(261.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(17.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(17.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (203.4)<span></span>
</td>
<td class="num">$ (261.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929864432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,399.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">33.8<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(17.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">1,385.0<span></span>
</td>
<td class="nump">1,429.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(5.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,379.1<span></span>
</td>
<td class="nump">$ 1,429.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929350640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">94.0<span></span>
</td>
<td class="nump">264.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues related to amendment of contract manufacturing agreement</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">109.3<span></span>
</td>
<td class="nump">292.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6935250752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>2019 Share Repurchase Program</div></th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>December 2019 Share Repurchase Program</div></th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 13,031.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (240.4)<span></span>
</td>
<td class="nump">$ 16,257.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(221.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (655.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (655.8)<span></span>
</td>
<td class="num">$ (655.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (65.6)<span></span>
</td>
<td class="num">$ (590.2)<span></span>
</td>
<td class="num">$ (655.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="nump">48.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="num">(49.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">13,822.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(219.8)<span></span>
</td>
<td class="nump">17,026.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,829.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(219.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">13,339.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">13,343.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,399.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,392.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(13.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (941.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (941.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (71.0)<span></span>
</td>
<td class="num">$ (1,208.1)<span></span>
</td>
<td class="nump">$ 1,279.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (15.6)<span></span>
</td>
<td class="num">$ (925.5)<span></span>
</td>
<td class="nump">$ 941.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(47.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Adoption of new accounting guidance</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">12,536.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (149.3)<span></span>
</td>
<td class="nump">$ 15,673.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">12,546.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="num">$ (10.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(191.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6934015856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,100.8<span></span>
</td>
<td class="nump">998.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">777.5<span></span>
</td>
<td class="nump">717.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">323.3<span></span>
</td>
<td class="nump">281.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">466.0<span></span>
</td>
<td class="nump">500.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">292.6<span></span>
</td>
<td class="nump">327.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">173.4<span></span>
</td>
<td class="nump">173.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">522.4<span></span>
</td>
<td class="nump">460.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">277.7<span></span>
</td>
<td class="nump">245.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">244.7<span></span>
</td>
<td class="nump">215.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,117.5<span></span>
</td>
<td class="nump">1,983.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,347.8<span></span>
</td>
<td class="nump">1,290.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">769.7<span></span>
</td>
<td class="nump">693.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">565.0<span></span>
</td>
<td class="nump">518.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">223.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">329.6<span></span>
</td>
<td class="nump">295.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">133.5<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">133.5<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,904.6<span></span>
</td>
<td class="nump">2,680.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,583.2<span></span>
</td>
<td class="nump">1,513.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,321.4<span></span>
</td>
<td class="nump">$ 1,166.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831254016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6935109088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BAN2401Member', window );">BAN2401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ElenbecestatCollaborationMember', window );">Elenbecestat Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member', window );">UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global Licensing Collaboration Agreement, Shares, Purchased</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global Licensing Collaboration Agreement, Shares Purchased Per Share</a></td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets', window );">Global Licensing Collaboration Agreement, Payment, Selection of Targets</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</a></td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</a></td>
<td class="nump">380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">162.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">89.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.7<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Selection of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ElenbecestatCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ElenbecestatCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6935297360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(4.10%)<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Denmark assets held for sale</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">22.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6930069904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="num">(11,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,399,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,408,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,952,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,881,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,446,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,527,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">71,500,000<span></span>
</td>
<td class="nump">$ 68,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">193,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,379,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,379,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,426,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,497,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (4,952,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,881,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 154,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 956,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN [Member] | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 161,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929352672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 341.5<span></span>
</td>
<td class="nump">$ 421.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6933234800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,247.0<span></span>
</td>
<td class="nump">$ 2,965.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(16.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,238.6<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">2,238.6<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">923.8<span></span>
</td>
<td class="nump">1,057.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">921.8<span></span>
</td>
<td class="nump">1,058.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">442.7<span></span>
</td>
<td class="nump">633.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">431.7<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">343.2<span></span>
</td>
<td class="nump">502.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">346.6<span></span>
</td>
<td class="nump">503.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">361.5<span></span>
</td>
<td class="nump">510.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">363.8<span></span>
</td>
<td class="nump">510.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">175.1<span></span>
</td>
<td class="nump">260.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">174.0<span></span>
</td>
<td class="nump">260.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">286.2<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">132.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 276.1<span></span>
</td>
<td class="nump">$ 337.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6915753776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(44.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>376.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(18.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(120.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>357.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text">The following table summarizes our gain (loss) on investments, net, that relates to our equity securities held as of <span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(60.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>375.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of March 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(60.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>376.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,046.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>309.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>209.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>154.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>147.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>148.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>78.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>662.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>726.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,437.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,765.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831254816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(32.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(139.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(135.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(20.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>60.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(63.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(63.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(32.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(203.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(149.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(17.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>37.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(17.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(261.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(219.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:44%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>50
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #V@9=0!@'UK>\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>R$E*&2;U9:6G#08K;.QF;+4UBV-C:R1]^SE9
MFS*V!]C1TN]/GT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2F1-];AY\
M=(KR,QXA*/VAC@@UYVMP2,HH4C !B[ 0F6R-%CJB(A\O>*,7?/B,W0PS&K!#
MASTEJ,H*F)PFAO/8M7 #3##"Z-)W <U"G*M_8N<.L$MR3'9)#<-0#LV<RSM4
M\/;T^#*O6]@^D>HUYE_)"CH'W+#KY-?F8;O?,5GSFA=\5=3-OEJ+:B7X_?OD
M^L/O)NR\L0?[CXVO@K*%7W<AOP!02P,$%     @ ]H&74)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M?1#$*_BV(TS =X'C*R2OX#N/, 'K!4ZYX"$FWWR ";W# D==\"33S%<!F'E
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M2U6U15=I%'1#LR_RW>VF+%[:_C+IKNOKJ?;UIJW.XXE]>/NWP?H_4$L#!!0
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M?K#)4%#Z<+S&LQW&;#"\:<<?Q*9OG/T#4$L#!!0    ( /:!EU!G[37;M@$
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M%X[O_=G,8S8;#H?E!['U&Y=_ %!+ P04    " #V@9=0]@W^?[4!  #2 P
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q]4V%OVR 0_2N('U 2G+91
M9%MJ6E6=M$E1JVV?B7VV4<&X@./NW_? KN=MUKX =]Q[]^XXTL'85]< >/*N
M5>LRVGC?'1AS10-:N"O308LWE;%:>#1MS5QG0901I!7CF\T-TT*V-$^C[V3S
MU/1>R19.EKA>:V%_'4&9(:-;^NEXEG7C@X/E:2=J> '_O3M9M-C,4DH-K9.F
M)1:JC-YM#\==B(\!/R0,;G$FH9*S,:_!^%)F=!,$@8+"!P:!VP7N0:E A#+>
M)DXZIPS Y?F3_3'6CK6<A8-[HW[*TC<9W5-20B5ZY9_-\ 13/=>43,5_A0LH
M# ]*,$=AE(LK*7KGC9Y84(H6[^,NV[@/X\UU,L'6 7P"\!FPCWG8F"@J?Q!>
MY*DU [%C[SL1GGA[X-B;(CAC*^(=BG?HO>0\N4G9)1!-,<<QAB]BMG,$0_8Y
M!5]+<>3_P/DZ/%E5F$1X\H?"VW6"W2K!+A+L_EOB6LS^KR1LT5,-MH[3Y$AA
M^C9.\L([#^P=CV_R.WR<]F_"UK)UY&P\OFSL?V6,!Y2RN<(1:O"#S8:"RH?C
M+9[M.&:CX4TW_2 V?^/\ U!+ P04    " #V@9=0D^_BTK0!  #2 P  &0
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MCR\;^U\;XP&E)#<X0BU^L,504/MP?(=G.XW99'C3SS^(+=^X^ -02P,$%
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MU"&:]VB[<<U&)]AN>D%L?L;%'U!+ P04    " #V@9=0"Z&U@;4!  #2 P
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M]_YLQC$;#8?=](/8_(WSOU!+ P04    " #V@9=0(]P2;;4!  #2 P  &0
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MMXG;ZZ'UAX-5[3C5Z#1:BS]02P,$%     @ ]H&74#)<*Y&S 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL;5-A;YLP$/TKEG] G3A9FT6
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M9%&M1Q4G>>-=!_8V/B)Y#Y^G_2<S'5<6G;7S+QO[WVKMP$M)KOP(]?Z#K8:
MUH7C5W\V\YC-AM/#\H/(^HVK?U!+ P04    " #V@9=0J]0+E-(!  "<!
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MGHHM8-!H.[TU<[E<F"708ES? K(]2.5?4$L#!!0    ( /:!EU#<> "_W0$
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MLY?3K9P"+?KYP<'+JY?_!5!+ P04    " #V@9=0;LN[6]P!   !!0  &0
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MQOKIO9OKZ2U/"ZOZN4W)\J\H_P!02P,$%     @ ]H&74#>PJ(JV 0  T@,
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M=\Y+[Z9X#3BTUF\?W%[/;WD.K!J6,27K?T7U!U!+ P04    " #V@9=06QO
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M_0.;'0&U"^87;YMQS4;'Z6YZ061^QL4_4$L#!!0    ( /:!EU#IZ13!TP$
M )L$   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;'54VX[;(!#]%<0'
M+#&.O6UD6]IL5;52*T5;M7TF]OBB!>,"B;=_7\".UW+H2V#&YS)#&+)1JE?=
M ACT)GBO<]P:,QP(T64+@ND'.4!OO]12"69LJ!JB!P6L\B3!"=WM4B)8U^,B
M\[F3*C)Y,;SKX:20O@C!U-\C<#GF.,*WQ$O7M,8E2)$-K($?8'X.)V4CLJA4
MG8!>=[)'"NH</T6'8^KP'O"K@U&O]LAU<I;RU05?JQSO7$' H31.@=GE"L_
MN1.R9?R9-?%BZ8CK_4W]L^_=]G)F&IXE_]U5ILWQ!XPJJ-F%FQ<Y?H&YGP2C
MN?EO< 5NX:X2ZU%*KOTO*B_:2#&KV%($>YO6KO?K..O?:&$"G0ET0R"3D:_\
M$S.LR)0<D9K.?F#N+XX.U)Y-Z9+^*/PW6[RVV6L1)U%&KDYHQAPG#%UAWA'$
MJB\6-&1QI'=T&J;'P0IC3X_7]#0)"^R# GLOL%\)/-)-A_>0./E/D4G0(PD(
MQ!N3$&8?-DF#)NF=0!1]W)C<8^)D>UID=3D$J,:/A4:EO/1^)%?99?*>J+]<
M[_!I;+\SU72]1F=I[!7U%ZF6TH M9?=@&V[M2[$$'&KCMH]VKZ9YF0(CA_DI
M(,M[5/P#4$L#!!0    ( /:!EU!P:# ]PP$  #<$   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;&U4[6Z;,!1]%<L/4!,2TBX"I*95M4F;%'5:]]N!
M"UCU![--Z-Y^MB&,9?X3^U[..?=<VS?YJ/2[Z0 L^A!<F@)WUO8'0DS5@:#F
M3O4@W9=&:4&M"W5+3*^!UH$D.$F39$\$91*7><B==)FKP7(FX:21&82@^O<1
MN!H+O,'7Q"MK.^L3I,Q[VL)WL#_ZDW81651J)D :IB32T!3X<7,X9AX? &\,
M1K/:(]_)6:EW'WRI"YQX0\"ALEZ!NN4"3\"Y%W(V?LV:>"GIB>O]5?TE].YZ
M.5,#3XK_9+7M"OR 40T-';A]5>-GF/O),)J;_PH7X [NG;@:E>(F_*)J,%:)
M6<59$?1C6ID,ZSCK7VEQ0CH3TAL"F0H%Y\_4TC+7:D1Z.ON>^BO>'%)W-I5/
MAJ,(WYQYX[*7<IOM<W+Q0C/F.&'2%6:S((A37TJDL1+']#]Z&J=OHPZW@;Y=
MT_=97& 7%=@%@=T_+=[?M!C#/,2+9-$B643@TTV1"&:?W!0AJXL3H-OP9 VJ
MU"##N*RRRU0\IN'B_\*GD?I&=<ND06=EW?,)E]PH9<%92>Z<E\Y-\1)P:*S?
MWKN]GM[R%%C5SV-*EO^*\@]02P,$%     @ ]H&74$MN2%#) 0  -P0  !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL?53;;IPP$/T5RQ\0LV;95BM
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M'<$,!\"P9KQKP/2%#.\:,'TAQ;L&<-(*9@F079DE ;,< ,N:\; !\Q<R/&S
M_(44#QMB#QN_008BS;T_#ICD $C67%:98H.L:@.NW""MWD#\+SO7-1>=84H-
M!."8>U$D!5-L('*J#013;B"2Z@T$*#B(RPV BITM4C#E!B)FFCO;E8*I-Q Y
M!0>"J3@0224'(O:J%(2.WZ^+^'B6K&<G#E-W( #:FJO&$$SE@<@I/1!,[8%(
M*CX0P+4:KU84I0<))7O\)KFJ(E16I-E"(*X2*,/D2JX62*;8W.^J:7F;5"2C
MTTDHE-9&[FX]*53<E_7S4-/9+!ZJUT/;EP1.KIX+1S\.9:,7U^_Z@M*A /)'
MF%,UZN]%_;P]-(LO5=M6^TU?[/A456W9]5.LN@G^4A:/YR^[\JGM_^P?,>M3
M$>CI2UL=-Z<*U_6YS/;V/U!+ P04    " #V@9=0_'N17E<#  #L#@  &0
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M$?<!,R!0C"9N@"!O0<Q"OZ(911PN,(#MN$/>!QR!^PWY#_1+#QIW G*36;\
M,"_Q5L&"(+A_$=# L;]  ?<<"C]@"]QU*'K$EFA>KQO-W@_.Z 5>$7XULTY8
M.;O54K\J1Z?#/-UY>@!,SO=ZSIK!\$;3#>GOF%_+6E@G)M5X,4/@PI@D2J6[
M4FX4ZKM@V%!RD7JY5FO>#<=N(UG3#WYG^/K(_@%02P,$%     @ ]H&74*N
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M\UHU7\/Z>]&]/.DNJOS4OQCR+F^GEO\#4$L#!!0    ( /:!EU#GP3GR\P$
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MI2^#/;(EYPIT(\%&.ZWUFS0%%$IEIHF>"W<S7:!X-SXZ:'KYLG]02P,$%
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M>.1#XMJ7,QR%Q%4K*8Y"7J_:(,0FXNFG ">A?"%PO<D93D+B>I,4)R&)716
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M&!JET6*8PY0MAC,<)*-<(%@<!2DL)P+E1( </)+38I+!.HRE.* C.0 LCFG
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MHB4#+N :1Q\H<@17.8+*O!<M!!KB@4L= ;5.HP$7<"DC^H%HX<)#_<H#HH5
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M!.> 0VWL=(US-;X$8V!D/[UR='YJBS=02P,$%     @ ]H&74%'H.,E6 @
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M-K;M4@3MV XVVU]/<OO:=(=Q>UP-K_.'DZ8\CW]5A-?_2W;_ U!+ P04
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M=#+5;\Z$<"1,^I[8DUK<6=,$HS.7PTR,J6[<>L))/UY*8+H9-_\ 4$L#!!0
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M$F%0$=V1[$$TH8P6,P14D?:AES#T"$'/C39)Z,5R P%4K'UI(LP]0MQSHTV
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M^_>\/19UYSPR+H9--1(>&.-4<!1;Y#HG\94P/)3TP.5M(N[;?E3N'SAK]&>
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M>7>IZ#J2M?V%R1UN;:O_4$L#!!0    ( /:!EU#@[" HNP(  .8)   9
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M^C93]Z([-'0/DA_Z U$XG,H6_P%02P,$%     @ ]H&74-CVOK)_ @  0PD
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M82%K4,@:($"6$ AC_W40!L-"D \7#Q^@".WJ 8 6YQ5DBAZ(>5#)$$"Q*&4
M:+%#(.C!WX/ FK=%P8(BL4\M@(FCV-8"@1Z4% 171X0!"KNH0*#58I<@D+TP
MWJSU-)2?39<6SH%=6JF+_,PZW02V@6Y=ECW7-P33TCYHANO%3\+/52N</9.J
M,9KV=6),4J71?U*EKU0WFFE2TY/4PUB-^=#6AXEDW7AE\:9[4_8?4$L#!!0
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MPA)G*6>=P^V_VV)]B;Q=J+J?ZZ!IMOFFVB-4])YM$C]%=RW48PX6XX\PWH!
M2GU(X2^E./@S^B3!<8Z(DG\AISEDNUTV$2S6&1A^,#811\L"X:) : 3"<:/B
M[:11%A,;3&,QFU4P*78.^A1LXE6X;"9:-!/-S'A^.#%C,9M1'B^(9G9.T<R.
M%X3)ZC_-C1?MQ//>)),\AWB6)UE[,S=+J&"$LF;0Z'93X*69',+)V:V1^I*,
MHL-P>O+UZYC$#][N:&?,NXR=>-\Q+^M&.!<FU=LS+Z1@3((RN5ZIGE5JR X'
M H74VXW:<SMJ[$&RMI^B:!CEV5]02P,$%     @ ]H&74%?++Y9%!   ?A4
M !D   !X;"]W;W)K<VAE971S+W-H965T-S8N>&ULE9CICN(X%(5?)<H#)-ZR
M(4 J*%HSTHQ4ZM%,_TZ!6=1)S"2AZ'G[R>*B@WW<@OI1).;XGGL=?['Q_*KJ
M[\U1RM;[4195L_"/;7N>A6&S/<HR;P)UEE7WS5[59=YVM_4A;,ZUS'=#I[((
M&2%Q6.:GRE_.A[:W>CE7E[8X5?*M]II+6>;U?RM9J.O"I_YGP]?3X=CV#>%R
M?LX/\B_9_GU^J[N[\!9E=RIEU9Q4Y=5RO_!?Z&PCLK[#H/CG)*_-Y-KK2WE7
MZGM_\_MNX9,^(UG(;=N'R+N/#[F61=%'ZO+X5P?U;YY]Q^GU9_0O0_%=,>]Y
M(]>J^';:M<>%G_K>3N[S2]%^5=??I"XH\CU=_1_R0Q:=O,^D\]BJHAG^>]M+
MTZI21^E2*?,?X^>I&CZO.OYG-]R!Z0[LUJ'S_E4'KCOPGQW$+SL(W4$\ZA#I
M#I'A$(ZU#X/YFK?Y<EZKJU>/\^&<]]..SJ+N<6W[QN'I#-]UX]ETK1_+)!7S
M\*,/I#6K4<,F&AXG]YI76T-OBK#+X)8&0VFLF-4]2:-[BS72Q$8:MH;=*S:V
M(DIQIAP.&!_ZB[LL$AQ P !B",#O C@RB&" "&20&56.FFS05(,F=GC$T".V
M/3*" R0P0/)XE2D,D#Y0Y:B))E5R@3TRZ)&!*AW3EA*,#WF\3NH@D((LF(G7
M*(HGI0H>1 XCR-@+9<"(FT;,,F(T<%6$$:& D4R81DCD*@B31 4(8;P1-EHT
MG23"98-YHP"XS($\Q3C1^(EI@H&BR2/3)+&XIYG#!F-' 7>9*U-,%<T>+Y9A
MK!@!61CTK[1H6BQCCD?+,'O,9B\EQ/2AU@QBCM<,P^0QF[R44--F%*43FRQ@
ME$S^7$LJQI#9A*6$F:[<GC'.0<08,AO#E'#3Q\:0">)84A@&D=D@IL3<K&C1
MU"AUV6!8F;WXI20R;6++AF;.>C#2S$8Z);%IE-B+G+,@S#1[8"U=:=%T(J2N
M>8"Y9_9RFA+'>Y)C[OD3RRG'2'.$=&J\)SE"VO7T.(::(Z@-O-9:=(>7,94V
M6C--)G&\7[AC3XHVI>9F28N2NXGDVD)PC#I'J%M&PC:*G$88=0Y0IZ[G@S'F
M3ZRY' /* :"4FG,IL<JE64#-00&JF#E'!8/,T>)L[N"TZ,Z)!-:DLU5I%H@'
M5AN.Z>> ?LIP"('I%T_0+S#]XI'-M!9-:\]<3T)@^ 6 GW)'" RMX$]4Z_@I
M"7"TYJ>P<12!8U,H,(T"[8#->:=%4Q\6.-YC B,KP,I+72$PLN*)'YX"4R9L
MRL"HVOPP%ABG(AND(L[!QV )]"O5&OS,^ME&6<#-=("*!K&13C@Y.RIE?1@.
M\AIOJRY5VX_LI/5V6/C"^K,GHWU%9VL*VE_I;#,>!?X,/YY,_IG7AU/5>.^J
M;54YG$OME6IEEWSW"O.]H\QWMYM"[MO^,NFNZ_%$<+QIU5F?=H:W(]?E_U!+
M P04    " #V@9=0XC80$L<$  "$&   &0   'AL+W=O<FMS:&5E=',O<VAE
M970W-RYX;6R56=MRHS@0_167WQ>06@AP.:Y*XF1RV:E*S=;N/I-8B5T#Q@LD
MGOW[Y:)X0=V=D)?8R*=O4I\CH2R/1?FSVAI3SW[EV;XZFV_K^K#P_>II:_*T
M\HJ#V3>_/!=EGM;-8_GB5X?2I)O.*,]\&03:S]/=?KY:=F,/Y6I9O-;9;F\>
MREGUFN=I^>^%R8KCV5S,WP=^[%ZV=3O@KY:'],7\8>H_#P]E\^2?O&QVN=E7
MNV(_*\WSV?Q<+.Z5;@TZQ%\[<ZP&WV=M*8]%\;-]N-V<S8,V(Y.9I[IUD38?
M;^;29%GKJ<GC'^MT?HK9&@Z_OWN_[HIOBGE,*W-99'_O-O7V;![/9QOSG+YF
M]8_B>&-L0>%\9JO_W;R9K(&WF30QGHJLZO[.GEZKNLBMER:5//W5?^[VW>?1
M^G\WHPVD-9 G RD^- !K %,-E#504PU":Q!.-=#60$\UB*Q!--4@M@;Q5(/$
M&B13#43POG+!9)/38@O'Q.^[I&N[=5JGJV59'&=ESYQ#VA)4+!JKQGD[VC5R
M]V/3>E4S^K:*1;CTWUI/%G/18^0  SH:8]88(TX(OTGAE(<D\[B0R%Y#,(YQ
M26&$DP?&@(['F"L"$SE^KJE8<HSYAC&QT&/,#85QYNZ6B@5CS!WEQZGKGL(D
M]"H W0W0>8"A!QG0'A3M074>U,B#NT8])NDP^P[CK/351XA1%B&=14ADX:S>
MNL=$@QA">6ZK8)",O8C.1=.Y:)2+=@BVUBA*)% J&!3&'D.RB$XE0JF$B9-*
M#]&#*!""\IQVO")@*DX&.8_2B>ET8CPS$;/.">TAF=ZOK;B2 A@063@=>T6"
M)!.(4UI!-"6X,HI!.E*.[GP"&F=#Z^VYD(0/)/P2+;..M.=HW*6%"1@V<)AX
MCKOK3]V-,V<T2@ QC\X4W5M0,@H5,H$8*1-3M,R"-"<CXTB,7(DI>B6P%OVF
M.0$0C!@)K$9H\M8"2XT,/&8G$8S6""PVL72%3V ="4&X#?;-PD8-ID/A.8MQ
M2[F+ \^9R3O2712PJ\;(E\#Z%4OM5DB!F U$,"HGDL^W$(O1'^\A!(K?1"2C
MF)(20T9U)2.&4DQ7;LE(F,02%@<N:RPH'/(SX (QBB.QXD2QNW%:T#"0!B8.
M(SB2$)S B7,C\=D(F'Z2C-Q(+#<0N0=Z"QK6(P4W<8S:2$)M@M@M2*."!*/4
MDM$:26E-[!84X07BZF$8+RDRHT:(D7J"2\1;"QHF$W-%,ZH@L2K$[BO3VH)&
MI]P$9Y/@)>!( HPJ %8%Q1V1@%$%^((J *,*@%4!'7(!'T3 <PAP18 DN[,#
M]T)%'%: T5M@9 '4%V:%H3Q0)PSWT 28\H*C(C"4!X+R[HOSF@0Q8@D,YX'@
M/#"'8&#X#/$79I:A(1 TQ#.;8.WA9E8Q!%.88'AF"5 HF'Y3# L5\:("7+(,
M"Y7\PDT"PQTUY:"O\+8KN,.(XNXLB'T7F+<2Q1!,A5\HF.&.FG XOU=XNY32
M71U_</^7F_*EN[:N9D_%Z[YN PQ&3U?CY[*]/W3&+\3B4A#C:[&XIL9OQ>*N
MOX?\/VQ_/_\]+5]V^VKV6-1UD7=7CL]%49NFIL!K)F]KTLWI(3//=?LU:KZ7
M_;UX_U 7!WOG[Y_^\;#Z#U!+ P04    " #V@9=0#=XOX( "  # "   &0
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M(L"'-P@"87PXR!P,,@<$@D&R8TP03BP)LN%ZM8$P$]L"390\>GY=$5C0*^0
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MCB[7=]DZ_RX@4;?D>F*S#FA,$RV#%^LQZ+1)E,,*6C8\*?CP%.=/"1RU#)#
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M*THB6?GRS?,L 4*#HC+]PGMY((7O$VY.K7V<K?D()G!52(2EV."F$]"9EE8
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M.*XTP@ Q<?5E?$#%;%64) @?^&YFT"/^$'/2#ML5W52&!>K(2.V+.&B/YY0
M5WJ#T4! P$+5$_ A-,8_Z,-32_)7G#SHX4S,7E'>^SB>^/<*-[8F)"_=(D81
M#K/*4N,P7YKT,!'<&>$=GE,D@\U\1[1^ !*8*<6H?)="FVECF;?ST[)3Q(FN
M^EZ*TKD)*V1\Y6UYFDR)\G\[LETO[0.L+[@ RJYFO6>%W.A+6MBU"0(!A#+,
M#X/?Z2)94N"?O;JDF2LK5#T;[8'"@B:@)"M/%-$*-@3$,5GS,#.&LXEA>"L#
M.[9?D:"!+" ._D(XJ/@'\;+1^A'$*XJ&K7(S8 3"KTZ97]6.8QC4:;<-#.K"
M*5IO<L#JYRS_A"Q-RU*Q?NJ6+YCS(S3,4KXT0$M1\"@L\)2*E^LQ_7(ZJIC.
M5]_#W9#80\8W8E!!8<XGZ8^P M+EX95K%/:#'A%7X>$U_JZ3IA/Q'%Q[W"$Q
MI2&[01O!7?:P>D:Y<B\\&6" @LF_XN3=[BN3K>\\<O*#F?#8F_#P;CU>L=0S
M:!_W$:_.10N0;.!"RUIX3%?&^<[:S3DI6E>&_Z(O*CB?9^LI9:BLZ;61LP8!
M(L ]NT*-Z0X#_$ +Q_PVC'FL(-YD#HKY0R(L(?*7D?C+8'T/;SC-/;%S^Y:H
MKT-#%"6(TC)30(=+9HVFI.T;I9B-O>PB]TR%EN,JB4.DJG',ABLAB=LIL^?]
M(5N^-LN-M%,7D.H]AMQ)?L!+:%6)+/$&,R2H?8JH0@>T,43?UK:CTBVK9Z2C
M]G$"('\:MH=5(@,*+ZJ]H""3S7B!Z7Z*5OEF1\]I'1449I0]%S^Q!V[X2E9F
MZ;JA7)[USRRQ<6@V?$\2H.\PC7-D"B8:N:@P]A>)[*[53<Z)B$HE2]!0SH\0
M#&$@)9!8E#8W003'<ZN/HWH0&REDA]5RM*S1YXU'$VT)\6?&/JQZ*R7<:+4M
M=I*C\@TBSIIM.2'Y^?!5$V2-0\'BZ0@50)9+4"NGVB8BDAI;?A0K"(V3TB5Z
M-["35_8P1U, (*[W.'LX-H9INR)2I,X1Q;8B+A%J$,,?Q>G<M*M#0AB\R1&N
M#(X1*-,C4%545PLF64=\'*B=L!$:P4TV;>W.V'Y:Y/C'(S,2N_XQ*8P1A32%
M"0;(P&.R1HY],]"Y 5"C3Y9.W(1!(S8)H$46<GA/V]\1Z:W]"[FOM0;J= 1*
MZ24>F& F [N*3'0CX[:2VN6&"*R3A_U0&A?AT/J_1JCX%I+QMC3J2HZ$B5X#
M]CE.4C&J-B<&>"G96/:T Q1>?8GWFD5O$KO)M2.^>O/T(=HJ*8#C4XH^4:!H
M-V^.VX/NH'/2/Z.HQS1#.>G\_=WQ,DYC+J)<4#W1138'!9 <,[-DG*PR"H><
M@  %V/L)-@ 4I1-:7[P+L_*C/F&?+@)I',.9)%FNW=W&_UUL%DLX?E2 <M2#
MC/%^66PF,U 6<O1REU^R[G&Z&#</@(NY1'?RAR.B?XQN&*U*V@FFY9 /D"W"
MM/X;RACJ,,]^:5<%H#L 5(2!T07;7$%.>J2(V&(>QTL0*C[!%9EM5K.%#1['
MQVT@O!7$9!>T5$#&-%8Q-*3TJ9Q_B16<DH5GO81]TW7:F*4=G Q:[6#!Z<NX
M28:#L4.1I%-F<QAL1MM6\PC.&S6NT"5!7ZQS&1Q>W=S^*5HL7UT<?8E'/'(8
M/XN8/&QB='5'DQF2IW@R2RT./ #L$JZ<1#9M<H5AT#9 Q:#$>HF@.!CV-'!@
M82K"6!F*7HQ;A1%BH%5I;#.U?)-]$B.@\FP3S5>)3;HA7T. K 1-+,ECPM;"
M8CT^7H&\0A9P!W^ QGL*:P39"8V/)M0#;L1\HHVH9Y)G &(SR:\4"^6-@]?9
M!-,H15HRH;9/=/C^[IXHA7'1'!<4G( Q*A*!LJG+T@$,3;-CI>D_)?D:4T5&
MOQRYRV3BWF <"E3*XU4BMCI.M@"8^$Z8VOL AX=H\9S!R4R/R2@)<\I*K6_)
M&&;426&A&O/STF8Z4@43+RF%G>LBSYM8*4;1#D@6R2*/EPF!),;8K">@JI,C
M<^<20@ F,#T/NUX@,Y-9EF?HS<>P?SR#' X,8Y!<@% 8_.,8-O")[F43%)G;
MS[%+ ID X86I36 0,]5\(U>- RLPC,R=$O-5WF\W.+R]>7OK(4#M5KL_[K59
MNP]:/9PMG$Y"7M6LB-3X#(7ZW9)Z3V03]N$V5K,C]*Y,199#VW71B%M4C 4N
M@5=1*SCH#EJ#MBVZ@7M#XF3] 6@75%?-OF\VLL(Z$O#@P6G_I#6T)*F:0$33
M'_35,]Z<[#G6Q4<TJ$I!2X#MQQ,G?1BIM[ ZL(1^"<%GPV@JYT.0HC)?+K\V
M1S4?5R@^:6<DPM(BU;555L3X4*SJEB6.05K807?8ZEH(A,XG?] Y;?7M#[P'
M*Y3R)JAL,Q':E\MDVP+(5I6 NQ=Q--/!2>O4SE0:NI$1FO'V9X*6Z$@$QS/Z
M5<N64[&?V#+QIGJ.+5.32<"#LK4_HI#'0CZBI7&C"Q;@+!A;L&',LU5E:&7$
M<GIM3@,A9ONP)AMP^>;8A#17O-86E/'%CV1E)) 2S[+Q"#P/7G$Z5(M]);M1
M90G"=!\ [@ I"6;&H7GQA+!D7B!%BFLU44HM3,.6*8?/SEO+,3YD-I8N%I&K
MDN2$I%(T# >?Q-.?0#)*#1(51T%CZ9O@(.BT$>%J"Z$&)ZT!4(J7Y;!*':?@
MI-T&$<A:$SL='*J^#F5P>-IIG05';&[D(@N=5B^XKZ,"!\'IH MWM$H'R()D
MQ$&54FA Q9'+$KXW=9B#CX[-4C@>7]0O01]7S3@"Y-A@3 [(+8 E9!ZT3W)I
M(VI3T1I\;PQ4'(5DB :'IV'\\11#J%/C"A O5NG6">.O$+V&YYB"]4_;2O9T
MT1?:5:*$4 <Q%LV5:F[X,$K[W:X_ZAV*SP)T"F;SC)0J HHAY4+J>18+%15S
M3P$HXE:>5JH"&L9'8=CV$X^6V=0:;4%*:3<<V!1:WZ:$#C5BLO.TN6AM%V?D
MRQ6LAV'EWI+\C@&R?&'0VQLR;UIQ?B_(!IA.QD8"ZX-EM0B=RA$Y/ W&%2A*
M++0H*6Y >#G+"T.\&]PF3&:M$U*?49(N06X@E2<;(R>4X$@^49<CMIJM*:V
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ME;Y,[VH/MD%N5B18@^DPT1+!+_9$[@U!J>'=P2TITK^:],\16O@?XUUH='#
M LI%71FE"Z]B4K?5;W^/!P>LI/<]?NQ_']QC]\='5I]=J I\U"8KZV,K>.LX
M1KNK^-8,J:DL/I+%^^6:R"H@F6YQJ5\'QR8^E>_CKJ=68]*B>!5;<-:F])E(
M'L]CQ54>;,2.5!0*_=XYI*EA>1>LZZDIDLH7#)WCQ+N&?A\?'U.+_39Z@7Q
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M<E6:)DD)!*)E9[DY80^Z(DQ@F%0LY14D8X@!13=P3>'; ]X,7W-TW/G3+>>
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MC])H&H7!Y1I+Z8023H$SC-88\@$\H:I=.>.N;]@H&S7H.>R9ASYARCDR9B\
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MR>MSE8;M^<:>(]M9[7&7#O-0@@^.8&W:'35:<E"P/&9"%$8_TJ'+QQ\*U*$
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M!G]Q)09-,=?N%J,JC(^;F4/G[+0?2L$_N"N?TNPY-96 RC *K9P[HH99P<\
M]=5L@B8\O$AA,)I_BH$SLMN(#(<DSL$/BS3F=A;Z_C&1&H$\.T[2:6;J7N/A
MCEJAC'F>+.>1$7W"X.U<U-K*6#31VSQ"GE7Y]>8).  _\C,&(&;!Q[N1F>)Z
MO43<6\TQXK0(?C9-B_&)=]%D'F<@-%5H!X_V[NZ]OV$U$[^RPNPTWA$<48J!
M+:7!9!EW<%[9'_;#<Y3H1=[-DODR"M[%6+,9(&XA<C>/-F-T_ KX"*CW&>=3
MUD/I_M<*A,PTO\))S $!U-G:'1%"_>=FNJY  X3FN]&1D%/"2$#I9WSY(GZ
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MPXTT/K*1E?BPNJ WQ=U^2WJ;D=O,D(U&)0<,,*-D#+(V(!#'>11VL5CPN-]
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M8U/.S+E#.;;XOD;/V(2@*\":84PE1%0 U+5EEJ@D]MN]8M\41?K%.A>VCUN
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MYUB,$\ L:ST!1GBT!-DBS=WC?,CRB=+[TLZ Z+;534>]'*4G$,"[>1\YI//
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M0:!\GTK(GS,#!N<40FA6_N 0AGA S$(D<5_GJPMBWG0$$13SK0-C'F&DMG:
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M;,"#0;UK4DM$L+&_X)B4S'XU>,U7Z?@W4$L#!!0    ( /:!EU#&YB]_Q04
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MH>R;_FIX6]Y=X^GO->__ U!+ P04    " #V@9=0=)CAXWP"  !"+P  &@
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M;',O+G)E;'-02P$"% ,4    " #V@9=0)^B'#H(   "Q    $
M    @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /:!EU & ?6M
M[P   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( /:!EU"97)PC$ 8  )PG   3              "  ;<"  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ]H&74(,@W\8R P  .P\
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M965T-2YX;6Q02P$"% ,4    " #V@9=0,'HI-> $  #S%P  &
M    @ '#&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M]H&74&G6CB-&!P  ]RH  !@              ( !V1\  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /:!EU#T&D3EM0$  -(#   8
M          "  54G  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " #V@9=03Z=>#[0!  #2 P  &               @ % *0  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ]H&74$6[A=NW 0  T@,
M !D              ( !*BL  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " #V@9=09^TUV[8!  #2 P  &0              @ $8+0
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /:!EU"DWU'V
MM0$  -(#   9              "  04O  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ ]H&74/8-_G^U 0  T@,  !D
M ( !\3   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #V
M@9=0D^_BTK0!  #2 P  &0              @ '=,@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /:!EU ZL+,TM $  -(#   9
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M970Q.2YX;6Q02P$"% ,4    " #V@9=0MF"36+8!  #2 P  &0
M    @ %B/@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M /:!EU!<U]+ZLP$  -(#   9              "  4]   !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ ]H&74#[P^.ZQ 0  T@,  !D
M             ( !.4(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " #V@9=088JEBK$!  #2 P  &0              @ $A1   >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /:!EU +H;6!M0$
M -(#   9              "  0E&  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ ]H&74"/<$FVU 0  T@,  !D              ( !
M]4<  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #V@9=0
MUQ?#8ND!  !F!0  &0              @ 'A20  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( /:!EU R7"N1LP$  -(#   9
M      "  0%,  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ ]H&74++<8XOO 0  904  !D              ( !ZTT  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #V@9=0)CQ@3K4!  #2 P
M&0              @ $14   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( /:!EU"KU N4T@$  )P$   9              "  ?U1  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ]H&74 ;[QN;0
M 0  G 0  !D              ( !!E0  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " #V@9=0W'@ O]T!   !!0  &0
M@ $-5@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /:!
MEU!NR[M;W $   $%   9              "  2%8  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ ]H&74+[2V]_% 0  -P0  !D
M         ( !-%H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " #V@9=0-["HBK8!  #2 P  &0              @ $P7   >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( /:!EU"%_E#WP@$  #<$
M   9              "  1U>  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ ]H&74%L;P,&T 0  T@,  !D              ( !%F
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #V@9=0Z>D4
MP=,!  ";!   &0              @ $!8@  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( /:!EU!P:# ]PP$  #<$   9
M  "  0MD  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M]H&74$MN2%#) 0  -P0  !D              ( !!68  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " #V@9=0_S $L8,#   O$   &0
M            @ $%:   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( /:!EU#H#JA>3P(  (T'   9              "  ;]K  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ]H&74,$B*$N0 @
MJ0@  !D              ( !16X  'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " #V@9=0*^0Y$*\&  !R*P  &0              @ $,
M<0  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /:!EU#\
M>Y%>5P,  .P.   9              "  ?)W  !X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ ]H&74(:HXOGL 0  ,P4  !D
M     ( !@'L  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
M" #V@9=0,*7"!TL"   9!P  &0              @ &C?0  >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /:!EU -&5PMLP(  "4*   9
M              "  26   !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!
M A0#%     @ ]H&74,SMPPEO @  B0@  !D              ( !#X,  'AL
M+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #V@9=0JX 4N $"
M  !Y!0  &0              @ &UA0  >&PO=V]R:W-H965T<R]S:&5E=#4P
M+GAM;%!+ 0(4 Q0    ( /:!EU I$&:][@0  *D:   9              "
M >V'  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ]H&7
M4.?!.?+S 0  !04  !D              ( !$HT  'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " #V@9=0E8'I5-<%   4)P  &0
M        @ $\CP  >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( /:!EU C*66=OP(   0+   9              "  4J5  !X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ ]H&74!44IAPU @  7P8
M !D              ( !0)@  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " #V@9=0RTK=5;8"  !7"@  &0              @ &LF@
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( /:!EU!F)6JY
MXP$  '8%   9              "  9F=  !X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ ]H&74%'H.,E6 @  (@@  !D
M ( !LY\  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #V
M@9=0+!7)AZP$   [&0  &0              @ % H@  >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /:!EU!;6SL/8@(  +8'   9
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M970V-"YX;6Q02P$"% ,4    " #V@9=0ZI9-Y%D"   E!P  &0
M    @ $*MP  >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (
M /:!EU"#1"D<O (  &4*   9              "  9JY  !X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL4$L! A0#%     @ ]H&74+FNK0W_!   $!L  !D
M             ( !C;P  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"
M% ,4    " #V@9=0_1;D7QD#  "7#   &0              @ '#P0  >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( /:!EU#8R5Y4H@(
M ,$)   9              "  1/%  !X;"]W;W)K<VAE971S+W-H965T-CDN
M>&UL4$L! A0#%     @ ]H&74.#L("B[ @  Y@D  !D              ( !
M[,<  'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " #V@9=0
M7SQ ]3 #  "A#0  &0              @ '>R@  >&PO=V]R:W-H965T<R]S
M:&5E=#<Q+GAM;%!+ 0(4 Q0    ( /:!EU#8]KZR?P(  $,)   9
M      "  47.  !X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%
M  @ ]H&74,P-:5+] 0  5@4  !D              ( !^]   'AL+W=O<FMS
M:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " #V@9=0@FRSKYD#  !)#P
M&0              @ $OTP  >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+
M 0(4 Q0    ( /:!EU#$1BA0(@(  -8%   9              "  ?_6  !X
M;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ ]H&74%?++Y9%
M!   ?A4  !D              ( !6-D  'AL+W=O<FMS:&5E=',O<VAE970W
M-BYX;6Q02P$"% ,4    " #V@9=0XC80$L<$  "$&   &0
M@ '4W0  >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( /:!
MEU -WB_@@ (  , (   9              "  =+B  !X;"]W;W)K<VAE971S
M+W-H965T-S@N>&UL4$L! A0#%     @ ]H&74!3>2W/P 0  # 4  !D
M         ( !B>4  'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
M    " #V@9=0@S%K+VNH  "1K0( %               @ &PYP  >&PO<VAA
M<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #V@9=0>BCTL(0"  "B#@  #0
M            @ %-D $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /:!EU#&
MYB]_Q04  .(S   /              "  ?R2 0!X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " #V@9=0=)CAXWP"  !"+P  &@              @ 'NF $
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #V@9=0)V75
M&B "   -+@  $P              @ &BFP$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     6 !8 !H8  #SG0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6915769712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:13%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,952.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,426.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,497.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>956.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>956.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,399.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,952.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,446.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,527.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:<div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020 (remaining nine months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>193.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,757.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,752.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831237120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:13%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,952.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,426.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,497.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>956.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>956.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,399.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,952.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,446.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,527.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$71.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$68.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no impairment charges.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Completed Technology</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Completed technology also includes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$154.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D Related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$700.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of&#160;trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The TGN program has experienced numerous delays in development in the periods since we acquired the program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain indication, for which we also have an IPR&amp;D asset. Data from that trial is expected in mid-2020. This data may affect the economic value of vixotrigine </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and the IPR&amp;D assets for one or both programs could be&#160;impaired if assumptions used in determining their fair value change. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value associated with our vixotrigine IPR&amp;D assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$161.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020 (remaining nine months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>193.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,757.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,752.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span> accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831252352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,636.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,590.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$48.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$52.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.7 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.9 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. In the first quarter of 2020 we placed approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$256.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of fixed assets in service related to the facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$12.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6935210208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">28.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 651.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="nump">&#8361; 670.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.8<span></span>
</td>
<td class="nump">$ 58.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 24.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember', window );">Deferred tax liability | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6835959616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in Unrecognized Tax Benefits is Reasonably Possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="nump">$ 59.1<span></span>
</td>
<td class="nump">$ 59.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919411536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,974.1<span></span>
</td>
<td class="nump">$ 2,541.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">121.8<span></span>
</td>
<td class="nump">384.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">36.9<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,705.4<span></span>
</td>
<td class="nump">1,628.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="nump">$ 159.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6915011392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 210.9<span></span>
</td>
<td class="nump">$ 169.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">475.2<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">172.7<span></span>
</td>
<td class="nump">174.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 858.8<span></span>
</td>
<td class="nump">$ 804.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6836621328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 5,961.7<span></span>
</td>
<td class="nump">$ 5,954.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">6,681.3<span></span>
</td>
<td class="nump">6,553.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,498.1<span></span>
</td>
<td class="nump">1,509.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,501.8<span></span>
</td>
<td class="nump">1,495.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,022.0<span></span>
</td>
<td class="nump">1,038.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">996.9<span></span>
</td>
<td class="nump">996.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,838.1<span></span>
</td>
<td class="nump">1,897.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,739.9<span></span>
</td>
<td class="nump">1,739.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">2,323.1<span></span>
</td>
<td class="nump">2,107.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,723.1<span></span>
</td>
<td class="nump">$ 1,722.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919165648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,399.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>172.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>173.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>197.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6918996096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,974.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,974.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,353.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,353.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>710.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>710.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,620.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,344.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>345.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,920.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,912.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,498.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,501.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,509.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,022.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>996.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>996.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,838.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,739.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,897.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,739.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,323.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,723.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,107.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,681.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,961.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,553.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,954.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>421.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6726813776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">For the Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>43.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>162.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>89.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6591699312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>210.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>475.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>460.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>172.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>858.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831206688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,116.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>186.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>103.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>79.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,559.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$34.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$34.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$31.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Interest Rate Swap Contracts</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">seven</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$22.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$698.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$793.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recorded as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912603232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>777.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>323.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,100.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>717.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>998.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>292.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>173.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>466.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>327.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>500.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>277.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>522.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>245.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>460.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,347.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>769.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,290.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>693.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,983.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>235.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>565.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>223.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>295.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>518.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>124.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>124.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>218.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>218.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>174.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>174.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,583.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,321.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,904.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,513.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,166.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,680.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>131.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,027.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>200.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>827.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,033.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(16.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(73.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(310.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(383.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(112.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(432.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(549.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>145.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,096.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>39.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,281.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>235.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,046.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,281.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>390.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>179.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>520.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>517.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>94.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>109.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>292.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929164496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>33.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>43.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6918988848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years from the first commercial sale of any product using such a licensed compound.  </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of the Neurimmune Agreement and made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune to further reduce the </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, under the terms of the Neurimmune Agreement, we would be required to pay Neurimmune a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;if aducanumab is launched in the U.S.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$22.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831290832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">14 months<span></span>
</td>
<td class="text">14 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6932646064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,220.2<span></span>
</td>
<td class="nump">$ 655.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember', window );">December 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>432</ContextCount>
  <ElementCount>438</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>142</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Divestitures Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestitures</Role>
      <ShortName>Divestitures Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Revenues Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenues</Role>
      <ShortName>Revenues Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2132100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2136100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables</Role>
      <ShortName>Summary of separately identifiable assets acquired and liabilities assumed (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2330301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2332301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetails</Role>
      <ShortName>Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Divestitures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDetailsTextual</Role>
      <ShortName>Divestitures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestitures</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesByProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherRevenuesDetails</Role>
      <ShortName>Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2421406 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2430402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2432402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2432403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-2020331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2436401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-2020331x10q.htm">biib-2020331x10q.htm</File>
    <File>biib-20200331.xsd</File>
    <File>biib-20200331_cal.xml</File>
    <File>biib-20200331_def.xml</File>
    <File>biib-20200331_lab.xml</File>
    <File>biib-20200331_pre.xml</File>
    <File>biib-2020331xex311.htm</File>
    <File>biib-2020331xex312.htm</File>
    <File>biib-2020331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biogenlogoa10.jpg</File>
    <File>chart-0b79355e2c74500eae0.jpg</File>
    <File>chart-0e90e35cb3f356fdb65.jpg</File>
    <File>chart-12ab3b9cf42c502a82c.jpg</File>
    <File>chart-21a631c632245214b5c.jpg</File>
    <File>chart-23a7c01770e356d29ff.jpg</File>
    <File>chart-2dae770040575c09957.jpg</File>
    <File>chart-4bc2b65e63bf598aaeb.jpg</File>
    <File>chart-5576b2a7fe2b5bfabd8.jpg</File>
    <File>chart-7f0043a713055b78858.jpg</File>
    <File>chart-80323542940f5f3e9fd.jpg</File>
    <File>chart-8808588ca10451cd818.jpg</File>
    <File>chart-9c451125cbd651c0abd.jpg</File>
    <File>chart-9f17d12ff13d514ba12.jpg</File>
    <File>chart-a0675ec327835197bd6.jpg</File>
    <File>chart-a8b4db707bd75762992.jpg</File>
    <File>chart-bec93acf6eb55fb08e4.jpg</File>
    <File>chart-d3a8fa49540b5980939.jpg</File>
    <File>chart-d48ca46993295751b22.jpg</File>
    <File>chart-db872ef72f75548e83c.jpg</File>
    <File>chart-dffb73ef4c6252a6985.jpg</File>
    <File>chart-e41c9713c67058c3bab.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6921737376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,033.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(16.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(383.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(549.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,281.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">131.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">200.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(73.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(112.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">145.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">1,027.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">827.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(15.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(310.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(432.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,096.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(4.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 39.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6933150080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>Assets</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ClinicalAssetsAcquired', window );">Clinical Assets Acquired | Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes', window );">Tax Basis of Investments, Cost for Income Tax Purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member', window );">BIIB118</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 635,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments for pre-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Fair value, in-process research and development, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Deferred tax liabilities, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember', window );">Post-acquisition equity compensation | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ClinicalAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ClinicalAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Indefinite Lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9972-128506<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9979-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of investments for Federal income tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(8)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C(11)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611282-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929587280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">454.3<span></span>
</td>
<td class="nump">602.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">476.3<span></span>
</td>
<td class="nump">563.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">570.1<span></span>
</td>
<td class="nump">567.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">71.5<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">71.8<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,714.4<span></span>
</td>
<td class="nump">1,987.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,819.9<span></span>
</td>
<td class="nump">1,502.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(120.5)<span></span>
</td>
<td class="nump">357.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,699.4<span></span>
</td>
<td class="nump">1,860.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">292.0<span></span>
</td>
<td class="nump">422.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">28.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,392.6<span></span>
</td>
<td class="nump">1,408.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(6.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,399.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">172.8<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">173.1<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,904.6<span></span>
</td>
<td class="nump">$ 2,680.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">520.4<span></span>
</td>
<td class="nump">517.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6749661936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">31.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">14.60%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 206.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929721456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,392.6<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">119.9<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">67.7<span></span>
</td>
<td class="nump">45.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">36.9<span></span>
</td>
<td class="nump">228.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Unrealized (gain) loss on strategic investments</a></td>
<td class="num">(62.0)<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss on equity method investment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">45.7<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(238.4)<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="num">(78.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">62.2<span></span>
</td>
<td class="num">(129.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">347.4<span></span>
</td>
<td class="nump">138.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">223.0<span></span>
</td>
<td class="nump">170.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="nump">18.5<span></span>
</td>
<td class="num">(171.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">1,467.3<span></span>
</td>
<td class="nump">1,459.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">2,389.3<span></span>
</td>
<td class="nump">1,489.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(1,684.7)<span></span>
</td>
<td class="num">(825.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(300.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(149.7)<span></span>
</td>
<td class="num">(127.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(37.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="nump">442.9<span></span>
</td>
<td class="nump">238.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(2,220.2)<span></span>
</td>
<td class="num">(655.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(29.6)<span></span>
</td>
<td class="num">(32.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(2,245.3)<span></span>
</td>
<td class="num">(679.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(335.1)<span></span>
</td>
<td class="nump">1,019.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(12.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,913.7<span></span>
</td>
<td class="nump">1,224.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 2,591.3<span></span>
</td>
<td class="nump">$ 2,243.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919113200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,757.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,752.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6934599648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions', window );">Fair value measurements, changes in valuation inputs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">194,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="num">$ (11,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Future payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value from changes in the inputs, assumptions, or model used to calculate the fair value of the contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116651436&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831799360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6930119040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="nump">$ 77.3<span></span>
</td>
<td class="num">$ (376.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,357.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">$ 801.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 803.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912091120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (69.2)<span></span>
</td>
<td class="nump">$ 49.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">76.4<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831252352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Divestitures</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. We determined that the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale and recorded an initial loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$174.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This estimated loss, which was subsequently remeasured each reporting period, included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$115.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting our estimated fair value of the assets and liabilities held for sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and included our initial estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$120.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$59.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this planned transaction in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> this transaction closed and we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$881.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which may be adjusted based on contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction in the third quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These materials were sold at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6598975904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,974.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,974.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,353.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,353.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>710.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>710.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,620.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,344.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>345.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,920.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,912.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. Our investments in equity securities include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares in Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:18%;"/><td style="width:13%;"/><td style="width:13%;"/><td style="width:30%;"/><td style="width:13%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable Input</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted Average</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligation</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>$341.5</span></span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounted cash flow</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.40% to 2.53%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.44%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Timing of achievement of development milestones</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 to 2027</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from the low-teens to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,498.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,501.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,509.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,022.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>996.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>996.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,838.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,739.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,897.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,739.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,323.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,723.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,107.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,681.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,961.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,553.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,954.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>421.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$194.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$197.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities and changes in the expected timing of the achievement of certain remaining developmental milestones, partially offset by the passage of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the expected timing of the achievement of certain remaining development milestones, changes in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919067760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$941.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (March 2019 Share Repurchase Program), which was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2020 through April 22, 2020, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our December 2019 Share Repurchase Program. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our December 2019 Share Repurchase Program as of April 22, 2020.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(32.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(139.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(135.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(20.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>60.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(63.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(26.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(63.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(32.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(203.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(149.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(17.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>37.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(17.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(261.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(219.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:44%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919062336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919082736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,116.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>186.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>103.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>79.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,559.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-2020331x10q.htm": {
   "axisCustom": 5,
   "axisStandard": 32,
   "contextCount": 432,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-2020331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 684,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 23,
    "http://www.biogenidec.com/20200331": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 33
   },
   "keyCustom": 56,
   "keyStandard": 382,
   "memberCustom": 67,
   "memberStandard": 67,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Divestitures Divestitures",
     "role": "http://www.biogenidec.com/role/DivestituresDivestitures",
     "shortName": "Divestitures Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118100 - Disclosure - Revenues Revenues",
     "role": "http://www.biogenidec.com/role/RevenuesRevenues",
     "shortName": "Revenues Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121100 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122100 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123100 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129100 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130100 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsPerShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131100 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/ShareBasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132100 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133100 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134100 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135100 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136100 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)",
     "role": "http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables",
     "shortName": "Summary of separately identifiable assets acquired and liabilities assumed (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320301 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323301 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330301 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331301 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334301 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "D2019Q2",
      "decimals": "INF",
      "lang": null,
      "name": "biib:ClinicalAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Assets",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Business Acquisition (Details)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
     "shortName": "Business Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - Divestitures (Details Textual)",
     "role": "http://www.biogenidec.com/role/DivestituresDetailsTextual",
     "shortName": "Divestitures (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "I2019Q3Denmark",
      "decimals": "-5",
      "lang": null,
      "name": "biib:InventoryrawmaterialssoldtoFUJIFILM",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418402 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesByProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
     "shortName": "Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
     "shortName": "Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails",
     "shortName": "Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/OtherRevenuesDetails",
     "shortName": "Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember",
      "decimals": "INF",
      "lang": null,
      "name": "biib:EntityWidePercentageOfRevenueFromMajorDistributors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419402 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421403 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421404 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421405 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421406 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422402 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422403 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422404 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422405 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422406 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423402 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424401 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429402 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430402 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431402 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431403 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432402 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432403 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BAN2401Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BAN2401Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435401 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436401 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 142,
   "tag": {
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AVONEXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AVONEX",
        "label": "AVONEX [Member]",
        "terseLabel": "AVONEX"
       }
      }
     },
     "localname": "AVONEXMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20200331",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional Milestone Payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BAN2401 [Member]",
        "label": "BAN2401 [Member]",
        "terseLabel": "BAN2401"
       }
      }
     },
     "localname": "BAN2401Member",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB118Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB118 [Member]",
        "label": "BIIB118 [Member]",
        "terseLabel": "BIIB118"
       }
      }
     },
     "localname": "BIIB118Member",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BioverativMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioverativ [Member]",
        "label": "Bioverativ [Member]",
        "terseLabel": "Bioverativ"
       }
      }
     },
     "localname": "BioverativMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ClinicalAssetsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Assets Acquired",
        "label": "Clinical Assets Acquired",
        "terseLabel": "Clinical Assets Acquired"
       }
      }
     },
     "localname": "ClinicalAssetsAcquired",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_December2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2019 Share Repurchase Program [Member]",
        "label": "December 2019 Share Repurchase Program [Member]",
        "terseLabel": "December 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "December2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredtaxliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liability [Member]",
        "label": "Deferred tax liability [Member]",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredtaxliabilityMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenmarkManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denmark Manufacturing Operations [Member]",
        "label": "Denmark Manufacturing Operations [Member]",
        "terseLabel": "Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DenmarkManufacturingOperationsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20200331",
     "xbrltype": "stringItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ElenbecestatCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Elenbecestat Collaboration [Member]",
        "label": "Elenbecestat Collaboration [Member]",
        "terseLabel": "Elenbecestat Collaboration"
       }
      }
     },
     "localname": "ElenbecestatCollaborationMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "label": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "terseLabel": "Fair value, in-process research and development, discount rate"
       }
      }
     },
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "label": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Amount, Shares Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementAmountSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "label": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Selection of Targets"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentSelectionofTargets",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "label": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "label": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares, Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "label": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares Purchased Per Share"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchasedPerShare",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In-licensed patents.",
        "label": "In Licensed Patents [Member]",
        "terseLabel": "Acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "InLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventoryrawmaterialssoldtoFUJIFILM": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory raw materials sold to FUJIFILM",
        "label": "Inventory raw materials sold to FUJIFILM",
        "terseLabel": "Inventory raw materials sold to FUJIFILM"
       }
      }
     },
     "localname": "InventoryrawmaterialssoldtoFUJIFILM",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "label": "Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "terseLabel": "Investments By Consolidated And Nonconsolidated Entities [Axis]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "label": "Investments By Consolidated And Nonconsolidated Entities [Domain]",
        "terseLabel": "Investments By Consolidated And Nonconsolidated Entities [Domain]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20200331",
     "xbrltype": "stringItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_March2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "March 2019 Share Repurchase Program [Member]",
        "label": "March 2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "March2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Noncontrolling interest, increase (decrease) other"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20200331",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Out-licensed patents"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PostacquisitionequitycompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Post-acquisition equity compensation [Member]",
        "label": "Post-acquisition equity compensation [Member]",
        "terseLabel": "Post-acquisition equity compensation"
       }
      }
     },
     "localname": "PostacquisitionequitycompensationMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential Future Milestone Payments Commitment To Third Party Approximately"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20200331",
     "xbrltype": "stringItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Approval Milestone [Member]",
        "label": "Regulatory Approval Milestone [Member]",
        "terseLabel": "Regulatory Approval Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryApprovalMilestoneMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement [Member]"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SkyhawkTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Skyhawk Therapeutics [Member]",
        "label": "Skyhawk Therapeutics [Member]",
        "terseLabel": "Skyhawk Therapeutics"
       }
      }
     },
     "localname": "SkyhawkTherapeuticsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN [Member]"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TecfideraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TecfideraMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20200331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r171",
      "r274",
      "r278",
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r169",
      "r274",
      "r276",
      "r466",
      "r467"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r170",
      "r274",
      "r277",
      "r468",
      "r479",
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r21",
      "r41",
      "r172",
      "r173",
      "r275"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r37",
      "r428",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r83",
      "r88",
      "r89",
      "r282",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r88",
      "r96",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r88",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r88",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r85",
      "r88",
      "r89",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r78",
      "r88",
      "r89",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r125",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r285",
      "r290",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r125",
      "r221",
      "r228"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r187",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r125",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r165",
      "r426",
      "r450"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r74"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r178",
      "r204"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable equity securities, fair value",
        "totalLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Marketable equity securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "totalLabel": "Marketable equity securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r182",
      "r185",
      "r445"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r182",
      "r184",
      "r444"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r175",
      "r179",
      "r204"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r177",
      "r204"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r177",
      "r204"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r286",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r367",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r326",
      "r327",
      "r330"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r326",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business Combination, Contingent Consideration, Liability, Measurement Input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r326",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r297",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Fair value of post-combination equity compensation"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r29",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r122",
      "r127",
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r122",
      "r405"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r67",
      "r249",
      "r438",
      "r458"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r92",
      "r94",
      "r95"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r342",
      "r343",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r341",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnauditedCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r344",
      "r358",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r437",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r280",
      "r283",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r33",
      "r35",
      "r36",
      "r427",
      "r429",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior Notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r65",
      "r132",
      "r262",
      "r265",
      "r266",
      "r267",
      "r409",
      "r410",
      "r412",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r130",
      "r310",
      "r313"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r298",
      "r307"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r296",
      "r308",
      "r309",
      "r332",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "terseLabel": "Deferred tax liabilities, goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r125",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r125",
      "r162"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairments"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r75",
      "r76",
      "r369",
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r75",
      "r76",
      "r369",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r368",
      "r370",
      "r377",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r366",
      "r368",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r374",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Gain (loss) on reclassification of cash flow hedges, effective portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r375",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r1",
      "r3",
      "r5",
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r15",
      "r299",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Tax expense on disposal group"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration expected to be received for sale of Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Expected costs to sell disposal group"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r125",
      "r235",
      "r240"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r135",
      "r415",
      "r435",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r135",
      "r415",
      "r436",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r101",
      "r139",
      "r142",
      "r144",
      "r145",
      "r146",
      "r149",
      "r441",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r101",
      "r139",
      "r142",
      "r144",
      "r145",
      "r146",
      "r149",
      "r441",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "negatedTerseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r134",
      "r300",
      "r301"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r300",
      "r301",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r300",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Denmark assets held for sale"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r300",
      "r301",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r300",
      "r301",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r300",
      "r301",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "verboseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r300",
      "r301",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r300",
      "r301",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r300",
      "r301",
      "r312"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r54",
      "r166",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "verboseLabel": "Less: Net gains (losses) recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized gains (losses) recognized during the period on equity securities held as of March 31"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r30",
      "r34",
      "r193",
      "r434",
      "r449",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r389",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r390",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r389",
      "r390",
      "r393",
      "r394",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging [Member]"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r390",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r390",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r390",
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r395",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "terseLabel": "Contingent consideration impairment",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments",
        "terseLabel": "Future payment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r367",
      "r372",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r222",
      "r224",
      "r227",
      "r231",
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r227",
      "r425"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r222",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r402",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r280",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r368",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r215",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r366",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r125",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r99",
      "r125",
      "r163",
      "r195",
      "r439",
      "r462"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss of investee, net of tax",
        "negatedTerseLabel": "Our share of Samsung Bioepis gains (losses)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "negatedLabel": "Loss on equity method investment",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
        "negatedTerseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r242",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r164",
      "r314"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "negatedTerseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "terseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Unrealized (gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r143",
      "r148"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r223",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r223",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r220",
      "r225"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r97",
      "r161",
      "r408",
      "r411",
      "r442"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r47",
      "r211"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r20",
      "r72",
      "r210"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r49",
      "r211"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r48",
      "r211"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r105",
      "r160"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r471",
      "r473",
      "r475",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r471",
      "r473",
      "r475",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r432",
      "r456"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r36",
      "r257",
      "r429",
      "r452"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r249",
      "r250",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Brazil tax assessment, including interest and penalties"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r251",
      "r253",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r71",
      "r431",
      "r455"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r122",
      "r123",
      "r126"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r90",
      "r93",
      "r100",
      "r126",
      "r148",
      "r440",
      "r463"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r93",
      "r346",
      "r356"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to noncontrolling interests, net of tax",
        "verboseLabel": "Net income (loss) attributable to noncontrolling interest, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r36",
      "r429",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Contractual commitments for the construction of the facility"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r80",
      "r81",
      "r86"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r88",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r77",
      "r407"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r91",
      "r94",
      "r96",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r91",
      "r94",
      "r341",
      "r342",
      "r348"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r84",
      "r86"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r367",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r62"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expenses and other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments for pre-combination equity compensation"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r112",
      "r116",
      "r136"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r109",
      "r113",
      "r176"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r114",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Total transaction value"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Contingent consideration paid related to Fumapharm AG acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net distribution to noncontrolling interest",
        "terseLabel": "Payments to Noncontrolling Interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r117",
      "r119",
      "r136"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r109",
      "r110",
      "r176"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r111",
      "r176"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r90",
      "r93",
      "r121",
      "r165",
      "r168",
      "r341",
      "r345",
      "r347",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r55",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r31",
      "r32",
      "r239",
      "r457"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r38",
      "r430",
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Future minimum batch production for Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "negatedTerseLabel": "Gain (loss) on investments, net",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r88",
      "r89",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r295",
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r125",
      "r246",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r268",
      "r454"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenues related to amendment of contract manufacturing agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r98",
      "r158",
      "r159",
      "r167"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "negatedTerseLabel": "Product revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r183",
      "r186",
      "r188",
      "r189",
      "r190",
      "r192",
      "r443",
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r368",
      "r377",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r285",
      "r289",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r285",
      "r289",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r222",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r28",
      "r50",
      "r51",
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r56",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r68",
      "r131",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r104",
      "r209"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in fair value from changes in the inputs, assumptions, or model used to calculate the fair value of the contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.",
        "label": "Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions",
        "terseLabel": "Fair value measurements, changes in valuation inputs"
       }
      }
     },
     "localname": "ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r284",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "negatedPeriodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r70",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r261",
      "r268",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r40",
      "r261",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r261",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r39",
      "r40",
      "r261",
      "r268",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r39",
      "r40",
      "r261",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r44",
      "r45",
      "r174"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r339",
      "r340",
      "r355"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Adoption of new accounting guidance"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes": {
     "auth_ref": [
      "r472",
      "r474",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of investments for Federal income tax purposes.",
        "label": "Tax Basis of Investments, Cost for Income Tax Purposes",
        "terseLabel": "Tax Basis of Investments, Cost for Income Tax Purposes"
       }
      }
     },
     "localname": "TaxBasisOfInvestmentsCostForIncomeTaxPurposes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r69",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r40",
      "r261",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r40",
      "r261",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r69",
      "r270",
      "r271"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r261",
      "r268",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r280",
      "r433",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r140",
      "r146"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3444-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9972-128506"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9979-128506"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b),(c),(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(8)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(11)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(7)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r484": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r485": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r486": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r487": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919149488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(44.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>376.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(18.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(120.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>357.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$77.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$376.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our holdings in equity and debt securities in the prior year comparative period. The net losses recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects a decrease in the fair value in our investment in Ionis common stock from December 31, 2019. The following table summarizes our gain (loss) on investments, net, that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(60.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>375.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of March 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(60.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>376.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,046.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>309.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>209.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>154.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>147.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>148.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>78.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>662.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>726.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,437.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,765.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,357.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,348.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$801.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$803.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6911751760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS  and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Internal Use Software</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an insignificant amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>biib-2020331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20200331"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20200331.xsd" xlink:type="simple"/>
    <context id="FD2020Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2020Q2Apr22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Denmark">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q2Apr01-Apr22_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_ElenbecestatCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ElenbecestatCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BAN2401Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BAN2401Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="Assets">
        <measure>biib:Assets</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2019Q1QTD"
      id="Fact-BE759A00528103D38E8EA3ABC08EA095-wk-Fact-BE759A00528103D38E8EA3ABC08EA095">P14M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2020Q1YTD"
      id="Fact-A4DAB426EB5BC684746BA46510DA16B1-wk-Fact-A4DAB426EB5BC684746BA46510DA16B1">P14M</biib:AverageMaturityOfMarketableSecurities>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      id="Fact-41049643AD145AA2B130F660E7E8AFB7-wk-Fact-41049643AD145AA2B130F660E7E8AFB7">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2020Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact-09D506618FE158B397A0EA490C63676F-wk-Fact-09D506618FE158B397A0EA490C63676F">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2019Q4"
      decimals="-5"
      id="Fact-E94D0F643D4B35A2A419A4B45339591B-wk-Fact-E94D0F643D4B35A2A419A4B45339591B"
      unitRef="usd">22700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <dei:AmendmentFlag
      contextRef="FD2020Q1YTD"
      id="Fact-A1A0BFFA652F52B587CE616D155B3700-wk-Fact-A1A0BFFA652F52B587CE616D155B3700">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q1YTD"
      id="Fact-CFE018B378775665BEB08C43355A63AB-wk-Fact-CFE018B378775665BEB08C43355A63AB">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q1YTD"
      id="Fact-822FFD30C861526795CB236918C386FE-wk-Fact-822FFD30C861526795CB236918C386FE">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q1YTD"
      id="Fact-F801D1819F5F5765AD557D4F1A16824B-wk-Fact-F801D1819F5F5765AD557D4F1A16824B">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q1YTD"
      id="Fact-37B8E2145E095B2FB63A8DEB5D5D10FA-wk-Fact-37B8E2145E095B2FB63A8DEB5D5D10FA">0000875045</dei:EntityCentralIndexKey>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact-3322F41DD23BDAF92DBCA39B1471C117-wk-Fact-3322F41DD23BDAF92DBCA39B1471C117"
      unitRef="number">0.0253</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact-07DA040BBC29BA113CA4A39B1440FAE4-wk-Fact-07DA040BBC29BA113CA4A39B1440FAE4"
      unitRef="number">0.0240</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-2A00764DBC255448B6EC02B74F49766E-wk-Fact-2A00764DBC255448B6EC02B74F49766E"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-A2E30888404D5EE291F13A55081AC892-wk-Fact-A2E30888404D5EE291F13A55081AC892"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="INF"
      id="Fact-89FE8A77B0C45D3A82F6A29F2BCF8000-wk-Fact-89FE8A77B0C45D3A82F6A29F2BCF8000"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="INF"
      id="Fact-79B99F6CA97851EEB776C8B0C323E15D-wk-Fact-79B99F6CA97851EEB776C8B0C323E15D"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="INF"
      id="Fact-2F7550805D4E537BB3D7C2322A9346A8-wk-Fact-2F7550805D4E537BB3D7C2322A9346A8"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-1D5B786D125A550C85CAA46161AC5616-wk-Fact-1D5B786D125A550C85CAA46161AC5616">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-35B1996F33518339B93AA4619962ACC3-wk-Fact-35B1996F33518339B93AA4619962ACC3">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2020Q1YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      id="Fact-68DF96FB57403675193AA463CCB0D163-wk-Fact-68DF96FB57403675193AA463CCB0D163">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-DD51B44FDE25AF1AAF3FA3BC205F5969-wk-Fact-DD51B44FDE25AF1AAF3FA3BC205F5969">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-01FFE3B9DC0CC3E5A62EA3BBD3B0A8FB-wk-Fact-01FFE3B9DC0CC3E5A62EA3BBD3B0A8FB">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeTermOfContract
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      id="Fact-16B8F578928FEAE57CF5A45FC177D90E-wk-Fact-16B8F578928FEAE57CF5A45FC177D90E">P7M</us-gaap:DerivativeTermOfContract>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-DB5B126C5A7F5C7A9460614F2442F50C-wk-Fact-DB5B126C5A7F5C7A9460614F2442F50C">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-985702C93F345A6FB6E1C856D8801B81-wk-Fact-985702C93F345A6FB6E1C856D8801B81">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-45DFFED86819525799E7E23409C446F5-wk-Fact-45DFFED86819525799E7E23409C446F5">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-528507DB169757AC8D6CCA2B62D18710-wk-Fact-528507DB169757AC8D6CCA2B62D18710">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-C846ED53A3DA5659BC29AE7F983F2E31-wk-Fact-C846ED53A3DA5659BC29AE7F983F2E31">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-B4C5093E7C8D58E6993148995BA4CC90-wk-Fact-B4C5093E7C8D58E6993148995BA4CC90">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q1QTD"
      decimals="INF"
      id="Fact-591E504BD5C0CABE5FF9A38C98689EC6-wk-Fact-591E504BD5C0CABE5FF9A38C98689EC6"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="Fact-6B7C2B625E7FBB6B070AA38B8C1BE03A-wk-Fact-6B7C2B625E7FBB6B070AA38B8C1BE03A"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-25CF6E03ED7958D8AD16550E92781BC4-wk-Fact-25CF6E03ED7958D8AD16550E92781BC4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-DE092FFE73005195B4D6CE55AF4CDD8E-wk-Fact-DE092FFE73005195B4D6CE55AF4CDD8E"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <dei:DocumentType
      contextRef="FD2020Q1YTD"
      id="d6284084e774-wk-Fact-9E1C63B980225665AFD76E8A6D49F549">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q1YTD"
      id="d6284084e792-wk-Fact-2996D1F5C4B35B5DA7165B50326C8FA5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q1YTD"
      id="d6284084e802-wk-Fact-4BAD8D88AC545954A0C837AEEE25E1B3">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q1YTD"
      id="d6284084e822-wk-Fact-F4BE16E5AE8F53199B9FB1B8FBD67530">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q1YTD"
      id="d6284084e832-wk-Fact-C258B18EFF57556A8DE152F81374FD49">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q1YTD"
      id="d6284084e841-wk-Fact-4C9803C4D09A57B38927419263380380">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q1YTD"
      id="d6284084e863-wk-Fact-195AA48F721D5AE9844F5373280656B5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q1YTD"
      id="d6284084e873-wk-Fact-0C1EAD5584C5529C87E4556BBAE26CC9">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q1YTD"
      id="d6284084e898-wk-Fact-75BB9BE0CBAF5EF59458C603560AC852">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q1YTD"
      id="d6284084e903-wk-Fact-AB610A1554DB59B8B681A03DFE4A23D0">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q1YTD"
      id="d6284084e908-wk-Fact-5DE227B3398F5394AC1AD75E9B38BCD4">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q1YTD"
      id="d6284084e913-wk-Fact-10DB515F7DA35D8D804BAC1E27806F98">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q1YTD"
      id="d6284084e921-wk-Fact-87238C90C6E451F48C76BDB9A3082B10">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q1YTD"
      id="d6284084e926-wk-Fact-A42B83D6F91C5B7E9E3098E576A9E3B5">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q1YTD"
      id="d6284084e987-wk-Fact-AAEA88AEE72A5FBB87EFE3DCB6DDEFD8">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q1YTD"
      id="d6284084e997-wk-Fact-66862D6F4C655DBCB93A2F3D9623ED73">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q1YTD"
      id="d6284084e1012-wk-Fact-3E64E99A15D05A7682D3F0D6840E81FF">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q1YTD"
      id="d6284084e1017-wk-Fact-BB2C9FC847655F1384508B285EB0BF59">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q1YTD"
      id="d6284084e1035-wk-Fact-98C5B83D14715E4684BFF3A0C557FF85">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q1YTD"
      id="d6284084e1070-wk-Fact-17048B31DA565C79A1B708393154CDCD">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q1YTD"
      id="d6284084e1116-wk-Fact-94BDCEAA8D0454709624A539E9F7820D">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q1YTD"
      id="d6284084e1142-wk-Fact-51CF62786AD453089542092BD9875239">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q1YTD"
      id="d6284084e1152-wk-Fact-99E9A60F86325C82B3306B207984DCA5">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q2Apr22"
      decimals="INF"
      id="d6284084e1170-wk-Fact-BA1CC73B2B5651FDB561611DE3AE13F1"
      unitRef="shares">163187486</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d6288638e911-wk-Fact-6DD5F1948E5C5CCCAEDCAF91E2F6813B"
      unitRef="usd">2904600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d6288638e930-wk-Fact-7384EBD5465D5546AC62CCFE15F4F263"
      unitRef="usd">2680000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d6288638e945-wk-Fact-5C1B4A3E5E705C3DBAAB3B3D2CBBDB7F"
      unitRef="usd">520400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d6288638e964-wk-Fact-C51A11646BE4542D85918CCC5A2C7AE2"
      unitRef="usd">517400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d6288638e984-wk-Fact-49E487F43286591DAFFC57ED16F39618"
      unitRef="usd">109300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d6288638e1003-wk-Fact-8A0940D374CF51D083D84F7631628605"
      unitRef="usd">292400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1023-wk-Fact-67A79A4334385AEA9579EC0864CE619E"
      unitRef="usd">3534300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1042-wk-Fact-F59EB6B836105D99B02E696E73F0C35B"
      unitRef="usd">3489800000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1103-wk-Fact-77CE25C6A5955795B876F6097771B582"
      unitRef="usd">454300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1122-wk-Fact-A0684D74D79157138A5968FFB4727C64"
      unitRef="usd">602000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1142-wk-Fact-6A1B8246EDC45F38BE6FCC39833F957F"
      unitRef="usd">476300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1161-wk-Fact-A07D838079A3557BBD7BFBD318C414B8"
      unitRef="usd">563700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1181-wk-Fact-B1B1C54A525258B3815BE89318686BEC"
      unitRef="usd">570100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1200-wk-Fact-836757F917F65D499520B7D6AC8AE137"
      unitRef="usd">567700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1221-wk-Fact-13DF614395235DA29BFA4FB1CE46B0EA"
      unitRef="usd">71500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1240-wk-Fact-D01715617B805CDF8467FFF75B1E78EB"
      unitRef="usd">68200000</us-gaap:AmortizationOfIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1260-wk-Fact-C92342AD40AF5405B447A64BA994BED8"
      unitRef="usd">71800000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1279-wk-Fact-F9AA5718E5295572BF87104C4FE5C9D1"
      unitRef="usd">58100000</biib:Collaborationprofitlosssharing>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1299-wk-Fact-6BA6F831A1FE5DDCADE05EC186CA4462"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6288638e1318-wk-Fact-C5F084F1A6D853B18FB7DA17A7BFDDCC"
      unitRef="usd">115500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1338-wk-Fact-30C421DF9F73516DA7CC5CB1364D68F6"
      unitRef="usd">4600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1358-wk-Fact-C6C1AC30CB4E5EB1972C8B88035C202E"
      unitRef="usd">-11500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1378-wk-Fact-EBC927E55ECC5B908782BC0037BC0481"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1397-wk-Fact-DE085C0D0B2B5AE69525919F7BB21506"
      unitRef="usd">400000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1417-wk-Fact-225BCF3C3F255604B4154C5CB5F42644"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1436-wk-Fact-EB31B50657855EA88ACF984F577F9CD0"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1456-wk-Fact-AA0E84E467C75D2BB452C1CF861B9793"
      unitRef="usd">1714400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1475-wk-Fact-DDCA304686FA51309917955C5C74D208"
      unitRef="usd">1987100000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1495-wk-Fact-1242610DC3A558A6ADC5F3666973270E"
      unitRef="usd">1819900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1514-wk-Fact-7BB1936389A0598E8E9C4EFFC9B9713B"
      unitRef="usd">1502700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1534-wk-Fact-095EC1AAC9A25CD9B7B7A910B16D60A8"
      unitRef="usd">-120500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1554-wk-Fact-F27571BB0E665301A0F41E41FA9CBCC3"
      unitRef="usd">357300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1574-wk-Fact-CB357BE0FB8356AFB56C3F00FF9F30DE"
      unitRef="usd">1699400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1593-wk-Fact-CBF283110D6D550C8935AFA9D9953011"
      unitRef="usd">1860000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1613-wk-Fact-9156FD9A2D78535CA2B0C79FDFD99BF0"
      unitRef="usd">292000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1632-wk-Fact-CBB36E1C1C7558A8A96C566D9177B34B"
      unitRef="usd">422500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1653-wk-Fact-860174F550AC598398F8F8B8BF2CF6C4"
      unitRef="usd">-14800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1672-wk-Fact-7B423D07C24357D7A0FDE253FD8563E4"
      unitRef="usd">-28700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1692-wk-Fact-4199EDD4FFD756B7B0FD3FA1BB63DAF0"
      unitRef="usd">1392600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1711-wk-Fact-DF052A332F6F579395B041A3F28BDF67"
      unitRef="usd">1408800000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1731-wk-Fact-E8E6F2D8020956B982BCB7187DA957CD"
      unitRef="usd">-6500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1751-wk-Fact-D1AE363A3E745509A3A74EBE4BC60CCB"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e1776-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e1795-wk-Fact-FDA77C2428AF554989EED78CF2C2AEA1"
      unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d6288638e1897-wk-Fact-58BD9C385B6153B89B00E6CAB98D5048"
      unitRef="usdPerShare">8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d6288638e1916-wk-Fact-DA4914AC28BB5D54A6ED20A7C3B1AE1B"
      unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d6288638e1936-wk-Fact-109F49C09A985F67A8E373CDC627D891"
      unitRef="usdPerShare">8.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d6288638e1955-wk-Fact-A1A2EFBA9A5B5CA4AC66E81D00E64648"
      unitRef="usdPerShare">7.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e2052-wk-Fact-71CBFF9E20095155A1063474D4C8BA5A"
      unitRef="shares">172800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e2071-wk-Fact-8C58D4EB1D6251F29A5B7EBA8DD1F024"
      unitRef="shares">196600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6288638e2092-wk-Fact-413B006A143E53BD99DB85074CA369D8"
      unitRef="shares">173100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6288638e2111-wk-Fact-15574C2EB65A522E829F10B43239453D"
      unitRef="shares">197000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e870-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e889-wk-Fact-FDA77C2428AF554989EED78CF2C2AEA1"
      unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e945-wk-Fact-C0318CA1062A527494733AE65EABEEC6"
      unitRef="usd">-7800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e965-wk-Fact-05FB684B59A353DD936C266C7D4178DB"
      unitRef="usd">6900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e985-wk-Fact-AE62E9836A285C7FB3421ED220549164"
      unitRef="usd">33800000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1004-wk-Fact-256E0EC4BCA0541ABEC01249A13890C2"
      unitRef="usd">16900000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e1024-wk-Fact-756171E441B157A98467E768E66895AD"
      unitRef="usd">23000000.0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1043-wk-Fact-07AEC6DC97ED5FFB85FBD7ED4C2514C6"
      unitRef="usd">14000000.0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e1063-wk-Fact-DD04B0206F6D5FD1807678CE6EC2B85E"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1082-wk-Fact-5EF1AD86A1595801BD7A0AC7A2954BF5"
      unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e1102-wk-Fact-B5B3A2AAF22B535993E3DC4B8B5F75B9"
      unitRef="usd">-63900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1122-wk-Fact-82FA6F14E34B57E994F4988C13C3BD3D"
      unitRef="usd">-17800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e1143-wk-Fact-5B8C18C3243E5D5AAD152B2A77B3C58D"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1163-wk-Fact-49C6AFCCB21C5CB19609F8B635C4A0F1"
      unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e1183-wk-Fact-18A41409123F57F29261C2A4D5CDEBDE"
      unitRef="usd">1385000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1202-wk-Fact-B6FDD288DEB55FA09303CFE7BD51576C"
      unitRef="usd">1429400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e1223-wk-Fact-05117F37C5465704ACA5654B798AD022"
      unitRef="usd">-5900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1243-wk-Fact-D4601141F4D9577F985314E7032A8750"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6289510e1268-wk-Fact-5F0BB58B6B2A5B1585B32780C8DDC783"
      unitRef="usd">1379100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6289510e1287-wk-Fact-AA6713EA12EF5BB893E2E61BAA1152A8"
      unitRef="usd">1429400000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e912-wk-Fact-9E3BC132605A53179E58E06AE7023F80"
      unitRef="usd">2591300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e931-wk-Fact-B03EF7F09BF05D95ADF9E2B230C12C79"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e946-wk-Fact-AF04C9845A4550519959DBEFA976148F"
      unitRef="usd">1269100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e965-wk-Fact-904EBE773D4F5E6A9D60741F7D34BC96"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e985-wk-Fact-68C9E4E720B05E3BBDD4D71786DF4EE3"
      unitRef="usd">2092600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1004-wk-Fact-39E56DB8DE1C5CB0A6A73F0DF9F1D2EC"
      unitRef="usd">1880500000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1024-wk-Fact-15DAFABFE317534A9839B38088FE2D14"
      unitRef="usd">511600000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1043-wk-Fact-AEEEAA0C876C5A738E9FDA8B17CC717F"
      unitRef="usd">590200000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1063-wk-Fact-94DA70047DDC570698CB696B939357E0"
      unitRef="usd">858800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1082-wk-Fact-2FFAC78B3D545117B101AC318FE3ABBC"
      unitRef="usd">804200000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1102-wk-Fact-54AADF515E4B573589DDD09A74208296"
      unitRef="usd">683800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1121-wk-Fact-8A2B7D1849ED507F9AE8B6BF287456FF"
      unitRef="usd">631000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1141-wk-Fact-1004E716E9D75D9EB1BD7F8357BB005A"
      unitRef="usd">8007200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1160-wk-Fact-8AAAEB08C51B5C7C8E26895E6505B4C8"
      unitRef="usd">8381800000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1180-wk-Fact-9BD52EF2DF8157AA8CD120A9A1802965"
      unitRef="usd">969500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1199-wk-Fact-1A0C0F27D85653CC9255C3493714626B"
      unitRef="usd">1408100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1220-wk-Fact-96DE043D4B9B514EA70C9505E514959F"
      unitRef="usd">3281600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1239-wk-Fact-95207BB579915990922C304989290725"
      unitRef="usd">3247300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1259-wk-Fact-100DC9AF86FF5D3785AE526D70B873F8"
      unitRef="usd">422000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1278-wk-Fact-98FB78D2F30554F78D859647290D9B54"
      unitRef="usd">427000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1298-wk-Fact-AD1C5EB68CF65DC3984A7409445F526B"
      unitRef="usd">3446900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1317-wk-Fact-82009BD2AC26575E958204C37D75B0DB"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1337-wk-Fact-5680A01230085EC6BEF71F889D7F44A5"
      unitRef="usd">5752000000.0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1356-wk-Fact-A6A4D09C94CD5944861219FC074EF1A3"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1376-wk-Fact-FA37454DC6705F1089979A75ED1A521C"
      unitRef="usd">3109400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1395-wk-Fact-77D0B708F3B3538F8CD131B724CC0DAB"
      unitRef="usd">3232100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1415-wk-Fact-EB285A38F5215617B60EC7F386653555"
      unitRef="usd">1130600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1434-wk-Fact-268213F6648F53EB926A46CA8BC4F44C"
      unitRef="usd">1252800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1459-wk-Fact-0CDB39262C9B5C6F9B23777F80183E67"
      unitRef="usd">26119200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1478-wk-Fact-59CAF36B1A4E5EE9B24508364CA382D7"
      unitRef="usd">27234300000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1580-wk-Fact-76978170110C51738E6564D3F70B968C"
      unitRef="usd">1501800000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1599-wk-Fact-21866A1A55D658CD8EDB6BFC2EB0584D"
      unitRef="usd">1495800000</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1614-wk-Fact-CD29CDF186285D27B67954D956C7D4F5"
      unitRef="usd">310000000.0</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1633-wk-Fact-B6BE4939126F5963881E01F407642944"
      unitRef="usd">71400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1654-wk-Fact-A9FAC8D03FC0557AA677BAC810C75731"
      unitRef="usd">389000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1673-wk-Fact-439B48A6D7E8587688D30E92AC457B59"
      unitRef="usd">530800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1693-wk-Fact-2E91A66DD1E458A083A3758FECA481A5"
      unitRef="usd">2437800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1712-wk-Fact-97EC7EE1ECE85247B1145A8455CBCD68"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1732-wk-Fact-5584167DAA415C38BE453E0D918C4A9F"
      unitRef="usd">4638600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1751-wk-Fact-69EB85132FDA5106842CAFAC8A9E24CD"
      unitRef="usd">4863800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1771-wk-Fact-18ED34FA4C655E4D95680B3F591943BD"
      unitRef="usd">4459900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1790-wk-Fact-A88A8E8C7E785E2B91C1E4D980349CF9"
      unitRef="usd">4459000000.0</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1810-wk-Fact-E660E565045D5F2A860C5F2B73E4D6AB"
      unitRef="usd">2722800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1829-wk-Fact-19DC9D5C82515950976A3DC21EE25169"
      unitRef="usd">2810800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1849-wk-Fact-C65F20A72D7E55BEA521049A6BD49481"
      unitRef="usd">403700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1868-wk-Fact-77C6B9EC17E1512BABEBF711DECEDFC3"
      unitRef="usd">412700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1888-wk-Fact-3979DB5E0C6C5D6D9A9F95E7EF93829D"
      unitRef="usd">1357300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1907-wk-Fact-13BA7A88BF675D4EA00EE608833C04FB"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e1927-wk-Fact-76B4DA13D7C2517AA56CEDFB07492F26"
      unitRef="usd">13582300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e1946-wk-Fact-6F539162417750CBADCED7D22AEFFBFC"
      unitRef="usd">13895200000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2020Q1"
      id="d6288639e1966-wk-Fact-D58DF02739465DB6B3F3ECA7F584826F"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d6288639e1984-wk-Fact-165CC6763049575481A61D0D790A0AA4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2086-wk-Fact-FE15F450D01B55749D8B184CA4166526"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2105-wk-Fact-7FD388D112845ED6833D944D3B2C2D05"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2125-wk-Fact-40964C8781055C209A8BF33EE6F22CCF"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2144-wk-Fact-9B2727AE3D6B5CB0AD866F75EEC280CA"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2164-wk-Fact-D24EB0D8053150FEA91F0C9F6B25386F"
      unitRef="usd">100000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2183-wk-Fact-2E70DC0CCE94516E8F0CB96A845EF0DE"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2203-wk-Fact-9B13E96C51445E7A8D54697EFDAC6991"
      unitRef="usd">-149300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2223-wk-Fact-ACAB9874DC005EDD9E4AF5B9CE727C30"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2244-wk-Fact-2C28C111714552F4937B90697D166F4A"
      unitRef="usd">15673100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2263-wk-Fact-7DF1742CEA145CFB8417269D6AD0A7B7"
      unitRef="usd">16455400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2283-wk-Fact-1B3A1F61F6805787AC1A4C99EA9C90F6"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2303-wk-Fact-16E1C1AE476557F19818F5AA13097340"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2324-wk-Fact-A16AED5F52FF5C17821FB367F609D039"
      unitRef="usd">12546900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2343-wk-Fact-0DBEA1C192225E35B1FDAED1EDB23329"
      unitRef="usd">13343200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2363-wk-Fact-8D90401DF38E5BAC9A30B4E1FF1BF965"
      unitRef="usd">-10000000.0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2383-wk-Fact-B13DD615DE505FFFA130E62DD8FDE9A3"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2404-wk-Fact-29BE2ECE9A485DDBB6B3AE92B3B006E3"
      unitRef="usd">12536900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2423-wk-Fact-0E2A62FA2C405909B2F8AD85E16A99BB"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6288639e2448-wk-Fact-8C00695905B85DFA9738C8F829563A57"
      unitRef="usd">26119200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6288639e2467-wk-Fact-7565973E1C995CE295AA15C1C55E7247"
      unitRef="usd">27234300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e911-wk-Fact-4199EDD4FFD756B7B0FD3FA1BB63DAF0"
      unitRef="usd">1392600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e930-wk-Fact-DF052A332F6F579395B041A3F28BDF67"
      unitRef="usd">1408800000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e986-wk-Fact-810637FABA705C0AA1193AA26FE78221"
      unitRef="usd">119900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1005-wk-Fact-D32407AA7A565E3E8B8A09C8FC9DC906"
      unitRef="usd">121100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1025-wk-Fact-225BCF3C3F255604B4154C5CB5F42644"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1044-wk-Fact-EB31B50657855EA88ACF984F577F9CD0"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1064-wk-Fact-A9D71A8C343D508ABF40849B8FC99672"
      unitRef="usd">67700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1083-wk-Fact-4A9D618F43F65E77823D22E7C0C3CE92"
      unitRef="usd">45700000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1103-wk-Fact-30C421DF9F73516DA7CC5CB1364D68F6"
      unitRef="usd">4600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1123-wk-Fact-C6C1AC30CB4E5EB1972C8B88035C202E"
      unitRef="usd">-11500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1143-wk-Fact-23C45A092B7D545BB21C5D11F38E5FA7"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1162-wk-Fact-0E4E0BA32F745EDD9B63D72ED9EAB841"
      unitRef="usd">-115500000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1182-wk-Fact-4F887C6F9AB85667B72559C183EAC8AC"
      unitRef="usd">36900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1201-wk-Fact-780860699B5E5CE8ACAA726A93456289"
      unitRef="usd">228000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1222-wk-Fact-778B6325242B5F9C92E3E9A0201967BA"
      unitRef="usd">-62000000.0</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1241-wk-Fact-11E7182A5591570DB9FE2BE68B2B67C2"
      unitRef="usd">375000000.0</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1262-wk-Fact-A43B37833ACA52C2A9D06A7ADE26ED13"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1281-wk-Fact-FC17FB12F1A35F799FC5AD4283937565"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1301-wk-Fact-B8192F9CC03655CA940C4AB592450A71"
      unitRef="usd">-45700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1320-wk-Fact-A3490EB2CFBC56F69DA80EB1F931407B"
      unitRef="usd">-50700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1381-wk-Fact-4D8532C3BED250959E6EA69BBE21B642"
      unitRef="usd">238400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1401-wk-Fact-D224FA708E025959837C2A58669281F4"
      unitRef="usd">136600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1422-wk-Fact-8959F674F3E57403914FA3505E5EB778"
      unitRef="usd">-78600000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1441-wk-Fact-8AD8D46D92201C093B56A3505E8E8085"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1461-wk-Fact-2E1022760CEC58C49172AF436571DFF6"
      unitRef="usd">62200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1481-wk-Fact-FD2068B5B4975A3E90C297D1BF6AB085"
      unitRef="usd">-129000000.0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1501-wk-Fact-143B780CBA7F5955AEC0E33BD498F7A2"
      unitRef="usd">-347400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1521-wk-Fact-9F1BAAC57D3B52A1BE348B6C35CEAD27"
      unitRef="usd">-138400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1542-wk-Fact-3D06773286005FECB87A0243AE6D42FD"
      unitRef="usd">223000000.0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1561-wk-Fact-FD9C9D593E9D5551B9B5BEF6AB135E59"
      unitRef="usd">170300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1581-wk-Fact-13F6EA0871C95D3D9AE8306196A4A32B"
      unitRef="usd">-18500000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1600-wk-Fact-20BDF30FF61B58E9998A410EEE744FEF"
      unitRef="usd">171100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1621-wk-Fact-A53253F8727458F9B277284D06ED8BCA"
      unitRef="usd">1467300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1640-wk-Fact-588C12CBFDCB573DB60B84CAD01D910D"
      unitRef="usd">1459500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1702-wk-Fact-B2C977AFB43A5B6D846E35244FB2DF92"
      unitRef="usd">2389300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1721-wk-Fact-A4A4FD4E66E65DF4BA4CD8A5C026A640"
      unitRef="usd">1489200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1741-wk-Fact-A6B124D432DA55C6B70465A17E221C0C"
      unitRef="usd">1684700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1761-wk-Fact-AE8E6E95D552529C9FFF0BE1159247E5"
      unitRef="usd">825000000.0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1782-wk-Fact-F1063F33E51B5CABB59A12D35EA607C2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1801-wk-Fact-FD363536D83C54FDBA14F57929F3DC4B"
      unitRef="usd">300000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1822-wk-Fact-7D32BE90701854CF8F7EB3CB769666B8"
      unitRef="usd">149700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1842-wk-Fact-73A133B00F47554F860060B3CEDF2157"
      unitRef="usd">127100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1863-wk-Fact-E5028E61DD15548A916018DD40E9F4C1"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1883-wk-Fact-F276101F49755EA3B935ED9B99354D9D"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1903-wk-Fact-12DD9035274258208EBDD6A25E5EE0BB"
      unitRef="usd">37000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1923-wk-Fact-D230F0689E6A5546A81B729D2D656A0B"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1943-wk-Fact-6825DADBC91F5C88A7DD8929D52D98B5"
      unitRef="usd">500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e1962-wk-Fact-ED15A26ED140519F9B607D6607E78077"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e1982-wk-Fact-FAF1E4FE04605BA389139DAE95C7286B"
      unitRef="usd">500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2002-wk-Fact-72D72D3CA77B51CB876492350762DCC2"
      unitRef="usd">-1700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e2022-wk-Fact-C5D4A5E6A59A5B53A681521C40913824"
      unitRef="usd">442900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2041-wk-Fact-73E27DAF8E70566382BB464AE27E8BF0"
      unitRef="usd">238800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e2103-wk-Fact-F45CEAC8FC665627991A58E5F2588D73"
      unitRef="usd">2220200000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2123-wk-Fact-F5F9549A6A5150D8967280D473756047"
      unitRef="usd">655800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e2144-wk-Fact-67A8DA12505C53739505B2978A1CEA4A"
      unitRef="usd">29600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2164-wk-Fact-14EA6E04E84D5E8D89318E7128184B83"
      unitRef="usd">32200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e2185-wk-Fact-D93CC2B160875147ACC0105935028876"
      unitRef="usd">4500000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2204-wk-Fact-5AADD14A68625D21B42DDE7F5C8A063E"
      unitRef="usd">8700000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e2224-wk-Fact-B5B585A539CE525696198FCB93D6C26D"
      unitRef="usd">-2245300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2244-wk-Fact-2C6C6345E35E5BB6BADBC1B200E9AF61"
      unitRef="usd">-679300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e2265-wk-Fact-A1B7B85971F75F0B9C5EFFBFF870CC75"
      unitRef="usd">-335100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2285-wk-Fact-D5BE7268B09853D39FEEEE36D70F7905"
      unitRef="usd">1019000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6291576e2305-wk-Fact-7EBE2B568ADC5697BF3724791F4A54CF"
      unitRef="usd">12700000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6291576e2324-wk-Fact-C6CF844D24305DD7814C9AAA77B739E3"
      unitRef="usd">-400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6291576e2345-wk-Fact-B03EF7F09BF05D95ADF9E2B230C12C79"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-5"
      id="d6291576e2364-wk-Fact-96E609DCAE575BEFA8157EB7A5A6C744"
      unitRef="usd">1224600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6291576e2389-wk-Fact-9E3BC132605A53179E58E06AE7023F80"
      unitRef="usd">2591300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q1"
      decimals="-5"
      id="d6291576e2408-wk-Fact-D28BE5C30EEB5EB2A83EE108E8063739"
      unitRef="usd">2243200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e1314-wk-Fact-147D51E29DA753038FF6B72AC4EB69A5"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e1333-wk-Fact-29AFCC29691855678DD9C4AFA016A174"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e1347-wk-Fact-E00670A64B1E52D8A1E9609F6015AADB"
      unitRef="shares">198000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e1367-wk-Fact-BDE06542D6775EFDB0D5CB202E7A3BE9"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e1386-wk-Fact-FE98E1AB4E81571589665487BF5DB7DE"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6298639e1405-wk-Fact-0D1360EE860F5D16BDFBB26C49D9266B"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e1426-wk-Fact-A2BF105A88AB5C5989C651C2943E1C17"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e1440-wk-Fact-422B65741C0D535F997EBFC221545C6E"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e1460-wk-Fact-498CB27721CB574CB17A0E08ADD2A4B3"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6298639e1481-wk-Fact-0DBEA1C192225E35B1FDAED1EDB23329"
      unitRef="usd">13343200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e1500-wk-Fact-A9BCFDE518FE5CD0A2316970AC4D77BE"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6298639e1520-wk-Fact-0E2A62FA2C405909B2F8AD85E16A99BB"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e1642-wk-Fact-5B8ED4DAAEED5AF880893716931AA3C6"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e1695-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e1714-wk-Fact-EDD74A72062656D18F621B6FEA712DF3"
      unitRef="usd">-6500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e1734-wk-Fact-4199EDD4FFD756B7B0FD3FA1BB63DAF0"
      unitRef="usd">1392600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6298639e1841-wk-Fact-5244F9E418825CB7A899B22D502E6D7A"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e1915-wk-Fact-5B8C18C3243E5D5AAD152B2A77B3C58D"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e1935-wk-Fact-DCAD131E5D83508B8A391B19C9A9E895"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e1954-wk-Fact-8E4E2B856AF889A5D5EFA355A5AA2449"
      unitRef="usd">-13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2103-wk-Fact-A3719D729132566CA1CC689921AB3638"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2118-wk-Fact-61CDA54B15FE5E3180B3AC6D3628CC0D"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2139-wk-Fact-CE7CBD4F54285B4A0872A355A5B58D4D"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2178-wk-Fact-CE7CBD4F54285B4A0872A355A5B58D4D"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e2233-wk-Fact-3F31435C3175584ABB84D90E7EEA56E8"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e2249-wk-Fact-9348561A23F551F7AACE03D5AAF507C1"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e2268-wk-Fact-3A21B5C121435E7EB52DFFBDFC97BBA8"
      unitRef="usd">71000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e2308-wk-Fact-7B8E26C38DD65FD794DF1D3C11B34665"
      unitRef="usd">1208100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2328-wk-Fact-D00C46586D45551AB70A90871AF32DA8"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2342-wk-Fact-864CA399D43E5EC09A230DE193FF5051"
      unitRef="usd">-1279100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2362-wk-Fact-AFC2B8379AEFAC85B66CA355A5C75440"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2400-wk-Fact-AFC2B8379AEFAC85B66CA355A5C75440"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2546-wk-Fact-7DC56ACC84EF5C1408CFA354946A716E"
      unitRef="shares">3200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2561-wk-Fact-287F5A082C7BD4A8C027A354E1E43D36"
      unitRef="usd">941100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2582-wk-Fact-A2B3291640081C21DAFBA355656139BB"
      unitRef="usd">941100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2621-wk-Fact-A2B3291640081C21DAFBA355656139BB"
      unitRef="usd">941100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e2676-wk-Fact-8EA0CCDD4EA8230782D1A35654C689DE"
      unitRef="shares">3200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e2692-wk-Fact-7E32FC748CFBFE9D7134A3639538838F"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e2711-wk-Fact-7CE8AD1729C24BD461A9A356BF963747"
      unitRef="usd">15600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e2751-wk-Fact-DEF036E534B263DE9126A35F8BAB5F2F"
      unitRef="usd">925500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2771-wk-Fact-E424172CA32D0445D6E9A35F8E6BB903"
      unitRef="shares">3200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e2785-wk-Fact-FBC23C36B89210D63908A35F90CE685D"
      unitRef="usd">-941100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2805-wk-Fact-0CCE965FD720384BCB42A363A9952452"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e2843-wk-Fact-0CCE965FD720384BCB42A363A9952452"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e2897-wk-Fact-23BF7BB1E339507DA196D751FC0EFC5E"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e2912-wk-Fact-A232D6172B275666AF95342412325E69"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e2931-wk-Fact-59E26BA2405652849505221F7A5036F8"
      unitRef="usd">18100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3023-wk-Fact-137A0E62BD03FAC1BE43A355A69409BA"
      unitRef="usd">18100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3061-wk-Fact-137A0E62BD03FAC1BE43A355A69409BA"
      unitRef="usd">18100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e3115-wk-Fact-23ABA915D9DB527BB9137164AB27A56E"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e3130-wk-Fact-410ECEA64372564A864B93943F91C3C0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e3149-wk-Fact-C2BA427AFB3D522996E53FD5AAD1A9DA"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e3188-wk-Fact-9E88C70662925EA8935C8F1B40F3C5CB"
      unitRef="usd">47800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3242-wk-Fact-F43E86761D81B5E17712A355A683DFD0"
      unitRef="usd">-47800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3281-wk-Fact-F43E86761D81B5E17712A355A683DFD0"
      unitRef="usd">-47800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e3371-wk-Fact-EB5F804D75B75A22B90F15586A13E3E7"
      unitRef="usd">-69200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3463-wk-Fact-7FE76D3B3E4319519D03A355A5BB18C7"
      unitRef="usd">-69200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3501-wk-Fact-7FE76D3B3E4319519D03A355A5BB18C7"
      unitRef="usd">-69200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e3589-wk-Fact-83BB0DBE0E2B55461528A360320773D5"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3682-wk-Fact-7D4728E5E93A1AC78ED6A3609963B7DD"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6298639e3721-wk-Fact-7D4728E5E93A1AC78ED6A3609963B7DD"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e3743-wk-Fact-41399AB25B065C7C8FE2D69F215307D4"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e3762-wk-Fact-22A19A6BAB0C557BB615DFB533100589"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e3775-wk-Fact-9DA5E9DEE64751DCA6F8AF793669FC3A"
      unitRef="shares">191100000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e3794-wk-Fact-7341D4EC40CA561EAA15BBA734F0D083"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e3812-wk-Fact-AA8AFDDD082851ABAB69E9AF9B924AAD"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6298639e3830-wk-Fact-48AEBC0042B15A5D99D2E7582DEC9CF9"
      unitRef="usd">-149300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e3850-wk-Fact-A8C4C108D3E65F93B318E87C6911D590"
      unitRef="usd">15673100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e3863-wk-Fact-188702686C1B5E2E88F0B60C682536D2"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e3882-wk-Fact-8AEE1CBF18B55881AF1FFC4EAFD3F397"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6298639e3902-wk-Fact-A16AED5F52FF5C17821FB367F609D039"
      unitRef="usd">12546900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e3920-wk-Fact-44EB24242A3F57CFA1C0ECC9172A9017"
      unitRef="usd">-10000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6298639e3939-wk-Fact-29BE2ECE9A485DDBB6B3AE92B3B006E3"
      unitRef="usd">12536900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e4541-wk-Fact-D365F775A0F9555188D9BFD5A4CFB376"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e4560-wk-Fact-62951BA4915C56AC803CEAEA8922ADE2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e4574-wk-Fact-C8C13C9944255A57817D2EB87EE687DD"
      unitRef="shares">221000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e4594-wk-Fact-506A842079665D9E8E6A18F3E42CBD27"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e4613-wk-Fact-4ACDA1EB70C05910A151B787E955F94B"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6298639e4632-wk-Fact-E10F4EA3D4205F73B61EE49DC60B45F6"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e4653-wk-Fact-E44B4063B0F05F82835F61CE0AC0A9AA"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e4667-wk-Fact-07B9EF830EEF519CB546B849C54BFB46"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e4687-wk-Fact-6776CCF1E8BF59DFAEA9443F9FEE7380"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e4708-wk-Fact-41E5280F7C7157F59173D118B8028BE5"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e4727-wk-Fact-2B44137F3C435981A93F9D0A63E7EEA8"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d6298639e4747-wk-Fact-F42112474AA0504EA70566E6AE468C99"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e4869-wk-Fact-3A3DD757C2DC5B498B6F08B9EB2C48A2"
      unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e4922-wk-Fact-76A5ED2F7C04844A6DCEA35593BAC488"
      unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e4941-wk-Fact-DCD2FCAD6DAA57D39C1D82BEEAC5B5AE"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6298639e4960-wk-Fact-DF052A332F6F579395B041A3F28BDF67"
      unitRef="usd">1408800000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6298639e5067-wk-Fact-F3FD0686FCCB524EB94E371B43673704"
      unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e5140-wk-Fact-D96ED917EADB0C08F616A355924A4865"
      unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e5159-wk-Fact-BD62C37EC73B507FAE1CE6D9F591039F"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6298639e5178-wk-Fact-F19F2DEE77D456948CD78605F057955D"
      unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e5358-wk-Fact-359F3B95456B1CAD1EC7A355933750DA"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e5377-wk-Fact-42CB3BCC47E25D739888F1D6AE03A94B"
      unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6298639e5396-wk-Fact-E692CE74E306582C8D22225118E54A46"
      unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e5542-wk-Fact-C3D02352D0C379F678B2A36CD04F1883"
      unitRef="shares">2400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e5557-wk-Fact-FEB25B0F3A83886C809EA36CD3803E5E"
      unitRef="usd">655800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e5578-wk-Fact-9D5DF1D7D26DD5773130A36CD68BF078"
      unitRef="usd">655800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e5617-wk-Fact-45B68F44868F2A40BCEEA36CD9A99305"
      unitRef="usd">655800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e5672-wk-Fact-2081DA4ABD815B734B3FA36D3675B012"
      unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e5688-wk-Fact-C405B30BC513ED998B4FA36D3935FA46"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e5707-wk-Fact-346194DBE4E76D72C1B4A36D3C248D48"
      unitRef="usd">65600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e5747-wk-Fact-645119D130B664D7629BA36D3F60B691"
      unitRef="usd">590200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e5767-wk-Fact-3AED67959A01286AFF56A36D43CE9A1B"
      unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e5781-wk-Fact-5C06B85EB22AF76688E3A36D46B8F5B4"
      unitRef="usd">655800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e5801-wk-Fact-75C1B43FEFDED055FCB6A36D48FAA5E3"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6298639e5839-wk-Fact-42028526182084CBFC1AA36D4BEBD02E"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e5893-wk-Fact-6CF4159D0480561090AF1CE0D6C5C26D"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e5908-wk-Fact-96884FC8CC6D5CB0902ED9E864962EC3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e5927-wk-Fact-0BC22EE0C6905205AE5D0BB9F20BA5A4"
      unitRef="usd">16600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e6019-wk-Fact-1F6955F949DF796BE26AA3559355F649"
      unitRef="usd">16600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6298639e6057-wk-Fact-402E3DFDA79E56C2A92B5DC83BF1BDEE"
      unitRef="usd">16600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e6111-wk-Fact-0A6174D2BDB25A4A86D849D555B82B00"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e6126-wk-Fact-F6C41E3757A05B75A7E57623FD9D6BFD"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e6145-wk-Fact-B0CC17BA7E3A5316A9E5D0FB539772BE"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e6184-wk-Fact-E1F33DABF1EE365048C8A36E740951F7"
      unitRef="usd">-48900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e6238-wk-Fact-9494D6B85F263D2FDEAAA355926D7B86"
      unitRef="usd">-48900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6298639e6277-wk-Fact-8D567C16DD5E5707A8DF73CCB01C0000"
      unitRef="usd">48900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e6366-wk-Fact-D487A9F89FB250C6B54C78C067354168"
      unitRef="usd">49000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e6405-wk-Fact-6753DC8516495FF5A875856187EEFD8A"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e6458-wk-Fact-25D6A85FF2F67E9FAC74A35592D48FA6"
      unitRef="usd">49000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6298639e6496-wk-Fact-67584C28BBC75E06979F6E115920FF33"
      unitRef="usd">49000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e6518-wk-Fact-92A30762EE2E5FEA86AF29464F78564A"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d6298639e6537-wk-Fact-44102CF37349559EBA9B6CD424EE681B"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e6551-wk-Fact-20B53D15949B5199A585679875FF6C23"
      unitRef="shares">219000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d6298639e6571-wk-Fact-FFE85BFCBB7D58249A7469B5C52AFBA5"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d6298639e6590-wk-Fact-4B4EF0655A1E5C5897A3B89FBD69A977"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6298639e6609-wk-Fact-16EF8724AFCA56CD9E55FE439CAD781E"
      unitRef="usd">-219800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d6298639e6630-wk-Fact-9181FCE451A3522EA5EA972E68F55AFC"
      unitRef="usd">17026700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e6644-wk-Fact-87512526BDA4548D922D944E99515447"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d6298639e6664-wk-Fact-4D64B30365CD59488FE40F95952E03A3"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6298639e6685-wk-Fact-F01B1006CAD5535DAAF5BEF311185D7A"
      unitRef="usd">13829900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d6298639e6704-wk-Fact-C56083C8572E5E8E89ADF1D916465226"
      unitRef="usd">-7900000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1"
      decimals="-5"
      id="d6298639e6724-wk-Fact-F28D7B612D4F5044997580E79AE60519"
      unitRef="usd">13822000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-E5AE4492987C5BE883DDF00F2391C2EE-0-wk-Fact-6A013FE9853758E5803FC7E90672D920">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS  and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &#x201c;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x201d; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Internal Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an insignificant amount of additional assets being recorded on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-E4522282AAFD5C7E9C31849C46672299-0-wk-Fact-C9F12BD49E795FF9A155D6B1DA896928">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS  and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-4D7AB7C514B55033B0F8247E754C873A-0-wk-Fact-71481388443358E6B297FEC0E40A4940">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &#x201c;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x201d; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d6298862e855-wk-Fact-35BAF8F08B5F5BAA98689CDEF69C6A39"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-290600B0FA2259E5A6C77DDF15CC691A-0-wk-Fact-1D13E11943BE57F582EBC608080A6EEE">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d6298862e879-wk-Fact-1B2B6F8E7CA558E09D5D18E3503F6B76"
      unitRef="number">1</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="FD2020Q1YTD"
      id="TextSelection-2D56022413645E06AE8D55F9F87ED1EA-0-wk-Fact-4022A979D0E95B32A3E9B0E8E2646BD1">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-BB08D144B88E5973AC76A5570F178B26-0-wk-Fact-A5375EC6CF205CAEADBBE3C1FBCDA23C">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Internal Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an insignificant amount of additional assets being recorded on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-6B78267481905C27B5B75BEF4B35FEB8-0-wk-Fact-F7737A1D66BC57B9899A0FBF5C2697BD">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB118 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In particular, we plan to develop the Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#x2019;s disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this acquisition, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$635.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquisition of Nightstar Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of this acquisition, we paid NST shareholders &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$25.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for each issued and outstanding NST share, which totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$847.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$26.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$18.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recognized as a charge to selling, general and administrative expense with the remaining &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We finalized purchase accounting for this acquisition in the fourth quarter of 2019. The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(81.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of the IPR&amp;amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$480.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have recorded an additional IPR&amp;amp;D asset related to BIIB112 of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$220.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;amp;D intangible assets, which have &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member"
      decimals="-5"
      id="d6299201e768-wk-Fact-3FC90659224C2907DBDBA37249E560ED"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member"
      decimals="-5"
      id="d6299201e772-wk-Fact-99ACD7918EBAA0EA257EA78D7EC455C1"
      unitRef="usd">635000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:ClinicalAssetsAcquired
      contextRef="D2019Q2"
      decimals="INF"
      id="d6299201e782-wk-Fact-660E10114389D03DEE5CA830D727C7EB"
      unitRef="Assets">2</biib:ClinicalAssetsAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="2"
      id="d6299201e789-wk-Fact-97193A4702D85FCFBF4C2110AEA42926"
      unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e793-wk-Fact-259D7FF271B4575BA9920CE2620D1780"
      unitRef="usd">847600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e797-wk-Fact-8EE56AF9C7D150C58B9B790C1FCFCFC7"
      unitRef="usd">4600000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember"
      decimals="-5"
      id="d6299201e801-wk-Fact-C2B78EB9CAA2553EB224BB73F8C575F6"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d6299201e805-wk-Fact-F0FC3521C49C51BFB8A625D22292497A"
      unitRef="usd">18400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d6299201e810-wk-Fact-ADA5D8E6563A5612A829A61A8C430B53"
      unitRef="usd">7800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-9A7BFC6259E6569C8F823EFD7AC16B96-0-wk-Fact-F7004B6AD2E653B0884B810C9D2CD808">:&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(81.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e866-wk-Fact-1AA7CDBDCAA65C52A34E2E00BD55A502"
      unitRef="usd">107800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e881-wk-Fact-EBA7A0F88E725872A0C38BEEA5CD8F3D"
      unitRef="usd">7500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e901-wk-Fact-897E6E0751DE5F48943183B3EB308A83"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e921-wk-Fact-427A724879C45B30B50683032B815D05"
      unitRef="usd">117500000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e941-wk-Fact-6AB40C2973DD54C2B17C1CFBC1D180E4"
      unitRef="usd">81900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e962-wk-Fact-1AFA284F35D05799AA996DA293F76908"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e987-wk-Fact-33B1C372116D53E7ACAE530E264F3D55"
      unitRef="usd">852200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="3"
      id="d6299201e999-wk-Fact-37862AD762DA55C8A37B792B685C441A"
      unitRef="number">0.125</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e1003-wk-Fact-C3F35836087052ED98215D865377A8CE"
      unitRef="usd">480000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e1007-wk-Fact-E76DB618A8085584989BD70260C4E61A"
      unitRef="usd">220000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes
      contextRef="FI2020Q1"
      decimals="0"
      id="d6299201e1014-wk-Fact-070E9C6656CF7C7FCC14A832F70726E4"
      unitRef="usd">0</us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6299201e1018-wk-Fact-B116079FFB97582C916C4060236A234A"
      unitRef="usd">35500000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-E2CB5D74CD68552FA988AF3E37C6F398-0-wk-Fact-8EA82CD3D8C85B298FD7C90262B81A82">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark. We determined that the assets and liabilities related to our Hiller&#xf8;d, Denmark manufacturing operations met the criteria to be classified as held for sale and recorded an initial loss of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$174.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our condensed consolidated statements of income in the first quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This estimated loss, which was subsequently remeasured each reporting period, included a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$115.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting our estimated fair value of the assets and liabilities held for sale as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, adjusted for our expected costs to sell our Hiller&#xf8;d, Denmark manufacturing operations of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and included our initial estimate of the fair value of an adverse commitment of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$120.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the guarantee of future minimum batch production at the Hiller&#xf8;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$59.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this planned transaction in the first quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; this transaction closed and we received approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$881.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, which may be adjusted based on contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#xf8;d facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#xf8;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#xf8;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction in the third quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These materials were sold at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6299354e764-wk-Fact-BAD3AA00C6C7B21CA71EA37E2D78E026"
      unitRef="usd">174600000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6299354e772-wk-Fact-C5F084F1A6D853B18FB7DA17A7BFDDCC"
      unitRef="usd">115500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6299354e780-wk-Fact-B73ADFE2D90182E7CA6AA380AD0B66E0"
      unitRef="usd">10000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6299354e785-wk-Fact-8C54B342EE26D47014BFA38144B3A1FE"
      unitRef="usd">120000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2020Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6299354e789-wk-Fact-EFB75A60F3EA17A2E8F6A381C54A5D48"
      unitRef="usd">59100000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6299354e800-wk-Fact-4FAD233BB63E5E6B9384D60E9CC37AF8"
      unitRef="usd">881900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2020Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6299354e807-wk-Fact-71E142F7CC1251389807EE36C522416D"
      unitRef="usd">74000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="I2019Q3Denmark"
      decimals="-5"
      id="d6299354e833-wk-Fact-2FFBD82F6E845B6D84A93F33AEDCAFC6"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-EB3D286995D75C2DB984870778CA8AA5-0-wk-Fact-CBA57C5E3A8C5F9C966093256BBB38D4">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fumarate*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;777.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;323.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,100.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;717.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;998.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;292.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;173.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;466.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;327.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;500.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;277.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;522.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;245.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;460.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;28.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;28.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,347.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;769.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,290.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;693.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,983.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;235.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;565.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;223.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;295.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;518.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;124.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;124.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;218.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;218.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;174.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;174.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,583.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,321.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,904.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,513.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,166.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,680.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,027.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;200.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;827.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,033.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(16.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(73.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(310.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(383.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(112.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(432.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(549.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;145.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,096.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;39.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,281.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;235.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,046.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,281.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;390.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;179.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;520.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;517.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Genentech, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;94.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;109.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;292.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$206.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we license certain of our manufacturing-related intellectual property to the customer. We are eligible to receive up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$500.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in a series of three payments. The first payment is due upon a regulatory achievement related to the customer&#x2019;s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-AEB5A5FDFA465785A995381C5DC8AE00-0-wk-Fact-2DC64E2631C058F79184A45F87B207E9">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fumarate*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;777.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;323.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,100.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;717.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;998.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;292.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;173.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;466.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;327.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;500.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;277.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;522.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;245.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;460.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;28.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;28.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,347.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;769.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,117.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,290.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;693.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,983.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;235.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;565.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;223.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;295.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;518.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;124.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;124.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;218.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;218.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;174.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;174.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,583.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,321.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,904.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,513.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,166.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,680.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1348-wk-Fact-DD8F7BA1D8525BF49CA4BF6F0D63F48D"
      unitRef="usd">777500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1367-wk-Fact-0645B14D11A2598E990DE7F80BE7776E"
      unitRef="usd">323300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d6304303e1387-wk-Fact-95EEC0A2FF375DFCB1D4D05C4E90A829"
      unitRef="usd">1100800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1406-wk-Fact-36E059173BFC53018DB4DD5982DCFAEE"
      unitRef="usd">717700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1425-wk-Fact-AE721FC8DD735487B7A95C2969C42C72"
      unitRef="usd">281100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d6304303e1445-wk-Fact-AA30AA6FEEE55B6E8A4695DF65150AD0"
      unitRef="usd">998800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1465-wk-Fact-9D5AEB6EC5D35A4AA87DCF1EFF4DD34D"
      unitRef="usd">292600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1484-wk-Fact-9E87772CE17F57748C5C1584A7B3238A"
      unitRef="usd">173400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d6304303e1503-wk-Fact-6A87CBD94A395A78AA6D05E1323CCFDB"
      unitRef="usd">466000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1523-wk-Fact-14AEDBF812E85FCD9E66260E648A025E"
      unitRef="usd">327300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1542-wk-Fact-10B61AECA1B65E9383C6C1949FD5E9DE"
      unitRef="usd">173600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d6304303e1562-wk-Fact-73D40D3DFFCB57209D9DBBD1CBB0ED0F"
      unitRef="usd">500900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1587-wk-Fact-B326E02C901E5FBDA9C3284B588C2F3E"
      unitRef="usd">277700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1606-wk-Fact-8360373164F257A8A9DFD4AA89AE308E"
      unitRef="usd">244700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d6304303e1625-wk-Fact-48DC9D93BA165116BE850B9D0946F8A3"
      unitRef="usd">522400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1645-wk-Fact-7A2903761BA95B54BF1EF7D78C784595"
      unitRef="usd">245000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1664-wk-Fact-FFB940CF4F165CA5AFE785A107666BA1"
      unitRef="usd">215400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d6304303e1684-wk-Fact-40DCF4E1432450B0B845A8F029C91576"
      unitRef="usd">460400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1709-wk-Fact-918BEA969C0E5F69BF518E42366EE66A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1728-wk-Fact-937EDC022D5A5AA696D020ACB72AA82E"
      unitRef="usd">28300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d6304303e1747-wk-Fact-886F75FD806F5C158C17C596E512E81B"
      unitRef="usd">28300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1767-wk-Fact-8D678ADE9F545123B04FF8313CE1419E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1786-wk-Fact-4271413674CB5F939D166F0781D15231"
      unitRef="usd">22900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d6304303e1806-wk-Fact-989F4F1608135A2CA79FC08F30BEEC52"
      unitRef="usd">22900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1831-wk-Fact-89689120EB265032A4467E302D6DD5B5"
      unitRef="usd">1347800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1850-wk-Fact-6788EE24A3D050F8B613038B15265A22"
      unitRef="usd">769700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d6304303e1869-wk-Fact-D7EC36ACAD6756D1AE55ACF8E1B79F16"
      unitRef="usd">2117500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e1889-wk-Fact-CEC7EEB05A3950218F3F0D3A92A9D5A8"
      unitRef="usd">1290000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e1908-wk-Fact-AB69EFA20D5E5659A7C3A16BCD21C364"
      unitRef="usd">693000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d6304303e1928-wk-Fact-3AE767426FAB562BAF8B1C3B26E56FDE"
      unitRef="usd">1983000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2208-wk-Fact-099B4C15A03D530191D4DB8AF2EA6627"
      unitRef="usd">235400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2227-wk-Fact-E28E632589465E17B201F3CA2A7379FA"
      unitRef="usd">329600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d6304303e2246-wk-Fact-82EFB202B0165A83ADFE63ABA7D86861"
      unitRef="usd">565000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2266-wk-Fact-7776C0FFED5553848678104ACEE7D17F"
      unitRef="usd">223300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2285-wk-Fact-B348888A71C25B61A9F0A0C6D1636E40"
      unitRef="usd">295200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d6304303e2305-wk-Fact-4EFF89F344F4532095162D10C34172A5"
      unitRef="usd">518500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2584-wk-Fact-A1AE1C9EEBF656289F625770D69DA70F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2603-wk-Fact-A3B0CF04E2CD5B068E6469BC223770B5"
      unitRef="usd">133500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d6304303e2622-wk-Fact-945A419C4FB45536A528A94FDE1B2485"
      unitRef="usd">133500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2642-wk-Fact-D52E06FBAD8354D6BEC3010A567B347C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2661-wk-Fact-F7C4854247EA586DAE1F0B259B818A99"
      unitRef="usd">124000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d6304303e2681-wk-Fact-6E7660BEFAC858B786650D38BB6B5F00"
      unitRef="usd">124000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2706-wk-Fact-EB97929C25DE5DBB91F528104B2EF396"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2725-wk-Fact-286659174BDE52B2AF74784D85FC4420"
      unitRef="usd">61600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d6304303e2744-wk-Fact-6927A325FDE45762AF9F255F361634CB"
      unitRef="usd">61600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2764-wk-Fact-7E7D119BC25C5408AB0334BDC4718951"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2783-wk-Fact-78ECBC32A7265A52838B820FDD950E5B"
      unitRef="usd">35700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d6304303e2803-wk-Fact-2220B05B39585E4785C5B58E44E8789E"
      unitRef="usd">35700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2828-wk-Fact-3A826B5CF31C5D3994F27282749E0F35"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2847-wk-Fact-19E87F032CA25D0B965DC5B6B987EABC"
      unitRef="usd">23700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d6304303e2866-wk-Fact-D1B78B16E7275CA8B60BAD71261932DF"
      unitRef="usd">23700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2886-wk-Fact-40A8AFBC4027514BAF7078ABC50AB2DF"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2905-wk-Fact-65C17DA4F12B53D7B95BA57ED86C71B6"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d6304303e2925-wk-Fact-9EBCC6BE992359BE96381CAFF3284EA6"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e2950-wk-Fact-CECB76B3052F5C40A2FC75F32C52669D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e2969-wk-Fact-D9895B16F3D4525CA46026EE41C548A4"
      unitRef="usd">218800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d6304303e2988-wk-Fact-E0CA27D4898253668D32D6D734F76B77"
      unitRef="usd">218800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e3008-wk-Fact-5523430644105A31B6CA4175E7A8B3A6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e3027-wk-Fact-1C64E73DCFD758A19A46D5BD8B18A98C"
      unitRef="usd">174400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d6304303e3047-wk-Fact-0C6F4C346947562F823FFC94F9A6D425"
      unitRef="usd">174400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e3328-wk-Fact-247344CC304F5B90A7576657954CD548"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e3347-wk-Fact-6179CA0357E659ABA2F2E28E776EA4DF"
      unitRef="usd">3300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d6304303e3366-wk-Fact-0848B91759315F2F8EBC4930EFBD3308"
      unitRef="usd">3300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e3386-wk-Fact-DC2075534874553AB06A5CB537E47409"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e3405-wk-Fact-2C7AE49A43DC5ECC9E42BD79D7E7BEA0"
      unitRef="usd">4100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d6304303e3425-wk-Fact-694D1CD487A7522EADEC037FA04078E2"
      unitRef="usd">4100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e3455-wk-Fact-6F90B429EBCF5C2D866783C1E925C432"
      unitRef="usd">1583200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e3474-wk-Fact-BF94E08E2EB351ADA8C04A0B207F2631"
      unitRef="usd">1321400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d6304303e3494-wk-Fact-6DD5F1948E5C5CCCAEDCAF91E2F6813B"
      unitRef="usd">2904600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d6304303e3513-wk-Fact-BD3B4248CF7F5A409959F495B89BE074"
      unitRef="usd">1513300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d6304303e3532-wk-Fact-8B62E11CFECA543DA98233D5F6318DE7"
      unitRef="usd">1166700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d6304303e3552-wk-Fact-7384EBD5465D5546AC62CCFE15F4F263"
      unitRef="usd">2680000000.0</us-gaap:Revenues>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="INF"
      id="d6304303e3571-wk-Fact-516D340D51455C31BA4C9506473D3FA3"
      unitRef="number">0.300</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="INF"
      id="d6304303e3575-wk-Fact-CA3CF5C80F4F565199C6DB7CC9E69D01"
      unitRef="number">0.146</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="3"
      id="d6304303e3587-wk-Fact-E13D55C0C88656D684B70521B1BC24A6"
      unitRef="number">0.313</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d6304303e3592-wk-Fact-0B8900DC61C05B80971AEDB9AD39D255"
      unitRef="number">0.142</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-514D726EF8CE557985613F8E46E42B47-0-wk-Fact-8FBB4A2EEE5452138F55DB5DFDD3D337">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,027.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;200.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;827.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,033.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(16.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(73.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(310.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(383.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(112.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(432.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(549.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;145.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,096.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;39.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,281.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d6304303e3750-wk-Fact-1DA42F369A6B54599BF21412911CE44D"
      unitRef="usd">131100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d6304303e3769-wk-Fact-ACD42097DFF054B98CB6E2557F24C003"
      unitRef="usd">1027300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d6304303e3789-wk-Fact-0FA2A298C7A056379A4B45B8C7259E5E"
      unitRef="usd">40500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6304303e3808-wk-Fact-69530C8A18485050B373ADC68F2B0E32"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d6304303e3828-wk-Fact-F153EF29B97C5F4BA510504ED7E05B5A"
      unitRef="usd">200700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d6304303e3847-wk-Fact-B377CD75C31C553BB64C5A7662E8CFB8"
      unitRef="usd">827900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d6304303e3866-wk-Fact-745EB3A91A425E7B82E16BB719C8C5D3"
      unitRef="usd">4700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6304303e3886-wk-Fact-EB09CA95B8E35D289143DF14B83BDC07"
      unitRef="usd">1033300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d6304303e3911-wk-Fact-0453A8BB670357DFB7A9B3156ADE8365"
      unitRef="usd">500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d6304303e3931-wk-Fact-73ABD40DC3DA5CDE9AFD60503B1BB486"
      unitRef="usd">15900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d6304303e3951-wk-Fact-30E079D2DAC55CD9B57891F8E4BEC277"
      unitRef="usd">500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6304303e3972-wk-Fact-8A0F2CB0608E5A9B988D14B9030C2E4B"
      unitRef="usd">16900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d6304303e3998-wk-Fact-914F0466C7D758188F08CD31C29A7BF0"
      unitRef="usd">73400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d6304303e4018-wk-Fact-2C76846906F055B09C9CAF94F8871EC5"
      unitRef="usd">310300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d6304303e4038-wk-Fact-188AAA1141675BAD9EA6C31F03F8CF91"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6304303e4058-wk-Fact-9DFC6F3259FB5B2A8A2A187CF40A955F"
      unitRef="usd">383700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d6304303e4084-wk-Fact-71DF82A69C565876A60E700101DB4B41"
      unitRef="usd">112200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d6304303e4104-wk-Fact-8DBA303847F35C42A90325E65107AC95"
      unitRef="usd">432800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d6304303e4124-wk-Fact-4F81F818B617588E8BF33E44776C3AE9"
      unitRef="usd">4800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6304303e4145-wk-Fact-11E7BBFFFF3B57FFBB91725C6B48D5D4"
      unitRef="usd">549800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d6304303e4176-wk-Fact-CAAC7B324B7851879909C250EAFEA06D"
      unitRef="usd">145700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d6304303e4195-wk-Fact-5B10D49C2AC15A47ACFEF3654EEC1A9A"
      unitRef="usd">1096200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d6304303e4215-wk-Fact-2D1FF151CDFC51FBB2F72BD78DB414BA"
      unitRef="usd">39900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6304303e4234-wk-Fact-077D868269775B1388A7EB0DC649F943"
      unitRef="usd">1281800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-48C562B8E2E050ACA45C9BBF8C3C0112-0-wk-Fact-33315DC456925A3AB4424F8D0D483179">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;235.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,046.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,281.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d6304303e4344-wk-Fact-33E531F21D0058E39FA8097C00B1464F"
      unitRef="usd">235400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d6304303e4363-wk-Fact-3F20B3F170EB555CB9232E5197D66A98"
      unitRef="usd">197800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d6304303e4383-wk-Fact-625419BB27195A409EDB1EB81379D384"
      unitRef="usd">1046400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d6304303e4402-wk-Fact-787C6E6AC74D5288BFC68E3A0EBA4216"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6304303e4432-wk-Fact-077D868269775B1388A7EB0DC649F943"
      unitRef="usd">1281800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6304303e4451-wk-Fact-69530C8A18485050B373ADC68F2B0E32"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-7895875F99C25265A5D86641D476A5AE-0-wk-Fact-CE51A9FD39895C068474F877BBBB8F0B">&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;390.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;179.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;520.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;517.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d6304303e4600-wk-Fact-622EFBB39F1B5BDE853CEC1E2991CB1B"
      unitRef="usd">341300000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d6304303e4619-wk-Fact-DE08577F1C1C5ADA8B63DFD45DC6CB43"
      unitRef="usd">390800000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d6304303e4639-wk-Fact-A26ECDD7197F5337BD4852A2CAEC983A"
      unitRef="usd">179100000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d6304303e4658-wk-Fact-1939D35029C15C47B4E619BA8981454B"
      unitRef="usd">126600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d6304303e4688-wk-Fact-5C1B4A3E5E705C3DBAAB3B3D2CBBDB7F"
      unitRef="usd">520400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d6304303e4707-wk-Fact-C51A11646BE4542D85918CCC5A2C7AE2"
      unitRef="usd">517400000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F2D37D2DAC6956CBA7FD4C03A3929076-0-wk-Fact-892C0411B8D75BD8AFFC7D3E11965127">&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;94.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;109.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;292.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d6304303e4912-wk-Fact-42AF16F1B0995CEDB28E59BEAE5E1879"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d6304303e4931-wk-Fact-8E82EA88AD305A7B9E79FD695E6A883E"
      unitRef="usd">24800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d6304303e4951-wk-Fact-769DD060BF45CA98143FA4841C20CF20"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d6304303e4970-wk-Fact-E7EEBB06A35FA5B6605CA48420D90117"
      unitRef="usd">-400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d6304303e5042-wk-Fact-F10EB460835358F6B4FAC3D437EDEDB2"
      unitRef="usd">11400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d6304303e5061-wk-Fact-AA8E658EE74156359E809D5D7A82677D"
      unitRef="usd">3900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d6304303e5086-wk-Fact-18049EC6E92C51BFA4C27ED406150074"
      unitRef="usd">94000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d6304303e5105-wk-Fact-7EC3CC34C2A1510B80AE1B725F3426AB"
      unitRef="usd">264100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d6304303e5135-wk-Fact-49E487F43286591DAFFC57ED16F39618"
      unitRef="usd">109300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d6304303e5154-wk-Fact-8A0940D374CF51D083D84F7631628605"
      unitRef="usd">292400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d6304303e5177-wk-Fact-08E50019229A51219701931BE914D1A6"
      unitRef="usd">206800000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d6304303e5184-wk-Fact-BD7DDEB499A15D7BB0048E05754122E6"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-676477A1A8DB57CF97BB50E99373E8D4-0-wk-Fact-4013F2229D345ED3912413480E6138F8">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;210.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;475.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;460.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;172.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;174.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;858.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-92C91D5AE26154789933330A324051C8-0-wk-Fact-A7D82601EDA254F3863B470109B62EBC">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;210.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;475.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;460.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;172.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;174.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;858.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6304686e857-wk-Fact-C143F958434656DDB8D80DC100E8B4CF"
      unitRef="usd">210900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6304686e876-wk-Fact-0665F2D70D9C5B53B6D976984DC235A8"
      unitRef="usd">169700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6304686e896-wk-Fact-9584344E12CA5EF29774F4B4C75A544F"
      unitRef="usd">475200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6304686e915-wk-Fact-E204ACAAE47D5EAEB0C2C86F999B5FF2"
      unitRef="usd">460000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6304686e940-wk-Fact-6133615B0E625300A4EC5983263E44BD"
      unitRef="usd">172700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6304686e959-wk-Fact-333CA897E01C54D88B8F5503CFCCD582"
      unitRef="usd">174500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6304686e989-wk-Fact-9685F4EEBEED595F81747BF356685BDD"
      unitRef="usd">858800000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6304686e1008-wk-Fact-D87FD10CDF3F5AD1B31DE4EBD429A21E"
      unitRef="usd">804200000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-AAA6CE72851D59B8BB7A1BE37E75D9BE-0-wk-Fact-327C0C1846D7593D817641A803D68626">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-28 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,952.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,426.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,497.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;956.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;956.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&#160;and&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,399.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,952.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,446.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,527.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization and impairment of acquired intangible assets totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$71.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$68.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. The net book value of the TYSABRI asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Completed technology also includes &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$154.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;amp;D programs with an estimated fair value of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$700.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of&#160;trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The TGN program has experienced numerous delays in development in the periods since we acquired the program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain indication, for which we also have an IPR&amp;amp;D asset. Data from that trial is expected in mid-2020. This data may affect the economic value of vixotrigine &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and the IPR&amp;amp;D assets for one or both programs could be&#160;impaired if assumptions used in determining their fair value change. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value associated with our vixotrigine IPR&amp;amp;D assets was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$161.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the second quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020 (remaining nine months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;193.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,757.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,752.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt; accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B1E26FDB7A0454DEA17E7D19D4A4AB58-0-wk-Fact-F3010D28529555598EB1CA5FCE6AECD7">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-28 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,952.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,426.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,497.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;956.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;956.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&#160;and&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,399.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,952.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,446.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,527.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d6306201e1111-wk-Fact-384885E4CA5E5614915BE53C82FBFD48"
      unitRef="usd">7379300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d6306201e1130-wk-Fact-06B1CADA5C545DADA7BC54039C387CCE"
      unitRef="usd">4952900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d6306201e1151-wk-Fact-7CA02D290BDD5BCE95D2AF3448976FAC"
      unitRef="usd">2426400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d6306201e1170-wk-Fact-4DF25675EF5457B2B28B43F05E8A6446"
      unitRef="usd">7379300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d6306201e1189-wk-Fact-214E91B6C60A5C9CAEEBA73DDFFA740D"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d6306201e1210-wk-Fact-6B6C85264A265899B13137D406A41E30"
      unitRef="usd">2497900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d6306201e1235-wk-Fact-9CA98E3199035460A51202DC2B91AD89"
      unitRef="usd">956500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d6306201e1254-wk-Fact-FE779E823A4D55E69952F704B99D5FB6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d6306201e1274-wk-Fact-9CA98E3199035460A51202DC2B91AD89"
      unitRef="usd">956500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d6306201e1293-wk-Fact-9E646CAE64E45A5CB62556DC59BFF61A"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d6306201e1312-wk-Fact-6FF6B36A10195F5F81602A7DE230826E"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d6306201e1332-wk-Fact-9E646CAE64E45A5CB62556DC59BFF61A"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d6306201e1365-wk-Fact-4EA26653D9F95A1284A3B044C20731EB"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d6306201e1384-wk-Fact-6FFAECA6B9AD56199BBDB1C364674240"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d6306201e1404-wk-Fact-4EA26653D9F95A1284A3B044C20731EB"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d6306201e1423-wk-Fact-0D01D2578D255C14B4BF98233C18300B"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d6306201e1442-wk-Fact-747771D0C5F35EF5A4EED17A0491FABC"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d6306201e1462-wk-Fact-0D01D2578D255C14B4BF98233C18300B"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1497-wk-Fact-B3A7481E4282582092798A45726216CC"
      unitRef="usd">8399800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1516-wk-Fact-A6646BAEE7F251C98B0F12B1CE428D89"
      unitRef="usd">4952900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1537-wk-Fact-AD1C5EB68CF65DC3984A7409445F526B"
      unitRef="usd">3446900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6306201e1556-wk-Fact-C9FDEBD5212F51F3B83BA35AECC81364"
      unitRef="usd">8408800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6306201e1575-wk-Fact-4A782876278A5D59A2D65A565546107C"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6306201e1596-wk-Fact-82009BD2AC26575E958204C37D75B0DB"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6306201e1624-wk-Fact-13DF614395235DA29BFA4FB1CE46B0EA"
      unitRef="usd">71500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6306201e1628-wk-Fact-D01715617B805CDF8467FFF75B1E78EB"
      unitRef="usd">68200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-8"
      id="d6306201e1655-wk-Fact-17E95872B4825281983A626C231AEF18"
      unitRef="usd">1800000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d6306201e1659-wk-Fact-59F129C14F1C50E7ADC65F1AB766BA97"
      unitRef="usd">154600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d6306201e1673-wk-Fact-897E6E0751DE5F48943183B3EB308A83"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q1_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d6306201e1701-wk-Fact-26EFDDEED3886F349918A38E7C9B27C6"
      unitRef="usd">161700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-248AB122BE845D8FAF734A20162F81AF-0-wk-Fact-E210E843BF005897B0EC6090F287B6A0">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020 (remaining nine months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;193.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1787-wk-Fact-7001314163F55C92829F7DEF7AEE3833"
      unitRef="usd">193000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1807-wk-Fact-98CD7EDD59FF57DE971B59AEFC96E123"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1832-wk-Fact-E8CD205B8A3550B595EAFF119DFC63AE"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1857-wk-Fact-321B57684F045DE1AEE03BE15B7E1836"
      unitRef="usd">230000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1882-wk-Fact-EA59BD3686535CA79300975AD9D7DC04"
      unitRef="usd">230000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e1907-wk-Fact-683B34CCA9D45E988531355298A84F6F"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F9DE9C6598635023BD69A87FA1C4782D-0-wk-Fact-7CE590ECDA165B24962EB547511C8722">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,757.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,752.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6306201e2001-wk-Fact-A6A4D09C94CD5944861219FC074EF1A3"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6306201e2021-wk-Fact-8757DC23C58E59588930453297262B96"
      unitRef="usd">-5800000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6306201e2052-wk-Fact-5680A01230085EC6BEF71F889D7F44A5"
      unitRef="usd">5752000000.0</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="FI2020Q1"
      decimals="-6"
      id="d6306201e2075-wk-Fact-38C8E238412C5CEB91379D3965C22977"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B19DA2CAC460595A810C502CEC498247-0-wk-Fact-E39A65EB9F2E51579F700086DBA1F97B">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,974.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,974.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,353.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,353.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;710.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;710.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,620.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,344.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;345.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,920.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,912.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;354.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; material impairments of our assets measured and carried at fair value during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. Our investments in equity securities include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares in Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:middle;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;$341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.40% to 2.53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.44%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Timing of achievement of development milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020 to 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from the low-teens to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,498.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,501.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,509.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,022.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;996.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,038.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;996.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,838.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,739.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,897.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,739.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,323.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,723.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,681.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,961.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,553.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;421.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$194.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$197.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities and changes in the expected timing of the achievement of certain remaining developmental milestones, partially offset by the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to changes in the expected timing of the achievement of certain remaining development milestones, changes in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2443DE88817A51A2BD7E87DD382A8599-0-wk-Fact-1274DCD8745152CC86881B61B0C1982C">&lt;div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,974.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,974.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,353.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,353.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;710.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;710.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,620.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,344.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;345.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,920.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,912.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;354.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1018-wk-Fact-B378B551E520590AB09C3C12B9D67A84"
      unitRef="usd">1974100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1037-wk-Fact-CB21E29706F55CFBB75EDA01B21AF2EF"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1057-wk-Fact-6D4B9176D6F854659F64A053CF81B573"
      unitRef="usd">1974100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1076-wk-Fact-AB41C03848115A0E918B7602F839ABA6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1183-wk-Fact-9EBE2F28FAA3552297BBFC18F1AA85E5"
      unitRef="usd">1353500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1202-wk-Fact-0FD38268214D5570A67D013F97429FB4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1221-wk-Fact-8EAAA37BE6A85C0BB830F01B490FC060"
      unitRef="usd">1353500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1241-wk-Fact-E1AB79FE11A3594EA25980F0434830BC"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1266-wk-Fact-DF7B3A730A3558A89D73985B4C36A030"
      unitRef="usd">710400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1285-wk-Fact-390412DD960956DBA8D95A40D253E187"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1304-wk-Fact-00CBDC438DCA547C89D27059490A5B28"
      unitRef="usd">710400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1324-wk-Fact-B8A0773AB0515FF2981B0747BF472FF1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1349-wk-Fact-6AD4605A9D82540A99B539BEFBFF05F5"
      unitRef="usd">174700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1368-wk-Fact-79D7AC2999B5575F8F04B696AF1D1254"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1387-wk-Fact-19810BF0D4FD58CD97691E2B404F4963"
      unitRef="usd">174700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1407-wk-Fact-3CB5E9514CE05EC9AD9CDB8BC4B275B6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1432-wk-Fact-2D73AEFDCE1F5F98BB6455E41940C380"
      unitRef="usd">276100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1451-wk-Fact-37D9D6F03D0253FF8CF2DE7C06125969"
      unitRef="usd">276100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1470-wk-Fact-4BA70F6578CD57E48B866BE179AAFAB8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1490-wk-Fact-8072550106E55CC0AFD306D766B6C116"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1515-wk-Fact-EFF3BDCADDBB52A7B55151C2A74D07B8"
      unitRef="usd">107300000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1534-wk-Fact-5C423490826150E28458686F3016995E"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1553-wk-Fact-889E49FE89F45BC4A19AF2CBC7A70615"
      unitRef="usd">107300000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1573-wk-Fact-07B4F8372C7F54ADA9AAF64F82FD3DCC"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1598-wk-Fact-FA68D0EB12DD54FFBE5F3CDEDFDCD06C"
      unitRef="usd">24500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1617-wk-Fact-1ACA410E8FD65AEFBDC3CE6C1496E728"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1636-wk-Fact-F47A25A5DB775889BC2E611919C3569C"
      unitRef="usd">24500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1656-wk-Fact-48845CF292525429AA0E035B9D9FB911"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1686-wk-Fact-C29873DD372C5514B1259FE7EE286C12"
      unitRef="usd">4620600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1705-wk-Fact-C78D01BD24F256889488145C7804F35D"
      unitRef="usd">276100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1725-wk-Fact-D9F6483C245A5549BF6D8691E1BC684E"
      unitRef="usd">4344500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1744-wk-Fact-75ADAC2E201C58F8BD075E04A0BFB3FA"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1857-wk-Fact-C4C23214E30D55F5B8402E42E6EF0842"
      unitRef="usd">3700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1876-wk-Fact-6EDE006FA19F5958AB9BC13D61CF7AFF"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1896-wk-Fact-A80D5AEA32915B068AF804A00B8CAE42"
      unitRef="usd">3700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1915-wk-Fact-5B26B75A3BBA5AD1994269ACFE5B3F38"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1935-wk-Fact-A241D77DA43757859E88B218D8DF4959"
      unitRef="usd">341500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1954-wk-Fact-C525E159E57657CF97E2BAFC8F675B4C"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1973-wk-Fact-6B2FCAA31E1154AFAD023CDFB91FE6F9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e1993-wk-Fact-C0638850EB625735B55771C08E04066C"
      unitRef="usd">341500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2023-wk-Fact-EB0E533AB48654E39CF13983AA19BB8D"
      unitRef="usd">345200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2042-wk-Fact-AFF3AEC3CA515284BD696157FF53C372"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2062-wk-Fact-E5BC5895F92E517C9787C3E08DDE9A57"
      unitRef="usd">3700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2081-wk-Fact-F3CBC51F07A55067A576C2C60BD7DF3B"
      unitRef="usd">341500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2332-wk-Fact-B75FE33AC3135BB188DF2E822AF3CFE0"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2351-wk-Fact-495016F666A1583D87BCB2F3D4AD4D00"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2371-wk-Fact-326C8C894DA857D3AFC5CDC6696025EA"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2390-wk-Fact-7E7267968FEA5BBC9284CFE1C8B5C80B"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2497-wk-Fact-CFEBE65D90025361A0815511C0DB2C34"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2516-wk-Fact-8EE318626B6E506C81B7F7661605AE14"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2535-wk-Fact-3DD26F31363158CAAFD7E9D62D3C0893"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2555-wk-Fact-DDA31A00BC445128B2F5F3FEF273B92B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2580-wk-Fact-AE5267ECFCE25B9C99C822568A097BD7"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2599-wk-Fact-B75D098624005C0DBD1FCC21254DA38B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2618-wk-Fact-3EB90575FE065F7284249EEA33047ABA"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2638-wk-Fact-7FE4718887F559C68A6A9D8128741D8C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2663-wk-Fact-D8B3286A32425DB5B1572FD4DF27692D"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2682-wk-Fact-779DBBD9B8FC59FEB60F66CD257A8EA9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2701-wk-Fact-20982C0B82DC5F61AF397F6BF8DA89AB"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2721-wk-Fact-75E93F13566557298DF019946856E777"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2746-wk-Fact-F5C0D294C3A059ED908CF3CEA386A2A8"
      unitRef="usd">337500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2765-wk-Fact-BD26AC5117985F238DB14704E2CCA0DC"
      unitRef="usd">7900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2784-wk-Fact-A7FAE436542A541D860B325A3E7A7019"
      unitRef="usd">329600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2804-wk-Fact-FA5C6A5CF4735CAC8E41883231D962EF"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2829-wk-Fact-C031AD532CC85ACA98D96627EF97040A"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2848-wk-Fact-8EED231159515722B140192BD5CDDC86"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2867-wk-Fact-50AA0B03BF1A50C3AF7D99A412E5F030"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2887-wk-Fact-3B953F75E1D85AAA8E1AD772D5D3FD2F"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2912-wk-Fact-8C57280BF8CF53B884A875E0D653B3F5"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2931-wk-Fact-EF2BB8B573F459DC85C2340A6CD46159"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2950-wk-Fact-010B2B3F47475461BA3DB3E7D4A4A122"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e2970-wk-Fact-2961B70F407A593BA1216DEBB77E48CB"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3000-wk-Fact-26DBCE37A7C15628864754084B6CCDFE"
      unitRef="usd">5920400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3019-wk-Fact-E7FC502F5F99548A934012C0D08453A3"
      unitRef="usd">7900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3039-wk-Fact-14CC5894943D50D8A156E519922F64D7"
      unitRef="usd">5912500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3058-wk-Fact-0D8ED8424EEF50D38BABDFAED0C6E7DD"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3171-wk-Fact-803038251E2F53DA8B4D781DFB1E463F"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3190-wk-Fact-2FB97746513E53708282A0A6490BDAEA"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3210-wk-Fact-C8D91EAADDEC548CB1992F6E067EAAA1"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3229-wk-Fact-919E6C5E5CBE576B998196D35F8F1DDA"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3249-wk-Fact-C50B6687D5F9558389CCCA3B381F48D2"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3268-wk-Fact-134EC611D85554C08F1A7CFDE01628CE"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3287-wk-Fact-C8764DED37D2510A9BE1E6A4C064E5EE"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3307-wk-Fact-DB8EDDADF35A5B1F8AEE066F6FF56189"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3337-wk-Fact-28C0DA8234575CC8A4473CB15AFDECF8"
      unitRef="usd">354400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3356-wk-Fact-88703E6814F9564DA8DF8361ABB27942"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3376-wk-Fact-8785C6EC51D95F868A976532B631AEF9"
      unitRef="usd">8300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3395-wk-Fact-049EEDD4B009535D943E603710DA34C8"
      unitRef="usd">346100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d6310551e3415-wk-Fact-0A9601487976558EAE7B7910BBE41A2E"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d6310551e3427-wk-Fact-655F5DABF4145102817289E7009F5008"
      unitRef="usd">0</us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e3547-wk-Fact-A241D77DA43757859E88B218D8DF4959"
      unitRef="usd">341500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="4"
      id="d6310551e3567-wk-Fact-DA15728FF32FE50F8738A39ED4488E80"
      unitRef="number">0.0244</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-1072D17FD3CF5B2B86FC27119C7D66FD-0-wk-Fact-1D42CE31024854A191840A0EDD97DBCD">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,498.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,501.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,509.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,022.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;996.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,038.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;996.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,838.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,739.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,897.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,739.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,323.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,723.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,681.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,961.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,553.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d6310551e3851-wk-Fact-2C8E4509F9D754D7882694FD8C9774E7"
      unitRef="usd">1498100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d6310551e3870-wk-Fact-06D331B8AF6E5EABBD68C112BF64113B"
      unitRef="usd">1501800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d6310551e3890-wk-Fact-5A348BECC1BF5CA1ABC7DDF5AA3C03CF"
      unitRef="usd">1509600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d6310551e3909-wk-Fact-1AAB4A7855C05D6982CC667163BB4CFD"
      unitRef="usd">1495800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d6310551e3929-wk-Fact-F984C8ED9C245D8BA9004864E1E4A196"
      unitRef="usd">1022000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d6310551e3948-wk-Fact-94F4E7D8CC335C6793C171ECC859C385"
      unitRef="usd">996900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d6310551e3967-wk-Fact-9E389335BA71585AB0660C8FEFAE971D"
      unitRef="usd">1038900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d6310551e3987-wk-Fact-4552C1B4936B538F9D1A7733FC089AAB"
      unitRef="usd">996600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d6310551e4012-wk-Fact-2224250EEBF157DF92A9486E06B3C013"
      unitRef="usd">1838100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d6310551e4031-wk-Fact-7E728E0FAA6D5772AF81AC391FF01FE7"
      unitRef="usd">1739900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d6310551e4050-wk-Fact-77CB852ECDA454BF8C90CAE7D1A9BCC5"
      unitRef="usd">1897200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d6310551e4070-wk-Fact-F8718553C46A557988E9B18EB903997D"
      unitRef="usd">1739500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d6310551e4095-wk-Fact-0112504A383650E293A8AC105042FB27"
      unitRef="usd">2323100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d6310551e4114-wk-Fact-A11FC8A8B2095528805B9BBE21748136"
      unitRef="usd">1723100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d6310551e4133-wk-Fact-F976206955165000AB7B3A0470550677"
      unitRef="usd">2107900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d6310551e4153-wk-Fact-EB38D65108655C1E9C6B7C197259EFDA"
      unitRef="usd">1722900000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6310551e4183-wk-Fact-E2AB1040AA655C4088C248BD92C7C6C6"
      unitRef="usd">6681300000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6310551e4202-wk-Fact-8173EF9D28965CE5A58B6A5AC097E6A6"
      unitRef="usd">5961700000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6310551e4222-wk-Fact-5E669EB166C5593FB4F67A8AB702B4A5"
      unitRef="usd">6553600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6310551e4241-wk-Fact-A135B64548EA5D9986E92BBAC1EA1EB6"
      unitRef="usd">5954800000</us-gaap:NotesPayable>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F495BF14A8785FFF9049AF4E0272A976-0-wk-Fact-D8BD0F2288915206AB6D54A520142381">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;341.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;421.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e4411-wk-Fact-4489BAD8B5D452909EFC914606996B04"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e4430-wk-Fact-0612B0E40CDC5A2893FD7E79C66873B0"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6310551e4450-wk-Fact-30C421DF9F73516DA7CC5CB1364D68F6"
      unitRef="usd">4600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6310551e4470-wk-Fact-C6C1AC30CB4E5EB1972C8B88035C202E"
      unitRef="usd">-11500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6310551e4495-wk-Fact-6F6BE75ED9C55E31A3AA80CFCFF8519B"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6310551e4514-wk-Fact-55BF164BBD9C5E3099D934A584534AAC"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e4544-wk-Fact-A241D77DA43757859E88B218D8DF4959"
      unitRef="usd">341500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d6310551e4563-wk-Fact-081BA42E46A7557EB1239CECE4D9420D"
      unitRef="usd">421300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6310551e4591-wk-Fact-34867ABFFD835ECF9406F187AC3D73A7"
      unitRef="usd">194200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6310551e4595-wk-Fact-4C3BC3AD245A5F7FADC91FACAA658454"
      unitRef="usd">197700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-7B39885F71965F39AD8039949C0FD0A3-0-wk-Fact-F7CE7F76FD8A5EC0815C310FCA2A9E2E">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;121.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;384.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;36.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;368.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,705.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,628.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;110.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;159.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,974.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;923.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;921.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;442.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;431.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;346.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;361.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;363.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;175.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,247.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(16.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,238.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;286.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(16.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,057.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,058.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;633.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;636.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;502.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;503.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;510.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;510.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;218.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,269.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,267.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,562.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,560.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;846.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;856.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,234.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,230.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;123.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;123.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,238.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,247.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,389.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(19.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$331.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$393.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The decrease in our strategic investment portfolio for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was primarily due to a decrease in the fair value of our remaining investment in Ionis common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our June 2018 investment in Ionis common stock, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-968CB8EFDA625A3199FB4EA5A8D6A4A3-0-wk-Fact-09DAB671C23059CE9CFF99AC3AAB956A">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;121.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;384.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;36.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;368.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,705.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,628.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;110.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;159.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,974.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d6314374e854-wk-Fact-90779FD80DC956A1B7E94EDB24B514E4"
      unitRef="usd">121800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d6314374e873-wk-Fact-4698CB48202959D3984A31EE9F0AD458"
      unitRef="usd">384400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d6314374e893-wk-Fact-8D3D44754A275E42AC1A8B8A118EF313"
      unitRef="usd">36900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d6314374e912-wk-Fact-C70E6EA12D8D5DE8BB7701E461E8E156"
      unitRef="usd">368800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d6314374e937-wk-Fact-4CC5F300C041517AA4FCA679DE58DB33"
      unitRef="usd">1705400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d6314374e956-wk-Fact-02653CCF02B75F0DBF0B025F7CE23C08"
      unitRef="usd">1628500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d6314374e981-wk-Fact-93211B12CBA65D65A844A0413C41174D"
      unitRef="usd">110000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d6314374e1000-wk-Fact-544B874E05695356B947557AA6745EDA"
      unitRef="usd">159400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e1030-wk-Fact-1161B09C0B2C59A29DA7636421777FC6"
      unitRef="usd">1974100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e1049-wk-Fact-6BD0C3B3316455F0A4B8C05D8591A5F7"
      unitRef="usd">2541100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F86E11ED9F025A0BBE80CA18F5FACFEE-0-wk-Fact-90B6AED21D19593B88CB9AE85FAF93A4">The following tables summarize our marketable debt and equity securities:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;923.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;921.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;442.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;431.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;346.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;361.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;363.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;175.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,247.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(16.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,238.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;286.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(16.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;276.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,057.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,058.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;633.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;636.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;502.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;503.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;510.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;510.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;218.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1311-wk-Fact-26166A446C3557C69977D7B9CA9F9735"
      unitRef="usd">923800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1330-wk-Fact-1A89D61BE98E5F0CA8273775423B8205"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1350-wk-Fact-E2A6C569EB5C5D8F89429DE8DB155741"
      unitRef="usd">2200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1370-wk-Fact-BC88FE2F5F1A509DA39F1453D6B0DF2E"
      unitRef="usd">921800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1390-wk-Fact-147E1FE5A80352B290352107C41B88D3"
      unitRef="usd">442700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1409-wk-Fact-DD82A2756A425C2B84E0EB7053C92AC6"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1428-wk-Fact-881F7EC1406E57ED848A567A1868A53B"
      unitRef="usd">11600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1449-wk-Fact-ADBCF16C33BD5A50B809A7567CA133B5"
      unitRef="usd">431700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1561-wk-Fact-31D6FB0334085581AB08514E118DC486"
      unitRef="usd">343200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1580-wk-Fact-4EC50D9953265108966DD877EA23A2CE"
      unitRef="usd">3400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1599-wk-Fact-9FC1E4491BE05D65BE9BA1B512CD210C"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1619-wk-Fact-F18FEF803DDC56D78DE59068D9882ADA"
      unitRef="usd">346600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1644-wk-Fact-69A6501817F95E5B9F9556E9668A886B"
      unitRef="usd">361500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1663-wk-Fact-602A7BC36C475CBB986C45BB312BC3E4"
      unitRef="usd">2500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1682-wk-Fact-33539C12010053FEA3A746F1EF5B26D5"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1703-wk-Fact-45337A187BD85F1091121DAC679E7024"
      unitRef="usd">363800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1815-wk-Fact-2378BD0126965140941C7D1CA317D1B0"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1834-wk-Fact-3DBD3AA7871D5DBDBBB0B0C6AC5FDDBD"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1853-wk-Fact-FAE38AE4FF9355C88F266475C7C02144"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e1873-wk-Fact-62CCC0A5D94153F1933BD3CC9222E857"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1898-wk-Fact-6AC30353AB29528AAFCCA5E17A5C7D1A"
      unitRef="usd">175100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1917-wk-Fact-9FED9A85C92650059930C77D7E9D4A8F"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1936-wk-Fact-ECFB75F6C8EC52B48C86EBA84D757778"
      unitRef="usd">2100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e1957-wk-Fact-9743686D2354570784F360067086785A"
      unitRef="usd">174000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e1987-wk-Fact-318A1EACE088579DB2AA45D1147E6B6C"
      unitRef="usd">2247000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e2006-wk-Fact-95BB8CA12997549183CA1858F9BCA49F"
      unitRef="usd">7700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e2026-wk-Fact-5B0EB04DBD3F5E5D908D233DD135DA72"
      unitRef="usd">16100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e2046-wk-Fact-621B2D3A45C7509695C0040C13C9EA59"
      unitRef="usd">2238600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e2072-wk-Fact-5189413FF5B957799469DE75E997BA2E"
      unitRef="usd">286200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e2091-wk-Fact-4E8D893532F35C56AF44BB941B201FF4"
      unitRef="usd">6500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e2111-wk-Fact-4876887F3A345618B999B40BF9491EB0"
      unitRef="usd">16600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e2131-wk-Fact-F8362495911254FD8AD6306527F0D316"
      unitRef="usd">276100000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2373-wk-Fact-F461CF1EC0725B02A28F37DD9878D766"
      unitRef="usd">1057200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2392-wk-Fact-4E10D956847057FC94DAAB5BA789D002"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2412-wk-Fact-09BF3890B70C5423AF159B9CA991D202"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2431-wk-Fact-41A0265B849B5815988A6405DAD9CBD0"
      unitRef="usd">1058200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2451-wk-Fact-B180695013AA5C66B6281B05E5E5C13E"
      unitRef="usd">633900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2470-wk-Fact-A9B3EA9BC12152BDA67DCD5F53DB03E4"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2489-wk-Fact-C040EAD0C8D05D5182F6396DED261086"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2509-wk-Fact-A16B70EA78445EB3B7CFE8BC2F8D5CAE"
      unitRef="usd">636900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2621-wk-Fact-F2FB0DC610F7552C8E0B480AB83FACCC"
      unitRef="usd">502900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2640-wk-Fact-B912A7350387563695A5D6E0E8B0AC90"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2659-wk-Fact-5B23808C3D7958ACBCC2BD2C96067654"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2679-wk-Fact-268F8B3DF1125AD2AE2F29E596C225F8"
      unitRef="usd">503300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2704-wk-Fact-EE7FA375114550879EF4AC80E44F0C44"
      unitRef="usd">510100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2723-wk-Fact-76117572611954C28ED92395F450AD3E"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2742-wk-Fact-A6FD0B82288A5A579159F85E2425CD97"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2763-wk-Fact-4287784BACD2552B9ABFD30515EF4171"
      unitRef="usd">510600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2875-wk-Fact-8C669AA726555E2C8081C1ABD1D286B1"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2894-wk-Fact-5BDF942A29825AED8C9DEC9F42D98710"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2913-wk-Fact-14306C9C1495553B8DFC06F58171C36C"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d6314374e2933-wk-Fact-22AF37A7C3105C73B0522A4E979916F7"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2958-wk-Fact-75D35BD801595C18B4C024D52FEC35BD"
      unitRef="usd">260200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2977-wk-Fact-6CCD04B7A6A95CB2A7853CD3A59BE7A7"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e2996-wk-Fact-CF6118A4E9375819A26E686A30BABD78"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d6314374e3017-wk-Fact-336E949792F458E480707B15A467FCA2"
      unitRef="usd">260600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3047-wk-Fact-36A47D9DE5B15B54B624548697E75B5F"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3066-wk-Fact-14B29001654C51E2BA5FC62A41A0E282"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3086-wk-Fact-A0078BC94CB256CB80C7995DBF550286"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3106-wk-Fact-DED572DF46F352598852164663BF4491"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e3132-wk-Fact-0E1E937AB90E512F8053B3202744E191"
      unitRef="usd">218400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e3151-wk-Fact-6F6986382C0C57D8812711B12FC9F40C"
      unitRef="usd">132100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e3171-wk-Fact-F57DA4A2E85C5296AA750E910308C574"
      unitRef="usd">13000000.0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d6314374e3191-wk-Fact-6271C274F9375EE99CAA4BEF3D38EC9B"
      unitRef="usd">337500000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D4A772DF1DDE51D896F04B169A6080A0-0-wk-Fact-3AE6EF01923553E1B0C66F40C76085B9">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,269.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,267.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,562.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,560.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;846.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;856.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,234.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,230.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;123.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;123.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,238.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,247.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3452-wk-Fact-DEC0587CA2797883E8F4A3A112A2190F"
      unitRef="usd">1269100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3471-wk-Fact-DC82951C5BB9364D2222A3A111F3E19E"
      unitRef="usd">1267700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3491-wk-Fact-897E1F9309289B4185DAA3A112044E25"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3510-wk-Fact-31699CB0898ACF04D0B0A3A11240E7DE"
      unitRef="usd">1560800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3530-wk-Fact-E21A55433BA97FDA82C7A3A112561093"
      unitRef="usd">846000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3549-wk-Fact-08783233BFB73FFF64F4A3A111D82379"
      unitRef="usd">856300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3568-wk-Fact-BDBA6A0B064E0BD8D40EA3A1121A532A"
      unitRef="usd">1234500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3588-wk-Fact-17DC8C4F4F3F29438D21A3A1128D380E"
      unitRef="usd">1230400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3613-wk-Fact-AEF2EFFCF42C242DD13CA3A1127C54D1"
      unitRef="usd">123500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3632-wk-Fact-4DCA39D358E321B7A8CBA3A1122B3E01"
      unitRef="usd">123000000.0</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3651-wk-Fact-80A52832F02271ABF35AA3A112B87894"
      unitRef="usd">173600000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3671-wk-Fact-EDB1C9314914F3CF0A8FA3A11267C7A1"
      unitRef="usd">173800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3701-wk-Fact-A74379C1995A5B898D34690C1557D5B9"
      unitRef="usd">2238600000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6314374e3720-wk-Fact-318A1EACE088579DB2AA45D1147E6B6C"
      unitRef="usd">2247000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3740-wk-Fact-BED8FE9EA4515EA88A825A2E4DF0B086"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6314374e3759-wk-Fact-36A47D9DE5B15B54B624548697E75B5F"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-79786588E9EB538FA9C48EFFE1E41BFE-0-wk-Fact-B2EEB5176ECD56D7B8A28214EBB6F6ED">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,389.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(19.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6314374e3933-wk-Fact-B2C977AFB43A5B6D846E35244FB2DF92"
      unitRef="usd">2389300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6314374e3952-wk-Fact-A4A4FD4E66E65DF4BA4CD8A5C026A640"
      unitRef="usd">1489200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6314374e3972-wk-Fact-DE0B565F5F5F50A8A70B4DADF3D75C94"
      unitRef="usd">5700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6314374e3991-wk-Fact-1B3485D6552458B2B5C2E9ED5337F73B"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6314374e4021-wk-Fact-DD96080551285E5DBE94EADB1B511654"
      unitRef="usd">19100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6314374e4041-wk-Fact-EFCBD32CDFFA58249F2CA392F3DF4A72"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d6314374e4073-wk-Fact-B587018CF03B573DA5DB556F39954893"
      unitRef="usd">331900000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d6314374e4077-wk-Fact-95FAFA5D3D0B5E67B5EA9EE1798B6142"
      unitRef="usd">393900000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-5DFC4C7B69EC53C38AD481017D5645C2-0-wk-Fact-8C6D55FF421D5038974B41E612BD08BB">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,116.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;186.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;103.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,559.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$34.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect the net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$34.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$31.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of these gains are expected to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, we entered into interest rate swaps with an aggregate notional amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. The carrying value of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had remaining durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;seven&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$22.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$698.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$793.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recorded as a component of other income (expense), net for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-185A80745CB35C60835BBE8EE4E192DC-0-wk-Fact-86F27B28B2CB522184DD9E4BF48E645E">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,116.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;186.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;103.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,559.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e930-wk-Fact-6F91BF77D77555BE9CCE263ACEAE9BAE"
      unitRef="usd">2116400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e949-wk-Fact-21C9F61F9D1259A08D6A2110076461F6"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e969-wk-Fact-BDCC36223FC35ECAA89E7DB78E36CF7E"
      unitRef="usd">186100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e988-wk-Fact-00C308CDDAD252D480FCE24C5EABC890"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1013-wk-Fact-E1F41A57B81B59F680BE9F86FC3180DA"
      unitRef="usd">103100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1032-wk-Fact-647B713E25A557648CBA00B9E134CFDE"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1057-wk-Fact-45DAC7153DDE5DFF904FCF64DBF0850B"
      unitRef="usd">79500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1076-wk-Fact-795A06A086DE528C8E200A423933A77C"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1101-wk-Fact-E1D5AD986B915A4E98EA3E3124B2EC8A"
      unitRef="usd">74500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1120-wk-Fact-D2B8359577185F9986C9E15A5C2EC0CB"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1150-wk-Fact-E225BEA61E4450909AB665BA42AB0D21"
      unitRef="usd">2559600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1169-wk-Fact-E81D1FF1A9B45BE281D0BC8822D684FA"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6317282e1189-wk-Fact-FFBF6DFD9BF9530A8DEDD866EFCE9E96"
      unitRef="usd">-34400000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6317282e1193-wk-Fact-920EA00334B15A6D9BDF2ECA985EE484"
      unitRef="usd">500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6317282e1205-wk-Fact-FFBF6DFD9BF9530A8DEDD866EFCE9E96"
      unitRef="usd">-34400000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2020Q1_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      decimals="-5"
      id="d6317282e1214-wk-Fact-4D51F4B528E7526D84E423A88757792F"
      unitRef="usd">-31800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2EAF79C70F125D09B26F6E43A454E586-0-wk-Fact-F37BC3C08C115805BB60233932B5B928">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d6317282e1585-wk-Fact-F9061C4D01A352FCB2B239507D35ED21"
      unitRef="usd">27000000.0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d6317282e1604-wk-Fact-A337263C3AFD57F78551E5862C956967"
      unitRef="usd">14800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d6317282e1634-wk-Fact-E49FDB41CC8E56BFB6E105B8A22BE62F"
      unitRef="usd">9300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d6317282e1653-wk-Fact-5E5599F02E2F522C9C5E128F571DBDF1"
      unitRef="usd">3700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d6317282e1678-wk-Fact-7A467B615E21565EAF9D54AA37F7BE2E"
      unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d6317282e1698-wk-Fact-0C3DC9FB30EF55E09DF09DD49ABBE524"
      unitRef="usd">-500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d6317282e1729-wk-Fact-ACD99908AD4E57CE8037D1D7970F86F1"
      unitRef="usd">-900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d6317282e1749-wk-Fact-B8A507AEEC5D5738AE2095A7BF8DAEE7"
      unitRef="usd">-900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d6317282e1777-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e1781-wk-Fact-2B76C94FFF6750199B37D2D0ED2EB644"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d6317282e1785-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d6317282e1789-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d6317282e1798-wk-Fact-A36E5578901CC5E3BF4EA3B09DA2BC1E"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d6317282e1802-wk-Fact-D63F12D371B95A73A08FAEFF195CAD07"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d6317282e1817-wk-Fact-96BB724CF6885BCAA9AA54D473EF0BFF"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d6317282e1821-wk-Fact-720567AD23835BBCB3F827AA344F9E49"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d6317282e1828-wk-Fact-A6D14020D25E777E54D5A3B220AA218D"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6317282e1832-wk-Fact-1BEA17CFCAA7375BED7DA3B377FDCA27"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e1847-wk-Fact-3A4A79F6EA225C389997305579DC1348"
      unitRef="usd">22700000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e1851-wk-Fact-5E741C66394EF1159B8BA3B400FBBB4C"
      unitRef="usd">1500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2020Q1_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e1864-wk-Fact-290391C81EC556A7B1EB024127C17FA1"
      unitRef="usd">2000000.0</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e1868-wk-Fact-D9435D5331195B74A16ABB86792871EA"
      unitRef="usd">2900000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-3B179FA15228544E86A40254B3F22FB1-0-wk-Fact-55E762C32615523D837D9A555B9C244B">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e2402-wk-Fact-2CAE2082C95A5C13BB7AE03EF045D8E9"
      unitRef="usd">24200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e2421-wk-Fact-56C7AE667D695B559A2F275DC42C91CC"
      unitRef="usd">11800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e2451-wk-Fact-8557E83CB85653FEB148034DB4F81DC6"
      unitRef="usd">-300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e2471-wk-Fact-4085EE046866564DBCD054A9704543D8"
      unitRef="usd">4400000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d6317282e2501-wk-Fact-D168632F934E5DCBBB94BEB10C05C18F"
      unitRef="usd">900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q1QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d6317282e2520-wk-Fact-58F2D72753005A269686196CD6FD3738"
      unitRef="usd">2200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d6317282e2546-wk-Fact-F20F9B3E25B65716B0B317C047F8ECC2"
      unitRef="usd">698400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d6317282e2550-wk-Fact-FFC3C8812FBC515D80BDE3120968F428"
      unitRef="usd">793800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6317282e2562-wk-Fact-48EEFFE8AB82596DB1EB9335577D6E61"
      unitRef="usd">2400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6317282e2575-wk-Fact-89EE4DC5858051BEBD01669A2F47C76C"
      unitRef="usd">-4800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-5E24B2DCAE695EDFA13134192CD4912A-0-wk-Fact-CF63D5D2A68B53B5BC97DFCD56135A26">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e2756-wk-Fact-2985FA3696F351D1ABF86ED639BDCDB0"
      unitRef="usd">72300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e2775-wk-Fact-C893C4009619535DB6DA8C07648D5ED4"
      unitRef="usd">33800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e2810-wk-Fact-C90DD9BDB9B8509EA306BE6E2173067E"
      unitRef="usd">4000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e2829-wk-Fact-7241EC2614475B6D9E7BC049C8963901"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e2864-wk-Fact-7A8243527BA95A18B5451B9BC9E1961D"
      unitRef="usd">800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d6317282e2883-wk-Fact-EE45F7B2E9EF54D9B447D3CFF37BC5EA"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d6317282e2918-wk-Fact-677730435872F5ECDACEA3B676DDA8ED"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d6317282e2937-wk-Fact-F3490844FF4C75FF0CB7A3B67D5B50F6"
      unitRef="usd">1700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e3084-wk-Fact-A543DDE9BBD584524C64A3B5AA4DF62F"
      unitRef="usd">25900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d6317282e3103-wk-Fact-69206C7346BDF5CAD47DA3B5AED6694B"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d6317282e3251-wk-Fact-5F9AD274843B0B343F66A3B6C4370E9C"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d6317282e3270-wk-Fact-A36E5578901CC5E3BF4EA3B09DA2BC1E"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d6317282e3417-wk-Fact-C8877F9C594850C0B0E937B49813C0A5"
      unitRef="usd">5100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d6317282e3436-wk-Fact-ACCC4A22E0EA56F7AD2B9377C6EC4234"
      unitRef="usd">8000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d6317282e3471-wk-Fact-6A8E5E012454564D9656FEBA77EA94A3"
      unitRef="usd">2900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d6317282e3490-wk-Fact-81B4B7F3A8BD5C4CB7BB063B8DD85F86"
      unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-3AC0B2C4DC9F5328B7C3563ADAE6941C-0-wk-Fact-55CCDB49C6BE53D992CEB7B312FA5EA0">Property, Plant and Equipment&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,636.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,590.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, depreciation expense totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$48.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$52.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. In the first quarter of 2020 we placed approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$256.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of fixed assets in service related to the facility. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$12.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding related to the construction of this facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6317479e762-wk-Fact-FBA31F7508D2540A9A9AE7CB1349448F"
      unitRef="usd">1636700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6317479e766-wk-Fact-5B6E9214726E55A6A0AD8CF1924DEA9A"
      unitRef="usd">1590900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6317479e793-wk-Fact-AF02C0140161592097CC47CD10372279"
      unitRef="usd">48400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6317479e797-wk-Fact-1A334AF48DDD5A1CBD4A5DA8E293CB14"
      unitRef="usd">52900000</us-gaap:Depreciation>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d6317479e815-wk-Fact-BE6E6AE5010E51C19471D0C93728D38B"
      unitRef="usd">1700000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d6317479e819-wk-Fact-1D0E809E19835E358579DD1E96302D93"
      unitRef="usd">1900000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-5"
      id="d6317479e823-wk-Fact-36593C827AEB38FC41B0A479DBC6CAD6"
      unitRef="usd">256800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:OtherCommitment
      contextRef="FI2020Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-5"
      id="d6317479e832-wk-Fact-FE2B53C1594859869C254C897EEEE131"
      unitRef="usd">12100000</us-gaap:OtherCommitment>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-0F6C4D5E06655ADAAB19BADD301BF876-0-wk-Fact-09D4B9AACDB95ED0B653726DE40BDF5B">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2019 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$941.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (March 2019 Share Repurchase Program), which was completed as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From April 1, 2020 through April 22, 2020, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our December 2019 Share Repurchase Program. Approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remained available under our December 2019 Share Repurchase Program as of April 22, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(32.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(139.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(135.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(20.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;60.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(63.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(63.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;41.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(32.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(203.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(149.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(30.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(261.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(219.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(16.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d6321970e764-wk-Fact-04610C96BFF3BC75DFEBA486BF2C5596"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6321970e768-wk-Fact-0908DFEF6A98BAEA293DA486F91FD376"
      unitRef="shares">3200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6321970e772-wk-Fact-B9DFE833D7383EEB0928A4871860A595"
      unitRef="usd">941100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d6321970e787-wk-Fact-539783922B5A5136A4E1486A469BF123"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d6321970e795-wk-Fact-E77F395F580058B3AAE558E69FDDA5C5"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q1QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d6321970e799-wk-Fact-8F89326216AA5D7BA2FC348E72E10C1D"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2020Q2Apr01-Apr22_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d6321970e815-wk-Fact-43925C0FA6E05735BADEB82C30627693"
      unitRef="shares">4000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D2020Q2Apr01-Apr22_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-8"
      id="d6321970e819-wk-Fact-4ABCDCE139FA5209A3CC8A7489F3BB7C"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="FI2020Q1_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d6321970e823-wk-Fact-EEA848FB19FC58D78D30E2644FE9B4CC"
      unitRef="usd">2800000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-A344C47FAAC25AC5A786B3EA2A7B3661-0-wk-Fact-7409F6CF074F52728C7D7F258F086726">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(32.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(139.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(135.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(20.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;60.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(63.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(63.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;41.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(32.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(203.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(149.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(30.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(261.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(219.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e1031-wk-Fact-88B1D414E14359568EE45D7F309C8803"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e1050-wk-Fact-C18401FCFBD6573CADA9CB87749C3116"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e1070-wk-Fact-82326CBE29DE5E33A1AB7D7B0AC79977"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e1089-wk-Fact-89BF0EC097F55C14A560AC276731B286"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e1109-wk-Fact-735C1B32969353A8ACBB374F5E2FC9B7"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6321970e1130-wk-Fact-ACAB9874DC005EDD9E4AF5B9CE727C30"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e1151-wk-Fact-93983BF22D79524DA9E23C56D0E644B1"
      unitRef="usd">-20800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e1171-wk-Fact-23599E3663335B06B19FD99AEDD7557D"
      unitRef="usd">60700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e1190-wk-Fact-BE8AE7BAFED255CE9B2C4253BD979A89"
      unitRef="usd">23900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e1210-wk-Fact-AFA3207883805916A524B23DE757057B"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e1229-wk-Fact-9FF6D1FB44335F3D9FC1573C361A6EDF"
      unitRef="usd">-63900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6321970e1250-wk-Fact-05E0F2DDB2B45FA1A46D663F3A77CAB6"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e1275-wk-Fact-12A18A5166CA5465A5543A3F08776073"
      unitRef="usd">13000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e1294-wk-Fact-85CD3B50F3BD5D50B59D716203EC6D50"
      unitRef="usd">-26900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e1314-wk-Fact-2F45EDC10A705D03A6F5FD361536D507"
      unitRef="usd">-900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e1335-wk-Fact-C16BD88EC6C85CCCBD3FF56A775C45AE"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e1354-wk-Fact-41A89E058E825BE5B64F6BBF0E466CED"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6321970e1374-wk-Fact-1E33505B3B005104B6C62AD6462F22CE"
      unitRef="usd">-14800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e1400-wk-Fact-F3F79DEFF2995001B90CFD76F40BB78A"
      unitRef="usd">-7800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e1420-wk-Fact-82BA5FE089DF58C7B21C6B0D51C8B76D"
      unitRef="usd">33800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e1439-wk-Fact-D743D51606E8500DA07F413094EF3A58"
      unitRef="usd">23000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e1459-wk-Fact-EA92606CFB5E5E21BC5B6234FA4930F9"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e1478-wk-Fact-C3631E44D3F8507781067589A269BC21"
      unitRef="usd">-63900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6321970e1499-wk-Fact-5B8C18C3243E5D5AAD152B2A77B3C58D"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e1530-wk-Fact-5C81F4F92CB65BDB980687272A68D3FF"
      unitRef="usd">-3600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e1550-wk-Fact-07B925C5DAEC5E128A8ED97C1426AE18"
      unitRef="usd">41600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e1570-wk-Fact-FDA894B1D9A554A6A12A80F561F12F0B"
      unitRef="usd">48100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e1589-wk-Fact-5FA8CE828DA25F319A206B4DFBD5F0C7"
      unitRef="usd">-32000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e1609-wk-Fact-BF3BE00F579952909C11ECDA64A8A772"
      unitRef="usd">-203400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6321970e1630-wk-Fact-9B13E96C51445E7A8D54697EFDAC6991"
      unitRef="usd">-149300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e1820-wk-Fact-9ABB8C30C78056D1B628EB446BB90E31"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e1840-wk-Fact-B9EBAE6B0F06562E823E81DB45C5B5DA"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e1860-wk-Fact-3705E1CB0B5C5C72927A5C576A46AC10"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e1879-wk-Fact-D22984F3D56C55229157F2C3ADF37E1C"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e1899-wk-Fact-ACD8F3CCCCFD58D0A341D9371469F86A"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d6321970e1920-wk-Fact-80FC49EC49215A83A2F5D12F76D61646"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e1941-wk-Fact-B9217F4A56485BA680F30D97F9B83F90"
      unitRef="usd">7100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e1960-wk-Fact-AA7E0F4C03FD593EBD8016DC00F8762E"
      unitRef="usd">31200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e1979-wk-Fact-A9E7E80C7AE759C38364B2E10E29D108"
      unitRef="usd">16200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e1999-wk-Fact-9EE42AA61E775E50842553938CD9AE2F"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e2018-wk-Fact-A6BFF2D05BA9504BAB7898BD51794AF2"
      unitRef="usd">-17800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6321970e2039-wk-Fact-63F83752B1D25949B10607B2156346EA"
      unitRef="usd">37300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e2064-wk-Fact-F7C32A8432785518BCC2724A37652BE7"
      unitRef="usd">-200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2084-wk-Fact-710F6A0AD3FA5BB2B0FB8DA6C996EAEF"
      unitRef="usd">-14300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e2104-wk-Fact-D7C76A1D104456BBB4709E2ACEB9EA9C"
      unitRef="usd">-2200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e2125-wk-Fact-197E8ED996FE57D492A40E223D86FC8A"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e2144-wk-Fact-7D2A41ED2B0455AA876284B6323450C5"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6321970e2164-wk-Fact-ACB08EA7ED7F5A15A817C67BCABF7CBF"
      unitRef="usd">-16700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e2190-wk-Fact-D21218962F3A571281FA8F1E273D8274"
      unitRef="usd">6900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2209-wk-Fact-A7394281D3EF504C8A16D29AD2E22CBB"
      unitRef="usd">16900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e2228-wk-Fact-F841975CE7865FC8B5C88E02C3C45D56"
      unitRef="usd">14000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e2248-wk-Fact-A1BDF68EBCD65A48A43C863359B54EF2"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e2267-wk-Fact-4BAEDB36C2295F408A36D78904D73FB1"
      unitRef="usd">-17800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6321970e2288-wk-Fact-49C6AFCCB21C5CB19609F8B635C4A0F1"
      unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e2318-wk-Fact-802A8D58905156AD984688472D6F0D79"
      unitRef="usd">2900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2337-wk-Fact-221D31ABA08F59BB94E10E51199B0800"
      unitRef="usd">51600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e2357-wk-Fact-8D0D743B85EC5FDB9BD8270D2E3D9392"
      unitRef="usd">17500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d6321970e2376-wk-Fact-9B1929F5F3BE5D4A817F4C2EFA704294"
      unitRef="usd">-30700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d6321970e2396-wk-Fact-BCA468DF086358F2AE90BDD7A85A6B9E"
      unitRef="usd">-261100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q1"
      decimals="-5"
      id="d6321970e2417-wk-Fact-B99AFFC109AF5D9EADBDF8FDBC9E2C9C"
      unitRef="usd">-219800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-087787AD788E5193845BA3C531BB364F-0-wk-Fact-A9F97BB9A15754B59DFC3FD352154D0C">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(16.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;14.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e2636-wk-Fact-F479886B35765D0D9CDBDCC1C24836AD"
      unitRef="usd">-16400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e2656-wk-Fact-008F07EB9BC850469612FA1493547539"
      unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e2681-wk-Fact-6D2B469036CB51D995D93CC78E00422F"
      unitRef="usd">3400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d6321970e2700-wk-Fact-83FB7D1C4EBB55E2A4419804D7AA9790"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2782-wk-Fact-95C4123023A1597293155084B0EBF8BC"
      unitRef="usd">27000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2801-wk-Fact-7FA72A4E21D452238E59D5A26E925824"
      unitRef="usd">-14800000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2831-wk-Fact-27350FB11FA55C86AB65822664125EA8"
      unitRef="usd">100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2851-wk-Fact-8CD130E0F09259F99A7FCA4576198747"
      unitRef="usd">500000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2882-wk-Fact-67DA7C0D85B0500DB664882FBB05562D"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2901-wk-Fact-090FECE247D75598AC839C1132CC2043"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2931-wk-Fact-0D103598D58057A7A2B91841306C91D4"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d6321970e2951-wk-Fact-F59DBBF765305FABB0F148F16FC3B76E"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e3034-wk-Fact-23F15B1A079A5931B72598455FEFAAF5"
      unitRef="usd">900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d6321970e3053-wk-Fact-D18DF01E31E3556BB9F1CA2024D0CA88"
      unitRef="usd">2200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6321970e3139-wk-Fact-A111FA0756FA5EC681930B864EAF88EA"
      unitRef="usd">14800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d6321970e3158-wk-Fact-9BDF1893C4C6559B90EA7054D7D73C30"
      unitRef="usd">16700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-792C7A8A9ACE5F86A97ADDDEB3D11A2C-0-wk-Fact-D3064B88F5B75D488189ED37351511A8">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&#160;per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,399.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;172.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;173.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;197.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2C6C143C24EA56A2B2B672931ADB4EE5-0-wk-Fact-4958AF267CB354B19426ADB4310FA1E7">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,399.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;172.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;173.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;197.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319287e948-wk-Fact-B4A244AE45BB5E2D8FAF0D792DE59446"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319287e967-wk-Fact-FDA77C2428AF554989EED78CF2C2AEA1"
      unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319287e1033-wk-Fact-71CBFF9E20095155A1063474D4C8BA5A"
      unitRef="shares">172800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319287e1052-wk-Fact-8C58D4EB1D6251F29A5B7EBA8DD1F024"
      unitRef="shares">196600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d6319287e1123-wk-Fact-0B81145B9838591294F48B4A2986FEE7"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d6319287e1142-wk-Fact-EA13AF3E9D285512913BB10D9F30EDAE"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d6319287e1167-wk-Fact-70C366AF1AB9550DB8D189310F413E0A"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d6319287e1186-wk-Fact-48351DDD25C458A18B5F85D7A5EC0894"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d6319287e1211-wk-Fact-42D48AAFAB24552EA96BCC103E6A69EA"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d6319287e1230-wk-Fact-9986231F3BF750998789B50829D52E50"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319287e1255-wk-Fact-08A6C3F0EE6B5029A93684D05F9FBE0B"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319287e1274-wk-Fact-4E36F9A02D1E59BBA7D215E99795768F"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319287e1300-wk-Fact-413B006A143E53BD99DB85074CA369D8"
      unitRef="shares">173100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319287e1319-wk-Fact-15574C2EB65A522E829F10B43239453D"
      unitRef="shares">197000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-09A15436B89A57DB8C5117D465046393-0-wk-Fact-AA187709E10B52C9A29C1B720C0B7356">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;43.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;76.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;19.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;76.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D5BAEEE1A990523A8B79BF3D159F7242-0-wk-Fact-EB4A96FCA71C51A895C187695C614FAF">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;43.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;76.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d6319284e889-wk-Fact-319C9005517D53D89FB22D008AFE03E0"
      unitRef="usd">33300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d6319284e908-wk-Fact-AA60F00A92155C55921B377DE792EE72"
      unitRef="usd">21700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d6319284e923-wk-Fact-3E9FF5E93FC85533AFB5147F7EB0A7F6"
      unitRef="usd">43100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d6319284e942-wk-Fact-1CE7943564E2504BA89D1E6A693B3CB6"
      unitRef="usd">27800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319284e962-wk-Fact-C87943EB873651FBA40FD6630928A3AC"
      unitRef="usd">76400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319284e981-wk-Fact-B671DCE3ACFE5E019E63E9E2FDC0AD37"
      unitRef="usd">49500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319284e1001-wk-Fact-B37CC63E45B8582DBE9A428693438297"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319284e1021-wk-Fact-5FD4D1282D9A5CA0B7F377D6B6CFC3E4"
      unitRef="usd">3300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319284e1042-wk-Fact-D0F1DCC5C6DD582EB75781A615A27F58"
      unitRef="usd">74900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319284e1061-wk-Fact-56EBA1D22F895BCBB8D83E33F6DC3C51"
      unitRef="usd">46200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319284e1081-wk-Fact-326F30EA38D257EBA29E91816CA0426C"
      unitRef="usd">13300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319284e1101-wk-Fact-BC5DFECFF3325A05999CD86684F84051"
      unitRef="usd">7400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6319284e1127-wk-Fact-DDC3FD376F615E9D938270B8692D9AC9"
      unitRef="usd">61600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d6319284e1146-wk-Fact-52A2ACD0EA2F5B7E86BA9457C00E5BB0"
      unitRef="usd">38800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-528F3C04EA2153139EE869D7E02C3676-0-wk-Fact-56060C9934BD58C3ACA2BA154FCA1DAF">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;19.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;76.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d6319284e1285-wk-Fact-B7D17B92F19E5168906348078AD1262B"
      unitRef="usd">19100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d6319284e1304-wk-Fact-FA98211DD6735E61BBC836FBD494FA39"
      unitRef="usd">7700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d6319284e1319-wk-Fact-CED5C19B09995DB38460E20F2C216421"
      unitRef="usd">37500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d6319284e1338-wk-Fact-3D216D9F4F765CE48F4DF9208F279D54"
      unitRef="usd">34700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d6319284e1358-wk-Fact-CC76F5E1281757A983B9DFCE6D880383"
      unitRef="usd">-1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d6319284e1378-wk-Fact-2B32211A65065A37A0364D620BC58F0E"
      unitRef="usd">-1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d6319284e1399-wk-Fact-9754DBC5665B501EBED87B2848283977"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d6319284e1419-wk-Fact-484C161310D953B4A24BC4D214EEA57E"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d6319284e1439-wk-Fact-5E26E70F2E215725968AA84F26DADEEF"
      unitRef="usd">10300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d6319284e1458-wk-Fact-B4D289206390545C90A2D40057C539B8"
      unitRef="usd">2000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d6319284e1478-wk-Fact-615F5FE6916C5E8E9CDB602474559427"
      unitRef="usd">8900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d6319284e1497-wk-Fact-640366E39A4E531BA455DD61D29D6401"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d6319284e1517-wk-Fact-D3E76583F9185F76BC7C68B850B3B3E4"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d6319284e1536-wk-Fact-4D1AFAFB7A7C57889DAD0C41DE54E66E"
      unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319284e1556-wk-Fact-C87943EB873651FBA40FD6630928A3AC"
      unitRef="usd">76400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319284e1575-wk-Fact-B671DCE3ACFE5E019E63E9E2FDC0AD37"
      unitRef="usd">49500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319284e1595-wk-Fact-B37CC63E45B8582DBE9A428693438297"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319284e1615-wk-Fact-5FD4D1282D9A5CA0B7F377D6B6CFC3E4"
      unitRef="usd">3300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6319284e1642-wk-Fact-D0F1DCC5C6DD582EB75781A615A27F58"
      unitRef="usd">74900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6319284e1661-wk-Fact-56EBA1D22F895BCBB8D83E33F6DC3C51"
      unitRef="usd">46200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-312FB67DE3875094889F5BF2F9137583-0-wk-Fact-BE541C1197815D7797CBDC147BF74264">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Coronavirus Aid, Relief and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Corporate taxpayers may carryback net operating losses (NOLs) originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, or to our net deferred tax assets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in 2019, the decrease in our effective tax rate was primarily due to the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$59.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax expense recognized in the first quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the planned divestiture of our Hiller&#xf8;d, Denmark manufacturing operations and the tax effects of changes in the value of our equity investments where we recognized a gain in the first quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to a loss in the first quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Although we recognized a loss on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2020 we became aware of a withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions.&#160;We are evaluating whether the&#160;interpretation of this regulation could apply to our facts and circumstances, and, upon conclusion of our analysis, we may establish a reserve related to this matter during the second quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&#160;If a reserve is required, we do not expect that the exposure will be material to our results of operations, cash flows or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D32434C967C055279AE499AF8BB84F47-0-wk-Fact-D937B1EFC8AB564D84DBAEA0D2CF3A55">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e883-wk-Fact-A4C396BB3B48563791E2584A167E67E4"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q1QTD"
      decimals="INF"
      id="d6322626e898-wk-Fact-4EB173032E4F583D956EB6F637204F0F"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e914-wk-Fact-427D6ED1F8C558F4B5A9CC461A4F9DA8"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e928-wk-Fact-10470F268CDB541E8E740ACBCA310230"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e943-wk-Fact-B8DEB5F6F0365DA7A95FB1A6319FB081"
      unitRef="number">-0.041</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e958-wk-Fact-6ADF03D30BE755BD9C64291976E9F110"
      unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e974-wk-Fact-5E651083B8145A64BF530603D1A072CF"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e989-wk-Fact-C48E885EB787539A83116FE629CB2DBB"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e1005-wk-Fact-06973379645C502EBA24876EACA7FD62"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e1019-wk-Fact-0B5511AA6A1B5B3E9DDEC34A377CC56D"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e1034-wk-Fact-ED58258ACBD05F9499CF169A17940F99"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q1QTD"
      decimals="INF"
      id="d6322626e1048-wk-Fact-3BAE5F1FA9BB531182572B4543B31F67"
      unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e1063-wk-Fact-105C314D18AA5A18B43517E3083535BA"
      unitRef="number">0.006</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e1077-wk-Fact-089DA960578B5CACBF677AA769B72E49"
      unitRef="number">0.019</biib:EffectiveTaxRateReconciliationGILTItax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e1092-wk-Fact-2C988DA881E25FF89AC1F622569BA3B1"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e1106-wk-Fact-F4B64435ACD750D29065043357BDEF47"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e1121-wk-Fact-8FDA53A5CE065E87890A083A42F3F55F"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e1136-wk-Fact-4A94451070785FDCB65B62A57955FCF2"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d6322626e1153-wk-Fact-8FDDBFE211FD555BB8E1798FD85335C2"
      unitRef="number">0.172</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q1QTD"
      decimals="3"
      id="d6322626e1168-wk-Fact-DC10E59368F35C648F4130B904812F76"
      unitRef="number">0.227</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d6322626e1200-wk-Fact-7EA822A4C5DABBB17C3BA4919FC49F83"
      unitRef="usd">59100000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6322626e1240-wk-Fact-563E9BAE229DDAD42AD1A4929FEF0F95"
      unitRef="usd">75000000.0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-8E35A1173AFB578598442168A2D2776D-0-wk-Fact-E3689CDA0E1C5A089E2AA393C75EE198">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(44.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;376.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(18.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(120.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;357.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the change in other income (expense), net primarily reflects net losses totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$77.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$376.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our holdings in equity and debt securities in the prior year comparative period. The net losses recognized during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily reflects a decrease in the fair value in our investment in Ionis common stock from December 31, 2019. The following table summarizes our gain (loss) on investments, net, that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(60.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;375.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of March 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(60.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;376.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,046.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;309.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;209.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;154.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;147.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;148.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;78.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;662.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;726.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,437.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,765.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,357.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,348.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and included accrued income taxes totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$801.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$803.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-4304AC164C805063B289549A2CBB7EFF-0-wk-Fact-CF69B7A9DA88527D9D426D4E6B9D45C7">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(44.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;376.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(18.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(120.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;357.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e905-wk-Fact-F11F8A4631035D699B8F4C2474F2ED97"
      unitRef="usd">24400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e924-wk-Fact-8257096515865FE5B5F99BA194B8FCA0"
      unitRef="usd">31200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e944-wk-Fact-51AC853220DB507091111736ED32AB81"
      unitRef="usd">44300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e964-wk-Fact-0880B829DD3059EE87B421FF8CAA6EAC"
      unitRef="usd">47900000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e990-wk-Fact-682E6519C869CD502993A49E56998071"
      unitRef="usd">-77300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1010-wk-Fact-7D41C22E1363B43FA1DFA49E6A1C622B"
      unitRef="usd">376400000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e1035-wk-Fact-4B54A42FEB145B18B3087AF552986637"
      unitRef="usd">-18900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1055-wk-Fact-4D6F5FAD0D3E57F6928FFBC7BBFD1D8F"
      unitRef="usd">-2200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e1081-wk-Fact-F11353D3809654709602091280787988"
      unitRef="usd">-4400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1101-wk-Fact-1008E3FC67C952E5806DC6A301C1DCE7"
      unitRef="usd">-200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e1132-wk-Fact-095EC1AAC9A25CD9B7B7A910B16D60A8"
      unitRef="usd">-120500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1152-wk-Fact-F27571BB0E665301A0F41E41FA9CBCC3"
      unitRef="usd">357300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e1187-wk-Fact-682E6519C869CD502993A49E56998071"
      unitRef="usd">-77300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1191-wk-Fact-7D41C22E1363B43FA1DFA49E6A1C622B"
      unitRef="usd">376400000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-CC9499E36B04571891C1B39568E69C42-0-wk-Fact-76EDFA7D2C975DA98821E027A037AC87">The following table summarizes our gain (loss) on investments, net, that relates to our equity securities held as of &lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(60.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;375.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of March 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(60.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;376.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e1341-wk-Fact-5769D38011605B3DA573AC11D4AAFA3E"
      unitRef="usd">-60900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1361-wk-Fact-79FCBC55ADAC5421945DC2CB390FF69F"
      unitRef="usd">375300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e1381-wk-Fact-6F73BF4466A45309B65AF963448F4469"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1400-wk-Fact-4BDE2DCA0B335699B84B8D881C55C867"
      unitRef="usd">800000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d6323917e1430-wk-Fact-9136AF64C5195BB1878814864F1D0376"
      unitRef="usd">-60900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d6323917e1450-wk-Fact-46E7F534783E5BFEB93E0F89E1B9CE7D"
      unitRef="usd">376100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B4835236968D576986B8D4E14CF9DA70-0-wk-Fact-C18EC6F00F0D59F78C185F9BD0B21252">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,046.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;309.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;209.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;154.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;281.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;147.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;148.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;78.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;662.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;726.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,437.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,765.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d6323917e1558-wk-Fact-625419BB27195A409EDB1EB81379D384"
      unitRef="usd">1046400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d6323917e1577-wk-Fact-787C6E6AC74D5288BFC68E3A0EBA4216"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1597-wk-Fact-25A4AF8C177250DC9A9B679BDF90E468"
      unitRef="usd">190300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1616-wk-Fact-F4A534EAB6335939B33E7304725A7C55"
      unitRef="usd">309100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1641-wk-Fact-130CCA166A235D2190A61AA751141337"
      unitRef="usd">209900000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1660-wk-Fact-918890B4E32E595399000F4239CA1299"
      unitRef="usd">220900000</us-gaap:AccruedRoyaltiesCurrent>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1685-wk-Fact-C2F14BFE440A53EAA536AC5D47DABB7D"
      unitRef="usd">154600000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1704-wk-Fact-B5C273AB2D3255CBAA4818A22A84EACF"
      unitRef="usd">281600000</biib:Collaborationexpensesaccrual>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1729-wk-Fact-86A010107361519385D36A3D384FCB2D"
      unitRef="usd">147300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1748-wk-Fact-F7996E0C67D357D68BD0B42507737679"
      unitRef="usd">148400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1773-wk-Fact-5D46B33C50765824B4E8E4B1F99D19C2"
      unitRef="usd">27300000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1792-wk-Fact-7E014DB67B185D9F92682CC9EBD75634"
      unitRef="usd">78000000.0</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1817-wk-Fact-F090786751A4515786ECFAE124FF0A4B"
      unitRef="usd">662000000.0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1836-wk-Fact-0555D145BAB65771B7A9DC7F50D63D9D"
      unitRef="usd">726700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1866-wk-Fact-2E91A66DD1E458A083A3758FECA481A5"
      unitRef="usd">2437800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1885-wk-Fact-97EC7EE1ECE85247B1145A8455CBCD68"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1911-wk-Fact-3979DB5E0C6C5D6D9A9F95E7EF93829D"
      unitRef="usd">1357300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1915-wk-Fact-13BA7A88BF675D4EA00EE608833C04FB"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6323917e1927-wk-Fact-7B2013AA28C755E886B74BB70700C2FB"
      unitRef="usd">801300000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6323917e1932-wk-Fact-014A938CB7135118A6A1475ABFBBBA89"
      unitRef="usd">803300000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-112A0B64756E5F33BE10C6E037DB1828-0-wk-Fact-7479EBF5CD545CFF992BE62A8C003664">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early AD. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;For the Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;43.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, total development expense incurred by the two parties related to the BAN2401 and Elenbecestat Collaboration and our share of development expense reflected in research and development expense in our condensed consolidated statements of income were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$68.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$34.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the termination of various clinical trials and research and development contracts net of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;19.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;89.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;22.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;UCB Pharma S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, total development expense incurred by the collaboration was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$19.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our share of the development expense was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$9.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and was reflected in research and development expense in our condensed consolidated statements of income. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, operating expenses related to the collaboration were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2020 we entered into a global licensing collaboration agreement with Sangamo Therapeutics, Inc. (Sangamo), which closed in April 2020, to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#x2019;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the closing of this transaction in April 2020, we purchased &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$225.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of Sangamo common stock, or approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$9.21&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; per share, which are subject to transfer restrictions. During the second quarter of 2020 we plan to record an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$85.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We will also make an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$125.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that will be recorded as research and development expense in the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$80.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; relates to the selection of targets, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$380.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Skyhawk Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as potential royalties on net commercial sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$38.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our condensed consolidated statements of income and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. In October &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership percentage remained at approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$115 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to inventory, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$615 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to developed technology and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$170 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to IPR&amp;amp;D. A deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$225 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years, respectively, one quarter in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized losses on our investment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These losses reflect our share of income totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and amortization of basis differences totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;651.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$531.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;670.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$580.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2019 Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this transaction, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Samsung Bioepis in January 2020, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$63.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in 2019 and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$37.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as an intangible asset in 2019. Additionally, we may pay Samsung Bioepis up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$210.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development, regulatory and sales-based milestones, including a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; development milestone that we may pay in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also acquired an option to extend the term of our current European commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and obtained exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$71.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect Samsung Bioepis' &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$58.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$24.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income. Following the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$85.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of March 31, 2020 and December 31, 2019, respectively. Amounts payable to Samsung Bioepis as of March 31, 2020, were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$19.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment related to the 2019 transaction, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read Note 18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt; Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-E7368F26D7A85395AB6C205E37F25955-0-wk-Fact-F1C0A9D97E7657C3AB03C3DDE776EF56">&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;For the Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;43.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e870-wk-Fact-8549370DD6F48C6F63AEA4A69D2247FB"
      unitRef="usd">43500000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e895-wk-Fact-B1A0D4B3813CE7019166A4A69E9FB1A1"
      unitRef="usd">21800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e920-wk-Fact-E5660D2CA7B07A542F69A4A6DC88D504"
      unitRef="usd">4900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e945-wk-Fact-0BE9FF3D5F9FA6B836C3A4A6DF326263"
      unitRef="usd">2400000</biib:Expensereflectedwithinstatementsofincome>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_BAN2401Member"
      decimals="-5"
      id="d6324929e964-wk-Fact-AC1398E8656964F493E9A7C278FFEBE6"
      unitRef="usd">68000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_ElenbecestatCollaborationMember"
      decimals="-5"
      id="d6324929e968-wk-Fact-1DBC9F0C1CF34A16E48FA7C288F81554"
      unitRef="usd">34000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d6324929e992-wk-Fact-4967267CD22A5532ACCB542F6D21B86F"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1002-wk-Fact-931C8426CDB05B2EA00BF564B9AEDD0C"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d6324929e1006-wk-Fact-4967267CD22A5532ACCB542F6D21B86F"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-80BD18242B1453C381E81529CA46C2B6-0-wk-Fact-7170E622E59151D18ABA38DCE59CE834">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;19.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;89.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;22.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1153-wk-Fact-D637275309475B0790AB927977E0AB2D"
      unitRef="usd">19100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1172-wk-Fact-4A1EF4896F1A5D62B1F2B577898AC565"
      unitRef="usd">162500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1197-wk-Fact-1EB00702D52A5105BEA741B63651DC92"
      unitRef="usd">10500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1216-wk-Fact-0577D09B876F58979A9229411FE21BA7"
      unitRef="usd">89400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1241-wk-Fact-25E5EC966FCC5ADCB9A4F2878F0BD458"
      unitRef="usd">22700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1260-wk-Fact-23F69315ECA15E219AB8A5F00C12F402"
      unitRef="usd">20900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1285-wk-Fact-62D13F35FD5F5FC2A6999592B9CD20FF"
      unitRef="usd">12300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d6324929e1304-wk-Fact-C5B2B09B89FD57D5959CEAD40320D0F5"
      unitRef="usd">11600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member"
      decimals="-5"
      id="d6324929e1337-wk-Fact-BA106204D8883D21C6EEA6BD249D5AB4"
      unitRef="usd">19000000.0</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member"
      decimals="-5"
      id="d6324929e1341-wk-Fact-94B1399DBE00EEE18CB3A6BDBFE21EDB"
      unitRef="usd">9500000</biib:ExpenseIncurredByCollaboration>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d6324929e1370-wk-Fact-63D6FE8C56629C581929A6B4D5714453"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-6"
      id="d6324929e1374-wk-Fact-45CDB0D803B49AB9840AA6B7031F7A99"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="2"
      id="d6324929e1378-wk-Fact-4E1BD862B971C7920BECA6B7DC4BC7EF"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d6324929e1382-wk-Fact-992050CAFADA485F42C6A6B86E0D1F18"
      unitRef="usd">85000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d6324929e1386-wk-Fact-F1D670F291BEC33872DAA6B8E62BBDA9"
      unitRef="usd">125000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-8"
      id="d6324929e1393-wk-Fact-D33720C868CDAAEFF13BA6BA3A703B72"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d6324929e1397-wk-Fact-8986F31A6AE761DF74AFA6BB16DADEBD"
      unitRef="usd">80000000.0</biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-8"
      id="d6324929e1401-wk-Fact-CD4D893C7454C306EB04A6BBFB6B8D19"
      unitRef="usd">1900000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d6324929e1405-wk-Fact-2453D76D8BACAEF85A3CA6BCB04C5011"
      unitRef="usd">380000000.0</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones>
    <biib:AdditionalMilestonePayment
      contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-8"
      id="d6324929e1415-wk-Fact-D80EDDCA5AFB525EAFE834292B956C69"
      unitRef="usd">2400000000</biib:AdditionalMilestonePayment>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d6324929e1422-wk-Fact-7190AB5D73765397B9B440CFC2FE3C1B"
      unitRef="usd">74000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d6324929e1426-wk-Fact-6FA5024678F651DCA0EDEEDFE0A3F501"
      unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d6324929e1430-wk-Fact-1138B633F0335E088B4384304C6CC0E2"
      unitRef="usd">35500000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d6324929e1437-wk-Fact-22F4635E170FDC861051A6AFD622F542"
      unitRef="usd">15000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d6324929e1451-wk-Fact-96BB724CF6885BCAA9AA54D473EF0BFF"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d6324929e1455-wk-Fact-720567AD23835BBCB3F827AA344F9E49"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d6324929e1459-wk-Fact-A6D14020D25E777E54D5A3B220AA218D"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1463-wk-Fact-70E60339614B5AFBB016F04ABFA91F7C"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d6324929e1472-wk-Fact-720567AD23835BBCB3F827AA344F9E49"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-6"
      id="d6324929e1482-wk-Fact-57DF0C990B415A56871F4F2105DDCF91"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      decimals="-6"
      id="d6324929e1486-wk-Fact-4AC1B97336245B03915795229E85B701"
      unitRef="usd">115000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d6324929e1490-wk-Fact-96DC2E0B79EF5C07A7DB886558D5AF31"
      unitRef="usd">615000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d6324929e1494-wk-Fact-0EE2480AF3D65C7D989D1EECA8254B57"
      unitRef="usd">170000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember"
      decimals="-6"
      id="d6324929e1498-wk-Fact-21C0B0E205FC584F992D32314841F942"
      unitRef="usd">225000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      id="d6324929e1503-wk-Fact-10A59290A3815DD98B5BFD8BAD8FA203">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d6324929e1507-wk-Fact-944E40874FE058FE89D24E0E98D6E051">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1525-wk-Fact-35790B70F9CD5BDB870AFD6D0E5E3A29"
      unitRef="usd">14800000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1529-wk-Fact-E94D9094C44A5DD884E19EAC445083DA"
      unitRef="usd">6100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1533-wk-Fact-B59F3DA8E3E3557AACC45660A3BE24B7"
      unitRef="usd">-20900000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d6324929e1548-wk-Fact-81B8D8EC0BF35537BB490D634AFBC7E2"
      unitRef="KRW">651100000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1552-wk-Fact-AB8FD620FD30576EA40A1036BC9AA643"
      unitRef="usd">531600000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d6324929e1556-wk-Fact-CEE0BB3718C45686B3E3BF1A79CF83CF"
      unitRef="KRW">670800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1561-wk-Fact-F79E91422D635C019B6AD1FF0898A4B3"
      unitRef="usd">580200000</us-gaap:EquityMethodInvestments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1574-wk-Fact-E6BD172893E4E234F182A6A6CFCD0ADC"
      unitRef="usd">100000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1578-wk-Fact-1B2A998B5AAE2766D325A6A8AB30FB80"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1582-wk-Fact-335FFCB1215D2C499FF0A6A949341B46"
      unitRef="usd">37000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1586-wk-Fact-0707812CC54134C0D708A6AA1EFBFE6E"
      unitRef="usd">210000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:AdditionalMilestonePayment
      contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1590-wk-Fact-8BF83ABFCAAB33FE5AC0A6AA9ACDEE65"
      unitRef="usd">15000000.0</biib:AdditionalMilestonePayment>
    <biib:ContractOptionExerciseFee
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1597-wk-Fact-144579D60A47A5E6E8B0A6AB2A5EA7EC"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d6324929e1611-wk-Fact-EC40A27C5FFD534FA71A4152AD70BA11"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1623-wk-Fact-630E5D07AE1E5743993F855D0632EA8D"
      unitRef="usd">71800000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d6324929e1627-wk-Fact-EC40A27C5FFD534FA71A4152AD70BA11"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1632-wk-Fact-BD36F11679355D8F8DB9AA0CE429813F"
      unitRef="usd">58100000</biib:Collaborationprofitlosssharing>
    <biib:ContractOptionExerciseFee
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1636-wk-Fact-144579D60A47A5E6E8B0A6AB2A5EA7EC"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d6324929e1658-wk-Fact-6373CF7EB00C5DF1B5774F43C6B6A0AE"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d6324929e1662-wk-Fact-9734F5172F0D5BBC9193F5EE5D92C759"
      unitRef="usd">24800000</us-gaap:Revenues>
    <us-gaap:DueFromRelatedParties
      contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1674-wk-Fact-A85750B88405E3115C0AA6AC73459891"
      unitRef="usd">3800000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1678-wk-Fact-70EC9D96256CA9EF54E6A6ACC0D562F5"
      unitRef="usd">85000000.0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1682-wk-Fact-BC7464C60A7408F40CB8A6AE5CAE1679"
      unitRef="usd">19800000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d6324929e1686-wk-Fact-2DAD51A508358A97D2ADA6AEB54560CA"
      unitRef="usd">100000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-0FA00EA33A865D1FB75A9B0CE039565E-0-wk-Fact-E50953CDFB91587693CEC9A56D715A2F">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years from the first commercial sale of any product using such a licensed compound.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune in exchange for a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune to further reduce the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additionally, under the terms of the Neurimmune Agreement, we would be required to pay Neurimmune a milestone payment of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;if aducanumab is launched in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$22.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d6324126e790-wk-Fact-D8071934C330186F5A39A4B199DA0BE7"
      unitRef="usd">150000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="2"
      id="d6324126e794-wk-Fact-9DC457CD2E7C5F59AC4FA4B1C2A8C60D"
      unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d6324126e798-wk-Fact-ECD5B91D70A8F63F5E52A4B1EA5E63AE"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="2"
      id="d6324126e805-wk-Fact-DA77AC55AC0E7622323DA4B217F1F539"
      unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d6324126e812-wk-Fact-D626C559336DC2C31286A4B2512E5203"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d6324126e816-wk-Fact-3CE2E87269F2FA919EFAA4B279F14D1F"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2020Q1"
      decimals="-5"
      id="d6324126e863-wk-Fact-2749A5C55AD956EAACA8CA34FB9603C7"
      unitRef="usd">22700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-069259B546075EF695AF8D9227887E8B-0-wk-Fact-3E8F6EC589165822B17B3C45FECE6942">&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#x2018;510 Patent, and against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#x2018;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has been set for September 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court and a hearing in both cases has been set for May 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$200.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent), which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA was dismissed in the fourth quarter of 2019. We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#x2018;514 Patent expires in February 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial is ongoing in the West Virginia action against Mylan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 we filed an action in the Delaware Court under the Hatch-Waxman Act against Banner Life Sciences LLC (Banner) for infringement of our U.S. Patent No. 7,619,001 (the &#x2018;001 patent) expiring on June 20, 2020, and claiming treatment of MS with dimethyl fumarate or methyl hydrogen fumarate or a combination thereof. In April 2020 the U.S. Court of Appeals for the Federal Circuit affirmed the Delaware Court&#x2019;s judgment that Banner&#x2019;s drug product does not infringe the &#x2018;001 patent. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and no hearing date has been set. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO revoked Forward Pharma&#x2019;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for June 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing on the merits has been set in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and a hearing has been set for July 2020 in our appeal in the German action. No date for a hearing on the merits has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;ex parte&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#x2018;755 Patent, which request was granted in January 2020 and is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Annulment Proceeding in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#x2019;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. No hearing date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="FI2019Q4"
      decimals="-5"
      id="d6325237e824-wk-Fact-BA207A19AD44B236374BA47F0B115893"
      unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="FD2020Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR"
      decimals="-5"
      id="d6325237e916-wk-Fact-B66C1AEABD035AD9B9B533206E145AD7"
      unitRef="usd">70000000.0</us-gaap:LossContingencyDamagesSoughtValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912268272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">341.3<span></span>
</td>
<td class="nump">390.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">179.1<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 520.4<span></span>
</td>
<td class="nump">$ 517.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831252352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS  and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Internal Use Software</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an insignificant amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6932965136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark Manufacturing Operations</a></td>
<td class="nump">74.0<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="nump">$ 59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929287728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,591.3<span></span>
</td>
<td class="nump">$ 2,913.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,269.1<span></span>
</td>
<td class="nump">1,562.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,092.6<span></span>
</td>
<td class="nump">1,880.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">511.6<span></span>
</td>
<td class="nump">590.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">858.8<span></span>
</td>
<td class="nump">804.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">683.8<span></span>
</td>
<td class="nump">631.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,007.2<span></span>
</td>
<td class="nump">8,381.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">969.5<span></span>
</td>
<td class="nump">1,408.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,281.6<span></span>
</td>
<td class="nump">3,247.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">422.0<span></span>
</td>
<td class="nump">427.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,446.9<span></span>
</td>
<td class="nump">3,527.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,752.0<span></span>
</td>
<td class="nump">5,757.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">3,109.4<span></span>
</td>
<td class="nump">3,232.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,130.6<span></span>
</td>
<td class="nump">1,252.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,119.2<span></span>
</td>
<td class="nump">27,234.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">1,501.8<span></span>
</td>
<td class="nump">1,495.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">310.0<span></span>
</td>
<td class="nump">71.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">389.0<span></span>
</td>
<td class="nump">530.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,437.8<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,638.6<span></span>
</td>
<td class="nump">4,863.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">4,459.9<span></span>
</td>
<td class="nump">4,459.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">2,722.8<span></span>
</td>
<td class="nump">2,810.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">403.7<span></span>
</td>
<td class="nump">412.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,357.3<span></span>
</td>
<td class="nump">1,348.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,582.3<span></span>
</td>
<td class="nump">13,895.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(149.3)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">15,673.1<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">12,546.9<span></span>
</td>
<td class="nump">13,343.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">12,536.9<span></span>
</td>
<td class="nump">13,339.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 26,119.2<span></span>
</td>
<td class="nump">$ 27,234.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919194560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,269.1<span></span>
</td>
<td class="nump">$ 1,562.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,267.7<span></span>
</td>
<td class="nump">1,560.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">846.0<span></span>
</td>
<td class="nump">1,234.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">856.3<span></span>
</td>
<td class="nump">1,230.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">123.5<span></span>
</td>
<td class="nump">173.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">123.0<span></span>
</td>
<td class="nump">173.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,247.0<span></span>
</td>
<td class="nump">2,965.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,238.6<span></span>
</td>
<td class="nump">$ 2,970.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6933635504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.4)<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 698.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 793.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,559.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging [Member] | Interest rate swap | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,116.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6913885296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (120.5)<span></span>
</td>
<td class="nump">$ 357.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">292.0<span></span>
</td>
<td class="nump">422.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(3,534.3)<span></span>
</td>
<td class="num">(3,489.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,399.1<span></span>
</td>
<td class="nump">1,408.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(27.0)<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831279536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early AD. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">For the Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>43.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total development expense incurred by the two parties related to the BAN2401 and Elenbecestat Collaboration and our share of development expense reflected in research and development expense in our condensed consolidated statements of income were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$68.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$34.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>162.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>89.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">UCB Pharma S.A.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total development expense incurred by the collaboration was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$19.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our share of the development expense was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and was reflected in research and development expense in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, operating expenses related to the collaboration were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2020 we entered into a global licensing collaboration agreement with Sangamo Therapeutics, Inc. (Sangamo), which closed in April 2020, to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in April 2020, we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$225.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of Sangamo common stock, or approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.21</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> per share, which are subject to transfer restrictions. During the second quarter of 2020 we plan to record an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$85.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We will also make an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that will be recorded as research and development expense in the second quarter of 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$80.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the selection of targets, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.9 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$380.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$38.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. In October </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$115 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$615 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$170 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$225 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These losses reflect our share of income totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>651.1 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$531.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>670.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$580.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Transaction</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Samsung Bioepis in January 2020, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$63.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in 2019 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$37.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as an intangible asset in 2019. Additionally, we may pay Samsung Bioepis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$210.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development, regulatory and sales-based milestones, including a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> development milestone that we may pay in 2020. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also acquired an option to extend the term of our current European commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and obtained exclusive rights to commercialize these products in China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Commercial Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$71.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$58.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$24.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income. Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$85.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of March 31, 2020 and December 31, 2019, respectively. Amounts payable to Samsung Bioepis as of March 31, 2020, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment related to the 2019 transaction, as discussed above.</span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span> Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831205888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of separately identifiable assets acquired and liabilities assumed (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AcquisitionsAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</a></td>
<td class="text">:<div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(81.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AcquisitionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AcquisitionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6929177136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,187,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6911775968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912432944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,281.8<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">197.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,046.4<span></span>
</td>
<td class="nump">$ 1,001.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919147360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In particular, we plan to develop the Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this acquisition, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$635.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>two</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$847.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$26.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We finalized purchase accounting for this acquisition in the fourth quarter of 2019. The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(81.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$480.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$220.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6922035584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,752.0<span></span>
</td>
<td class="nump">$ 5,757.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred Tax Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 852.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6935342288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,399.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">172.8<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">173.1<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919274496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 2,389.3<span></span>
</td>
<td class="nump">$ 1,489.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (19.1)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6931874608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,636.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,590.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">48.4<span></span>
</td>
<td class="nump">$ 52.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">256.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6933276384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,238.6<span></span>
</td>
<td class="nump">$ 2,970.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,974.1<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">276.1<span></span>
</td>
<td class="nump">337.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">107.3<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,620.6<span></span>
</td>
<td class="nump">5,920.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">341.5<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">$ 346.1<span></span>
</td>
<td class="nump">$ 421.3<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">345.2<span></span>
</td>
<td class="nump">354.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,353.5<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">710.4<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">174.7<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">276.1<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">276.1<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,974.1<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">329.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">107.3<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,344.5<span></span>
</td>
<td class="nump">5,912.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,353.5<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">710.4<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">174.7<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">341.5<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">341.5<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6836483536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Measurement Input, Discount Rate [Member]<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6921739104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 24.4<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(44.3)<span></span>
</td>
<td class="num">(47.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">(77.3)<span></span>
</td>
<td class="nump">376.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(18.9)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(120.5)<span></span>
</td>
<td class="nump">357.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(60.9)<span></span>
</td>
<td class="nump">375.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized during the period on equity securities sold during the period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities held as of March 31</a></td>
<td class="num">(60.9)<span></span>
</td>
<td class="nump">$ 376.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,281.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expenses</a></td>
<td class="nump">190.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">209.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">154.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">147.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction in progress</a></td>
<td class="nump">27.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">662.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,437.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,046.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,001.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6930136960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (69.2)<span></span>
</td>
<td class="nump">$ 49.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">76.4<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(13.3)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">33.3<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">43.1<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 61.6<span></span>
</td>
<td class="nump">$ 38.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6836795152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member] | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember', window );">Regulatory Approval Milestone [Member] | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831198640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,399.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>172.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>173.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>197.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6916403280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>777.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>323.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,100.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>717.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>281.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>998.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>292.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>173.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>466.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>327.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>500.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>277.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>522.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>245.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>460.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,347.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>769.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,117.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,290.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>693.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,983.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>235.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>565.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>223.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>295.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>518.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>124.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>124.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>218.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>218.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>174.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>174.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,583.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,321.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,904.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,513.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,166.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,680.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.6%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.2%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>131.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,027.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>200.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>827.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,033.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(16.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(73.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(310.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(383.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(112.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(432.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(549.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>145.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,096.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>39.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,281.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>235.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,046.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,281.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>341.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>390.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>179.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>520.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>517.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>94.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>109.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>292.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$206.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we license certain of our manufacturing-related intellectual property to the customer. We are eligible to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in a series of three payments. The first payment is due upon a regulatory achievement related to the customer&#8217;s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831262064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>121.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>384.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>368.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,705.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,628.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>110.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>159.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,974.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>923.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>921.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>442.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>431.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>346.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>361.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>363.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>175.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,247.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,238.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>286.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(16.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,058.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>633.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>636.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>502.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>503.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>510.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>510.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>218.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,269.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,267.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,562.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,560.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>846.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>856.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,234.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,230.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>123.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>123.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>173.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,238.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,247.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,389.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$331.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$393.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to a decrease in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831247472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>33.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>43.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>76.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919083264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>March 31,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>121.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>384.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>368.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,705.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,628.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>110.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>159.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,974.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>923.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>921.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>442.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>431.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>346.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>361.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>363.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>175.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,247.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,238.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>286.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(16.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,058.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>633.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>636.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>502.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>503.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>510.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>510.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>218.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,269.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,267.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,562.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,560.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>846.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>856.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,234.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,230.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>123.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>123.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>173.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,238.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,247.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,389.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
